0001125376-24-000018.txt : 20240201 0001125376-24-000018.hdr.sgml : 20240201 20240201160504 ACCESSION NUMBER: 0001125376-24-000018 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 127 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240201 DATE AS OF CHANGE: 20240201 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ENSIGN GROUP, INC CENTRAL INDEX KEY: 0001125376 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-SKILLED NURSING CARE FACILITIES [8051] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 330861263 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33757 FILM NUMBER: 24586875 BUSINESS ADDRESS: STREET 1: 29222 RANCHO VIEJO RD. STREET 2: SUITE 127 CITY: SAN JUAN CAPISTRANO STATE: CA ZIP: 92675 BUSINESS PHONE: (949) 487-9500 MAIL ADDRESS: STREET 1: 29222 RANCHO VIEJO RD. STREET 2: SUITE 127 CITY: SAN JUAN CAPISTRANO STATE: CA ZIP: 92675 FORMER COMPANY: FORMER CONFORMED NAME: ENSIGN GROUP INC DATE OF NAME CHANGE: 20000930 10-K 1 ensg-20231231.htm 10-K ensg-20231231
00011253762023FYfalseP3Y0M0DP10YP4M0DP5Y0MP3Y0Mhttp://fasb.org/us-gaap/2023#RevenueFromContractWithCustomerExcludingAssessedTax33423100011253762023-01-012023-12-3100011253762023-06-30iso4217:USD00011253762024-01-29xbrli:shares00011253762023-12-3100011253762022-12-31iso4217:USDxbrli:shares0001125376us-gaap:ServiceMember2023-01-012023-12-310001125376us-gaap:ServiceMember2022-01-012022-12-310001125376us-gaap:ServiceMember2021-01-012021-12-310001125376ensg:RentalMember2023-01-012023-12-310001125376ensg:RentalMember2022-01-012022-12-310001125376ensg:RentalMember2021-01-012021-12-3100011253762022-01-012022-12-3100011253762021-01-012021-12-310001125376us-gaap:CommonStockMember2020-12-310001125376us-gaap:AdditionalPaidInCapitalMember2020-12-310001125376us-gaap:RetainedEarningsMember2020-12-310001125376us-gaap:TreasuryStockCommonMember2020-12-310001125376us-gaap:NoncontrollingInterestMember2020-12-3100011253762020-12-310001125376us-gaap:CommonStockMember2021-01-012021-12-310001125376us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310001125376us-gaap:TreasuryStockCommonMember2021-01-012021-12-310001125376us-gaap:RetainedEarningsMember2021-01-012021-12-310001125376us-gaap:NoncontrollingInterestMember2021-01-012021-12-310001125376us-gaap:CommonStockMember2021-12-310001125376us-gaap:AdditionalPaidInCapitalMember2021-12-310001125376us-gaap:RetainedEarningsMember2021-12-310001125376us-gaap:TreasuryStockCommonMember2021-12-310001125376us-gaap:NoncontrollingInterestMember2021-12-3100011253762021-12-310001125376us-gaap:CommonStockMember2022-01-012022-12-310001125376us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310001125376us-gaap:TreasuryStockCommonMember2022-01-012022-12-310001125376us-gaap:RetainedEarningsMember2022-01-012022-12-310001125376us-gaap:NoncontrollingInterestMember2022-01-012022-12-310001125376us-gaap:CommonStockMember2022-12-310001125376us-gaap:AdditionalPaidInCapitalMember2022-12-310001125376us-gaap:RetainedEarningsMember2022-12-310001125376us-gaap:TreasuryStockCommonMember2022-12-310001125376us-gaap:NoncontrollingInterestMember2022-12-310001125376us-gaap:CommonStockMember2023-01-012023-12-310001125376us-gaap:AdditionalPaidInCapitalMember2023-01-012023-12-310001125376us-gaap:TreasuryStockCommonMember2023-01-012023-12-310001125376us-gaap:RetainedEarningsMember2023-01-012023-12-310001125376us-gaap:NoncontrollingInterestMember2023-01-012023-12-310001125376us-gaap:CommonStockMember2023-12-310001125376us-gaap:AdditionalPaidInCapitalMember2023-12-310001125376us-gaap:RetainedEarningsMember2023-12-310001125376us-gaap:TreasuryStockCommonMember2023-12-310001125376us-gaap:NoncontrollingInterestMember2023-12-31ensg:facilityensg:bedensg:senior_living_unitensg:property0001125376us-gaap:WhollyOwnedPropertiesMember2023-12-310001125376ensg:ThirdPartyOperatorsMember2023-12-31ensg:operation0001125376srt:MinimumMember2023-12-310001125376srt:MaximumMember2023-12-31ensg:leaseensg:option0001125376ensg:AssembledOccupancyAcquiredMembersrt:MinimumMember2023-12-310001125376ensg:AssembledOccupancyAcquiredMembersrt:MaximumMember2023-12-310001125376us-gaap:TradeNamesMember2023-12-310001125376us-gaap:CustomerRelationshipsMember2023-12-310001125376ensg:SelfInsuranceRetentionPerClaimMemberus-gaap:GeneralLiabilityMembersrt:ParentCompanyMember2023-12-310001125376us-gaap:GeneralLiabilityMemberensg:AggregateDeductibleMemberstpr:CAsrt:ParentCompanyMember2023-12-310001125376ensg:NonCaliforniaMemberus-gaap:GeneralLiabilityMemberensg:AggregateDeductibleMembersrt:ParentCompanyMember2023-12-310001125376us-gaap:GeneralLiabilityMembernaics:ZZ524292ensg:PerOccurenceMemberensg:AllStatesExceptColoradoMember2023-12-310001125376us-gaap:GeneralLiabilityMembernaics:ZZ524292ensg:AllStatesExceptColoradoMemberensg:PerFacilityMember2023-12-310001125376us-gaap:GeneralLiabilityMembernaics:ZZ524292ensg:AllStatesExceptColoradoMemberensg:BlanketAggregateMember2023-12-310001125376stpr:COus-gaap:GeneralLiabilityMembernaics:ZZ524292ensg:PerOccurenceMember2023-12-310001125376stpr:COus-gaap:GeneralLiabilityMembernaics:ZZ524292ensg:PerFacilityMember2023-12-310001125376us-gaap:SubsequentEventMemberensg:SelfInsuranceRetentionPerClaimMemberus-gaap:GeneralLiabilityMemberstpr:CAsrt:ParentCompanyMember2024-02-010001125376us-gaap:SubsequentEventMemberus-gaap:GeneralLiabilityMemberensg:AggregateDeductibleMemberstpr:CAsrt:ParentCompanyMember2024-02-010001125376ensg:NonCaliforniaMemberus-gaap:SubsequentEventMemberensg:SelfInsuranceRetentionPerClaimMemberus-gaap:GeneralLiabilityMembersrt:ParentCompanyMember2024-02-010001125376ensg:NonCaliforniaMemberus-gaap:SubsequentEventMemberus-gaap:GeneralLiabilityMemberensg:AggregateDeductibleMembersrt:ParentCompanyMember2024-02-010001125376us-gaap:SubsequentEventMemberus-gaap:GeneralLiabilityMembernaics:ZZ524292ensg:PerOccurenceMemberensg:AllStatesExceptColoradoMember2024-02-010001125376us-gaap:SubsequentEventMemberus-gaap:GeneralLiabilityMembernaics:ZZ524292ensg:AllStatesExceptColoradoMemberensg:PerFacilityMember2024-02-010001125376us-gaap:SubsequentEventMemberus-gaap:GeneralLiabilityMembernaics:ZZ524292ensg:BlanketAggregateMemberensg:AllStatesExceptColoradoMember2024-02-010001125376us-gaap:WorkersCompensationInsuranceMember2023-12-310001125376stpr:TXus-gaap:WorkersCompensationInsuranceMember2023-12-310001125376us-gaap:WorkersCompensationInsuranceMemberensg:LossSensitiveLimitPerClaimMemberensg:OtherStatesExceptCaliforniaTexasAndWashingtonMember2023-12-310001125376ensg:SelfInsuranceRetentionPerClaimMemberus-gaap:GeneralLiabilityMember2023-12-310001125376ensg:StopLossInsuranceLimitPerClaimMemberensg:HealthLiabilityInsuranceMember2023-12-310001125376ensg:StopLossInsuranceLimitPerClaimMemberensg:HealthLiabilityInsuranceMember2021-12-310001125376us-gaap:ServiceMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberensg:MedicaidAndMedicareMember2023-01-012023-12-31xbrli:pure0001125376us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberensg:MedicaidAndMedicareMember2022-01-012022-12-310001125376us-gaap:ServiceMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberensg:MedicaidAndMedicareMember2021-01-012021-12-310001125376us-gaap:ServiceMemberensg:MedicaidMember2023-01-012023-12-310001125376us-gaap:ServiceMemberensg:MedicaidMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-12-310001125376us-gaap:ServiceMemberensg:MedicaidMember2022-01-012022-12-310001125376us-gaap:ServiceMemberensg:MedicaidMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-01-012022-12-310001125376us-gaap:ServiceMemberensg:MedicaidMember2021-01-012021-12-310001125376us-gaap:ServiceMemberensg:MedicaidMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-01-012021-12-310001125376ensg:MedicareMemberus-gaap:ServiceMember2023-01-012023-12-310001125376us-gaap:ServiceMemberensg:MedicareMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-12-310001125376ensg:MedicareMemberus-gaap:ServiceMember2022-01-012022-12-310001125376us-gaap:ServiceMemberensg:MedicareMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-01-012022-12-310001125376ensg:MedicareMemberus-gaap:ServiceMember2021-01-012021-12-310001125376us-gaap:ServiceMemberensg:MedicareMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-01-012021-12-310001125376ensg:MedicaidSkilledMemberus-gaap:ServiceMember2023-01-012023-12-310001125376us-gaap:ServiceMemberensg:MedicaidSkilledMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-12-310001125376ensg:MedicaidSkilledMemberus-gaap:ServiceMember2022-01-012022-12-310001125376us-gaap:ServiceMemberensg:MedicaidSkilledMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-01-012022-12-310001125376ensg:MedicaidSkilledMemberus-gaap:ServiceMember2021-01-012021-12-310001125376us-gaap:ServiceMemberensg:MedicaidSkilledMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-01-012021-12-310001125376us-gaap:ServiceMemberensg:MedicaidAndMedicareMember2023-01-012023-12-310001125376us-gaap:ServiceMemberensg:MedicaidAndMedicareMember2022-01-012022-12-310001125376us-gaap:ServiceMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberensg:MedicaidAndMedicareMember2022-01-012022-12-310001125376us-gaap:ServiceMemberensg:MedicaidAndMedicareMember2021-01-012021-12-310001125376us-gaap:ServiceMemberensg:ManagedCareMember2023-01-012023-12-310001125376us-gaap:ServiceMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberensg:ManagedCareMember2023-01-012023-12-310001125376us-gaap:ServiceMemberensg:ManagedCareMember2022-01-012022-12-310001125376us-gaap:ServiceMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberensg:ManagedCareMember2022-01-012022-12-310001125376us-gaap:ServiceMemberensg:ManagedCareMember2021-01-012021-12-310001125376us-gaap:ServiceMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberensg:ManagedCareMember2021-01-012021-12-310001125376ensg:PrivatePayAndOtherMemberus-gaap:ServiceMember2023-01-012023-12-310001125376ensg:PrivatePayAndOtherMemberus-gaap:ServiceMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-12-310001125376ensg:PrivatePayAndOtherMemberus-gaap:ServiceMember2022-01-012022-12-310001125376ensg:PrivatePayAndOtherMemberus-gaap:ServiceMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-01-012022-12-310001125376ensg:PrivatePayAndOtherMemberus-gaap:ServiceMember2021-01-012021-12-310001125376ensg:PrivatePayAndOtherMemberus-gaap:ServiceMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-01-012021-12-310001125376us-gaap:ServiceMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-12-310001125376us-gaap:ServiceMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-01-012022-12-310001125376us-gaap:ServiceMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-01-012021-12-3100011253762020-01-012020-12-3100011253762021-03-012021-03-310001125376ensg:MedicaidMember2023-12-310001125376ensg:MedicaidMember2022-12-310001125376ensg:ManagedCareMember2023-12-310001125376ensg:ManagedCareMember2022-12-310001125376ensg:MedicareMember2023-12-310001125376ensg:MedicareMember2022-12-310001125376ensg:PrivatePayAndOtherMember2023-12-310001125376ensg:PrivatePayAndOtherMember2022-12-310001125376us-gaap:FairValueInputsLevel2Membersrt:SubsidiariesMember2023-12-310001125376us-gaap:FairValueInputsLevel2Membersrt:SubsidiariesMember2022-12-310001125376us-gaap:FairValueInputsLevel2Member2023-12-310001125376us-gaap:FairValueInputsLevel2Member2022-12-310001125376ensg:StandardBearerHealthcareREITIncMember2023-12-310001125376ensg:StandardBearerHealthcareREITIncMemberus-gaap:WhollyOwnedPropertiesMember2023-12-310001125376ensg:ThirdPartiesMemberensg:StandardBearerHealthcareREITIncMember2023-12-310001125376ensg:StandardBearerHealthcareREITIncMemberensg:OwnedPropertiesMember2023-01-012023-12-310001125376ensg:CampusOperationMemberensg:StandardBearerHealthcareREITIncMember2023-01-012023-12-310001125376ensg:StandardBearerHealthcareREITIncMemberus-gaap:SeriesOfIndividuallyImmaterialAssetAcquisitionsMember2023-01-012023-12-310001125376ensg:StandardBearerHealthcareREITIncMemberensg:OwnedPropertiesMember2022-01-012022-12-310001125376ensg:StandardBearerHealthcareREITIncMemberus-gaap:SeriesOfIndividuallyImmaterialAssetAcquisitionsMember2022-01-012022-12-310001125376ensg:SkilledNursingOperationsMemberensg:StandardBearerHealthcareREITIncMember2022-01-012022-12-31ensg:skilled_nursing_property00011253762022-01-012022-01-310001125376ensg:StandardBearerMasterLeasesMembersrt:MinimumMember2022-01-310001125376ensg:StandardBearerMasterLeasesMembersrt:MaximumMember2022-01-310001125376ensg:StandardBearerMasterLeasesMember2022-01-31ensg:renewal0001125376ensg:StandardBearerMasterLeasesMember2023-01-012023-12-310001125376ensg:StandardBearerMasterLeasesMember2022-01-012022-12-310001125376ensg:StandardBearerMasterLeasesMember2021-01-012021-12-310001125376ensg:StandardBearerMasterLeasesMemberus-gaap:ManagementServiceBaseMember2023-01-012023-12-310001125376ensg:StandardBearerMasterLeasesMemberus-gaap:ManagementServiceIncentiveMember2023-01-012023-12-310001125376ensg:ManagementServiceTotalMemberensg:StandardBearerMasterLeasesMember2023-01-012023-12-310001125376ensg:StandardBearerMasterLeasesMemberus-gaap:ManagementServiceBaseMember2022-01-012022-12-310001125376ensg:StandardBearerMasterLeasesMemberus-gaap:ManagementServiceBaseMember2021-01-012021-12-310001125376ensg:TruistBankMemberus-gaap:BaseRateMemberus-gaap:RevolvingCreditFacilityMembersrt:MinimumMember2022-04-082022-04-080001125376ensg:TruistBankMemberus-gaap:BaseRateMemberus-gaap:RevolvingCreditFacilityMembersrt:MaximumMember2022-04-082022-04-080001125376ensg:TruistBankMemberensg:SecuredOvernightFinancingRateSOFRMemberus-gaap:RevolvingCreditFacilityMembersrt:MinimumMember2022-04-082022-04-080001125376ensg:TruistBankMemberensg:SecuredOvernightFinancingRateSOFRMemberus-gaap:RevolvingCreditFacilityMembersrt:MaximumMember2022-04-082022-04-080001125376ensg:StandardBearerEquityPlanMember2022-01-012022-01-310001125376ensg:StandardBearerEquityPlanMember2022-01-012022-12-310001125376ensg:StandardBearerEquityPlanMember2023-01-012023-12-310001125376us-gaap:RestrictedStockMemberensg:StandardBearerEquityPlanMember2022-01-012022-12-310001125376us-gaap:RestrictedStockMemberensg:StandardBearerEquityPlanMember2023-01-012023-12-310001125376ensg:SkilledNursingOperationsMember2023-01-012023-12-310001125376ensg:CampusOperationMember2023-01-012023-12-310001125376ensg:SkilledNursingOperationsMember2023-12-310001125376ensg:SeniorLivingFacilitiesMember2023-12-310001125376ensg:SkilledNursingOperationsMemberus-gaap:SubsequentEventMember2024-01-012024-02-010001125376us-gaap:SubsequentEventMemberensg:SkilledNursingOperationsMember2024-02-010001125376ensg:SkilledNursingOperationsMember2022-01-012022-12-310001125376ensg:CampusOperationMember2022-01-012022-12-310001125376ensg:SeniorLivingFacilitiesMember2022-01-012022-12-310001125376ensg:SkilledNursingOperationsMember2022-12-310001125376ensg:SeniorLivingFacilitiesMember2022-12-310001125376us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2022-01-012022-12-310001125376ensg:SkilledNursingOperationsMember2021-01-012021-12-310001125376ensg:RealEstatePurchasesMember2021-01-012021-12-31ensg:business0001125376ensg:RealEstatePurchasesOfPreviousOperationsMember2021-01-012021-12-310001125376ensg:SkilledNursingOperationsMember2021-12-310001125376us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2021-01-012021-12-310001125376us-gaap:LandMemberensg:AcquiredOperationsMember2023-01-012023-12-310001125376us-gaap:LandMemberensg:AcquiredOperationsMember2022-01-012022-12-310001125376us-gaap:LandMemberensg:AcquiredOperationsMember2021-01-012021-12-310001125376ensg:AcquiredOperationsMemberus-gaap:BuildingAndBuildingImprovementsMember2023-01-012023-12-310001125376ensg:AcquiredOperationsMemberus-gaap:BuildingAndBuildingImprovementsMember2022-01-012022-12-310001125376ensg:AcquiredOperationsMemberus-gaap:BuildingAndBuildingImprovementsMember2021-01-012021-12-310001125376us-gaap:FurnitureAndFixturesMemberensg:AcquiredOperationsMember2023-01-012023-12-310001125376us-gaap:FurnitureAndFixturesMemberensg:AcquiredOperationsMember2022-01-012022-12-310001125376us-gaap:FurnitureAndFixturesMemberensg:AcquiredOperationsMember2021-01-012021-12-310001125376ensg:AssembledOccupancyAcquiredMemberensg:AcquiredOperationsMember2023-01-012023-12-310001125376ensg:AssembledOccupancyAcquiredMemberensg:AcquiredOperationsMember2022-01-012022-12-310001125376ensg:AssembledOccupancyAcquiredMemberensg:AcquiredOperationsMember2021-01-012021-12-310001125376ensg:AcquiredOperationsMember2023-01-012023-12-310001125376ensg:AcquiredOperationsMember2022-01-012022-12-310001125376ensg:AcquiredOperationsMember2021-01-012021-12-31ensg:segment0001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:SkilledServicesSegmentMember2023-01-012023-12-310001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:StandardBearerSegmentMember2023-01-012023-12-310001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberus-gaap:AllOtherSegmentsMember2023-01-012023-12-310001125376srt:ConsolidationEliminationsMemberus-gaap:ServiceMember2023-01-012023-12-310001125376us-gaap:OperatingSegmentsMemberensg:RentalMemberensg:SkilledServicesSegmentMember2023-01-012023-12-310001125376us-gaap:OperatingSegmentsMemberensg:StandardBearerSegmentMemberensg:RentalMember2023-01-012023-12-310001125376us-gaap:OperatingSegmentsMemberensg:RentalMemberus-gaap:AllOtherSegmentsMember2023-01-012023-12-310001125376srt:ConsolidationEliminationsMemberensg:RentalMember2023-01-012023-12-310001125376us-gaap:OperatingSegmentsMemberensg:SkilledServicesSegmentMember2023-01-012023-12-310001125376us-gaap:OperatingSegmentsMemberensg:StandardBearerSegmentMember2023-01-012023-12-310001125376us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember2023-01-012023-12-310001125376srt:ConsolidationEliminationsMember2023-01-012023-12-310001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:SkilledServicesSegmentMember2022-01-012022-12-310001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:StandardBearerSegmentMember2022-01-012022-12-310001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberus-gaap:AllOtherSegmentsMember2022-01-012022-12-310001125376srt:ConsolidationEliminationsMemberus-gaap:ServiceMember2022-01-012022-12-310001125376us-gaap:OperatingSegmentsMemberensg:RentalMemberensg:SkilledServicesSegmentMember2022-01-012022-12-310001125376us-gaap:OperatingSegmentsMemberensg:StandardBearerSegmentMemberensg:RentalMember2022-01-012022-12-310001125376us-gaap:OperatingSegmentsMemberensg:RentalMemberus-gaap:AllOtherSegmentsMember2022-01-012022-12-310001125376srt:ConsolidationEliminationsMemberensg:RentalMember2022-01-012022-12-310001125376us-gaap:OperatingSegmentsMemberensg:SkilledServicesSegmentMember2022-01-012022-12-310001125376us-gaap:OperatingSegmentsMemberensg:StandardBearerSegmentMember2022-01-012022-12-310001125376us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember2022-01-012022-12-310001125376srt:ConsolidationEliminationsMember2022-01-012022-12-310001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:SkilledServicesSegmentMember2021-01-012021-12-310001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:StandardBearerSegmentMember2021-01-012021-12-310001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberus-gaap:AllOtherSegmentsMember2021-01-012021-12-310001125376srt:ConsolidationEliminationsMemberus-gaap:ServiceMember2021-01-012021-12-310001125376us-gaap:OperatingSegmentsMemberensg:RentalMemberensg:SkilledServicesSegmentMember2021-01-012021-12-310001125376us-gaap:OperatingSegmentsMemberensg:StandardBearerSegmentMemberensg:RentalMember2021-01-012021-12-310001125376us-gaap:OperatingSegmentsMemberensg:RentalMemberus-gaap:AllOtherSegmentsMember2021-01-012021-12-310001125376srt:ConsolidationEliminationsMemberensg:RentalMember2021-01-012021-12-310001125376us-gaap:OperatingSegmentsMemberensg:SkilledServicesSegmentMember2021-01-012021-12-310001125376us-gaap:OperatingSegmentsMemberensg:StandardBearerSegmentMember2021-01-012021-12-310001125376us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember2021-01-012021-12-310001125376srt:ConsolidationEliminationsMember2021-01-012021-12-310001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:SkilledServicesSegmentMemberensg:MedicaidMember2023-01-012023-12-310001125376us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMemberensg:MedicaidMember2023-01-012023-12-310001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:MedicareMemberensg:SkilledServicesSegmentMember2023-01-012023-12-310001125376us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMemberensg:MedicareMember2023-01-012023-12-310001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:MedicaidSkilledMemberensg:SkilledServicesSegmentMember2023-01-012023-12-310001125376us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMemberensg:MedicaidSkilledMember2023-01-012023-12-310001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:SkilledServicesSegmentMemberensg:MedicaidAndMedicareMember2023-01-012023-12-310001125376us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMemberensg:MedicaidAndMedicareMember2023-01-012023-12-310001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:SkilledServicesSegmentMemberensg:ManagedCareMember2023-01-012023-12-310001125376us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMemberensg:ManagedCareMember2023-01-012023-12-310001125376ensg:PrivatePayAndOtherMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:SkilledServicesSegmentMember2023-01-012023-12-310001125376ensg:PrivatePayAndOtherMemberus-gaap:CorporateNonSegmentMemberus-gaap:ServiceMember2023-01-012023-12-310001125376us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMember2023-01-012023-12-310001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:SkilledServicesSegmentMemberensg:MedicaidMember2022-01-012022-12-310001125376us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMemberensg:MedicaidMember2022-01-012022-12-310001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:MedicareMemberensg:SkilledServicesSegmentMember2022-01-012022-12-310001125376us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMemberensg:MedicareMember2022-01-012022-12-310001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:MedicaidSkilledMemberensg:SkilledServicesSegmentMember2022-01-012022-12-310001125376us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMemberensg:MedicaidSkilledMember2022-01-012022-12-310001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:SkilledServicesSegmentMemberensg:MedicaidAndMedicareMember2022-01-012022-12-310001125376us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMemberensg:MedicaidAndMedicareMember2022-01-012022-12-310001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:SkilledServicesSegmentMemberensg:ManagedCareMember2022-01-012022-12-310001125376us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMemberensg:ManagedCareMember2022-01-012022-12-310001125376ensg:PrivatePayAndOtherMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:SkilledServicesSegmentMember2022-01-012022-12-310001125376ensg:PrivatePayAndOtherMemberus-gaap:CorporateNonSegmentMemberus-gaap:ServiceMember2022-01-012022-12-310001125376us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMember2022-01-012022-12-310001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:SkilledServicesSegmentMemberensg:MedicaidMember2021-01-012021-12-310001125376us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMemberensg:MedicaidMember2021-01-012021-12-310001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:MedicareMemberensg:SkilledServicesSegmentMember2021-01-012021-12-310001125376us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMemberensg:MedicareMember2021-01-012021-12-310001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:MedicaidSkilledMemberensg:SkilledServicesSegmentMember2021-01-012021-12-310001125376us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMemberensg:MedicaidSkilledMember2021-01-012021-12-310001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:SkilledServicesSegmentMemberensg:MedicaidAndMedicareMember2021-01-012021-12-310001125376us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMemberensg:MedicaidAndMedicareMember2021-01-012021-12-310001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:SkilledServicesSegmentMemberensg:ManagedCareMember2021-01-012021-12-310001125376us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMemberensg:ManagedCareMember2021-01-012021-12-310001125376ensg:PrivatePayAndOtherMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:SkilledServicesSegmentMember2021-01-012021-12-310001125376ensg:PrivatePayAndOtherMemberus-gaap:CorporateNonSegmentMemberus-gaap:ServiceMember2021-01-012021-12-310001125376us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMember2021-01-012021-12-310001125376us-gaap:LandMember2023-12-310001125376us-gaap:LandMember2022-12-310001125376us-gaap:BuildingAndBuildingImprovementsMember2023-12-310001125376us-gaap:BuildingAndBuildingImprovementsMember2022-12-310001125376us-gaap:LeaseholdImprovementsMember2023-12-310001125376us-gaap:LeaseholdImprovementsMember2022-12-310001125376us-gaap:EquipmentMember2023-12-310001125376us-gaap:EquipmentMember2022-12-310001125376us-gaap:FurnitureAndFixturesMember2023-12-310001125376us-gaap:FurnitureAndFixturesMember2022-12-310001125376us-gaap:ConstructionInProgressMember2023-12-310001125376us-gaap:ConstructionInProgressMember2022-12-310001125376us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberensg:SeniorLivingOperationsMember2022-01-012022-12-310001125376ensg:AssembledOccupancyAcquiredMember2023-01-012023-12-310001125376ensg:AssembledOccupancyAcquiredMember2023-12-310001125376ensg:AssembledOccupancyAcquiredMember2022-12-310001125376us-gaap:TradeNamesMember2023-01-012023-12-310001125376us-gaap:TradeNamesMember2022-12-310001125376us-gaap:CustomerRelationshipsMember2023-01-012023-12-310001125376us-gaap:CustomerRelationshipsMember2022-12-310001125376ensg:DepreciationAndAmortizationMember2023-01-012023-12-310001125376ensg:DepreciationAndAmortizationMember2022-01-012022-12-310001125376ensg:DepreciationAndAmortizationMember2021-01-012021-12-310001125376us-gaap:TradeNamesMember2023-12-310001125376us-gaap:TradeNamesMember2022-12-310001125376ensg:MedicareandMedicaidLicensesMember2023-12-310001125376ensg:MedicareandMedicaidLicensesMember2022-12-310001125376ensg:MedicareandMedicaidLicensesMember2023-01-012023-12-310001125376ensg:MedicareandMedicaidLicensesMember2022-01-012022-12-310001125376ensg:MedicareandMedicaidLicensesMember2021-01-012021-12-310001125376us-gaap:OperatingSegmentsMemberensg:SkilledServicesSegmentMember2020-12-310001125376us-gaap:CorporateNonSegmentMember2020-12-310001125376us-gaap:CorporateNonSegmentMember2021-01-012021-12-310001125376us-gaap:OperatingSegmentsMemberensg:SkilledServicesSegmentMember2021-12-310001125376us-gaap:CorporateNonSegmentMember2021-12-310001125376us-gaap:CorporateNonSegmentMember2022-01-012022-12-310001125376us-gaap:OperatingSegmentsMemberensg:SkilledServicesSegmentMember2022-12-310001125376us-gaap:CorporateNonSegmentMember2022-12-310001125376us-gaap:OperatingSegmentsMemberensg:SkilledServicesSegmentMember2023-12-310001125376us-gaap:CorporateNonSegmentMember2023-12-310001125376us-gaap:CollateralizedDebtObligationsMember2023-12-310001125376us-gaap:CollateralizedDebtObligationsMember2022-12-310001125376ensg:TruistBankMemberus-gaap:RevolvingCreditFacilityMember2023-12-310001125376ensg:TruistBankMemberus-gaap:RevolvingCreditFacilityMembersrt:MinimumMember2022-04-082022-04-080001125376ensg:TruistBankMemberus-gaap:RevolvingCreditFacilityMembersrt:MaximumMember2022-04-082022-04-080001125376ensg:TruistBankMemberus-gaap:RevolvingCreditFacilityMember2022-04-080001125376ensg:HUDInsuredMortgagesMemberensg:TwentyThreeSubsidiariesMemberus-gaap:CollateralizedDebtObligationsMember2023-12-31ensg:subsidiary0001125376ensg:HUDInsuredMortgagesMemberus-gaap:CollateralizedDebtObligationsMembersrt:MinimumMember2023-12-310001125376ensg:HUDInsuredMortgagesMemberus-gaap:CollateralizedDebtObligationsMembersrt:MaximumMember2023-12-310001125376ensg:HUDInsuredMortgagesMemberus-gaap:CollateralizedDebtObligationsMemberensg:FirstThreeYearsMember2023-12-310001125376ensg:HUDInsuredMortgagesMemberensg:InTheFourthYearMemberus-gaap:CollateralizedDebtObligationsMember2023-12-310001125376ensg:HUDInsuredMortgagesMemberus-gaap:CollateralizedDebtObligationsMemberensg:YearsFiveThroughTenMember2023-12-310001125376ensg:HUDInsuredMortgagesMemberus-gaap:CollateralizedDebtObligationsMemberensg:AfterYearTenMember2023-12-310001125376ensg:HUDInsuredMortgagesMemberus-gaap:CollateralizedDebtObligationsMembersrt:MinimumMember2023-01-012023-12-310001125376ensg:HUDInsuredMortgagesMemberus-gaap:CollateralizedDebtObligationsMembersrt:MaximumMember2023-01-012023-12-310001125376ensg:A53PromissoryNoteMemberus-gaap:CollateralizedDebtObligationsMember2023-12-310001125376ensg:A53PromissoryNoteMemberus-gaap:CollateralizedDebtObligationsMember2023-01-012023-12-310001125376us-gaap:LetterOfCreditMember2023-01-012023-12-31ensg:plan0001125376ensg:A2022PlanMember2023-12-310001125376ensg:A2022PlanMember2023-01-012023-12-310001125376ensg:A2022PlanMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember2023-01-012023-12-31ensg:installment0001125376ensg:ExercisePriceRangeTwoMember2023-01-012023-12-310001125376ensg:ExercisePriceRangeTwoMember2023-12-310001125376ensg:ExercisePriceRangeThreeMember2023-01-012023-12-310001125376ensg:ExercisePriceRangeThreeMember2023-12-310001125376ensg:ExercisePriceRangeFourMember2023-01-012023-12-310001125376ensg:ExercisePriceRangeFourMember2023-12-310001125376ensg:ExercisePriceRangeFiveMember2023-01-012023-12-310001125376ensg:ExercisePriceRangeFiveMember2023-12-310001125376ensg:ExercisePriceRangeSixMember2023-01-012023-12-310001125376ensg:ExercisePriceRangeSixMember2023-12-310001125376ensg:ExercisePriceRangeSevenMember2023-01-012023-12-310001125376ensg:ExercisePriceRangeSevenMember2023-12-310001125376ensg:ExercisePriceRangeEightMember2023-01-012023-12-310001125376ensg:ExercisePriceRangeEightMember2023-12-310001125376ensg:ExercisePriceRangeNineMember2023-01-012023-12-310001125376ensg:ExercisePriceRangeNineMember2023-12-310001125376ensg:ExercisePriceRangeTenMember2023-01-012023-12-310001125376ensg:ExercisePriceRangeTenMember2023-12-310001125376ensg:ExercisePriceRangeElevenMember2023-01-012023-12-310001125376ensg:ExercisePriceRangeElevenMember2023-12-310001125376us-gaap:EmployeeStockOptionMember2023-01-012023-12-310001125376us-gaap:EmployeeStockOptionMember2022-01-012022-12-310001125376us-gaap:EmployeeStockOptionMember2021-01-012021-12-310001125376us-gaap:RestrictedStockMember2023-01-012023-12-310001125376us-gaap:RestrictedStockMember2022-01-012022-12-310001125376us-gaap:RestrictedStockMember2021-01-012021-12-310001125376us-gaap:RestrictedStockMembersrt:MinimumMember2023-01-012023-12-310001125376us-gaap:RestrictedStockMembersrt:MaximumMember2023-01-012023-12-310001125376us-gaap:RestrictedStockMembersrt:MinimumMember2022-01-012022-12-310001125376us-gaap:RestrictedStockMembersrt:MaximumMember2022-01-012022-12-310001125376us-gaap:RestrictedStockMembersrt:MinimumMember2021-01-012021-12-310001125376us-gaap:RestrictedStockMembersrt:MaximumMember2021-01-012021-12-310001125376us-gaap:RestrictedStockMember2020-12-310001125376us-gaap:RestrictedStockMember2021-12-310001125376us-gaap:RestrictedStockMember2022-12-310001125376us-gaap:RestrictedStockMember2023-12-310001125376us-gaap:RestrictedStockMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember2023-01-012023-12-310001125376us-gaap:RestrictedStockMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMembersrt:MinimumMember2023-01-012023-12-310001125376us-gaap:RestrictedStockMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMembersrt:MaximumMember2023-01-012023-12-310001125376ensg:A2019LTIPlanMemberus-gaap:SpinoffMember2019-08-270001125376ensg:A2019LTIPlanMemberus-gaap:SpinoffMember2019-08-272019-08-270001125376ensg:A2019LTIPlanMemberus-gaap:SpinoffMember2023-01-012023-12-310001125376ensg:A2019LTIPlanMemberus-gaap:SpinoffMember2022-01-012022-12-310001125376ensg:A2019LTIPlanMemberus-gaap:SpinoffMember2021-01-012021-12-310001125376ensg:StockAwardsMember2023-01-012023-12-310001125376ensg:StockAwardsMember2022-01-012022-12-310001125376ensg:StockAwardsMember2021-01-012021-12-310001125376us-gaap:EmployeeStockOptionMember2023-12-310001125376ensg:CareTrustREITMember2023-12-310001125376ensg:CareTrustREITMemberensg:TripleNetLeaseArrangementsMember2023-12-31ensg:agreement0001125376ensg:CareTrustREITMemberensg:TripleNetLeaseArrangementsMembersrt:MinimumMember2023-12-310001125376ensg:CareTrustREITMemberensg:TripleNetLeaseArrangementsMembersrt:MaximumMember2023-12-310001125376ensg:CareTrustREITMemberensg:PurchaseOptionMember2023-12-310001125376ensg:CareTrustREITMember2023-01-012023-12-310001125376ensg:CareTrustREITMember2022-01-012022-12-310001125376ensg:CareTrustREITMember2021-01-012021-12-310001125376ensg:VariousLandlordsMembersrt:MinimumMember2023-12-310001125376ensg:VariousLandlordsMembersrt:MaximumMember2023-12-310001125376ensg:VariousLandlordsMemberus-gaap:EquipmentMembersrt:MinimumMember2023-12-310001125376ensg:VariousLandlordsMemberus-gaap:EquipmentMembersrt:MaximumMember2023-12-310001125376ensg:CostofSalesandGeneralandAdministrativeExpenseMember2023-01-012023-12-310001125376ensg:CostofSalesandGeneralandAdministrativeExpenseMember2022-01-012022-12-310001125376ensg:CostofSalesandGeneralandAdministrativeExpenseMember2021-01-012021-12-310001125376ensg:VariousLandlordsMember2023-12-310001125376ensg:AmendedMasterLeaseAgreementMember2023-12-310001125376ensg:SkilledNursingOperationsMemberensg:NewMasterLeaseAgreeementMember2023-01-012023-12-310001125376ensg:SkilledNursingOperationsMemberensg:AmendedMasterLeaseMember2023-01-012023-12-310001125376ensg:SubleaseOfStandAlongSkilledNursingOperationsMember2023-01-012023-12-310001125376ensg:NewMasterLeaseAgreeementMember2023-01-012023-12-310001125376ensg:SubleaseOfStandAlongSkilledNursingOperationsMember2023-12-310001125376ensg:SubleaseOfStandAlongSkilledNursingOperationsMember2022-12-310001125376ensg:SubleaseOfStandAlongSkilledNursingOperationsMember2021-12-310001125376us-gaap:CostOfSalesMember2023-01-012023-12-310001125376us-gaap:CostOfSalesMember2022-01-012022-12-310001125376us-gaap:CostOfSalesMember2021-01-012021-12-310001125376us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-12-310001125376us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-12-310001125376us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-12-310001125376ensg:SkilledNursingOperationsMemberus-gaap:SubsequentEventMemberensg:AmendedMasterLeaseAgreementMember2024-01-012024-02-010001125376ensg:SkilledNursingOperationsMemberus-gaap:SubsequentEventMemberensg:AmendedMasterLeaseAgreementMember2024-02-010001125376ensg:LeasesToThirdPartyOperatorsMemberensg:ThePennantGroupInc.Member2023-01-012023-12-310001125376ensg:LeasesToThirdPartyOperatorsMembersrt:MinimumMember2023-12-310001125376ensg:LeasesToThirdPartyOperatorsMembersrt:MaximumMember2023-12-310001125376ensg:LeaseOfCampusOperationMember2023-01-012023-12-310001125376ensg:LeaseOfCampusOperationMember2023-12-310001125376ensg:LeasesToThirdPartyOperatorsMemberensg:ThePennantGroupInc.Member2022-01-012022-12-310001125376ensg:LeasesToThirdPartyOperatorsMemberensg:ThePennantGroupInc.Member2021-01-012021-12-310001125376ensg:LeasesToThirdPartyOperatorsMemberensg:ThirdPartyTenantsMember2023-01-012023-12-310001125376ensg:LeasesToThirdPartyOperatorsMemberensg:ThirdPartyTenantsMember2022-01-012022-12-310001125376ensg:LeasesToThirdPartyOperatorsMemberensg:ThirdPartyTenantsMember2021-01-012021-12-310001125376ensg:LeasesToThirdPartyOperatorsMember2023-01-012023-12-310001125376ensg:LeasesToThirdPartyOperatorsMember2022-01-012022-12-310001125376ensg:LeasesToThirdPartyOperatorsMember2021-01-012021-12-310001125376us-gaap:QualifiedPlanMember2023-01-012023-12-310001125376us-gaap:QualifiedPlanMember2022-01-012022-12-310001125376us-gaap:QualifiedPlanMember2021-01-012021-12-310001125376us-gaap:NonqualifiedPlanMember2023-01-012023-12-310001125376us-gaap:ProfessionalMalpracticeLiabilityMember2023-12-310001125376us-gaap:ProfessionalMalpracticeLiabilityMember2022-12-310001125376us-gaap:SubsequentEventMember2024-01-192024-01-190001125376us-gaap:SubsequentEventMember2024-02-010001125376us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberensg:MedicaidAndMedicareMember2023-01-012023-12-310001125376us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberensg:MedicaidAndMedicareMember2022-01-012022-12-310001125376us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberensg:MedicaidAndMedicareMember2023-01-012023-12-310001125376us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberensg:MedicaidAndMedicareMember2021-01-012021-12-310001125376ensg:August2023RepurchaseProgramMember2023-08-290001125376ensg:August2023RepurchaseProgramMember2023-08-292023-08-290001125376ensg:July2022RepurchaseProgramMember2022-07-280001125376ensg:July2022RepurchaseProgramMember2022-07-282022-07-2800011253762023-10-012023-12-310001125376ensg:ChristopherRChristensenMember2023-10-012023-12-310001125376ensg:ChristopherRChristensenMember2023-01-012023-12-310001125376ensg:ChristopherRChristensenMember2023-12-310001125376ensg:BeverlyBWittekindMember2023-10-012023-12-310001125376ensg:BeverlyBWittekindMember2023-01-012023-12-310001125376ensg:BeverlyBWittekindMember2023-12-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________
FORM 10-K
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
For the fiscal year ended December 31, 2023.
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
For the transition period from                      to                     .
Commission file number: 001-33757
_____________________________
ensignlogoofficiala01.jpg
THE ENSIGN GROUP, INC.
(Exact Name of Registrant as Specified in Its Charter)

Delaware33-0861263
(State or Other Jurisdiction of(I.R.S. Employer
Incorporation or Organization)Identification No.)

29222 Rancho Viejo Road, Suite 127
San Juan Capistrano, CA 92675
(Address of Principal Executive Offices and Zip Code)
(949487-9500
(Registrant’s Telephone Number, Including Area Code)
_____________________________
Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001 per shareENSGNASDAQ Global Select Market

Securities registered pursuant to Section 12(g) of the Act:
None
Indicate by check mark:
if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.þYesNo
if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.YesþNo
whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.þYesNo
whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).þYesNo
whether the registrant is a large accelerated filer, an accelerated filer, non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act:
Large accelerated filerþAccelerated filerNon-accelerated filerSmaller reporting companyEmerging growth company
If an emerging growth company, indicate if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.YesNo
whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section-404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.YesNo
If securities are registered pursuant to Section 12(b) of the Act, whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. YesþNo
whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).YesþNo
whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).YesþNo
As of June 30, 2023, the aggregate market value of the Registrant's Common Stock held by non-affiliates was:
Common Stock$3,156,373,000
The aggregate market value of Common Stock was computed by reference to the closing price as of the last business day of the registrant's most recently completed second fiscal quarter. Shares of Common Stock held by each executive officer, director and each person owning more than 10% of the outstanding Common Stock of the registrant have been excluded (in the amount of $2,014,396,000) in that such persons may be deemed to be affiliates of the registrant. This determination of affiliate status is not necessarily a conclusive determination for other purposes.
As of January 29, 2024, 56,665,741 shares of the registrant’s common stock, $0.001 par value, were outstanding.

DOCUMENTS INCORPORATED BY REFERENCE:
Part III of this Form 10-K incorporates information by reference from the Registrant's definitive proxy statement for the Registrant's 2024 Annual Meeting of Stockholders to be filed within 120 days after the close of the fiscal year covered by this annual report.



THE ENSIGN GROUP, INC.
INDEX TO ANNUAL REPORT ON FORM 10-K
FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023
TABLE OF CONTENTS
PART I
PART II.
PART III.
PART IV.



CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 
This Annual Report on Form 10-K contains forward-looking statements, which include, but are not limited to our expected future financial position, results of operations, cash flows, financing plans, business strategy, budgets, capital expenditures, competitive positions, growth opportunities and plans and objectives of management. Forward-looking statements can often be identified by words such as “anticipates,” “expects,” “intends,” “plans,” “predicts,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” “would,” “could,” “potential,” “continue,” “ongoing,” similar expressions, and variations or negatives of these words. These statements are subject to the safe harbors under Private Securities Litigation Reform Act of 1995. These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors, some of which are listed under the section “Risk Factors” in Part I, Item 1A of this Annual Report on Form 10-K. Accordingly, you should not rely upon forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this Annual Report, and are based on our current expectations, estimates and projections about our industry and business, management's beliefs, and certain assumptions made by us, all of which are subject to change. We undertake no obligation to revise or update publicly any forward-looking statement for any reason, except as otherwise required by law.

As used in this Annual Report on Form 10-K, the words, "Ensign," "Company," “we,” “our” and “us” refer to The Ensign Group, Inc. and its consolidated subsidiaries. All of our independent subsidiaries, the Service Center (defined below) and our wholly-owned captive insurance subsidiary (the Captive Insurance) and captive real estate investment trust called Standard Bearer Healthcare REIT, Inc. (Standard Bearer) are operated by separate, wholly-owned, independent subsidiaries that have their own management, employees and assets. References herein to the consolidated “Company” and “its” assets and activities, as well as the use of the terms “we,” “us,” “our” and similar terms in this Annual Report on Form 10-K are not meant to imply, nor should it be construed as meaning, that The Ensign Group, Inc. has direct operating assets, employees or revenue, or that any of the subsidiaries are operated by The Ensign Group.

 
The Ensign Group, Inc. is a holding company with no direct operating assets, employees or revenues. In addition, certain of our wholly-owned independent subsidiaries, collectively referred to as the Service Center, provide centralized accounting, payroll, human resources, information technology, legal, risk management and other centralized services to the other independent subsidiaries through contractual relationships with such subsidiaries. The Captive Insurance provides some claims-made coverage to our independent subsidiaries for general and professional liability, as well as for certain workers' compensation insurance liabilities. Standard Bearer owns and manages our real estate business.

The Service Center address is 29222 Rancho Viejo Rd Suite 127, San Juan Capistrano, CA 92675, and our telephone number is (949) 487-9500. Our corporate website is located at www.ensigngroup.net. The information contained in, or that can be accessed through, our website does not constitute a part of this Annual Report on Form 10-K.

EnsignTM is our United States trademark. All other trademarks and trade names appearing in this annual report are the property of their respective owners.




PART I.
ITEM 1. BUSINESS
Founded in 1999, The Ensign Group, Inc. ("Ensign") is a holding company with independent subsidiaries that provide skilled nursing, senior living and rehabilitative services, as well as other ancillary businesses (including mobile diagnostics and medical transportation), in 13 states. As part of our investment strategy, we also acquire, lease and own healthcare real estate to service the post-acute care continuum through acquisition and investment opportunities in healthcare properties. For the year ended December 31, 2023, we generated approximately 96.0% of our revenue from our skilled nursing facilities. The remainder of our revenue is primarily generated from our real estate properties, senior living services and other ancillary services.
OPERATIONS
Overview
As of December 31, 2023, we offered skilled nursing, senior living and rehabilitative care services through 297 skilled nursing and senior living facilities. Of the 297 facilities, we operated 214 facilities under long-term lease arrangements and have options to purchase 11 of those 214 facilities. Our real estate portfolio includes 113 owned real estate properties, which included 83 facilities operated and managed by us, 30 operations leased to and operated by third-party operators, and the Service Center's California location. Of the 30 real estate operations leased to third-party operators, one senior living facility is located on the same real estate property as a skilled nursing facility that we own and operate.
Our Unique Approach and Structure
The name "Ensign" is synonymous with a "flag" or a "standard" and refers to our goal of setting the standard by which all others in our industry are measured. We believe that through our efforts and leadership, we can foster a new level of patient care and professional competence at our independent subsidiaries, and set a new industry standard for each patient we service. We view healthcare services primarily as a local business. We believe our success is largely driven by our proven ability to build strong relationships with key stakeholders in local healthcare communities, in part, by leveraging our reputation for providing superior care. Accordingly, our brand strategy and organizational structure promotes the empowerment of local leadership and staff to make their facility the “operation of choice” in their community. This is accomplished by allowing local leadership to discern and address the unique needs and priorities of healthcare professionals, customers and other stakeholders in the local community or market, and then work to create a superior service offering for, and reputation in, their particular community. This local empowerment is unique within the healthcare services industry.
We believe that our localized approach encourages prospective patients and referral sources to choose or recommend our local operations. In addition, our leaders are enabled and motivated to share real-time operating data and otherwise benchmark clinical and operational performance against their peers in order to improve clinical care, enhance patient satisfaction and augment operational efficiencies, promoting the sharing of best practices.
We organize our independent subsidiaries into portfolio companies, which we believe has enabled us to maintain a local, field-driven organizational structure, attract additional qualified leadership talent, and to identify, acquire, and improve operations at a generally faster rate. Each of our portfolio companies has its own leader. These leaders, who are generally taken from the ranks of operational CEOs, serve as leadership resources within their own portfolio companies, and have the primary responsibility for recruiting qualified talent, finding potential acquisition targets, and identifying other internal and external growth opportunities. We believe this organizational structure has improved the quality of our recruiting and will continue to facilitate successful acquisitions.
Since we spun-off our owned real estate properties into a public real estate investment trust (REIT) in 2014, we have continued to expand our real estate portfolio. Following the real estate spin-off, we have acquired and currently own 113 real estate properties, including 30 real estate properties that are leased to a third parties under triple-net long-term leases. We manage and operate the remaining real estate properties, including the Service Center's California location. We are committed to growing our real estate portfolio, which we believe will further enhance our earnings and maximize long-term shareholder value.

1

To continue with our growth strategy on our real estate portfolio, in January 2022, we formed Standard Bearer. Standard Bearer owns and manages our real estate business. The REIT structure allows us to better demonstrate the growing value of our owned real estate and provide us with an efficient vehicle for future acquisitions of properties that could be operated by our independent subsidiaries or other third parties. We believe this structure gives us new pathways to growth with transactions we would not have considered in the past. Standard Bearer elected to be taxed as a REIT, for U.S. federal income tax purposes, commencing with its taxable year ended December 31, 2022. The real estate portfolio in Standard Bearer consists of 108 of our 113 owned real estate properties. During the year ended December 31, 2023, Standard Bearer acquired the real estate of three stand-alone skilled nursing facilities and two campus operations. Of these additions, the three skilled nursing facilities and one campus operation acquired are operated by the Company's independent subsidiaries. The remaining campus operation is leased to a third-party operator. For further details on the Standard Bearer REIT, refer to Note 6, Standard Bearer, in Notes to the Consolidated Financial Statements of this Annual Report on Form 10-K.
SEGMENTS
We have two reportable segments: (1) skilled services, which includes the operation of skilled nursing facilities and rehabilitation therapy services and (2) Standard Bearer, which is comprised of select properties owned by us through our captive REIT and leased to skilled nursing and senior living operations, including our own independent subsidiaries and third-party operators.
We also report an “all other” category that includes operating results from our senior living operations, mobile diagnostics, transportation, other real estate and other ancillary operations. These businesses are neither significant individually, nor in aggregate, and therefore do not constitute a reportable segment. Our Chief Executive Officer, who is our chief operating decision maker, or CODM, reviews financial information at the operating segment level. We have presented our segment results in this Annual Report on Form 10-K on a comparative basis to conform to the segment structure. For more information about our operating segments, as well as financial information, see Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations and Note 8, Business Segments of the Notes to the Consolidated Financial Statements.
Skilled Services
As of December 31, 2023, our skilled nursing companies provided skilled nursing care at 286 operations, with 30,602 operational beds, in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. We provide short and long-term nursing care services for patients with chronic conditions, prolonged illness, and the elderly. Our residents are often high-acuity patients that come to our facilities to recover from strokes, cardiovascular and respiratory conditions, neurological conditions, joint replacements, and other muscular or skeletal disorders. We use interdisciplinary teams of experienced medical professionals to provide services prescribed by physicians. These medical professionals provide individualized comprehensive nursing care to our short-stay and long-stay patients. Many of our skilled nursing facilities are equipped to provide specialty care, such as on-site dialysis, ventilator care, cardiac and pulmonary management. We also provide standard services such as room and board, special nutritional programs, social services, recreational activities, entertainment, and other services. We are dedicated to ensuring our residents are happy, comfortable, and motivated to achieve their health goals through the provision of quality care. We generate our skilled services revenue from Medicaid, Medicare, managed care, commercial insurance, and private pay. During the year ended December 31, 2023, approximately 46.9% and 27.5% of our skilled services revenue was derived from Medicaid and Medicare programs, respectively.
Standard Bearer
We engage in the acquisition and leasing of skilled nursing and senior living properties. We generate rental revenue primarily by leasing post-acute care properties we acquired to healthcare operators under triple-net lease arrangements, whereby the tenant is solely responsible for the costs related to the property, including property taxes, insurance and maintenance and repair costs, subject to certain exceptions. As of December 31, 2023, our real estate portfolio within Standard Bearer is comprised of 108 real estate properties located in Arizona, California, Colorado, Idaho, Kansas, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. Of these properties, 79 are leased to our independent subsidiaries and 30 are leased to operations wholly-owned and managed by third-party operators. Of the 30 real estate operations leased to third-party operators, one senior living operation is located on the same real estate property as a skilled nursing facility that we own and operate. During the year ended December 31, 2023, we generated rental revenues of $82.5 million, of which $66.7 million was derived from our independent subsidiaries, and therefore eliminated in consolidation.

2

Other
Revenue from our senior living operations, mobile diagnostics, transportation, other real estate and other ancillary operations comprise approximately 4.2% of our annual revenue.

Senior Living — As of December 31, 2023, we had an aggregate of 3,121 senior living units across 38 operations, of which 27 were located on the same site location as our skilled nursing care operations. Our senior living communities located in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Texas, Utah and Washington, provide residential accommodations, activities, meals, housekeeping and assistance in the activities of daily living to seniors who are independent or who require some support, but not the level of nursing care provided in a skilled nursing operation. Our independent living units are non-licensed independent living apartments in which residents are independent and require no support with the activities of daily living.
Our senior living operations comprise approximately 2.0% of our annual revenue. We generate revenue at these units primarily from private pay sources, with a small portion derived from Medicaid or other state-specific programs. Specifically, during the year ended December 31, 2023, approximately 60.7% of our senior living revenue was derived from private pay sources.
Ancillary — As of December 31, 2023, we held a majority membership interest of ancillary operations located in Arizona, California, Colorado, Idaho, Texas, Utah and Washington. We have invested in and are exploring new business lines that are complementary to our existing skilled services and senior living services. These new business lines consist of mobile ancillary services, including digital x-ray, ultrasound, electrocardiograms, sub-acute services, dialysis, respiratory, long-term care pharmacy and patient transportation to people in their homes or at long-term care facilities. To date, these businesses were not meaningful contributors to our operating results.
GROWTH

We have an established track record of successful acquisitions. Much of our historical growth can be attributed to implementing our expertise in acquiring real estate or leasing both under-performing and performing post-acute care operations and transforming them into market leaders in clinical quality, staff competency, employee loyalty and financial performance. With each acquisition, we apply our core operating expertise to improve these operations, both clinically and financially. In years where pricing has been high, we have focused on the integration and improvement of our existing independent subsidiaries while limiting our acquisitions to strategically situated properties.

From January 1, 2013 through December 31, 2023, we acquired 238 facilities, which added 20,485 operational skilled nursing beds and 4,803 senior living units to our independent subsidiaries, including the operations that were contributed in the spin-off to Pennant Group, Inc. (Pennant) in 2019. The following table summarizes cumulative skilled nursing and senior living operations, operational skilled nursing beds and senior living unit counts at the end of 2013 and each of the last five years to reflect our growth over a ten-year period and five-year period as a result of the acquisition of these facilities:

 December 31,
 
2013(2)
2019(1)
2020202120222023
Cumulative number of skilled nursing and senior living operations119 223 228 245 271 297 
Cumulative number of operational skilled nursing beds10,949 22,625 23,172 25,032 28,130 30,602 
Cumulative number of senior living units1,968 2,154 2,254 2,237 3,021 3,121 
(1) Number of operational beds and number of operations for 2019 include operational beds and operations that we no longer operated. The number of operations and operational beds do not include the closed facilities beginning in the year of their closures.
(2) Included in the 2013 number of operational units and number of operations are the operational units and senior living operations that we contributed to Pennant in 2019. In 2019 and forward, the number of operations and operational units do not include operations transferred to Pennant.
We have also invested in new business lines that are complementary to our existing businesses, such as ancillary services. We plan to continue to grow our revenue and earnings by:

continuing to grow our talent base and develop future leaders;

increasing the overall percentage or “mix” of higher acuity patients;

focusing on organic growth and internal operating efficiencies;

continuing to acquire additional operations in existing and new markets;
3


expanding and renovating our existing operations, and

strategically investing in and integrating other post-acute care healthcare businesses.
New Market CEO and New Ventures Programs. In order to broaden our reach into new markets, and in an effort to provide existing leaders in our company with the entrepreneurial opportunity and challenge of entering a new market and starting a new business, we established our New Market CEO program in 2006. Supported by our Service Center and other resources, a New Market CEO evaluates a target market, develops a comprehensive business plan, and relocates to the target market to find talent and connect with other providers, regulators and the healthcare community in that market, with the goal of ultimately acquiring businesses and establishing an operating platform for future growth. In addition, this program includes other lines of business that are closely related to the skilled nursing industry. The New Ventures program encourages our local leaders to evaluate service offerings with the goal of establishing an operating platform in new markets and new businesses. We believe that this program will not only continue to drive growth, but will also provide a valuable training ground for our next generation of leaders, who will have experienced the challenges of growing and operating a new business.
OPERATION EXPANSIONS
During the year ended December 31, 2023, we expanded through a combination of long-term leases and real estate purchases, with the addition of 25 stand-alone skilled nursing operations and one campus operation. Of these additions, Standard Bearer acquired the real estate of three of the stand-alone skilled nursing operations and one campus operation, which were leased back to Ensign's independent subsidiaries. These new operations added a total of 2,483 operational skilled nursing beds and 94 operational senior living units to be operated by our independent subsidiaries. Additionally, we invested in new ancillary services that are complementary to our existing businesses.
Subsequent to December 31, 2023, we expanded through a long-term lease, with the addition of two stand-alone skilled nursing operations totaling 241 operational skilled nursing beds to be operated by our independent subsidiaries, including one in a new state, Tennessee.
For further discussion of our acquisitions, see Note 7, Operation Expansions in the Notes to the Consolidated Financial Statements.
QUALITY OF CARE MEASURES
Improvement in Acquired Facilities The Five-Star Quality Rating System introduced by the Centers for Medicare and Medicaid Services (CMS) intends to help consumers, their families and caregivers compare nursing homes more easily. The Five-Star Quality Rating System gives each skilled nursing operation a rating between one and five stars in various categories including health inspections, staffing and quality measures (QM). We have a strong history of quickly improving the quality of care in the facilities we acquire. Thus, as new assessments are conducted post-acquisition, the star ratings see consistent improvement. At the time of acquisition, the majority of our facilities have 1 and 2-Star ratings.
Over the last few years, CMS has modified the star rating requirements. These changes have been significant and made it more difficult to achieve a 4 or 5-Star rating, resulting in certain skilled nursing operations losing stars in their "Quality" and "Staffing" ratings, which negatively impacted the "Overall" ratings. Nevertheless, we continue to demonstrate strong performance in the Five-Star Quality Rating System. We believe compliance and quality outcomes are precursors to outstanding financial performance. Thus, we strive to aggressively increase quality and compliance in every facility we acquire, and to adjust our overall policies to adapt to CMS’s changing criteria for the Five-Star Quality Rating System.
On October 1, 2023, a significant change impacting the QM category was a shift in focus from a resident's functional status to their functional abilities and goals, commonly referred to as the Minimum Data Set (MDS) Section G to Section GG. The transition will result in numerous QM modifications and changes which will impact the Five-Star rating. As part of this change, starting in April 2024, CMS will freeze the associated new and modified quality measures as part of the transition on the Nursing Home Compare website. Starting in October 2024, CMS will replace the short-stay functionality QM with the new cross-setting functionality QM, which is used in the SNF Quality Reporting Program (QRP). The remaining three measures will continue to be frozen until January 2025 while the data for the equivalent measures are collected. Therefore, the predictability and movement in the QM ratings during 2024 will not necessarily be consistent with our current quality performance. In addition, what and how we are measuring the QM will not be consistent with the historical practice and accordingly will be not comparable. Therefore, depending on the changes, we may experience periods of time where the number of facilities with 4 or 5-Star ratings decline.
4

The table below summarizes the number of our facilities with 4 and 5-Star ratings since 2019:
 As of December 31,
 20192020202120222023
4 and 5-Star Quality Rated skilled nursing facilities102 116 114 113 134 

Above-Average Ratings Additionally, despite the fact that Ensign’s acquisition of facilities with 1 or 2-Star ratings skews our company-wide ratings, our mean score on the Five-Star Quality Rating System is 65.4%, which exceeds the national average score of 57.2%. Our average cycle 1 health inspections for all of our facilities, which is based on the latest inspections, is 7.9% better than the national average.
INDUSTRY TRENDS
The post-acute care industry has evolved to meet the growing demand for post-acute and custodial healthcare services generated by an aging population, increasing life expectancies and the trend toward shifting patient care to lower cost settings. The industry has evolved in recent years, which we believe has led to a number of favorable improvements in the industry, as described below:
Shift of Patient Care to Lower Cost Alternatives The growth of the senior population in the U.S. continues to increase healthcare costs, often faster than the available funding from government-sponsored healthcare programs. In response, federal and state governments have adopted cost-containment measures that encourage the treatment of patients in more cost-effective settings such as skilled nursing facilities, for which the staffing requirements and associated costs are often significantly lower than acute care hospitals and other post-acute care settings. As a result, skilled nursing facilities are generally serving a larger population of higher acuity patients than in the past.
Significant Acquisition and Consolidation Opportunities The skilled nursing industry is large and highly fragmented, characterized predominantly by numerous local and regional providers. Due to the increasing demands from hospitals and insurance carriers to implement sophisticated and expensive reporting systems, we believe this fragmentation provides us with significant acquisition and consolidation opportunities.
Improving Supply and Demand Balance The number of skilled nursing facilities has declined modestly over the past several years. We expect that the supply and demand balance in the skilled nursing industry will continue to improve due to the shift of patient care to lower cost settings, an aging population and increasing life expectancies.
Increased Demand Driven by Aging Populations As seniors account for an increasing percentage of the total U.S. population, we believe the demand for skilled nursing and senior living services will continue to increase. According to the census projection released by the U.S. Census Bureau in early 2020, between 2016 and 2030, the number of individuals over 65 years old is projected to be one of the fastest growing segments of the United States population, growing from 15% to 21%. The Bureau expects this segment to increase nearly 50% to 73 million, as compared to the total U.S. population which is projected to increase by 10% over that time period. Furthermore, the generation currently retiring has accumulated less savings than prior generations, creating demand for more affordable senior housing and skilled nursing services. As a high-quality provider in lower cost settings, we believe we are well-positioned to benefit from this trend.
Value-based Care and Reimbursement Reform In response to rising healthcare spending in the United States, commercial, government and other payors are generally shifting away from fee-for-service (FFS) payment models towards value-based models, including risk-based payment models that tie financial incentives to quality, efficiency and coordination of care. We believe that patient-centered outcomes driven reimbursement models will continue to grow in prominence. Many of our operations already receive value-based payments, and as valued-based payment systems continue to increase in prominence, it is our view that our strong clinical outcomes will be increasingly rewarded.

5

A significant goal of U.S. federal health care reform is to transform the delivery of health care by changing reimbursement to reflect and support a focus on equity, payment for value, and efficacious delivery of person-centered care. Reimbursement models and demonstrations that increase accountability and provide financial incentives to encourage efficiency, affordability, and high-quality care, have been developed and implemented by government and commercial third-party payers. Special focus is placed on increasing the number of beneficiaries in care relationships with accountability for quality and total cost of care, improvements in care coordination, reducing inequities at the population level, and supporting care innovation to close care gaps and increase access. The most prominent value-based models designed to accomplish these aims include Accountable Care Models (e.g., MSSP ACOs, ACO REACH) and Disease-Specific & Episode-Based Models (e.g., BPCI Advanced, GUIDE Model, CJR). These models, alongside State & Community, Statutory, and Health Plan Models, are aimed at alignment across payers and care settings, leveraging effective clinical tools, outcomes-focused payment approaches, and stakeholder-led policy development. Reimbursement methodology reform includes Value-Based Purchasing (VBP), in which a portion of provider reimbursement is redistributed based on relative performance, or improvement on designated economic, clinical quality and patient satisfaction metrics. These reimbursement methodologies and similar programs are likely to continue and expand, both in government and commercial health plans. Many of our operations already participate in value-based initiatives and models. With our focus on quality care and strong clinical outcomes, Ensign is well-positioned to benefit from these outcome-based payment models.
We believe the post-acute industry has been and will continue to be impacted by several other trends. The use of long-term care insurance is increasing among seniors as a means of planning for the costs of skilled nursing services. In addition, as a result of increased mobility in society, reduction of average family size and the increased number of two-wage earner couples, more residents are looking for alternatives outside the family for their care.
Our business is affected by seasonal fluctuations in occupancy and acuity which are most prominent when comparing the summer and winter months of the calendar year.
REVENUE SOURCES

 
We derive revenue primarily from the Medicaid and Medicare programs, managed care and commercial insurance payors and private pay patients. The majority of our revenue is derived from skilled nursing, which is highly dependent upon the Medicaid and Medicare programs. Thus, any changes to payment models, reimbursements and budgets impact our revenue, some positively and some negatively. A detailed discussion of the regulatory framework impacting our business is found in the Government Regulation section below. See also, Item 1A., Risk Factors.
A brief overview of each of our revenue sources is as follows:
Medicaid  Medicaid is a program financed by state funds and matching federal funds administered by the states and their political subdivisions, and often go by state-specific names, such as Medi-Cal in California and the Arizona Healthcare Cost Containment System in Arizona. Medicaid programs generally provide health benefits for qualifying individuals, and may supplement Medicare benefits for the disabled and for persons aged 65 and older meeting financial eligibility requirements. Medicaid reimbursement formulas are established by each state with the approval of the federal government in accordance with federal guidelines. Seniors who enter skilled nursing facilities as private pay clients can become eligible for Medicaid once they have substantially depleted their assets. Medicaid is generally the largest source of funding for most skilled nursing facilities.
Medicaid reimbursement varies from state to state and is based upon a number of different systems, including cost-based, prospective payment; case mixed adjusted payments and negotiated rate systems. Rates are subject to a state’s annual budgetary requirements and funding, statutory and regulatory changes and interpretations and rulings by individual state agencies and State Plan Amendments approved by CMS.

Medicaid typically covers patients that require standard room and board services and provides reimbursement rates that are generally lower than rates earned from other sources. We monitor our payor mix to measure the level received from each payor across each of our business units. We intend to continue to focus on enhancing our care offerings to accommodate more high acuity patients.


6

Approximately 87.2% of our Medicaid revenue comes from Arizona, California, Colorado, Texas, Utah and Washington. In California, the state enacted legislation expanding their Medicaid program, which in recent years has continued to see budget increases, but will see Medicaid spending decrease in the 2023-2024 period. It is projected that California General Fund spending on California Medicaid will be $225.9 billion for the 2023-2024 budget year, which is a decrease of 3.7% from its 2022-2023 budget estimate. California also estimates that the 2024-2025 budget year's Medicaid spending will decrease by $0.4 billion to $36.6 billion. Over the longer term, however, California expects its Medicaid spending to increase, reaching more than $43 billion by the 2027-2028 budget year. Texas is one of the remaining states that has not expanded Medicaid under the Affordable Care Act. Texas lawmakers have, in the past, underfunded Medicaid, requiring an infusion of state and federal funds. Funding for the 2023-2024 Texas biennium includes approximately $144.0 billion in general revenue funds, which is an increase of 10.5% in general funds from the 2022-2023 biennium amounts. In Arizona, the state enacted legislation expanding their Medicaid program in 2013, but has seen decreased Medicaid enrollments in recent years. Their 2023 budget for the state Medicaid program included $16.8 billion from the general fund, a decrease of 2.8% from the 2022. The 2024 budget is expected to increase by 2.0% from 2023 to $17.8 billion. In Utah, the fiscal year 2022 Medicaid spending was $4.6 billion and the state’s budget for 2023 fiscal year Medicaid spending, which will continue into 2024, is expected to be similar.

Medicare  Medicare is a federal program that provides healthcare benefits to individuals who are 65 years of age or older or are disabled. To achieve and maintain Medicare certification, a skilled nursing facility must sign a Medicare provider agreement and meet the CMS “Conditions of Participation” on an ongoing basis, as determined in periodic facility inspections or “surveys” conducted primarily by the state licensing agency in the state where the facility is located. Medicare pays for inpatient skilled nursing facility services under the prospective payment system (PPS). Under PPS, facilities are paid a predetermined amount per patient, per day, for certain services. Medicare Part A skilled nursing facility coverage is limited to 100 days per episode of illness for those beneficiaries who require daily care following discharge from an acute care hospital.
For Medicare beneficiaries who qualify for the Medicare Part A coverage, rehabilitation services are included in the per diem payment. For beneficiaries who do not meet the coverage criteria for Part A services, rehabilitation services may qualify for the services to be provided under Medicare Part B.
Managed Care and Private Insurance  Managed care patients consist of individuals who are insured by certain third-party entities, or who are Medicare beneficiaries who have assigned their Medicare benefits to a senior managed care organization plan. Another type of insurance, long-term care insurance, is also becoming more available to consumers, but is not expected to contribute significantly to industry revenues in the near term.
Private and Other Payors  Private and other payors consist primarily of individuals, family members or other third parties who directly pay for the services we provide.
Rental Revenue Real estate rental revenue is generated by leasing post-acute care properties that we acquired to healthcare operators under triple-net lease arrangements, whereby the tenant is solely responsible for the costs related to the property, including property taxes, insurance and maintenance and repair costs, subject to certain exceptions.
The following charts sets forth our total service revenue by payor source generated by our consolidated operations and skilled services segment as a percentage of total revenue for the year ended December 31, 2023 and 2022, respectively:



7

CONSOLIDATED SERVICE REVENUE BY PAYOR
65316532

SKILLED SERVICES REVENUE BY PAYOR
65686569
Payor Sources as a Percentage of Skilled Services The following table sets forth our percentage of skilled nursing patient days by payor source:
 Year Ended December 31,
 20232022
Percentage of Skilled Nursing Days:
Medicare12.3 %13.5 %
Managed care13.0 13.1 
Other skilled5.1 5.2 
SKILLED MIX30.4 31.8 
Private and other payors11.0 10.3 
Medicaid58.6 57.9 
TOTAL SKILLED NURSING100.0 %100.0 %
8

REIMBURSEMENT FOR SPECIFIC SERVICES

Reimbursement for Skilled Services  Skilled nursing facility revenue is primarily derived from Medicaid, Medicare, managed care and private payors. Our skilled nursing operations provide Medicaid-covered services to eligible individuals consisting of nursing care, room and board and social services. In addition, states may, at their option, cover other services such as physical, occupational and speech therapies.

Historically, adjustments to reimbursement under Medicare and Medicaid have had a significant effect on our revenue and results of operations. Recently enacted, pending and proposed legislation and administrative rulemaking at the federal and state levels could have similar effects on our business. Efforts to impose reduced reimbursement rates, greater discounts and more stringent cost controls by government and other payors are expected to continue for the foreseeable future and could adversely affect our business, financial condition and results of operations. Additionally, any delay or default by the federal or state governments in making Medicare and/or Medicaid reimbursement payments could materially and adversely affect our business, financial condition and results of operations.

Reimbursement for Rehabilitation Therapy Services  Rehabilitation therapy revenue is primarily received from private pay, managed care and Medicare for services provided at skilled nursing operations and senior living operations. The payments are based on negotiated patient per diem rates or a negotiated fee schedule based on the type of service rendered.

Reimbursement for Senior Living  Senior living facility revenue is primarily derived from private pay patients at rates we established, with only a small portion of such revenue derived from state-specific programs such as Medicaid.

Reimbursement for Other Ancillary Services  Other ancillary revenue, such as mobile diagnostics and medical transportation, is primarily derived from Medicare Part B, Medicaid, managed care and private payors at rates we establish based upon the services we provide and market conditions in the area of operation.
RENTAL REVENUE

Rental revenue from third-party rental property tenants Standard Bearer's owned properties are leased pursuant to non-cancelable operating leases, generally with an initial term of 10 to 20 years. All of the leases for post-acute care healthcare properties contain renewal options. The leases provide for fixed minimum base rent during the initial and renewal periods. Standard Bearer's leases contain provisions for specified annual increases over the rents of the prior year and those increases are generally calculated based on the Consumer Price Index.

Each lease is a triple net lease which requires the lessee to pay all taxes, insurance, maintenance and repairs, capital and non-capital expenditures and other costs necessary in the operations of the facilities. In addition, Standard Bearer's leases with third-parties are typically structured as master leases. The master leases consist of multiple leases, each with its own pool of properties, that have varying maturities and diversity in property geography.

If a lessee makes payments for taxes and insurance directly to a third-party on our behalf, we are required to exclude these payments from variable payments and from revenue recognition in our consolidated statements of income. Otherwise, tenant reimbursements paid to us for taxes and insurance are classified as additional rental revenue recognized by us on a gross basis.

Rental revenue from our independent subsidiaries Rental revenue from our independent subsidiaries is based on mutually agreed-upon base rents that are subject to change from time to time. Intercompany revenue is eliminated in consolidation, along with the corresponding intercompany rent expenses of the related healthcare facilities.
COMPETITION

 
The post-acute care industry is highly competitive, and we expect that the industry will become increasingly competitive in the future. The industry is highly fragmented and characterized by numerous local and regional providers, in addition to large national providers that have achieved geographic diversity and economies of scale. Our independent subsidiaries also compete with inpatient rehabilitation facilities and long-term acute care hospitals. Increasingly, we are competing with home health and community-based providers who have developed programs designed to provide services to seniors outside a facility-based setting, potentially decreasing the time they need the higher level of care provided in a skilled nursing facility. Competitiveness may vary significantly from location to location, depending upon factors such as the number of competing facilities, availability of services, expertise of staff, and the physical appearance and amenities of each location. We believe that the primary competitive factors in the post-acute care industry are:
9


ability to attract and to retain qualified management and caregivers;

reputation and achievements of quality healthcare outcomes;

attractiveness and location of facilities;

the expertise and commitment of the management team and employees; and

community value, including amenities and ancillary services.

 
 
We seek to compete effectively in each market by establishing a reputation within the local community as the “operation of choice.” This means that the operation leaders are generally free to discern and address the unique needs and priorities of healthcare professionals, customers and other stakeholders in the local community or market, and then create a superior service offering and reputation for that particular community or market that is calculated to encourage prospective customers and referral sources to choose or recommend the operation.

Increased competition could limit our ability to attract and retain patients, maintain or increase rates or to expand our business. Some of our competitors have greater financial and other resources than we have, may have greater brand recognition and may be more established in their respective communities than we are. Competing companies may also offer newer facilities or different programs or services than we offer, and may therefore attract individuals who are currently patients of our facilities, potential patients of our facilities, or who are otherwise receiving our healthcare services. Other competitors may have lower expenses or other competitive advantages than us and, therefore, provide services at lower prices than we offer.

Our other services, such as senior living facilities and other ancillary services, also compete with local, regional, and national companies. The primary competitive factors in these businesses are similar to those for our skilled nursing facilities and include reputation, cost of services, quality of clinical services, responsiveness to patient/resident needs, location and the ability to provide support in other areas such as third-party reimbursement, information management and patient recordkeeping.

Our Standard Bearer segment competes for real property investments with healthcare providers, healthcare-related REITs, real estate partnerships, banks, private equity funds, venture capital funds and other investors. Some of these competitors are significantly larger and have greater financial resources and lower costs of capital than us. Our ability to compete successfully for real property investments will be determined by numerous factors, including our ability to identify suitable acquisition targets, our ability to negotiate acceptable terms for any such acquisition and our cost of capital in the event an acquisition requires debt or equity financing.
OUR COMPETITIVE STRENGTHS

 
We believe that we are well positioned to benefit from the ongoing changes within our industry. We believe that our ability to acquire, integrate and improve our facilities is a direct result of the following key competitive strengths:

 Experienced and Dedicated Employees  We believe that our independent subsidiaries' employees are among the best in their respective industries. We believe each of our independent subsidiaries is led by an experienced and caring leadership team, including dedicated front-line care staff, who participates daily in the clinical and operational improvement of their individual operations. We have been successful in attracting, training, incentivizing and retaining a core group of outstanding business and clinical leaders to spearhead our independent subsidiaries. These leaders operate as separate local businesses. With broad local control, these talented leaders and their care staffs are able to quickly meet the needs of their patients and residents, employees and local communities, without waiting for permission to act or being bound to a “one-size-fits-all” corporate strategy.

 Unique Incentive Programs  We believe that our employee compensation programs are unique within the industry. Employee stock options and performance bonuses, based on achieving target clinical quality, cultural, compliance and financial benchmarks, represent a significant component of total compensation for our operational leaders. We believe that these compensation programs assist us in encouraging our leaders and key employees to act with a shared ownership mentality. Furthermore, our leaders are motivated to help local operations within a defined “cluster” and "market," which is a group of geographically proximate operations that share clinical best practices, real-time financial data and other resources and information.

10

 Staff and Leadership Development We have a company-wide commitment to ongoing education, training and professional development. Accordingly, our operational leaders participate in regular training. Most participate in training sessions at Ensign University, our in-house educational system. Other training opportunities are generally offered via on-demand training tools, including podcasts. In addition, we offer weekly cultural and interactive educational topics including leadership development, our values, updates on Medicaid and Medicare billing requirements, updates on new regulations or legislation, infection control, emerging healthcare service alternatives and other relevant clinical, business and industry specific coursework. Additionally, we encourage and provide ongoing education classes for our clinical staff to maintain licensing and increase the breadth of their knowledge and expertise. We believe that our commitment to, and substantial investment in, ongoing education will further strengthen the quality of our operational leaders and staff, and the quality of the care they provide to our patients and residents.

 Innovative Service Center Approach  We do not maintain a corporate headquarters; rather, we operate a Service Center to support the efforts of each operation. Our Service Center is a dedicated service organization that acts as a resource and provides centralized information technology, human resources, accounting, payroll, legal, risk management, educational and other back office support services, so that local leaders can focus on delivering top-quality care and efficient business operations. Our Service Center approach allows individual operations to function with the strength, synergies and economies of scale found in larger organizations, but without what we believe are the disadvantages of a top-down management structure or corporate hierarchy. We believe our Service Center approach is unique within the industry, and allows us to preserve the “one-operation-at-a-time” focus and culture that has contributed to our success.

Proven Track Record of Successful Acquisitions  We have established a disciplined acquisition strategy that is focused on selectively acquiring operations within our target markets. Our acquisition strategy is driven by our operations team. Prospective leaders are included in the decision-making process and compensated as these acquired operations reach pre-established clinical quality and financial benchmarks, helping to ensure that we only undertake acquisitions that key leaders believe can become clinically sound and contribute to our financial performance.

As of December 31, 2023, we have expanded to 297 facilities with an aggregate of 30,602 operational skilled nursing beds and 3,121 senior living units, through both long-term leases and real estate purchases. We believe our experience in acquiring these operations and our demonstrated success in significantly improving their operations enables us to consider a broad range of acquisition targets. In addition, we believe we have developed expertise in transitioning newly acquired operations to our unique organizational culture and systems, which enables us to acquire operations with limited disruption to patients, residents and operating staff, while significantly improving quality of care. We have also constructed new facilities to target demand, which exists for high-end healthcare facilities when we determine that market conditions justify the cost of new construction in some of our markets.

Successful Real Estate Investment Strategy As part of our Standard Bearer segment, we maintain a real estate portfolio of long-term healthcare facilities diversified by geographic location and operated by a diverse group of established healthcare providers. We are focused on selectively acquiring real estate properties based on our industry experience and opportunistic strategy, which we believe provides us with greater investment and purchasing opportunities. Due to our credit strength, we have the ability to acquire large portfolios of real estate properties; a portion of which can be managed and operated by our independent subsidiaries and their established healthcare leaders and a portion of which can be leased to third parties.

As of December 31, 2023, our real estate portfolio consists of 113 owned facilities, which include properties leased to and operated by third parties and properties we managed and operated. We believe our real estate investment strategy has allowed us to accumulate a portfolio that aids our healthcare operators in improving performance and generating additional returns through leases with third parties.

 
Reputation for Quality Care  We believe that we have achieved a reputation for high-quality and cost-effective care and services to our patients and residents within the communities we serve. We believe that our achievement of quality outcomes enhances our reputation for quality, that when coupled with the integrated services that we offer, allows us to attract patients that require more intensive and medically complex care and generally result in higher reimbursement rates than lower acuity patients.


11

Community Focused Approach  We view our services primarily as a local, community-based business. Our local leadership-centered management culture enables each operation's nursing support staff and leaders to meet the unique needs of their patients and local communities. We believe that our commitment to this “one-operation-at-a-time” philosophy helps to ensure that each operation, its patients, their family members and the community will receive the individualized attention they need. By serving our patients, their families, the community and our fellow healthcare professionals, we strive to make each individual business the operation of choice in its local community.

 
We further believe that when choosing a healthcare provider, consumers usually choose a person or people they know and trust, rather than a corporation or business. Therefore, rather than pursuing a traditional organization-wide branding strategy, we actively seek to develop the operations brand at the local level, serving and marketing one-on-one to caregivers, our patients, their families, the community and our fellow healthcare professionals in the local market.

Investment in Information Technology  We utilize information technology that enables our operational leaders to access, and to share with their peers, both clinical and financial performance data in real time. Armed with relevant and current information, our operation leaders and their management teams are able to share best practices and the latest information, adjust to challenges and opportunities on a timely basis, improve quality of care, mitigate risk and improve both clinical outcomes and financial performance. We have also invested in specialized healthcare technology systems to assist our nursing and support staff. We have installed software and touch-screen interface systems in each operation to enable our clinical staff to more efficiently monitor and deliver patient care and record patient information. We believe these systems have improved the quality of our medical and billing records, while improving the productivity of our staff.
OUR GROWTH STRATEGY

We believe that the following strategies are primarily responsible for our growth to date, and will continue to drive the growth of our business:

 
Grow Talent Base and Develop Future Leaders  Our primary growth strategy is to expand our talent base and develop future leaders. A key component of our organizational culture is our belief that strong local leadership is a primary key to the success of each operation. While we believe that significant acquisition opportunities exist, we have generally followed a disciplined approach to growth that permits us to acquire an operation only when we believe, among other things, that we will have qualified leadership for that operation. To develop these leaders, we have a rigorous “CEO-in-Training Program” that attracts proven business leaders from various industries and backgrounds, and provides them the knowledge and hands-on training they need to successfully lead one of our independent subsidiaries. We generally have between 25 and 30 prospective administrators progressing through the various stages of this training program, which is generally much more rigorous, hands-on and intensive than the minimum 1,000 hours of training mandated by the licensing requirements of most states where we do business. Once administrators are licensed and assigned to an operation, they continue to learn and develop in our operational Chief Executive Officer Program (CEO Program), which facilitates the continued development of these talented business leaders into outstanding operational chief executive officers, through regular peer review, our Ensign University and on-the-job training.

 
In addition, our Chief Operating Officer Program (COO Program) recruits and trains highly qualified Directors of Nursing to lead the clinical programs in our operations. Working together with their operational CEO and/or administrator, other key operational leaders and front-line staff, these experienced nurses manage delivery of care and other clinical personnel and programs to optimize both clinical outcomes and employee and patient satisfaction.

 
Increase Mix of High Acuity Patients  Many skilled nursing facilities are serving an increasingly larger population of patients who require a high level of skilled nursing and rehabilitative care, whom we refer to as high acuity patients, as a result of government and other payors seeking lower-cost alternatives to traditional acute-care hospitals. We generally receive higher reimbursement rates for providing care for these medically complex patients. In addition, many of these patients require therapy and other rehabilitative services, which we are able to provide as part of our integrated service offerings. Where higher complex services are medically necessary and prescribed by a patient's physician or other appropriate healthcare professional, we generally receive additional revenue in connection with the provision of those services. By making these integrated services available to such patients, and maintaining established clinical standards in the delivery of those services, we are able to increase our overall revenues. We believe that we can continue to attract high acuity patients to our operations by maintaining and enhancing our reputation for quality care and continuing our community focused approach.
 


12

Focus on Organic Growth and Internal Operating Efficiencies  We plan to continue to grow organically by focusing on increasing patient occupancy within our existing operations. Although some of the facilities we have acquired were in good physical and operating condition, the majority have been clinically and financially troubled, with some facilities having had occupancy rates as low as 30% at the time of acquisition. Additionally, we believe that incremental operating margins on the last 20% of our beds/units are significantly higher than on the first 80%, offering opportunities to improve financial performance within our existing facilities. Our overall occupancy is impacted significantly by the number of facilities acquired and the operational occupancy on the acquisition date. Therefore, consolidated occupancy will vary significantly based on these factors. Our average occupancy rates for our skilled nursing facilities were 78.5% and 75.3% for the years ended December 31, 2023 and 2022, respectively. Our average occupancy rates in 2023 continue to rebound from pandemic levels and as we shift to an endemic, we anticipate the return of our seasonal occupancy and skilled mix. Throughout most of our history, our seasonality trends for skilled nursing occupancy and skilled mix typically included the greatest growth during the first and fourth quarters and softening in the second and third quarters.
We also believe we can generate organic growth by improving operating efficiencies and the quality of care at the patient level. By focusing on staff development, clinical systems and the efficient delivery of quality patient care, we believe we are able to deliver higher quality care at lower costs than many of our competitors.

Historically, we have achieved incremental occupancy and revenue growth by creating or expanding clinical service offerings in existing operations. For example, by expanding clinical programs to provide outpatient therapy services in many markets, we are able to increase revenue while spreading the fixed costs of maintaining these programs over a larger patient base. Outpatient therapy has also proven to be an effective marketing tool, raising the visibility of our facilities in their local communities and enhancing the reputation of our facilities with short-stay rehabilitation patients.

Add New Facilities and Expand Existing Facilities  One of our growth strategies includes the acquisition of new and existing facilities from third parties and the expansion and upgrade of current facilities. In the near term, we plan to take advantage of the fragmented skilled nursing industry by acquiring operations within select geographic markets and may consider the construction of new facilities. In addition, we have targeted facilities that we believed were performing and operations that were underperforming, where we believed we could improve service delivery, occupancy rates and cash flow. With experienced leaders in place at the community level and demonstrated success in significantly improving operating conditions at acquired facilities, we believe that we are well positioned for continued growth. While the integration of underperforming facilities generally has a negative short-term effect on overall operating margins, these facilities are typically accretive to earnings within 12 to 18 months following their acquisition. For the facilities that we acquired from 2002 through 2023, the aggregate EBITDAR as a percentage of revenue improved from 15.9% during the first full three months of operations to 17.6% during the thirteenth through fifteenth months of operation and to 18.9% during the 45th quarter of operation.
Standard Bearer Portfolio Growth An important part of our business strategy is to continue to expand and diversify our real estate portfolio through accretive acquisition and investment opportunities in healthcare properties. Our execution of this strategy hinges on our ability to successfully identify, secure and consummate beneficial transactions. We have a proven track record of acquiring properties that we have determined are investment opportunities and develop these into thriving properties that are well-suited for operational purposes. We then use these properties for our skilled nursing or senior living operations, or we lease the properties to other long-term care facility operators. We expect that our REIT structure will allow us to expand our real estate footprint while bringing the best operational practices to our own and other operators in the industry.
HUMAN CAPITAL

At December 31, 2023, we had approximately 35,300 full-time equivalent employees who were employed by our Service Center and our independent subsidiaries. For the year ended December 31, 2023, approximately 60.0% of our total expenses were payroll related. Periodically, market forces, which vary by region, require that we increase wages in excess of general inflation or in excess of increases in reimbursement rates we receive. We believe that we staff appropriately, focusing primarily on the acuity level and day-to-day needs of our patients and residents. In most of the states where we operate, our skilled nursing facilities are subject to state mandated minimum staffing ratios, so our ability to reduce costs by decreasing staff, notwithstanding decreases in acuity or need, is limited and subject to government audits and penalties in some states. We seek to manage our labor costs by improving staff retention, improving operating efficiencies, maintaining competitive wage rates and benefits and reducing reliance on overtime compensation and temporary nursing agency services. The Service Center's Chief Human Capital Officer, together with its Diversity, Equity and Inclusion (DEI) and Environmental, Social and Governance (ESG) Committees, oversee the following human capital initiatives:

13

Our Culture The operation of our skilled nursing and senior living facilities requires a large number of highly skilled healthcare professionals and support staff. Our employees are at the heart of our Company and we are committed to their health, professional development and workplace satisfaction. Our core values, which focuses on developing our employees, fostering an ownership mentality and allowing for intelligent risk taking, guide us in our decision making and inspire us to be better people, both professionally and personally.

 
Compensation and Benefits The healthcare industry as a whole has been experiencing shortages of qualified professional clinical staff. We believe that our ability to attract and retain qualified professional clinical staff stems from our ability to offer attractive wage and benefits packages, a high level of employee training, an empowered culture that provides incentives for individual efforts and a quality work environment.

Diversity and Inclusion We value diversity in our recruiting, hiring and career development practices. Our commitment is to provide equal opportunity and fair treatment to all individuals based on merit and without discrimination. In 2022, we formed our DEI Committee, a multidisciplinary group led by our Chief Executive Officer, to advance our DEI initiatives throughout the organization.

Training and Development We provide training and development to all employees. We have many training programs at all levels such as our CEO in Training, Director of Nursing in Training, Director of Rehab in Training, nursing certified assistant schools, weekly culture trainings, boot camps and annual meetings, where we focus on both career and professional development.

Social Sustainability We continuously work towards bridging the gap between what the healthcare system currently provides and the basic needs of individuals. We aim to have an enduring impact on the communities in which we live and work. Elevate Charities is a non-profit organization that is dedicated to elevating the condition and quality of life for members of the senior healthcare community - employees, caregivers, family members, patients and residents. Elevate Charities has three unique funds: Heritage Fund, Heritage Scholarship Fund and the Emergency Fund.

The Heritage Fund and the Heritage Scholarship Fund engage in a mission to enhance the quality of life for seniors in our communities through caring service, fulfilling essential needs and providing education to caregivers. The Heritage Fund helps the caregiver identify specific and practical ways to meet the needs of those under their care. This can help provide a better life, improved experience and greater satisfaction for our aging population. The financial support provided by the Heritage Fund benefits seniors directly. In addition, the Heritage Scholarship Fund helps qualified clinical professionals who may not be able to afford to advance in the field of long-term care. Through grants and scholarships, the fund helps these qualified professionals gain the education needed to advance in the field of senior-focused healthcare. Since 2019, we awarded 191 scholarships to employees in our workforce.

Lastly, the Emergency Fund is a way of passing the hat to help our co-workers whose lives are affected by tragedy. This program is funded for our team members by our team members. All team members can contribute to the fund either through a one-time donation or by recurring payroll deduction. In 2023, approximately 86% of those employed by our independent subsidiaries contributed to the Emergency Fund. In 2023, we distributed approximately $3.2 million in grants to members of our independent subsidiaries. To date, the Emergency Fund has distributed over 14,600 grants totaling almost $15.7 million to members of our independent subsidiaries in their time of need.

For additional information on human capital matters, please see our most recent proxy statement or ESG report, each of which is available on our website at www.ensigngroup.net. For additional information on Elevate Charities, please visit www.elevatecharities.org. The information contained in, or that can be accessed through, either of the foregoing websites does not constitute a part of this Annual Report on Form 10-K.

GOVERNMENT REGULATION
General
Healthcare is an area of extensive and frequent regulatory change. Changes in the law or new interpretations of existing laws may have a significant impact on our revenue, costs and business operations. Our independent subsidiaries that provide healthcare services are subject to federal, state and local laws relating to, among other things, licensure, quality and adequacy of care, physical plant requirements, life safety, personnel and operating policies. In addition, these same subsidiaries are subject to federal and state laws that govern billing and reimbursement, relationships with vendors, business relationships with physicians and workplace protection for healthcare staff. Such laws include (but are not limited to) the Anti-Kickback Statute (AKS), the federal False Claims Act (FCA), the Stark Law and state corporate practice of medicine statutes.
14

Governmental and other authorities periodically inspect our independent subsidiaries to verify continued compliance with applicable regulations and standards. The operations must pass these inspections to remain licensed under state laws and to comply with Medicare and Medicaid provider agreements and applicable Conditions of Participation. The operations can only participate in these third-party payment programs if inspections by regulatory authorities reveal that the operations are in substantial compliance with applicable state and federal requirements. In the ordinary course of business, federal or state regulatory authorities may issue notices to the operations alleging deficiencies in certain regulatory practices, which may require corrective action to regain and maintain compliance. In some cases, federal or state regulators may impose other remedies including imposition of civil monetary penalties, temporary admission and/or payment bans, loss of certification as a provider in the Medicare or Medicaid program, or revocation of a state operating license.
We believe that the regulatory environment surrounding the healthcare industry subjects providers to intense scrutiny. In the ordinary course of business, providers are subject to inquiries, investigations and audits by federal and state agencies related to compliance with participation and payment rules under government payment programs. These inquiries may originate from HHS, Office of the Inspector General (OIG), state Medicaid agencies, state Attorney Generals, local and state ombudsman offices and CMS Recovery Audit Contractors, among other agencies. In response to the inquiries, investigations and audits, federal and state agencies continue to impose citations for regulatory deficiencies and other regulatory penalties, including demands for refund of overpayments, expanded civil monetary penalties that extend over long periods of time and date back to incidents prior to surveyor visits, Medicare and Medicaid payment bans and terminations from those programs, which may be temporary or permanent in nature. We vigorously contest each such regulatory outcome when appropriate; however, there are significant legal and other expenses involved that consume our financial and personnel resources. Expansion of enforcement activity could adversely affect our business, financial condition or the results of operations.
Proposed, Anticipated and Recently Issued Rulemaking and Administrative Actions
The federal government, through CMS rulemaking, Presidential executive actions or Congressional legislation, and state and local governments have recently released the following proposed rulemaking or administrative actions that may have an impact on our independent Skilled Nursing Facilities (SNFs) or assisted living facilities:
Biden-Harris Administration's Nursing Home Care Priorities The Biden-Harris Administration is seeking reform around reimbursement, staffing levels, standards of care, increased transparency and public disclosure of ownership, and enhanced civil remedies as a means of enforcement against those facilities that do not satisfy CMS’s standards. Proposed rules based on these directives have already been published in 2023, including those highlighted below and observers expect additional rules to be issued this year and in the future. Final rules will follow publication of these proposed rules after a notice-and-comment period required by law.
Ownership Transparency Final Rule On November 15, 2023, CMS published its final rule requiring SNFs to publicly disclose certain additional information regarding their ownership and managerial relationships. The final rule requires disclosures to include the identity of any person or legal entity that: (1) exercises financial, operational, or managerial control over any facility or part of a facility, or provides services to a facility that include its policies and procedures or cash management services; (2) leases or subleases real property to the facility, or owns 5% or more of the real property’s total value; and (3) provides any management or administrative services (or consults regarding the same), or provides accounting or financial services to the SNF. The rule also expands ownership and control interest disclosures to include information about each member of the facilities governing body, individuals or entities serving as officers, directors, members, partners or managing employees, and a comprehensive breakdown of the organizational structure of any additional disclosable party that is not a natural person along with a description of their relationships with the facility.

Certain states have adopted laws reflecting their concerns regarding ownership transparency. For example, in July 2023, Iowa adopted laws requiring disclosure of ownership information not previously required for licensure to promote transparency. Additionally, in July 2023, the California Department of Health Care Access and Information of the California Health and Human Services Agency issued a notice of proposed rulemaking containing regulations that would implement financial and ownership transparency requirements for California-licensed SNFs that are required by California law passed in 2021.

15

Federal Legislation — On March 9, 2023, the Home and Community-Based Services (HCBS) Access Act was introduced to expand access to and resources available for HCBS. This bill provides Medicaid funding to individuals who provide direct home- and community-based care to adults over the age of 60 or people who have disabilities. This bill also provides financial resources for the training of these direct care providers, who are intended to provide services to the elderly or disabled that range from advocacy and community integration to transportation and daily assistance tasks ranging from bathing and laundry to meal preparation and housekeeping. As of the date of filing, no further action has been taken on the HCBS Access Act since its introduction and referral to the House of Representatives committees.
On October 24, 2023, the HCBS Relief Act was introduced to provide additional funds to states to stabilize their HCBS service delivery networks, recruit and retain HCBS direct care workers, and meet long-term service and support needs of people eligible for Medicaid home and community-based services. Under the HCBS Relief act, states would receive a temporary 10% increase in the applicable Federal Medical Assistance Percentage (FMAP) under Medicaid for certain approved home and community-based services that are provided during FY 2024 through FY 2025.To qualify for the enhanced rate, a state much commit to initiatives aimed at improving the provision of services. This includes offering additional advantages to home health aides and assisting individuals in transition from nursing facilities back to their homes. As of the date of this filing, no action has been taken on the HCBS Relief Act since its introduction and referral to the Senate Committee on Finance.
State Legislation — Many states in which our independent subsidiaries operate have introduced or passed legislation that would create or change laws and regulations related to our business and industry.
In the past, California had discussed issuing proposed regulations on direct care spending requirements that may have affected our business and SNFs operating within that state. These proposals have included requirements for healthcare facilities certified by CMS, including SNFs, to report all annual revenues to the State of California by June 30 of each year and certify that a stated percentage of all non-Medicare revenues should be used for direct patient-related services, including staffing and operational costs.
On October 13, 2023, the California Governor signed into law a bill that impacts the minimum wages of healthcare workers. Effective June 1, 2024, the law raises the minimum wage for California healthcare employees and sets a new wage threshold for those who are considered exempt healthcare employees. The bill only becomes effective for SNFs if a patient care minimum spending requirement bill is also passed. We anticipate that a minimum spending bill will be proposed in the near future.
Final Rule Fiscal Year 2024 Skilled Nursing Facility Prospective Payment System (SNF PPS) On July 31, 2023, CMS published its final rule updating the Medicare payment rates within the SNF PPS for FY 2024 (SNF PPS FY 2024 Final Rule). The SNF PPS FY 2024 Final Rule modifies the SNF Quality Reporting Program (QRP) and the SNF Value-Based Purchasing (VBP) Program. The SNF PPS FY 2024 Final Rule finalized the rates to be paid in the 2024 fiscal year.
The SNF PPS FY 2024 Final Rule increases the Medicare payment rate aggregate net market basket by 4.0%. The increase includes a 6.4% net market basket update to the payment rates of 3.0%, plus a 3.6% market basket forecast error adjustment, less a 0.2% productivity adjustment, as well as a negative 2.3% in the FY 2024 SNF PPS rates due to the second phase of the Patient Driven Payment Model (PDPM) parity adjustment recalibration. The net effect of these changes is expected to be an overall 4.0% increase in payments to SNFs in FY 2024. This final rule also updates the SNF QRP for FY 2024 and future years, including the adoption of two new quality reporting measures, modification of one measure and removal of three measures resulting in public reporting of four QRP measures. Additionally, the SNF PPS FY 2024 Final Rule makes changes to the SNF VBP Program. Specifically, this final rule adopts four new measures: the nursing staff turnover measure, the discharge function score measure, the long stay hospitalization measure per 1,000 resident days and the percent of residents experiencing one or more falls with a major injury (long stay); the existing SNF 30-day all-cause readmission measure (SNFRM) is replaced with the SNF within stay potentially preventable readmissions (SNF WS PPR) measure beginning in FY 2028.
SNF PPS FY 2024 Final Rule adopted the Nursing Staff Turnover (NST) measure for the SNF VBP program beginning with the FY 2026 program year. This is a structural measure that has been collected and publicly reported on Care Compare, and the measure assesses the stability of the staffing within a SNF using nursing staff turnover. The NST measure uses facility-reported, electronic data from CMS’ Payroll-Based Journal (PBJ) system to calculate annual turnover rates for nursing staff, including RNs, LPNs, and nurse assistants. Facilities would begin reporting this measure in FY 2024, with payment effects beginning in FY 2026.


16

The NST measure looks at six consecutive quarters of data. It starts with a baseline quarter and the first two quarters of the performance period to identify eligible employees. Then, it uses the next four quarters to find the number of employment cycles that ended in turnover. Finally, the data from the sixth quarter is validated to identify gaps in days worked that began in the last 60 days of the fifth quarter used for the measure. The measure score is then calculated by comparing the total number of eligible employees with 60-day gaps in working during the specified periods.
Proposed CMS Minimum Staffing Mandate On September 1, 2023, CMS issued its proposed rule that would establish minimum staffing standards for long-term care facilities. This proposed rule contains three primary staffing proposals: 1) minimum staffing standards of 0.55 hours per resident per day (HPRD) for registered nurses (RNs) and 2.45 HPRD for certified nurse aids (CNAs); 2) a requirement to have a RN on-site 24 hours per day, seven days per week; and 3) requirements for enhanced facility assessments. The proposed rule features a staggered implementation of these requirements, including a possible hardship exemption for select facilities. As this is a proposed rule, CMS has requested and received stakeholder feedback on all components of this regulation so that these comments may be considered prior to CMS's publication of a final rule. Additionally, the proposed rule would increase the reporting and transparency of Medicaid payments made to a facility for its direct care, including state-level reporting requirements and provisions for states and CMS to make information about payments made to long-term care facilities public.

Facility self-assessments would also be enhanced under this proposed rule. CMS proposes that the facility self-assessment be updated regarding staffing to contain or clarify: 1) that facilities must use evidence-based methods when planning for resident care, including accommodation of behavioral health needs; 2) requiring facilities to use the self-assessment to assess the specific needs of each resident, with adjustments made for changes in the resident population; 3) requiring that facilities include the input of staff, including leadership, management, nurse staff and other direct care providers who render other services to residents; 4) requiring that the staffing plan maximize recruitment and retention of staff in a manner consistent with the President’s April 2023 Executive Order on increasing access to high-quality care and supporting caregivers.

A hardship exemption for CMS’s proposed minimum staffing standards is also set forth in the proposed rule. Long-term care facilities could qualify for a temporary hardship exemption from new minimum staffing ratios upon meeting specific criteria that demonstrate: 1) workforce unavailability based on an absence of providers relative to individuals in the age group of recipients within a specific geographic location; 2) a facility’s good faith efforts to hire and retain staff through a recruitment and retention plan; and 3) a financial commitment to staffing by documenting the total annual amount spent on direct care staff. A survey would be required to assess the residents’ health and safety before CMS would consider granting such a hardship exemption. Any facility that received a hardship exemption from the minimum staffing requirement would have this exemption noted on the Care Compare website rating skilled nursing facilities. Further, facilities would not be eligible to receive an exemption if they: 1) failed to submit their data to the payroll-based journal system; 2) have been identified as a special focus facility; or 3) have been identified at any time within the preceding 12 months as having insufficient staffing that was either widespread or a pattern, with resulting actual harm to residents, or receiving an immediate jeopardy citation regarding insufficient staffing. Even after receiving an exemption, a facility would still be required to maintain sufficient staff around-the-clock to provide care and monitor resident health.

If finalized, this proposed rule would have a staggered and phased implementation over a period of three years, with the phases differentiated between rural and non-rural facilities. For facilities in urban areas, the final rule’s facility assessment requirements would become effective within 60 days of the final rule’s publication, with the proposed rule’s round-the-clock on-site RN requirement becoming effective two years after the final rule’s publication; and the above-referenced minimum staffing of 0.55 HPRD for RNs and 2.45 HPRD for NAs would take effect three years after the final rule’s publication. For rural facilities, the final rule’s facility assessment requirements would still become effective within 60 days of the final rule’s publication but the proposed rule’s round-the-clock on-site RN requirement would become effective three years after the final rule’s publication, and the above-referenced minimum staffing of 0.55 HPRD for RNs and 2.45 HPRD for NAs would take effect five years after the final rule’s publication.

This minimum staffing proposed rule also seeks further information from stakeholders regarding alternative policies for establishing minimum nurse staffing standards. In particular, CMS seeks comment on an alternative total nurse staffing standard of 3.48 HPRD (among other alternatives), which would include minimum individual standards of 0.55 HPRD for RNs and 2.45 HPRD for NAs, in addition to other nurse staffing as needed to attain a total of 3.48 HPRD across all nurse types. CMS also seeks stakeholder comments regarding the benefits and trade-offs of using different standards, evidence, or methodologies used by states that have adopted minimum nursing standards to inform its own standard-setting.


17

Since the minimum staffing rule was proposed, there have been two bills (one in the House and a companion bill in the Senate), that were introduced that would block the rule from taking effect. The Senate bill has garnered broad bi-partisan support and is endorsed by over 90 organizations. These bills reason that the proposed minimum staffing standard would endanger rural nursing facilities, subjecting them to potential fines and closures for failure to comply and might require them to discharge residents or limit the number of residents they accept in an effort to meeting the requirements of the bill. It is uncertain which if any of these bills will pass and we will ultimately need to comply with the any final rules congress enacts.
Coronavirus

In March of 2020, in an effort to promote efficient care delivery and to decrease the spread of COVID-19, federal, state and local regulators implemented new regulations and waived, (in some cases temporarily), certain existing regulations, including those discussed below. These new regulations and waivers of the other regulations expired on May 11, 2023.
Temporary suspension of certain patient coverage criteria and documentation and care requirements CMS issued a series of temporary waivers, rules, and guidance, suspending various Medicare patient coverage criteria as it related to the COVID-19 pandemic to ensure patients continued to have adequate access to care, notwithstanding the burdens placed on healthcare providers HHS also waived requirements specific to SNFs. During this time, CMS also suspended and reduced the priority of standard audit activities in order to focus on patient care. While all of these waivers expired with the termination of the PHE on May 11, 2023, others were terminated at various points in 2021 and 2022 during the PHE. Certain rules, such as requirements for COVID-19 reporting, testing, and vaccination remained in place through the end of the PHE.
Testing requirements Beginning in April 2020, authorities in several states in which our independent subsidiaries are located began to mandate widespread COVID-19 testing at all SNFs and assisted living facilities based on guidance from the Centers for Disease Control and Prevention (CDC). During the PHE, CMS issued revised parameters for testing, requiring routine testing of only unvaccinated staff and then further revised its guidance in September of 2022 to specify only symptomatic individuals and their close contacts, (including staff and residents), should be tested for COVID-19. On June 5, 2023, CMS published a final rule containing changes to COVID-19 vaccination, reporting, testing, and other requirements (Omnibus Final Rule), which took effect August 4th, 2023, and ended the COVID-19 testing and reporting requirements for SNFs and assisted living facilities imposed during the PHE. All of the federal, state and local government vaccines mandates have been rescinded since the end of the PHE.
Changes to Medicaid Reimbursement In March of 2020, the Families First Coronavirus Relief Act (FFCRA) provided a 6.2% increase to the Federal Medicaid Assistance Percentage (FMAP) during the PHE. The FFCRA also imposed conditions restricting the disenrollment and standards for re-enrolling Medicaid beneficiaries to promote continuous care of beneficiaries during the PHE. The Consolidated Appropriations Act of 2023 (CAA 2023) amended these Medicaid enrollment protections and increased FMAP funding provided in the FFCRA. In the first quarter of 2023, the FMAP increase CMS provides to the states remained elevated by 6.2%, but this amount decreased to 5% for April through June 2023, 2.5% for July through September 2023, and 1.5% for October through December 2023 before tapering to 0% by the end of 2023. The ultimate amount of Medicaid funding provided from each state varied substantially based on each state's policies.
Under the CAA 2023, states were allowed to begin disenrolling Medicaid beneficiaries and resuming Medicaid eligibility determinations beginning on April 1, 2023 upon satisfying conditions that include reviewing Medicaid beneficiaries' eligibility and have begun doing so. On August 30, 2023, CMS advised all 50 states in a letter to their respective Medicaid administrators to observe federal Medicaid regulations in making these redeterminations, including requirements to make eligibility determinations on an individual basis rather than a per-household basis. CMS has worked with 12 states regarding their respective redetermination and disenrollment processes, and previously paused policy in six states. As a result of this activity, the redetermination and disenrollment period that began on April 1, 2023 has not proceeded as rapidly as some may have expected.
Medicare
Medicare presently accounts for approximately 27.5% of our skilled nursing services revenue year-to-date, being our second-largest payor. The Medicare program and its reimbursement rates and rules are subject to frequent change. These include statutory and regulatory changes, rate adjustments, administrative or executive orders and government funding restrictions, all of which may materially adversely affect the rates at which Medicare reimburses us for our services. Budget pressures often lead the federal government to reduce or place limits on reimbursement rates under Medicare. Implementation of these and other types of measures has in the past, and could in the future, result in substantial reductions in our revenue and operating margins.

18

Patient-Driven Payment Model (PDPM)
The SNF PPS Rule became effective October 1, 2019. The SNF PPS Rule included a new case mix model that focuses on the patient’s condition (clinically relevant factors) and resulting care needs, rather than on the volume of care provided, to determine Medicare reimbursement. The case mix model is called the PDPM, which utilizes clinically relevant factors for determining Medicare payment by using diagnosis codes and other patient characteristics as the basis for patient classification. PDPM utilizes five case-mix adjusted payment components: physician therapy, occupational therapy, speech language pathology, nursing and social services and non-therapy ancillary services. It also uses a sixth non-case mix component to cover utilization of SNFs' resources that do not vary depending on resident characteristics. PDPM replaces the existing methodology and is intended to achieve a more value-based, unified post-acute care payment system. For example, PDPM adjusts Medicare payments based on each aspect of a resident’s care. Under the SNF PPS PDPM system, the payment to SNFs and nursing homes is based heavily on the patient’s condition rather than the specific services provided by each SNF.
Skilled Nursing Facility - Quality Reporting Program (SNF QRP)
The Improving Medicare Post-Acute Care Transformation Act of 2014 (IMPACT Act) provided data reporting requirements for certain Post-Acute-Care (PAC) providers. If a SNF does not submit required quality data as required by the IMPACT Act, its payment rates are reduced by 2.0% for each such fiscal year, which may result in payment rates for a fiscal year being less than the preceding fiscal year.
The SNF QRP standardized patient assessment data elements. The SNF QRP applies to freestanding SNFs, SNFs affiliated with acute care facilities and all non-critical access hospital swing-bed rural hospitals. These data elements are the subject of frequent change and adjustment. CMS's rulemaking often identifies new data elements to be reported.
In July of 2022, CMS announced revisions to calculating its five-star ratings for the Nursing Home Compare website. Under this new calculation, points are assigned to a SNF based on its performance across six measures: (1) case-mix adjusted total nurse staffing levels (including registered nurses, licensed practical nurses, and nursing aides), measured by hours per resident per day; (2) case-mix adjusted registered nurse staffing levels, measured by hours per resident per day; (3) case-mix adjusted total nurse staffing levels (including registered nurses, licensed practical nurses, and nursing aides), measured by hours per resident day on the weekend; (4) total nurse turnover, defined as the percentage of nursing staff that left the nursing home over a 12-month period; (5) registered nurse turnover, defined as the percentage of registered nursing staff that left the nursing home over a 12-month period; and (6) administrator turnover, defined as the percentage of administrators that left the nursing home over a 12-month period. These six measures will be measured on a quarterly basis.
These six new measures were included in the five-star rating in October 2022. In addition, CMS also implemented a planned increase to the quality measure reporting thresholds, increasing each threshold by one-half of the average improvement of quality measure scores since CMS last set quality measure thresholds. Going forward, CMS plans to implement similar rating threshold increases every six months.
On July 29, 2022, CMS announced the adoption of a process measure for influenza vaccination coverage among healthcare personnel within SNFs. This measure will be determined by the percentage of SNF healthcare personnel who receive an influenza vaccine any time from when it first becomes available through March 31 of the following year. SNFs began submitting this data on October 1, 2022.
On July 31, 2023, CMS published the SNF PPS FY 2024 Final Rule, which included changes to the SNF QRP, including adopting, removing and modifying specific measures. The final rule also includes policy changes and the public reporting of four measures. The final rule adopts the Discharge Function Score (DC Function) measure, which determines the functional condition of residents by examining the proportion of SNF residents who achieve or surpass a projected discharge functionality score. The assessment includes consideration of mobility and self-care, utilizing data from the Minimum Data Set (MDS). The DC Function will replace the current process and is scheduled to go into effect for the FY 2025 SNF QRP.
CMS will adopt two measures for the SNF QRP starting in FY 2026. First, CMS will raise the Data Completion Thresholds for the MDS. SNFs must report required quality measure data and standardized resident assessment data gathered using the MDS for at least 90% of the assessments they submit to CMS. SNFs who fail to meet this requirement will be subject to a 2% reduction on their applicable fiscal year payment starting in FY 2026. Second, CMS will adopt the Patient/Resident COVID-19 Vaccine metric. This metric highlights the number of patient stays in which SNF patients received the COVID-19 vaccine.

19

The SNF PPS FY 2024 Final Rule also modifies the SNF QRP’s Healthcare Professional (HCP) Covid Vaccine Measure. The measure will track the proportion of healthcare staff vaccinated for COVID-19 and have kept their vaccination status current per the CDC recommendations. Previously, SNFs were only obligated to disclose whether their healthcare workers had completed the initial vaccination series for COVID-19. Now, there is an added requirement to report the total count of healthcare employees who have maintained their COVID-19 vaccination status in line with CDC recommendations.
The SNF PPS FY 2024 Final Rule also removed the Application of Functional Assessment/Care Plan measures from the SNF QRP. CMS stated the decision stemmed from two primary reasons: first, the consistently high-performance levels among SNFs make it challenging for CMS to identify significant advancements; and second, the DC Function measure aligns more closely with the preferred functional outcomes for residents.
Medicare Annual Payment Rule
CMS is required to calculate an annual Medicare market-basket update to the payment rates. On July 31, 2023, CMS issued the SNF PPS FY 2024 Final Rule, which will result in a net increase of 4.0% in Medicare payments to SNFs in fiscal year 2024. This increase results from the 6.4% net market basket update to the payment rates, which is based on a 3.0% SNF market basket increase plus a 3.6% market basket forecast error adjustment, less a 0.2% productivity adjustment and a negative 2.3% adjustment as a result of the recalibrated parity adjustment.
On July 29, 2022, CMS issued a final rule for fiscal year 2023 that increased the Medicare payment rates to aggregate net market basket by 2.7%. The increase results from the 5.1% update to the market basket, which is based on a 3.9% current year market basket increase plus a 1.5% market basket error adjustment, less a 0.3% productivity adjustment and a negative 2.3% adjustment as a result of the recalibrated parity adjustment. The recalibrated parity adjustment is being phased in at a rate of 2.3% per year on both the SNF PPS FY 2024 and FY 2023 Final Rules.
Sequestration of Medicare Rates
The Budget Control Act of 2011 requires a mandatory, across the board reduction in federal spending, called a sequestration. Medicare FFS claims with dates of service or dates of discharge on or after April 1, 2013 incur a 2.0% reduction in Medicare payments through at least 2023, unless Congress takes further action. Under the CARES Act, there was a temporary suspension of the 2.0% reduction of Medicare claim reimbursements as a result of the COVID-19 pandemic which lasted until June 2022. Under the CAA 2023, a further 4% cut to Medicare spending that would have been required under the Statutory Pay-As-You-Go Act of 2010 (PAYGO) was waived for fiscal years 2023 and 2024. Instead, the CAA 2023 deferred any further Medicare sequestration under PAYGO until fiscal year 2025. The CAA 2023 also offset planned Medicare sequestrations that would have been as high as 4.0% and instead maintained fee schedule cuts of approximately 2%.
Skilled Nursing Facility Value-Based Purchasing (SNF-VBP) Program

The SNF-VBP Program rewards SNFs with incentive payments based on the quality of care they provide to Medicare beneficiaries, as measured by a hospital readmissions measure. CMS annually adjusts its payment rules for SNFs using the SNF-VBP Program. The program also introduced quality measures to assess how health information is shared and adopted a number of standardized patient assessment data elements that assess factors such as cognitive function and mental status, special services and social determinants of health. CMS uses regulations to specify how it measures the performance for SNFs as well as the data that SNFs are to report to CMS. The deadlines for baseline period quality measure quarterly reporting and performance periods and standards began in the 2023 program year. The final rule for the fiscal year 2023 SNF PPS also provided for SNF-VBP program expansion beyond the use of its single, all-cause hospital readmission measure to determine payment, with the inclusion of measures in fiscal year 2026 for SNF healthcare associated infections requiring hospitalization (SNF HAI) and total nursing hours per resident day measures and in fiscal year 2027, the discharge to community post-acute care measure for SNFs, which assess the rate of successful discharges to the community from a SNF setting.


20

The SNF PPS FY 2024 Final Rule elected to replace the SNFRM measure with the SNF within-stay (WS) potentially preventable readmission (PPR) measure beginning in the FY 2028 program year. The PPR measure assesses the risk-standardized rate of unplanned and potentially avoidable readmissions during SNF stays for Medicare fee-for-service beneficiaries. The new SNF WS PPR measure refines the original Skilled Nursing Facility 30-Day Potentially Preventable Readmission (SNFPPR) measure, which followed the requirements of the Protecting Access to Medicare Act (PAMA) of 2014. The refinement in the SNF WS PPR measure shifts the observation window from a fixed 30-day post-hospital discharge to the duration of the SNF stay. Moreover, the time gap allowed between the prior inpatient discharge and the SNF admission has been extended from one day to 30 days. These changes, based on feedback from expert panels and a 2015 partnership, better align the measure with the IMPACT Act's provisions and enhance the reliability of tracking preventable readmissions. Additionally, the SNF WS PPR measure's calculations use two years of Medicare claims data to generate a provider-specific risk-standardized readmission rate.
Part B Rehabilitation Requirements

Some of our revenue is paid by the Medicare Part B program under a fee schedule. Part B services are limited with a payment cap by combined speech-language pathology services (SLP), physical therapy (PT) services and a separate annual cap for occupational therapy (OT) services. The Bipartisan Budget Act of 2018 (BBA) establishes coding modifier requirements to obtain payments beyond certain payment thresholds, discussed below and reaffirms the specific $3,000 claim audit threshold requirements for Medicare Administrative Contractors. For PT and SLP combined the threshold for coding modifier requirements was $2,230 for CY 2023 with the same threshold for OT services. The KX modifier is added to medical claims to indicate the providing clinician attests that the services corresponding to that claim were medically necessary and that the justification for those services is contained within the patient’s medical records. This modifier is intended for use where the services will exceed the threshold for those services set by the BBA and updated by annual fee schedule rules, yet are still appropriate and medically necessary, and thus should be compensated by Medicare.
Consistent with CMS’s “Patients over Paperwork” initiative, the agency has also been moving toward eliminating burdensome claims-based functional reporting requirements. Beginning in 2021, CMS rescinded 21 problematic National Correct Coding Initiative edits impacting outpatient therapy services, including services furnished under Medicare Part B primarily related to PT and OT services, removing a coding burden caused by requirements for additional documentation and claim modifier coding.
Additionally, the Multiple Procedure Payment Reduction (MPPR) continues at a 50% reduction, which is applied to therapy procedures by reducing payments for practice expense of the second and subsequent procedures when services provided beyond one unit of one procedure are provided on the same day. The implementation of MPPR includes (1) facilities that provide Medicare Part B speech-language pathology, occupational therapy and physical therapy services and bill under the same provider number; and (2) providers in private practice, including speech-language pathologists, who perform and bill for multiple services in a single day.
Through the end of coverage year 2024, certain of our Part B services provided through telehealth will still qualify for Medicare reimbursement based on flexibility first provided under the Emergency Waivers, which added physical therapy, occupational therapy and speech-language pathology to the list of approved telehealth Providers for the Medicare Part B programs provided by a SNF. During the PHE, CMS added certain PT and OT services to the list of Medicare-covered telehealth services on a temporary basis, some of which were made permanent for use and new codes were added for PT, OT, or SLP telehealth services—including some “sometimes therapy” codes that were not subject to MPPR. The CAA 2023 extended certain, but not all, telehealth flexibilities until December 31, 2024, allowing certain telehealth flexibilities to continue after the PHE's expiration.
On November 2, 2023, CMS published the CY 2024 Physician Fee Schedule (CY 2024 PFS Final Rule), which changes Medicare payments under the Physician Fee Schedule (PFS) and other Medicare Part B components. The CY 2024 PFS Final Rule contains a conversion factor of $32.74, which is a decrease of $1.15 from the calendar year 2023 PFS conversion factor of $33.89. This CY 2024 conversion factor is 3.4% lower than the CY 2023 conversion factor. Under the CY 2024 PFS Final Rule, overall payment rates for Medicare Part B services are to be reduced by 1.25% compared to calendar year 2023.


21

The CY 2024 PFS Final Rule contains provisions to make payments when physicians and certain non-physician practitioners, such as physician assistants, nurse practitioners, physical therapists, occupational therapists and clinical psychologists, involve caregivers in implementing an individualized plan of treatment or therapy. These provisions incentivize the training of caregivers and provide additional funds to offset the costs of training these caregivers through participation in licensed healthcare providers’ course of care for patients and residents. For PT and SLP combined, the threshold for coding modifier requirements increases to $2,330 for CY 2024 with the same threshold for OT services. The KX modifier is added to medical claims to indicate the providing clinician attests that the services corresponding to that claim were medically necessary and that the justification for those services is contained within the patient’s medical records. A new Caregiver Education Code has been made available to therapists providing face-to-face education to patient caregivers.

The CY 2024 PFS Final Rule will allow for general supervision of therapy assistants by PTs and OTs for remote therapeutic monitoring (RTM) services. This change may affect the rate of reimbursement for PT and OT services in the future and may affect the desirability and utilization of physical therapy assistants and occupational therapy assistants for certain patient services. Additionally, the CY 2024 PFS Final rule adds certain health and well-being coaching services that Medicare will reimburse on a temporary basis for CY 2024. The final rule also adds risk assessments for social determinants of health to the list of telehealth services Medicare will reimburse on a permanent basis.
Programs of All-Inclusive Care for the Elderly
The requirements under the Programs of All-Inclusive Care for the Elderly (PACE) provide greater operational flexibility and update information under the Medicare and Medicaid programs, including leniency in compliance with program requirements during and after a 3-year trial period and relieving restrictions placed on the team that assesses and provides for the needs of each PACE participant. Further, non-physician primary care providers can provide certain services in place of primary care physicians. On February 1, 2023, CMS issued its final rule, which takes effect on April 3, 2023, requiring the collection of data by Medicare Advantage organizations and their service providers and the submission of data to CMS for risk adjustment data validation (RADV) audits. The purpose of these RADV audits is to maintain the accuracy of risk-adjusted payments made to Medicare Advantage organizations.
Decisions Regarding Skilled Nursing Facility Payment
Reimbursement rates and rules are subject to frequent change that historically, have had a significant effect on our revenue. The federal government and state governments continue to focus on efforts to curb spending on healthcare programs such as Medicare and Medicaid. We are not able to predict the outcome of the legislative process. We also cannot predict the extent to which proposals will be adopted or, if adopted and implemented, what effect, if any, such proposals and existing new legislation will have on us. Efforts to impose reduced allowances, greater discounts and more stringent cost controls by government and other payors are expected to continue and could adversely affect our business, financial condition and results of operations.
These include statutory and regulatory changes, rate adjustments (including retroactive adjustments), administrative or executive orders and government funding restrictions influenced by budgetary or political pressures, may materially adversely affect the rates at which Medicare reimburses us for our services. Implementation of these and other types of measures has in the past, and could in the future, result in substantial reductions in our revenue and operating margins. For a discussion of historic adjustments and recent changes to the Medicare program and other reimbursement rates, see Part I, Item 1A Risk Factors under the headings Risks Related to Our Business and Industry.
Patient Protection and Affordable Care Act
Various healthcare reform provisions became law upon enactment of the ACA. The reforms contained in the ACA have affected our independent subsidiaries in some manner and are directed in large part at increased quality and cost reductions. Several of the reforms are very significant and could ultimately change the nature of our services, the methods of payment for our services and the underlying regulatory environment.
The Inflation Reduction Act of 2022 (IRA), which continued and expanded certain provisions of the ACA, extended the premium subsidies paid by the federal government, until the end of 2024, resulting in subsidies being available to offset or reduce the costs of private health insurance policies for qualifying individuals. This may aid older patients in obtaining or keeping their health insurance in order to pay for long-term care services. The CAA 2023 revised the funds available to fund Medicare in 2023 and deferred the PAYGO sequestration of Medicare expenses.

22

The 2024 presidential election may significantly alter the current regulatory framework and impact our business and the health care industry, including any further extensions or expansions of certain ACA provisions, namely recent rulemaking activity regarding ACA Section 1557's anti-discrimination provisions. We continually monitor these developments so we can respond to the changing regulatory environment impacting our business.
Requirements of Participation
CMS has requirements that providers, including SNFs, must meet in order to participate in the Medicare and Medicaid Programs. Some of these requirements can be burdensome and costly.
One such requirement of participation in the Medicare and Medicaid programs involves limitations around the use of pre-dispute, binding arbitration agreements by SNFs. CMS has issued guidance and direction around arbitration that must be satisfied for any agreement to be enforceable and which may result in adverse consequences for our business if not followed. Congress has routinely introduced, but not passed, legislation addressing the issue of arbitration agreements used by SNFs. While legislative action is possible in the future, federal regulations and state/federal laws remain our primary source of authority over the use of pre-dispute binding arbitration agreements.
On June 29, 2022, CMS announced updated guidance for Phase 2 and 3 of the Requirements of Participation. CMS distributed these updates to surveyors and state agencies in order to, among other things, enhance responses to resident complaints and reported incidents. This guidance focuses on the following topics: (1) resident abuse and neglect (including reporting of abuse); (2) admission, transfer and discharge; (3) mental health and substance abuse disorders; (4) nurse staffing and reporting of payroll to evaluate staffing sufficiency; (5) residents’ rights (including visitation); (6) potential inaccurate diagnoses or assessments; (7) prescription and use of pharmaceuticals, including psychotropics and drugs that act like psychotropics; (8) infection prevention and control; (9) arbitration of disputes between facilities and residents; (10) psychosocial outcomes and related severity; and (11) the timeliness and completion of state investigations to improve consistency in the application of standards among various states.
On July 29, 2022, CMS updated the Medicare Requirements of Participation for SNFs, which includes the modification of requirements associated with a facility's physical environment to minimize unnecessary renovation expenses in order to avoid closure of SNFs due to the related expense. CMS "grandfathered" certain facilities and will allow SNFs that were participating in Medicare before July 5, 2016 and that previously used the Fire Safety Evaluation System (FSES) to continue using the 2001 FSES mandatory values when determining compliance with applicable standards. CMS also updated the Requirements of Participation to revise existing qualification requirements for directors of food and nutrition services in SNFs, while "grandfathering" in directors with two or more years of experience and certain minimum training in food safety so they may continue in that role without satisfying further educational requirements.
On February 17, 2023, CMS revised the survey resources that CMS and state surveyors use in evaluating SNFs’ compliance with federal Requirements for Participation. This revision incorporated the recent changes to CMS’ focused infection control survey item, which CMS had removed in favor of standard infection control survey measures. These changes were made to the most recent revision of long-term care facility survey documents that CMS had last revised in October of 2022. These updates provided more information for state surveyors to utilize when evaluating SNFs’ compliance with the Medicare Requirements of Participation, as well as included guidance for facilities on operationalizing compliance with these requirements based on how surveyors would measure and evaluate facility performance.
Civil and Criminal Fraud and Abuse Laws and Enforcement
Various complex federal and state laws exist which govern a wide array of referrals, relationships and arrangements, and prohibit fraud by healthcare providers. Governmental agencies are devoting increasing attention and resources to such anti-fraud efforts. The Balanced Budget Act of 1997 expanded the penalties for healthcare fraud. Additionally, the government or those acting on its behalf may bring an action under the FCA, alleging that a healthcare provider has defrauded the government by submitting a claim for items or services not rendered as claimed, which may include coding errors, billing for services not provided and submitting false or erroneous cost reports. The FCA clarifies that if an item or service is provided in violation of the AKS, the claim submitted for those items or services is a false claim that may be prosecuted under the FCA as a false claim. Under the qui tam or “whistleblower” provisions of the FCA, a private individual with knowledge of fraud may bring a claim on behalf of the federal government and receive a percentage of the federal government’s recovery. The Biden-Harris Administration has also signaled an increasing focus on nursing home performance and the reimbursement nursing homes receive from federal healthcare payment programs. Many states also have a false claim prohibition that mirrors or closely tracks the federal FCA.

23

Federal law also provides that the OIG has the authority to exclude individuals and entities from federally funded health care programs on a number of grounds, including, but not limited to, certain types of criminal offenses, licensure revocations or suspensions and exclusion from state or other federal healthcare programs. CMS can recover overpayments from health care providers up to six years following the year in which payment was made.
In 2021, the OIG released the result of an audit finding that Medicare overpaid millions of dollars for chronic care management (CCM) services. The OIG's 2021 report found that in calendar years 2017 and 2018, Medicare overpaid millions of dollars in CCM claims. In 2022, the OIG released an audit revealing that CMS had not collected $226 million, or 45%, of identified overpayments within that period, potentially affecting SNFs. These investigatory actions by OIG demonstrate its increased scrutiny into post-hospital SNF care provided to beneficiaries and may encourage additional oversight or stricter compliance standards. In 2023, representatives of the DOJ speaking at certain industry events, including the American Health Law Association’s Fraud and Compliance Forum, have indicated that its healthcare enforcement trends would emphasize opioid prescribing, Medicare Advantage and managed care plan fraud, and COVID-19 related fraud, including under various relief programs available during and in conjunction with the pandemic. In November of 2023, OIG added to its work plan an audit of nursing homes' nurse staffing hours reported in CMS's payroll-based journal, for which OIG expects to issue a report in FY 2025. In addition, the OIG identified the following areas as its "key goals" for oversight: (1) protecting residents from fraud, abuse, neglect, and promoting quality of care; (2) promoting emergency preparedness and emergency response efforts: (3) strengthening frontline oversight; and (4) supporting federal monitoring of nursing homes to mitigate risks to residents.
Our business model, like those of some other for-profit operators, is based in part on seeking out higher acuity patients whom we believe are generally more profitable. Over time our overall patient mix has consistently shifted to higher acuity in most facilities we operate. We also use specialized care-delivery software that assists our caregivers in more accurately capturing and recording services in order to, among other things, increase reimbursement to levels appropriate for the care actually delivered. These efforts may place us under greater scrutiny with the OIG, CMS, our fiscal intermediaries, recovery audit contractors and others.
Federal Healthcare Reform
Five-Star Quality Reporting Metrics The Quality Payment Program (QPP) was created under the Medicare Access and Children's Health Insurance Program (CHIP) Reauthorization Act of 2015. This program was based on the Merit-based Incentive Payment System (MIPS) or the use of Alternative Payment Models (APM), which relied on quality data CMS gathered and evaluated using the Five-Star Quality Rating system, which includes a rating of one to five in various categories. These categories include (but are not limited to) the results of surveys conducted by state inspectors, other health inspection outcomes, staffing, spending, readmissions and stay durations; the data collected and its weighting in determining a rating on a scale of one to five stars is subject to periodic and ongoing revision, re-balancing and adjustment by CMS to reflect market conditions and CMS’s priorities in patient care. Since 2020, CMS’s measurement of the data reported by providers, including SNFs, has become more competitive and resulted in a reduction of four- and five-star rankings available under CMS’s Five-Star Quality Rating system.
The Five-Star Quality reporting system for nursing homes is displayed on CMS's consumer-based Nursing Home Compare website, along with a consumer alert icon next to nursing homes that have been cited for incidents of abuse, neglect, or exploitation on the Nursing Home Compare website. The Nursing Home Compare website is updated monthly with CMS’s refresh of survey inspection results on that website. Additionally, in April of 2022, the Nursing Home Compare website began publishing the ownership information for Medicare-enrolled nursing facilities based on disclosures made to CMS from 2016 through 2022 due to mergers, acquisitions, or other changes in ownership, to allow for the identification of common ownership of nursing facilities. In addition, the Five Star Quality Ratings incorporated staffing data such as staff tenure and SNF weekend staffing beginning with the October 2022 refresh of the Nursing Home Compare website.
Based on the Nursing Home Five-Star Quality Rating System’s Technical Users’ Guide updated in 2023, CMS will be auditing schizophrenia coding within the MDS reported to CMS, with adjustments to quality ratings based on any inaccuracies in this schizophrenia-related data. Additionally, the outcome of citations that a facility has informally disputed will only be included in the calculation of a facility’s star rating once the dispute is completed and the underlying survey considered final. CMS also revised the nursing-home level exclusion criteria used on the administrator turnover measure, adding information regarding its calculation of the staff turnover measure and publishing an updated ratings table, which identifies the points needed for each nursing facility to obtain certain star ratings within its state. Importantly, the new guidelines limit only 10% of nursing facilities can receive a five-star rating in the state where it operates.


24

In September 2023, CMS announced that it will update the staffing level case-mix adjustment methodology and freeze four of the quality measures used in the Nursing Home Five-Star Quality Rating System beginning with the April 2024 refresh of the Nursing Home Compare website’s data. This freeze is implemented to accommodate changes to the MDS so that information that will be added to the MDS can be gathered. For three months, until the July 2024 refresh of the Nursing Home Compare website rankings, CMS will freeze the staffing level measures for all SNFs. Beginning with the July 2024 refresh, CMS will change the staffing case-mix adjustment methodology to a model based on PDPM, which is discussed above. The Nursing Home Compare website will then begin posting staffing level measures that use this PDPM methodology. To incentivize SNFs to submit accurate staffing data, CMS will revise the staffing methodology to penalize SNFs that fail to submit staffing data, or submit erroneous data, by awarding them the lowest possible score for those measures beginning in April of 2024.
State Legislation Concerning Nursing Home Supervision California passed into law a bill which changes the limitations, or “caps,” on non-economic damages that can be awarded in medical negligence cases filed against healthcare providers (including skilled nursing and long-term care facilities). Beginning on January 1, 2023, non-economic damages (i.e., pain and suffering) available to plaintiffs suing healthcare providers in medical malpractice and professional negligence cases increased from $0.25 million to $0.35 million, and will then increase over the following ten years up to a $0.75 million cap. Once the limit reaches $0.75 million, a 2% annual inflationary adjustment will attach beginning on January 1, 2034. In wrongful death cases that arise from claims of medical malpractice and professional negligence, the cap on non-economic damages increased from $0.25 million to $0.50 million on January 1, 2023, and increase every year thereafter for ten years until the cap on non-economic damages in such cases is $1.0 million; thereafter, this cap will also be subject to an annual 2% increase. The caps are separate as to each claim, meaning that there is one cap for negligence and one cap for wrongful death. The new limits on non-economic damages apply prospectively to lawsuits filed on and after January 1, 2023.
On September 27, 2022, California’s Governor signed into law the Skilled Nursing Facility Ownership and Management Reform Act of 2022. This law increases the oversight authority of the California Department of Public Health, and changes several provisions regarding SNF licensing in the State of California. This includes eliminating previous regulatory provisions that permitted SNFs to operate in advance of receiving their formal license from the State. This law also requires SNF license applicants to disclose additional information in connection with a license application and evaluates more data regarding the applicant’s prior operations, including prior citations, CMS sanctions and legal proceedings against the applicant or other facilities owned or managed by the applicant before issuing a license.

United States Supreme Court Decisions – On June 8, 2023, the United States Supreme Court issued its opinion in Health and Hospital Corporation of Marion County, Indiana (HHC) v. Talevski, which pertained to claims of mistreatment in a nursing home. The nursing home was publicly owned by the government county where it operated, rather than privately owned. The question before the Supreme Court was whether the Nursing Home Reform Act, passed as part of the Omnibus Budget Reconciliation Act of 1987, gave Talevski the right to sue HHC for a violation of his civil rights under 42 U.S.C. § 1983, a specific statute that allows for claims against persons who act for and on behalf of any government entity. The Supreme Court held that Talevski’s civil rights claim against HHC could proceed. While the facts of this case are of limited precedential value to our independent subsidiaries, which are not owned by and do not act on behalf of any government entity, this decision may draw wider public interest into claims against SNFs and assisted living facilities generally.
Monitoring Compliance in Our Facilities 

Governmental agencies and other authorities periodically inspect our independent subsidiaries to assess compliance with various standards, rules and regulations, with potential fines, sanctions and other penalties for noncompliance. Unannounced surveys or inspections generally occur at least annually and may also follow a government agency's receipt of a complaint about a facility. Facilities must pass these inspections to maintain licensure under state law, to obtain or maintain certification under the Medicare and Medicaid programs, to continue participation in the Veterans Administration program at some facilities, and to comply with provider contracts with managed care clients at many facilities. From time to time, our independent subsidiaries, like others in the healthcare industry, may receive notices from federal and state regulatory agencies of an alleged failure to substantially comply with applicable standards, rules or regulations. These notices may require corrective action, may impose civil monetary penalties for noncompliance, and may threaten or impose other operating restrictions on SNFs such as admission holds, provisional skilled nursing license, or increased staffing requirements. If our independent subsidiaries fail to comply with these directives or otherwise fail to comply substantially with licensure and certification laws, rules and regulations, the facility could lose its certification as a Medicare or Medicaid provider, or lose its license permitting operation in the State.


25

Facilities with otherwise acceptable regulatory histories generally are given an opportunity to correct deficiencies and continue their participation in the Medicare and Medicaid programs by a certain date, usually within six months of inspection; however, although where denial of payment remedies are asserted, such interim remedies go into effect much sooner. Facilities with deficiencies that immediately jeopardize patient health and safety and those that are classified as poor performing facilities, however, may not be given an opportunity to correct their deficiencies prior to the imposition of remedies and other enforcement actions. Moreover, facilities with poor regulatory histories continue to be classified by CMS as poor performing facilities notwithstanding any intervening change in ownership, unless the new owner obtains a new Medicare provider agreement instead of assuming the facility's existing agreement. However, new owners nearly always assume the existing Medicare provider agreement due to the difficulty and time delays generally associated with obtaining new Medicare certifications, especially in previously certified locations with sub-par operating histories. Accordingly, facilities that have poor regulatory histories before acquisition by our independent subsidiaries and that develop new deficiencies after acquisition are more likely to have sanctions imposed upon them by CMS or state regulators.
In addition, CMS has increased its focus on facilities with a history of serious or sustained quality of care problems through the special focus facility (SFF) initiative. SFFs receive heightened scrutiny and more frequent regulatory surveys. Failure to improve the quality of care can result in fines and termination from participation in Medicare and Medicaid. A facility “graduates” from the program once it demonstrates significant improvements in quality of care that are continued over a defined period of time.
On October 21, 2022, CMS issued a Memorandum identifying the changes it intends to make in connection with the oversight of those facilities that fall under the SFF Program, including increased penalties for SFFs that fail to improve their performance upon further inspection by CMS, increasing the standards SFFs must meet to graduate from the SFF program, maintaining heightened oversight of any SFF for a period of three years after it graduates and increasing the technical assistance CMS provides to SFFs.
Sanctions such as denial of payment for new admissions often are scheduled to go into effect before surveyors return to verify compliance. Generally, if the surveyors confirm that the facility is in compliance upon their return, the sanctions never take effect. However, if they determine that the facility is not in compliance, the denial of payment goes into effect retroactive to the date given in the original notice, leaving operators with the task of deciding whether to continue accepting patients after the potential denial of payment date--risking the retroactive denial of revenue. Some of our independent subsidiaries have been or will be in denial of payment status due to findings of continued regulatory deficiencies, resulting in an actual loss of revenue associated with patients admitted after the denial of payment date. Additional sanctions could ensue and, if imposed, could include various remedies up to and including decertification.
CMS has undertaken several initiatives to increase or intensify Medicaid and Medicare survey and enforcement activities, including federal oversight of state surveyors. CMS is taking steps to focus more survey and enforcement efforts on facilities with findings of substandard care or repeat violations of Medicaid and Medicare standards and to identify multi-facility providers with patterns of noncompliance. CMS is also increasing its oversight of state survey agencies and requiring state agencies to use enforcement sanctions and remedies more promptly when substandard care or repeat violations are identified, to investigate complaints more promptly, and to survey facilities more consistently.
Regulations Regarding Financial Arrangements  
We are also subject to federal and state laws that regulate financial arrangement by and between healthcare providers, such as the federal and state anti-kickback laws, the Stark laws, and various state anti-referral laws.
The Social Security Act prohibits the knowing and willful offer, payment, solicitation, or receipt of any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce the referral of an individual, in return for recommending, or to arrange for, the referral of an individual for any item or service payable under any federal healthcare program, including Medicare or Medicaid. The OIG has issued regulations that create “safe harbors” for certain conduct and business relationships that are deemed protected under the Social Security Act. In order to receive safe harbor protection, all of the requirements of a safe harbor must be met. The fact that a given business arrangement does not fall within one of these safe harbors does not render the arrangement per se illegal. Business arrangements of healthcare service providers that fail to satisfy the applicable safe harbor criteria, if investigated, will be evaluated on a case-by-case basis based upon all facts and circumstances and risk increased scrutiny and possible sanctions by enforcement authorities.


26

Violations of the Social Security Act can result in inflation-adjusted criminal penalties of more than $0.1 million and ten years imprisonment. It can also result in inflation-adjusted civil monetary penalties of more than $0.1 million per violation and an assessment of up to three times the total amount of remuneration offered, paid, solicited, or received. It may also result in an individual's or organization's exclusion from future participation in federal healthcare programs. State Medicaid programs are required to enact an anti-kickback statute. Many states in which our independent subsidiaries operate have adopted or are considering similar legislative proposals, some of which extend beyond that state's Medicaid program, to prohibit the payment or receipt of remuneration for the referral of patients regardless of the source of payment for the care.

Additionally, the "Stark Law" of the Social Security Act provides that a physician may not refer a Medicare or Medicaid patient for a “designated health service” to an entity with which the physician or an immediate family member has a financial relationship unless the financial arrangement meets an exception under the Stark Law or its regulations. Designated health services include, in relevant part, inpatient and outpatient hospital services, PT, OT, SLP, durable medical equipment, prosthetics, orthotics and supplies, diagnostic imaging, and home health services. Under the Stark Law, a “financial relationship” is defined as an ownership or investment interest or a compensation arrangement. If such a financial relationship exists and does not meet a Stark Law exception, the entity is disallowed from seeking payment under the Medicare or Medicaid programs or from collecting from the patient or other payor. Statutory and regulatory exceptions and exemptions to this exist and have specific rules that must be followed to qualify for such exception or exemption. Any funds collected for an item or service resulting from a referral that violates the Stark Law are not eligible for payment by federal healthcare programs and must be repaid. Violations of the Stark Law may result in the imposition of civil monetary penalties, including, treble damages. Individuals and organizations may also be excluded from participation in federal healthcare programs for Stark Law violations. Many states have enacted healthcare provider referral laws that go beyond physician self-referrals or apply to a greater range of services than just the designated health services under the Stark Law.
Regulations Regarding Patient Record Confidentiality
Health care providers are also subject to laws and regulations enacted to protect the confidentiality of patient health information and patients' right to access such information. For example, HHS has issued rules pursuant to HIPAA, including the Health Information Technology for Economic and Clinical Health (HITECH) Act which governs our use and disclosure of protected health information of patients. We and our independent subsidiaries have established policies and procedures to comply with HIPAA privacy and security requirements and our independent subsidiaries have adopted and implemented HIPAA compliance plans, which we believe comply with the HIPAA privacy and security regulations, which impose significant costs for ongoing compliance activities.
There are numerous other laws and legislative and regulatory initiatives at the federal and state levels addressing privacy and security concerns. Our independent subsidiaries are also subject to any federal or state privacy-related laws that are more restrictive than the privacy regulations issued under HIPAA.

On January 17, 2024, CMS published the CMS Interoperability and Prior Authorization Final Rule (Interoperability Final Rule), which affects the data standards and application programming interfaces (APIs) used by entities that are payors for our services, including but not limited to Medicare Advantage organizations, Medicaid fee-for-service providers, and managed care organizations. This new rule requires these payor entities to adopt new patient access APIs beginning January 1, 2026, and to complete implementation of both patient and provider access APIs by January 1, 2027, to facilitate the sharing of payor information with payors and providers. While the purpose of this final rule is predominantly oriented to sharing information in the clinical setting and expediting the exchange of prior authorization data, this new rule may have implications for our business and how information is shared among our independent subsidiaries that participate in these programs, the payors, residents, and residents’ families involved in their care.
Antitrust Laws 

We are also subject to federal and state antitrust laws. Enforcement of the antitrust laws against healthcare providers is common, and antitrust liability may arise in a wide variety of circumstances, including third party contracting, physician relations, joint venture, merger, affiliation and acquisition activities. On February 3, 2023, the DOJ’s Antitrust Division withdrew its support for three policies that had been jointly created by the DOJ and the Federal Trade Commission (FTC) in 1993, 1996, and 2011, announcing instead, without providing further alternative guidance, that the DOJ would take a case-by-case enforcement approach to evaluate conduct in the healthcare industry, citing that the previous policies were outdated and overly permissive. Similarly, on July 14, 2023, the FTC withdrew two antitrust policy statements related to enforcement in healthcare markets. Moving forward, the FTC will evaluate mergers and conduct in healthcare markets on a case-by-case basis using principles of antitrust enforcement and competition policy.

27

On July 19, 2023, the DOJ and FTC released a draft joint statement of antitrust policy that outlines 13 guidelines to be used when determining if a merger is unlawfully anticompetitive under antitrust laws. These guidelines cover various aspects of antitrust enforcement relevant to SNF and senior living facilities, such as market concentration, competition between firms, risk of coordination, elimination of potential entrants, control of products or services, vertical mergers, dominant positions, trends toward concentration, series of multiple acquisitions, multi-sided platforms, competing buyers, partial ownership or minority interests and overall impact on competition. The draft joint statement also includes detailed sections on the application of the guidelines, defining relevant markets and approaches to rebuttal evidence. These proposed statements are not exhaustive and the DOJ and FTC may focus on one or multiple guidelines depending on the specific circumstances of each merger. These proposed general statements of antitrust policy, once finalized, may be a prelude to a new joint statement of healthcare antitrust policy of the DOJ and FTC, with the agencies’ finalized general statements providing insight into whether healthcare-specific statements will be issued. This development and potential new guidance regarding DOJ and FTC antitrust policy increases risk and uncertainty regarding transactions that may be subject to criminal and civil enforcement by federal and state agencies, as well as by private litigants.
Americans with Disabilities Act
Our independent subsidiaries must also comply with the ADA, and similar state and local laws to the extent that the facilities are "public accommodations" as defined in those laws. The obligation to comply with the ADA and other similar laws is an ongoing obligation, and the independent subsidiaries continue to assess their facilities relative to ADA compliance and make appropriate modifications as needed.
Civil Rights

On January 25, 2024, the Office for Civil Rights (OCR) for HHS issued guidance to hospitals and long-term care facilities, emphasizing their obligation under CMS regulations to ensure non-discriminatory visitation policies, especially during public health emergencies. This guidance, part of the U.S. National Strategy to Counter Antisemitism, clarifies that these facilities cannot discriminate based on religion or other classes or characteristics protected against discrimination under federal civil rights laws. The guidance includes examples where non-compliance occurred, such as unequal treatment based on religious affiliation or dietary restrictions, and stricter screening processes for certain religious groups. OCR offers assistance to facilities to obtain compliance with these standards and encourages residents and other affected individuals to file complaints with OCR for potential administrative or civil action in cases of civil rights violations.
Real Estate Investment Trust (REIT) Qualification
We elected for Standard Bearer to be taxed as a REIT for U.S. federal income tax purposes beginning with its taxable year ended December 31, 2022. Standard Bearer's qualification as a REIT will depend upon its ability to meet, on a continuing basis, various complex requirements under the Internal Revenue Code, relating to, among other things, the sources of its gross income, the composition and value of its assets, distribution levels to its shareholders and the concentration of ownership of its capital stock. We believe that Standard Bearer is organized in conformity with the requirements for qualification and taxation as a REIT under the Code and that its manner of operation has and will enable it to continue to meet the requirements for qualification and taxation as a REIT.
REGULATIONS SPECIFIC TO SENIOR LIVING COMMUNITIES AND ANCILLARY SERVICES

As previously mentioned, senior living services revenue (approximately 2.0% of total revenue) is primarily derived from private pay residents, with a small portion of senior living revenue derived from Medicaid funds. Thus, some of the regulations discussed above applicable to Medicaid providers, also apply to senior living.

A majority of states provide, or are approved to provide, Medicaid payments for personal care and medical services to some residents in licensed senior living communities. As rates paid to senior living community operators are generally lower than rates paid to SNF operators, some states use Medicaid funding of senior living services as a means of lowering the cost of services for residents who may not need the higher level of health services provided in SNFs. States that administer Medicaid programs for services in senior living communities are responsible for monitoring the participating communities and, as a result of the growth of senior living in recent years, these states have adopted licensing standards applicable to senior living communities.


28

CMS has continued to commence a series of actions to increase its oversight of state quality assurance programs for senior living communities and has provided guidance and technical assistance to states to improve their ability to monitor and improve the quality of services paid through Medicaid waiver programs. CMS is encouraging state Medicaid programs to expand their use of home and community-based services as alternatives to facility-based services, pursuant to provisions of the ACA, and other authorities, through the use of several programs.
The types of laws and statutes affecting the regulatory landscape of the post-acute industry continue to expand and the pressure to enforce those laws by federal and state authorities continues to grow as well. In order to operate our businesses, we and our independent subsidiaries must comply with federal, state and local laws from healthcare including provisions regarding patient safety, staffing, and prescription drugs to environmental issues. Changes in the law or new interpretations of existing laws may have an adverse impact on our methods and costs of doing business.

ENVIRONMENTAL MATTERS

 We strive to reduce our environmental impact through initiatives to modernize our facilities, conserve water, optimize waste, work towards a paperless office and partner with green vendors. Our ongoing and planned facility modernization initiatives include solar projects, heating, ventilation and air condition (HVAC) upgrades, water systems updates, lighting retrofits and utility upgrades. Additionally, we track and evaluate the utilities used by our facilities to drive our initiatives. For the year ended December 31, 2023, we spent $106.2 million on purchases of property improvements and equipment which included facility modernization initiatives.

Risk Management and Strategy
We identify and assess environmental risk to the organization by:
Conducting assessments of transition risks, which are risks related to the transition to a lower-carbon economy, and physical risks, which are risks related to the physical impacts of climate change.
Identifying climate-related opportunities, which includes programs to reduce electricity usage and carbon emissions at our independent subsidiaries.
Identifying the potential financial impact of transition risks, physical risks and climate-related opportunities.
Developing and implementing our strategy, which focuses on monitoring environmental policy and on-going developments, ensuring community resiliency, evaluating usage of energy management systems and tools, building operational and emergency response systems, performing hazard vulnerability assessments and tracking and responding to developing natural disasters.

Governance

Ensign's environmental management team (EMT) is part of our ESG Committee. The EMT is led by the Service Center's leadership team members including Construction and Asset Development as well as its Executive Management. The EMT is responsible for:

Implementation and continuous execution of our environment management system and policy.
Development of the Company's environmental management policy.
Identification of climate related risks under the Task Force on Climate-Related Financial Disclosures framework.
Providing structure and support to our independent subsidiaries that are led by local operators to make decisions on their capital expenditure projects at their facilities. The team advises our local field operators on best practices and identifies opportunities for them to assess priorities of projects that may be chosen to be executed.
Overseeing environmental programs which include the evaluation and installation of LED lighting, solar panel, improved doors and insulation, automated HVAC controls and thermal efficiency projects related to micro-turbine, demand control ventilation.
Development of target goals for reduction of carbon emissions, savings and ENERGY STAR scores.
Tracking and monitoring of currently available environmental metrics such as utility usage and development of an energy management system that tracks greenhouse gas emissions and more.
Preparing for applicable environmental audits in the future.

29

Our business is subject to a variety of federal, state and local environmental laws and regulations. As a healthcare provider, we face regulatory requirements in areas of air and water quality control, medical and low-level radioactive waste management and disposal, asbestos management, response to mold and lead-based paint in our facilities and employee safety.

 As an owner or operator of our facilities, we also may be required to investigate and remediate hazardous substances that are located on and/or under the property, including any such substances that may have migrated off, or may have been discharged or transported from the property. Part of our operations involves the handling, use, storage, transportation, disposal and discharge of medical, biological, infectious, toxic, flammable and other hazardous materials, wastes, pollutants or contaminants. In addition, we are sometimes unable to determine with certainty whether prior uses of our facilities and properties or surrounding properties may have produced continuing environmental contamination or noncompliance, particularly where the timing or cost of making such determinations is not deemed cost-effective. These activities, as well as the possible presence of such materials in, on and under our properties, may result in damage to individuals, property or the environment; may interrupt operations or increase costs; may result in legal liability, damages, injunctions or fines; may result in investigations, administrative proceedings, penalties or other governmental agency actions; and may not be covered by insurance.

We believe that we are in material compliance with applicable environmental and occupational health and safety requirements. However, we cannot assure you that we will not encounter liabilities with respect to these regulations in the future, and such liabilities may result in material adverse consequences to our operations or financial condition.
AVAILABLE INFORMATION

We are subject to the reporting requirements under the Securities Exchange Act of 1934, as amended (the Exchange Act). Consequently, we are required to file reports and information with the Securities and Exchange Commission (SEC), including reports on the following forms: annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act. These reports, proxy and information statements and other information concerning our company may be accessed through the SEC's website at http://www.sec.gov.

You may also find on our website at www.ensigngroup.net, electronic copies of our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act. Such filings are placed on our website as soon as reasonably possible after they are filed with the SEC. All such filings are available free of charge. The information contained in, or that can be accessed through, our website does not constitute a part of this Annual Report on Form 10-K.
30

Item 1A. RISK FACTORS
We are providing the following summary of the risk factors contained in our Form 10-K to enhance the readability and accessibility of our risk factor disclosures. We encourage our stockholders to carefully review the risk factors contained in this Form 10-K in their entirety for additional information regarding the risks and uncertainties that could cause our actual results to vary materially from recent results or from our anticipated future results.

Risks Related to our Business and Industry
The rules of Medicare and Medicaid, including reductions of reimbursement rates, changes to spending requirements, data reporting, measurement and evaluation standards could have a material, adverse effect on our revenues, financial condition and results of operations.
Reforms to the U.S. healthcare system, including new regulations under the ACA, new transparency and disclosure requirements, potential federal and state standards for minimum nurse staffing levels, continue to impose new requirements upon us that could materially impact our business.
Changes in the U.S. political environment may result in significant changes to the regulatory framework, enforcement, and reimbursements in our industry.
We are subject to various government reviews, audits and investigations that could adversely affect our business, including an obligation to refund amounts previously paid to us, potential criminal charges, loss of licensure, the imposition of fines and sanctions.
We are subject to extensive and complex laws and government regulations. If we are not operating in compliance with these laws and regulations or if these laws and regulations change, we could be required to make significant expenditures or change our operations in order to bring our facilities and operations into compliance.
Public and government calls for increased enforcement efforts toward SNFs, potential rulemaking that may result in enhanced enforcement and penalties, and new guidance for surveyors regarding the review of SNFs and enforcement of their Requirements of Participation, could result in increased scrutiny by state and federal survey agencies, including sanctions that could negatively affect our financial condition and results of operations.
CMS’s changes to the SFF program and its look-back period may create greater risk of our facilities being subject to this program and subject to potential fines and sanctions, even after graduating from the SFF program.
Federal minimum staffing mandates may adversely affect our labor costs, ability to maintain desired levels of patient or resident capacity, and profitability.
Future cost containment initiatives undertaken by payors may limit our revenue and profitability.
Changes in Medicare reimbursements for physician and non-physician services could impact reimbursement for medical professionals.
We face numerous risks related to the COVID-19 PHE's expiration and surrounding wind-down and uncertainty, which could individually or in the aggregate have a material adverse effect on our business, financial condition, liquidity, results of operations and prospects.
We may be subject to increased investigation and enforcement activities related to HIPAA violations.
Security breaches and other cyber-security incidents could violate security laws and subject us to significant liability.
If our independent subsidiaries are not fully reimbursed for all services for which each facility bills through consolidated billing, our revenue, financial condition and results of operations could be adversely affected.
Increased competition for, or a shortage of, nurses and other skilled personnel, could increase our staffing and labor costs and subject us to monetary fines resulting from a failure to maintain minimum staffing requirements, or may affect reimbursement.
Annual caps, uncertainty regarding reimbursement and other cost-reductions for outpatient therapy services may reduce our future revenue and profitability or cause us to incur losses.
Increased scrutiny of our activities and billing practices by the OIG or other regulatory authorities may result in an increase in regulatory monitoring and oversight, decreased reimbursement rates, or otherwise adversely affect our business, financial condition and results of operations.
State efforts to regulate or deregulate the healthcare services industry or the construction or expansion of healthcare facilities could impair our ability to expand our operations, or could result in increased competition.
Newly enacted legislation in the States where our independent subsidiaries are located may impact the volume of cases filed and the overall cost of those cases from a defense and indemnity standpoint.
Changes to federal and state employment-related laws and regulations could increase our cost of doing business.
Required regulatory approvals could delay or prohibit transfers of our healthcare operations, which could result in periods in which we are unable to receive reimbursement for such properties.
Compliance with federal and state fair housing, fire, safety, staffing, and other regulations may require us to incur unexpected expenses, which could be costly to us.
Our revenue, financial condition and results of operations could be negatively impacted by any changes in the acuity mix of patients in our independent subsidiaries as well as payor mix and payment methodologies.
We are subject to litigation that could result in significant legal costs and large settlement amounts or damage awards. Similarly, a change in the enforceability of arbitration provisions between SNFs and senior living facilities and residents and patients may affect the risks we face from claims and potential litigation.
31

If our regular internal investigations into the care delivery, recordkeeping and billing processes of our independent subsidiaries detect instances of noncompliance, efforts to correct such non-compliance could materially decrease our revenue.
We may be unable to complete future facility or business acquisitions at attractive prices or at all, or may elect to dispose of underperforming or non-strategic independent subsidiaries, either of which could decrease our revenue.
We may not be able to successfully integrate acquired facilities and businesses into our operations, or we may be exposed to costs, liabilities and regulatory issues that may adversely affect our operations.
In undertaking acquisitions, we may be adversely impacted by costs, liabilities and regulatory issues that may adversely affect our operations.
If we do not achieve or maintain competitive quality of care ratings from CMS or private organizations engaged in similar monitoring activities, our business may be negatively affected.
If we are unable to obtain insurance, or if insurance becomes more costly for us to obtain, our business may be adversely affected, and our self-insurance programs may expose us to significant and unexpected costs and losses.
The geographic concentration of our independent subsidiaries could leave us vulnerable to economic downturn, regulatory changes or acts of nature in those areas.
The actions of a national labor union that has pursued a negative publicity campaign criticizing our business in the past may adversely affect our revenue and our profitability.
The risks associated with leased property where our independent subsidiaries operate could adversely affect our business, financial position or results of operations.
Failure to generate sufficient cash flow to cover required payments or meet operating covenants under our long-term debt, mortgages and long-term operating leases could result in defaults under such agreements and cross-defaults under other debt, mortgage or operating lease arrangements, which could harm our independent subsidiaries and cause us to lose facilities or experience foreclosures.
A continued housing slowdown or housing downturn could decrease demand for senior living services.
As we continue to acquire and lease real estate assets, we may not be successful in identifying and consummating these transactions.
As we expand our presence in other relevant healthcare industries, we would become subject to risks in a market in which we have limited experience.
If our referral sources fail to view us as an attractive skilled nursing provider, or if our referral sources otherwise refer fewer patients, our patient base may decrease.
We may need additional capital to fund our independent subsidiaries and finance our growth, and we may not be able to obtain it on terms acceptable to us, or at all, which may limit our ability to grow.
The condition of the financial markets could limit the availability of debt and equity financing sources to fund the capital and liquidity requirements of our business.
Delays in reimbursement may cause liquidity problems.
The utilization and expansion of managed care organizations may contribute to delays or reductions in our reimbursement, including Managed Medicaid.
Compliance with the regulations of the Department of Housing and Urban Development may require us to make unanticipated expenditures which could increase our costs.
Failure to safeguard our patient trust funds may subject us to citations, fines and penalties.
We are a holding company with no operations and rely upon our multiple independent subsidiaries.
Certain directors who serve on our Board of Directors also serve as directors of Pennant, and ownership of shares of Pennant common stock by our directors and executive officers may create, or appear to create, conflicts of interest.
Standard Bearer's failure to qualify as a REIT may cause it to be subject to U.S. federal income tax. Additionally, legislative or other actions affecting REITs could have a negative effect on Standard Bearer.

Risks Related to Ownership of our Common Stock
We may not be able to pay or maintain dividends and the failure to do so would adversely affect our stock price.
Our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law contain provisions that could discourage transactions resulting in a change in control, which may negatively affect the market price of our common stock.
32

You should carefully consider each of the following risk factors and all other information set forth in this information statement. The risk factors generally have been separated into two categories: risks relating to our business and our industry and risks relating to our common stock. Based on the information currently known to us, we believe that the following information identifies the most significant risk factors affecting our company in each of these categories of risks. However, the risks and uncertainties we face are not limited to those set forth in the risk factors described below. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business. In addition, past financial performance may not be a reliable indicator of future performance and historical trends should not be used to anticipate results or trends in future periods.
 If any of the following risks and uncertainties develops into actual events, these events could have a material adverse effect on our business, financial condition or results of operations. In such case, the trading price of our common stock could decline. You should carefully read the following risk factors, together with the financial statements, related notes and other information contained in this Annual Report on Form 10-K. This Annual Report on Form 10-K contains forward-looking statements that contain risks and uncertainties. Please refer to the section entitled "Cautionary Note Regarding Forward-Looking Statements" on page 1 of this Annual Report on Form 10-K in connection with your consideration of the risk factors and other important factors that may affect future results described below.
Risks Related to Our Business and Industry

The rules of Medicare and Medicaid, including reductions of reimbursement rates, changes to spending requirements, data reporting, measurement and evaluation standards could have a material, adverse effect on our revenues, financial condition and results of operations.

We derived 26.6% and 27.7% of our service revenue from the Medicare programs for the year ended December 31, 2023 and 2022, respectively. In addition, many other payors may use published Medicare rates as a basis for reimbursements. Accordingly, if Medicare reimbursement rates are reduced or fail to increase as quickly as our costs, if there are changes in the rules governing the Medicare program that are disadvantageous to our business or industry, or if there are delays in Medicare payments, our business and results of operations will be adversely affected.

The Medicare program and its reimbursement rates and rules are subject to frequent change, including statutory and regulatory changes, rate adjustments (including retroactive adjustments), annual caps that limit the amount that can be paid (including deductible and coinsurance amounts), administrative or executive orders and government funding restrictions, all of which may materially adversely affect the rates at which Medicare reimburses us for our services. See Item 1., under Government Regulation, Sequestration of Medicare Rates, for further information. Implementation of these and other types of measures has in the past and could in the future result in substantial reductions in our revenue and operating margins.

Additionally, payments can be delayed or declined due to determinations that certain costs are not reimbursable or reasonable because either adequate or additional documentation was not provided or because certain services were not covered or considered medically necessary. Additionally, revenue from these payors can be retroactively adjusted after a new examination during the claims settlement process or as a result of post-payment audits. New legislation and regulatory proposals could impose further limitations on government payments to healthcare providers.

CMS often changes the rules governing the Medicare program, including those governing reimbursement. Changes to the Medicare program that could adversely affect our business could include, but are not limited to the following:
administrative or legislative changes to base rates or the bases for payment;
limits on the services or types of providers for which Medicare will provide reimbursement;
changes in methodology for patient assessment and/or determination of payment levels;
changes in staff requirements (i.e., requiring all workers to be vaccinated against COVID-19 and receive booster injections for those vaccinations) as a condition of payment or eligibility for Medicare reimbursement (See also, Item 1., under Government Regulation);
the reduction or elimination of annual rate increases, or the end of the reduced payments deferment (See also, Item 1., under Government Regulation); and
an increase in co-payments or deductibles payable by beneficiaries.
Among the changes being implemented by CMS are provisions of the IMPACT Act, which imposes a stringent timeline for implementing benchmark quality measures and data metrics across facilities that include SNFs. The enactment mandates specific actions to design a unified payment methodology for post-acute providers, which CMS implements through ongoing regulations. The costs of final implementation may be significant, with potential fines and payment reductions resulting from a failure to meet CMS's implementation requirements.  

33

Reductions in reimbursement rates or the scope of services being reimbursed could have a material, adverse effect on our revenue, financial condition and results of operations or even result in reimbursement rates that are insufficient to cover our operating costs. Congress’s budgetary planning has also resulted in a difficulty to financially forecast, as the Medicare conversion factor paid under the CAA 2023 was 2.5% greater than the conversion factor provided for in the CY 2023 PFS final rule. Nonetheless, the 2023 conversion factor for CY 2023 was lower than CY 2022 PFS's conversion factor. In contrast, the CY 2024 PFS conversion factor decreased 3.34% from the CY 2023 PFS conversion factor. This decrease takes into account the expiration of the 2.5% statutory payment increase for 2023, the addition of a 1.25% statutory payment increase for 2024, a 0% conversion factor update, and a 2.17% budget-neutrality adjustment.

On July 31, 2023, the CMS released its final rule for the SNF PPS for FY 2024 which will increase payments by a net 4.0% in FY 2024 compared to FY 2023. The final rule includes updates to the SNF Quality Reporting Program and SNF Value-based Purchasing Program that assess staff turnover, discharge success, res-hospitalization, and resident falls with injuries, which may adversely affect revenues obtained through the Medicare program. The SNF FY 2024 Final Rule may result in an increase in payments relative to FY 2023 depending on the performance of our individual independent subsidiaries as evaluated by CMS. The final rule will also replace the SNF 30-day All-cause Readmission measure with the SNF Within Stay Potentially Reasonable Readmissions standard beginning in fiscal year 2025, which may also reduce the compensation our independent subsidiaries may receive under the SNF VBP program.

As discussed in more detail in Item 1., under Government Regulation, CMS implemented a final rule in October 2019 implementing a new case-mix classification system, PDPM, that focuses on the clinical condition of the patient. CMS may make future adjustments to reimbursement levels and underlying reimbursement formulae as it continues to monitor the impact of PDPM on patient outcomes and budget neutrality. The Biden-Harris Administration continues to study the nursing home industry and for HHS to issue proposed rules based on those studies, including changes to SNF facility reimbursement, including the SNF-VBP Program, may also adversely affect our reimbursement. These metrics potentially affecting our revenues and expenses in future government fiscal years include the SNF healthcare-associated infections (HAI) measurement, total nursing hours per resident day measures, and discharge to community - post acute care measure. The Interoperability Final Rule’s implementation beginning in 2026, and to be completed by January 1, 2027, may also adversely affect our reimbursement paid through Medicare, specifically including Medicare Advantage.

Loss of Medicare reimbursement, or a delay or default by the government in making Medicare payments, would also have a material adverse effect on our revenue. Non-compliance with Medicare regulations exist, and any penalty, suspension, termination, or other sanction under any state’s Medicaid program could lead to reciprocal and commensurate penalties being imposed under the Medicare program, up to termination or rescission of our Medicare participation and payor agreements as noted above.
A significant portion of reimbursement for skilled nursing services comes from Medicaid. In fact, Medicaid is our largest source of revenue, accounting for 46.0% of our revenue for both the year ended December 31, 2023 and 2022, respectively. Medicaid is a state-administered program financed by both state funds and matching federal funds. Medicaid spending has increased rapidly in recent years, becoming a significant component of state budgets, which has led both the federal government and many states to institute measures aimed at controlling the growth of Medicaid spending, and in some instances reducing aggregate Medicaid spending. Since a significant portion of our revenue is generated from our skilled nursing independent subsidiaries in California, Texas and Arizona, any budget reductions or delays in these states could adversely affect our net patient service revenue and profitability. Due to recent fluctuations in state budgets many of the states in which we operate (including those with current budget surpluses), are seeking to contain costs on Medicaid outlays for SNFs, and any such decline could adversely affect our financial condition and results of operations.
The Medicaid program and its reimbursement rates and rules are subject to frequent change at both the federal and state level, including through changes in laws, regulations, rate adjustments (including retroactive adjustments), administrative or executive orders and government funding restrictions, all of which may materially adversely affect the rates at which our services are reimbursed by state Medicaid plans or the amount of expense we incur.

34

To generate funds to pay for the increasing costs of the Medicaid program, many states utilize financial arrangements commonly referred to as provider taxes. Under provider tax arrangements, states collect taxes from healthcare providers and then use the revenue to pay the providers as a Medicaid expenditure, which allows the states to then claim additional federal matching funds on the additional reimbursements. Current federal law provides for a cap on the maximum allowable provider tax as a percentage of the providers' total revenue. There can be no assurance that federal law will continue to provide matching federal funds on state Medicaid expenditures funded through provider taxes, or that the current caps on provider taxes will not be reduced. Any discontinuance or reduction in federal matching of provider tax-related Medicaid expenditures could have a significant and adverse effect on states' Medicaid expenditures, and as a result could have a material and adverse effect on our business, financial condition or results of operations.

The CAA 2023 provided for the wind-down and termination of increased FMAP payments under the FFCRA, and also provided for the disenrollment of Medicaid beneficiaries who have participated in the program since early in the COVID-19 pandemic. CMS’s increased FMAP payments declined from 6.2% to 5% in the second quarter of 2023, 2.5% in the third quarter, and 1.5% in the fourth quarter before CMS’s increased FMAP spending ends entirely. The CAA 2023 granted CMS the authority to impose fines, penalties, and other sanctions upon states that do not comply with this law’s requirements for the unwinding of increased FMAP payments. As a result, these reductions may impose further burdens on the Medicaid programs in states where we operate in the form of fines and penalties, which may result in reduced payments.

Beginning on April 1, 2023, states were allowed to begin disenrolling Medicaid beneficiaries. CMS guidance allowing for a return to Medicaid’s historical renewal, enrollment, and eligibility determination practices permits states up to 14 months to initiate and process traditional Medicaid renewals. The CAA 2023’s allowance of disenrollment and return to traditional Medicaid renewal processes, which will include pre-COVID eligibility determinations, may result in a reduction of the number of Medicaid beneficiaries and may result in a reduction of our current and potential patient population. As a result, there may be fewer current or potential patients able to pay for our independent subsidiaries’ services, and increased competition for Medicaid beneficiaries able to provide reimbursement for those services. As of December 2023, nearly 12 million people were reported to be disenrolled from Medicaid as part of this disenrollment process.

CMS is concerned that states are terminating enrollees without definitively establishing their eligibility due to state residents not receiving eligibility forms or understanding instructions. CMS is monitoring states' compliance with federal requirements and is working with the affected states to address issues related to renewal requirements. States risk losing federal Medicaid matching funds for non-compliance with CMS’s instructions, which could result in reduced Medicaid funds available for timely reimbursement of the Company’s independent subsidiaries for their operations. Estimates suggest that roughly 17 million people may lose Medicaid coverage during the redetermination process through their scheduled completion in May of 2024.

Medicaid is an important source of funding for our independent subsidiaries. The Company may be adversely affected by the disenrollment of Medicaid beneficiaries, which may lead to a reduction in reimbursement that may adversely impact our revenue and profit. The temporary restoration of Medicaid benefits in states where redetermination has been paused can help relieve some of these economic concerns. The disruption caused by the temporary pauses and restoration of Medicaid coverage for beneficiaries can also create operational challenges for our independent subsidiaries, including adverse effects on cash flow, available funds to pay wages for staffing, and overall financial stability.

The ultimate impact of Medicaid disenrollment on the Company’s finances and operations will depend on individual states' specific circumstances and actions.
State-Level Direct Spending Requirements could negatively impact our results of operations

Certain states where the Company operates have implemented direct spending requirements requiring SNFs to spend a portion of their revenue, particularly including Medicaid-derived revenue, on expenses directly relating to care. These spending requirements could affect our operational results and place the Company at higher risk of suffering non-compliance consequences, such as penalties, pay-backs, restrict admissions and/or operational/financial penalties.


35

For example, Washington state incorporates the costs of direct care, indirect care, and capital expenditures for SNF services in computing the State’s Medicaid payments to nursing facilities. Using periodically updated calculations that account for factors including case acuity, fair market value of capital expenditures, inflation, and facility performance, Washington sets facility compensation so that the majority of Medicaid reimbursement paid to a skilled nursing facility is used for care-related activities, with limitations on how much a facility’s reimbursement may increase from year to year. Washington state first adopted this care-based payment model in 2015 and has periodically updated it since, including in 2020, 2022, and 2023; it is expected that Washington will continue to amend this law in the future. For state fiscal year 2024, Texas requires all nursing facilities must show that funds paid to SNFs by Texas’s Medicaid program, including both fee-for-service and managed care reimbursement, were expanded for direct care activities, including direct care staff wages and benefits. In addition, California in the past has proposed bills that, if passed, would require nursing facilities to spend a stated percentage of revenue on direct patient-related services. While the most recent attempt by the California Assembly (Bill 1537) to impose direct spending requirements on SNFs has been placed in suspense with no action has been taken on, similar legislation in the future may seek to impose identical or analogous funding requirements for SNFs operating in California.
Reforms to the U.S. healthcare system, including new regulations under the ACA, continue to impose new requirements upon us that could materially impact our business

As discussed in greater detail in Item 1., under Government Regulation, the ACA has resulted in significant changes to our operations and reimbursement models for services we provide. CMS continues to issue rules to implement the ACA, including most recently, new rules regarding the implementation of the anti-discrimination provisions and proposed rules requiring the disclosure of SNF ownership, organization, management and the identity of the real property owners from which the SNF leases or subleases its operating space. With the passage of the IRA in August of 2022, Congress continues to expand and supplement the ACA, including through the continuation of federally funded insurance premium subsidies. This modification of the ACA by the IRA indicates that Congress may continue to change and expand the ACA in the future.

The efficacy of the ACA is the subject of much debate among members of Congress and the public and it has been the subject of extensive litigation before numerous courts, including the United States Supreme Court, with varying outcomes — some expanding and others limiting the ACA. If the ACA is repealed or any elements of the ACA that are beneficial to our business are materially amended or changed, such as provisions regarding the health insurance industry, reimbursement and insurance coverage by payers, our business, operating results and financial condition could be harmed. Thus, the future impact of the ACA on our business is difficult to predict and its continued uncertain future may negatively impact our business.

While it is not possible to predict whether and when any such changes will occur, specific proposals discussed during and after the midterm election in 2022, including a repeal or material amendment of the ACA, could harm our business, operating results and financial condition. The ACA continues to be a salient political topic and proposed changes to it may become the subject of campaign promises, litigation, administrative action, or legislation leading up to or following the 2024 Presidential election. In addition, even if the ACA is not amended or repealed, the President and the executive branch of the federal government, as well as CMS and HHS have a significant impact on the implementation of the provisions of the ACA, and a new administration could make changes impacting the implementation and enforcement of the ACA, which could harm our business, operating results and financial condition. We have already seen this with regulatory activity promulgating rules regarding anti-discrimination under Section 1557 of the ACA and most recently proposed rulemaking requiring the disclosure of SNF ownership and service providers under Section 6101 of the ACA. If we are slow or unable to adapt to any such changes, our business, operating results and financial condition could be adversely affected.

Similarly, the Nursing Home Improvement Act proposed during the prior Congress may be re-introduced in the future and could ultimately have an impact on our business due to the proposed 2% decrease in payments to SNFs, as well as the staffing and reporting requirements contained within the bill. While it is difficult to determine whether the Nursing Home Improvement Act or an identical bill will even be reintroduced, if ultimately signed into law, this bill may negatively impact our business, with the scope and nature of its consequences unknown.

On November 15, 2023, CMS issued a final rule that, requires SNFs to disclose certain information regarding their ownership and managerial relationships, which is more invasive and comprehensive than the ownership information already disclosed through Medicare's Nursing Home Compare website. Refer to Item 1., under Government Regulation, for additional information. The breadth of disclosure required by this new rule may be adverse to our business interests and detrimental to our operations, revenue, and profitability and may have a chilling effect on investment due to the depth of the new reporting and transparency requirements.

36

We cannot predict what effect future reforms to the U.S. healthcare system will have on our business, including the demand for our services or the amount of reimbursement available for those services. However, it is possible these new laws may lower reimbursement or increase the cost of doing business and adversely affect our business.
The changes in Congress due to the most recent U.S. midterm elections in 2022, changes in representation, and actions in anticipation of the 2024 Presidential election may result in significant changes to regulatory framework, enforcements and reimbursements.

The most recent midterm elections in 2022 and resulting change in control of the House of Representatives, and representative departures that are expected to further narrow the margin of Republican control over the House of Representatives, could result in significant changes in, and has resulted in uncertainty with respect to, legislation, regulation, implementation or repeal of laws and rules related to government health programs, including Medicare and Medicaid. Democratic proposals for Medicare for All or significant expansion of Medicare, could significantly impact our business and the healthcare industry if implemented, although the implementation of such proposals remains unlikely under the political party currently holding a majority within the House of Representatives. Additionally, Congress’s passage of the IRA in August of 2022, which expanded upon and continued certain provisions of the ACA, indicates that additional legislative changes to the ACA may be forthcoming. If proposed policies specific to nursing facilities are implemented, these may result in significant regulatory changes, increased survey frequency and scope, and increased penalties for non-compliance. As both political parties have begun their Presidential primaries and congressional elections in 2024, each of them may seek to introduce or pass legislation that would either expand or reduce the scope of the ACA as a credential for future campaigning. Based on the IRA and inflationary pressures in the economy, the ACA and affordability of healthcare generally may be a campaign issue and lead to promises, administrative action, or legislation that could adversely affect our business. As a result, future legislation may be proposed or passed that may adversely affect our business, operating results and financial condition.

We continually monitor these developments in order to respond to the changing regulatory environment impacting our business. While it is not possible to predict whether and when any such changes will occur, specific proposals discussed during and after the election, including a repeal or material amendment of the ACA (whether to increase or decrease its scope), could harm our business, operating results and financial condition. If we are slow or unable to adapt to any such changes, our business, operating results and financial condition could be adversely affected.
We are subject to various government reviews, audits and investigations that could adversely affect our business, including an obligation to refund amounts previously paid to us, potential criminal charges, the imposition of fines, and/or the loss of our right to participate in Medicare and Medicaid programs.
As a result of our participation in the Medicaid and Medicare programs, we are subject to various governmental reviews, audits and investigations to verify our compliance with the rules associated with these programs and related applicable laws and regulations, including our claims for payments submitted to those programs, which are subject to reviews by Recovery Audit Contractors, Zone Program Integrity Contractors, Program Safeguard Contractors, Unified Program Integrity Contractors, Supplemental Medical Review Contractors and Medicaid Integrity Contractors programs, (collectively referred to as Reviews). In these Reviews, third-party firms engaged by CMS conduct extensive analysis of claims data and medical and other records to identify potential improper payments under the federal and state programs. As discussed above, the Biden-Harris Administration has called for HHS and CMS to increase the level of scrutiny of SNF facilities and requested those agencies to adopt rules that would impose greater penalties upon non-compliant SNF operators. On February 17, 2023, CMS most recently updated the survey resources that CMS and state surveyors use in evaluating our SNFs’ compliance with federal Requirements for Participation, incorporating recent changes to CMS’s methods for surveying infection control procedures.
On June 29, 2022, CMS announced updated guidance for Phase 2 and 3 of the requirements of participation, discussed in greater detail in Item 1., under Government Regulation. The application of CMS’s new guidance could result in more aggressive and stringent surveys, and potential fines, penalties, sanctions, or administrative actions taken against our independent subsidiaries. Also described in Item 1., under Government Regulation, the Interoperability Final Rule and its changes intended to facilitate data exchange between and among patients, providers, and payors, will be implemented beginning in 2026 and must be fully implemented by January 1, 2027. This rule and the greater access to and use of data between and among payors transmitting funds for state and federal healthcare programs, may also trigger additional scrutiny or review of facilities such as ours, and may adversely affect our reimbursement paid through state and federal programs including Medicaid.


37

CMS announced a new nationwide audit the “SNF 5-Claim Probe & Educate Review” in which the Medicare Administrative Contractors will review five claims from each of the facilities to check for compliance with PDPM billings, which could result in individual claim payment denials if errors are identified. All facilities that are not undergoing Targeted Probe and Educate (TPE) reviews, or have not recently passed a TPE review, will be subject to the nationwide audit.

Private pay sources also reserve the right to conduct audits. We believe that billing and reimbursement errors and disagreements are common in our industry, and thus we are regularly engaged in reviews, audits and appeals of our claims for reimbursement due to the subjectivities inherent in the process related to patient diagnosis and care, record keeping, claims processing and other aspects of the patient service and reimbursement processes, and the errors and disagreements those subjectivities can produce. An adverse review, audit or investigation could result in:

an obligation to refund amounts previously paid to us pursuant to the Medicare or Medicaid programs or from private payors, in amounts that could be material to our business;
state or federal agencies imposing fines, penalties or other sanctions on us;
temporary or permanent loss of our right to participate in the Medicare or Medicaid programs or one or more private payor networks;
an increase in private litigation against us; and
damage to our reputation in the geographies served by our independent subsidiaries.
Although we have always been subject to post-payment audits and reviews, more intensive “probe reviews” performed by Medicare administrative contractors in recent years appear to be a regular procedure with our fiscal intermediaries. All findings of overpayment from CMS contractors are eligible for appeal. With the exception of rare findings of overpayment related to objective errors in Medicare payment methodology or claims processing, we utilize all defenses reasonably available to us to demonstrate that the services provided meet all clinical and regulatory requirements for reimbursement.
In cases where claim and documentation review by a CMS contractor results in repeated unsatisfactory results, an operation can be subjected to protracted regulatory oversight. This CMS oversight may include education and sampling of claims, extended pre-payment review, referral of the operating business to recovery audit or integrity contractors, or extrapolation of an error rate to other reimbursement made outside of specifically reviewed claims. Ongoing failure to demonstrate improvement towards meeting all claim filing and documentation requirements could ultimately lead to Medicare decertification. As of December 31, 2023 and through the filing date of this report, 40 of our independent subsidiaries had reviews scheduled or in process, either pre- or post-payment. We anticipate that these reviews could increase in frequency in the future.

Additionally, both federal and state government agencies have heightened and coordinated civil and criminal enforcement efforts as part of numerous ongoing investigations of healthcare companies and, in particular, SNFs. The focus of these investigations includes, among other things, billing and cost reporting practices; quality of care provided; financial relationships with referral sources; and the medical necessity of rendered services. For example, refer to the matter discussed in Item 3. Legal Proceedings.

If we should agree to a settlement of claims or obligations under Medicare statutes, the FCA, or similar federal or state statutes and related regulations, our business, financial condition and results of operations and cash flows could be materially and adversely affected, and our stock price could be adversely impacted. Among other things, any settlement or litigation could involve the payment of substantial sums to settle any alleged civil violations and may also include our assumption of specific procedural and financial obligations going forward under a corporate integrity agreement or other arrangement with the government.

If the government or a court were to conclude that errors and deficiencies constitute criminal violations and/or that such errors and deficiencies resulted in the submission of false claims to federal healthcare programs, or were to discover other problems in addition to the ones identified by the probe reviews that rose to actionable levels, we and certain of our officers might face potential criminal charges and civil claims, administrative sanctions and penalties for amounts that could be material to our business, results of operations and financial condition. In addition, we or some of the key personnel of our independent subsidiaries could be temporarily or permanently excluded from future participation in state and federal healthcare reimbursement programs such as Medicaid and Medicare.


38

If any of our independent subsidiaries is decertified or loses its licenses, our revenue, financial condition or results of operations would be adversely affected. In addition, the report of such issues at any of our independent subsidiaries could harm our reputation for quality care and lead to a reduction in the patient referrals to and ultimately a reduction in occupancy at these facilities. Also, responding to auditing and enforcement efforts diverts material time, resources and attention away from our management team and our staff, and could have a materially detrimental impact on our results of operations during and after any such investigation or proceedings, regardless of whether we prevail on the underlying claim.
We are subject to extensive and complex laws and government regulations. If we are not operating in compliance with these laws and regulations or if these laws and regulations change, we could be required to make significant expenditures or change our operations in order to bring our facilities and operations into compliance.
 
We, along with other companies in the healthcare industry, are required to comply with extensive and complex laws and regulations at the federal, state and local government levels relating to, among other things:

licensure and certification;
disclosure of ownership and affiliated parties;
adequacy and quality of healthcare services;
qualifications of healthcare and support personnel;
state-specified and potential federal mandates for specific nurse staffing levels;
quality and maintenance of medical equipment and facilities;
confidentiality, maintenance and security issues associated with medical records and claims processing;
relationships with physicians and other referral sources and recipients;
constraints on protective contractual provisions with patients and third-party payors;
operating policies and procedures;
addition of facilities and services; and
billing for services.
The laws and regulations governing our operations, along with the terms of participation in various government programs, regulate how we conduct our business, the services we offer, and our interactions with patients and other healthcare providers. These laws and regulations are subject to frequent change. As noted above, the Biden-Harris Administration has called upon HHS and CMS to study and propose new rules regarding staffing requirements and reimbursement for the nursing home industry, including tying reimbursement to staffing levels, salary, benefits, and retention. CMS's recently finalized ownership transparency rule, discussed in Item 1., under Government Regulation, may provide an additional basis for further investigation, administrative action and ultimately fines, penalties, or sanctions if finalized, and may dissuade parties from working with us or our independent subsidiaries due to the reporting and disclosure obligations of being an Additional Disclosable Party under that final rule.

We believe that such regulations that may adversely affect our business, operation and profitability may increase in the future and we cannot predict the ultimate content, timing or impact on us of any healthcare reform legislation. If we fail to comply with these applicable laws and regulations, or their interpretations as determined by courts or enforced by regulators, we could suffer civil or criminal penalties and other detrimental consequences, including denial of reimbursement, imposition of fines, temporary suspension of admission of new patients, suspension or decertification from the Medicaid and Medicare programs, restrictions on our ability to acquire new facilities or expand or operate existing facilities, the loss of our licenses to operate and the loss of our ability to participate in federal and state reimbursement programs. Additionally, in the future, different interpretations or enforcement of these laws and regulations could subject our current or past practices to allegations of impropriety or illegality or could require us to make changes in our facilities, equipment, personnel, services, capital expenditure programs and operating expenses.

As discussed in greater detail in Item 1., under Government Regulation, we are subject to federal and state laws intended to prevent healthcare fraud and abuse. Possible sanctions for violation of any of these laws and regulations include loss of eligibility to participate in federal and state reimbursement programs and civil and criminal penalties. If we fail to comply, even inadvertently, with any of these requirements, we could be required to alter our operations, refund payments to the government, enter into a corporate integrity agreement, deferred prosecution or similar agreements with state or federal government agencies, and become subject to significant civil and criminal penalties.


39

These anti-fraud and abuse laws and regulations are complex, and we do not always have the benefit of significant regulatory or judicial interpretation of these laws and regulations. While we do not believe we are in violation of these prohibitions, we cannot assure you that governmental officials charged with the responsibility for enforcing these prohibitions will not assert that we are violating the provisions of such laws and regulations. Our company is currently aware of litigation filed by an individual related to allegations that certain of our independent SNFs may have violated the FCA or the AKS with respect to the relationships between certain SNFs and persons who served as medical directors. While our independent subsidiaries maintain policies and procedures to promote compliance with the FCA, the AKS, and other applicable regulatory requirements, we cannot predict when the investigation will be resolved, the outcome of the investigation or its potential impact on our company.

On September 1, 2023, CMS issued a proposed rule setting forth proposed minimum nurse staffing requirements for SNFs. As discussed in more detail in Item 1., under Government Regulation, this proposed rule contains three primary staffing proposals: 1) minimum nurse staffing standards of 0.55 HPRD for RNs and 2.45 HPRD for NAs; 2) a requirement to have a RN on-site 24 hours per day, seven days per week; and 3) requirements for enhanced facility assessments. The proposed rule features a staggered implementation of these requirements, with potential accommodations for facilities that can demonstrate financial hardship and a delayed implementation schedule for rural facilities. Within this proposed rule, CMS also seeks comments about other staffing models, including alternate, higher standards for imposing staffing minimums, which will have a potentially adverse effect on our operations and profitability, the extent of which currently is not known. Pending legislation in both the House of Representative and the Senate has been introduced to prevent CMS's proposed minimum staffing rule from taking effect, however the outcome of this legislation is unknown and we cannot predict proposed legislation might be finalized.

We are unable to predict the future course of federal, state and local regulation or legislation, including as it pertains to Medicare, Medicaid, or fraud and abuse laws, and how they are enforced. Changes in the regulatory framework, our failure to obtain or renew required regulatory approvals, credentials, qualifications, or licenses or to comply with applicable regulatory requirements, or the imposition of other enforcement sanctions, fines or penalties could have a material adverse effect upon our business, financial condition or results of operations. Furthermore, should we lose licenses or certifications for a number of our facilities or other businesses as a result of regulatory action or legal proceedings, we could be deemed to be in default under some of our agreements, including agreements governing outstanding indebtedness.
Public and government calls for increased survey and enforcement efforts toward SNFs, and potential rulemaking that may result in enhanced enforcement and penalties, could result in increased scrutiny by state and federal survey agencies. In addition, potential sanctions and remedies based upon alleged regulatory deficiencies could negatively affect our financial condition and results of operations.

As CMS turns its attention to enhancing enforcement activities towards SNFs, as discussed in Item 1., under Government Regulation, state survey agencies will have more accountability for their survey and enforcement efforts. The enhanced penalties against SFFs under the Biden-Harris Administration, discussed in greater detail in Item 1., under Government Regulation, represents further federal calls for oversight and penalties for low-ranked and underperforming SNFs. These enhanced penalties and enforcement activities precedes greater focus by CMS in obtaining oversight over SFFs, and continuing that oversight even after those SFFs improve, and subjecting them to more exacting and routine oversight. The likely result may be more frequent surveys of our independent subsidiaries, with more substantial penalties, fines and consequences if they do not perform well. For low-performing facilities in the SFF program, the standards for successfully emerging from that program and not being subject to ongoing and enhanced government oversight will be higher and measured over a longer period of time, prolonging the risks of monetary penalties, fines and potential suspension or exclusion from the Medicare and Medicaid programs.

As discussed in Item 1., under Government Regulation, from time to time in the ordinary course of business, we receive deficiency reports from state and federal regulatory bodies resulting from such inspections or surveys. CMS's updated guidance to these surveyors incorporate recent changes to CMS’s methods for surveying infection control procedures. Additionally, CMS's recently finalized rule requiring disclosure of ownership and financial relationships between nursing facilities and property owners or management entities, as well as other state rules over ownership transparency, may provide an additional basis for further investigation, administrative action, and ultimately fines, penalties, or sanctions and could dissuade individuals and businesses from doing business with us or our independent subsidiaries.


40

Although most inspection deficiencies are resolved through an agreed-upon plan of corrective action, the reviewing agency typically has the authority to take further action against a licensed or certified facility. These remedial actions could result in the imposition of fines, imposition of a license to a conditional or provisional status, suspension or revocation of a license, suspension or denial of payment for new admissions, loss of certification as a provider under state or federal healthcare programs, or imposition of other sanctions, including criminal penalties. In the past, we have experienced inspection deficiencies that have resulted in the imposition of a provisional license and could experience these results in the future.

Furthermore, in some states, citation of one independent subsidiaries could negatively impact other independent subsidiaries in the same state. Revocation of a license at a given facility could therefore impair our ability to obtain new licenses or to renew, or maintain, existing licenses at other facilities, which may also trigger defaults or cross-defaults under our leases and our credit arrangements, or adversely affect our ability to operate or obtain financing in the future. CMS’s proposed rules requiring disclosure of ownership, management and the owners of real property lessors or sublessors, which are greater and more intrusive than existing disclosure requirements heighten this risk. Our failure to comply with applicable legal and regulatory requirements in any single facility could negatively impact our financial condition and results of operations.

From time to time, we have opted to voluntarily stop accepting new patients pending completion of a new state survey, in order to avoid possible denial of payment for new admissions during the deficiency cure period, or simply to avoid straining staff and other resources while retraining staff, upgrading operating systems or making other operational improvements. If we elect to voluntary close any operations in the future or to opt to stop accepting new patients pending completion of a state or federal survey, it could negatively impact our financial condition and results of operation.

We have received notices of potential sanctions and remedies based upon alleged regulatory deficiencies from time to time, and such sanctions have been imposed on some of our independent subsidiaries. We have had independent subsidiaries placed on SFF status in the past and other independent subsidiaries may be identified for such status in the future. We currently have one facility placed on SFF status.
CMS’s changes to the SFF program and its look-back period may create greater risk of our facilities being subject to this program and subject to potential fines and sanctions, even after graduating from the SFF program.

As discussed in discussed in greater detail in Item 1., under Government Regulation, in October of 2022 CMS updated the SFF program with the intent to reduce the amount of time a SNF spends as an SFF and increase the number of nursing homes that progress through the SFF program. CMS clarified certain details of the SFF program updates in 2023 and how they are to be implemented by each state survey agency (SA). As part of the revisions to the SFF program, a priority in revising the SFF program was to address “yo-yo” noncompliance of SNFs that would graduate from the SFF program only to later see their compliance and quality measures regress after graduation, potentially requiring readmission to the SFF program. Among the measures implemented to avoid this issue of “yo-yo” noncompliance was a three-year lookback period for facilities that graduate from the SFF program to ensure that the quality and compliance improvements achieved through the SFF program were sustained. Facilities that graduate from the SFF program but continue to demonstrate poor compliance as evidenced by any SA’s survey, such as for actual harm, substandard quality of care, or immediate jeopardy deficiencies, may be subject to enhanced enforcement by CMS, up to and including termination from the Medicare and/or Medicaid programs.

This three-year lookback for sustained improvements by facilities that graduate the SFF program poses risk for our independent subsidiaries, specifically those that may be subject to the SFF program or that have been subject to the SFF program in the past. As of December 31, 2023, we have three facilities graduated from the SFF program within the past three years. First, for SNFs that are selected by CMS for participation in the SFF program, or which currently are in the SFF program, even graduation from the program is no longer an assurance that the SNF will be able to continue its operations. Even one survey with a significant compliance deficiency, such as actual harm or an immediate jeopardy deficiency, may result in CMS—acting solely within its discretion—terminating the SNF’s Medicare or Medicaid participation, likely triggering the termination of other payor contracts and rendering the facility economically unviable. Second, and relatedly, for SNFs that have graduated from the SFF program, they are subject to a three-year period of enhanced scrutiny where adverse findings by a SA and a single survey’s finding of poor compliance may result in CMS discretionarily terminating that facility’s Medicare and/or Medicaid participation, which would likely cause other payors to terminate their agreements with the facility as well. As a result, the financial and manpower resources needed for graduation from the SFF program may be for nothing if, in the three years following graduation from the SFF program, a SNF receives a poor survey result and permits CMS to impose fines and penalties up to the termination of the facility’s Medicare and Medicaid participation.

41

As discussed above, Medicare and Medicaid represent significant sources of payment for our independent subsidiaries. Any of our facilities’ loss of a Medicare or Medicaid contract would significantly harm the financial performance of that facility. Additionally, if CMS perceived there to be common upstream ownership of multiple facilities that were participants in or graduates of the SFF program, CMS may seek to take enforcement actions against those other facilities due to their common ownership based on another facility’s deficiencies after graduating the SFF program, with CMS imposing penalties up to and potentially including termination of those SNFs’ participation in the Medicare and/or Medicaid programs.
Federal minimum staffing mandates may adversely affect our labor costs, ability to maintain desired levels of patient or resident capacity, and profitability.

On September 1, 2023, CMS issued a proposed rule setting forth proposed minimum nurse staffing requirements for SNFs. As discussed in more detail in Item 1., under Government Regulation, this proposed rule contains three primary staffing proposals: 1) minimum nurse staffing standards of 0.55 HPRD for RNs and 2.45 HPRD for NAs; 2) a requirement to have a RN on-site 24 hours per day, seven days per week; and 3) requirements for enhanced facility assessments. The proposed rule features a staggered implementation of these requirements, with potential accommodations for facilities that can demonstrate financial hardship and a delayed implementation schedule for rural facilities. Within this proposed rule, CMS also seeks comments about other staffing models, including alternate, higher standards for imposing staffing minimums, which will have a potentially adverse effect on our operations and profitability, the extent of which currently is not known.

While the full effects of these proposed federal staff level minimums are not fully known at this time, the expected effects likely will be studied by industry groups in the coming months, to include within responsive comments submitted to CMS for consideration while any final rule is being prepared. The exact effects of these proposed minimum staffing levels cannot be ascertained without a final rule that will specify the required number of staff for the Company’s independent subsidiaries to comply with such a regulation, we expect that such a mandate will have adverse financial consequences upon our business. Depending on the requirements of a final mandate and the time period over which its requirements are phased in, we may be required to hire substantially more staff members, particularly nurse practitioners, registered nurses, licensed practical nurses and nursing aides than currently staffed. Additionally, a federal mandate of this nature would place similar pressure on our competitors and result in sudden, expanded demand for nursing staff across the SNF industry. This sudden demand across the SNF industry may exacerbate an already difficult labor market, with demand for nursing staff far outstripping the supply of qualified individuals, and the salary requirements of both current and prospective staff increasing markedly to increase the likelihood of recruiting and retaining skilled caregivers.
Future cost containment initiatives undertaken by private third-party payors may limit our revenue and profitability.

Our non-Medicare and non-Medicaid revenue and profitability are affected by continuing efforts of third-party payors to maintain or reduce costs of healthcare, such as by lowering payment rates, narrowing the scope of covered services, increasing case management review of services and negotiating pricing. In addition, sustained unfavorable economic conditions may affect the number of patients enrolled in managed care programs and the profitability of managed care companies, which could result in reduced payment rates.

Third-party payors may not make timely payments for our services, and we may be unable to maintain our current payor or revenue mix. We are continuing our efforts to develop our non-Medicare and non-Medicaid sources of revenue and any changes in payment levels from current or future third-party payors could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.
Changes in Medicare reimbursements for physician and non-physician services could impact reimbursement for medical professionals.

As discussed in greater detail in Item 1., under Government Regulation, MACRA revised the payment system for physician and non-physician services. The changes to the therapy caps imposed on Medicare Part B outpatient therapy from this law have been changed by the BBA, and are subject to future budgetary changes through rulemaking and legislation, resulting in ongoing uncertainty regarding payment for these Medicare Part B services. Under the CY 2024 PF Final Rule, reductions in conversion factor, payments to providers and conditions imposed in exchange for higher payments may impose operational requirements and working conditions that further detract from and reduce our financial performance. Similarly, new final rules concerning the PACE program and the information it will collect from our independent subsidiaries may adversely affect the risk-adjusted reimbursement.


42

We face numerous risks related to the COVID-19 PHE’s expiration and surrounding wind-down and uncertainty, which could individually or in the aggregate have a material adverse effect on our business, financial condition, liquidity, results of operations and prospects.

The extent to which the COVID-19 PHE's termination will affect our operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence. The remains uncertainty as to what changes will be made to HHS’s emergency response requirements for our SNFs and senior living facilities in order to better respond to the issues experienced during the COVID-19 PHE. Additionally, the expiration of the Emergency Waivers and other flexibilities allowed under the COVID-19 PHE create the risk of non-compliance and delays in operation as more attention is required to ensure that our operations comply with applicable laws and regulations.

As discussed in Item 1., under Government Regulation, federal, state and local regulators implemented new regulations and waived existing regulations to promote care delivery during the COVID-19 PHE, which ended as of May 11, 2023. The ending of the Emergency Waivers and wind-down of other flexibilities may require and continue to require operational change requirements on short notice. The reinstatement of waived state and federal regulations has not occurred simultaneously, requiring heightened monitoring to ensure compliance.

We and our independent subsidiaries may face continued challenges from ongoing infection control and emergency preparedness requirements made part of state laws or regulations as a result of the COVID-19 endemic. Additionally, the long-term effects of the COVID-19 pandemic may include long-term decline in demand for care in SNFs and senior living facilities, which will be borne out only through time. The extent and duration of the impact of the COVID-19 pandemic on our stock price is uncertain, our stock price may be more volatile, and our ability to raise capital could be impacted.
We may be subject to increased investigation and enforcement activities related to HIPAA violations.

HIPAA, as amended by the HITECH Act, requires us to adopt and maintain business procedures and systems designed to protect the privacy, security and integrity of patients' individual health information, in addition to state laws governing the privacy of patient information. We must comply with these state privacy laws to the extent that they are more protective of healthcare information or provide additional protections not afforded by HIPAA. The regulations enacting HIPAA periodically change and the last proposed change was issued in late 2022. This proposed rulemaking may be made final in 2023 and, if adopted as proposed, may require our independent subsidiaries to modify certain policies, procedures and practices regarding the disclosure of residents’ information. If we fail to comply with these state and federal laws, we could be subject to criminal penalties, civil sanctions, litigation, and be forced to modify our policies and procedures, in addition to undertaking costly breach notification and remediation efforts, as well as sustaining reputational harm.

In addition to breaches of protected patient information, under HIPAA and the 21st Century Cures Act (Cures Act) and other federal regulations, healthcare entities are also required to afford patients with certain rights of access to their health information and to promote sharing of patient data between and among healthcare providers involved in the same patient's course of care. Recently, the Office for Civil Rights, the agency responsible for HIPAA enforcement, has targeted investigative and enforcement efforts on violations of patients’ rights of access, imposing significant fines for violations largely initiated from patient complaints. If we fail to comply with our obligations under HIPAA, we could face significant fines. Likewise, if we fail to comply with our obligations under the Cures Act, we could face fines from the Office of the National Coordinator for Health Information Technology, the agency responsible for Cures Act enforcement.
Security breaches and other cyber-security incidents could violate security laws and subject us to significant liability.

Healthcare businesses are increasingly the target of cyberattacks whereby hackers disrupt business operations or obtain protected health information, often demanding large ransoms. At the end of the first quarter of 2023, the healthcare sector saw a 60% increase in the average weekly number of cyberattacks over 2021. By August of 2023, industry observers note that cybersecurity breaches in the healthcare industry had become less frequent, but larger in scope and affecting more patients than the prior year. Our business is dependent on the proper functioning and availability of our computer systems and networks. We cannot assure you that our safety and security measures and disaster recovery plan will prevent damage, interruption or breach of our information systems and operations. Additionally, we cannot control the safety and security of our information held by third-party vendors with whom we contract. The techniques used to obtain unauthorized access, disable or degrade service, or sabotage systems change frequently and may be difficult to detect, and as such we (or third-party vendors) may be unable to anticipate these techniques or implement adequate preventive measures. In addition, hardware, software or applications we (or third-party vendors) develop or procure from third parties may contain defects in design or manufacture or other problems that could unexpectedly compromise the security of information systems.
43

Unauthorized parties may attempt to gain access to our systems or facilities, or those of third parties with whom we do business, through fraud or other forms of deception.

On occasion, we have acquired additional information systems through our business acquisitions, and these acquired systems may expose us to risk. We also license certain third-party software to support our operations and information systems. Our inability, or the inability of third-party vendors, to continue to maintain and upgrade information systems and software could disrupt or reduce the efficiency of our operations. In addition, costs and potential problems and interruptions associated with the implementation of new or upgraded systems and technology or with maintenance or adequate support of existing systems also could disrupt or reduce the efficiency of our operations.

A cyber-attack or other incident that bypasses the security measures of our information systems could cause a security breach, which may lead to a material disruption to our information systems infrastructure or business, significant costs to remediate (e.g., data recovery) and may involve a significant loss of business or patient health information. If a cyber-attack or other unauthorized attempt to access our systems or facilities were successful, it could also result in the theft, destruction, loss, misappropriation or release of confidential information or intellectual property, and could cause operational or business delays that may materially impact our ability to provide various healthcare services. Any successful cyber-attack or other unauthorized attempt to access our systems or facilities also could result in negative publicity which could damage our reputation or brand with our patients, referral sources, payors or other third parties and could subject us to a number of adverse consequences, the vast majority of which are not insurable, including but not limited to, disruptions in our operations, regulatory and other civil and criminal penalties, fines, investigations and enforcement actions (including, but not limited to, those arising from the SEC, Federal Trade Commission, Office of Civil Rights, the OIG or state attorneys general), fines, private litigation with those affected by the data breach (including class action litigation), loss of customers, disputes with payors and increased operating expense, which either individually or in the aggregate could have a material adverse effect on our business, financial position, results of operations, liquidity, and stock price.
We may not be fully reimbursed for all services for which each facility bills through consolidated billing, which could adversely affect our revenue, financial condition and results of operations.

SNFs are required to perform consolidated billing for certain items and services furnished to patients and residents. The consolidated billing requirement requires the SNF to effectively bill for the entire package of care that its patients receive in these situations. Post-hospitalization skilled nursing services must be “bundled” into the hospital's diagnostic related group (DRG) payment in certain circumstances, in which case the hospital and SNF must effectively divide the payment that otherwise would have been made to the hospital. Although this practice is uncommon, it adversely affects SNF utilization and payments, whether due to the practical difficulty of this apportionment or hospitals being reluctant to lose revenue by discharging patients to a SNF. If more payments are required to be bundled in the future, this trend may continue, with our SNFs not receiving full reimbursement for all the services they provide, and have a further adverse effect on SNF utilization and revenue.
Increased competition for, or a shortage of, nurses and other skilled personnel could increase our staffing and labor costs and subject us to monetary fines.

Our success depends upon our ability to retain and attract nurses and other skilled personnel, such as Certified Nurse Assistants, social workers and speech, physical and occupational therapists, as well as skilled management personnel responsible for day-to-day facility operation. Each facility has a facility leader responsible for the overall day-to-day operations of the facility, including quality of care, social services and financial performance. Depending upon the size of the facility, each facility leader is supported by facility staff who are directly responsible for day-to-day care of the patients, marketing and community outreach programs. Other key positions supporting each facility may include individuals responsible for physical, occupational and speech therapy, food service and maintenance. We compete with various healthcare service providers, including other skilled nursing providers, in retaining and attracting qualified and skilled personnel.

Our independent SNFs are located in the states of Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Tennessee, Texas, Utah, Washington and Wisconsin. All states follow the current federal regulation relative to staffing, which establishes that SNFs are required to staff to meet the needs of the residents present in the facility. In addition, several states have established minimum staffing requirements for facilities operating in those states.

44

Failure to comply with these requirements can, among other things, jeopardize a facility's compliance with the conditions of participation under relevant state and federal healthcare programs. If a facility is determined to be out of compliance with these requirements, it may be subject to a notice of deficiency, a citation, or a significant fine or litigation risk, with penalties including the suspension of patient admissions and the termination of Medicaid participation, or the suspension, revocation or non-renewal of the SNF's license.

On September 1, 2023, CMS published a long-awaited proposed rule setting forth proposed SNF minimum staffing requirements at the federal level. In relevant part, these proposed federal standards require 1) minimum nurse staffing standards of 0.55 HPRD for RNs and 2.45 HPRD for NAs; and 2) a requirement to have a RN on-site 24 hours per day, seven days per week. This proposed rule contains numerous other provisions discussed in more detail in Item 1., under Government Regulation. Comments are still being submitted for this proposed rule, and the substance of both the comments and any revisions to the later-issued final rule setting forth minimum staffing requirements may influence the effect that this rule has on our business and its financial performance.

Nonetheless, for the federal government or any state government to materially change the way compliance with the minimum staffing standard is calculated or enforced, our labor costs could increase and the current shortage of healthcare workers could impact us more significantly. The broader labor market where we compete is in a state of disequilibrium where the needs of businesses such as ours outstrip the supply of available and willing workers. There is additional upward pressure on wages from different industries and more generally due to the current rate of inflation. Some of these industries compete with us for labor and others that do not, which makes it difficult to make significant hourly wage and salary increases due to the fixed nature of our reimbursement under insurance contracts as well as Medicare and Medicaid, in addition to our increasing variable costs. Due to the limited supply of qualified applicants who seek or are willing to accept employment, these broader concerns, may increase our labor costs or lead to potential staffing shortages, reduced operations to comply with applicable laws and regulations, or difficulty complying with those laws and regulations at current operational levels.

Federal laws and regulations, including the proposed minimum nurse staffing levels if they are made final, may increase our costs of maintaining qualified nursing and skilled personnel, or make it more difficult for us to attract or retain qualified nurses and skilled staff members. Proposed legislation, such as the previously proposed Nursing Home Improvement Act and the proposed HCBS Access Act, may make it more expensive to compete for, hire, and retain nursing staff, if passed into law in substantially the same form as previously introduced to Congress. The Biden-Harris Administration's desire to increase staffing level requirements for the nursing home industry and to tie reimbursement to the salary, benefits, and retention of staff also may increase our labor costs. CMS has published guidance to surveyors addressing topics that specifically include nurse staffing and collection of payroll data to evaluate appropriate staffing levels, which may lead to future regulation that increase our staffing requirements and labor costs or lower revenues.

Similar state-level requirements in the states where our independent SNFs operate, whether such requirements are passed by statute, regulation, or executive order, may result in a shortage or inability to obtain nurses and skilled staff. Prior concerns about the COVID-19 vaccination IFR may be abated by the Omnibus Final Rule’s withdrawal of that IFR. The withdrawal of the COVID-19 vaccination IFR may allow for nursing and other personnel unwilling to receive the COVID-19 vaccination to re-enter the workforce for Medicare-certified facilities and increase the pool of hirable talent.

Increased competition for, or a shortage of, nurses or other trained personnel, or general ongoing inflationary pressures may require that we enhance our pay and benefits packages to compete effectively for such personnel. Turnover rates and the magnitude of the shortage of nurses or other trained personnel vary substantially from facility to facility, and may adversely affect those facilities' quality ratings based on data reported to CMS. In addition, state laws regarding minimum wage increases, such as California’s minimum wage increases for both health care and fast-food workers, may intensify competition for unskilled labor in both skilled and unskilled settings. For skilled workers within the skilled care market where we operate, the costs of skilled labor, which are already greater than unskilled labor, could increase further. Similarly, the increased minimum wage of unskilled labor will not only increase the cost of unskilled labor, but may also have effects that dissuade workers from training to join the skilled workforce to earn higher wage growth, resulting in a smaller pool of available skilled workers and further increased competition—and higher wages—for them. If we fail to attract and retain qualified and skilled personnel, our ability to conduct our business operations could be harmed.

45

Annual caps and other cost-reductions for outpatient therapy services may reduce our future revenue and profitability or cause us to incur losses.

As discussed in detail in Item 1., under Government Regulation, sub-heading Part B Rehabilitation Requirements, several government actions have been taken in recent years to try and contain the costs of rehabilitation therapy services provided under Medicare Part B, including the MPPR, institution of annual caps, mandatory medical reviews for annual claims beyond a certain monetary threshold, and a reduction in reimbursement rates for therapy assistant claim modifiers. Of specific concern has been CMS efforts to lower Medicare Part B reimbursement rates for outpatient therapy services in 2021, 2022 and 2023. Such cost-containment measures and ongoing payment changes could have an adverse effect on our revenue.
The Office of the Inspector General or other regulatory authorities may choose to more closely scrutinize billing practices in areas where we operate or propose to expand, which could result in an increase in regulatory monitoring and oversight, decreased reimbursement rates, or otherwise adversely affect our business, financial condition and results of operations.

As discussed in greater detail in Item 1., under Government Regulation, Civil and Criminal Fraud and Abuse Laws and Enforcement, the OIG regularly conducts investigations regarding certain payment or compliance issues within the healthcare industry. The OIG identified SNF compliance as an issue of concern in its 2021 and 2022 semi-annual reports to Congress, and its January 2023 study regarding SNF emergency preparedness identified the need for further oversight and addition of SNF emergency readiness to the OIG's 2023 work plan. In November of 2023, OIG added to its work plan an audit of nursing homes' nurse staffing hours reported in CMS's payroll-based journal, for which OIG expects to issue a report in FY 2025. Nursing homes were also a topic of discussion in the OIG’s 2023 semiannual report to Congress, which emphasized the continued protection and oversight of care that nursing facilities provide to residents. Among other things, the OIG recommended a reduction in the use of psychotropic drugs in nursing homes and urged CMS to evaluate the appropriateness of psychotropic drug use among residents, including the use of data to identify nursing homes with higher rates of use for potential further scrutiny and action. Based on this information, SNFs in particular are potential targets for more robust scrutiny and examination by regulators. Recent publications and statements by the Biden-Harris Administration have also called for greater scrutiny of SNF facilities.

To respond to the local community needs and the shifting of higher acuity patients from the acute care setting to the SNF setting, over time our overall patient mix has consistently shifted to higher acuity and higher-resource utilization patients in most facilities we operate. We also use specialized care-delivery software that assists our caregivers in more accurately capturing and recording activities of daily living services, among other things. These efforts may place us under greater scrutiny with the OIG, CMS, our fiscal intermediaries, recovery audit contractors and others.
State efforts to regulate or deregulate the healthcare services industry or the construction or expansion of healthcare facilities could impair our ability to expand our operations, or could result in increased competition.

Some states require healthcare providers, including SNFs, to obtain prior approval, known as a certificate of need, for: (1) the purchase, construction or expansion of healthcare facilities; (2) capital expenditures exceeding a prescribed amount; or (3) changes in services or bed capacity.

Other states that do not require certificates of need have effectively barred the expansion of existing facilities and the establishment of new ones by placing partial or complete moratoria on the number of new Medicaid beds those states will certify in certain areas or throughout the entire state. Still other states have established such stringent development standards and approval procedures for constructing new healthcare facilities that the construction of new facilities, or the expansion or renovation of existing facilities, may become cost-prohibitive or extremely time-consuming. In addition, some states require the approval of the state Attorney General for acquisition of a facility being operated by a non-profit organization.

Our ability to acquire or construct new facilities or expand or provide new services at existing facilities would be adversely affected if we are unable to obtain the necessary approvals, if there are changes in the standards applicable to those approvals, or if we experience delays and increased expenses associated with obtaining those approvals. We may not be able to obtain licensure, certificate of need approval, Medicaid certification, state Attorney General approval or other necessary approvals for future expansion projects. Conversely, the elimination or reduction of state regulations that limit the construction, expansion or renovation of new or existing facilities could result in increased competition to us or result in overbuilding of facilities in some of our markets. If overbuilding in the skilled nursing industry in the markets in which we operate were to occur, it could reduce the occupancy rates of existing facilities and, in some cases, might reduce the private rates that we charge for our services.

46

Newly enacted and proposed legislation in the States where our independent subsidiaries are located may affect our operations in terms of individual litigation and the broader regulatory environment.

A bill in the State of California was recently signed into law which increases the cap of non-economic damages awarded to plaintiffs who are successful in medical malpractice litigation. The cap increases from $0.25 million to $0.35 million beginning on January 1, 2023, then increases over the following 10 years until the cap reaches a maximum of $0.75 million, with further adjustments for inflation. In wrongful death cases, the cap increases from $0.25 million to $0.5 million on January 1, 2023, with incremental increases over the following 10 years until the cap reaches a maximum of $1.0 million, with adjustments for inflation. Due to California's influence on other states, other jurisdictions where we operate may enact similar laws. Similar to the potential incentive of increased damages caps, the Supreme Court’s recent decision in certain case may increase public interest in potential claims against SNFs and senior living facilities, particularly pertaining to specific civil rights claims against governmental actors rather than general liability claims against privately owned SNFs such as those operated by our independent subsidiaries. While there may be additional claims and litigation that arise from the Supreme Court's decision that have an adverse impact on our cash flow, it is not expected that the decision will have a significant impact on our business.

Another example, California’s adoption of the Skilled Nursing Facility Ownership and Management Reform Act of 2022, discussed in Item 1., Government Regulation, imposes new requirements for obtaining licenses to operate SNFs. These new requirements may delay or limit the ability to obtain new SNF licenses within that state, whether through acquisition of existing facilities or opening a new facility. This new law's obligations may increase the costs of obtaining licensure, make applications more time-consuming and complex, and may result in civil penalties and other sanctions against our independent subsidiaries in the event they are not compliant with these new licensure application requirements. As a result, this new law may delay or impede growth within California. As with the bill that increases the cap of non-economic damages for medical malpractice litigation, California’s influence on other states may result in this legislation becoming a model for other states and having similar, potentially adverse effects within those jurisdictions as well.

More recently, California’s legislature has proposed bills related to increasing the minimum wage for workers, spending requirements and increased disclosure. As discussed in Item 1., Government Regulation, these proposed bills would create new and costly obligations on our independent subsidiaries if they became law and if enacted, would adversely affect our business, operations, and profitability.

As another example, Texas passed a bill which partially restored Medicaid state relief funding for SNFs through August 31, 2023, while it also considered legislation that contained direct care spending requirements and ownership, similar to proposed federal rulemaking discussed in Item 1., Government Regulation. While this bill provided financial relief to our independent subsidiaries in Texas, other proposed bills may impose the same regulatory requirements and limitations inherent in both the proposed legislation in other states and the federally proposed rule requiring disclosure of such information in applications and change-of-ownership disclosures, which may adversely affect our business, operations, and profitability.
Changes to federal and state employment-related laws and regulations could increase our cost of doing business.

Our independent subsidiaries are subject to a variety of federal and state employment-related laws and regulations, including, but not limited to, the U.S. Fair Labor Standards Act that governs such matters as minimum wages, overtime and other working conditions, the ADA and similar state laws that provide civil rights protections to individuals with disabilities in the context of employment, public accommodations and other areas, the National Labor Relations Act, regulations of the EEOC, regulations of the Office of Civil Rights, regulations of state attorney generals, family leave mandates and a variety of similar laws enacted by the federal and state governments that govern these and other employment law matters.

On October 13, 2023, the California Governor signed into law a bill that impacts the minimum wage of healthcare workers. Effective June 1, 2024, the law raises the minimum wage for California healthcare employees and sets a new standard salary threshold for those who are considered exempt healthcare employees. The bill only becomes effective for SNFs if a patient care minimum spending bill is also passed, which is expected to be introduced in the near future. If the minimum wage that must be paid to SNF employees in California increases, this would result in increased labor costs and challenges achieving or maintaining profitability within the state. Further, as states raise industry specific minimum wages employees will anticipate higher pay, placing additional pressure on our business to meet wage demands and compete for skilled talent in an already challenging labor market.


47

The Biden-Harris Administration has requested HHS and CMS study and issue proposed rules regarding care-based careers, including improving access to training, increasing the attractiveness of compensation in care-based positions, and improving the retention and career progression of care workers. The administration has sought proposed rules that tie some of these issues, such as wages and retention, to Medicare reimbursement for facilities. Other pending legislation, such as the HCBS Access Act, indicate a legislative priority of providing funding for care-based careers that may affect our pool of desired workers. Rising operating costs due to labor shortages, greater compensation and incentives required to attract and retain qualified personnel and higher-than-usual inflation on items including energy, utilities, food and other goods used in our facilities and the costs for transporting these items could increase our cost and decrease our profits.

On September 1, 2023, CMS published a long-awaited proposed rule setting forth proposed SNF minimum staffing requirements at the federal level. In relevant part, these proposed federal standards require 1) minimum nurse staffing standards of 0.55 HPRD for RNs and 2.45 HPRD for NAs; and 2) a requirement to have a RN on-site 24 hours per day, seven days per week. This proposed rule contains numerous other provisions discussed in more detail in Item 1., under Government Regulation. Comments are still being submitted for this proposed rule, and the substance of both the comments and any revisions to the later-issued final rule setting forth minimum staffing requirements may influence the effect that this rule has on our business and its financial performance. Any implementation of this proposed rule, however, is likely to increase demand for labor, including skilled caregivers, increase our costs, and may adversely affect our financial performance.

The compliance costs associated with these laws and evolving regulations could be substantial. By way of example, all of our independent subsidiaries are required to comply with the ADA, which has separate compliance requirements for “public accommodations” and “commercial properties,” but generally requires that buildings be made accessible to people with disabilities. Compliance with ADA requirements could require removal of access barriers and non-compliance could result in imposition of government fines or an award of damages to private litigants. Further legislation may impose additional burdens or restrictions with respect to access by disabled persons. In addition, federal proposals to introduce a system of mandated health insurance and flexible work time and other similar initiatives could, if implemented, adversely affect our operations. We also may be subject to employee-related claims such as wrongful discharge, discrimination or violation of equal employment law. While we are insured for these types of claims, we could be subject to damages that are not covered by our insurance policies or that exceed our insurance limits, and we may be required to pay such damages directly, which would negatively impact our cash flow from operations.
Required regulatory approvals could delay or prohibit transfers of our healthcare operations, which could result in periods in which we are unable to receive reimbursement for such properties.

The operations of our independent subsidiaries must be licensed under applicable state law and, depending upon the type of operation, certified or approved as providers under the Medicare and/or Medicaid programs. In the process of acquiring or transferring operating assets, our operations must receive change of ownership approvals from state licensing agencies, Medicare and Medicaid as well as third-party payors. Proposed rules regarding the disclosure of SNF facility ownership, if made effective, may increase the scrutiny placed on companies that operate, directly or indirectly, multiple SNFs, and may subject our licensing and approval process to additional scrutiny or delays. If there are any delays in receiving regulatory approvals from the applicable federal, state or local government agencies, or the inability to receive such approvals, such delays or denials could result in delayed or lost reimbursement related to periods of service prior to the receipt of such approvals, which could negatively impact our cash position.
Compliance with federal and state fair housing, fire, safety and other regulations may require us to make unanticipated expenditures, which could be costly to us.

We must comply with the federal Fair Housing Act and similar state laws, which prohibit us from discriminating against individuals if it would cause such individuals to face barriers in gaining residency in any of our independent subsidiaries. Additionally, the Fair Housing Act and other similar state laws require that we advertise our services in such a way that we promote diversity and not limit it. We may be required, among other things, to change our marketing techniques to comply with these requirements.


48

In addition, our independent subsidiaries are required to operate in compliance with applicable fire and safety regulations, building codes and other land use regulations and food licensing or certification requirements as they may be adopted by governmental agencies and bodies from time to time. Like other healthcare facilities, our independent SNFs are subject to periodic surveys or inspections by governmental authorities to assess and assure compliance with regulatory requirements. Surveys occur on a regular (often annual or biannual) schedule, and special surveys may result from a specific complaint filed by a patient, a family member or one of our competitors. We may be required to make substantial capital expenditures to comply with these requirements. In some cases, we may be unable to comply with new regulations prior to their effective date exposing us to potential fines or regulatory action.
We depend largely upon reimbursement from third-party payors, and our revenue, financial condition and results of operations could be negatively impacted by any changes in the acuity mix of patients in our independent subsidiaries as well as payor mix and payment methodologies.

Our revenue is affected by the percentage of the patients of our independent subsidiaries who require a high level of skilled nursing and rehabilitative care, whom we refer to as high acuity patients, and by our mix of payment sources. Changes in the acuity level of patients we attract, as well as our payor mix among Medicaid, Medicare, private payors and managed care companies, significantly affect our profitability. We generally receive higher reimbursement rates for high acuity patients, and payors reimburse us at different rates. For the year ended December 31, 2023 and 2022, 72.6% and 73.7%, of our revenue was provided by government payors that reimburse us at predetermined rates, respectively. If our labor or other operating costs increase, we will be unable to recover such increased costs from government payors. Accordingly, if we fail to maintain our proportion of high acuity patients or if there is any significant increase in the percentage of the patients of our independent subsidiaries for whom we receive Medicaid reimbursement, our results of operations may be adversely affected.

Initiatives undertaken by major insurers and managed care companies to contain healthcare costs may adversely affect our business. These tactics include contracting with healthcare providers to obtain services on a discounted basis. We believe that this trend will continue and may limit reimbursements for healthcare services. If insurers or managed care companies from whom we receive substantial payments were to reduce the amounts they pay for services and we did not wish to accept such reductions, we may lose patients if we choose not to renew our contracts with these insurers at lower rates. Additionally, trade publications within the healthcare industry have reported on the trend of payors using the No Surprises Act as a means to force re-negotiation of reimbursement rates for providers and facilities, leading to litigation between these providers and/or facilities against payors and it may adversely affect us as well.

As discussed under Item 1., Government Regulation, the Biden-Harris Administration has requested HHS and CMS conduct studies to evaluate potential staffing, data reporting, employee compensation and retention, and resident experience regulations that may result in a reduction of our revenue from Medicare and Medicaid. CMS first requested information regarding these priorities in 2022 and subsequently published further requests for information from the public in the Federal Register to aid in studies and anticipated rulemaking. CMS's proposed rule regarding disclosure of significant information regarding their ownership, operations, management and the owners of real property leased or subleased by our independent subsidiaries, may result in additional regulatory requirements for participation in those programs.
We are subject to litigation that could result in significant legal costs and large settlement amounts or damage awards.

The skilled nursing business involves a significant risk of liability given the age and health of the patients and residents of our independent subsidiaries and the services we provide. The industry has experienced an increased trend in the number and severity of litigation claims, due in part to the number of large verdicts, including large punitive damage awards. These claims are filed based upon a wide variety of claims and theories, including deficiencies under conditions of participation under certain state and federal healthcare programs. Plaintiffs' attorneys have become increasingly more aggressive in their pursuit of claims against healthcare providers, including skilled nursing providers, employing a wide variety of advertising and solicitation activities to generate more claims. The increased caps on damages awarded in such actions, as discussed above, may trigger a larger number of these lawsuits against our independent subsidiaries in California and other states that adopt similar legislation. The defense of lawsuits has in the past, and may in the future, result in significant legal costs, regardless of the outcome. Additionally, increases to the frequency and/or severity of losses from such claims and suits may result in increased liability insurance premiums or a decline in available insurance coverage levels, which could materially and adversely affect our business, financial condition and results of operations.


49

We have in the past been subject to class action litigation involving claims of violations of various regulatory requirements and been able to settle these claims without an ongoing material adverse effect on our business. Future claims could be brought that may materially affect our business, financial condition and results of operations. Other claims and suits, including class actions, continue to be filed against us and other companies in our industry. For example, there has been a general increase in the number of wage and hour class action claims filed in several of the jurisdictions where we operate, typically based on alleged failures to permit or properly compensate for meal and rest periods, or failure to pay for time worked. If there were a significant increase in the number of these claims against us or an increase in amounts owing should plaintiffs be successful in their claims, this could have a material adverse effect to our business, financial condition, results of operations and cash flows.

We are subject to potential lawsuits under the FCA and comparable state laws alleging submission of fraudulent claims for services to any healthcare program (such as Medicare or Medicaid) or other payor. Under the qui tam or "whistleblower" provisions of the FCA, a private individual with knowledge of fraud or potential fraud may bring a claim on behalf of the federal government and receive a percentage of the federal government's recovery. Due to these whistleblower incentives, qui tam lawsuits have become more frequent. For example, despite the decision of the DOJ to decline to participate in litigation based on the subject matter of its previously issued CID, the involved qui tam relator moved forward with the complaint in December 2020. Refer to Item 3. Legal Proceedings for additional information on this case.

Beyond our skilled nursing business, we engage in numerous ancillary businesses through one or more of our subsidiaries. These ancillary businesses generally support and provide services complementary to our operations, including but not limited to non-emergent ground transportation for patients and residents. Our ancillary businesses may also be the subject of claims, lawsuits, and regulatory oversight that are specific to the particular services they offer. Noncompliance with the laws and regulations that may apply to our ancillary businesses may result in fines, penalties, and civil claims paid by our affected independent subsidiaries. Specific to our non-emergent ground transportation business, the drivers employed by this business may be subject to additional state-specific regulations regarding working time allowed to be spent driving, waiting time, and break or rest periods, and violations of these rules may lead to regulatory fines, penalties, or claims to be paid to individual drivers, in addition to the general employment risks described above.

Our ancillary businesses also are susceptible to general liability claims based on facts and circumstances that are specific to their activities and operations, such as claims for automobile-involved accidents against our non-emergent ground transportation business. The defense of claims and lawsuits relating to our ancillary businesses in the past, and may in the future, result in significant legal costs, regardless of the outcome. As our ancillary businesses grow, the independent subsidiaries may be subject to increased frequency and/or severity of losses from such claims and suits which may result in increased liability insurance premiums and decline in available coverage as described above, which could materially and adversely affect our business, financial condition and results of operations.

In addition, we contract with a variety of landlords, lenders, vendors, suppliers, consultants and other individuals and businesses. These contracts typically contain covenants and default provisions. If the other party to one or more of our contracts were to allege that we have violated the contract terms, we could be subject to civil liabilities which could have a material adverse effect on our financial condition and results of operations.

If litigation is instituted against one or more of our subsidiaries, a successful plaintiff might attempt to hold us or another subsidiary liable for the alleged wrongdoing of the subsidiary principally targeted by the litigation. If a court in such litigation decided to disregard the corporate form, the resulting judgment could increase our liability and adversely affect our financial condition and results of operations.

Congress has repeatedly considered, without passage, a bill that would require, among other things, that agreements to arbitrate nursing home disputes be made after the dispute has arisen rather than before prospective patients move in, to prevent nursing home operators and prospective patients from mutually entering into a pre-admission pre-dispute arbitration agreement. This bill, known as the Fairness in Nursing Home Arbitration Act, was introduced in the House of Representatives in 2021; the bill and its analogue introduced in the Senate have never made it out of the committees to which they were referred for discussion. This legislation or similar bills have not yet been introduced in the current session of Congress, which commenced at the beginning of 2023.


50

Our independent subsidiaries use arbitration agreements, which have generally been favored by the courts, to streamline the dispute resolution process and reduce our exposure to legal fees and excessive jury awards. CMS has identified these arbitration agreements as an area of focus and issued guidance to state surveyors regarding federal requirements for the use of arbitration agreements in nursing home care, with non-compliance potentially resulting in fines and other sanctions. If we are not able to secure pre-admission arbitration agreements, our litigation exposure and costs of defense in patient liability actions could increase, our liability insurance premiums could increase, and our business may be adversely affected.

The outcomes of any of these litigation matters are difficult to predict and litigation and other legal claims are subject to inherent uncertainties. Those uncertainties include, but are not limited to, litigation costs and attorneys’ fees, unpredictable judicial or jury decisions and the differing laws and judicial proclivities regarding damage awards among the states in which we operate. A further complication is that even where the possibility of an adverse outcome is remote under traditional legal analysis, juries sometimes substitute their subjective views in place of facts and established legal principles. Unexpected outcomes in such legal proceedings, or changes in management’s evaluation or predictions of the likely outcomes of such proceedings (possibly resulting in changes in established reserves) could have a material adverse effect on our business, financial condition, and results of operations.
We conduct regular internal investigations into the care delivery, recordkeeping and billing processes of our independent subsidiaries. These reviews sometimes detect instances of noncompliance which we attempt to correct, which can decrease our revenue.

As an operator of healthcare facilities, we have a program to help us comply with various requirements of federal and private healthcare programs. Our compliance program includes, among other things, (1) policies and procedures modeled after applicable laws, regulations, sub-regulatory guidance and industry practices and customs that govern the clinical, reimbursement and operational aspects of our subsidiaries; (2) training about our compliance process for all of the employees of our independent subsidiaries, our directors and officers, and training about Medicare and Medicaid laws, fraud and abuse prevention, clinical standards and practices, and claim submission and reimbursement policies and procedures for appropriate employees; and (3) internal controls that monitor, among other things, the accuracy of claims, reimbursement submissions, cost reports and source documents, provision of patient care, services, and supplies as required by applicable standards and laws, accuracy of clinical assessment and treatment documentation, and implementation of judicial and regulatory requirements (i.e., background checks, licensing and training).

From time to time our systems and controls highlight potential compliance issues, which we investigate as they arise. Historically, we have, and will continue to do so in the future, initiated internal inquiries into possible recordkeeping and related irregularities at our independent SNFs, which were detected by our internal compliance team in the course of its ongoing reviews.

Through these internal inquiries, we have identified potential deficiencies in the assessment of and recordkeeping for small subsets of patients. We have assisted in implementing, targeted improvements in the assessment and recordkeeping practices to make them consistent with the existing standards and policies applicable to our independent SNFs. We continue to monitor the measures implemented for effectiveness and perform follow-up reviews to ensure compliance. Consistent with healthcare industry accounting practices, we record any charge for refunded payments against revenue in the period in which the claim adjustment becomes known.

If additional reviews result in identification and quantification of additional amounts to be refunded, we will accrue additional liabilities for claim costs and interest, and repay any amounts due in normal course and within the time permitted by law. Failure to refund overpayments within required time frames (as described in greater detail above) could result in FCA liability and our business, financial condition and results of operations could be materially and adversely affected and our stock price could decline.
We may be unable to complete future facility or business acquisitions at attractive prices or at all, which may adversely affect our revenue; we may also elect to dispose of underperforming or non-strategic independent subsidiaries, which would also decrease our revenue.

To date, our revenue growth has been significantly impacted by our acquisition of new facilities and businesses. Subject to general market conditions and the availability of essential resources and leadership within our company, we continue to seek both single-and multi-facility acquisition and business acquisition opportunities that are consistent with our geographic, financial and operating objectives.

51

We face competition for the acquisition of facilities and businesses and expect this competition to increase. Based upon factors such as our ability to identify suitable acquisition candidates, future regulations affecting our ability to purchase facilities, the purchase price of the facilities, increasing interest rates for debt-financed purchases, prevailing market conditions, the availability of leadership to manage new facilities and our own willingness to take on new operations, the rate at which we have historically acquired facilities has fluctuated significantly. In the future, we anticipate the rate at which we may acquire facilities will continue to fluctuate, which may affect our revenue.

We have also previously acquired a few facilities, which were or have proven to be non-strategic or less desirable, and we may consider disposing of such facilities or exchanging them for facilities that are more desirable, either because they were included in larger, indivisible groups of facilities or under other circumstances. To the extent we dispose of such a facility without simultaneously acquiring a facility in exchange, our revenue may decrease.
We may not be able to successfully integrate acquired facilities and businesses into our operations, and we may not achieve the benefits we expect from any of our facility acquisitions.

We may not be able to successfully or efficiently integrate new acquisitions of facilities and businesses with our existing independent subsidiaries, culture and systems. The process of integrating acquisitions into our existing operations may result in unforeseen operating difficulties, divert management's attention from existing operations, or require an unexpected commitment of staff and financial resources, and may ultimately be unsuccessful. Existing operations available for acquisition frequently serve or target different markets than those that we currently serve. We also may determine that renovations of acquired facilities and changes in staff and operating management personnel are necessary to successfully integrate those acquisitions into our existing operations. We may not be able to recover the costs incurred to reposition or renovate newly independent subsidiaries. The financial benefits we expect to realize from many of our acquisitions are largely dependent upon our ability to improve clinical performance, overcome regulatory deficiencies, rehabilitate or improve the reputation of the operations in the community, increase and maintain occupancy, control costs, and in some cases change the patient acuity mix. If we are unable to accomplish any of these objectives at the independent subsidiaries we acquire, we will not realize the anticipated benefits and we may experience lower than anticipated profits, or even losses.
During the year ended December 31, 2023, we expanded our operations and real estate portfolio through a combination of long-term leases and real estate purchases, with the addition of 26 skilled nursing operations. This growth has placed and will continue to place significant demands on our current management resources. Our ability to manage our growth effectively and to successfully integrate new acquisitions into our existing business will require us to continue to expand our operational, financial and management information systems and to continue to retain, attract, train, motivate and manage key employees, including facility-level leaders and our local directors of nursing. We may not be successful in attracting qualified individuals necessary for future acquisitions to be successful, and our management team may expend significant time and energy working to attract qualified personnel to manage facilities we may acquire in the future. Also, the newly acquired facilities may require us to spend significant time improving services that have historically been substandard, and if we are unable to improve such facilities quickly enough, we may be subject to litigation and/or loss of licensure or certification. If we are not able to successfully overcome these and other integration challenges, we may not achieve the benefits we expect from any of our acquisitions, and our business may suffer.
In undertaking acquisitions, we may be adversely impacted by costs, liabilities and regulatory issues that may adversely affect our operations.

In undertaking acquisitions, we also may be adversely impacted by unforeseen liabilities attributable to the prior providers who operated those facilities, against whom we may have little or no recourse. Many facilities we have historically acquired were underperforming financially and had clinical and regulatory issues prior to and at the time of acquisition. Even where we have improved independent subsidiaries and patient care at facilities that we have acquired, we still may face post-acquisition regulatory issues related to pre-acquisition events. These may include, without limitation, payment recoupment related to our predecessors' prior noncompliance, the imposition of fines, penalties, operational restrictions or special regulatory status. Further, we may incur post-acquisition compliance risk due to the difficulty or impossibility of immediately or quickly bringing non-compliant facilities into full compliance. Diligence materials pertaining to acquisition targets, especially the underperforming facilities that often represent the greatest opportunity for return, are often inadequate, inaccurate or impossible to obtain, sometimes requiring us to make acquisition decisions with incomplete information. Despite our due diligence procedures, facilities that we have acquired or may acquire in the future may generate unexpectedly low returns, may cause us to incur substantial losses, may require unexpected levels of management time, expenditures or other resources, or may otherwise not meet a risk profile that our investors find acceptable.

52

In addition, we might encounter unanticipated difficulties and expenditures relating to any of the acquired facilities, including contingent liabilities. For example, when we acquire a facility, we generally assume the facility's existing Medicare provider number for purposes of billing Medicare for services. If CMS later determines that the prior owner of the facility had received overpayments from Medicare for the period of time during which it operated the facility, or had incurred fines in connection with the operation of the facility, CMS could hold us liable for repayment of the overpayments or fines. We may be unable to improve every facility that we acquire. In addition, operation of these facilities may divert management time and attention from other operations and priorities, negatively impact cash flows, result in adverse or unanticipated accounting charges, or otherwise damage other areas of our company if they are not timely and adequately improved.

We also incur regulatory risk in acquiring certain facilities due to the licensing, certification and other regulatory requirements affecting our right to operate the acquired facilities. For example, in order to acquire facilities on a predictable schedule, or to acquire declining operations quickly to prevent further pre-acquisition declines, we frequently acquire such facilities prior to receiving license approval or provider certification. We operate such facilities as the interim manager for the outgoing licensee, assuming financial responsibility, among other obligations for the facility. To the extent that we may be unable or delayed in obtaining a license, we may need to operate the facility under a management agreement from the prior operator. Any inability in obtaining consent from the prior operator of a target acquisition to utilizing its license in this manner could impact our ability to acquire additional facilities. Further, anticipated future regulations may cause delays in acquiring the required licenses and certifications, if it is possible to do so at all. If we were subsequently denied licensure or certification for any reason, we might not realize the expected benefits of the acquisition and would likely incur unanticipated costs and other challenges which could cause our business to suffer.
If we do not achieve or maintain competitive quality of care ratings from CMS or private organizations engaged in similar monitoring activities, our business may be negatively affected.

As discussed in Item 1., under Government Regulation, CMS provides comparative public data, rating every SNF operating in each state based upon quality-of-care indicators. Certain private organizations engage in similar monitoring and ranking activities. CMS’s system is the Five-Star Quality Rating System which gives each nursing home a rating of between one and five stars in various categories, with five-star ratings harder to obtain over time. The ratings are available on a consumer-facing website, Nursing Home Compare. In cases of acquisitions, the previous operator's clinical ratings are included in our overall Five-Star Quality Rating and the rating may not reflect the improvements we were able to make until it is recalculated. Based on CMS's guidance and regulations, we expect more data to be collected by CMS and reported on the Nursing Home Compare website in the future. Additionally, CMS's ownership transparency final rule, which requires the disclosure of SNF ownership and affiliated parties, will ultimately provide for the public disclosure of information reported to CMS under that rule. This publicly available information may result in potential residents perceiving our highly rated facilities to be less desirable if they share ownership with lower rated facilities, even if the lower rated facility is a new acquisition or has a lower score for reasons beyond our control.

CMS continues to increase quality measure thresholds, making it more difficult to achieve upward and five-star ratings. CMS increased its quality measure thresholds in October of 2022, making it more difficult for facilities to obtain or maintain four- and five-star ratings, which were most recently re-calculated in July of 2023, allowing only 10% of nursing facilities within a state to receive a five-star rating. CMS discloses the increasing standards for four- and five-star ratings in its star rating cut point table, which discloses the points needed for each star rating within every state. CMS has indicated that it will increase these quality measure thresholds every six months. Some facilities may see a decline in their overall five-star rating absent any new inspection information, and as a result the five-star ratings of our independent subsidiaries may decline even as their quality measures remain unchanged or improve. Additionally, on the Nursing Home Compare website, CMS recently began displaying a consumer alert icon next to nursing homes that have been cited on inspection reports for incidents of abuse, neglect, or exploitation. In July of 2022, CMS updated the scoring measures used for SNFs to include six dimensions of staffing and turnover, which may adversely affect the rating of our facilities on the Nursing Home Compare website.

In July 2023, CMS revised the nursing-home level exclusion criteria used on the administrator turnover measure, adding information regarding its calculation of the staff turnover measure and publishing an updated ratings table, which identifies the points needed for each nursing facility to obtain certain star ratings within its state. This change made it more competitive to obtain a five-star rating, and more difficult to maintain such a rating once achieved. Only 10% of nursing facilities can receive a five-star rating in the state where it operates. The July 2023 change also increases the pressure on our independent subsidiaries to obtain a smaller number of available five-star ratings, as lower ratings may make it more difficult to attract prospective residents to receive our services.


53

In September 2023, CMS announced that it will update the staffing level case-mix adjustment methodology and freeze four of the quality measures used in the Nursing Home Five-Star Quality Rating System beginning with the April 2024 refresh of the Nursing Home Compare website data. In July 2024, CMS will change the staffing case-mix adjustment methodology to a model based on PDPM. The Nursing Home Compare website will then begin posting staffing level measures that use this methodology. CMS will revise the staffing rating thresholds to maintain the same distribution of points for staffing measures that will be affected by this freeze and replacement. Further, CMS will penalize SNFs that submit erroneous data, or fail to submit data, by awarding them the lowest possible rating on that measure. We may be significantly affected if any of our independent subsidiaries fail to submit information for the MDS in 2024, or if CMS deems their MDS submissions to be erroneous. In addition to the uncertainty created by coming changes to CMS’s five-star ratings that currently are unknown, the potential negative consequences of freezing unfavorable data may adversely affect our star rating and negatively impact our ability to attract residents.

Providing quality patient care is the cornerstone of our business. We believe that hospitals, physicians and other referral sources refer patients to us in large part because of our reputation for delivering quality care. If we should fail to achieve our internal rating goals or fail to exceed the national average rating on the Five-Star Quality Rating System, including due to nursing and administrative staffing and turnover, or have facilities displaying a consumer alert icon for incidents of abuse, neglect, or exploitation, it may affect our ability to generate referrals, which could have a material adverse effect upon our business and consolidated financial condition, results of operations and cash flows.
If we are unable to obtain insurance, or if insurance becomes more costly for us to obtain, our business may be adversely affected.

It may become more difficult and costly for us to obtain coverage for resident care liabilities and other risks, including property, automobile and casualty insurance. For example, the following circumstances may adversely affect our ability to obtain insurance at favorable rates:

we experience higher-than-expected professional liability, property and casualty, or other types of claims or losses;
we receive survey deficiencies or citations of higher-than-normal scope or severity;
we acquire especially troubled operations or facilities that present unattractive risks to current or prospective insurers;
insurers choose to stop operating or offering policies in certain states due to changes in economic conditions or laws;
insurers tighten underwriting standards applicable to us or our industry; or
insurers or reinsurers are unable or unwilling to insure us or the industry at historical premiums and coverage levels.

If any of these potential circumstances were to occur, our insurance carriers may cancel or not renew our policies, or require us to significantly increase our self-insured retention levels or pay substantially higher premiums for the same or reduced coverage for insurance, including workers compensation, property and casualty, automobile, employment practices liability, directors and officers liability, employee healthcare and general and professional liability coverages.

In some states, the law prohibits or limits insurance coverage for the risk of punitive damages arising from professional liability and general liability claims or litigation. Other states where we operate have experienced a withdrawal of insurers from the marketplace due to prior losses, or are at risk of insurers leaving the market due to changes in the law that make it difficult for those insurers to operate within the state. Coverage for punitive damages is also excluded under some insurance policies. As a result, we may be liable for punitive damage awards in these states that either are not covered or are in excess of our insurance policy limits. Claims against us, regardless of their merit or eventual outcome, could also inhibit our ability to attract patients or expand our business and could require our management to devote time to matters unrelated to the day-to-day operation of our business.

With few exceptions, workers compensation and employee health insurance costs have also increased markedly in recent years and are expected to increase in the future. To partially offset these increases, we have increased the amounts of our self-insured retention and deductibles in connection with general and professional liability claims. We also have implemented a self-insurance program for workers compensation in all states, and elected non-subscriber status for workers compensation in Texas. Due to the nature of our business and the residents we serve, including the risk of claims from residents as well as potential governmental action, it may be difficult to complete the underwriting process and obtain insurance at commercially reasonable rates. If we are unable to obtain insurance, or if insurance becomes more costly for us to obtain, or if the coverage levels we can economically obtain decline, our business may be adversely affected.

54

Our self-insurance programs may expose us to significant and unexpected costs and losses.

We have maintained general and professional liability insurance since 2002 and workers compensation insurance since 2005 through a wholly-owned captive insurance subsidiary to insure our self-insurance reimbursements and deductibles as part of a continually evolving overall risk management strategy. We establish the insurance loss reserves based on an estimation process that uses information obtained from both company-specific and industry data. The estimation process requires us to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and our assumptions about emerging trends, we, along with an independent actuary, develop information about the size of ultimate claims based on our historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damages with respect to unpaid claims. It is possible, however, that the actual liabilities may exceed our estimates of loss. We may also experience an unexpectedly large number of successful claims or claims that result in costs or liability significantly in excess of our projections. For these and other reasons, our self-insurance reserves could prove to be inadequate, resulting in liabilities in excess of our available insurance and self-insurance. If a successful claim is made against us and it is not covered by our insurance or exceeds the insurance policy limits, our business may be negatively and materially impacted.

Further, because our self-insurance reimbursements under our general and professional liability and workers compensation programs applies on a per claim basis, there is no limit to the maximum number of claims or the total amount for which we could incur liability in any policy period.

We also self-insure our employee health benefits. With respect to our health benefits self-insurance, our reserves and premiums are computed based on a mix of company specific and general industry data that is not specific to our own company. Even with a combination of limited company-specific loss data and general industry data, our loss reserves are based on actuarial estimates that may not correlate to actual loss experience in the future. Therefore, our reserves may prove to be insufficient and we may be exposed to significant and unexpected losses.
The geographic concentration of our independent subsidiaries could leave us vulnerable to an economic downturn, regulatory changes or acts of nature in those areas.

Our independent subsidiaries located in Arizona, California, and Texas account for the majority of our total revenue. As a result of this concentration, the conditions of local economies and real estate markets, changes in governmental rules, presence and participation of insurers, regulations and reimbursement rates or criteria, changes in demographics, state funding, acts of nature and other factors that may result in a decrease in demand and/or reimbursement for skilled nursing services in these states could have a disproportionately adverse effect on our revenue, costs and results of operations. Moreover, since over 24% of our independent subsidiaries are located in California, we are particularly susceptible to revenue loss, cost increase or damage caused by natural disasters such as electrical power shortages, fires, earthquakes or mudslides, or increased liabilities that may arise from regulations as discussed within Item 1., under Government Regulation.

In addition, our independent subsidiaries in Iowa, Nebraska, Kansas, South Carolina, Washington and Texas are more susceptible to revenue loss, cost increases or damage caused by natural disasters including hurricanes, tornadoes and flooding. These acts of nature may cause disruption to us, the employees of our independent subsidiaries, which could have an adverse impact on the patients of our independent subsidiaries and our business. In order to provide care for the patients of our independent subsidiaries, we are dependent on consistent and reliable delivery of food, pharmaceuticals, utilities and other goods to our independent subsidiaries, and the availability of employees to provide services. If the delivery of goods or the ability of employees to reach our independent subsidiaries were interrupted in any material respect due to a natural disaster or other reasons, it would have a significant impact on our independent subsidiaries and our business. Furthermore, the impact, or impending threat, of a natural disaster may require that we evacuate one or more facilities, which would be costly and would involve risks, including potentially fatal risks, for the patients. The impact of disasters and similar events is inherently uncertain. Such events could harm the patients and employees of our independent subsidiaries, severely damage or destroy one or more of our independent subsidiaries, harm our business, reputation and financial performance, or otherwise cause our business to suffer in ways that we currently cannot predict.

55

The actions of a national labor union that has pursued a negative publicity campaign criticizing our business in the past may adversely affect our revenue and our profitability.

We continue to maintain our right to inform the employees of our independent subsidiaries about our views of the potential impact of unionization upon the workplace generally and upon individual employees. Historically, the staff at our independent subsidiaries that have been approached to unionize have uniformly rejected union organizing efforts. Forthcoming proposed rules from CMS, which, based on the Biden-Harris Administration's executive orders discussed under Government Regulation in Item 1., as well as potential legislation such as the HCBS Access Act aimed toward providing more resources to those considering care-based careers, may increase the likelihood of employee unionization due to increased emphasis on care-based careers in SNF facilities. If employees decide to unionize, our cost of doing business could increase, and we could experience contract delays, difficulty in adapting to a changing regulatory and economic environment, cultural conflicts between unionized and non-unionized employees, strikes and work stoppages, and we may conclude that affected facilities or operations would be uneconomical to continue operating.
Because we lease the majority of our independent subsidiaries, we are subject to risks associated with leased real property, including risks relating to lease termination, lease extensions and special charges, any of which could adversely affect our business, financial position or results of operations.

As of December 31, 2023, we leased 214 of our 297 independent subsidiaries. Most of our leases are triple-net leases, which means that, in addition to rent, we are required to pay for the costs related to the property (including property taxes, insurance, and maintenance and repair costs). We are responsible for paying these costs notwithstanding the fact that some of the benefits associated with paying these costs accrue to the landlords as owners of the associated facilities.

Each lease provides that the landlord may terminate the lease for a variety of reasons, including the default in any payment of rent, taxes or other payment obligations or the breach of any other covenant or agreement in the lease. Termination of a lease could result in a default under our debt agreements and could adversely affect our business, financial position or results of operations. There can be no assurance that we will be able to comply with all of our obligations under the leases in the future.
Failure to generate sufficient cash flow to cover required payments or meet operating covenants under our long-term debt, mortgages and long-term operating leases could result in defaults under such agreements and cross-defaults under other debt, mortgage or operating lease arrangements, which could harm our independent subsidiaries and cause us to lose facilities or experience foreclosures.

Our Credit Facility has a borrowing capacity of up to $600.0 million in aggregate principal amount. As of December 31, 2023 and through the filing date of this report, we had no outstanding borrowings under our Credit Facility. Twenty-three of our subsidiaries have mortgage loans insured with the Department of Housing and Urban Development (HUD) for an aggregate amount of $150.2 million, which subjects these subsidiaries to HUD oversight and periodic inspections. The terms of the mortgage loans range from 25- to 35-years.

We also have one outstanding promissory note with an aggregate principal amount of approximately $2.1 million as of December 31, 2023. The term of the note is 12 years. Because this promissory note is insured with HUD, our borrower subsidiary under the note is subject to HUD oversight and periodic inspections.

In addition, we had $2.7 billion of future operating lease obligations as of December 31, 2023. We intend to continue financing our independent subsidiaries through mortgage financing, long-term operating leases and other types of financing, including borrowings under our lines of credit and future credit facilities we may obtain.

We may not generate sufficient cash flow from operations to cover required interest, principal and lease payments. In addition, our outstanding Credit Facility and mortgage loans contain restrictive covenants and require us to maintain or satisfy specified coverage tests on a consolidated basis and on a facility or facilities basis. These restrictions and operating covenants include, among other things, requirements with respect to occupancy, debt service coverage, project yield, net leverage ratios, minimum interest coverage ratios and minimum asset coverage ratios. These restrictions may interfere with our ability to obtain additional advances under our Credit Facility or to obtain new financing or to engage in other business activities, which may inhibit our ability to grow our business and increase revenue.


56

From time to time, the financial performance of one or more of our mortgaged facilities may not comply with the required operating covenants under the terms of the mortgage. Any non-payment, noncompliance or other default under our financing arrangements could, subject to cure provisions, cause the lender to foreclose upon the facility or facilities securing such indebtedness or, in the case of a lease, cause the lessor to terminate the lease, each with a consequent loss of revenue and asset value to us or a loss of property. Furthermore, in many cases, indebtedness is secured by both a mortgage on one or more facilities, and a guaranty by us. In the event of a default under one of these scenarios, the lender could avoid judicial procedures required to foreclose on real property by declaring all amounts outstanding under the guaranty immediately due and payable, and requiring us to fulfill our obligations to make such payments. If any of these scenarios were to occur, our financial condition would be adversely affected. For tax purposes, a foreclosure on any of our properties would be treated as a sale of the property for a price equal to the outstanding balance of the debt secured by the mortgage. If the outstanding balance of the debt secured by the mortgage exceeds our tax basis in the property, we would recognize taxable income on foreclosure, but would not receive any cash proceeds, which would negatively impact our earnings and cash position. Further, because our mortgages and operating leases generally contain cross-default and cross-collateralization provisions, a default by us related to one facility could affect a significant number of other facilities and their corresponding financing arrangements and operating leases.

Because our term loans, promissory note, bonds, mortgages and lease obligations are fixed expenses and secured by specific assets, and because our revolving loan obligations are secured by virtually all of our assets, if reimbursement rates, patient acuity mix or occupancy levels decline, or if for any reason we are unable to meet our loan or lease obligations, we may not be able to cover our costs and some or all of our assets may become at risk. Our ability to make payments of principal and interest on our indebtedness and to make lease payments on our operating leases depends upon our future performance, which will be subject to general economic conditions, industry cycles and financial, business and other factors affecting our independent subsidiaries, many of which are beyond our control. If we are unable to generate sufficient cash flow from operations in the future to service our debt or to make lease payments on our operating leases, we may be required, among other things, to seek additional financing in the debt or equity markets, refinance or restructure all or a portion of our indebtedness, sell selected assets, reduce or delay planned capital expenditures or delay or abandon desirable acquisitions. Such measures might not be sufficient to enable us to service our debt or to make lease payments on our operating leases. The failure to make required payments on our debt or operating leases or the delay or abandonment of our planned growth strategy could result in an adverse effect on our future ability to generate revenue and sustain profitability. In addition, any such financing, refinancing or sale of assets might not be available on terms that are economically favorable to us, or at all.
Move-in and occupancy rates may remain unpredictable even after the COVID-19 pandemic is over.

Occupancy levels at our operations have not returned to pre-COVID-19 rates despite the end of the PHE. Facilities experiencing decreases in move-in rates cite resident or family member concerns as the basis for such decreases. These and other similar concerns may continue to impact our ability to attract new residents and our ability to retain existing residents.
A housing downturn could decrease demand for senior living services.
Seniors often use the proceeds of home sales to fund their admission to senior living facilities. A downturn in the housing markets, including reductions in sales prices caused by increasing mortgage interest rates, economic uncertainty, recession, or a reduction in activity in the market for residential real estate, could adversely affect seniors’ ability to afford our resident fees and entrance fees. If national or local housing markets enter a persistent decline, our occupancy rates, revenues, results of operations and cash flow could be negatively impacted.
As we continue to acquire and lease real estate assets, we may not be successful in identifying and consummating these transactions.

We lease 30 of our properties to third-party operators. In the future, we might expand our leasing property portfolio to additional tenants. We have very limited control over the success or failure of our tenants’ and operators’ businesses and, at any time, a tenant or operator may experience a downturn in its business that weakens its financial condition. If that happens, the tenant or operator may fail to make its payments to us when due. Although our lease agreements give us the right to exercise certain remedies in the event of default on the obligations owing to us, we may determine not to do so if we believe that enforcement of our rights would be more detrimental to our business than seeking alternative approaches.

57

An important part of our business strategy is to continue to expand and diversify our real estate portfolio through accretive acquisition and investment opportunities in healthcare properties. Our execution of this strategy by successfully identifying, securing and consummating beneficial transactions is made more challenging by increased competition and can be affected by many factors, including our relationships with current and prospective tenants, our ability to obtain debt and equity capital at costs comparable to or better than our competitors and our ability to negotiate favorable terms with property owners seeking to sell and other contractual counterparties. Our competitors for these opportunities include healthcare REITs, real estate partnerships, healthcare providers, healthcare lenders and other investors, including developers, banks, insurance companies, pension funds, government-sponsored entities and private equity firms, some of whom may have greater financial resources and lower costs of capital than we do. Potential regulations may affect the ability of these entities, as well as ourselves, to compete for these opportunities or enter into transactions for real estate related to our business. If we are unsuccessful at identifying and capitalizing on investment or acquisition opportunities, our growth and profitability in our real estate investment portfolio may be adversely affected.

Investments in and acquisitions of healthcare properties entail risks associated with real estate investments generally, including risks that the investment will not achieve expected returns, that the cost estimates for necessary property improvements will prove inaccurate or that the tenant or operator will fail to meet performance expectations. Income from properties and yields from investments in our properties may be affected by many factors, including changes in governmental regulation (such as licensing and government payment), general or local economic conditions (such as fluctuations in interest rates, senior savings, and employment conditions), the available local supply of and demand for improved real estate, a reduction in rental income as the result of an inability to maintain occupancy levels, natural disasters (such as hurricanes, earthquakes and floods) or similar factors. Furthermore, healthcare properties are often highly customized, and the development or redevelopment of such properties may require costly tenant-specific improvements. As a result, we cannot assure you that we will achieve the economic benefit we expect from acquisition or investment opportunities.
As we expand our presence in other relevant healthcare industries, we would become subject to risks in a market in which we have limited experience.
The majority of our independent subsidiaries have historically been SNFs. As we expand our presence in other relevant healthcare industries, our existing overall business model will continue to change and expose our company to risks in markets in which we have limited experience, such as the Eliminating Kickbacks in Recovery Act and other state laws that are not as well-developed in regulation and decisional authority as their federal equivalents. We expect that we will have to adjust certain elements of our existing business model, which could have an adverse effect on our business.
If our referral sources fail to view us as an attractive skilled nursing provider, or if our referral sources otherwise refer fewer patients, our patient base may decrease.
We rely significantly on appropriate referrals from hospitals, physicians, and other healthcare providers in the communities in which we deliver our services to attract appropriate residents and patients to our independent subsidiaries. Our referral sources are not obligated to refer business to us and may refer business to other healthcare providers. We believe many of our referral sources refer business to us as a result of the quality of our patient care and our efforts to establish and build a relationship with our referral sources. If we lose, or fail to maintain, existing relationships with our referral resources, fail to develop new relationships, or if we are perceived by our referral sources as not providing high quality patient care, our occupancy rate and the quality of our patient mix could suffer. In addition, if any of our referral sources have a reduction in patients whom they can refer due to a decrease in their business, our occupancy rate and the quality of our patient mix could suffer.

58

We may need additional capital to fund our independent subsidiaries and finance our growth, and we may not be able to obtain it on terms acceptable to us, or at all, which may limit our ability to grow.
Our ability to maintain and enhance our independent subsidiaries and equipment in a suitable condition to meet regulatory standards, operate efficiently and remain competitive in our markets requires us to commit substantial resources to continued investment in our independent subsidiaries and equipment. We are sometimes more aggressive than our competitors in capital spending to address issues that arise in connection with aging and obsolete facilities and equipment. In addition, continued expansion of our business through the acquisition of existing facilities, expansion of our existing facilities and construction of new facilities may require additional capital, particularly if we were to accelerate our acquisition and expansion plans. Financing may not be available to us or may be available to us only on terms that are not favorable, including being subject to interest rates that are higher than those incurred in the recent past. In addition, some of our outstanding indebtedness and long-term leases restrict, among other things, our ability to incur additional debt. If we are unable to raise additional funds or obtain additional funds on terms acceptable to us, we may have to delay or abandon some or all of our growth strategies. Further, if additional funds are raised through the issuance of additional equity securities, the percentage ownership of our stockholders would be diluted. Any newly issued equity securities may have rights, preferences or privileges senior to those of our common stock.
The condition of the financial markets, including volatility and deterioration in the capital and credit markets, could limit the availability of debt and equity financing sources to fund the capital and liquidity requirements of our business, as well as negatively impact or impair the value of our current portfolio of cash, cash equivalents and investments, including U.S. Treasury securities and U.S.-backed investments.

Our cash, cash equivalents and investments are held in a variety of interest-bearing instruments, including U.S. treasury securities. As a result of the uncertain domestic and global political, economic, credit and financial market conditions, including the significant increases in the federal funds rate since 2021, an increase in the Consumer Price Index of 7% in 2022, expected Consumer Price Index increases above historical norms for 2023, investments in these types of financial instruments pose risks arising from liquidity and credit concerns. Given that future deterioration in the U.S. and global credit and financial markets is a possibility, no assurance can be made that losses or significant deterioration in the fair value of our cash, cash equivalents, or investments will not occur. Uncertainty surrounding the trading market for U.S. government securities or impairment of the U.S. government's ability to satisfy its obligations under such treasury securities could impact the liquidity or valuation of our current portfolio of cash, cash equivalents, and investments, a substantial portion of which were invested in U.S. treasury securities. Further, continued domestic and international political uncertainty, along with credit, and financial market uncertainty, may make it difficult for us to liquidate our investments prior to their maturity without incurring a loss, which would have a material adverse effect on our consolidated financial position, results of operations or cash flows.
We may need additional capital if a substantial acquisition or other growth opportunity becomes available or if unexpected events occur or opportunities arise. U.S. capital markets can be volatile. We cannot assure you that additional capital will be available or available on terms acceptable to us. If capital is not available, we may not be able to fund internal or external business expansion or respond to competitive pressures or other market conditions.
Delays in reimbursement may cause liquidity problems.
If we experience problems with our billing information systems or if issues arise with Medicare, Medicaid or other payors, we may encounter delays in our payment cycle. From time to time, we have experienced such delays as a result of government payors instituting planned reimbursement delays for budget balancing purposes or as a result of prepayment reviews.
Some states in which we operate are operating with budget deficits or could have budget deficit in the future, which may delay reimbursement in a manner that would adversely affect our liquidity. In addition, from time to time, procedural issues require us to resubmit or appeal claims before payment is remitted, which contributes to our aged receivables. Unanticipated delays in receiving reimbursement from state programs or commercial payors due to changes in their policies or billing or audit procedures may adversely impact our liquidity and working capital.

59

The continued use and growth of managed care organizations (MCOs) may contribute to delays or reductions in our reimbursement, including Managed Medicaid.
In forty-one states, including some of the largest where we operate, state Medicaid benefits are administered through MCOs. Typically, these MCOs manage commercial health and federal Medicare Advantage benefits under a managed care contract. Nationally, MCOs cover approximately 57 million and 30 million Medicaid and Medicare Advantage beneficiaries, respectively. MCOs may be more aggressive than state Medicaid and federal Medicare agencies in denying claims or seeking recoupment of payments so that their services under these managed contracts are profitable. The additional steps created by the use of MCOs in disbursement of funds creates more risk of delayed, reduced, or recouped payments for our independent subsidiaries, and additional avenues for risks that include fines and other sanctions, including suspension or exclusion from participation in various governmental programs.
Compliance with the regulations of the Department of Housing and Urban Development may require us to make unanticipated expenditures which could increase our costs.
Twenty-three of our independent subsidiaries are currently subject to regulatory agreements with HUD that give the Commissioner of HUD broad authority to require us to be replaced as the operator of those facilities in the event that the Commissioner determines there are operational deficiencies at such facilities under HUD regulations. Compliance with HUD's requirements can often be difficult because these requirements are not always consistent with the requirements of other federal and state agencies. Appealing a failed inspection can be costly and time-consuming and, if we do not successfully remediate the failed inspection, we could be precluded from obtaining HUD financing in the future or we may encounter limitations or prohibitions on our operation of HUD-insured facilities.
If we fail to safeguard the monies held in our patient trust funds, we will be required to reimburse such monies, and we may be subject to citations, fines and penalties.

Each of our independent subsidiaries is required by federal law to maintain a patient trust fund to safeguard certain assets of their residents and patients. If any money held in a patient trust fund is misappropriated, we are required to reimburse the patient trust fund for the amount of money that was misappropriated. If any monies held in our patient trust funds are misappropriated in the future and are unrecoverable, we will be required to reimburse such monies, and we may be subject to citations, fines and penalties pursuant to federal and state laws.
We are a holding company with no operations and rely upon our multiple independent subsidiaries to provide us with the funds necessary to meet our financial obligations. Liabilities of any one or more of our subsidiaries could be imposed upon us or our other subsidiaries.

We are a holding company with no direct operating assets, employees or revenue. Each of our independent subsidiaries is operated through a separate, wholly-owned, independent subsidiary, which has its own management, employees and assets. Our principal assets are the equity interests we directly or indirectly hold in our multiple operating and real estate holding subsidiaries. As a result, we are dependent upon distributions from our subsidiaries to generate the funds necessary to meet our financial obligations and pay dividends. Our subsidiaries are legally distinct from us and have no obligation to make funds available to us. The ability of our subsidiaries to make distributions to us will depend substantially on their respective operating results and will be subject to restrictions under, among other things, the laws of their jurisdiction of organization, which may limit the amount of funds available for distribution to investors or stockholders, agreements of those subsidiaries, the terms of our financing arrangements and the terms of any future financing arrangements of our subsidiaries.
If the separation of Pennant fails to qualify as generally tax-free for U.S. federal income tax purposes, we and our stockholders could be subject to significant tax liabilities.

The spin-off in 2019 is intended to qualify for tax-free treatment to us and our stockholders for U.S. federal income tax purposes. Accordingly, completion of the transaction was conditioned upon, among other things, our receipt of opinions from outside tax advisors that the distributions would qualify as a transaction that is intended to be tax-free to both us and our stockholders for U.S. federal income tax purposes under Sections 355 and 368(a)(1)(D) of the Internal Revenue Code. The opinions were based on and relied on, among other things, certain facts and assumptions, as well as certain representations, statements and undertakings, including those relating to the past and future conduct. If any of these facts, assumptions, representations, statements or undertakings is, or becomes, inaccurate or incomplete, or if any of the parties' breach any of their respective covenants relating to the transactions, the tax opinions may be invalid. Moreover, the opinions are not binding on the IRS or any courts. Accordingly, notwithstanding receipt of the opinion, the IRS could determine that the distribution and certain related transactions should be treated as taxable transactions for U.S. federal income tax purposes.

60

If the spin-off fails to qualify as a transaction that is generally tax-free under Sections 355 and 368(a)(1)(D) of the Internal Revenue Code, in general, for U.S. federal income tax purposes, we would recognize taxable gain with respect to the distributed securities and our stockholders who received securities in such distribution would be subject to tax as if they had received a taxable distribution equal to the fair market value of such shares.

We also have obligations to provide indemnification to a number of parties as a result of the transaction. Any indemnity obligations for tax issues or other liabilities related to the spin-off, could be significant and could adversely impact our business.
Certain directors who serve on our Board of Directors also serve as directors of Pennant, and ownership of shares of Pennant common stock by our directors and executive officers may create, or appear to create, conflicts of interest.

Certain of our directors who serve on our Board of Directors also serve on the board of directors of Pennant. This may create, or appear to create, conflicts of interest when our, or Pennant's management and directors face decisions that could have different implications for us and Pennant, including the resolution of any dispute regarding the terms of the agreements governing the spin-off transaction and the relationship between us and Pennant after the spin-off transaction or any other commercial agreements entered into in the future between us and Pennant and the allocation of such directors’ time between us and Pennant.

All of our executive officers and some of our non-employee directors own shares of the common stock of Pennant. The continued ownership of such common stock by our directors and executive officers following the spin-off creates, or may create, the appearance of a conflict of interest when these directors and executive officers are faced with decisions that could have different implications for us and Pennant.

If Standard Bearer fails to qualify or remain qualified as a REIT, it will be subject to U.S. federal income tax as a regular corporation and could face substantial tax liability.

Standard Bearer currently operates, and intends to continue to operate, in a manner that allows it to qualify to be taxed as a REIT for U.S. federal income tax purposes. Standard Bearer elected to be taxed as a REIT for U.S. federal income tax purposes beginning with its taxable year ended December 31, 2022.

If Standard Bearer fails to qualify to be taxed as a REIT in any year, it would be subject to U.S. federal income tax, including any applicable alternative minimum tax, on our taxable income at regular corporate rates, and dividends paid to its shareholders would not be deductible by it in computing its taxable income. Any resulting corporate liability could be substantial and would reduce the amount of cash available for distribution to its shareholders. Unless it was entitled to relief under certain Code provisions, it also would be disqualified from re-electing to be taxed as a REIT for the four taxable years following the year in which it failed to qualify to be taxed as a REIT.

Legislative or other actions affecting REITs could have a negative effect on Standard Bearer.

The rules dealing with U.S. federal income taxation are constantly under review by persons involved in the legislative process and by the IRS and the U.S. Department of the Treasury (Treasury). Changes to the tax laws or interpretations thereof, with or without retroactive application, could materially and adversely affect Standard Bearer's investors or Standard Bearer. We cannot predict how changes in the tax laws, including any tax reform called for by the current presidential administration, might affect Standard Bearer or its investors. New legislation, Treasury regulations, administrative interpretations or court decisions could significantly and negatively affect its ability to qualify to be taxed as a REIT or the U.S. federal income tax consequences to Standard Bearer or its investors of such qualification. For instance, the Tax Cuts and Jobs Act (TCJA) significantly changed the U.S. federal income tax laws applicable to businesses and their owners, including REITs and their shareholders. Technical corrections or other amendments to the TCJA or administrative guidance interpreting the TCJA may be forthcoming at any time. We cannot predict the long-term effect of the TCJA or any future law changes on REITs or their shareholders. Changes to the U.S. federal tax laws and interpretations thereof, whether under the TCJA or otherwise, could adversely affect an investment in our stock. Additionally, REIT's that are related to our operation will likely be subject to the disclosure requirements of CMS's ownership transparency final rule, and may subject these REITs to additional public scrutiny.

No prediction can be made regarding whether new legislation or regulation (including new tax measures) will be enacted by legislative bodies or governmental agencies, nor can we predict what consequences would result from this legislation or regulation. Accordingly, no assurance can be given that the currently anticipated tax treatment of an investment will not be modified by legislative, judicial or administrative changes, possibly with retroactive effect.

61

Standard Bearer could fail to qualify to be taxed as a REIT if income it receives from our tenants is not treated as qualifying income.

Under applicable provisions of the Code, Standard Bearer will not be treated as a REIT unless it satisfies various requirements, including requirements relating to the sources of its gross income. Rents received or accrued by it from its tenants will not be treated as qualifying rent for purposes of these requirements if the leases are not respected as true leases for U.S. federal income tax purposes and are instead treated as service contracts, joint ventures or other arrangements. If the leases are not respected as true leases for U.S. federal income tax purposes, Standard Bearer will likely fail to qualify to be taxed as a REIT.

Even if Standard Bearer remains qualified as a REIT, it may face other tax liabilities that reduce its cash flow.

Even if Standard Bearer remain qualified for taxation as a REIT, it may be subject to certain U.S. federal, state, and local taxes on its income and assets, including taxes on any undistributed income and state or local income, property and transfer taxes. For example, Standard Bearer may hold some of its assets or conduct certain of its activities through one or more taxable REIT subsidiaries (each, a TRS) or other subsidiary corporations that will be subject to U.S. federal, state, and local corporate-level income taxes as regular C corporations. In addition, it may incur a 100% excise tax on transactions with a TRS if they are not conducted on an arm’s-length basis. Any of these taxes would decrease cash available for distribution to its shareholders.

Risks Related to Ownership of our Common Stock
We may not be able to pay or maintain dividends and the failure to do so would adversely affect our stock price.

Our ability to pay and maintain cash dividends is based on many factors, including our ability to make and finance acquisitions, our ability to negotiate favorable lease and other contractual terms, anticipated operating cost levels, the level of demand for occupancy at our facilities, the rates we charge and actual results that may vary substantially from estimates. Some of the factors are beyond our control and a change in any such factor could affect our ability to pay or maintain dividends. The Credit Facility restricts our ability to pay dividends to stockholders if we receive notice that we are in default under the agreement. The failure to pay or maintain dividends could adversely affect our stock price.
Our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law contain provisions that could discourage transactions resulting in a change in control, which may negatively affect the market price of our common stock.

Our amended and restated certificate of incorporation and our amended and restated bylaws contain provisions that may enable our Board of Directors to resist a change in control. These provisions may discourage, delay or prevent a change in the ownership of our company or a change in our management, even if doing so might be beneficial to our stockholders. In addition, these provisions could limit the price that investors would be willing to pay in the future for shares of our common stock. Such provisions set forth in our amended and restated certificate of incorporation or our amended and restated bylaws include:

our Board of Directors is authorized, without prior stockholder approval, to create and issue preferred stock, commonly referred to as “blank check” preferred stock, with rights senior to those of common stock;
advance notice requirements for stockholders to nominate individuals to serve on our Board of Directors or to submit proposals that can be acted upon at stockholder meetings;
our Board of Directors is classified so not all members of our board are elected at one time, which may make it more difficult for a person who acquires control of a majority of our outstanding voting stock to replace our directors;
stockholder action by written consent is limited;
special meetings of the stockholders are permitted to be called only by the chairman of our Board of Directors, our chief executive officer or by a majority of our Board of Directors;
stockholders are not permitted to cumulate their votes for the election of directors;
newly created directorships resulting from an increase in the authorized number of directors or vacancies on our Board of Directors are filled only by majority vote of the remaining directors;
our Board of Directors is expressly authorized to make, alter or repeal our bylaws; and
stockholders are permitted to amend our bylaws only upon receiving the affirmative vote of at least a majority of our outstanding common stock.
62

We are also subject to the anti-takeover provisions of Section 203 of the General Corporation Law of the State of Delaware. Under these provisions, if anyone becomes an “interested stockholder,” we may not enter into a “business combination” with that person for three years without special approval, which could discourage a third-party from making a takeover offer and could delay or prevent a change of control. For purposes of Section 203, “interested stockholder” means, generally, someone owning more than 15% or more of our outstanding voting stock or an affiliate of ours that owned 15% or more of our outstanding voting stock during the past three years, subject to certain exceptions as described in Section 203.

These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could discourage acquisition proposals and make it more difficult or expensive for stockholders or potential acquirers to obtain control of our Board of Directors or initiate actions that are opposed by our then-current Board of Directors, including delaying or impeding a merger, tender offer or proxy contest involving us. Any delay or prevention of a change of control transaction or changes in our Board of Directors could cause the market price of our common stock to decline.

Item 1B. UNRESOLVED STAFF COMMENTS

    None.

Item 1C. CYBERSECURITY

We utilize information technology that enables our operational leaders to access and share with their peers, both clinical and financial performance data in real time. Armed with relevant and current information, our operation leaders and their management teams can share best practices and the latest information, adjust to challenges and opportunities on a timely basis, improve quality of care, mitigate risk and improve both clinical outcomes and financial performance. We have also invested in specialized healthcare technology systems to assist our nursing and support staff. We have installed software and touch-screen interface systems in each operation to enable our clinical staff to monitor and deliver patient care and record patient information more efficiently. We believe these systems have improved the quality of our medical and billing records, while improving the productivity of our staff. Such uses of information systems give rise to cybersecurity risks, including system disruption, security breach, ransomware, theft, espionage and inadvertent release of information.

RISK MANAGEMENT AND STRATEGY

Risk Management
We assess and identify security risk to the organization by:
conducting assessments of risk including likelihood and magnitude from unauthorized access, use, disclosure, disruption, modification or destruction of information systems and the related information processes, stored, or transmitted.
performing risk assessments and producing security assessment reports that document the results of the assessment for use and review by information technology (IT) senior leadership, including the Service Center's Chief Information Officer.
ensuring security controls are assessed for effectiveness, are implemented correctly, operating as intended and producing the desired outcome; and
continuously scanning for vulnerabilities and remedying all vulnerabilities in accordance with the associated risk.

Monitoring
We have established a continuous monitoring strategy and program, which includes:
a set of defined security metrics to be monitored.
performance of security control assessments on an ongoing basis.
addressing results of analysis and reporting security status to the executive team.
monitoring information systems to detect attacks and indicators of potential attacks.
identification of unauthorized use of the information system resources; and
deployment of monitoring devices strategically within the information system environment.
63

Data Protection

We have implemented an Information Security Management System (ISMS) Program to secure sensitive data protected by us. This program includes:
Establishing policies governing data security.
Monitoring data access throughout the organization’s independent subsidiaries.
Providing continuous security training and awareness.
Establishing controls over devices on the network which are actively tracked, monitored and evaluated for new, missing, or updated software needed to strengthen security on the device, patch known vulnerabilities, or stabilize software or operating system issues.
Protecting sensitive data through encryption techniques.
Designing and implementing systems to include backup and recoverability principles, such as periodic data backups and safeguards in the case of a disaster.

Incident Management Plan
Our cybersecurity incident management plan comprises the following six-step process:
The Service Center's Chief Information Officer and Director of Information Security lead its Information Security Office (ISO) team in the development, documentation, review and testing of security procedures and incident management procedures. Beyond initial creation, procedures are continually re-assessed, updated and tested on an ongoing basis.
The Service Center's Chief Information Officer and Director of Information Security work with the Executive Team on the identification, assessment, verification and classification of incidents to determine affected stakeholders and appropriate parties for contact.
The Service Center's Chief Information Officer and Director of Information Security are responsible for launching the Incident Response Team (IRT) if necessary and for notification to the Executive Team, who in turn will contact the Board of Directors and the Audit Committee to validate that the response is being addressed appropriately.
The IRT, in consultation with outside experts if needed, is responsible for the following:
Initial containment by making tactical changes to the computing environment to mitigate active threats based on currently known information.
Analysis to establish the root cause of incidents, identification and evidence collection from all affected machines and log sources, threat intelligence and other information sources. Once all appropriate information has been collected, we perform a careful analysis using forensically-sound tools and methods to prevent any contamination of evidence.
Incident containment by further analyzing additional information and further identifying any additional compromised machines or resources not previously identified.
Incident eradication by re-assessing the root cause of incidents where solutions are then implemented to solve underlying problems and prevent re-occurrence.
Recovery and restoring normal business functionality, which includes the reversal of any damage caused by the incident and responding as necessary.
Review after closure of each incident and conducting a lessons learned analysis to improve prevention and help to make incident response processes more efficient and effective. Also, the IRT evaluates competency and any additional training requirements needed. A final incident report will then be provided to key stakeholders and IRT members, which includes, but is not limited to the summary of the incident and its impact, a timeline of events, a detailed description of the incident, an evaluation of the organizational response and an assessment of the damages.

We have not experienced a material cybersecurity breach in the past five years and, as a result, there have been no charges related to a breach in the past five years. Moreover, no risks from cybersecurity threats have materially affected our business strategy, results of operations, or financial condition. While we have implemented processes and procedures that we believe are tailored to address and mitigate the cybersecurity threats that our Company faces, there can be no assurances that such an incident will not occur despite our efforts, as more fully described in Item 1A. Risk Factors.


64

GOVERNANCE

Our Audit Committee receives quarterly reports on our information security and cyber fraud prevention programs from the Service Center's Chief Information Officer and Director of Information Security, who each have over 24 years of experience in IT, including various leadership roles at other large corporations. One of the three members of our Audit Committee is a cybersecurity expert.

The ISO has been established by the Service Center's Chief Information Officer, with dedicated cyber security staff focusing on security monitoring, vulnerability management, incident response, risk assessments, employee training, security engineering and management of cyber security policies, standards and regulatory compliance. Like many organizations, we align to a Cyber Security Framework and take a risk-based approach during control assessment and implementation. We align to the National Institute of Standards and Technology (NIST) Special Publication 800-53 Revision 4, a globally recognized cyber security framework of Policies, Standards and Controls that comprises of five categories of defense – Identify, Protect, Detect, Respond and Recover. We are committed to the protection of our data, systems, network and continually invest in enhancements to mitigate or reduce the impact from a cyber security threat. We conduct periodic tests to maintain readiness and resiliency while regularly reviewing policies in the interest of protecting data security. External companies or agencies may be called upon to provide consulting, guidance, assistance, or some other form of support in response to a cybersecurity incident. The regular training of employees, at least annually, on the ever-present threat of cybersecurity helps maintain data security.

Item 2.     PROPERTIES

Service Center  Our primary Service Center is located at our San Juan Capistrano, California campus, which we acquired for a purchase price of $31.0 million to accommodate our growing Service Center team. The property consists of approximately 108,058 square feet of usable office space. In addition, we lease a portion of the space within the campus to third-party tenants. We also have service centers located in Tempe, Arizona, San Antonio, Texas and Salt Lake City, Utah.

Operating Facilities We operate 297 independent subsidiaries in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin, with the operational capacity to serve approximately 34,000 patients as of December 31, 2023. Of the 297 facilities, we operate 214 facilities under long-term lease arrangements and have options to purchase 11 of those 214 facilities. The results of our independent subsidiaries are reflected in our skilled services segment for our skilled nursing operations and in the "All Other" category for our senior living operations.

 
The following table provides summary information regarding the location of our facilities, operational beds and units by property type as of December 31, 2023:
Operated Facilities
Leased without a Purchase Option Leased with a Purchase OptionOwned Total
Facilities Beds/UnitsFacilities Beds/UnitsFacilities Beds/UnitsFacilitiesBeds/Units
California 595,734111,227706,961
Texas 566,9295714222,9148310,557
Arizona 233,336131,930365,266
Wisconsin 21002100
Utah 121,31121597661212,131
Colorado 161,66811258916252,709
Washington 121,0984413161,511
Idaho 75535470121,023
Nebraska536423907754
Kansas 145332544588828
Iowa 63996399
South Carolina4582554491,126
Nevada23582358
20322,377111,3238310,02329733,723
65

The following table sets forth the location of our facilities and the number of operational beds and units located at our skilled nursing, senior living and campus facilities as of December 31, 2023:
Facility CountsBed / Unit Counts
Skilled Nursing OperationsSenior Living Communities Campus OperationsTotal Skilled Nursing Beds Senior Living Units Total Beds / Units
California 673706,7641976,961
Texas 7715839,95460310,557
Arizona 3015364,5357315,266
Wisconsin 22100100
Utah 1821211,9681632,131
Colorado 1951251,9867232,709
Washington 151161,413981,511
Idaho 111121,002211,023
Nebraska4127413341754
Kansas 178615213828
Iowa 42636831399
South Carolina991,1261,126
Nevada22358358
259112729730,6023,12133,723

Real Estate Properties As of December 31, 2023, we owned 113 real estate properties in Arizona, California, Colorado, Idaho, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin, which include 83 of the 297 facilities that we operate and manage. Of our 113 real estate properties, 30 operations are leased to and operated by third-party operators. One senior living facility is located on the same real estate property as a skilled nursing facility that we own and operate. We further own the real estate property of our Service Center's California location and continue to lease a portion of the office space to third-party tenants. Our Standard Bearer segment reflects the results of operations for 108 of the 113 owned real estate properties.

The following table provides summary information regarding the location of our owned real estate properties as of December 31, 2023:
Owned and Operated by Ensign(1)
Owned and Leased to Third-Party Operators(1)
Service Center
Total Properties(1)
California112114
Texas(1)
22627
Arizona 13114
Wisconsin 21921
Utah 77
Colorado 88
Washington 415
Idaho 55
Nebraska22
Kansas 44
South Carolina55
Nevada11
83301113
(1) One senior living operation in Texas, which is owned by Ensign and leased to a third-party operator, is located on the same real estate property as a skilled nursing facility that we own and operate. In this situation, the senior living operation is included in the total under "Owned and Leased to Third Party Operators" and the skilled nursing operation is included in the total under "Owned and Operated by Ensign", however, the amount reflected under "Total Properties" only recognizes the operation as a single property.

66

Item 3.     LEGAL PROCEEDINGS
IndemnitiesFrom time to time, we enter into certain types of contracts that contingently require us to indemnify parties against third-party claims. These contracts primarily include (i) certain real estate leases, under which we may be required to indemnify property owners or prior facility operators for post-transfer environmental or other liabilities and other claims arising from our use of the applicable premises, (ii) operations transfer agreements, in which we agree to indemnify past operators of facilities we acquire against certain liabilities arising from the transfer of the operation and/or the operation thereof after the transfer to our independent subsidiary, (iii) certain lending agreements, under which we may be required to indemnify the lender against various claims and liabilities, and (iv) certain agreements with our officers, directors and others, under which we may be required to indemnify such persons for liabilities based on the nature of their relationship to us. The terms of such obligations vary by contract and, in most instances, do not expressly state or include a specific or maximum dollar amount. Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted. Consequently, because no claims have been asserted, no liabilities have been recorded for these obligations on our balance sheets for any of the periods presented.
In connection with the spin-off transaction in 2019, certain landlords required, in exchange for their consent to the transaction, that our lease guarantees remain in place for a certain period of time following the spin-off. These guarantees could result in significant additional liabilities and obligations for us if Pennant were to default on their obligations under their leases with respect to these properties.
Litigation and Regulatory MattersLaws and regulations governing Medicare and Medicaid programs are complex and subject to review and interpretation. Compliance with such laws and regulations is evaluated regularly, the results of which can be subject to future governmental review and interpretation, and can include significant regulatory action with fines, penalties, and exclusion from certain governmental programs. Included in these laws and regulations is monitoring performed by the Office of Civil Rights which covers the Health Insurance Portability and Accountability Act of 1996, the terms of which require healthcare providers (among other things) to safeguard the privacy and security of certain patient protected health information.
Both government and private pay sources have instituted cost-containment measures designed to limit payments made to providers of healthcare services, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect us.
We and our independent subsidiaries are party to various legal actions and administrative proceedings and are subject to various claims arising in the ordinary course of business, including claims that services provided to patients by our independent subsidiaries have resulted in injury or death, and claims related to employment and commercial matters. For example, in a four-week medical negligence trial in the State of Arizona, the jury returned a verdict against one of our independent subsidiaries in late November 2023. We intend to appeal the verdict. We have in the past appealed and have in some circumstances received returned decisions in our favor. Although we intend to vigorously defend against these claims and in general these types of claims and cases, there can be no assurance that the outcomes of these matters will not have a material adverse effect on operational results and financial condition. Additionally, in certain states in which we have or have had independent subsidiaries, insurance coverage for the risk of punitive damages arising from general and professional liability litigation may not be available due to state law and/or public policy prohibitions. There can be no assurance that we and or our independent subsidiaries will not be liable for punitive damages awarded in litigation arising in states for which punitive damage insurance coverage is not available.
The skilled nursing and post-acute care industry is heavily regulated. As such, we and our independent subsidiaries are continuously subject to state and federal regulatory scrutiny, supervision and control in the ordinary course of business. Such regulatory scrutiny often includes inquiries, investigations, examinations, audits, site visits and surveys, some of which are non-routine. In addition to being subject to direct regulatory oversight from state and federal agencies, the skilled nursing and post-acute care industry is also subject to regulatory requirements which, if noncompliance is identified, could result in civil, administrative or criminal fines, penalties or restitutionary relief, and reimbursement; authorities could also seek the suspension or exclusion of the provider or individual from participation in their programs. We believe that there has been, and will continue to be, an increase in governmental investigations of post-acute providers, particularly in the area of Medicare/Medicaid false claims, as well as an increase in enforcement actions resulting from these investigations. Adverse determinations in civil legal proceedings or governmental investigations, whether currently asserted or arising in the future, could have a material adverse effect on our financial position, results of operations, and cash flows. Additionally, such proceedings and/or investigation can be a distraction to the business.

67

For example, in 2020, the U.S. House of Representatives Select Subcommittee on the Coronavirus Crisis launched a nation-wide investigation into the COVID-19 pandemic, which included the impact of the coronavirus on residents and employees in nursing homes. In June 2020, we and our independent subsidiaries received a document and information request from the House Select Subcommittee. We and our independent subsidiaries cooperated in responding to this inquiry. In July 2022 and thereafter, we and our independent subsidiaries received follow up requests for additional documents and information. We and our independent subsidiaries responded to these requests and cooperated with the House Select Subcommittee in connection with its investigation. On December 9, 2022, the House Select Subcommittee issued its final report summarizing its investigation and related recommendations designed "to strengthen the nation's ability to prevent and respond to public health and economic emergencies." According to the information provided by the House Select Subcommittee, the issuance of this report was the House Select Subcommittee's final official act in connection with their assigned responsibilities. Also, we, on behalf of our independent subsidiaries, received a Civil Investigative Demand (CID) from the U.S. Department of Justice (DOJ) in January of 2024 indicating that the DOJ is investigating the Company to determine whether we have caused the submission of claims to Medicare and Texas Medicaid for services which were unnecessary or otherwise not consistent with existing reimbursement requirements. The CID covers the period from January 1, 2016 to the present. As a general matter, our independent subsidiaries maintain policies and procedures to promote compliance with all applicable Medicare and Medicaid requirements, including, but not limited to those relating to the presentation of claims for reimbursement for services provided. We intend to fully cooperate with the DOJ in response to the CID. However, we cannot predict the outcome of the investigation or its potential impact to the consolidated financial statements.
In addition to the potential lawsuits and claims described above, we and our independent subsidiaries are also subject to potential lawsuits under the FCA and comparable state laws alleging submission of fraudulent claims for services to any healthcare program (such as Medicare or Medicaid) or other payor. A violation may provide the basis for exclusion from federally funded healthcare programs. Such exclusions could have a correlative negative impact on our financial performance. In addition, and pursuant to the qui tam or "whistleblower" provisions of the FCA, a private individual with knowledge of fraud or potential fraud may bring a claim on behalf of the federal government and receive a percentage of the federal government's recovery. Due to these whistleblower incentives, qui tam lawsuits have become more frequent.
For example, on May 31, 2018, we, on behalf of our independent subsidiaries, received a CID from the DOJ stating that it was investigating to determine whether there had been a violation of the False Claims Act (FCA) and/or the Anti-Kickback Statute (AKS) with respect to the relationships between certain of our independent subsidiaries and persons who serve or have served as medical directors. We fully cooperated with the DOJ and promptly responded to its requests for information. In April 2020, we were advised that the DOJ declined to intervene in any subsequent action filed in connection with the subject matter of this investigation. Despite the decision of the DOJ to decline to participate in litigation based on the subject matter of its previously issued CID, the involved qui tam relator moved forward with the complaint in December 2020. From that time until December 2023, and notwithstanding our success in early pre-trial motions, we continued to incur legal defense costs and fees, including significant amounts as part of discovery in the fourth quarter of 2023. In early January 2024, we entered into mediation and on January 19, 2024, the parties agreed to settle the civil case for $48.0 million, subject to the review of the DOJ and other relevant government entities. The settlement does not include admissions on the part of the Company or our independent subsidiaries, and we maintain that we have and continue to comply with all applicable State and Federal statutes (including but not limited to the FCA and the AKS).
In addition to the FCA, some states, including California, Arizona and Texas, have enacted similar whistleblower and false claims laws and regulations. Further, the Deficit Reduction Act of 2005 created incentives for states to enact anti-fraud legislation modeled on the FCA. As such, we and our independent subsidiaries could face increased scrutiny, potential liability and legal expenses and costs based on claims under state false claims acts in markets where our independent subsidiaries do business.
In May 2009, Congress passed the FERA which made significant changes to the FCA and expanded the types of activities subject to prosecution and whistleblower liability. Following changes by FERA, health care providers face significant penalties for the knowing retention of government overpayments, even if no false claim was involved. Health care providers can now be liable for knowingly and improperly avoiding or decreasing an obligation to pay money or property to the government. This includes the retention of any government overpayment. The government can argue, therefore, that an FCA violation can occur without any affirmative fraudulent action or statement, as long as the action or statement is knowingly improper. In addition, FERA extended protections against retaliation for whistleblowers, including protections not only for employees, but also contractors and agents. Thus, an employment relationship is generally not required in order to qualify for protection against retaliation for whistleblowing.

68

Healthcare litigation (including class action litigation) is common and is filed based upon a wide variety of claims and theories, and our independent subsidiaries are routinely subjected to varying types of claims, including class action "staffing" suits where the allegation is understaffing at the facility level. These class-action “staffing” suits have the potential to result in large jury verdicts and settlements. We expect the plaintiffs' bar to continue to be aggressive in their pursuit of these staffing and similar claims.
We and our independent subsidiaries have been, and continue to be, subject to claims, findings and legal actions that arise in the ordinary course of the various businesses, including in connection with the delivery of healthcare and non-healthcare services. These claims include but are not limited to potential claims related to patient care and treatment (professional negligence claims) as well as employment related claims. In addition, we and our independent subsidiaries, and others in the industry, are subject to claims and lawsuits in connection with COVID-19 and facility preparation for and/or response to the COVID-19 pandemic. While we have been able to settle or otherwise resolve many of these types of claims without an ongoing material adverse effect on our business, a significant increase in the number of these claims, or an increase in the amounts owing should plaintiffs be successful in their prosecution of remaining or future claims, could materially adversely affect our business, financial condition, results of operations and cash flows. In addition, these claims could impact our ability to procure insurance to cover our exposure related to the various services provided by our independent subsidiaries to their residents, customers and patients.
Claims and suits, including class actions, continue to be filed against our independent subsidiaries and other companies in the post-acute care industry. We and our independent subsidiaries have been subjected to, and/or are currently involved in, class action litigation alleging violations (alone or in combination) of state and federal wage and hour law as related to the alleged failure to pay wages, to timely provide and authorize meal and rest breaks, and other such similar causes of action. We do not believe that the ultimate resolution of these actions will have a material adverse effect on our business, cash flows, financial condition or results of operations.
Medicare Revenue RecoupmentsWe and our independent subsidiaries are subject to regulatory reviews relating to the provision of Medicare services, billings and potential overpayments resulting from reviews conducted via RAC, Program Safeguard Contractors, and Medicaid Integrity Contractors (collectively referred to as Reviews). For several months during the COVID-19 pandemic, CMS suspended its Targeted Probe and Educate (TPE) Program. Beginning in August 2020, CMS resumed TPE Program activity. If an operation fails a Review and/or subsequent Reviews, the operation could then be subject to extended review or an extrapolation of the identified error rate to billings in the same time period. We anticipate that these Reviews could increase in frequency in the future. As of December 31, 2023, and through the filing date of this report, 40 of our independent subsidiaries had Reviews scheduled or in process.
In June 2023, CMS announced a new nationwide audit, the “SNF 5-Claim Probe & Educate Review”, in which the Medicare Administrative Contractors will review five claims from each SNF to check for compliance. In implementing this SNF 5-Claim Probe & Educate Review, CMS acknowledged that the increase in observed improper payments from 2021 to 2022 may have arisen from a “misunderstanding” by SNFs about how to appropriately bill for claims of service after October 1, 2019. All facilities that are not undergoing TPE reviews, or have not recently passed a TPE review, will be subject to the nationwide audit. MACs will complete only one round of probe-and-educate for each SNF, rather than the three rounds that typically occur in the TPE Program. Additionally, CMS’s education for each SNF will be individualized and based on observed claim review errors, with rationales for denial explained to the SNF on a claim-by-claim basis. This program will apply only to claims submitted after October 1, 2019, and will exclude claims containing a COVID-19 diagnosis.

Item 4.     MINE SAFETY DISCLOSURES

    None.
PART II.
Item 5.     MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
Market Information

Our common stock has been traded under the symbol “ENSG” on the NASDAQ Global Select Market since our initial public offering on November 8, 2007. Prior to that time, there was no public market for our common stock. As of January 29, 2024, there were approximately 315 holders of record of our common stock.


69

Notwithstanding anything to the contrary set forth in any of our filings under the Securities Act or the Exchange Act that might incorporate future filings, including the Annual Report on Form 10-K, in whole or in part, the Stock Performance Graph and supporting data which follows shall not be deemed to be incorporated by reference into any such filings except to the extent that we specifically incorporate any such information into any such future filings.

The graph below shows the cumulative total stockholder return of investment of $100 (and the reinvestment of any dividends thereafter) on December 31, 2018 in (i) our common stock, (ii) the Skilled Nursing Facilities Peer Group 1 and (iii) the NASDAQ Market Index. Our stock price performance shown in the graph below is not indicative of future stock price performance.

Since our inception in 1999, we completed the spin-off of two independent publicly traded companies. On June 1, 2014, Ensign completed the spin-off of CareTrust REIT, Inc. (CareTrust) into an independent publicly traded company. On October 1, 2019, Ensign completed the spin-off of The Pennant Group, Inc. (Pennant) with the pro rata distribution of 1.18 shares of Pennant’s common stock for every share of Ensign’s common stock to our stockholders, pursuant to which Pennant became an independent company. Pennant's stock traded at $6.15 at opening price on the first day of trading and closed at $15.09. Ensign's stock price was reduced by the same value on the same day. For the purpose of this graph, the effect of the final separation of Pennant is reflected in the cumulative total return of Ensign Common Stock as a reinvested dividend.

COMPARISON OF 60 MONTH CUMULATIVE TOTAL RETURN*
Among Ensign Group, the NASDAQ Composite Index and Our Peer Group
December 2023

2018
*Assumes $100 invested on December 31, 2018 in stock in index, including reinvestment of dividends.
Fiscal year ended December 31.
December 31,
201820192020202120222023
The Ensign Group, Inc.(2)
$100.00 $127.85 $206.31 $238.12 $268.99 $319.74 
NASDAQ Market Index100.00 136.69 198.10 242.03 163.28 236.17 
Peer Group(1)
100.00 123.99 122.37 128.11 108.87 141.47 
(1) The current composition of our Peer Group is as follows: Amedysis, Inc., CareTrust REIT Inc., Encompass Healthcare Corp., LTC Properties, Inc., National Healthcare Corporation, National Health Investors, Inc., Omega Healthcare Investors, Inc., Select Medical Holdings Corp. and Welltower Inc.
(2) The value displayed only incorporates the value of The Ensign Group, Inc. stock and does not incorporate the value shareholders received in connection with our spin-off of The Pennant Group, Inc.

70

Dividend Policy
We do not have a formal dividend policy, but we currently intend to continue to pay regular quarterly dividends to the holders of our common stock. We have been a dividend-paying company since 2002 and have increased our dividend every year for the last 21 years.
Issuer Repurchases of Equity Securities
Stock Repurchase Programs On August 29, 2023, the Board of Directors approved a stock repurchase program pursuant to which we may repurchase up to $20.0 million of our common stock under the program for a period of approximately 12 months from September 1, 2023. Under this program, we are authorized to repurchase our issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. We did not purchase any shares pursuant to this stock repurchase program during the year ended December 31, 2023.
Previously on July 28, 2022, the Board of Directors approved a stock repurchase program pursuant to which we could repurchase up to $20.0 million of our common stock under the program for a period of approximately 12 months from August 2, 2022. Under this program, we were authorized to repurchase our issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. The share repurchase program does not obligate us to acquire any specific number of shares. The stock repurchase program expired on August 2, 2023 and is no longer in effect. We did not purchase any shares pursuant to this stock repurchase program.

Item 6.     [RESERVED]

Item 7.     MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion should be read in conjunction with the consolidated financial statements and accompanying notes, which appear elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those discussed below and elsewhere in this Annual Report on Form 10-K. See Part I. Item 1A. Risk Factors and Cautionary Note Regarding Forward-Looking Statements.
For discussion of 2021 items and year-over-year comparisons between 2022 and 2021 that are not included in this 2023 Form 10-K, refer to “Item 7. – Management’s Discussion and Analysis of Financial Condition and Results of Operations” found in our Form 10-K for the year ended December 31, 2022, that was filed with the Securities and Exchange Commission on February 2, 2023.
Overview
We are a provider of health care services across the post-acute care continuum. We engage in the operation, ownership, acquisition, development and leasing of skilled nursing, senior living and other healthcare related properties and ancillary businesses located in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. Our independent subsidiaries, each of which strive to be the operation of choice in the community they serve, provide a broad spectrum of services. As of December 31, 2023, we offered skilled nursing, senior living and rehabilitative care services through 297 skilled nursing and senior living facilities. Our real estate portfolio includes 113 owned real estate properties, which includes 83 facilities operated and managed by us, 30 operations leased to and operated by third-party operators and the Service Center location. Of the 30 real estate operations leased to third-party operators, one senior living facility is located on the same real estate property as a skilled nursing facility that we own and operate.

71

Ensign is a holding company with no direct operating assets, employees or revenues. Our subsidiaries are operated by separate, independent entities, each of which has its own management, employees and assets. In addition, certain of our wholly-owned subsidiaries including Ensign Services, Inc. and Cornet Limited, Inc., referred to collectively as the Service Center, provide centralized accounting, payroll, human resources, information technology, legal, risk management and other centralized services to the other independent subsidiaries through contractual relationships with such subsidiaries. We also have a wholly-owned captive insurance subsidiary that provides some claims-made coverage to our independent subsidiaries for general and professional liability, as well as coverage for certain workers’ compensation insurance liabilities and our captive real estate trust owns and operates our real estate portfolio. Our captive real estate investment trust, Standard Bearer, owns and manages our real estate business. References herein to the consolidated “Company” and “its” assets and activities, as well as the use of the terms “we,” “us,” “our” and similar terms in this Annual Report, are not meant to imply, nor should they be construed as meaning, that The Ensign Group, Inc. has direct operating assets, employees or revenue, or that any of the subsidiaries are operated by The Ensign Group.
Recent Activities
Operational UpdateOn May 11, 2023, the United States Department of Health and Human Services (HHS) ended the public health emergency (PHE). Our primary focus has always been and continues to be the health and safety of our patients, residents, employees and their respective families. Even with the end of the PHE, we continue to implement new measures and maintain existing ones to provide the safest possible environment within our sites of service, taking into consideration the vulnerable nature of our patients.
We continue to execute on key initiatives to rebuild occupancy lost due to the pandemic. Our combined Same Facilities and Transitioning Facilities occupancy is 78.9%, which represents a 3.2% increase compared to the prior year and is closer to our pre-pandemic occupancy levels, which was 80.1% in March 2020. As we shift to an endemic, we believe that we will continue to see the return of our seasonal occupancy and skilled mix. Throughout most of our history, our seasonality trends for skilled nursing occupancy and skilled mix typically included the greatest growth during the first and fourth quarters and softening in the second and third quarters. As we exited the pandemic and enter the endemic, we saw a shift towards pre-pandemic occupancy and skilled mix levels. This was possible due to the innovative approaches and strategic partnerships developed during the pandemic which supported our occupancy improvements and continue to enable us to gain additional market share. These key initiatives together with our dedication to our cultural and operational fundamentals resulted in a strong 2023 results.
We receive relief funding from various states, including healthcare relief funding under the American Rescue Plan Act (ARPA), increases in the Federal Medical Assistance Percentage (FMAP) under the Families First Coronavirus Response Act (FFCRA) and other state specific relief programs. We use this funding, which reimburses the recipient for healthcare and labor related patient care services and expenses that are attributable to the COVID-19 pandemic. The end of the PHE created a gradual phase down of the temporary increase in FMAP funding in 2023. State specific approaches have been developed including various states having increased their base rates to account for increases in expenses in the post-pandemic environment.
During the years ended December 31, 2023 and 2022, we recognized $64.8 million and $81.8 million, respectively, of combined state relief funding as revenue.
Standard Bearer UpdateIn January of 2022, we formed Standard Bearer Healthcare REIT, Inc. or Standard Bearer, a captive REIT. Standard Bearer is a holding company with subsidiaries that own a majority of our real estate portfolio. We expect the REIT structure to allow us to better demonstrate the growing value of our owned real estate and provide us with an efficient vehicle for future acquisitions of properties that could be operated by our independent subsidiaries or other third parties. This structure gives us new pathways to growth with transactions we would not have considered in the past.
During the year ended December 31, 2023, Standard Bearer acquired the real estate of three stand-alone skilled nursing facilities and two campus operations for an aggregate purchase price of $65.9 million. Of these additions, the three skilled nursing facilities and one campus operation acquired are operated by our independent subsidiaries and the other campus operation is leased to a new third-party operator. Our existing relationship with third-party operators within our industry allowed us to expand our growing REIT structure to operators outside of our organization.
As of December 31, 2023, the fair value of Standard Bearer's real estate portfolio is approximately $1.1 billion. The fair value was determined by a third-party independent valuation specialist and incorporated each property's rental income, capitalization rate, rental yield rate and discount rate.
72

Expansion into a New StateSubsequent to December 31, 2023, we expanded our operations into the state of Tennessee with the addition of one stand-alone skilled nursing operation. This expansion is part of our strategic vision to further strengthen our growing national presence in both existing and new attractive markets.
Common Stock Repurchase ProgramOn August 29, 2023, the Board of Directors approved a stock repurchase program pursuant to which we may repurchase up to $20.0 million of our common stock under the program for a period of approximately 12 months from September 1, 2023. We did not repurchase any shares pursuant to this program during the fiscal year 2023.
LitigationIn regard to the proceeding discussed in Item 3. Legal Proceedings, the parties agreed to settle the litigation for $48.0 million, subject to the review and approval of all parties, including the DOJ. The settlement does not include admissions on the part of the Company and the Company maintains that it has at all times complied and continues to comply with all applicable State and Federal statutes (including but not limited to the FCA and the AKS).
Key Performance Indicators
We manage the fiscal aspects of our business by monitoring key performance indicators that affect our financial performance. Revenue associated with these metrics is generated based on contractually agreed-upon amounts or rate, excluding the estimates of variable consideration under the revenue recognition standard, Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606. These indicators and their definitions include the following:
Skilled Services
Routine revenue Routine revenue is generated by the contracted daily rate charged for all contractually inclusive skilled nursing services. The inclusion of therapy and other ancillary treatments varies by payor source and by contract. Services provided outside of the routine contractual agreement are recorded separately as ancillary revenue, including Medicare Part B therapy services, and are not included in the routine revenue definition.
Skilled revenue The amount of routine revenue generated from patients in the skilled nursing facilities who are receiving higher levels of care under Medicare, managed care, Medicaid, or other skilled reimbursement programs. The other skilled patients who are included in this population represent very high acuity patients who are receiving high levels of nursing and ancillary services which are reimbursed by payors other than Medicare or managed care. Skilled revenue excludes any revenue generated from our senior living services.
Skilled mix The amount of our skilled revenue as a percentage of our total skilled nursing routine revenue. Skilled mix (in days) represents the number of days our Medicare, managed care, or other skilled patients are receiving skilled nursing services at the skilled nursing facilities divided by the total number of days patients from all payor sources are receiving skilled nursing services at the skilled nursing facilities for any given period.
Average daily rates The routine revenue by payor source for a period at the skilled nursing facilities divided by actual patient days for that revenue source for that given period. These rates exclude additional state relief funding, which includes ARPA, FFCRA and other state relief programs.
Occupancy percentage (operational beds) The total number of patients occupying a bed in a skilled nursing facility as a percentage of the beds in a facility which are available for occupancy during the measurement period.
Number of facilities and operational beds The total number of skilled nursing facilities that we own or operate and the total number of operational beds associated with these facilities.
Skilled Mix Like most skilled nursing providers, we measure both patient days and revenue by payor. Medicare, managed care and other skilled patients, whom we refer to as high acuity patients, typically require a higher level of skilled nursing and rehabilitative care. Accordingly, Medicare and managed care reimbursement rates are typically higher than from other payors. In most states, Medicaid reimbursement rates are generally the lowest of all payor types. Changes in the payor mix can significantly affect our revenue and profitability.

The following table summarizes our overall skilled mix from our skilled nursing services for the periods indicated as a percentage of our total skilled nursing routine revenue and as a percentage of total skilled nursing patient days:
Year Ended December 31,
Skilled Mix:20232022
Days30.4 %31.8 %
Revenue50.2 %52.0 %
73

Occupancy We define occupancy derived from our skilled services as the ratio of actual patient days (one patient day equals one patient occupying one bed for one day) during any measurement period to the number of beds in facilities which are available for occupancy during the measurement period. The number of beds in a skilled nursing facility that are actually operational and available for occupancy may be less than the total official licensed bed capacity. This sometimes occurs due to the permanent dedication of bed space to alternative purposes, such as enhanced therapy treatment space or other desirable uses calculated to improve service offerings and/or operational efficiencies in a facility. In some cases, three- and four-bed wards have been reduced to two-bed rooms for resident comfort, and larger wards have been reduced to conform to changes in Medicare requirements. These beds are seldom expected to be placed back into service. We believe that reporting occupancy based on operational beds is consistent with industry practices and provides a more useful measure of actual occupancy performance from period to period.

The following table summarizes our overall occupancy statistics for skilled nursing operations for the periods indicated:
Year Ended December 31,
Occupancy for skilled services:20232022
Operational beds at end of period30,602 28,130 
Available patient days10,940,320 9,614,460 
Actual patient days8,590,995 7,243,781 
Occupancy percentage (based on operational beds)78.5 %75.3 %
Segments
We have two reportable segments: (1) skilled services, which includes the operation of skilled nursing facilities and rehabilitation therapy services and (2) Standard Bearer, which is comprised of select properties owned by us through our captive REIT and leased to skilled nursing and senior living operations, including our own independent subsidiaries and third-party operators.
We also reported an “all other” category that includes operating results from our senior living operations, mobile diagnostics, transportation, other real estate and other ancillary operations. These businesses are neither significant individually, nor in aggregate and therefore do not constitute a reportable segment. Our Chief Executive Officer, who is our chief operating decision maker, or CODM, reviews financial information at the operating segment level.
Revenue Sources
Skilled Services Within our skilled nursing operations, we generate revenue from Medicaid, private pay, managed care and Medicare payors. We believe that our skilled mix, which we define as the number of days Medicare, managed care and other skilled patients are receiving services at our skilled nursing operations divided by the total number of days patients are receiving services at our skilled nursing operations, from all payor sources (less days from senior living services) for any given period, is an important indicator of our success in attracting high-acuity patients because it represents the percentage of our patients who are reimbursed by Medicare, managed care and other skilled payors, for whom we receive higher reimbursement rates.
We participate in supplemental payment programs and quality improvement programs in various states that provide supplemental Medicaid payments for skilled nursing facilities that are licensed to non-state government-owned entities such as city and county hospital districts. Numerous independent subsidiaries entered into transactions with various hospital districts providing for the transfer of the licenses for those skilled nursing facilities to the hospital districts. Each affected independent subsidiary agreement between the hospital district and our subsidiary is terminable by either party to fully restore the prior license status.
Standard Bearer We generate rental revenue primarily by leasing post-acute care properties that we acquired to healthcare operators under triple-net lease arrangements, whereby the tenants are solely responsible for the costs related to the property, including property taxes, insurance and maintenance and repair costs, subject to certain exceptions. As of December 31, 2023, our real estate portfolio within Standard Bearer is comprised of 108 real estate properties. Of these properties, 79 are leased to our independent subsidiaries and 30 are leased to facilities wholly-owned and managed by third-party operators. During the year ended December 31, 2023, we generated rental revenues of $82.5 million, of which $66.7 million, was derived from our independent subsidiaries' operators and therefore eliminated in consolidation.
74

Other Within our senior living operations, we generate revenue primarily from private pay sources, with a portion earned from Medicaid payors or through other state-specific programs. In addition, we hold majority membership interests in certain of our other ancillary operations. Payment for these services varies and is based upon the service provided. The payment is adjusted for an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk.
Primary Components of Expense
Cost of Services (exclusive of rent and depreciation and amortization shown separately) Our cost of services represents the costs of operating our independent subsidiaries, which primarily consists of payroll and related benefits, supplies, purchased services, and ancillary expenses such as the cost of pharmacy and therapy services provided to patients. Cost of services also includes the cost of general and professional liability insurance, rent expenses related to leasing our operational facilities that are not included in facility rent - cost of services, and other general cost of services with respect to our operations.
Facility Rent - Cost of Services Rent - cost of services consists solely of base minimum rent amounts payable under lease agreements to third-party real estate owners. Our independent subsidiaries lease and operate but do not own the underlying real estate and these amounts do not include taxes, insurance, impounds, capital reserves or other charges payable under the applicable lease agreements. Expenses related to leasing our operations are included in cost of services.
General and Administrative Expense General and administrative expense consists primarily of payroll and related benefits and travel expenses for our Service Center personnel, including training and other operational support. General and administrative expense also includes professional fees (including accounting and legal fees), litigation expense related to specific proceedings that are outside the ordinary course of business, costs relating to our information systems and stock-based compensation related to our Service Center employees.
Depreciation and Amortization Property and equipment are recorded at their original historical cost. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets. The following is a summary of the depreciable lives of our depreciable assets:
Buildings and improvements
Minimum of three years to a maximum of 59 years, generally 45 years
Leasehold improvementsShorter of the lease term or estimated useful life, generally 5 to 15 years
Furniture and equipment3 to 10 years
Critical Accounting Estimates
Our discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP). The preparation of these financial statements and related disclosures requires us to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. We believe that the application of the following accounting policies, which are important to our financial position and results of operations, require significant judgments and estimates on the part of management. For a summary of our significant accounting policies, including the accounting policies discussed below, see Note 2, Summary of Significant Accounting Policies of the Notes to Consolidated Financial Statements.
Variable consideration within revenue recognition Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction price. We determine the transaction price based on contractually agreed-upon amounts or rates, adjusted for estimates of variable consideration. We use the expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The amount of variable consideration which is included in the transaction price may be constrained and is included in the net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from our estimates, we adjust these estimates, which would affect net service revenue in the period such variances become known.

75

Self-insurance for general and professional liability The self-insured retention and deductible limits for general and professional liability for all states are self-insured through our wholly-owned captive insurance subsidiary (the Captive Insurance), the related assets and liabilities of which are included in the accompanying consolidated balance sheets. Our general and professional liability as of the year ended December 31, 2023 and 2022 was $117.7 million and $87.0 million, respectively.
Our policy is to accrue amounts equal to the actuarially estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. We develop information about the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluate the estimates for claim loss exposure on a quarterly basis. We use actuarial valuations to estimate the liability based on historical experience and industry information.
RESULTS OF OPERATIONS
We believe we exist to dignify and transform post-acute care. We set out a strategy to achieve our goal of ensuring our patients are receiving the best possible care through our ability to acquire, integrate and improve our operations. Our results serve as a strong indicator that our strategy is working and our transformation is underway. Over the last five years, our total revenue increased by $2.0 billion, or 112.5%, representing a 16.3% compound annual growth rate (CAGR) while our diluted GAAP earning per share (EPS) from continued operations grew by $2.56 from 2018 to $3.65 in 2023, representing a 27.4% CAGR.
Our total revenue for the year ended December 31, 2023 increased $703.9 million, or 23.3%, compared to the year ended December 31, 2022. Throughout 2023, we have continued to make progress on targeted initiatives related to increasing occupancy in our facilities, attracting and developing our people and acquiring new skilled nursing operations and integrating them with our proven cultural and operational principals. We continue to experience healthy growth in both revenue and operational earnings.
Our combined Same Facilities and Transitioning Facilities occupancy increased by 3.2% compared to 2022. As our census continues to return to pre-pandemic levels, we anticipate a return to our historical seasonality trends, which typically result in higher occupancy and skilled mix during the first and fourth quarters and softening in the second and third quarters. See Recent Activities for our operational update.
During the year ended December 31, 2023, we added 26 new operations, which included 17 operations in California. These California facilities include a group of highly skilled team members who will further our mission of dignifying long term care. We continue to work diligently with existing and recently acquired operations so that each can reach its full clinical and financial potential.
Our strength remains in our operating model, which empowers each operator to form their own market-specific strategy and adjust to the needs of their local medical communities, including methods for attracting new healthcare professionals into our workforce and retaining and developing existing staff. Despite continued labor pressures, there are positive trends on both turnover and agency usage in some of our markets. During 2023, we added over 5,000 team members, or 18%, to our independent subsidiaries and the Service Center.

The following table sets forth details of operating results for our revenue, expenses and earnings, and their respective components, as a percentage of total revenue for the periods indicated:
76

Year Ended December 31,
 20232022
REVENUE:
Service revenue99.4 %99.4 %
Rental revenue0.6 0.6 
TOTAL REVENUE100.0 %100.0 %
Expenses:
Cost of services78.9 77.8 
Rent—cost of services5.3 5.1 
General and administrative expense7.1 5.2 
Depreciation and amortization1.9 2.1 
TOTAL EXPENSES93.2 90.2 
Income from operations6.8 9.8 
Other income (expense):
Interest expense(0.2)(0.3)
Other income0.7 — 
Other income (expense), net0.5 (0.3)
Income before provision for income taxes7.3 9.5 
Provision for income taxes1.7 2.1 
NET INCOME5.6 7.4 
Less: net income attributable to noncontrolling interests — — 
 Net income attributable to The Ensign Group, Inc.5.6 %7.4 %
 Year Ended December 31,
 20232022
SEGMENT INCOME(1)
(In thousands)
Skilled services$464,925 $408,732 
Standard Bearer(2)
29,065 27,871 
NON-GAAP FINANCIAL MEASURES:
PERFORMANCE METRICS
Adjusted EBT365,310 314,609 
EBITDA(3)
327,303 359,209 
Adjusted EBITDA 419,496 383,570 
FFO for Standard Bearer
54,270 49,484 
VALUATION METRICS
Adjusted EBITDAR$616,854 
(1) Segment income represents operating results of the reportable segments excluding gain and loss on sale of assets, real estate insurance recoveries and losses, impairment charges and provision for income taxes. Included in segment income for Standard Bearer are expenses for intercompany management fees between Standard Bearer and the Service Center and intercompany interest expense. Segment income is reconciled to the Consolidated Statement of Income in Note 8, Business Segments in Notes to Financial Statements of this Annual Report on Form 10-K.
(2) Standard Bearer segment income includes rental revenue and expenses from our independent subsidiaries.
(3) EBITDA includes litigation related to specific proceedings arising outside of the ordinary course of business as discussed in Item 3. Legal Proceedings.

77

The following discussion includes references to Adjusted EBT, EBITDA, Adjusted EBITDA, Adjusted EBITDAR and Funds from Operations (FFO) which are non-GAAP financial measures (collectively, the Non-GAAP Financial Measures). Regulation G, Conditions for Use of Non-GAAP Financial Measures, and other provisions of the Securities Exchange Act of 1934, as amended (the Exchange Act), define and prescribe the conditions for use of certain non-GAAP financial information. These Non-GAAP Financial Measures are used in addition to and in conjunction with results presented in accordance with GAAP. These Non-GAAP Financial Measures should not be relied upon to the exclusion of GAAP financial measures. These Non-GAAP Financial Measures reflect an additional way of viewing aspects of our operations that, when viewed with our GAAP results and the accompanying reconciliations to corresponding GAAP financial measures, provide a more complete understanding of factors and trends affecting our business.

We believe the presentation of certain Non-GAAP Financial Measures are useful to investors and other external users of our financial statements regarding our results of operations because:

they are widely used by investors and analysts in our industry as a supplemental measure to evaluate the overall performance of companies in our industry without regard to items such as other income (expense), net and depreciation and amortization, which can vary substantially from company to company depending on the book value of assets, capital structure and the method by which assets were acquired; and

they help investors evaluate and compare the results of our operations from period to period by removing the impact of our capital structure and asset base from our operating results.

We use the Non-GAAP Financial Measures:

as measurements of our operating performance to assist us in comparing our operating performance on a consistent basis;
to allocate resources to enhance the financial performance of our business;
to assess the value of a potential acquisition;
to assess the value of a transformed operation's performance;
to evaluate the effectiveness of our operational strategies; and
to compare our operating performance to that of our competitors.

We use certain Non-GAAP Financial Measures to compare the operating performance of each operation. These measures are useful in this regard because they do not include such costs as other expense, income taxes, depreciation and amortization expense, which may vary from period-to-period depending upon various factors, including the method used to finance operations, the amount of debt that we have incurred, whether an operation is owned or leased, the date of acquisition of a facility or business, and the tax law of the state in which a business unit operates.

We also establish compensation programs and bonuses for our leaders that are partially based upon the achievement of Adjusted EBITDAR targets.

Despite the importance of these measures in analyzing our underlying business, designing incentive compensation and for our goal setting, the Non-GAAP Financial Measures have no standardized meaning defined by GAAP. Therefore, certain of our Non-GAAP Financial Measures have limitations as analytical tools, and they should not be considered in isolation, or as a substitute for analysis of our results as reported in accordance with GAAP. Some of these limitations are:

they do not reflect our current or future cash requirements for capital expenditures or contractual commitments;
they do not reflect changes in, or cash requirements for, our working capital needs;
they do not reflect the interest expense, or the cash requirements necessary to service interest or principal payments, on our debt;
they do not reflect rent expenses, which are necessary to operate our leased operations, in the case of Adjusted EBITDAR;
they do not reflect any income tax payments we may be required to make;
although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and do not reflect any cash requirements for such replacements; and
other companies in our industry may calculate these measures differently than we do, which may limit their usefulness as comparative measures.

78

We compensate for these limitations by using them only to supplement net income on a basis prepared in accordance with GAAP in order to provide a more complete understanding of the factors and trends affecting our business. Management strongly encourages investors to review our consolidated financial statements in their entirety and to not rely on any single financial measure. Because these Non-GAAP Financial Measures are not standardized, it may not be possible to compare these financial measures with other companies’ Non-GAAP financial measures having the same or similar names. These Non-GAAP Financial Measures should not be considered a substitute for, nor superior to, financial results and measures determined or calculated in accordance with GAAP. We strongly urge you to review the reconciliation of income from operations to the Non-GAAP Financial Measures in the table below, along with our Financial Statements and related notes included elsewhere in this document.

We use the following Non-GAAP financial measures that we believe are useful to investors as key valuation and operating performance measures:

PERFORMANCE MEASURES
Adjusted EBT

We adjust income before provision for income taxes (Adjusted EBT) when evaluating our performance because we believe that the exclusion of certain additional items described below provides useful supplemental information to investors regarding our ongoing operating performance. We believe that the presentation of Adjusted EBT, when combined with income before provision for income taxes and GAAP net income attributable to The Ensign Group, Inc., is beneficial to an investor’s complete understanding of our operating performance. We use this performance measure as an indicator of business performance, as well as for operational planning, decision-making purposes and to determine compensation in our executive compensation plan.

Adjusted EBT is income before provision for income taxes adjusted for non-core business items, which for the reported periods includes, to the extent applicable:

stock-based compensation expense;
litigation;
gain on sale of assets and business interruption of recoveries;
write-off of deferred financing fees;
acquisition related costs;
costs incurred related to new systems implementation; and
depreciation and amortization of patient base intangible assets.
EBITDA

We believe EBITDA is useful to investors in evaluating our operating performance because it helps investors evaluate and compare the results of our operations from period to period by removing the impact of our asset base (depreciation and amortization expense) from our operating results.

We calculate EBITDA as net income, adjusted for net losses attributable to noncontrolling interest, before (a) other income (expense), net, (b) provision for income taxes, and (c) depreciation and amortization.
Adjusted EBITDA

We adjust EBITDA when evaluating our performance because we believe that the exclusion of certain additional items described below provides useful supplemental information to investors regarding our ongoing operating performance, in the case of Adjusted EBITDA. We believe that the presentation of Adjusted EBITDA, when combined with EBITDA and GAAP net income attributable to The Ensign Group, Inc., is beneficial to an investor’s complete understanding of our operating performance.  

Adjusted EBITDA is EBITDA adjusted for the same non-core business items as listed in Adjusted EBT, except for depreciation and amortization of patient base intangible assets and write-off of deferred financing fees.

79

Funds from Operations (FFO)
We consider FFO to be a useful supplemental measure of the operating performance of Standard Bearer. Historical cost accounting for real estate assets in accordance with U.S. GAAP implicitly assumes that the value of real estate assets diminishes predictably over time as evidenced by the provision for depreciation. However, since real estate values have historically risen or fallen with market conditions, many real estate investors and analysts have considered presentations of operating results for real estate companies that use historical cost accounting to be insufficient. In response, the National Association of Real Estate Investment Trusts (NAREIT) created FFO as a supplemental measure of operating performance for REITs, which excludes historical cost depreciation from net income. We define (in accordance with the definition used by NAREIT) FFO to consist of Standard Bearer segment income, excluding depreciation and amortization related to real estate, gains or losses from the sale of real estate, insurance recoveries related to real estate and impairment of depreciable real estate assets.
VALUATION MEASURE
Adjusted EBITDAR

 We use Adjusted EBITDAR as one measure in determining the value of prospective acquisitions. It is also a commonly used measure by our management, research analysts and investors, to compare the enterprise value of different companies in the healthcare industry, without regard to differences in capital structures and leasing arrangements. Adjusted EBITDAR is a financial valuation measure that is not specified in GAAP. This measure is not displayed as a performance measure as it excludes rent expense, which is a normal and recurring operating expense, and is therefore presented only for the current period.

The adjustments made and previously described in the computation of Adjusted EBITDA are also made when computing Adjusted EBITDAR. We calculate Adjusted EBITDAR by excluding rent-cost of services from Adjusted EBITDA.

We believe the use of Adjusted EBITDAR allows the investor to compare operational results of companies who have operating and capital leases. A significant portion of capital lease expenditures are recorded in interest, whereas operating lease expenditures are recorded in rent expense.

The table below reconciles income before provision for income taxes to Adjusted EBT for the periods presented:
Year Ended December 31,
20232022
Consolidated statements of income data:
(In thousands)
Income before provision for income taxes$272,762 $289,089 
Stock-based compensation expense
30,767 22,720 
Litigation(a)
60,781 4,553 
Gain on sale of assets and business interruption recoveries (1,132)(4,380)
Write-off of deferred financing fees(b)
— 566 
Acquisition related costs(c)
814 669 
Costs incurred related to new systems implementation
963 1,072 
Depreciation and amortization - patient base(d)
355 320 
ADJUSTED EBT
$365,310 $314,609 
(a) Litigation relates to specific proceedings arising outside of the ordinary course of business, which includes the portion attributable to non-controlling interests.
(b) Represents the write-off of deferred financing fees associated with the amendment of the Credit Facility.
(c) Costs incurred to acquire operations that are not capitalizable.
(d) Included in depreciation and amortization are amortization expenses related to patient base intangible assets at newly acquired skilled nursing and senior living facilities.


80

The table below reconciles net income to EBITDA, Adjusted EBITDA and Adjusted EBITDAR for the periods presented:

Year Ended December 31,
20232022
Consolidated statements of income data:
(In thousands)
Net income $209,850 $224,652 
Less: net income (loss) attributable to noncontrolling interests
451 (29)
Add: Other (income) expense, net
(17,395)7,736 
Provision for income taxes
62,912 64,437 
Depreciation and amortization72,387 62,355 
EBITDA$327,303 $359,209 
Stock-based compensation expense
30,767 22,720 
Litigation(a)
60,781 4,280 
Gain on sale of assets and business interruption recoveries
(1,132)(4,380)
Acquisition related costs(b)
814 669 
Costs incurred related to new systems implementation
963 1,072 
ADJUSTED EBITDA
$419,496 $383,570 
Rent—cost of services197,358 153,049 
ADJUSTED EBITDAR
$616,854 
(a) Litigation relates to specific proceedings arising outside of the ordinary course of business, which excludes the portion attributable to non-controlling interests.
(b) Costs incurred to acquire operations that are not capitalizable.

Year Ended December 31, 2023 Compared to the Year Ended December 31, 2022
The following table sets forth details of operating results for our revenue and earnings, and their respective components, by our reportable segment for the periods indicated.
Year Ended December 31, 2023
 Skilled ServicesStandard BearerAll OtherEliminationsConsolidated
Total revenue $3,578,855 $82,486 $155,804 $(87,790)$3,729,355 
Total expenses, including other income (expense), net
3,113,930 53,421 377,055 (87,790)3,456,616 
Segment income (loss)464,925 29,065 (221,251)— 272,739 
Gain on sale of assets and insurance recoveries from real estate, net
23 
Income before provision for income taxes $272,762 
81

Year Ended December 31, 2022
 Skilled ServicesStandard BearerAll OtherEliminationsConsolidated
Total revenue $2,906,215 $72,937 $122,610 $(76,294)$3,025,468 
Total expenses, including other income (expense), net
2,497,483 45,066 273,391 (76,294)2,739,646 
Segment income (loss)408,732 27,871 (150,781)— 285,822 
Gain on sale of assets and insurance recoveries from real estate, net
3,267 
Income before provision for income taxes$289,089 
Our total revenue increased $703.9 million, or 23.3%, compared to the year ended December 31, 2022. The increase in revenue was primarily driven by an increase in occupancy of 3.2% from our skilled services Same Facilities and Transitioning Facilities coupled with increasing daily revenue rates and the impact of acquisitions. Specifically, our skilled services Recently Acquired Facilities increased total revenue by $450.0 million, when compared to the same period in 2022, with 52.0% of these operations being acquired in 2023. We believe this demonstrates our ability to increase our market share through strategic acquisitions of operations that have higher skilled mix and higher occupancy than our typical acquisitions. These increases are offset by a decrease in state relief revenue of $17.1 million as the end of the PHE created a gradual phase down of the temporary increase in FMAP funding. All state relief revenue is included in Medicaid revenue.
Skilled Services Segment

Revenue

The following table presents the skilled services revenue and key performance metrics by category during the year ended December 31, 2023 and 2022:
Year Ended December 31,
 20232022Change% Change
TOTAL FACILITY RESULTS:(Dollars in thousands)
Skilled services revenue$3,578,855 2,906,215 $672,640 23.1 %
Number of facilities at period end259 234 25 10.7 %
Number of campuses at period end(1)
27 26 3.8 %
Actual patient days8,590,995 7,243,781 1,347,214 18.6 %
Occupancy percentage — Operational beds78.5 %75.3 % 3.2 %
Skilled mix by nursing days30.4 %31.8 % (1.4)%
Skilled mix by nursing revenue50.2 %52.0 % (1.8)%
Year Ended December 31,
 20232022Change% Change
SAME FACILITY RESULTS:(2)
(Dollars in thousands)
Skilled services revenue$2,771,633 $2,569,807 $201,826 7.9 %
Number of facilities at period end189 189 — — %
Number of campuses at period end(1)
24 24 — — %
Actual patient days6,563,672 6,299,331 264,341 4.2 %
Occupancy percentage — Operational beds79.2 %76.0 % 3.2 %
Skilled mix by nursing days31.9 %33.0 % (1.1)%
Skilled mix by nursing revenue51.4 %53.3 % (1.9)%
82

Year Ended December 31,
20232022Change% Change
TRANSITIONING FACILITY RESULTS:(3)
(Dollars in thousands)
Skilled services revenue$251,872 $231,100 $20,772 9.0 %
Number of facilities at period end22 22 — — %
Number of campuses at period end(1)
— — %
Actual patient days655,659 625,085 30,574 4.9 %
Occupancy percentage — Operational beds76.1 %72.9 % 3.2 %
Skilled mix by nursing days21.4 %23.1 % (1.7)%
Skilled mix by nursing revenue38.5 %41.4 % (2.9)%
Year Ended December 31,
20232022Change% Change
RECENTLY ACQUIRED FACILITY RESULTS:(4)
(Dollars in thousands)
Skilled services revenue$555,350 $105,308 $450,042 NM
Number of facilities at period end48 23 25 NM
Number of campuses at period end(1)
NM
Actual patient days1,371,664 319,365 1,052,299 NM
Occupancy percentage — Operational beds76.8 %67.9 %NM
Skilled mix by nursing days27.5 %24.3 % NM
Skilled mix by nursing revenue49.3 %42.8 % NM
(1)Campus represents a facility that offers both skilled nursing and senior living services. Revenue and expenses related to skilled nursing and senior living services have been allocated and recorded in the respective operating segment.
(2)Same Facility results represent all facilities purchased prior to January 1, 2020.
(3)Transitioning Facility results represent all facilities purchased from January 1, 2020 to December 31, 2021.
(4)Recently Acquired Facility (Acquisitions) results represent all facilities purchased on or subsequent to January 1, 2022.

Skilled services revenue increased $672.6 million, or 23.1%, compared to the year ended December 31, 2022. The increases in skilled services revenue were across all payer types including increases in Medicaid revenue of $315.9 million, or 23.2%, Medicare revenue of $153.6 million, or 18.5%, managed care revenue of $140.4 million, or 26.7% and private revenue of $62.7 million, or 33.1%.

The increase in skilled services revenue was driven by strong performance across our existing skilled services operations as our census continued to recover in 2023, as well as the favorable impact of skilled census from our recent acquisitions. Our consolidated occupancy increased by 3.2% during the year ended December 31, 2023 compared to the same period in 2022.
Revenue in our Same Facilities increased $201.8 million, or 7.9%, compared to the same period in 2022, due to increases in occupancy from both skilled and long-term care patients and revenue per patient day. Our diligent efforts to strengthen our partnerships with various managed care organizations, hospitals and the local communities we operate in, increased our managed care revenue by 14.8%, mainly due to increases in managed care days of 7.2% and revenue per patient day of 5.3%. We continued to see a shift in our patient population from Medicare to managed care as Medicare Advantage enrollment accounts for a larger portion of the overall population. In addition, Medicaid revenue increased by $116.7 million or 9.9%, mainly from the increases in Medicaid days and revenue per patient day.
Revenue generated by our Transitioning Facilities increased $20.8 million, or 9.0%, primarily due to improved occupancy growth and an increase in revenue per patient day. Our Medicaid revenue increased by 10.9%, Managed Care revenue increased by 12.3% and private revenue increased by 18.1%, demonstrating our ability to focus on increasing occupancy across payer types.
Skilled services revenue generated by Recently Acquired Facilities increased by approximately $450.0 million compared to the year ended December 31, 2022. The increases were primarily due to 26 operational expansions in 2023 as well as the full year impact of the 24 operational expansions in 2022.
83

In the future, if we acquire additional turnaround or start-up operations, we typically expect to see lower occupancy rates and skilled mix and these metrics are expected to vary from period to period based upon the maturity of the facilities within our portfolio. Historically, we have generally experienced lower occupancy rates and lower skilled mix at Recently Acquired Facilities and therefore, we anticipate generally lower overall occupancy during years of growth. Included in our metrics for Recently Acquired Facilities are 17 facilities we acquired that are mature and have higher occupancy rates, higher skilled mix days and higher skilled mix revenue than our typical acquisitions.
The following table reflects the change in skilled nursing average daily revenue rates by payor source, excluding services that are not covered by the daily rate (1):
Year Ended December 31,
 Same FacilityTransitioningAcquisitionsTotal
 20232022202320222023202220232022
SKILLED NURSING AVERAGE DAILY REVENUE RATES
Medicare$722.96 $694.63 $696.37 $668.05 $788.00 $652.15 $733.47 $691.25 
Managed care537.29 510.18 536.93 501.73 555.55 455.19 539.25 508.53 
Other skilled598.35 576.46 529.08 530.18 441.89 429.84 575.34 563.56 
Total skilled revenue617.55 598.14 615.58 593.66 660.87 521.24 623.70 595.26 
Medicaid275.82 259.89 270.67 254.08 256.51 227.21 272.14 257.67 
Private and other payors263.81 250.80 253.15 248.63 263.71 199.34 262.93 248.54 
Total skilled nursing revenue
$383.56 $370.57 $342.57 $332.09 $368.46 $296.15 $378.02 $363.97 
(1) These rates exclude state relief funding and include sequestration reversal of 1% for the second quarter in 2022 and 2% for the first quarter of 2022.

Our Medicare daily rates at Same Facilities and Transitioning Facilities increased by 4.1% and 4.2%, respectively, compared to the year ended December 31, 2022. The increase is attributable to the 2.7% and 4.0% net market basket increase that became effective in October 2022 and October 2023, respectively, offset by the phased reinstatement of the sequestration. During the year ended December 31, 2022, Medicare daily rates included three months of sequestration suspension of 1%, three months of sequestration suspension of 2% and six months of no sequestration suspension.

Our average Medicaid rates increased 5.6% due to state reimbursement increases and our participation in supplemental Medicaid payment programs and quality improvement programs in various states. Medicaid rates exclude the amount of state relief revenue we recorded.
Payor Sources as a Percentage of Skilled Nursing Services We use our skilled mix as a measure of the quality of reimbursements we receive at our independent skilled nursing facilities over various periods.
The following tables set forth our percentage of skilled nursing patient revenue and days by payor source:

 Year Ended December 31,
 Same FacilityTransitioningAcquisitionsTotal
 20232022202320222023202220232022
PERCENTAGE OF SKILLED NURSING REVENUE
Medicare22.5 %26.0 %21.8 %24.9 %31.0 %20.4 %23.8 %25.7 %
Managed care20.1 19.2 12.6 12.6 13.3 9.9 18.5 18.3 
Other skilled8.8 8.1 4.1 3.9 5.0 12.5 7.9 8.0 
Skilled mix51.4 53.3 38.5 41.4 49.3 42.8 50.2 52.0 
Private and other payors7.5 7.0 8.6 8.1 8.0 6.4 7.6 7.0 
Medicaid41.1 39.7 52.9 50.5 42.7 50.8 42.2 41.0 
TOTAL SKILLED NURSING100.0 %100.0 %100.0 %100.0 %100.0 %100.0 %100.0 %100.0 %

84

 Year Ended December 31,
 Same FacilityTransitioningAcquisitionsTotal
 20232022202320222023202220232022
PERCENTAGE OF SKILLED NURSING DAYS
Medicare11.9 %13.9 %10.7 %12.4 %14.5 %9.3 %12.3 %13.5 %
Managed care14.4 14.0 8.0 8.3 8.8 6.4 13.0 13.1 
Other skilled5.6 5.1 2.7 2.4 4.2 8.6 5.1 5.2 
Skilled mix31.9 33.0 21.4 23.1 27.5 24.3 30.4 31.8 
Private and other payors11.0 10.4 11.7 10.8 11.1 9.5 11.0 10.3 
Medicaid57.1 56.6 66.9 66.1 61.4 66.2 58.6 57.9 
TOTAL SKILLED NURSING100.0 %100.0 %100.0 %100.0 %100.0 %100.0 %100.0 %100.0 %

Cost of Services

The following table sets forth total cost of services for our skilled services segment for the periods indicated (dollars in thousands):
 Year Ended December 31,Change
20232022$%
Cost of service$2,832,012 $2,267,691 $564,321 24.9 %
Revenue percentage79.1 %78.0 %1.1 %

Cost of services related to our skilled services segment increased by $564.3 million, or 24.9% from prior year. Cost of services as a percentage of revenue increased to 79.1% from 78.0%, due to increased costs related to general and professional liabilities reserves and wage expenses as a result of the labor environment. In addition, included in cost of services during the year ended December 31, 2023 is the expense related to the deferred compensation investment program of $2.4 million compared to a gain of $2.6 million during the year ended December 31, 2022.
Standard Bearer
 Year Ended December 31,Change
20232022$%
(Dollars in thousands)
Rental revenue generated from third-party tenants$15,774 $14,970 $804 5.4 %
Rental revenue generated from Ensign's independent subsidiaries
66,712 57,967 8,745 15.1 
TOTAL RENTAL REVENUE$82,486 $72,937 $9,549 13.1 %
Segment income29,065 27,871 1,194 4.3 
Depreciation and amortization25,205 21,613 3,592 16.6 
FFO$54,270 $49,484 $4,786 9.7 %
Rental revenue Our rental revenue, including revenue generated from our independent subsidiaries, increased by $9.5 million, or 13.1%, to $82.5 million, compared to the year ended December 31, 2022. The increase in revenue is primarily attributable to five real estate purchases as well as annual rent increases since the year ended December 31, 2022.
FFO Our FFO increased by $4.8 million, or 9.7%, to $54.3 million, compared to the year ended December 31, 2022. The increase in rental revenue of $9.5 million is offset by increases in interest expense of $4.3 million associated with the intercompany debt arrangements between Standard Bearer and us, as we continue to grow our real estate portfolio.

85

All Other Revenue
Our other revenue increased by $33.2 million, or 27.1%, to $155.8 million, compared to the year ended December 31, 2022. Other revenue for 2023 includes senior living revenue of $76.4 million, revenue from other ancillary services of $68.3 million and rental income of $11.1 million. The increase in other revenue is primarily attributable to our other ancillary services as well as senior living operations' occupancy starting to rebound from COVID-19.
Consolidated Financial Expenses
Rent-cost of services Our rent-cost of services as a percentage of total revenue increased by 0.2% to 5.3%, primarily due to lease obligations acquired as part of our 22 operational expansions with long-term leases since the year ended December 31, 2022.
General and administrative expense General and administrative expense increased $104.2 million or 65.6%, to $263.0 million. General and administrative expense as a percentage of revenue increased by 1.9% to 7.1%. This increase was primarily due to increases in litigation expense related to specific proceedings that are outside the ordinary course of business, system implementation costs, bonuses due to enhanced performance and headcount due to acquisition activity. Excluding the litigation expense, general and administrative expense as a percentage of revenue increased by 0.2% to 5.4%.
Depreciation and amortization Depreciation and amortization expense increased $10.0 million, or 16.1%, to $72.4 million. This increase was primarily related to the additional depreciation and amortization incurred as a result of our newly acquired operations and capital expenditures. Depreciation and amortization decreased 0.2%, to 1.9%, as a percentage of revenue.
Other income (expense), net Other income (expense), net as a percentage of revenue increased by 0.8%. Other income primarily includes interest income from our investments offset by interest expense related to our debt. Additionally, our deferred investment program may incur gains or losses depending on market performance. During the year ended December 31, 2023, the deferred compensation investment program had a gain of $4.6 million. During the year ended December 31, 2022, the deferred compensation investment program had a loss of $4.2 million. The offsetting expenses or reduction in expenses are allocated between cost of services and general and administrative expenses.
Provision for income taxes Our effective tax rate was 23.1% for the year ended December 31, 2023, compared to 22.3% for the same period in 2022. The effective tax rate for both periods is driven by the impact of excess tax benefits from stock-based compensation, partially offset by non-deductible expenses, including non-deductible compensation. See Note 14, Income Taxes, in the Financial Statements for further discussion.

Liquidity and Capital Resources
Our primary sources of liquidity have historically been derived from our cash flows from operations and long-term debt secured by our real property and our Credit Facility. Our liquidity as of December 31, 2023 is impacted by cash generated from strong operational performance and increased acquisition and share repurchase activities.
Historically, we have primarily financed the majority of our acquisitions through mortgages on our properties, our Credit Facility and cash generated from operations. Cash paid to fund acquisitions was $69.0 million and $101.1 million for the year ended December 31, 2023 and 2022, respectively. Total capital expenditures for property and equipment were $106.2 million and $87.5 million for the year ended December 31, 2023 and 2022, respectively. We currently have approximately $110.0 million budgeted for renovation projects in 2024. We believe our current cash balances, our cash flow from operations and the amounts available for borrowing under our Credit Facility will be sufficient to cover our operating needs for at least the next 12 months.

We may, in the future, seek to raise additional capital to fund growth, capital renovations, operations and other business activities, but such additional capital may not be available on acceptable terms, on a timely basis, or at all.
Our cash and cash equivalents as of December 31, 2023 consisted of bank term deposits, money market funds and U.S. Treasury bill related investments. In addition, as of December 31, 2023, we held investments of approximately $109.9 million. We believe our investments that were in an unrealized loss position as of December 31, 2023 do not require an allowance for expected credit losses, nor has any event occurred subsequent to that date that would indicate so.

86

As mentioned above, our primary source of cash is from our ongoing operations. Our positive cash flows have supported our business and have allowed us to pay regular dividends to our stockholders. We currently anticipate that existing cash and total investments as of December 31, 2023, along with projected operating cash flows and available financing, will support our normal business operations for the foreseeable future.
On August 29, 2023, the Board of Directors approved a stock repurchase program pursuant to which we may repurchase up to $20.0 million of our common stock under the program for a period of approximately 12 months from September 1, 2023. Under this program, we are authorized to repurchase our issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. The share repurchase program does not obligate us to acquire any specific number of shares. We did not purchase any shares pursuant to this stock repurchase program during the year ended December 31, 2023.
On July 28, 2022, the Board of Directors approved a stock repurchase program pursuant to which we may repurchase up to $20.0 million of our common stock under the program for a period of approximately 12 months from August 2, 2022. Under this program, we were authorized to repurchase our issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. The share repurchase program did not obligate us to acquire any specific number of shares. The stock repurchase program expired on August 2, 2023 and is no longer in effect. The Company did not purchase any shares pursuant to this stock repurchase program.
The following table presents selected data from our consolidated statement of cash flows for the periods presented:
Year Ended December 31,
 20232022
NET CASH PROVIDED BY/(USED IN):(In thousands)
Operating activities$376,666 $272,513 
Investing activities(182,698)(186,182)
Financing activities(612)(32,262)
Net increase in cash and cash equivalents193,356 54,069 
Cash and cash equivalents beginning of period316,270 262,201 
Cash and cash equivalents at end of period$509,626 $316,270 
Operating Activities
Cash provided by operating activities is net income adjusted for certain non-cash items and changes in operating assets and liabilities.
The $104.2 million increase in cash provided by operating activities for the year ended December 31, 2023 compared to the same period in 2022 was due to cash generated from improved results at our local operations as well as $24.2 million that was paid for deferred social security taxes in 2022, which did not occur in 2023.
Investing Activities
Investing cash flows consist primarily of capital expenditures, investment activities, insurance proceeds and cash used for acquisitions.
The $3.5 million decrease in cash used in investing activities for the year ended December 31, 2023 compared to the same period in 2022 was primarily due to a decrease in cash used for operational expansions of $32.1 million, offset by an increase in cash used for capital expenditures of $18.6 million, an increase in investments of $3.1 million and a decrease of cash proceeds from the sale of fixed assets and insurance proceeds of $7.7 million.
Financing Activities
Financing cash flows consist primarily of payment of dividends to stockholders, issuance and repayment of short-term and long-term debt, payment for share repurchases and sale of subsidiary shares.
87

The $31.7 million decrease in cash used in financing activities for the year ended December 31, 2023 compared to the same period in 2022, was primarily due to $29.9 million of share repurchases as part of our stock repurchase program in 2022.
A discussion of our cash flows for the year ended December 31, 2021 is included in Part II, Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources, included in our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission on February 2, 2023.
Material cash requirements from known contractual and other obligations
Total long-term debt obligations outstanding as of the end of each fiscal year were as follows:
 December 31,
 20232022202120202019
 (In thousands)
Credit facilities and term loans$— $— $— $— $210,000 
Mortgage loans and promissory note
152,388 156,271 159,967 117,806 120,350 
TOTAL$152,388 $156,271 $159,967 $117,806 $330,350 
Significant contractual obligations as of December 31, 2023 were as follows, including the future periods in which payments are expected:
  2024 2025 2026 2027 2028Thereafter Total
  (In thousands)
Operating lease obligations$191,352 $191,269 $191,058 $190,481 $189,224 $1,722,259 $2,675,643 
Long-term debt obligations3,950 4,086 4,227 3,897 3,779 132,449 152,388 
Interest payments on long-term debt4,623 4,487 4,346 4,207 4,091 54,436 76,190 
TOTAL$199,925 $199,842 $199,631 $198,585 $197,094 $1,909,144 $2,904,221 
Not included in the table above are our actuarially determined self-insured general and professional malpractice liability, workers' compensation and medical (including prescription drugs) and dental healthcare obligations, which are broken out between current and long-term liabilities in our financial statements included in this Annual Report on Form 10-K.
As part of the proceeding discussed in Item 3. Legal Proceedings, the parties agreed to settle the litigation for $48.0 million, subject to the review and approval of all parties, including the DOJ and other relevant government entities.
Credit Facility with a Lending Consortium Arranged by Truist
We maintain a revolving credit facility with Truist Securities (Truist) (the Credit Facility) with availability up to $600.0 million in aggregate principal amount. The maturity date of the Credit Facility is April 8, 2027. Borrowings are supported by a lending consortium arranged by Truist. The interest rates applicable to loans under the Credit Facility are, at our option, equal to either a base rate plus a margin ranging from 0.25% to 1.25% per annum or SOFR plus a margin range from 1.25% to 2.25% per annum, based on the Consolidated Total Net Debt to Consolidated EBITDA ratio (as defined in the Credit Facility). In addition, there is a commitment fee on the unused portion of the commitments that ranges from 0.20% to 0.40% per annum, depending on the Consolidated Total Net Debt to Consolidated EBITDA ratio.

88

Mortgage Loans and Promissory Note
As of December 31, 2023, 23 of our subsidiaries have mortgage loans insured with HUD for an aggregate amount of $150.2 million, which subjects these subsidiaries to HUD oversight and periodic inspections. The mortgage loans bear effective interest rates at a range of 3.1% to 4.2%, including fixed interest rates at a range of 2.4% to 3.3% per annum. In addition to the interest rate, we incur other fees for HUD placement, including but not limited to audit fees. Amounts borrowed under the mortgage loans may be prepaid, subject to prepayment fees of the principal balance on the date of prepayment. For the majority of the loans, during the first three years, the prepayment fee is 10.0%, and is reduced by 3.0% in the fourth year of the loan, and reduced by 1.0% per year for years five through ten of the loan. There is no prepayment penalty after year ten. The terms for all the mortgage loans are 25 to 35 years.
In addition to the HUD mortgage loans, one of our subsidiaries has a promissory note that bears a fixed interest rate of 5.3% per annum and has a term of 12 years. The note, which was used for an acquisition, is secured by the real property comprising the facility and the rent, issues and profits thereof, as well as all personal property used in the operation of the facility.
Operating Leases
As of December 31, 2023, 214 of our facilities are under long-term lease arrangements, of which 96 of the operations are under nine triple-net Master Leases and one stand-alone lease with CareTrust REIT, Inc. (CareTrust). The Master Leases consist of multiple leases, each with its own pool of properties, that have varying maturities and diversity in property geography. Under each master lease, our individual subsidiaries that operate those properties are the tenants and CareTrust's individual subsidiaries that own the properties subject to the Master Leases are the landlords. The rent structure under the Master Leases includes a fixed component, subject to annual escalation equal to the lesser of the percentage change in the Consumer Price Index (but not less than zero) or 2.5%. At our option, we can extend the Master Leases for two or three five-year renewal terms beyond the initial term, on the same terms and conditions. If we elect to renew the term of a Master Lease, the renewal will be effective as to all, but not less than all, of the leased property then subject to the Master Lease. Additionally, four of the 97 facilities leased from CareTrust include an option to purchase that we can exercise starting on December 1, 2024.
We also lease certain facilities and our administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from five to 20 years and is subject to annual escalation equal to the percentage change in the Consumer Price Index with a stated cap percentage. In addition, we lease certain of our equipment under non-cancelable operating leases with initial terms ranging from three to five years. Most of these leases contain renewal options, certain of which involve rent increases.
Eighty of our independent subsidiaries, excluding the subsidiaries that are operated under the Master Leases from CareTrust, are operated under 13 separate master lease arrangements. Under these master leases, a default at a single facility could subject one or more of the other independent subsidiaries covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of our leases, master lease agreements and debt financing instruments. In addition, other potential defaults related to an individual facility may cause a default of an entire master lease portfolio and could trigger cross-default provisions in our outstanding debt arrangements and other leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the lease without the consent of the landlord.
Inflation

We have historically derived a substantial portion of our revenue from the Medicare program. We also derive revenue from state Medicaid and similar reimbursement programs. Payments under these programs generally provide for reimbursement levels that are adjusted for inflation annually based upon the state’s fiscal year for the Medicaid programs and in each October for the Medicare program. These adjustments may not continue in the future, and even if received, such adjustments may not reflect the actual increase in our costs for providing healthcare services.

Labor, supply expenses and capital expenditures make up a substantial portion of our cost of services. Those expenses can be subject to increase in periods of rising inflation and when labor shortages occur in the marketplace. To date, we have generally been able to implement cost control measures or obtain increases in reimbursement sufficient to offset increases in these expenses. There can be no assurance that we will be able to anticipate fully or otherwise respond to any future inflationary pressures.

89

Item 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Interest Rate Risk We are exposed to risks associated with market changes in interest rates through our borrowing arrangements and investments. In particular, our Credit Facility exposes us to variability in interest payments due to changes in SOFR interest rates. We manage our exposure to this market risk by monitoring available financing alternatives. Our mortgages and promissory note require principal and interest payments through maturity pursuant to amortization schedules.

Our mortgages generally contain provisions that allow us to make repayments earlier than the stated maturity date. In some cases, we are not allowed to make early repayment prior to a cutoff date. Where prepayment is permitted, we are generally allowed to make prepayments only at a premium which is often designed to preserve a stated yield to the note holder. These prepayment rights may afford us opportunities to mitigate the risk of refinancing our debts at maturity at higher rates by refinancing prior to maturity.
We have a Credit Facility with Truist of up to $600.0 million in aggregate principal amount. We have no outstanding borrowings under our Credit Facility as of December 31, 2023 and through the filing date of this report. In addition, we have outstanding indebtedness under mortgage loans insured with HUD and a promissory note payable to a third party of $152.4 million, all of which are at fixed interest rates.

Our cash and cash equivalents as of December 31, 2023 consisted of bank term deposits, money market funds and U.S. Treasury bill related investments. In addition, as of December 31, 2023, we held investments of approximately $109.9 million. We believe our investments that were in an unrealized loss position as of December 31, 2023 do not require an allowance for expected credit losses, nor has any event occurred subsequent to that date that would indicate so. Our market risk exposure is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates. The primary objective of our investment activities is to preserve principal, while at the same time maximizing the income we receive from our investments without significantly increasing risk. Due to the low risk profile of our investment portfolio, an immediate 10.0% change in interest rates would not have a material effect on the fair market value of our portfolio. Accordingly, we would not expect our operating results or cash flows to be affected to any significant degree by the effect of a sudden change in market interest rates on our securities portfolio.

The above only incorporates those exposures that exist as of December 31, 2023 and does not consider those exposures or positions which could arise after that date. If we diversify our investment portfolio into securities and other investment alternatives, we may face increased risk and exposures as a result of interest risk and the securities markets in general.

90


Item 8.     FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 
THE ENSIGN GROUP, INC.
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
AND FINANCIAL STATEMENT SCHEDULE


91

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Stockholders and the Board of Directors of
The Ensign Group, Inc.
San Juan Capistrano, California

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of The Ensign Group Inc. and subsidiaries (the "Company") as of December 31, 2023, and 2022, the related consolidated statements of income, stockholders' equity, and cash flows, for each of the three years in the period ended December 31, 2023, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023, and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 1, 2024, expressed an unqualified opinion on the Company's internal control over financial reporting.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matter

The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

Self-Insurance Liabilities (General and Professional Liability Claims) - Refer to Notes 2 and 19 to the financial statements

Critical Audit Matter Description

The Company's self-insurance liabilities for general and professional liability claims totaled $117.7 million at December 31, 2023. The Company develops information about the size of the ultimate claims based on historical experience, current industry information, and actuarial analysis.


The determination of reserves for general and professional liability claims is highly subjective. Given the significant judgments in estimating the general and professional liability claims, we have determined this to be a critical audit matter. This required a high degree of auditor judgment and an increased extent of effort when performing audit procedures to evaluate the reasonableness of management estimates of reserves for open claims as well as for claims that are incurred but not reported (IBNR).

How the Critical Audit Matter Was Addressed in the Audit

Our audit procedures related to management’s judgment regarding the estimation of the reserve for general and professional liability claims included the following, among others:

We tested the effectiveness of controls over the reserve for general and professional liabilities, including those related to both the determination of reserves for open claims and estimation of the IBNR claims.

We obtained an understanding of the factors considered and assumptions made by management and its external actuarial specialists in developing the estimate of the general and professional liability reserves, including the sources of data relevant to these factors and assumptions. We tested underlying claims data, including testing the completeness and accuracy of open cases.

We involved our actuarial specialists to assist in our evaluation of the methodologies applied by management's specialist and to develop an independent range of expected reserves. We compared the recorded reserves to the estimated independent range.

We performed a retrospective review in which we compared the prior-year recorded amounts for ultimate losses and current liabilities to the subsequent claim emergence.


/s/ DELOITTE & TOUCHE LLP

Costa Mesa, California
February 1, 2024

We have served as the Company's auditor since 1999.
92

THE ENSIGN GROUP, INC.
CONSOLIDATED BALANCE SHEETS
(In thousands, except par values)
December 31,
20232022
ASSETS  
Current assets:   
Cash and cash equivalents$509,626 $316,270 
Accounts receivable—less allowance for doubtful accounts of $9,348 and $7,802 at December 31, 2023 and 2022, respectively
485,039 408,432 
Investments—current17,229 15,441 
Prepaid expenses and other current assets35,036 40,982 
Total current assets1,046,930 781,125 
Property and equipment, net1,090,771 992,010 
Right-of-use assets 1,756,430 1,450,995 
Insurance subsidiary deposits and investments 92,687 67,652 
Deferred tax assets67,124 39,643 
Restricted and other assets 40,205 37,291 
Intangible assets, net 6,525 6,437 
Goodwill76,869 76,869 
TOTAL ASSETS$4,177,541 $3,452,022 
LIABILITIES AND EQUITY  
Current liabilities:  
Accounts payable$92,811 $77,087 
Accrued wages and related liabilities332,568 289,810 
Lease liabilities—current 82,526 65,796 
Accrued self-insurance liabilities—current54,664 48,187 
Other accrued liabilities 168,228 97,309 
Current maturities of long-term debt3,950 3,883 
Total current liabilities734,747 582,072 
Long-term debt—less current maturities145,497 149,269 
Long-term lease liabilities—less current portion 1,639,326 1,355,113 
Accrued self-insurance liabilities—less current portion111,246 83,495 
Other long-term liabilities49,408 33,273 
TOTAL LIABILITIES$2,680,224 $2,203,222 
Commitments and contingencies (Notes 15 and 20)
EQUITY  
Ensign Group, Inc. stockholders' equity:
Common stock: $0.001 par value; 150,000, 59,987 and 56,597 shares authorized, shares issued and shares outstanding at December 31, 2023, respectively, and 100,000, 59,029 and 55,661 shares authorized, shares issued and shares outstanding at December 31, 2022, respectively
60 59 
Additional paid-in capital465,707 415,560 
Retained earnings1,142,653 946,339 
Common stock in treasury, at cost, 3,390 and 3,368 shares at December 31, 2023 and 2022, respectively
(116,555)(114,626)
Total Ensign Group, Inc. stockholders' equity1,491,865 1,247,332 
Non-controlling interest5,452 1,468 
Total equity$1,497,317 $1,248,800 
TOTAL LIABILITIES AND EQUITY$4,177,541 $3,452,022 
See accompanying notes to consolidated financial statements.
93

THE ENSIGN GROUP, INC.
CONSOLIDATED STATEMENTS OF INCOME

Year Ended December 31,
 202320222021
(In thousands, except per share data)
REVENUE
Service revenue$3,708,071 $3,008,711 $2,611,476 
Rental revenue21,284 16,757 15,985 
TOTAL REVENUE$3,729,355 $3,025,468 $2,627,461 
Expense:
Cost of services2,941,238 2,354,434 2,019,879 
Rent—cost of services 197,358 153,049 139,371 
General and administrative expense263,005 158,805 151,761 
Depreciation and amortization72,387 62,355 55,985 
TOTAL EXPENSES3,473,988 2,728,643 $2,366,996 
Income from operations255,367 296,825 260,465 
Other income (expense):
Interest expense(8,087)(8,931)(6,849)
Other income
25,482 1,195 4,388 
Other income (expense), net17,395 (7,736)$(2,461)
Income before provision for income taxes272,762 289,089 258,004 
Provision for income taxes62,912 64,437 60,279 
NET INCOME209,850 224,652 $197,725 
Less:
Net income (loss) attributable to noncontrolling interests451 (29)3,073 
Net income attributable to The Ensign Group, Inc.$209,399 $224,681 $194,652 
NET INCOME PER SHARE ATTRIBUTABLE TO THE ENSIGN GROUP INC.
Basic $3.76 $4.09 $3.57 
Diluted$3.65 $3.95 $3.42 
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING
Basic55,708 54,887 54,486 
Diluted57,323 56,871 56,925 
See accompanying notes to consolidated financial statements.
94

THE ENSIGN GROUP, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
 Common Stock Additional Paid-In Capital Retained Earnings Treasury Stock Non-Controlling Interest
(In thousands)Shares Amount   Shares Amount Total
BALANCE - JANUARY 1, 202154,626 $58 $338,177 $551,055 2,791 $(71,213)$150 $818,227 
Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards516 — 9,180 — — — — 9,180 
Issuance of restricted stock, net of forfeitures201 — 3,725 — — — — 3,725 
Shares of common stock used to satisfy tax withholding obligations(21)— — — 21 (1,711)— (1,711)
Dividends declared ($0.2125 per share)
— — — (11,715)— — — (11,715)
Employee stock award compensation— — 18,678 — — — — 18,678 
Repurchase of common stock (Note 21)
(132)— — — 132 (10,118)— (10,118)
Deconsolidation of an ancillary business— — — — — — (1,369)(1,369)
Capital contribution from noncontrolling interest holder— — — — — — 2,000 2,000 
Net income attributable to noncontrolling interest— — — — — — 3,073 3,073 
Noncontrolling interest attributable to subsidiary equity plan— — — — — — (2,908)(2,908)
Net income attributable to the Ensign Group, Inc.— — — 194,652 — — — 194,652 
BALANCE - DECEMBER 31, 202155,190 $58 $369,760 $733,992 2,944 $(83,042)$946 $1,021,714 
Issuance of common stock to employees and directors resulting from the exercise of stock options688 1 12,676 — — — — 12,677 
Issuance of restricted stock, net of forfeitures207 — 5,241 — — — — 5,241 
Shares of common stock used to satisfy tax withholding obligations(20)— — — 20 (1,702)— (1,702)
Dividends declared ($0.2225 per share)
— — — (12,334)— — — (12,334)
Employee stock award compensation— — 22,720 — — — — 22,720 
Repurchase of common stock (Note 21)
(404)— — — 404 (29,882)— (29,882)
Acquisition of noncontrolling interest shares— — (1,539)— — — 835 (704)
Issuance of noncontrolling interests through subsidiary equity plan— — 6,693 — — — — 6,693 
Net loss attributable to noncontrolling interest— — — — — — (29)(29)
Noncontrolling interest attributable to subsidiary equity plan— — 9 — — — (284)(275)
Net income attributable to the Ensign Group, Inc.— — — 224,681 — — — 224,681 
BALANCE - DECEMBER 31, 202255,661 $59 $415,560 $946,339 3,368 $(114,626)$1,468 $1,248,800 
Issuance of common stock to employees and directors resulting from the exercise of stock options759 1 18,368 — — — — 18,369 
Issuance of restricted stock, net of forfeitures199 — 5,068 — — — — 5,068 
Shares of common stock used to satisfy tax withholding obligations(22)— — — 22 (1,929)— (1,929)
Dividends declared ($0.2325 per share)
— — — (13,085)— — — (13,085)
Employee stock award compensation— — 30,754 — — — — 30,754 
Acquisition of noncontrolling interest shares— — (256)— — — — (256)
Net income attributable to noncontrolling interest— — — — — — 451 451 
Noncontrolling interest attributable to subsidiary equity plan— — (3,787)— — — 3,533 (254)
Net income attributable to the Ensign Group, Inc.— — — 209,399 — — — 209,399 
BALANCE - DECEMBER 31, 202356,597 $60 $465,707 $1,142,653 3,390 $(116,555)$5,452 $1,497,317 
See accompanying notes to consolidated financial statements.

95

THE ENSIGN GROUP, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
Year Ended December 31,
(In thousands)202320222021
Cash flows from operating activities:  
Net income $209,850 $224,652 $197,725 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization72,387 62,355 55,985 
Amortization of deferred financing fees1,067 1,036 859 
Non-cash leasing arrangement 870 493 485 
Write-off of deferred financing fees 566  
Deferred income taxes (27,481)(6,496)(724)
Provision for doubtful accounts 3,408 2,390 2,609 
Stock-based compensation30,767 22,720 18,678 
Cash received from insurance proceeds1,396 1,282 2,382 
Gain on sale of assets (123)(3,467)(1,371)
(Gain)/loss on insurance claims, legal matters and asset disposals
(1,368)3,926 (977)
Litigation
48,000   
Change in operating assets and liabilities 
Accounts receivable (79,818)(82,426)(30,771)
Prepaid income taxes814 809 (4,228)
Prepaid expenses and other assets6,993 (9,141)(4,898)
Deferred employer portion of social security taxes (Note 3)
 (24,155)(24,154)
Cash surrender value of life insurance policy premiums(16,072)(7,614)(10,953)
Deferred compensation liability16,044 7,637 11,078 
Operating lease obligations(6,564)345 (5,814)
Accounts payable15,924 17,870 7,117 
Accrued wages and related liabilities47,967 38,982 47,701 
Other accrued liabilities23,828 3,010 1,297 
Accrued self-insurance liabilities28,827 17,785 13,724 
Other long-term liabilities(50)(46)(66)
NET CASH PROVIDED BY OPERATING ACTIVITIES
$376,666 $272,513 $275,684 
Cash flows from investing activities:  
Purchase of property and equipment(106,180)(87,545)(69,550)
Cash payments for business acquisitions (Note 7)
 (16,400)(6,000)
Cash payments for asset acquisitions (Note 7)
(67,798)(84,736)(98,224)
Escrow deposits(1,216) 100 
Cash from insurance proceeds2,029 1,339 6,899 
Cash proceeds from the sale of assets 248 8,630 1,854 
Deconsolidation of an ancillary business  (1,984)
Cash payments for Medicare and Medicaid licenses  (106)
Purchases of investments(29,603)(21,975)(32,257)
Maturities of investments18,852 14,356 27,481 
Other restricted assets970 149 (2,120)
NET CASH USED IN INVESTING ACTIVITIES
$(182,698)$(186,182)$(173,907)
Cash flows from financing activities:  
Proceeds from debt (Note 15)
150 411 45,218 
Payments on debt (Note 15)
(4,033)(4,106)(3,056)
Issuance of common stock upon exercise of options18,369 12,677 9,180 
Repurchase of shares of common stock to satisfy tax withholding obligations(1,929)(1,702)(1,711)
Repurchase of shares of common stock (Note 21)
 (29,882)(10,118)
Dividends paid(12,890)(12,168)(11,548)
Proceeds from sale of subsidiary shares (Note 6)
 6,693  
Non-controlling interest distribution(4)(284)(2,908)
Purchase of non-controlling interest(256)(704)2,000 
Payments of deferred financing costs(19)(3,197)(1,172)
Proceeds from CARES Act Provider Relief Fund and Medicare Advance Payment Program (Note 3)  11,637 
Repayments of CARES Act Provider Relief Fund and Medicare Advance Payment Program (Note 3)  (113,660)
NET CASH USED IN FINANCING ACTIVITIES
$(612)$(32,262)$(76,138)
Net increase in cash and cash equivalents193,356 54,069 25,639 
Cash and cash equivalents beginning of period316,270 262,201 236,562 
Cash and cash equivalents end of period$509,626 $316,270 $262,201 

Year Ended December 31,
(In thousands)202320222021
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION  
Cash paid during the period for:  
Interest$7,025 $7,604 $5,690 
Income taxes$89,730 $70,055 $65,547 
Lease liabilities$196,942 $151,870 $138,795 
Non-cash financing and investing activity 
Accrued capital expenditures$4,600 $4,800 $3,700 
Accrued dividends declared$3,396 $3,201 $3,035 
Right-of-use assets obtained in exchange for new and modified operating lease obligations$376,550 $370,753 $198,593 

See accompanying notes to consolidated financial statements.
96

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Dollars, shares and options in thousands, except per share data)
1. DESCRIPTION OF BUSINESS
The Company — The Ensign Group, Inc. (collectively, Ensign or the Company), is a holding company with no direct operating assets, employees or revenue. The Company's independent subsidiaries provide health care services across the post-acute care continuum and engage in the ownership, acquisition, development and leasing of skilled nursing, senior living and other healthcare-related properties and other ancillary businesses. As of December 31, 2023, the Company's independent subsidiaries operated 297 facilities and other ancillary operations located in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. Subsequent to December 31, 2023, one of the Company's independent subsidiaries expanded its operations into Tennessee. The Company's independent subsidiaries have a collective capacity of approximately 30,600 operational skilled nursing beds and 3,100 senior living units. As of December 31, 2023, the Company's independent subsidiaries operated 214 facilities under long-term lease arrangements and had options to purchase 11 of those 214 facilities. The Company's real estate portfolio includes 113 owned real estate properties, which includes 83 facilities operated and managed by the Company's independent subsidiaries, 30 operations leased to and operated by third-party operators, and the Service Center (defined below) location. Of those 30 operations, one senior living facility is located on the same real estate property as a skilled nursing facility that an independent subsidiary owns and operates.
Certain of the Company’s wholly-owned independent subsidiaries, collectively referred to as the Service Center, provide specific accounting, payroll, human resources, information technology, legal, risk management and other centralized services to the other independent subsidiaries through contractual relationships with such subsidiaries. The Company also has a wholly-owned captive insurance subsidiary that provides some claims-made coverage to the Company’s independent subsidiaries for general and professional liabilities, as well as coverage for certain workers’ compensation insurance liabilities.
In 2022, the Company formed a captive real estate investment trust (REIT), which owns and manages its real estate business, called Standard Bearer Healthcare REIT, Inc. (Standard Bearer). The REIT structure provides the Company with an efficient vehicle for future acquisitions of properties that could be operated by Ensign's independent subsidiaries or other third parties. Refer to Note 6, Standard Bearer for additional information on Standard Bearer.
Each of the Company's independent subsidiaries are operated by wholly-owned subsidiaries that have their own management, employees and assets. References herein to the consolidated “Company” and “its” assets and activities in this Annual Report are not meant to imply, nor should it be construed as meaning that The Ensign Group, Inc. has direct operating assets, employees or revenue, or that any of the subsidiaries, are operated by The Ensign Group, Inc.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation The accompanying consolidated financial statements (the Financial Statements) have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company is the sole member or stockholder of various consolidated limited liability companies and corporations established to operate various acquired skilled nursing operations, senior living operations and related ancillary services. All intercompany transactions and balances have been eliminated in consolidation. The Company presents noncontrolling interests within the equity section of its consolidated balance sheets and the amount of consolidated net income that is attributable to The Ensign Group, Inc. and the noncontrolling interests in its consolidated statements of income. The Financial Statements include the accounts of all independent subsidiaries controlled by the Company through its ownership of a majority voting interest.
ReclassificationsCertain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements.
Estimates and Assumptions The preparation of the Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Company’s Financial Statements relate to revenue, acquired property and equipment, intangible assets and goodwill, right-of-use assets, impairment of long-lived assets, lease liabilities, general and professional liabilities, workers' compensation and healthcare claims included in accrued self-insurance liabilities and income taxes. Actual results could differ from those estimates.
97

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


Fair Value ConsiderationsThe Company’s financial instruments consist principally of cash and cash equivalents, debt security investments, accounts receivable, insurance subsidiary deposits, deferred compensation investment funds, equity investments, accounts payable and borrowings. The Company believes all of the financial instruments’ recorded values approximate fair values because of their nature or respective short durations.

Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions. See Note 5, Fair Value Measurements for additional information.

The Company's non-financial assets, which includes goodwill, intangible assets, property and equipment and right-of-use assets, are not required to be measured at fair value on a recurring basis. However, on a periodic basis, or whenever events or changes in circumstances indicate that their carrying value may not be recoverable, the Company assesses its long-lived assets for impairment. When impairment has occurred, such long-lived assets are written down to fair value.
Service Revenue RecognitionThe Company recognizes revenue in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with Customers (ASC 606). The Company's service revenue is derived primarily from providing healthcare services to its patients. Revenue is recognized when services are provided to patients at the amount that reflects the consideration that the Company expects to be entitled from patients and third-party payors, including Medicaid, Medicare and insurers (private and Medicare replacement plans), in exchange for providing patient care. The healthcare services provided pursuant to skilled patient contracts include routine services in exchange for a contractual agreed-upon amount or rate. Routine services are treated as a single performance obligation satisfied over time as services are rendered. As such, patient care services represent a bundle of services that are not capable of being distinct. Additionally, there may be ancillary services that are not included in the daily rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time, if and when those services are rendered.

Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction price. The Company determines the transaction price based on contractually agreed-upon amounts or rate on a per day basis, adjusted for estimates of variable consideration. The Company uses the expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The amount of variable consideration that is included in the transaction price may be constrained and is included in net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from the Company’s estimates, the Company adjusts these estimates, which would affect net revenue in the period such variances become known.

As the Company’s contracts with its patients have an original duration of one year or less, the Company uses the practical expedient applicable to its contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of the end of each reporting period or when the Company expects to recognize this revenue. In addition, the Company has applied the practical expedient provided by FASB ASC Topic 340, Other Assets and Deferred Costs, and all incremental customer contract acquisition costs are expensed as they are incurred because the amortization period would have been one year or less.
Rental Revenue Recognition The Company's rental revenues are primarily generated by leasing healthcare-related properties through triple-net lease arrangements, under which the tenant is solely responsible for the costs related to the property. Revenue for operating leases is recognized on a straight-line basis over the lease term when collectability of all minimum lease payments is probable in accordance with FASB ASC Topic 842, Leases (ASC 842). The Company has elected the single component practical expedient, which allows a lessor, by class of underlying asset, not to allocate the total consideration to the lease and non-lease components based on their relative stand-alone selling prices where certain criteria are met.

Tenant reimbursements related to property taxes and insurance are neither considered lease nor non-lease components under ASC 842. Lessee payments for taxes and insurance paid directly to a third party, on behalf of the Company, are excluded from variable lease payments and rental revenue in the Company’s consolidated statements of income. Otherwise, tenant reimbursements for taxes and insurance that are paid by the Company directly to a third party are classified as additional rental revenue and expense and recognized by the Company on a gross basis.
98

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


Accounts Receivable Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources, net of estimates for variable consideration.
Cash and Cash Equivalents Cash and cash equivalents consist of bank term deposits, money market funds and treasury bill related investments with original maturities of three months or less at time of purchase and therefore approximate fair value. The fair value of money market funds is determined based on “Level 1” inputs, which consist of unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets. The Company places its cash and short-term investments with high credit quality financial institutions.
Insurance Subsidiary Deposits and Investments — The Company's captive insurance subsidiary cash and cash equivalents, deposits and investments are designated to support long-term insurance subsidiary liabilities and have been classified as short-term and long-term assets based on the timing of expected future payments of the Company's captive insurance liabilities. The majority of these deposits and investments are currently held in AA, A and BBB rated debt security investments and the remainder is held in a bank account with a high credit quality financial institution.
The Company's non-qualified deferred compensation plan (the DCP)'s contracts insuring the lives of certain employees who are eligible to participate in the DCP are held in a rabbi trust. Cash surrender value of the contracts is based on funds that shadow the investment allocations specified by participants in the deferred compensation plan.
When evaluating an investment for its current expected credit losses, the Company reviews factors such as historical experience with defaults, losses, credit ratings, term, market sector and macroeconomic trends, including current conditions and forecasts to the extent they are reasonable and supportable.
Property and Equipment Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from three to 59 years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term.
Leases The Company leases skilled nursing facilities, senior living facilities and commercial office space. The Company determines if an arrangement is a lease and performs an evaluation to determine whether the lease should be classified as an operating or finance lease at the inception of the lease. As of December 31, 2023, the Company has one financing lease that is not material to the consolidated balance sheet. Rights and obligations of these leases are included as right-of-use assets and current and long-term lease liabilities on the Company's consolidated balance sheets. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of future lease payments. The Company utilizes a third-party valuation specialist to assist in estimating the incremental borrowing rate.
The Company records rent expense for operating leases on a straight-line basis over the term of the lease. The lease term used for straight-line rent expense is calculated from the date the Company is given control of the leased premises through the end of the lease term. Renewals are not assumed in the determination of the lease term unless they are deemed to be reasonably assured at the inception of the lease. The lease term used for this evaluation also provides the basis for establishing depreciable lives for buildings subject to lease and leasehold improvements.
The Company's real estate leases generally have initial lease terms of ten years or more and typically include one or more options to renew, with renewal terms that generally extend the lease term for an additional ten to 15 years. Exercise of the renewal options is generally subject to the satisfaction of certain conditions which vary by contract and generally follow payment terms that are consistent with those in place during the initial term. The Company reassesses the renewal option using a "reasonably certain" threshold, which is understood to be a high threshold. For leases where the Company is reasonably certain to exercise its renewal option, the option periods are included within the lease term and, therefore, the measurement of the right-of-use asset and lease liability. The Company's leases generally contain annual escalation clauses that are either fixed or variable in nature, some of which are dependent upon published indices. The Company recognizes lease expense for leases with an initial term of 12 months or less on a straight-line basis over the lease term. These leases are not recorded on the consolidated balance sheets. Certain of the Company's lease agreements include rental payments that are adjusted periodically for inflation. The lease agreements do not contain any material residual value guarantees or material restrictive covenants.

99

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


The Company subleases skilled nursing facilities to third-party operators and considers the subleases to be separate contracts as the Company is not relieved of its primary obligation under its operating lease. The rental income from third-parties related to these subleases is presented on a gross basis from the rent expense associated with the Company's lease obligations and is not material to the consolidated statements of income.
Impairment of Long-Lived Assets The Company reviews the carrying value of long-lived assets that are held and used in the Company’s independent subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the independent subsidiaries to which the assets relate, utilizing management’s best estimate, appropriate assumptions and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset. Management has evaluated its long-lived assets and determined there was no impairment during the years ended December 31, 2023, 2022, and 2021.
Intangible Assets and Goodwill Definite-lived intangible assets consist primarily of patient base, facility trade names and customer relationships. Patient base is amortized over a period of four to eight months, depending on the classification of the patients and the level of occupancy in a new acquisition on the acquisition date. Trade names at independent subsidiaries are amortized over 30 years and customer relationships are amortized over a period of up to 20 years.
The Company's indefinite-lived intangible assets consist of trade names and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable.
Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. The Company tests goodwill during the fourth quarter of each year or more often if events or circumstances indicate there may be impairment. The Company performs its analysis for each reporting unit that constitutes a business for which discrete financial information is produced and reviewed by operating segment management and provides services that are distinct from the other components of the operating segment, in accordance with the provisions of FASB ASC Topic 350, Intangibles—Goodwill and Other (ASC 350). This guidance provides the option to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. If, based on a review of qualitative factors, it is more likely than not that the fair value of a reporting unit is less than its carrying value, the Company performs a goodwill impairment test by comparing the carrying value of each reporting unit to its respective fair value. The Company determines the estimated fair value of each reporting unit using a discounted cash flow analysis. The fair value of the reporting unit is the implied fair value of goodwill. In the event a reporting unit's carrying value exceeds its fair value, an impairment loss will be recognized. An impairment loss is measured by the difference between the carrying value of the reporting unit and its fair value.
Management has evaluated its goodwill and intangible assets and determined there was no impairment during the years ended December 31, 2023, 2022, and 2021. The Company has recognized cumulative goodwill impairment losses of $7,410, since inception in 1999.
Self-Insurance — The Company is partially self-insured for general and professional liability claims up to a base amount per claim (the self-insured retention) with an aggregate, one-time deductible above this limit. Losses beyond these amounts are insured through third-party policies with coverage limits per claim, per location and on an aggregate basis for the Company. The combined self-insured retention is $500 per claim, subject to an additional one-time deductible of $1,250 for the Company's independent subsidiaries in California and a separate, one-time, deductible of $1,250 for the Company's independent subsidiaries not in California. For all independent subsidiaries, except those located in Colorado, the third-party coverage above these limits is $1,000 per claim, $3,000 per operation, with a $5,000 blanket aggregate limit and an additional state-specific aggregate where required by state law. In Colorado, the third-party coverage above these limits is $1,000 per claim and $3,000 per operation, which is independent of the aforementioned blanket aggregate limits that apply outside of Colorado.
Subsequent to December 31, 2023, the self-insured retention is $750 per claim, subject to an additional one-time deductible of $1,500 for the Company's independent subsidiaries in California. For the independent subsidiaries not in California, the self-insured retention is $650 per claim, subject to an additional one-time deductible of $1,350. For all independent subsidiaries, except those located in Colorado, the third-party coverage above these limits is $1,000 per claim, $3,000 per operation, with a $10,000 blanket aggregate limit and an additional state-specific aggregate where required by state law.
100

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


The majority of the self-insured retention and deductible limits for general and professional liabilities and workers' compensation liabilities are self-insured through the captive insurance subsidiary, the related assets and liabilities of which are included in the accompanying consolidated balance sheets. The captive insurance subsidiary is subject to certain statutory requirements as an insurance provider.
The Company’s policy is to accrue amounts equal to the actuarial estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. The Company develops information about the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluates the estimates for claim loss exposure on a quarterly basis. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information.
The Company’s independent subsidiaries are self-insured for workers’ compensation liabilities in California. To protect itself against loss exposure in California with this policy, the Company has purchased individual specific excess insurance coverage that insures individual claims that exceed $625 per occurrence. In Texas, the independent subsidiaries have elected non-subscriber status for workers’ compensation claims and the Company has purchased individual stop-loss coverage that insures individual claims that exceed $750 per occurrence. The Company’s independent subsidiaries in all other states, with the exception of Washington, are under a loss sensitive plan that insures individual claims that exceed $350 per occurrence. In the state of Washington, the Company is self-insured and has purchased individual specific excess insurance coverage that insures individual claims that exceed $500 per occurrence. For all of the self-insured plans and retention, the Company accrues amounts equal to the estimated costs to settle open claims, as well as an estimate of the cost of claims that have been incurred but not reported. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information.
The Company self-funds medical (including prescription drugs) and dental healthcare benefits to the majority of its employees. The Company is fully liable for all financial and legal aspects of these benefit plans. To protect itself against loss exposure with this policy, the Company has purchased individual stop-loss insurance coverage that insures individual claims that exceed $525 for each covered person for fiscal years 2023 and 2022, respectively, and $500 for each covered person for fiscal year 2021.
The Company believes that adequate provision has been made in the Financial Statements for liabilities that may arise out of patient care, workers’ compensation, healthcare benefits and related services provided to date. The amount of the Company’s reserves was determined based on an estimation process that uses information obtained from both company-specific and industry data. This estimation process requires the Company to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and the Company’s assumptions about emerging trends, the Company, with the assistance of an independent actuary, develops information about the size of ultimate claims based on the Company’s historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damage awards with respect to unpaid claims. The self-insured liabilities are based upon estimates, and while management believes that the estimates of loss are reasonable, the ultimate liability may be in excess of or less than the recorded amounts. Due to the inherent volatility of actuarially determined loss estimates, it is reasonably possible that the Company could experience changes in estimated losses that could be material to net income. If the Company’s actual liabilities exceed its estimates of losses, its future earnings, cash flows and financial condition would be adversely affected.
Income Taxes — Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized.
In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company’s estimates and assumptions, actual results could differ.

101

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


Standard Bearer elected to be taxed as a REIT, for U.S. federal income tax purposes, commencing with its taxable year ended December 31, 2022. Standard Bearer was organized, has operated and intends to continue to operate in a manner to qualify for taxation as a REIT. In order to qualify as a REIT, Standard Bearer must meet certain organizational and operational requirements, including a requirement to distribute to its shareholders, which in this case is the Company, at least 90% of its annual taxable income. As a REIT, Standard Bearer generally will not be subject to federal income tax to the extent it distributes as qualifying dividends, all of its REIT taxable income to its shareholders. If Standard Bearer fails to qualify as a REIT in any taxable year, it will be subject to federal income tax on its taxable income at regular corporate income tax rates and generally will not be permitted to qualify for treatment as a REIT for federal income tax purposes for the four taxable years following the year during which qualification is lost unless the Internal Revenue Service grants the Company relief under certain statutory provisions.
Noncontrolling Interest The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to The Ensign Group, Inc. in its consolidated statements of income. Net income per share is calculated based on net income attributable to The Ensign Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest.
Stock-Based CompensationThe Company measures and recognizes compensation expense for all stock-based payment awards made to employees and directors including employee stock options based on estimated fair values, ratably over the requisite service period of the award. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is based upon the number of grants and other variables.
Comprehensive Income The Company does not have any components of other comprehensive income recorded within its Financial Statements and, therefore, does not separately present a statement of comprehensive income in its Financial Statements.
Recent Accounting Pronouncements Except for rules and interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal securities laws and a limited number of grandfathered standards, the FASB ASC is the sole source of authoritative GAAP literature recognized by the FASB and applicable to the Company. For any new pronouncements announced, the Company considers whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on the Company's reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company's financial management and certain standards are under consideration.
Recent Accounting Standards Issued But Not Yet Adopted by the Company In October 2023, the FASB issued ASU 2023-06 "Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative", which amends U.S. GAAP to include 14 disclosure requirements that are currently required under SEC Regulation S-X or Regulation S-K. Each amendment will be effective on the date on which the SEC removes the related disclosure requirement from SEC Regulation S-X or Regulation S-K. The adoption is not expected to have a material impact on the Company's Notes to the Consolidated Financial Statements as these requirements were previously incorporated under the SEC Regulations.
In November 2023, the FASB issued ASU 2023-07 "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures", which requires the Company to expand the breadth and frequency of segment disclosures to include additional information about significant segment expenses, the chief operating decision maker (CODM) and other items, and also require the annual disclosures on an interim basis. This guidance is effective for annual periods beginning after December 15, 2023, which will be the Company's fiscal year 2024, with early adoption permitted. The Company is currently evaluating the impact of the ASU on its Quarterly and Annual Reports.
In December 2023, the FASB issued ASU 2023-09 "Income Taxes (Topic 740): Improvements to Income Tax Disclosures", which requires the Company to disclose disaggregated jurisdictional and categorical information for the tax rate reconciliation, income taxes paid and other income tax related amounts. This guidance is effective for annual periods beginning after December 15, 2024, which will be the Company's fiscal year 2025, with early adoption permitted. The adoption is expected to enhance the Company's Notes to the Consolidated Financial Statements. The Company is currently evaluating the impact of the ASU on its Annual Report.

102

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


3. REVENUE AND ACCOUNTS RECEIVABLE
Disaggregation of Revenue
The Company disaggregates revenue from contracts with its patients by payors. The Company determines that disaggregating revenue into these categories achieves the disclosure objectives to depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.
Revenue by Payor

The Company’s revenue is derived primarily from providing healthcare services to patients and is recognized on the date services are provided at amounts billable to individual patients, adjusted for estimates for variable consideration. For patients under reimbursement arrangements with third-party payors, including Medicaid, Medicare and private insurers, revenue is recorded based on contractually agreed-upon amounts or rates, adjusted for estimates for variable consideration, on a per patient, daily basis or as services are performed.

Revenue from the Medicare and Medicaid programs accounted for 72.6%, 73.7% and 73.6% for the years ended December 31, 2023, 2022, and 2021, respectively. Settlements with Medicare and Medicaid payors for retroactive adjustments due to audits and reviews are considered variable consideration and are included in the determination of the estimated transaction price. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Company’s historical settlement activity. Consistent with healthcare industry practices, any changes to these revenue estimates are recorded in the period the change or adjustment becomes known based on the final settlement. The Company recorded adjustments to revenue which were not material to the Company's revenue for the years ended December 31, 2023, 2022, and 2021.

Service revenue for the years ended December 31, 2023, 2022, and 2021 is summarized in the following tables:
 Year Ended December 31,
202320222021
Revenue% of RevenueRevenue% of RevenueRevenue% of Revenue
Medicaid(1)
$1,459,449 39.4 %$1,183,156 39.3 %$1,022,460 39.2 %
Medicare985,749 26.6 832,160 27.7 727,103 27.8 
Medicaid — skilled245,663 6.6 200,878 6.7 172,770 6.6 
Total Medicaid and Medicare2,690,861 72.6 2,216,194 73.7 1,922,333 73.6 
Managed care666,129 18.0 525,710 17.5 456,728 17.5 
Private and other(2)
351,081 9.4 266,807 8.8 232,415 8.9 
SERVICE REVENUE$3,708,071 100.0 %$3,008,711 100.0 %$2,611,476 100.0 %
(1) Medicaid payor includes revenue for senior living operations and revenue related to state relief funding.
(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.
In addition to the service revenue above, the Company's rental revenue derived from triple-net lease arrangements with third parties is $21,284, $16,757 and $15,985 for the years ended December 31, 2023, 2022, and 2021.
State relief funding
The Company received state relief funding through Medicaid programs from various states, including healthcare relief funding under the American Rescue Plan Act (ARPA), increases in the Federal Medical Assistance Percentage (FMAP) under the Families First Coronavirus Response Act (FFCRA) and other state specific relief programs. The funding generally incorporates specific use requirements primarily for direct patient care including labor related expenses that are attributable to the COVID-19 pandemic or are associated with providing patient care.
103

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


Revenues from these additional payments are recognized in accordance with ASC 606, subject to variable consideration constraints. In certain operations where the Company received additional payments that exceeded expenses incurred related to specific qualifiers, the Company recorded deferred revenue for the excess amount until additional expenses are incurred for recognition. Accordingly, the amount of state relief revenue recognized is limited to the actual related expenses incurred. As of years ended December 31, 2023 and 2022, the Company had $486 and $1,001 in unapplied state relief funds, respectively. During the years ended December 31, 2023, 2022, and 2021, the Company received an additional $64,238, $81,057, and $70,484 in state relief funding and recognized $64,753, $81,837, and $75,231, respectively, as revenue.
Federal relief funding
In prior years, as part of the Coronavirus Aid, Relief, and Economic Security Act of 2020 (the CARES Act), the Company received cash distributions of relief fund payments (Provider Relief Funds) and funds authorized by U.S. Department of Health and Human Services (HHS) to be used to protect residents of nursing homes and long-term care (LTC) facilities from the impact of COVID-19. During the years ended December 31, 2023 and 2022, the Company did not receive Provider Relief Funds. During the year ended December 31, 2021, the Company received and returned $11,637 in Provider Relief Funds.
In fiscal year 2020, the Company applied for and received $105,255 through the Medicare Accelerated and Advance Payment Program under the CARES Act. The purpose of the program is to assist in providing needed liquidity to care delivery providers. The Company repaid $3,232 of the funds in 2020 and the remaining funds of $102,023 in March 2021.
The CARES Act also provides for deferred payment of the employer portion of social security taxes through the end of 2020, with approximately 50% of the deferred amount due by December 31, 2021 and the remaining 50% due by December 31, 2022. The Company recorded $48,309 of deferred payments of social security taxes as a liability during 2020, and paid the first and second half of the payments in the fourth quarters of 2021 and 2022, respectively.
Balance Sheet Impact
Included in the Company’s consolidated balance sheets are contract balances, comprised of billed accounts receivable and unbilled receivables, which are the result of the timing of revenue recognition, billings and cash collections, as well as, contract liabilities, which primarily represent payments the Company receives in advance of services provided. The Company had no material contract liabilities and contract assets as of December 31, 2023 and 2022, or activity during the years ended December 31, 2023, 2022, and 2021.

Accounts receivable as of December 31, 2023 and 2022, is summarized in the following table:
December 31,
20232022
Medicaid$178,285 $157,878 
Managed care125,907 95,940 
Medicare85,512 76,526 
Private and other payors104,683 85,890 
 494,387 416,234 
Less: allowance for doubtful accounts(9,348)(7,802)
ACCOUNTS RECEIVABLE, NET$485,039 $408,432 
4. COMPUTATION OF NET INCOME PER COMMON SHARE

Basic net income per share is computed by dividing income from operations attributable to stockholders of The Ensign Group, Inc. by the weighted average number of outstanding common shares for the period. The computation of diluted net income per share is similar to the computation of basic net income per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued.
A reconciliation of the numerator and denominator used in the calculation of basic net income per common share follows:

104

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


Year Ended December 31,
 202320222021
NUMERATOR:
Net income$209,850 $224,652 $197,725 
Less: net income (loss) attributable to noncontrolling interests 451 (29)3,073 
Net income attributable to The Ensign Group, Inc. $209,399 $224,681 $194,652 
DENOMINATOR:
Weighted average shares outstanding for basic net income per share55,708 54,887 54,486 
Basic net income per common share:$3.76 $4.09 $3.57 

A reconciliation of the numerator and denominator used in the calculation of diluted net income per common share follows:

Year Ended December 31,
 202320222021
NUMERATOR:
Net income $209,850 $224,652 $197,725 
Less: net income (loss) attributable to noncontrolling interests451 (29)3,073 
Net income attributable to The Ensign Group, Inc. $209,399 $224,681 $194,652 
DENOMINATOR:
Weighted average common shares outstanding55,708 54,887 54,486 
Plus: incremental shares from assumed conversion (1)
1,615 1,984 2,439 
Adjusted weighted average common shares outstanding57,323 56,871 56,925 
Diluted net income per common share:$3.65 $3.95 $3.42 
(1) Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were 1,429, 780 and 198 for the years ended December 31, 2023, 2022 and 2021, respectively.
5. FAIR VALUE MEASUREMENTS

The Company's financial assets include the captive insurance subsidiary's deposits and investments designated to support long-term insurance subsidiary liabilities and are carried at amortized cost basis of $59,530 and $53,924 as of December 31, 2023 and 2022, respectively. As of December 31, 2023 and 2022, the amortized cost basis of the Company's financial assets included in the captive insurance subsidiary's investments are considered to approximate the fair value of these financial assets and are derived using Level 2 inputs.

Also included are contracts insuring the lives of certain employees who are eligible to participate in non-qualified deferred compensation plans that are held in a rabbi trust. The cash surrender value of these contracts is based on funds that shadow the investment allocations specified by participants in the deferred compensation plan and are held at fair value. As of December 31, 2023, and 2022, the fair value of the investment funds was $41,216 and $25,144, respectively, which are derived using Level 2 inputs.

Additionally, the Company has other investments held at historical cost basis, which are not material, where the fair value is derived using Level 3 inputs. The Company believes its amortized cost basis investments that were in an unrealized loss position as of December 31, 2023 and 2022 do not require an allowance for expected credit losses, nor has any event occurred through the filing date of this report that would indicate differently.

105

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


6. STANDARD BEARER
Standard Bearer's real estate portfolio consists of 108 of the Company's 113 owned real estate properties, of which 79 are operated and managed by the Company's independent subsidiaries and 30 are leased to and operated by third-party operators. Of those 30 operations, one senior living facility is located on the same real estate property as a skilled nursing facility that an independent subsidiary owns and operates. Standard Bearer elected to be taxed as a REIT, for U.S. federal income tax purposes, commencing with its taxable year ended December 31, 2022.
During the year ended December 31, 2023, Standard Bearer acquired the real estate of three stand-alone skilled nursing facilities and two campus operations for an aggregate purchase price of $65,899. Of these additions, the three skilled nursing facilities and one campus operation acquired are operated by the Company's independent subsidiaries and the other campus operation is leased to a third-party operator. During the year ended December 31, 2022, Standard Bearer acquired the real estate of ten skilled nursing facilities for an aggregate purchase price of $84,656, three of which were previously operated and managed by the Company's independent subsidiaries. Refer to Note 7, Operation Expansions, for additional information.
As part of the formation of Standard Bearer, certain of the Company's independent subsidiaries, Standard Bearer and Standard Bearer's independent real estate subsidiaries entered into several agreements that include leasing, management services and debt arrangements between the operations. All intercompany transactions have been eliminated in consolidation. Refer to Note 8, Business Segments, for additional information related to these intercompany eliminations as well as Standard Bearer as a reportable segment.
Intercompany master lease agreements
Certain of the Company's independent subsidiaries and 79 Standard Bearer independent real estate subsidiaries have entered into five triple-net master lease agreements (collectively, the Standard Bearer Master Leases). The lease periods range from 15 to 19 years with three five-year renewal options beyond the initial term, on the same terms and conditions. The rent structure under the Standard Bearer Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the independent subsidiaries are required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties; (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. Rental revenue generated from the Company's independent subsidiaries was $66,712, $57,967, and $44,165 for the years ended December 31, 2023, 2022, and 2021, respectively.
Intercompany management agreement
Standard Bearer has no employees. The Service Center provides personnel and services to Standard Bearer pursuant to the management agreement between Standard Bearer and the Service Center. The management agreement provides for a base management fee that is equal to 5% of total rental revenue and an incentive management fee that is equal to 5% of funds from operations (FFO) and is capped at 1% of total rental revenue, for a total of 6%. Management fee generated between Standard Bearer and the Service Center for the year ended December 31, 2023 and 2022 was $4,948 and $4,367, respectively. No management fees were recorded in 2021, which was prior to the formation of Standard Bearer.
Intercompany debt arrangements

Standard Bearer obtains its funding through various sources including operating cash flows, access to debt arrangements and intercompany loans. The intercompany debt arrangements include mortgage loans and the Credit Facility to fund acquisitions and working capital needs. The interest rate under the Credit Facility is a base rate plus a margin ranging from 0.25% to 1.25% per annum or SOFR plus a margin range from 1.25% to 2.25% per annum.

In addition, as the Department of Housing and Urban Development (HUD) mortgage loans and promissory note are entered into by real estate subsidiaries of Standard Bearer, the interest expense incurred from these debts are included in Standard Bearer's segment income. Refer to Note 15, Debt, for additional information related to these debts.

106

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


Equity Instrument Denominated in the Shares of a Subsidiary
As part of the formation of Standard Bearer in January of 2022, the Company established the Standard Bearer Healthcare REIT, Inc. 2022 Omnibus Incentive Plan (Standard Bearer Equity Plan). The Company may grant stock options and restricted stock awards under the Standard Bearer Equity Plan to employees and management of Ensign's independent subsidiaries. These awards generally vest over a period of five years or upon the occurrence of certain prescribed events. The value of the stock options and restricted stock awards is tied to the value of the common stock of Standard Bearer, which is determined based on an independent valuation of Standard Bearer. The awards can be put to Standard Bearer at various prescribed dates, which in no event is earlier than six months after vesting of the restricted awards or exercise of the stock options. The Company can also call the awards, generally upon employee termination. During the year ended December 31, 2022, Standard Bearer sold fully vested common shares from the Standard Bearer Equity Plan to shareholders for cash of $6,544. During the year ended December 31, 2023 and 2022, the Company did not grant any stock options nor restricted shares under the Standard Bearer Equity Plan.
Also, during the year ended December 31, 2022, Standard Bearer established shareholders of its preferred shares through contributions of cash of $149. These preferred shares were fully vested at the time of the contributions by the shareholders. The value of Standard Bearer common and preferred shares held by the Company are eliminated in consolidation and the value held by other shareholders are classified as noncontrolling interests on the Company's consolidated balance sheets.
7. OPERATION EXPANSIONS
The expansion focus of the Company's independent subsidiaries is to purchase or lease operations that are complementary to the current operations, accretive to the business, or otherwise advance the Company's strategy. The results of all independent subsidiaries are included in the Financial Statements subsequent to the date of acquisition. Acquisitions are accounted for using the acquisition method of accounting. The Company's independent subsidiaries also enter into long-term leases that may include options to purchase the facilities. As a result, from time to time, an independent real estate subsidiary will acquire the property of facilities that have previously been operated under third-party leases.
2023 Expansions
During the year ended December 31, 2023, the Company expanded its operations and real estate portfolio through a combination of long-term leases and real estate purchases, with the addition of 25 stand-alone skilled nursing operations and one campus operation. Of these additions, Standard Bearer acquired the real estate of three of the stand-alone skilled nursing operations and one campus operation, which were leased back to the Company's independent subsidiaries. Refer to Note 6, Standard Bearer, for additional information on the purchase of real estate properties. These new operations added a total of 2,483 operational skilled nursing beds and 94 operational senior living units to be operated by the Company's independent subsidiaries. The Company also invested in new ancillary services that are complementary to its existing businesses.
In connection with the new operations obtained through long-term leases, the Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with each prior operator as part of each transaction.
Subsequent to December 31, 2023, the Company expanded its operations through a long-term lease, with the addition of two stand-alone skilled nursing operations, totaling 241 operational skilled nursing beds operated by the Company's independent subsidiaries, including one in a new state, Tennessee.
2022 Expansions
During the year ended December 31, 2022, the Company expanded its operations and real estate portfolio through a combination of long-term leases and real estate purchases, with the addition of 23 stand-alone skilled nursing operations and one campus operation. Of these additions, Standard Bearer acquired the real estate of seven of the stand-alone skilled nursing operations, which were leased back to Ensign's independent subsidiaries. Refer to Note 6, Standard Bearer, for additional information on the purchases of real estate properties. In addition, the Company added five senior living operations that were transferred from The Pennant Group, Inc. (Pennant), three of which are part of campuses operated by the Company's independent subsidiaries. These new operations added a total of 3,058 operational skilled nursing beds and 674 operational senior living units to be operated by the Company's independent subsidiaries. The Company also invested in new ancillary services that are complementary to its existing businesses.
107

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


Of the new operations acquired during the year ended December 31, 2022, $16,400 was concentrated in goodwill and accordingly, the transactions were classified as business combinations.
In connection with the new operations obtained through long-term leases, the Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with each prior operator as part of each transaction.
2021 Acquisitions
During the year ended December 31, 2021, the Company expanded its operations through a combination of long-term leases and a real estate purchase, with the addition of 17 stand-alone skilled nursing operations and five real estate purchases, four of which the Company previously operated and continues to operate. The remaining real estate purchase is operated by Pennant. These new operations added a total of 1,832 operational skilled nursing beds operated by the Company's independent subsidiaries.
Of the new operations acquired during the year ended December 31, 2021, $6,000 was concentrated in goodwill and accordingly, the transactions were classified as business combinations.
In connection with the new operations made through long-term leases, the Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with the prior operator as part of each transaction.
The table below presents the allocation of the purchase price for the operations acquired during the years ended December 31, 2023, 2022, and 2021:
Year Ended December 31,
202320222021
Land$7,794 $15,527 $19,928 
Building and improvements57,488 65,070 77,975 
Equipment, furniture, and fixtures1,840 1,618 217 
Assembled occupancy346 367 29 
Goodwill 16,400 6,000 
Leased asset 1,909  
Other indefinite-lived intangible assets330 245 75 
TOTAL ACQUISITIONS$67,798 $101,136 $104,224 
The Company’s acquisition strategy has been focused on identifying both opportunistic and strategic acquisitions within its target markets that offer strong opportunities for return. The operations added by the Company are frequently underperforming financially and can have regulatory and clinical challenges to overcome. Financial information, especially with underperforming operations, is often inadequate, inaccurate or unavailable. Consequently, the Company believes that prior operating results are not a meaningful representation of the Company’s current operating results or indicative of the integration potential of its newly acquired independent subsidiaries. The assets added during the year ended December 31, 2023 were not material operations to the Company individually or in the aggregate. Accordingly, pro forma financial information is not presented. These additions have been included in the consolidated balance sheets of the Company, and the operating results have been included in the consolidated statements of income of the Company since the date the Company gained effective control.
8. BUSINESS SEGMENTS

The Company has two reportable segments: (1) skilled services, which includes the operation of skilled nursing facilities and rehabilitation therapy services and (2) Standard Bearer, which is comprised of selected real estate properties owned by Standard Bearer and leased to skilled nursing and senior living operators.

As of December 31, 2023, the skilled services segment includes 259 skilled nursing operations and 27 campus operations that provide both skilled nursing and rehabilitative care services and senior living services. The Company's Standard Bearer segment consists of 108 owned real estate properties.

108

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


The Company also reports an “All Other” category that includes results from its senior living operations, which includes 11 stand-alone senior living operations and the senior living operations at 27 campus operations that provide both skilled nursing and rehabilitative care services and senior living services. In addition, the "All Other" category includes mobile diagnostics, medical transportation, other real estate and other ancillary operations. Services included in the “All Other” category are insignificant individually, and therefore do not constitute a reportable segment.

The Company’s reportable segments are significant operating segments that offer differentiated services. The Company's CODM reviews financial information for each operating segment to evaluate performance and allocate capital resources. This structure reflects its current operational and financial management and provides the best structure to maximize the quality of care and investment strategy provided, while maintaining financial discipline. The Company's CODM does not review assets by segment in his resource allocation and therefore assets by segment are not disclosed below.

The accounting policies of the reportable segments are the same as those described in Note 2, Summary of Significant Accounting Policies. Intercompany revenue is eliminated in consolidation, along with corresponding intercompany expenses. Segment income and loss is defined as profit or loss from operations before provision for income taxes, excluding gain or loss from sale of real estate, real estate insurance recoveries and losses and impairment charges from operations. Included in segment income for Standard Bearer is expense for intercompany services provided by the Service Center as described in Note 6, Standard Bearer, as it is part of the CODM financial information.

The following tables set forth financial information for the segments:
 Year Ended December 31, 2023
 Skilled ServicesStandard Bearer
All Other (1)
Intercompany EliminationTotal
Service revenue(2)
$3,578,855 $ $144,667 $(15,451)$3,708,071 
Rental revenue(3)
 82,486 11,137 (72,339)21,284 
TOTAL REVENUE$3,578,855 $82,486 $155,804 $(87,790)$3,729,355 
Segment income (loss)464,925 29,065 (221,251) 272,739 
Gain on sale of assets and insurance recoveries from real estate, net
23 
Income before provision for income taxes$272,762 
Depreciation and amortization38,766 25,205 8,416  72,387 
Interest expense(4)
$ $19,761 $1,228 $(12,902)$8,087 
(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center.
(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's independent subsidiaries and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service.
(3) All Other rental revenue includes rental revenue associated with the Company's subleases to third parties of $3,897 for the year ended December 31, 2023. Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's independent subsidiaries. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense.
(4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. Intercompany interest expense is eliminated in the "Intercompany Elimination" column.

109

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


 Year Ended December 31, 2022
 Skilled ServicesStandard Bearer
All Other (1)
Intercompany EliminationTotal
Service revenue(2)
$2,906,215 $ $115,214 $(12,718)$3,008,711 
Rental revenue(3)
 72,937 7,396 (63,576)16,757 
TOTAL REVENUE$2,906,215 $72,937 $122,610 $(76,294)$3,025,468 
Segment income (loss)408,732 27,871 (150,781) 285,822 
Gain on sale of assets and insurance recoveries from real estate, net
3,267 
Income before provision for income taxes$289,089 
Depreciation and amortization33,224 21,613 7,518  62,355 
Interest expense(4)
$ $15,707 $1,870 $(8,646)$8,931 
(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center.
(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's independent subsidiaries and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service.
(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's independent subsidiaries. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense.
(4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. Intercompany interest expense is eliminated in the "Intercompany Elimination" column.
 
Year Ended December 31, 2021
 Skilled ServicesStandard Bearer
All Other (1)
Intercompany EliminationTotal
Service revenue(2)
$2,523,234 $ $95,276 $(7,034)$2,611,476 
Rental revenue(3)
 58,127 7,409 (49,551)15,985 
TOTAL REVENUE$2,523,234 $58,127 $102,685 $(56,585)$2,627,461 
Segment income (loss)373,603 31,876 (147,915) 257,564 
Gain on real estate insurance recoveries440 
Income before provision for income taxes $258,004 
Depreciation and amortization30,681 17,558 7,746  55,985 
Interest expense$ $6,842 $7 $ $6,849 
(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center.
(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's independent subsidiaries and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service.
(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's independent subsidiaries. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense.

Service revenue by major payor source were as follows:
 Year Ended December 31, 2023
 Skilled Services
All Other (3)
Total Service RevenueRevenue %
Medicaid(1)
$1,429,473 $29,976 $1,459,449 39.4 %
Medicare985,749  985,749 26.6 
Medicaid-skilled245,663  245,663 6.6 
Subtotal2,660,885 29,976 2,690,861 72.6 
Managed care666,129  666,129 18.0 
Private and other(2)
251,841 99,240 351,081 9.4 
TOTAL SERVICE REVENUE$3,578,855 $129,216 $3,708,071 100.0 %
(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding.
(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.
(3) All Other incorporates intercompany eliminations.
110

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


 Year Ended December 31, 2022
 Skilled Services
All Other (3)
Total Service RevenueRevenue %
Medicaid(1)
$1,158,309 $24,847 $1,183,156 39.3 %
Medicare832,160  832,160 27.7 
Medicaid-skilled200,878  200,878 6.7 
Subtotal2,191,347 24,847 2,216,194 73.7 
Managed care525,710  525,710 17.5 
Private and other(2)
189,158 77,649 266,807 8.8 
TOTAL SERVICE REVENUE$2,906,215 $102,496 $3,008,711 100.0 %
(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding.
(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.
(3) All Other incorporates intercompany eliminations.
 
Year Ended December 31, 2021
 Skilled Services
All Other (3)
Total Service RevenueRevenue %
Medicaid(1)
$1,007,061 $15,399 $1,022,460 39.2 %
Medicare727,103  727,103 27.8 
Medicaid-skilled172,770  172,770 6.6 
Subtotal1,906,934 15,399 1,922,333 73.6 
Managed care456,728  456,728 17.5 
Private and other(2)
159,572 72,843 232,415 8.9 
TOTAL SERVICE REVENUE$2,523,234 $88,242 $2,611,476 100.0 %
(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding.
(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.
(3) All Other incorporates intercompany eliminations.
9. PROPERTY AND EQUIPMENT - NET
Property and equipment, net consists of the following:
December 31,
20232022
Land$142,656 $134,864 
Buildings and improvements803,155 728,231 
Leasehold improvements172,064 150,903 
Equipment339,383 295,739 
Furniture and fixtures4,192 4,544 
Construction in progress25,563 17,521 
 1,487,013 1,331,802 
Less: accumulated depreciation(396,242)(339,792)
PROPERTY AND EQUIPMENT, NET$1,090,771 $992,010 
The Company completed the sale of assets for a sale price of $8,607 and recorded a gain of $3,467 within the Company's consolidated statement of income as cost of services during the year ended December 31, 2022. In addition, the Company evaluated its long-lived assets and did not record an impairment charge for the fiscal years ended 2023, 2022, and 2021. See also Note 6, Standard Bearer and Note 7, Operation Expansions for information on acquisitions during the year ended December 31, 2023.


111

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


10. INTANGIBLE ASSETS - NET

Weighted Average Life (Years)December 31,
20232022
Gross Carrying AmountAccumulated AmortizationGross Carrying AmountAccumulated Amortization
Intangible AssetsNetNet
Assembled occupancy0.3$781 $(742)$39 $435 $(388)$47 
Facility trade name30.0733 (439)294 733 (415)318 
Customer relationships18.44,582 (2,692)1,890 4,582 (2,482)2,100 
TOTAL $6,096 $(3,873)$2,223 $5,750 $(3,285)$2,465 

During the years ended December 31, 2023, 2022, and 2021, amortization expense was $1,790, $1,714 and $1,435, respectively, of which $1,202, $1,160 and $1,158 was related to the amortization of right-of-use assets, respectively. The Company did not record any impairment charge to intangible assets during the years ended December 31, 2023, 2022, and 2021.

Estimated amortization expense for each of the years ending December 31 is as follows:
YearAmount
2024274 
2025234 
2026234 
2027234 
2028234 
Thereafter1,013 
 $2,223 

Other indefinite-lived intangible assets consist of the following:
December 31,
20232022
Trade name$889 $889 
Medicare and Medicaid licenses3,413 3,083 
TOTAL$4,302 $3,972 

During the year ended December 31, 2023, the Company acquired $330 in Medicare and Medicaid licenses compared to $245 and $181 in the fiscal years 2022 and 2021, respectively.
11. GOODWILL

The Company anticipates that the majority of goodwill recognized will be fully deductible for tax purposes as of December 31, 2023. All of the Company's acquisitions during the year ended December 31, 2023 were classified as asset acquisitions and accordingly, no goodwill was recognized for these acquisitions. There were no other activities in goodwill during the year ended December 31, 2023. Provided that goodwill corresponds to the acquisition of a business and not merely the acquisition of real estate property, the Company's Standard Bearer segment appropriately does not carry a goodwill balance. The following table represents activity in goodwill by skilled service segment and "all other" category as of December 31, 2023, 2022 and 2021:
112

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


Goodwill
 Skilled ServicesAll OtherTotal
January 1, 2021$45,486 $8,983 $54,469 
Additions6,000  6,000 
December 31, 2021$51,486 $8,983 $60,469 
Additions16,400  16,400 
December 31, 2022$67,886 $8,983 $76,869 
December 31, 2023$67,886 $8,983 $76,869 
12. RESTRICTED AND OTHER ASSETS
Restricted and other assets consist of the following:
December 31,
20232022
Debt issuance costs, net$2,883 $3,753 
Long-term insurance losses recoverable asset15,913 10,512 
Capital improvement reserves with landlords and lenders4,870 6,446 
Deposits with landlords2,661 2,527 
Escrow deposits1,216  
Other12,662 14,053 
RESTRICTED AND OTHER ASSETS$40,205 $37,291 
Included in restricted and other assets as of December 31, 2023 and 2022 are anticipated insurance recoveries related to the Company's workers' compensation and general and professional liability claims that are recorded on a gross, rather than net, basis.
13. OTHER ACCRUED LIABILITIES

Other accrued liabilities consist of the following:
December 31,
20232022
Quality assurance fee$14,035 $7,701 
Refunds payable51,248 40,783 
Resident advances10,834 9,698 
Unapplied state relief funds486 1,001 
Cash held in trust for patients6,215 6,400 
Dividends payable3,396 3,201 
Property taxes12,875 10,926 
Accrued litigation (Note 20)
51,734 4,553 
Other17,405 13,046 
OTHER ACCRUED LIABILITIES$168,228 $97,309 

Quality assurance fee represents the aggregate of amounts payable to Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, Utah, Washington and Wisconsin as a result of a mandated fee based on patient days or licensed beds. Refunds payable includes payables related to overpayments, duplicate payments and credit balances from various payor sources. Resident advances occur when the Company receives payments in advance of services provided. Cash held in trust for patients reflects monies received from or on behalf of patients. Maintaining a trust account for patients is a regulatory requirement and, while the trust assets offset the liabilities, the Company assumes a fiduciary responsibility for these funds. The cash balance related to this liability is included in other current assets in the consolidated balance sheets.

113

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


14. INCOME TAXES
The provision for income taxes on continuing operations for the years ended December 31, 2023, 2022 and 2021 is summarized as follows:
 Year Ended December 31,
 2023 2022 2021
Current:   
Federal$73,092 $56,717 $49,105 
State17,301 14,216 11,898 
 90,393 70,933 61,003 
Deferred: 
Federal(22,280)(5,158)(716)
State(5,201)(1,338)(8)
(27,481)(6,496)(724)
     TOTAL$62,912 $64,437 $60,279 

A reconciliation of the federal statutory rate to the effective tax rate for income from continuing operations for the years ended December 31, 2023, 2022 and 2021, respectively, is comprised as follows:

 December 31,
 202320222021
Income tax expense at statutory rate21.0 %21.0 %21.0 %
State income taxes - net of federal benefit3.5 3.5 3.7 
Non-deductible expenses3.4 2.0 2.4 
Equity compensation(4.2)(3.6)(3.3)
Other adjustments(0.6)(0.6)(0.4)
TOTAL INCOME TAX PROVISION23.1 %22.3 %23.4 %

The Company's effective tax rate was 23.1% for the year ended December 31, 2023, compared to 22.3% for the same period in 2022 and 23.4% in 2021. The higher effective tax rate is due to higher non-deductible expenses compared to tax benefits from stock compensation.

The Company's deferred tax assets and liabilities as of December 31, 2023 and 2022 are summarized below.
114

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


 December 31,
 2023 2022
Deferred tax assets (liabilities): 
Accrued expenses$81,502 $61,685 
Revenue related reserves23,714 18,046 
Tax credits1,192 1,742 
Insurance16,864 11,910 
Lease liability 444,590 364,408 
State taxes  28 
567,862 457,819 
Valuation allowance(789)(789)
TOTAL DEFERRED TAX ASSETS567,073 457,030 
State taxes(280) 
Depreciation and amortization(52,334)(49,146)
Prepaid expenses(4,113)(5,150)
Right of use asset (443,222)(363,091)
TOTAL DEFERRED TAX LIABILITIES(499,949)(417,387)
NET DEFERRED TAX ASSETS$67,124 $39,643 
The Company had state credit carryforwards as of December 31, 2023 and 2022 of $1,192 and $1,742, respectively. These carryforwards almost entirely relate to state limitations on the application of Enterprise Zone employment-related tax credits. Unless the Company uses the Enterprise Zone credits beforehand, the carryforward began to expire in 2023. The remainder of these carryforwards relate to credits against the Texas margin tax and is expected to carryforward until 2027. As of December 31, 2023 and 2022, the valuation allowance of $789, for both years, was primarily recorded against the Enterprise Zone credits as the Company believes it is more likely than not that some of the benefit of the credits will not be realized.
The Company's operating loss carry forwards for states were not material during the year ended December 31, 2023 and 2022.
As of December 31, 2023, 2022 and 2021, the Company did not have any unrecognized tax benefits, net of its state benefits that would affect the Company's effective tax rate. The Company classifies interest and/or penalties on income tax liabilities or refunds as additional income tax expense or income. Such amounts are not material.
The federal statutes of limitations on the Company's 2019, 2018, and 2017 income tax years lapsed during the third quarter of 2023, 2022, and 2021, respectively. During the fourth quarter of each year, various state statutes of limitations also lapsed. The lapses during the years ended December 31, 2023 and 2022 had no impact on the Company's unrecognized tax benefits.
During the year ended December 31, 2021, the state of Wisconsin initiated and completed an examination of the Company's 2019, 2018, and 2017 state tax years with no adjustments. The Company is not under examination by any major income tax jurisdiction.
15. DEBT
Debt consists of the following:
December 31,
20232022
Mortgage loans and promissory note$152,388 $156,271 
Less: current maturities(3,950)(3,883)
Less: debt issuance costs, net(2,941)(3,119)
LONG-TERM DEBT LESS CURRENT MATURITIES$145,497 $149,269 

115

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


Credit Facility with a Lending Consortium Arranged by Truist

The Company maintains a revolving credit facility between the Company and its independent subsidiaries, including Standard Bearer as co-borrowers, and Truist Securities (Truist) (the Credit Facility) with a revolving line of credit of up to $600,000 in aggregate principal amount with a maturity date of April 8, 2027. Borrowings are supported by a lending consortium arranged by Truist. The interest rates applicable to loans under the Credit Facility are, at the Company's option, equal to either a base rate plus a margin ranging from 0.25% to 1.25% per annum or SOFR plus a margin range from 1.25% to 2.25% per annum, based on the Consolidated Total Net Debt to Consolidated EBITDA ratio (as defined in the Credit Facility). In addition, there is a commitment fee on the unused portion of the commitments that ranges from 0.20% to 0.40% per annum, depending on the Consolidated Total Net Debt to Consolidated EBITDA ratio. When the Company amended the Credit Facility in 2022 with the terms and conditions described above, it wrote off deferred financing costs of $566 and additional deferred financing costs of $3,197 were capitalized during the year ended December 31, 2022.

Borrowings made under the Credit Facility are guaranteed, jointly and severally, by certain of the Company’s wholly-owned subsidiaries, and are secured by a pledge of stock of the Company's material independent subsidiaries as well as a first lien on substantially all of such independent subsidiaries' personal property. The Credit Facility contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its independent subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend certain material agreements and pay certain dividends and other restricted payments. The Company must comply with financial maintenance covenants to be tested quarterly, consisting of (i) a maximum consolidated total net debt to consolidated EBITDA ratio (which shall not be greater than 3.00:1.00; provided that if the aggregate consideration for approved acquisitions in a six month period is greater than $50,000, then the ratio can be increased at the election of the Company with notice to the administrative agent to 3.50:1.00 for the first fiscal quarter and the immediately following three fiscal quarters), and (ii) a minimum interest/rent coverage ratio (which cannot be less than 1.50:1.00). As of December 31, 2023, there was no outstanding debt under the Credit Facility. The Company was in compliance with all loan covenants as of December 31, 2023.
Mortgage Loans and Promissory Note

The Company has 23 subsidiaries that have mortgage loans insured with HUD in the aggregate amount of $150,244, which subjects these subsidiaries to HUD oversight and periodic inspections. The mortgage loans bear effective interest rates in a range of 3.1% to 4.2%, including fixed interest rates in a range of 2.4% to 3.3% per annum. In addition to the interest rate, the Company incurs other fees for HUD placement, including but not limited to audit fees. Amounts borrowed under the mortgage loans may be prepaid, subject to prepayment fees based on the principal balance on the date of prepayment. For the majority of the loans, during the first three years, the prepayment fee is 10.0% and is reduced by 3.0% in the fourth year of the loan, and reduced by 1.0% per year for years five through ten of the loan. There is no prepayment penalty after year ten. The terms for all the mortgage loans are 25 to 35 years.

In addition to the HUD mortgage loans above, the Company has a promissory note of $2,144 that bears a fixed interest rate of 5.3% per annum and has a term of 12 years. The note, which was assumed as part of an acquisition, is secured by the real property comprising the facility and the rent, issues and profits thereof, as well as all personal property used in the operation of the facility.

Future principal payments due under the long-term debt arrangements discussed above are as follows:

Years Ending December 31,Amount
2024$3,950 
20254,086 
20264,227 
20273,897 
20283,779 
Thereafter132,449 
 $152,388 
Based on Level 2 inputs, the carrying value of the Company's long-term debt is considered to approximate the fair value of such debt for all periods presented based upon the interest rates that the Company believes it can currently obtain for similar debt.
116

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


Off-Balance Sheet Arrangements

As of December 31, 2023, the Company had approximately $6,255 of borrowing capacity under the Credit Facility pledged as collateral to secure outstanding letters of credit, which decreased by $455 from prior year.

16. OPTIONS AND AWARDS
Stock-based compensation expense consists of stock-based payment awards made to employees and directors, including employee stock options and restricted stock awards, based on estimated fair values. As stock-based compensation expense recognized in the Company’s consolidated statements of income for the years ended December 31, 2023, 2022, and 2021 was based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. The Company estimates forfeitures at the time of grant and, if necessary, revises the estimate in subsequent periods if actual forfeitures differ.
2022 Omnibus Incentive Plan (2022 Plan)  The Company has one active stock incentive plan, the 2022 Omnibus Incentive Plan (the 2022 Plan). Including the shares rolled over from the 2017 Omnibus Incentive Plan, the 2022 Plan provides for the issuance of 3,452 shares of common stock. The number of shares available to be issued under the 2022 Plan will be reduced by (i) one share for each share that relates to an option or stock appreciation right award and (ii) two shares for each share which relates to an award other than a stock option or stock appreciation right award (a full-value award). Non-employee director options, to the extent granted, will vest and become exercisable in three equal annual installments, or the length of the term if less than three years, on the completion of each year of service measured from the grant date. All other options generally vest over five years at 20% per year on the anniversary of the grant date. Options expire ten years from the date of grant. At December 31, 2023, the total number of shares available for issuance under the 2022 Plan was 1,454.
The Company uses the Black-Scholes option-pricing model to recognize the value of stock-based compensation expense for stock option awards. Determining the appropriate fair-value model and calculating the fair value of stock option awards at the grant date requires judgment, including estimating stock price volatility, expected option life, and forfeiture rates. The fair-value of the restricted stock awards at the grant date is based on the market price on the grant date, adjusted for forfeiture rates. The Company develops estimates based on historical data and market information, which can change significantly over time. The Black-Scholes model required the Company to make several key judgments including:
The expected option term is calculated by the average of the contractual term of the options and the weighted average vesting period for all options. The calculation of the expected option term is based on the Company's experience due to sufficient history.
The Company utilizes its own experience to calculate estimated volatility for options granted.
The dividend yield is based on the Company's historical pattern of dividends as well as expected dividend patterns.
The risk-free rate is based on the implied yield of U.S. Treasury notes as of the grant date with a remaining term approximately equal to the expected term.
Estimated forfeiture rate of approximately 5.08% per year is based on the Company's historical forfeiture activity of unvested stock options.
Stock Options
The Company granted 1,008, 581 and 621 stock options during the years ended December 31, 2023, 2022, and 2021, respectively. The Company used the following assumptions for stock options granted during the years ended December 31, 2023, 2022 and 2021:
Grant YearOptions GrantedWeighted Average Risk-Free RateExpected LifeWeighted Average VolatilityWeighted Average Dividend Yield
20231,0084.3%6.2 years41.3%0.2%
20225812.8%6.2 years42.1%0.3%
20216211.0%6.2 years42.4%0.3%
For the years ended December 31, 2023, 2022 and 2021, the following represents the exercise price and fair value displayed at grant date for stock option grants:
117

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


Grant YearGrantedWeighted Average Exercise PriceWeighted Average Fair Value of Options
20231,008$95.05 $43.85 
2022581$85.74 $37.83 
2021621$80.19 $32.82 
The weighted average exercise price equaled the weighted average fair value of common stock on the grant date for all options granted during the periods ended December 31, 2023, 2022 and 2021 and therefore, the intrinsic value was $0 at the date of grant.
The following table represents the employee stock option activity during the year ended December 31, 2023:
Number of Options OutstandingWeighted Average
Exercise Price
Number of
Options Vested
Weighted Average Exercise Price of Options Vested
January 1, 20214,038 $27.71 2,148 $16.66 
Granted621 80.19 
Forfeited(105)44.76 
Exercised(516)17.80 
December 31, 20214,038 $36.60 2,183 $21.02 
Granted581 85.74 
Forfeited(98)59.52 
Exercised(688)18.43 
December 31, 20223,833 $46.72 2,069 $28.87 
Granted1,008 95.05 
Forfeited(91)71.44 
Exercised(759)24.21 
December 31, 20233,991 $62.65 1,887 $39.58 
The following summary information reflects stock options outstanding, vested and related details as of December 31, 2023:
 Stock Options OutstandingStock Options Vested
Number OutstandingBlack-Scholes Fair ValueRemaining Contractual Life (Years)Vested and Exercisable
Year of GrantExercise Price
20148.94-16.0599 $484 199 
201518.20-21.39175 1,369 2175 
201615.93-16.86155 916 3155 
201715.80-19.41194 1,138 4194 
201822.49-32.71336 3,523 5336 
201941.07-45.76510 8,014 6383 
202044.84-59.49476 9,383 7257 
202173.47-83.64513 16,844 8189 
202279.79-94.88540 20,466 999 
2023$89.83-$98.83993 43,566 10 
TOTAL 3,991 $105,703  1,887 
The aggregate intrinsic value of options outstanding, vested and expected to vest as of December 31, 2023, 2022 and 2021 is as follows:
118

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


December 31,
Options202320222021
Outstanding$197,819 $183,593 $191,242 
Vested137,048 136,000 137,382 
Expected to vest56,759 43,232 48,548 
The intrinsic value is calculated as the difference between the market value of the underlying common stock and the exercise price of the options. At December 31, 2023, 2022 and 2021, the aggregate intrinsic value of options that vested during the years ended December 31, 2023, 2022 and 2021 was $31,658, $27,955, and $27,731, respectively. The total intrinsic value of options exercised during the years ended December 31, 2023, 2022 and 2021 was $56,186, $47,441, and $34,278, respectively.
Restricted Stock Awards
The Company granted 219, 233 and 222 restricted stock awards during the years ended December 31, 2023, 2022 and 2021, respectively. All awards were granted at an issue price of $0 and generally vest over five years. The fair value per share of restricted awards granted during the years ended December 31, 2023, 2022 and 2021 ranged from $89.83 to $98.31, $73.17 to $94.88 and $72.84 to $93.31, respectively. The fair value per share includes quarterly stock awards to non-employee directors.
A summary of the status of the Company's non-vested restricted stock awards as of December 31, 2023 and changes during the years ended December 31, 2023, 2022 and 2021 is presented below:
Non-Vested Restricted AwardsWeighted Average Grant Date Fair Value
Nonvested at January 1, 2021591 $38.90 
Granted222 81.65 
Vested(244)47.45 
Forfeited(20)45.64 
Nonvested at December 31, 2021549 $52.16 
Granted233 81.57 
Vested(269)54.06 
Forfeited(26)57.29 
Nonvested at December 31, 2022487 $64.92 
Granted219 92.04 
Vested(255)64.21 
Forfeited(20)71.53 
Nonvested at December 31, 2023431 $78.91 
During the year ended December 31, 2023, the Company granted 18 quarterly stock awards to non-employee directors for their service on the Company's board of directors from the 2022 Plan. The fair value per share of these stock awards ranged from $89.94 to $98.31 based on the market price on the grant date.
Long-Term Incentive Plan
On August 27, 2019, the Board approved the Long-Term Incentive Plan (the 2019 LTI Plan). The 2019 LTI Plan provides that certain employees of the Company who assisted in the consummation of the spin-off of Pennant from the Company in 2019 (spin-off transaction) were granted shares of restricted stock upon successful completion of the spin-off. The 2019 LTI Plan provides for the issuance of 500 shares of Pennant restricted stock. The shares are vested over five years at 20% per year on the anniversary of the grant date. If a recipient is terminated or voluntarily leaves the Company, all shares subject to restriction or not yet vested are entirely forfeited. The total stock-based compensation related to the 2019 LTI Plan was approximately $827, $836, and $854 for the years ended December 31, 2023, 2022 and 2021, respectively.

119

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


Stock-based compensation expense
Stock-based compensation expense recognized for the Company's equity incentive plans and long-term incentive plan for the years ended December 31, 2023, 2022 and 2021 was as follows:

Year Ended December 31,
 202320222021
Stock-based compensation expense related to stock options$17,221 $11,361 $8,459 
Stock-based compensation expense related to restricted stock awards11,845 9,920 8,385 
Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors1,688 1,439 1,834 
TOTAL$30,754 $22,720 $18,678 
In future periods, the Company expects to recognize approximately $67,750 and $29,245 in stock-based compensation expense for unvested options and unvested restricted stock awards, respectively, that were outstanding as of December 31, 2023. Future stock-based compensation expense will be recognized over 3.9 and 3.4 weighted average years for unvested options and restricted stock awards, respectively. There were 2,104 unvested and outstanding options as of December 31, 2023, of which 1,940 shares are expected to vest. The weighted average contractual life for options outstanding, vested and expected to vest as of December 31, 2023 was 6.7 years.

17. LEASES
The Company leases from CareTrust REIT, Inc. (CareTrust) real property associated with 97 independent skilled nursing and senior living facilities used in the Company’s operations, 96 of which are under nine “triple-net” master lease agreements (collectively, the Master Leases), which range in terms from 13 to 20 years. At the Company’s option, the Master Leases may be extended for two or three five-year renewal terms beyond the initial term, on the same terms and conditions. The extension of the term of any of the Master Leases is subject to the following conditions: (1) no event of default under any of the Master Leases having occurred and been continuing; and (2) the tenants providing timely notice of their intent to renew. The term of the Master Leases is subject to termination prior to the expiration of the current term upon default by the tenants in their obligations, if not cured within any applicable cure periods set forth in the Master Leases. If the Company elects to renew the term of a Master Lease, the renewal will be effective to all, but not less than all, of the leased property then subject to the Master Lease. Additionally, four of the 97 facilities leased from CareTrust include an option to purchase that the Company can exercise starting on December 1, 2024.
The Company does not have the ability to terminate the obligations under a Master Lease prior to its expiration without CareTrust’s consent. If a Master Lease is terminated prior to its expiration other than with CareTrust’s consent, the Company may be liable for damages and incur charges such as continued payment of rent through the end of the lease term as well as maintenance and repair costs for the leased property.
The rent structure under the Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the Company is required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The terms and conditions of the one stand-alone lease are substantially the same as those for the master leases described above. Total rent expense for continuing operations under the Master Leases was approximately $66,439, $64,178 and $59,571 for the years ended December 31, 2023, 2022 and 2021, respectively.
Among other things, under the Master Leases, the Company must maintain compliance with specified financial covenants measured on a quarterly basis, including a portfolio coverage ratio and a minimum rent coverage ratio. The Master Leases also include certain reporting, legal and authorization requirements. The Company is in compliance with requirements of the Master Leases as of December 31, 2023.
In connection with the spin-off that occurred in 2019, the Company guaranteed certain leases of Pennant based on the underlying terms of the leases. The Company does not consider these guarantees to be probable and the likelihood of Pennant defaulting is remote, and therefore no liabilities have been accrued.
120

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


The Company leases facilities where its independent subsidiaries operate and certain administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from five to 20 years. In addition, the Company leases certain of its equipment under non-cancelable operating leases with initial terms ranging from three to five years. Most of these leases contain renewal options, certain of which involve rent increases. Total rent expense for continuing operations inclusive of straight-line rent adjustments and rent associated with the Master Leases noted above, was $197,856, $153,174 and $139,458 for the years ended December 31, 2023, 2022 and 2021, respectively.
Eighty of the Company’s independent subsidiaries, excluding the subsidiaries that are operated under the Master Leases with CareTrust, are operated under 13 separate master lease arrangements. During 2023, the Company expanded its operations through three separate master lease arrangements for 22 stand-alone skilled nursing operations, of which 19 are operated by the Company's independent subsidiaries and the remaining three are subleased to a third-party operator. These three master leases increased the lease liabilities and right-of-use assets by $346,789 to reflect the new lease obligations and have initial lease terms of 18, 20 and 20 years, respectively. Under these master leases, a default at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of the Company’s leases, master lease agreements and debt financing instruments. In addition, other potential defaults related to an individual facility may cause a default of an entire master lease portfolio and could trigger cross-default provisions in the Company’s outstanding debt arrangements and other leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the lease without the consent of the landlord.

The components of operating lease expense are as follows:
Year Ended December 31,
202320222021
Rent - cost of services(1)
$197,358 $153,049 $139,371 
General and administrative expense498 125 87 
Depreciation and amortization(2)
1,202 1,160 1,158 
Variable lease costs(3)
20,454 16,938 14,077 
$219,512 $171,272 $154,693 
(1)Rent- cost of services includes deferred rent expense adjustments of $870, $493 and $485 for the years ended December 31, 2023, 2022 and 2021, respectively. Additionally, rent- cost of services includes other variable lease costs such as consumer price index increases and short-term leases of $10,259, $5,878, $3,702 for the years ended December 31, 2023, 2022, and 2021 respectively.
(2) Depreciation and amortization is related to the amortization of favorable and direct lease costs.
(3) Variable lease costs, including property taxes and insurance, are classified in cost of services in the Company's consolidated statements of income.

Future minimum lease payments for all third-party leases as of December 31, 2023 are as follows:
YearAmount
2024$191,352 
2025191,269 
2026191,058 
2027190,481 
2028189,224 
Thereafter1,722,259 
TOTAL LEASE PAYMENTS2,675,643 
Less: present value adjustment (953,791)
PRESENT VALUE OF TOTAL LEASE LIABILITIES1,721,852 
Less: current lease liabilities(82,526)
LONG-TERM OPERATING LEASE LIABILITIES$1,639,326 
Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company used its incremental borrowing rate based on the information available at the lease commencement date. As of December 31, 2023 and 2022, the weighted average remaining lease term is 14.9 years and 15.0 years and the weighted average discount rate used to determine the operating lease liabilities is 6.5% and 6.7%.
Subsequent to December 31, 2023, the Company amended an existing separate master lease arrangement to add two stand-alone skilled nursing facilities and extend the initial term to 20 years. This added a total of 241 operational skilled nursing beds operated by the Company's independent subsidiaries and the aggregate impact to the carrying value of lease liabilities and right-of-use assets related to the separate master lease agreement is estimated to be approximately $30,980.
121

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


Lessor Activities

The Company leases its owned real estate properties to third-party operators, of which 29 senior living operations are operated by Pennant. All of these properties are triple-net leases, whereby the respective tenants are responsible for all costs at the properties including: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The initial terms range from 14 to 16 years.

During 2023, the Company entered into a sublease agreement for three stand-alone skilled nursing operations with a third-party operator with an initial lease term of 18 years. Additionally, during the year, the Company entered into a lease agreement with a third-party operator for one campus operation with an initial lease term of 15 years.
Total rental income from all third-party sources for the years ended December 31, 2023, 2022 and 2021 is as follows:

Year Ended December 31,
202320222021
Pennant(1)
$15,048 $14,915 $14,073 
Other third-party(2)
6,236 1,842 1,912 
TOTAL$21,284 $16,757 $15,985 
(1) Pennant rental income includes variable rent such as property taxes of $1,296, $1,318, and $1,199 during the year ended December 31, 2023, 2022, and 2021. In addition, the number of senior living operations leased to and operated by Pennant was 29 during the year ended December 31, 2023 and decreased from 32 to 29 during the year ended December 31, 2022.
(2) Other third-party includes rental revenue associated with the Company's subleases to third parties of $3,897 for the year ended December 31, 2023. There was no sublease rental revenue for the years ended December 31, 2022 and 2021.
Future annual rental income for all third-party leases as of December 31, 2023 were as follows:
Year
Amount(1)
2024$22,191 
202521,565 
202621,269 
202721,176 
202821,151 
Thereafter129,586 
TOTAL$236,938 
(1) Annual rental income includes base rents and variable rental income pursuant to existing leases as of December 31, 2023.
18. DEFINED CONTRIBUTION PLANS

The Company has a 401(k) defined contribution plan (the 401(k) Plan), whereby eligible employees may contribute up to 90% of their annual basic earnings, subject to applicable annual Internal Revenue Code limits. Additionally, the 401(k) Plan provides for discretionary matching contributions (as defined in the 401(k) Plan) by the Company. The Company expensed matching contributions to the 401(k) Plan of $2,836, $2,418, and $2,121 during the years ended December 31, 2023, 2022 and 2021, respectively.

The Company has a non-qualified deferred compensation plan (DCP), whereby certain highly compensated employees who are otherwise ineligible to participate in the Company's 401(k) plan, may defer the receipt of a portion of their base compensation and, for certain employees, up to 100% of their eligible bonuses. Additionally, the DCP allows for the employee deferrals to be deposited into a rabbi trust and the funds are generally invested in individual variable life insurance contracts owned by the Company that are specifically designed to fund savings plans of this nature. The Company paid for related administrative costs, which were not significant during fiscal years 2023, 2022 and 2021.


122

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


As of the years ended December 31, 2023 and 2022, the Company accrued $49,201 and $33,017, respectively, as long term deferred compensation in other long term liabilities on the consolidated balance sheet. Cash surrender value of the contracts is based on investment funds that shadow the investment allocations specified by participants in the deferred compensation plan. Refer to Note 5, Fair Value Measurements for more information on the funds.

For the years ended December 31, 2023 and 2021, the Company recorded gains related to its DCP of $4,634 and $1,612, respectively, which are included in other income (expense), net, and recorded offsetting expenses of $4,887 and $1,758, respectively, which are allocated between cost of services and general and administrative expenses. For the year ended December 31, 2022, the Company recorded a loss related to its DCP of $4,188, which is included in other income (expense), net, and recorded an offsetting reduction in expense of $4,051, which is allocated between cost of services and general and administrative expenses.
19. SELF INSURANCE LIABILITIES

The following table represents activity in our insurance liabilities as of and for the years ended December 31, 2023 and 2022:
 
Amount
Balance January 1, 2022
$110,139 
Current year provisions115,793 
Claims paid and direct expenses(98,007)
Change in long-term insurance losses recoverable3,757 
Balance December 31, 2022
$131,682 
Current year provisions164,627 
Claims paid and direct expenses(135,799)
Change in long-term insurance losses recoverable5,400 
Balance December 31, 2023
$165,910 
 
 

Included in the table above are accrued general liability and professional malpractice liabilities on an undiscounted basis, net of anticipated insurance recoveries, of $117,744 and $87,000 as of December 31, 2023 and 2022, respectively. Included in long-term insurance losses recoverable as of December 31, 2023 and 2022 are anticipated insurance recoveries related to the Company's general and professional liability claims that are recorded on a gross rather than net basis in accordance with GAAP.
20. COMMITMENTS AND CONTINGENCIES
Indemnities From time to time, the Company enters into certain types of contracts that contingently require the Company to indemnify parties against third-party claims. These contracts primarily include (i) certain real estate leases, under which the Company may be required to indemnify property owners or prior facility operators for post-transfer environmental obligations or other liabilities and other claims arising from the Company’s use of the applicable premises, (ii) operations transfer agreements, in which the Company agrees to indemnify past operators of facilities the Company acquires against certain liabilities arising from the transfer of the operation and/or the operation thereof after the transfer to the Company's independent subsidiary, (iii) certain lending agreements, under which the Company may be required to indemnify the lender against various claims and liabilities, and (iv) certain agreements with the Company’s officers, directors and others, under which the Company may be required to indemnify such persons for liabilities based on the nature of their relationship to the Company. The terms of such obligations vary by contract and, in most instances, do not expressly state or include a specific or maximum dollar amount. Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted. Consequently, because no claims have been asserted, no liabilities have been recorded for these obligations on the Company’s consolidated balance sheets for any of the periods presented.
In connection with the spin-off in 2019, certain landlords required, in exchange for their consent to the transaction, that the Company's lease guarantees remain in place for a certain period of time following the transaction. These guarantees could result in significant additional liabilities and obligations for the Company if Pennant were to default on their obligations under their leases with respect to these properties.
123

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


Litigation and Regulatory Matters Laws and regulations governing Medicare and Medicaid programs are complex and subject to review and interpretation. Compliance with such laws and regulations is evaluated regularly, the results of which can be subject to future governmental review and interpretation, and can include significant regulatory action including fines, penalties, and exclusion from certain governmental programs. Included in these laws and regulations is monitoring performed by the Office of Civil Rights which covers the Health Insurance Portability and Accountability Act of 1996, the terms of which require healthcare providers (among other things) to safeguard the privacy and security of certain patient protected health information.
Both government and private pay sources have instituted cost-containment measures designed to limit payments made to providers of healthcare services, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect us.
The Company and its independent subsidiaries are party to various legal actions and administrative proceedings and are subject to various claims arising in the ordinary course of business, including claims that services provided to patients by the Company’s independent subsidiaries have resulted in injury or death, and claims related to employment and commercial matters. For example, in a four-week medical negligence trial in the State of Arizona, the jury returned a verdict against one of the Company’s independent subsidiaries in late November 2023. The Company intends to appeal the verdict. The Company has in the past appealed and have in some circumstances received returned decisions in its favor. Although the Company intends to vigorously defend against these claims and in general these types of claims and cases, there can be no assurance that the outcomes of these matters will not have a material adverse effect on operational results and financial condition. Additionally, in certain states in which the Company has or has had independent subsidiaries, insurance coverage for the risk of punitive damages arising from general and professional liability litigation may not be available due to state law and/or public policy prohibitions. There can be no assurance that the Company or its independent subsidiaries will not be liable for punitive damages awarded in litigation arising in states for which punitive damage insurance coverage is not available.
The skilled nursing and post-acute care industry is heavily regulated. As such, the Company and its independent subsidiaries are continuously subject to state and federal regulatory scrutiny, supervision and control in the ordinary course of business. Such regulatory scrutiny often includes inquiries, investigations, examinations, audits, site visits and surveys, some of which are non-routine. In addition to being subject to direct regulatory oversight from state and federal agencies, the skilled nursing and post-acute care industry is also subject to regulatory requirements which, if noncompliance is identified, could result in civil, administrative or criminal fines, penalties or restitutionary relief, and reimbursement; authorities could also seek the suspension or exclusion of the provider or individual from participation in their programs. The Company believes that there has been, and will continue to be, an increase in governmental investigations of post-acute providers, particularly in the area of Medicare/Medicaid false claims, as well as an increase in enforcement actions resulting from these investigations. Adverse determinations in civil legal proceedings or governmental investigations, whether currently asserted or arising in the future, could have a material adverse effect on the Company’s financial position, results of operations, and cash flows. Additionally, such proceedings and/or investigation can be a distraction to the business.
For example, in 2020, the U.S. House of Representatives Select Subcommittee on the Coronavirus Crisis launched a nation-wide investigation into the COVID-19 pandemic, which included the impact of the coronavirus on residents and employees in nursing homes. In June 2020, the Company and its independent subsidiaries received a document and information request from the House Select Subcommittee. The Company and its independent subsidiaries cooperated in responding to this inquiry. In July 2022 and thereafter, the Company and its independent subsidiaries received follow up requests for additional documents and information. The Company and its independent subsidiaries responded to these requests and cooperated with the House Select Subcommittee in connection with its investigation. On December 9, 2022, the House Select Subcommittee issued its final report summarizing its investigation and related recommendations designed "to strengthen the nation's ability to prevent and respond to public health and economic emergencies." According to the information provided by the House Select Subcommittee, the issuance of this report was the House Select Subcommittee's final official act in connection with their assigned responsibilities. Also, the Company, on behalf of its independent subsidiaries, received a Civil Investigative Demand (CID) from the U.S. Department of Justice (DOJ) in January of 2024 indicating that the DOJ is investigating the Company to determine whether it has caused the submission of claims to Medicare and Texas Medicaid for services which were unnecessary or otherwise not consistent with existing reimbursement requirements. The CID covers the period from January 1, 2016, to the present. As a general matter, the Company's independent subsidiaries maintain policies and procedures to promote compliance with all applicable Medicare and Medicaid requirements, including but not limited to those relating to the presentation of claims for reimbursement for services provided. The Company intends to fully cooperate with the DOJ in response to the CID. However, the Company cannot predict the outcome of the investigation or its potential impact on the consolidated financial statements.

124

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


In addition to the potential lawsuits and claims described above, the Company and its independent subsidiaries are also subject to potential lawsuits under the FCA and comparable state laws alleging submission of fraudulent claims for services to any healthcare program (such as Medicare or Medicaid) or other payor. A violation may provide the basis for exclusion from federally funded healthcare programs. Such exclusions could have a correlative negative impact on the Company’s financial performance. In addition, and pursuant to the qui tam or "whistleblower" provisions of the FCA, a private individual with knowledge of fraud or potential fraud may bring a claim on behalf of the federal government and receive a percentage of the federal government's recovery. Due to these whistleblower incentives, qui tam lawsuits have become more frequent.
For example, on May 31, 2018, the Company, on behalf of its independent subsidiaries, received a CID from the DOJ stating that it was investigating to determine whether there had been a violation of the False Claims Act (FCA) and/or the Anti-Kickback Statute (AKS) with respect to the relationships between certain of the Company’s independent subsidiaries and persons who serve or have served as medical directors. The Company fully cooperated with the DOJ and promptly responded to its requests for information. In April 2020, the Company was advised that the DOJ declined to intervene in any subsequent action filed in connection with the subject matter of this investigation. Despite the decision of the DOJ to decline to participate in litigation based on the subject matter of its previously issued CID, the involved qui tam relator moved forward with the complaint in December 2020. From that time until December 2023, and notwithstanding the Company's success in early pre-trial motions, the Company continued to incur legal defense costs and fees, including significant amounts as part of discovery in the fourth quarter of 2023. In early January 2024, the Company entered into mediation and on January 19, 2024, the parties agreed to settle the civil case for $48,000, subject to the review of the DOJ and other relevant government entities. The settlement does not include admissions on the part of the Company or its independent subsidiaries and the Company maintains that it has and continues to comply with all applicable State and Federal statutes (including but not limited to the FCA and the AKS).
In addition to the FCA, some states, including California, Arizona and Texas, have enacted similar whistleblower and false claims laws and regulations. Further, the Deficit Reduction Act of 2005 created incentives for states to enact anti-fraud legislation modeled on the FCA. As such, the Company and its independent subsidiaries could face increased scrutiny, potential liability and legal expenses and costs based on claims under state false claims acts in markets in which its independent subsidiaries do business.
In May 2009, Congress passed the FERA which made significant changes to the FCA and expanded the types of activities subject to prosecution and whistleblower liability. Following changes by FERA, health care providers face significant penalties for the knowing retention of government overpayments, even if no false claim was involved. Health care providers can now be liable for knowingly and improperly avoiding or decreasing an obligation to pay money or property to the government. This includes the retention of any government overpayment. The government can argue, therefore, that an FCA violation can occur without any affirmative fraudulent action or statement, as long as the action or statement is knowingly improper. In addition, FERA extended protections against retaliation for whistleblowers, including protections not only for employees, but also contractors and agents. Thus, an employment relationship is generally not required in order to qualify for protection against retaliation for whistleblowing.
Healthcare litigation (including class action litigation) is common and is filed based upon a wide variety of claims and theories, and the Company's independent subsidiaries are routinely subjected to varying types of claims, including class action "staffing" suits where the allegation is understaffing at the facility level. These class-action “staffing” suits have the potential to result in large jury verdicts and settlements and may result in significant legal costs. The Company expects the plaintiffs' bar to continue to be aggressive in their pursuit of these staffing and similar claims. While the Company has been able to settle these claims without an ongoing material adverse effect on its business, future claims could be brought that may materially affect its business, financial condition and results of operations.
Other claims and suits, including class actions, continue to be filed against the Company and other companies in its industry. The Company and its independent subsidiaries have been subjected to, and are currently involved in, class action litigation alleging violations (alone or in combination) of state and federal wage and hour laws as related to the alleged failure to pay wages, to timely provide and authorize meal and rest breaks, and related causes of action. The Company does not believe that the ultimate resolution of these actions will have an ongoing material adverse effect on the Company’s business, cash flows, financial condition or results of operations.

125

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


The Company and its independent subsidiaries are also subject to requests for information and investigations by other state and federal governmental entities (e.g., Offices of the Attorney General and Offices of the Inspector General). The Company cannot predict or provide any assurance as to the possible outcome of any inquiry, investigation or litigation. If any such inquiry, investigation or litigation were to proceed, and the Company and its independent subsidiaries are subjected to, alleged to be liable for, or agree to a settlement of, claims or obligations under federal Medicare statutes, the FCA, or similar state and federal statutes and related regulations, or if the Company or its independent subsidiaries are alleged or found to be liable on theories of general or professional negligence or wage and hour violations, the Company's business, financial condition and results of operations and cash flows could be materially and adversely affected and its stock price could be adversely impacted. Among other things, any settlement or litigation could involve the payment of substantial sums to settle any alleged violations and may also include the assumption of specific procedural and financial obligations by the Company or its independent subsidiaries under a Corporate Integrity Agreement and/or other such arrangement.
Cost-Containment Measures Both government and private pay sources have instituted cost-containment measures designed to limit payments made to providers of healthcare services, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect the Company.
Medicare Revenue Recoupments The Company's independent subsidiaries are subject to regulatory reviews relating to the provision of Medicare services, billings and potential overpayments as a result of Recovery Audit Contractors (RAC), Program Safeguard Contractors, and Medicaid Integrity Contractors programs (collectively referred to as Reviews). For several months during the COVID-19 pandemic, the Centers for Medicare and Medicaid Services (CMS) suspended its Targeted Probe and Educate (TPE) Program. Beginning in August 2020, CMS resumed TPE Program activity. If an operation fails a Review and/or subsequent Reviews, the operation could then be subject to extended review or an extrapolation of the identified error rate to billings in the same time period. The Company anticipates that these Reviews could increase in frequency in the future. As of December 31, 2023 and through the filing date of this report, 40 of the Company's independent subsidiaries had Reviews scheduled or in process.
In June 2023, CMS announced a new nationwide audit, the “SNF 5-Claim Probe & Educate Review”, in which the Medicare Administrative Contractors (MACs) will review five claims from each SNF to check for compliance. In implementing this SNF 5-Claim Probe & Educate Review, CMS acknowledged that the increase in observed improper payments from 2021 to 2022 may have arisen from a "misunderstanding" by SNFs about how to appropriately bill for claims of service after October 1, 2019. All facilities that are not undergoing TPE reviews, or have not recently passed a TPE review, will be subject to the nationwide audit. MACs will complete only one round of probe-and-educate for each SNF, rather than three rounds that typically occur in the TPE. Additionally, CMS's education for each SNF will be individualized and based on observed claim review errors, with rationales for denial explained to the SNF on a claim-by-claim basis. This program applies only to claims submitted after October 1, 2019, and will exclude claims containing a COVID-19 diagnosis.
Concentrations
Credit Risk — The Company has significant accounts receivable balances, the collectability of which is dependent on the availability of funds from certain governmental programs, primarily Medicare and Medicaid. These receivables represent the only significant concentration of credit risk for the Company. The Company does not believe there are significant credit risks associated with these governmental programs. The Company believes that an appropriate allowance has been recorded for the possibility of these receivables proving uncollectible, and continually monitors and adjusts these allowances as necessary.
The Company’s receivables from Medicare and Medicaid payor programs accounted for 53.4% and 56.3% of its total accounts receivable as of December 31, 2023 and 2022, respectively. Revenue from reimbursement under the Medicare and Medicaid programs accounted for 72.6%, 73.7% and 73.6% of the Company's revenue for the years ended December 31, 2023, 2022 and 2021, respectively.
Cash in Excess of FDIC Limits — The Company currently has bank deposits with financial institutions in the U.S. that exceed FDIC insurance limits. FDIC insurance provides protection for bank deposits up to $250. In addition, the Company has uninsured bank deposits with a financial institution outside the U.S. As of December 31, 2023, the Company's uninsured cash deposits are not material. All uninsured bank deposits are held at high quality credit institutions.

126

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)



21. COMMON STOCK REPURCHASE PROGRAM
On August 29, 2023, the Board of Directors approved a stock repurchase program pursuant to which the Company could repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months from September 1, 2023. Under this program, the Company is authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. The share repurchase program does not obligate us to acquire any specific number of shares. The Company did not purchase any shares pursuant to this stock repurchase program during the year ended December 31, 2023.
On July 28, 2022, the Board of Directors approved a stock repurchase program pursuant to which the Company could repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months from August 2, 2022. Under this program, the Company was authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. The share repurchase program did not obligate the Company to acquire any specific number of shares. The stock repurchase program expired on August 2, 2023 and is no longer in effect. The Company did not purchase any shares pursuant to this stock repurchase program.
In addition, the Company repurchased 404 shares of its common stock for $29,882 during the year ended December 31, 2022, and 132 shares of its common stock for $10,118 during the year ended December 31, 2021, related to two separate stock repurchase programs that are no longer in effect.
Item 9.     CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURES

    None.

Item 9A. CONTROLS AND PROCEDURES
(a) Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures

 
 
The Company maintains disclosure controls and procedures that are designed to ensure that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to its management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, our management recognized that any system of controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, as ours are designed to do, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

In connection with the preparation of this Annual Report on Form 10-K our management evaluated, with the participation of our Chief Executive Officer and our Chief Financial Officer, the effectiveness of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) promulgated under the Exchange Act. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Annual Report on Form 10-K.
(b) Management's Report on Internal Control over Financial Reporting

 
 
Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule 13a-15(f) promulgated under the Exchange Act. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control - Integrated Framework (2013). As a result of this assessment, management concluded that, as of December 31, 2023, our internal control over financial reporting was effective in providing reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

 
Our independent registered public accounting firm, Deloitte & Touche LLP, has audited the consolidated financial statements included in this Annual Report on Form 10-K and, as part of their audit, has issued an audit report, included herein, on the effectiveness of our internal control over financial reporting. Their report is set forth below.
(c) Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting, as defined in Rule 13a-15(f) promulgated under the Exchange Act, that occurred during the fourth quarter of fiscal 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
(d) Report of Independent Registered Public Accounting Firm

To the Stockholders and the Board of Directors of
The Ensign Group, Inc.
San Juan Capistrano, California

Opinion on Internal Control over Financial Reporting

We have audited the internal control over financial reporting of The Ensign Group, Inc. and subsidiaries (the “Company”) as of December 31, 2023, based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control — Integrated Framework (2013) issued by COSO.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December 31,2023, of the Company and our report dated February 1, 2024, expressed an unqualified opinion on those financial statements.

Basis for Opinion

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.


Definition and Limitations of Internal Control over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ DELOITTE & TOUCHE LLP

Costa Mesa, California February 1, 2024

Item 9B. OTHER INFORMATION

Rule 10b5-1 Plan Elections

Christopher R. Christensen, Co-founder, Executive Chairman and Chairman of the Board, entered into a Rule 10b5-1 trading arrangement on November 2, 2023 (the "Rule 10b5-1 Plan"). Mr. Christensen's 10b5-1 Plan provides for the potential sale of up to 110,700 shares of the Company's common stock between February 6, 2024 and December 31, 2024.

Beverly B. Wittekind, Vice President & General Counsel, entered into a Rule 10b5-1 trading arrangement on December 8, 2023 (the "Rule 10b5-1 Plan"). Ms. Wittekind's 10b5-1 Plan provides for the potential exercise of vested stock options and the associated sale of up to 10,000 shares of the Company's common stock between March 14, 2024 and October 31, 2024.

These Rule 10b5-1 trading arrangements were entered into during open trading windows and are intended to satisfy the affirmative defense conditions of Rule 10b5-1 (c) under the Securities Exchange Act of 1934, as amended, and the Company's policies regarding transactions in Company securities.

Item 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS
    
    Not applicable.

PART III.
Item 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

The information required by this Item is hereby incorporated by reference to our definitive proxy statement for the 2024 Annual Meeting of Stockholders.

We have adopted a code of ethics and business conduct that applies to all employees, including our Chief Executive Officer (our principal executive officer) and Chief Financial Officer (our principal financial officer), and employees of our subsidiaries, as well as each member of our Board of Directors. The code of ethics and business conduct is available on our website at www.ensigngroup.net under the Investor Relations section. The information contained in, or that can be accessed through, our website does not constitute a part of this Annual Report on Form 10-K. We intend to satisfy any disclosure requirement under Item 5.05 of Form 8-K regarding an amendment to, or waiver from, a provision of the code of ethics by posting such information on our website, at the address specified above.

127

Item 11. EXECUTIVE COMPENSATION

The information required by this Item is hereby incorporated by reference to our definitive proxy statement for the 2024 Annual Meeting of Stockholders.
Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The information required by this Item is hereby incorporated by reference to our definitive proxy statement for the 2024 Annual Meeting of Stockholders.
Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE

The information required by this Item is hereby incorporated by reference to our definitive proxy statement for the 2024 Annual Meeting of Stockholders.
Item 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

The information required by this Item is hereby incorporated by reference to our definitive proxy statement for the 2024 Annual Meeting of Stockholders. Our principal accountant is Deloitte & Touche LLP (PCAOB ID No.34).


128

PART IV.
Item 15. EXHIBITS, FINANCIAL STATEMENTS AND SCHEDULES

 
The following documents are filed as a part of this report:

 
(a) (1) Financial Statements:
The Financial Statements described in Part II. Item 8 and beginning on page 91 are filed as part of this Annual Report on Form 10-K.


 
(a) (3) Exhibits:  The following exhibits are filed or furnished with or incorporated by reference this Annual Report on Form 10-K.


Exhibit   File Exhibit Filing Filed
No.Exhibit Description*Form No. No. Date Herewith
Fifth Amended and Restated Certificate of Incorporation of The Ensign Group, Inc., filed with the Delaware Secretary of State on November 15, 200710-Q001-337573.1 12/21/2007 
Certificate of Amendment to the Fifth Amended and Restated Certificate of Incorporation of The Ensign Group, Inc., filed with the Delaware Secretary of State on February 4, 2020
10-K
001-337573.2 2/5/2020
Certificate of Amendment to the Fifth Amended and Restated Certificate of Incorporation of The Ensign Group, Inc., filed with the Delaware Secretary of State on May 18, 202310-Q001-337573.3 7/27/2023
Amended and Restated Bylaws of The Ensign Group, Inc.10-Q001-337573.2 12/21/2007 
Amendment to the Amended and Restated Bylaws, dated August 5, 20148-K001-337573.2 8/8/2014
Description of the Common stock of The Ensign Group, Inc.10-K001-337574.1 2/5/2020
Specimen common stock certificateS-1333-1428974.1 10/5/2007 
+The Ensign Group, Inc. 2007 Omnibus Incentive PlanS-1333-14289710.3 10/5/2007 
+Amendment to The Ensign Group, Inc. 2007 Omnibus Incentive Plan8-K001-3375799.2 7/28/2009 
+Form of 2007 Omnibus Incentive Plan Notice of Grant of Stock Options; and form of Non-Incentive Stock Option Award Terms and ConditionsS-1333-14279710.4 10/5/2007 
+Form of 2007 Omnibus Incentive Plan Restricted Stock AgreementS-1333-14289710.5 10/5/2007 
+Form of Indemnification Agreement entered into between The Ensign Group, Inc. and its directors, officers and certain key employeesS-1333-14289710.6 10/5/2007 
Form of Independent Consulting and Centralized Services Agreement between Ensign Facility Services, Inc. and certain of its subsidiariesS-1333-14289710.41 5/14/2007
Form of Health Insurance Benefit Agreement pursuant to which certain subsidiaries of The Ensign Group, Inc. participate in the Medicare programS-1333-14289710.48 10/19/2007
Form of Medi-Cal Provider Agreement pursuant to which certain subsidiaries of The Ensign Group, Inc. participate in the California Medicaid programS-1333-14289710.49 10/19/2007
Form of Provider Participation Agreement pursuant to which certain subsidiaries of The Ensign Group, Inc. participate in the Arizona Medicaid programS-1333-14289710.50 10/19/2007
129

Exhibit   File Exhibit Filing Filed
No.Exhibit Description*Form No. No. Date Herewith
Form of Contract to Provide Nursing Facility Services under the Texas Medical Assistance Program pursuant to which certain subsidiaries of The Ensign Group, Inc. participate in the Texas Medicaid programS-1333-14289710.51 10/19/2007
Form of Client Service Contract pursuant to which certain subsidiaries of The Ensign Group, Inc. participate in the Washington Medicaid programS-1333-14289710.52 10/19/2007
Form of Provider Agreement for Medicaid and UMAP pursuant to which certain subsidiaries of The Ensign Group, Inc. participate in the Utah Medicaid programS-1333-14289710.53 10/19/2007
Form of Medicaid Provider Agreement pursuant to which a subsidiary of The Ensign Group, Inc. participates in the Idaho Medicaid programS-1333-14289710.54 10/19/2007
Corporate Integrity Agreement between the Office of Inspector General of the Department of Health and Human Services and The Ensign Group, Inc. dated October 1, 2013.10-K001-3375710.74 2/13/2014
Settlement agreement dated October 1, 2013, entered into among the United States of America, acting through the United States Department of Justice and on behalf of the Office of Inspector General ("OIG-HHS") of the Department of Health and Human Services ("HHS") (collectively the "United States") and the Company.8-K001-3375710.75 5/8/2014
Form of Master Lease by and among certain subsidiaries of The Ensign Group, Inc. and certain subsidiaries of CareTrust REIT, Inc.8-K001-3375710.1 6/5/2014
Form of Guaranty of Master Lease by The Ensign Group, Inc. in favor of certain subsidiaries of CareTrust REIT, Inc., as landlords under the Master Leases8-K001-3375710.2 6/5/2014
Amended and Restated Credit Agreement as of February 5, 2016, by and among The Ensign Group, Inc., SunTrust Bank, now known as Truist, as administrative agent, and the lenders party thereto8-K001-3375710.1 2/8/2016
Second Amended Credit Agreement as of July 19, 2016, by and among The Ensign Group, Inc., SunTrust Bank, now known as Truist, as administrative agent, and the lenders party thereto8-K001-3375710.1 7/25/2016
The Ensign Group, Inc. 2017 Omnibus Incentive PlanDEF 14A001-33757A4/13/2017
Form of 2017 Omnibus Incentive Plan Notice of Grant of Stock Options; and form of Non-Incentive Stock Option Award Terms and Conditions10-K001-3375710.87 2/8/2018
Form of 2017 Omnibus Incentive Plan Restricted Stock Agreement10-K001-3375710.88 2/8/2018
Form of U.S. Department of Housing and Urban Development Healthcare Facility Note and schedule of individual subsidiary loans, by and among The Ensign Group, Inc.'s subsidiaries listed therein and U.S. Department of Housing and Urban Development8-K001-3375710.1 1/3/2018
Form of U.S. Department of Housing and Urban Development Security Instrument/Mortgage/Deed of Trust8-K001-3375710.2 1/3/2018
Third Amended and Restated Credit Agreement, dated as of October 1, 2019, by and among The Ensign Group, Inc., SunTrust Bank, now known as Truist, as administrative agent, and the lenders party thereto8-K001-3375710.4 10/1/2019
Lease Agreement, dated as of October 1, 2019, by and between The Ensign Group, Inc. and The Pennant Group, Inc.8-K001-3375710.5 10/1/2019
130

Exhibit   File Exhibit Filing Filed
No.Exhibit Description*Form No. No. Date Herewith
+The Ensign Services, Inc. Deferred Compensation Plan10-K001-3375710.1 2/3/2021
+First Amendment to The Ensign Services, Inc. Deferred Compensation Plan10-K001-3375710.2 2/3/2021
First Amendment to Third Amended and Restated Credit Agreement, dated as of February 8, 2022, by and among The Ensign Group, Inc., Standard Bearer Healthcare REIT, Inc., Truist Bank (as successor by merger to SunTrust Bank), as administrative agent, and the lenders party thereto10-K001-3375710.1 2/9/2022
Second Amendment to Third Amended and Restated Credit Agreement, dated as of April 8, 2022, by and among The Ensign Group, Inc. and Truist Bank, as administrative agent, and the lenders party thereto. 8-K001-3375710.1 4/12/2022
+The Ensign Group, Inc. 2022 Omnibus Incentive PlanDEF 14A001-33757A4/14/2022
+Form of 2022 Omnibus Incentive Plan Notice of Grant of Stock Options; and form of Non-Incentive Stock Option Award Terms and Conditions10-K001-3375710.32 2/2/2023
+Form of 2022 Omnibus Incentive Plan Restricted Stock Agreement10-K001-3375710.33 2/2/2023
Subsidiaries of The Ensign Group, Inc., as amendedX
Consent of Deloitte & Touche LLPX
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002X
Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002X
Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002X
Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002X
+Policy for Recovery of Erroneously Awarded Incentive-Based CompensationX
101 Interactive data file (furnished electronically herewith pursuant to Rule 406T of Regulations S-T)
104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
+Indicates management contract or compensatory plan.
*Documents not filed herewith are incorporated by reference to the prior filings identified in the table above.

Item 16.    FORM 10-K SUMMARY
Not applicable

131


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 THE ENSIGN GROUP, INC.
February 1, 2024BY: /s/ SUZANNE D. SNAPPER  
  Suzanne D. Snapper 
  
Chief Financial Officer, Executive Vice President and Director (Principal Financial Officer and Accounting Officer and Duly Authorized Officer) 

 
Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
 
SignatureTitle Date
/s/ BARRY R. PORTChief Executive Officer and Director (principal executive officer) February 1, 2024
Barry R. Port
/s/  SUZANNE D. SNAPPER
Chief Financial Officer, Executive Vice President and Director (principal financial officer and accounting officer and duly authorized officer) 
 February 1, 2024
Suzanne D. Snapper
/s/ CHRISTOPHER R. CHRISTENSENExecutive Chairman and Chairman of the Board February 1, 2024
Christopher R. Christensen
/s/  ANN S. BLOUINDirector February 1, 2024
Ann S. Blouin
/s/  SWATI B. ABBOTTDirector February 1, 2024
Swati B. Abbott
/s/  DAREN J. SHAWDirectorFebruary 1, 2024
Daren J. Shaw
/s/  JOHN O. AGWUNOBIDirector February 1, 2024
John O. Agwunobi
/s/  BARRY M. SMITHDirector February 1, 2024
Barry M. Smith

132
EX-21.1 2 ensg123123ex211.htm EX-21.1 Document

EXHIBIT 21.1
Legal NamePresident Company/ OwnerJurisdiction of Organization / Formation
2016 Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
2020 Health Holdings LLCThe Ensign Group, Inc.Nevada
2410 Stillhouse Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
24th Street Healthcare Associates LLCBandera Healthcare LLCNevada
Adipiscor, LLCThe Ensign Group, Inc.Nevada
Agape Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Alice Branch Healthcare LLCKeystone Care LLCNevada
Allen Creek Healthcare, Inc.Pennant Healthcare LLCNevada
Alvarado Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Amelia Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
American Lake Healthcare, Inc.Pennant Healthcare LLCNevada
American Pika Healthcare LLCPennant Healthcare LLCNevada
American Robin Healthcare, Inc.Keystone Care LLCNevada
Ann Arbor Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Anza Healthcare, Inc.Flagstone Healthcare South LLCNevada
Apache Trail Healthcare, Inc.Bandera Healthcare LLCNevada
Appaloosa Healthcare, Inc.Ellis Pointe Health Holdings LLCNevada
Apple Springs Healthcare, Inc.Keystone Care LLCNevada
Armstrong Healthcare, Inc.Keystone Care LLCNevada
Arris Health Services LLCCovalence Health Holdings LLCNevada
Arvada Healthcare, Inc.Endura Healthcare LLCNevada
Ascent Health Services LLCBridge Holding Company, LLCNevada
Atlantic Memorial Healthcare Associates, Inc.Flagstone Healthcare South LLCNevada
Avalanche Healthcare, Inc.Endura Healthcare LLCNevada
Avenues Healthcare, Inc.Milestone Healthcare LLCNevada
Avocado Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Aztec Healthcare, Inc.Bandera Healthcare LLCNevada
Bainbridge Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Bakorp, L.L.C.PMD Investments, LLCArizona
Bandera Healthcare LLCThe Ensign Group, Inc.Nevada
Banner Holdings LLCThe Ensign Group, Inc.Nevada
Bardwell Healthcare, Inc.Endura Healthcare LLCNevada
Baseline Healthcare, Inc.Endura Healthcare LLCNevada
Bayside Healthcare, Inc.Flagstone Healthcare South LLCNevada
Baywood Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Beacon Hill Healthcare, Inc.Pennant Healthcare LLCNevada
Beacon Purchasing LLCBanner Holdings LLCNevada
Bear Creek Senior Living, Inc.Pennant Healthcare LLCNevada
Bell Villa Care Associates LLCFlagstone Healthcare South LLCNevada
Bennett Healthcare LLCPennant Healthcare LLCNevada
Bernardo Heights Healthcare, Inc.Flagstone Healthcare South LLCNevada
Bertetti Healthcare, Inc.Keystone Care LLCNevada



Best SW Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Big Blue Healthcare LLCGateway Healthcare LLCNevada
Bijou Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Bijou Healthcare LLCEndura Healthcare LLCNevada
Black Ridge Canyon Healthcare LLCKeystone Care LLCNevada
Blackbird Senior Living, Inc.Bandera Healthcare LLCNevada
Bluebird Healthcare, Inc.Hopewell Healthcare LLCNevada
Bluebonnet Healthcare, Inc.Keystone Care LLCNevada
Bouverie Healthcare Services, Inc.Flagstone Healthcare North LLCNevada
Brackenridge Healthcare, Inc.Keystone Care LLCNevada
Bremer Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Brenwood Park Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Bridge Holding Company, LLCThe Ensign Group, Inc.Nevada
Bridger Health Holdings LLCThe Ensign Group, Inc.Nevada
Bridgestone Living LLCThe Ensign Group, Inc.Nevada
Broken Ridge Healthcare, Inc.Endura Healthcare LLCNevada
Brownsville Care Associates, Inc.Keystone Care LLCNevada
Bruce Neenah Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Buffalo Creek Healthcare LLCKeystone Care LLCNevada
Burch Creek Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
C Street Health Associates LLCFlagstone Healthcare Central LLCNevada
Calavaras Creek Healthcare LLCKeystone Care LLCNevada
Camarillo Community Care, Inc.Flagstone Healthcare Central LLCNevada
Canary Bend Healthcare LLCKeystone Care LLCNevada
Cane Island Healthcare, Inc.Keystone Care LLCNevada
Canyon Springs Senior Living, Inc.Bridgestone Living LLCNevada
Capstone Resources, Inc.Capstone Transportation Investments, Inc.Nevada
Capstone Transportation Investments, Inc.The Ensign Group, Inc.Nevada
Cardiff Healthcare, Inc.Milestone Healthcare LLCNevada
Cardinal Healthcare, Inc.Bandera Healthcare LLCNevada
Carolina Healthcare LLCHopewell Healthcare LLCNevada
Carrollton Heights Healthcare, Inc.Keystone Care LLCNevada
Castle Pines Healthcare LLCEndura Healthcare LLCNevada
Castle Rock Healthcare, Inc.Endura Healthcare LLCNevada
Cedar City Healthcare LLCMilestone Healthcare LLCNevada
Cedar Ridge Transportation LLCWoodland Transportation Holdings LLCNevada
Central Avenue Healthcare, Inc.Gateway Healthcare LLCNevada
Chaparral Healthcare, Inc.Keystone Care LLCNevada
Chateau Julia Healthcare, Inc.Endura Healthcare LLCNevada
Cherokee Healthcare, Inc.Gateway Healthcare LLCNevada
Cherry Hills Healthcare, Inc.Endura Healthcare LLCNevada
Chickadee Healthcare LLCKeystone Care LLCNevada
Circle Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
City Heights Health Associates LLCFlagstone Healthcare South LLCNevada
Claremont Foothills Health Associates LLCFlagstone Healthcare Central LLCNevada



Clark Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Claydelle Healthcare LLCFlagstone Healthcare South LLCNevada
Clear Skies Healthcare, Inc.Flagstone Healthcare South LLCNevada
Cloverleaf Healthcare LLCGateway Healthcare LLCNevada
Coalescence Health Services, LLCBridge Holding Company, LLCNevada
Coldwater Springs Healthcare, Inc.Bandera Healthcare LLCNevada
Columbia River Healthcare, Inc.Pennant Healthcare LLCNevada
Concord Avenue Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Congaree Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Conrad Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Constitution Road Healthcare, Inc.Endura Healthcare LLCNevada
Conway Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Copeland Healthcare, Inc.Keystone Care LLCNevada
Cornet Limited, Inc.The Ensign Group, Inc.Arizona
Costa Victoria Healthcare LLCFlagstone Healthcare South LLCNevada
Covalence Health Holdings LLCThe Ensign Group, Inc.Nevada
Cow Creek Healthcare, Inc.Keystone Care LLCNevada
Cress Creek Healthcare LLCPennant Healthcare LLCNevada
Crown Hill Healthcare LLCEndura Healthcare LLCNevada
Crystal Lake Healthcare, Inc.Keystone Care LLCNevada
Cypress Creek Healthcare, Inc.Keystone Care LLCNevada
D3T Enterprise, LLCWoodland Transportation Holdings LLCTexas
Da Vinci Healthcare, Inc.Bandera Healthcare LLCNevada
Daffodil Healthcare, Inc.Keystone Care LLCNevada
Dark Sky Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Davis Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
De Moisy Healthcare LLCMilestone Healthcare LLCNevada
Deer Creek Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Deergrass Healthcare, Inc.Flagstone Healthcare North LLCNevada
Desert Cove Healthcare, Inc.Bandera Healthcare LLCNevada
Desert Lily Healthcare, Inc.Bandera Healthcare LLCNevada
Desert Mallow Healthcare, Inc.Flagstone Healthcare South LLCNevada
Dessau Healthcare, Inc.Keystone Care LLCNevada
Devonshire Healthcare, Inc.Flagstone Healthcare South LLCNevada
Diamond Valley Health Holdings LLCThe Ensign Group, Inc.Nevada
Discovery Trail Healthcare, Inc.Gateway Healthcare LLCNevada
Dorothy Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Downey Community Care LLCFlagstone Healthcare South LLCNevada
Duck Creek Healthcare, Inc.Keystone Care LLCNevada
Dusk Healthcare, Inc.Flagstone Healthcare South LLCNevada
Eagle Harbor Healthcare LLCPennant Healthcare LLCNevada
East Mesa Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
East River Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Echo Canyon Healthcare, Inc.Bandera Healthcare LLCNevada
Eiffel Healthcare LLCKeystone Care LLCNevada



Elati Health Holdings LLCTurnberry Health Holdings LLCNevada
Elkhorn Health Holdings LLCThe Ensign Group, Inc.Nevada
Ellis Pointe Health Holdings LLCKeystone Care LLCNevada
Empirecare Health Associates LLCFlagstone Healthcare Central LLCNevada
Endura Healthcare LLCThe Ensign Group, Inc.Nevada
Ensidium Investments, LLCThe Ensign Group, Inc.Nevada
Ensign Cloverdale LLCFlagstone Healthcare North LLCNevada
Ensign Montgomery LLCFlagstone Healthcare North LLCNevada
Ensign Palm I LLCFlagstone Healthcare Central LLCNevada
Ensign Panorama LLCFlagstone Healthcare Central LLCNevada
Ensign Pleasanton LLCFlagstone Healthcare North LLCNevada
Ensign Sabino LLCBandera Healthcare LLCNevada
Ensign San Dimas LLCFlagstone Healthcare Central LLCNevada
Ensign Santa Rosa LLCFlagstone Healthcare North LLCNevada
Ensign Services, Inc.The Ensign Group, Inc.Nevada
Ensign Sonoma LLCFlagstone Healthcare North LLCNevada
Ensign Whittier East LLCFlagstone Healthcare South LLCNevada
Ensign Whittier West LLCFlagstone Healthcare South LLCNevada
Ensign Willits LLCFlagstone Healthcare North LLCNevada
Fawn Meadows Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Flagstone Healthcare Central LLCThe Ensign Group, Inc.Nevada
Flagstone Healthcare North LLCThe Ensign Group, Inc.Nevada
Flagstone Healthcare South LLCThe Ensign Group, Inc.Nevada
Flintrock Falls Healthcare, Inc.Keystone Care LLCNevada
Floyde Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Forney Lake Healthcare, Inc.Keystone Care LLCNevada
Forrest Hill Healthcare LLCKeystone Care LLCNevada
Fossil Creek Healthcare, Inc.Keystone Care LLCNevada
Founders Holdings LLCThe Ensign Group, Inc.Nevada
Founders RX LLCFounders Holdings LLCNevada
Fox Sparrow Healthcare, Inc.Keystone Care LLCNevada
Franklin Avenue Healthcare, Inc.Endura Healthcare LLCNevada
Franklin Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Fullerton Healthcare, Inc.Flagstone Healthcare South LLCNevada
Garwood Health Holdings II LLCStandard Bearer Healthcare OP, LPNevada
Gate Three Healthcare LLCFlagstone Healthcare South LLCNevada
Gateway Healthcare LLCThe Ensign Group, Inc.Nevada
Gem Healthcare, Inc.Pennant Healthcare LLCNevada
Getzendaner Healthcare, Inc.Keystone Care LLCNevada
Glendale Healthcare Associates LLCBandera Healthcare LLCNevada
Glimmer Healthcare, Inc.Flagstone Healthcare South LLCNevada
Golden Eagle Senior Living, Inc.Flagstone Healthcare Central LLCNevada
Golden Oaks Healthcare, Inc.Gateway Healthcare LLCNevada
Golden Years Program, Inc.Milestone Healthcare LLCNevada
Goldenstar Healthcare, Inc.Flagstone Healthcare Central LLCNevada



Goldfield Mountain Healthcare LLCBandera Healthcare LLCNevada
Good Hope Healthcare, Inc.Gateway Healthcare LLCNevada
Gooding Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Graceland Senior Living, Inc.Gateway Healthcare LLCNevada
Grand Avenue Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Grand Villa PHX, Inc.Keystone Care LLCNevada
Grassland Healthcare and Rehabilitation, Inc.Keystone Care LLCNevada
Green Bay Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Green Heron Senior Living, Inc.Bandera Healthcare LLCNevada
Green Mountain Healthcare LLCKeystone Care LLCNevada
Green Mountain Personalized Care, Inc.Keystone Care LLCNevada
Green Valley Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Gypsum Creek Healthcare, Inc.Gateway Healthcare LLCNevada
Harlan Heights Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Harlingen Healthcare, Inc.Keystone Care LLCNevada
Harmony Health Holdings LLCThe Ensign Group, Inc.Nevada
Harrison Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Hartwell Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
HB Healthcare Associates LLCFlagstone Healthcare South LLCNevada
Healthlift Medical Transportation, Inc.Capstone Transportation Investments, Inc.Nevada
Heartland Health Holdings II LLCStandard Bearer Healthcare OP, LPNevada
Highcross Healthcare, Inc.Endura Healthcare LLCNevada
Highland Healthcare LLCBandera Healthcare LLCNevada
Higley Healthcare, Inc.Bandera Healthcare LLCNevada
Hill Country Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Holford Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Hollyleaf Healthcare, Inc.Flagstone Healthcare South LLCNevada
Holman Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Homedale Healthcare, Inc.Pennant Healthcare LLCNevada
Hopewell Healthcare LLCThe Ensign Group, Inc.Nevada
Hoquiam Healthcare, Inc.Pennant Healthcare LLCNevada
Hub City Healthcare LLCKeystone Care LLCNevada
Hueneme Healthcare, Inc.Milestone Healthcare LLCNevada
Huntington Beach Convalescent Hospital Asset LLCLongboard Health Holdings LLCDelaware
Hutchins Healthcare, Inc.Keystone Care LLCNevada
Hyrum Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Immediate Clinic Seattle, Inc.Immediate Clinic Healthcare, Inc.Nevada
Ionic Health Services LLCCovalence Health Holdings LLCCalifornia
Iron Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Iron Horse Healthcare LLCGateway Healthcare LLCNevada
Jack Finney Healthcare, Inc.Keystone Care LLCNevada
JARR Transportation Group, Inc.Capstone Transportation Investments, Inc.Arizona
Jefferson Healthcare LLCFlagstone Healthcare South LLCNevada
Jordan Health Associates, Inc.Milestone Healthcare LLCNevada



JRT Healthcare, Inc.Pennant Healthcare LLCNevada
Kenosha Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Kettle Creek Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Keystone Care LLCThe Ensign Group, Inc.Nevada
Kingston Falls Healthcare LLCHopewell Healthcare LLCNevada
Klement Healthcare, Inc.Keystone Care LLCNevada
Knight Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Krypton Health Services LLCCovalence Health Holdings LLCNevada
La Jolla Skilled LLCFlagstone Healthcare South LLCNevada
La Veta Healthcare, Inc.Flagstone Healthcare South LLCNevada
Lake Cassidy Health Holdings LLCThe Ensign Group, Inc.Nevada
Lake Island Healthcare LLCKeystone Care LLCNevada
Lake Pleasant Healthcare, Inc.Bandera Healthcare LLCNevada
Lake Pointe Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Lake Washington Healthcare, Inc.Pennant Healthcare LLCNevada
Lakewood Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Lakewood Healthcare, Inc.Endura Healthcare LLCNevada
Ledbetter Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Legend Lake Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Lemon Grove Health Associates LLCFlagstone Healthcare South LLCNevada
Lightning Healthcare, Inc.Flagstone Healthcare North LLCNevada
Lil’ Tots Day Program, Inc.Milestone Healthcare LLCNevada
Lilly Road Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Lindahl Healthcare, Inc.Gateway Healthcare LLCNevada
Link Support Services, Inc.Cornet Limited, Inc.Nevada
Little Blue Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Little Mountain Healthcare, Inc.Pennant Healthcare LLCNevada
Little Village Day Care, Inc.Keystone Care LLCNevada
Littleton Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Livingston Care Associates, Inc.Keystone Care LLCNevada
Lone Pine Ridge Healthcare, Inc.Milestone Healthcare LLCNevada
Lone Star MTC, Inc.Capstone Transportation Investments, Inc.Nevada
Longboard Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Lookout Mountain Healthcare LLCBandera Healthcare LLCNevada
Lowell Healthcare, Inc.Endura Healthcare LLCNevada
Lucky Peak Healthcare, Inc.Pennant Healthcare LLCNevada
Ludden Healthcare LLCBandera Healthcare LLCNevada
Lynnwood Health Services, Inc.Pennant Healthcare LLCNevada
Madison Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Madison Pointe Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Magic Valley Senior Living, Inc.Bridgestone Living LLCNevada
Manitowoc Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Manor Park Healthcare LLCPennant Healthcare LLCNevada
Manzanita Healthcare, Inc.Flagstone Healthcare South LLCNevada
Maple Hills Healthcare, Inc.Gateway Healthcare LLCNevada



Marguerite Holdings LLCThe Ensign Group, Inc.Nevada
Mariano Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Marion Health Associates, Inc.Endura Healthcare LLCNevada
Marshall Lake Healthcare LLCKeystone Care LLCNevada
Mason Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
MavStar Medical Transportation, Inc.Capstone Transportation Investments, Inc.Nevada
McAllen Care Associates, Inc.Keystone Care LLCNevada
McAllen Community Healthcare LLCKeystone Care LLCNevada
McCall Healthcare LLCPennant Healthcare LLCNevada
McFarland Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
MedStar Medical Transportation, LLCJARR Transporation Group, Inc.Arizona
Menomonee Health Holdings LLCThe Ensign Group, Inc.Nevada
Meridian Healthcare LLCPennant Healthcare LLCNevada
Midland Nampa Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Midland Nampa Healthcare LLCPennant Healthcare LLCNevada
Midnight Healthcare, Inc.Flagstone Healthcare South LLCNevada
Milestone Healthcare LLCThe Ensign Group, Inc.Nevada
Mission Trails Healthcare LLCFlagstone Healthcare South LLCNevada
Misty Willow Healthcare, Inc.Keystone Care LLCNevada
Mockingbird Healthcare, Inc.Keystone Care LLCNevada
Monroe Healthcare, Inc.Gateway Healthcare LLCNevada
Montebella Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Moon Cove Healthcare, Inc.Pennant Healthcare LLCNevada
Moonflower Healthcare, Inc.Keystone Care LLCNevada
Moonrise Healthcare, Inc.Flagstone Healthcare South LLCNevada
Morning Glory Healthcare, Inc.Flagstone Healthcare Central LLCNevada
Mount Lemmon Healthcare LLCBandera Healthcare LLCNevada
Mountain View Retirement, Inc.Milestone Healthcare LLCNevada
Mountain Violet Healthcare, Inc.Flagstone Healthcare North LLCNevada
Murphy Health Holdings II LLCStandard Bearer Healthcare OP, LPNevada
Mussel Rock Healthcare, Inc.Flagstone Healthcare North LLCNevada
Mustang Ridge Healthcare, Inc.Keystone Care LLCNevada
Myrtle Springs Healthcare, Inc.Ellis Pointe Health Holdings LLCNevada
Nautilus Healthcare, Inc.Flagstone Healthcare South LLCNevada
NB Brown Rock Healthcare, Inc.Keystone Care LLCNevada
New England Medical Transportation, Inc.Capstone Transportation Investments, Inc.Nevada
Nightfall Healthcare, Inc.Flagstone Healthcare South LLCNevada
Nobel Health Properties LLCStandard Bearer Healthcare OP, LPNevada
Nordic Valley Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
North Mountain Healthcare LLCBandera Healthcare LLCNevada
North Parkway Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
North Parkway Healthcare LLCMilestone Healthcare LLCNevada
Northern Oaks Healthcare, Inc.Keystone Care LLCNevada
Oak Point Healthcare, Inc.Keystone Care LLCNevada
Oceanview Healthcare, Inc.Keystone Care LLCNevada



Ocotillo Healthcare, Inc.Bandera Healthcare LLCNevada
Old Pueblo Medical Transportation, Inc.Capstone Transportation Investments, Inc.Nevada
Olmstead Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Olympic Marmot Healthcare LLCPennant Healthcare LLCNevada
Olympus Health, Inc.Milestone Healthcare LLCNevada
Orange Grove Healthcare, Inc.Hopewell Healthcare LLCNevada
Orchard Bay Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Ottawa Healthcare LLCGateway Healthcare LLCNevada
Pacific Mobile Diagnostics Holdings (CA), LLCPMD Investments, LLCNevada
Padua Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Palm Valley Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Panorama Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Park Waverly Healthcare LLCBandera Healthcare LLCNevada
Parkside Healthcare, Inc.Flagstone Healthcare South LLCNevada
Pennant Healthcare LLCThe Ensign Group, Inc.Nevada
Peoria Healthcare LLCBandera Healthcare LLCNevada
Percheron Healthcare, Inc.Ellis Pointe Health Holdings LLCNevada
Permunitum LLCThe Ensign Group, Inc.Nevada
Perris Hills Healthcare LLCFlagstone Healthcare Central LLCNevada
Pikes Peak Healthcare, Inc.Endura Healthcare LLCNevada
Pine Forest Healthcare, Inc.Flagstone Healthcare South LLCNevada
Piney Lufkin Healthcare, Inc.Keystone Care LLCNevada
Pleasant Run Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
PMD Investments, LLCThe Ensign Group, Inc.Nevada
PMD X-Ray Services, LLCBakorp L.L.C.Nevada
PMDAZ, LLCBakorp L.L.C.Nevada
PMDCO, LLCBakorp L.L.C.Nevada
PMDTC, LLCBakorp L.L.C.Nevada
PMDUT, LLCBakorp L.L.C.Nevada
Pocatello Health Services, Inc.Pennant Healthcare LLCNevada
Pointe Meadow Healthcare, Inc.Milestone Healthcare LLCNevada
Pomerado Ranch Healthcare LLCKeystone Care LLCNevada
Ponderosa Pine Healthcare, Inc.Bandera Healthcare LLCNevada
Portside Healthcare, Inc.Flagstone Healthcare South LLCNevada
Powderhorn Mountain Healthcare LLCKeystone Care LLCNevada
Powers Park Healthcare, Inc.Flagstone Healthcare Central LLCNevada
Prairie Creek Healthcare, Inc.Gateway Healthcare LLCNevada
Prairie Ridge Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Presidio Health Associates LLCBandera Healthcare LLCNevada
Price Healthcare, Inc.Milestone Healthcare LLCNevada
Primrose Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Primrose Healthcare, Inc.Keystone Care LLCNevada
Quail Creek Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Queenston Healthcare, Inc.Keystone Care LLCNevada



Quorum Services, Inc.The Ensign Group, Inc.Nevada
Quorum Ventures, Inc.The Ensign Group, Inc.Nevada
Racine Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Radiant Hills Health Associates LLCBandera Healthcare LLCNevada
Railroad Crossing Healthcare, Inc.Hopewell Healthcare LLCNevada
Ramon Healthcare Associates LLCFlagstone Healthcare Central LLCNevada
Randolph Healthcare, Inc.Gateway Healthcare LLCNevada
Raven Lake Healthcare, Inc.Rocky Top Healthcare LLCNevada
Red Cliffs Healthcare, Inc.Milestone Healthcare LLCNevada
Red Mountain Healthcare LLCBandera Healthcare LLCNevada
Redbrook Healthcare Associates LLCFlagstone Healthcare Central LLCNevada
RenewCare of Scottsdale, Inc.Bandera Healthcare LLCNevada
Respire Health Services LLCCovalence Health Holdings LLCNevada
Richmond Senior Services, Inc.Keystone Care LLCNevada
Rio Hondo Healthcare, Inc.Flagstone Healthcare South LLCNevada
Rio Mesa Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
River Otter Healthcare LLCPennant Healthcare LLCNevada
Riverside Healthcare, Inc.Gateway Healthcare LLCNevada
Riverview Healthcare, Inc.Milestone Healthcare LLCNevada
Riverview Village Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Riverwalk Healthcare, Inc.Keystone Care LLCNevada
Roadrunner Healthcare, Inc.Keystone Care LLCNevada
Rock Canyon Healthcare LLCEndura Healthcare LLCNevada
Rock Hill Healthcare LLCHopewell Healthcare LLCNevada
Rocky Mountain Medical Transportation Company, Inc.Capstone Transportation Investments, Inc.Nevada
Rocky Top Healthcare LLCThe Ensign Group, Inc.Nevada
Rose Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Rose Park Healthcare Associates, Inc.Flagstone Healthcare South LLCNevada
Rosemead Health Holdings LLCThe Ensign Group, Inc.Nevada
Rowlett Creek Healthcare LLCKeystone Care LLCNevada
Royal View Healthcare LLCBandera Healthcare LLCNevada
Sage Meadow Healthcare, Inc.Keystone Care LLCNevada
Sage Terrace Healthcare LLCKeystone Care LLCNevada
Sagebrush Healthcare, Inc.Flagstone Healthcare North LLCNevada
Salado Creek Senior Care, Inc.Keystone Care LLCNevada
Saltwater Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Sand Hollow Healthcare LLCMilestone Healthcare LLCNevada
Sandpiper Senior Living LLCFlagstone Healthcare South LLCNevada
Santa Catalina Healthcare, Inc.Flagstone Healthcare South LLCNevada
Santa Maria Healthcare, Inc.Flagstone Healthcare Central LLCNevada
Santiago Healthcare LLCKeystone Care LLCNevada
Santiago Personal Care, Inc.Keystone Care LLCNevada
Savoy Healthcare, Inc.Keystone Care LLCNevada
Sawtooth Healthcare, Inc.Pennant Healthcare LLCNevada



Scandinavian Court Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Second West Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Sedgewood Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Sentinel Peak Healthcare LLCBandera Healthcare LLCNevada
Sheboygan Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Sherman Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Sherwood Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Sidewinder Healthcare, Inc.Endura Healthcare LLCNevada
Siena Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Somers Kenosha Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Songbird Healthcare, Inc.Keystone Care LLCNevada
South C Health Holdings LLCThe Ensign Group, Inc.Nevada
South Valley Healthcare, Inc.Milestone Healthcare LLCNevada
Southern Charm Healthcare LLCHopewell Healthcare LLCNevada
Southern Oaks Healthcare LLCKeystone Care LLCNevada
Southland Management LLCFlagstone Healthcare South LLCNevada
Southside Healthcare, Inc.Gateway Healthcare LLCNevada
Stagecoach Healthcare, Inc.Flagstone Healthcare Central LLCNevada
Standard Bearer Healthcare Merger Sub, LLCStandard Bearer Healthcare OP, LPMaryland
Standard Bearer Healthcare OP GP, LLCStandard Bearer Healthcare REIT, Inc.Delaware
Standard Bearer Healthcare OP, LP
Standard Bearer Healthcare REIT, Inc.;
Standard Bearer Healthcare OP GP, LLC
Delaware
Standard Bearer Healthcare REIT, Inc.The Ensign Group, Inc.Maryland
Standardbearer Insurance Company, Inc.The Ensign Group, Inc.Arizona
Stanton Lake Healthcare, Inc.Gateway Healthcare LLCNevada
Starburst Healthcare, Inc.Flagstone Healthcare South LLCNevada
Starling Healthcare, Inc.Hopewell Healthcare LLCNevada
Statler Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Steelhead Healthcare, Inc.Pennant Healthcare LLCNevada
Stevens Point Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Stoney Hill Healthcare LLCHopewell Healthcare LLCNevada
Storm Healthcare, Inc.Flagstone Healthcare North LLCNevada
Stoughton Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Streetcar Healthcare, Inc.Gateway Healthcare LLCNevada
Subacute Facility Services, Inc.Gateway Healthcare LLCNevada
Successor Healthcare LLCMilestone Healthcare LLCNevada
Summit Healthcare, Inc.The Ensign Group, Inc.Nevada
Summit Trail Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Sunflower Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Sungazer Healthcare, Inc.Flagstone Healthcare South LLCNevada
Sunland Health Associates LLCBandera Healthcare LLCNevada
Sunny Acres Health Holdings LLCThe Ensign Group, Inc.Nevada
Sunny Acres Healthcare LLCEndura Healthcare LLCNevada
Sunrise Mountain Healthcare LLCBandera Healthcare LLCNevada
Sweet Bay Healthcare LLCKeystone Care LLCNevada



Terrace Court Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
The Ensign Group, Inc.N/ADelaware
TheraTroopers CA, Inc.Theratroopers Holdings LLCNevada
Theratroopers Holdings LLCThe Ensign Group, Inc.Nevada
TheraTroopers, Inc.Theratroopers Holdings LLCNevada
Thompson Peak Healthcare LLCBandera Healthcare LLCNevada
Thorntree Healthcare, Inc.Keystone Care LLCNevada
Thunder Healthcare, Inc.Flagstone Healthcare North LLCNevada
Thunderbird Health Holdings LLCThe Ensign Group, Inc.Nevada
Top City Healthcare LLCGateway Healthcare LLCNevada
Tortolita Healthcare, Inc.Bandera Healthcare LLCNevada
Towers Park Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Towers Park Healthcare LLCKeystone Care LLCNevada
Towers Park Personal Care, Inc.Keystone Care LLCNevada
Town East Healthcare, Inc.Keystone Care LLCNevada
Tradewind Healthcare, Inc.Keystone Care LLCNevada
Treasure Hills Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Treasure Valley Senior Living, Inc.Bridgestone Living LLCNevada
Treaty Healthcare, Inc.Keystone Care LLCNevada
Tree City Healthcare, Inc.Keystone Care LLCNevada
Truckee Meadows Healthcare, Inc.Milestone Healthcare LLCNevada
Tulip Healthcare LLCGateway Healthcare LLCNevada
Turnberry Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Tustin Hills Healthcare, Inc.Flagstone Healthcare South LLCNevada
Two Rivers Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Two Trails Healthcare, Inc.Gateway Healthcare LLCNevada
Union Hill Healthcare, Inc.Pennant Healthcare LLCNevada
Upland Community Care, Inc.Flagstone Healthcare Central LLCNevada
Valley Ranch Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Valley View Health Services, Inc.Pennant Healthcare LLCNevada
Velda Rose Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Victoria Ventura Healthcare LLCFlagstone Healthcare Central LLCNevada
Victory Medical Transportation, Inc.Capstone Transportation Investments, Inc.Nevada
Viewpoint Healthcare LLCBandera Healthcare LLCNevada
Vista Woods Health Associates LLCFlagstone Healthcare South LLCNevada
Wallsville Healthcare LLCKeystone Care LLCNevada
Washington Heights Healthcare LLCMilestone Healthcare LLCNevada
Waterfall Canyon Healthcare LLCMilestone Healthcare LLCNevada
Watson Woods Healthcare, Inc.Bandera Healthcare LLCNevada
Wellington Healthcare, Inc.Keystone Care LLCNevada
West 5600 Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
West 5600 Healthcare LLCMilestone Healthcare LLCNevada
West Ashby Healthcare, Inc.Keystone Care LLCNevada
West Escondido Healthcare LLCFlagstone Healthcare South LLCNevada
West Meadow Health Holdings II LLCStandard Bearer Healthcare OP, LPNevada



West Olive Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
West Owyhee Health Holdings LLCThe Ensign Group, Inc.Nevada
West Pine Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
West Van Buren Healthcare, Inc.Endura Healthcare LLCNevada
Western Canal Healthcare LLCBandera Healthcare LLCNevada
Western Edge Health Holdings LLCTurnberry Health Holdings LLCNevada
Whispering Pines Healthcare, Inc.Keystone Care LLCNevada
Wildcreek Healthcare, Inc.Pennant Healthcare LLCNevada
Wildwood Healthcare, Inc.Pennant Healthcare LLCNevada
Willard Peak Group Home, Inc.Milestone Healthcare LLCNevada
Willow Canyon Healthcare LLCBandera Healthcare LLCNevada
Willow Springs Creek Healthcare, Inc.Keystone Care LLCNevada
Windsor Lake Healthcare, Inc.Endura Healthcare LLCNevada
Wisconsin Rapids Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Wolf Point Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Wolf River Healthcare LLCGateway Healthcare LLCNevada
Wood Bayou Healthcare, Inc.Keystone Care LLCNevada
Woodard Creek Healthcare LLCPennant Healthcare LLCNevada
Woodland Transportation Holdings LLCCapstone Transportation Investments, Inc.Nevada
Yellow Rose Health Holdings LLCThe Ensign Group, Inc.Nevada
Yellowstar Healthcare LLCKeystone Care LLCNevada
Youngtown Health, Inc.Bandera Healthcare LLCNevada
Yucca Flats Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Zion Healthcare, Inc.Milestone Healthcare LLCNevada


EX-23.1 3 ensg123123ex231.htm EX-23.1 Document

EXHIBIT 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM


We consent to the incorporation by reference in Registration Statement No. 333‐268018 on Form S‐8 of our reports dated February 1, 2024, relating to the financial statements of The Ensign Group, Inc. and the effectiveness of The Ensign Group, Inc.’s internal control over financial reporting, appearing in this Annual Report on Form 10‐K for the year ended December 31, 2023.

/s/ DELOITTE & TOUCHE LLP

Costa Mesa, California
February 1, 2024


EX-31.1 4 ensgq42023ex311.htm EX-31.1 Document

EXHIBIT 31.1

I, Barry R. Port, certify that:

1.I have reviewed this Annual Report on Form 10-K of The Ensign Group, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 1, 2024
     
 /s/ Barry R. Port   
 Name:  Barry R. Port 
 Title:  Chief Executive Officer and Director (principal executive officer) 



EX-31.2 5 ensgq42023ex312.htm EX-31.2 Document

EXHIBIT 31.2

I, Suzanne D. Snapper, certify that:

1.I have reviewed this Annual Report on Form 10-K of The Ensign Group, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date: February 1, 2024
    
 /s/ Suzanne D. Snapper   
 Name: Suzanne D. Snapper  
 Title:  Chief Financial Officer, Executive Vice President and Director (principal financial officer and accounting officer and duly authorized officer) 


EX-32.1 6 ensgq42023ex321.htm EX-32.1 Document

EXHIBIT 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. §1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of The Ensign Group, Inc. (the Company) on Form 10-K for the period ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Barry R. Port, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 1 The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d))); and
 
 2 The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
     
 /s/ Barry R. Port 
 Name:  Barry R. Port  
 Title:  
Chief Executive Officer and Director (principal executive officer) 
 
 
 
February 1, 2024
 

A signed original of this written statement required by 18 U.S.C. Section 1350 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.


EX-32.2 7 ensgq42023ex322.htm EX-32.2 Document

EXHIBIT 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. §1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of The Ensign Group, Inc. (the Company) on Form 10-K for the period ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Suzanne D. Snapper, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 1 The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d))); and
 
 2 The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
     
 /s/ Suzanne D. Snapper   
 Name:  Suzanne D. Snapper  
 Title:  Chief Financial Officer, Executive Vice President and Director (principal financial officer and accounting officer and duly authorized officer) 
 
 
February 1, 2024
 

A signed original of this written statement required by 18 U.S.C. Section 1350 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 


EX-97.0 8 ensg123123ex97.htm EX-97.0 Document

THE ENSIGN GROUP, INC.
POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED INCENTIVE-BASED COMPENSATION

(Effective November 2, 2023)

1.Purpose. The Ensign Group, Inc. (the “Company”) is adopting this policy to provide for the Company’s criteria and process of recovering certain incentive-based compensation erroneously awarded to or earned or received by certain officers under certain circumstances.

This policy is designed to comply with, and shall be interpreted to be consistent with, Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, as codified in Section 10D of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Rule 10D-1 promulgated under the Exchange Act (“Rule 10D-1”) and Listing Rule 5608 of the corporate governance rules (the “Listing Standards”) of The Nasdaq Stock Market (“Nasdaq”). Unless otherwise defined in this policy, capitalized terms shall have the meaning ascribed to such terms in Section 2.

2.Definitions. As used in this policy, the following capitalized terms shall have the meanings set forth below.

a.Accounting Restatement” means an accounting restatement of the Company’s financial statements due to the Company’s material noncompliance with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements (i.e., a “Big R” restatement), or to correct an error that is not material to the previously issued financial statements, but that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (i.e., a “little r” restatement).

b.Accounting Restatement Date” means the earlier to occur of (i) the date the Board, a committee of the Board, or the officer or officers of the Company authorized to take such action if the Board’s action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement and (ii) the date a court, regulator, or other legally authorized body directs the Company to prepare an Accounting Restatement.

c.Applicable Period” means, with respect to any Accounting Restatement, the three completed fiscal years immediately preceding the Accounting Restatement Date, as well as any transition period (that results from a change in the Company’s fiscal year) within or immediately following those three completed fiscal years (except that a transition period that comprises a period of at least nine months shall count as a completed fiscal year).

d.Board” means the board of directors of the Company.

e.Code” means the U.S. Internal Revenue Code of 1986, as amended. Any reference to a section of the Code or regulation thereunder includes such section or regulation, any valid regulation or other official guidance promulgated under such section, and any comparable provision of any future legislation or regulation amending, supplementing, or superseding such section or regulation.




f.Covered Executive Officer” means an individual who is currently or previously served as the Company’s principal executive officer, principal financial officer, principal accounting officer (or, if there is no such accounting officer, the controller), vice president of the Company in charge of a principal business unit, division, or function (such as sales, administration, or finance), an officer who performs (or performed) a policy-making function, or any other person who performs (or performed) similar policy-making functions for the Company or is otherwise determined to be an executive officer of the Company pursuant to Item 401(b) of Regulation S-K. An executive officer of the Company’s parent or subsidiary is deemed a “Covered Executive Officer” if the executive officer performs (or performed) such policy-making functions for the Company.

g.Erroneously Awarded Compensation” means, in the event of an Accounting Restatement, the amount of Incentive-Based Compensation previously received that exceeds the amount of Incentive-Based Compensation that otherwise would have been received had it been determined based on the restated amounts in such Accounting Restatement, and must be computed without regard to any taxes paid by the relevant Covered Executive Officer; provided, however, that for Incentive-Based Compensation based on stock price or total stockholder return, where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement: (i) the amount of Erroneously Awarded Compensation must be based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or total stockholder return upon which the Incentive-Based Compensation was received and (ii) the Company must maintain documentation of the determination of that reasonable estimate and provide such documentation to Nasdaq.

h.Financial Reporting Measure” means any measure that is determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements and any measure that is derived wholly or in part from such measure. A Financial Reporting Measure is not required to be presented within the Company’s financial statements or included in a filing with the U.S. Securities and Exchange Commission to qualify as a “Financial Reporting Measure.”

i.Incentive-Based Compensation” means any compensation (including, annual cash and stock award bonuses and other short- and long-term cash incentives) that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure. The Company’s principal element of compensation that is considered Incentive-Based Compensation is annual cash bonuses, which is primarily based upon a Financial Reporting Measure and modified utilizing other measures including but not limited to clinical metrics.

For the avoidance of doubt, the following forms of compensation shall not be considered Incentive-Based Compensation for purposes of this policy:
Salaries;
Bonuses paid solely by satisfying subjective standards;
Non-equity incentive plan awards earned solely by satisfying strategic or operational measures;
Wholly time-based equity awards; or
Discretionary bonuses or other compensation that is paid on a discretionary basis and not based wholly or in part on the attainment of a Financial Reporting Measure.



Incentive-Based Compensation is deemed “received” for purposes of this policy in the Company’s fiscal period during which the Financial Reporting Measure specified in the Incentive-Based Compensation award is attained, even if the payment or grant of such Incentive-Based Compensation occurs after the end of that period.

3.Administration. This policy shall be administered by the Compensation Committee of the Board (the “Compensation Committee”). The Compensation Committee is authorized to interpret and construe this policy and to make all determinations necessary, appropriate or advisable for the administration of this policy, in each case, to the extent permitted under the Listing Standards and in compliance with (or pursuant to an exemption from the application of) Section 409A of the Code. All determinations and decisions made by the Compensation Committee pursuant to the provisions of this policy shall be final, conclusive and binding on all persons, including the Company, its affiliates, its stockholders and Covered Executive Officers, and need not be uniform with respect to each person covered by this policy.
In the administration of this policy, the Compensation Committee is authorized and directed to consult with the full Board or such other committees of the Board as may be necessary or appropriate as to matters within the scope of such other committee’s responsibility and authority. Subject to any limitation of applicable law, the Compensation Committee may authorize and empower any officer or employee of the Company to take any and all actions necessary or appropriate to carry out the purpose and intent of this policy (other than with respect to any recovery under this policy involving such officer or employee). Any action or inaction by the Compensation Committee with respect to a Covered Executive Officer under this policy in no way limits the Compensation Committee’s decision to act or not to act with respect to any other Covered Executive Officer under this policy or under any similar policy, agreement or arrangement, nor shall any such action or inaction serve as a waiver of any rights the Company may have against any Covered Executive Officer other than as set forth in this policy.

4.Application of this Policy. This policy applies to all Incentive-Based Compensation received by a person: (a) after beginning service as a Covered Executive Officer; (b) who served as a Covered Executive Officer at any time during the performance period for such Incentive-Based Compensation; (c) while the Company had a listed class of securities on a national securities exchange; and (d) during the Applicable Period. For the avoidance of doubt, Incentive-Based Compensation that is subject to both a Financial Reporting Measure vesting condition and a service-based vesting condition shall be considered received when the relevant Financial Reporting Measure is achieved, even if the Incentive-Based Compensation continues to be subject to the service-based vesting condition.

5.Recovery Erroneously Awarded Compensation. In the event of an Accounting Restatement, the Company must recover Erroneously Awarded Compensation reasonably promptly, in amounts determined pursuant to this policy. The Company’s obligation to recover Erroneously Awarded Compensation is not dependent on the filing of restated financial statements. Recovery under this policy with respect to a Covered Executive Officer shall not require the finding of any misconduct by such Covered Executive Officer or such Covered Executive Officer being found responsible for the accounting error leading to an Accounting Restatement. In the event of an Accounting Restatement, the method for recouping Erroneously Awarded Compensation shall be determined by the Compensation Committee in its sole and absolute discretion, to the extent permitted under the Listing Standards and in compliance with (or pursuant to an exemption from the application of) Section 409A of the Code.




Recovery may include, without limitation, (i) reimbursement of all or a portion of any incentive compensation award, (ii) cancellation of incentive compensation awards, and (iii) any other method authorized by applicable law or contract.

The Company is authorized and directed pursuant to this policy to recover Erroneously Awarded Compensation in compliance with this policy unless the Compensation Committee has determined that recovery would be impracticable solely for the following limited reasons, and subject to the following procedural and disclosure requirements:

a.The direct expenses paid to a third party to assist in enforcing this policy would exceed the amount to be recovered. Before reaching such conclusion, the Compensation Committee must make a reasonable attempt to recover such Erroneously Awarded Compensation, document such reasonable attempt(s) to recover, and provide that documentation to Nasdaq;

b.Recovery would violate home country law where that law was adopted prior to November 28, 2022. Before reaching such conclusion, the Compensation Committee must obtain an opinion of home country counsel, acceptable to Nasdaq, that recovery would result in such a violation, and must provide such opinion to Nasdaq; or

c.Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Section 401(a)(13) or Section 411(a) of the Code.

6.Prohibition on Indemnification and Insurance Reimbursement. The Company is prohibited from indemnifying any Covered Executive Officer against the loss of any Erroneously Awarded Compensation. Further, the Company is prohibited from paying or reimbursing a Covered Executive Officer for the cost of purchasing insurance to cover any such loss. The Company is also prohibited from entering into any agreement or arrangement whereby this policy would not apply or fail to be enforced against a Covered Executive Officer.

7.Required Policy-Related Disclosure and Filings. The Company shall file all disclosures with respect to this policy in accordance with the requirements of the federal securities laws, including disclosures required by U.S. Securities and Exchange Commission filings. A copy of this policy and any amendments hereto shall be posted on the Company’s website and filed as an exhibit to the Company’s annual report on Form 10-K.

8.Amendment; Termination. The Board may amend this policy from time to time in its sole and absolute discretion and shall amend this policy as it deems necessary to reflect the Listing Standards or to comply with (or maintain an exemption from the application of) Section 409A of the Code. The Board may terminate this policy at any time; provided, that the termination of this policy would not cause the Company to violate any federal securities laws, or rules promulgated by the U.S. Securities and Exchange Commission or the Listing Standards.

9.Other Recovery Obligations; General Rights. The Board intends that this policy shall be applied in accordance with, and to the fullest extent of, applicable law. To the extent that the application of this policy would provide for recovery of Incentive-Based Compensation that the Company already recovered pursuant to Section 304 of the Sarbanes-Oxley Act or other recovery obligations, any such amount recovered from a Covered Executive Officer will be credited to any recovery required under this policy in respect of such Covered Executive Officer.




10.Effective Date. This policy shall be effective as of November 2, 2023. The terms of this policy shall apply to any Incentive-Based Compensation that is received by Covered Executive Officers on or after October 2, 2023, even if such Incentive-Based Compensation was approved, awarded or granted to Covered Executive Officers prior to such date.

This policy shall not limit the rights of the Company to take any other actions or pursue other remedies that the Company may deem appropriate under the circumstances and under applicable law, in each case, to the extent permitted under the Listing Standards and in compliance with (or pursuant to an exemption from the application of) Section 409A of the Code.

This policy is binding and enforceable against all Covered Executive Officers and their beneficiaries, heirs, executors, administrators or other legal representatives.

EX-101.SCH 9 ensg-20231231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONSOLIDATED STATEMENTS OF INCOME link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - DESCRIPTION OF BUSINESS link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - STANDARD BEARER link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - OPERATION EXPANSIONS link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - BUSINESS SEGMENTS link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - PROPERTY AND EQUIPMENT— NET link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - INTANGIBLE ASSETS — NET link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - GOODWILL link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - RESTRICTED AND OTHER ASSETS link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - OTHER ACCRUED LIABILITIES link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - OPTIONS AND AWARDS link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - DEFINED CONTRIBUTION PLANS link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - SELF INSURANCE LIABILITIES link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - COMMON STOCK REPURCHASE PROGRAM link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - OPERATION EXPANSIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - BUSINESS SEGMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - PROPERTY AND EQUIPMENT— NET (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - INTANGIBLE ASSETS — NET (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - GOODWILL (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - RESTRICTED AND OTHER ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - OTHER ACCRUED LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - OPTIONS AND AWARDS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - SELF INSURANCE LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - DESCRIPTION OF BUSINESS (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Leases and Leasehold Improvements (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets and Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Self-Insurance (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE -Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE - Accounts Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - FAIR VALUE MEASUREMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - STANDARD BEARER (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - OPERATION EXPANSIONS- Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - OPERATION EXPANSIONS - Purchase Price Allocation (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - BUSINESS SEGMENTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - BUSINESS SEGMENTS - Schedule of Segment Financial Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - BUSINESS SEGMENTS - Schedule of Service Revenue by Major Payor Source (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - PROPERTY AND EQUIPMENT— NET - Schedule of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - PROPERTY AND EQUIPMENT— NET - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - INTANGIBLE ASSETS — NET - Schedule of Finite Lived Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - INTANGIBLE ASSETS — NET - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - INTANGIBLE ASSETS — NET - Future Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - INTANGIBLE ASSETS — NET - Schedule of Indefinite-lived Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - GOODWILL (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - RESTRICTED AND OTHER ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - OTHER ACCRUED LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - INCOME TAXES - Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - INCOME TAXES - Tax Rate (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - INCOME TAXES - Narrative (YE) (Details) link:presentationLink link:calculationLink link:definitionLink 9954514 - Disclosure - INCOME TAXES - Deferred Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954515 - Disclosure - DEBT - Schedule of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954516 - Disclosure - DEBT - Credit Facility with a Lending Consortium Arranged by Truist (Details) link:presentationLink link:calculationLink link:definitionLink 9954517 - Disclosure - DEBT - Mortgage Loans and Promissory Notes and Off-Balance Sheet Arrangements (Details) link:presentationLink link:calculationLink link:definitionLink 9954518 - Disclosure - DEBT - Long-term Debt Arrangements (Details) link:presentationLink link:calculationLink link:definitionLink 9954519 - Disclosure - OPTIONS AND AWARDS - Stock Options, Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954520 - Disclosure - OPTIONS AND AWARDS - Valuation Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 9954521 - Disclosure - OPTIONS AND AWARDS - Exercise Price and Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9954522 - Disclosure - OPTIONS AND AWARDS - Options Outstanding Rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 9954523 - Disclosure - OPTIONS AND AWARDS - Options Outstanding by Exercise Price (Details) link:presentationLink link:calculationLink link:definitionLink 9954524 - Disclosure - OPTIONS AND AWARDS - Intrinsic Values (Details) link:presentationLink link:calculationLink link:definitionLink 9954525 - Disclosure - OPTIONS AND AWARDS - Restricted Stock Awards, Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954526 - Disclosure - OPTIONS AND AWARDS - Restricted Award Rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 9954527 - Disclosure - OPTIONS AND AWARDS - Long-Term Incentive Plan (Details) link:presentationLink link:calculationLink link:definitionLink 9954528 - Disclosure - OPTIONS AND AWARDS - Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954529 - Disclosure - LEASES - Lessee Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954530 - Disclosure - LEASES - Lessee Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 9954531 - Disclosure - LEASES - Lessee Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954531 - Disclosure - LEASES - Lessee Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954532 - Disclosure - LEASES - Lessor Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954533 - Disclosure - LEASES - Lessor Rental Income (Details) link:presentationLink link:calculationLink link:definitionLink 9954534 - Disclosure - LEASES - Lessor Future Minimum Lease Payments Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 9954535 - Disclosure - DEFINED CONTRIBUTION PLANS (Details) link:presentationLink link:calculationLink link:definitionLink 9954536 - Disclosure - SELF INSURANCE LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 9954537 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 9954538 - Disclosure - COMMON STOCK REPURCHASE PROGRAM (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 10 ensg-20231231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 11 ensg-20231231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 12 ensg-20231231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] All States Except Colorado All States Except Colorado [Member] All States Except Colorado [Domain] Stock Options Outstanding, Vested and Related Details Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block] Schedule of Other Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Other third-party Third Party Tenants [Member] Third Party Tenants [Member] Cash held in trust for patients Cash Held in Trust for Residents Cash held in trust for residents reflects monies received from, or on behalf of, residents. Maintaining a trust account for residents is a regulatory requirement and, while the trust assets offset the liability, the Company assumes a fiduciary responsibility for these funds. Line of credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Change in operating assets and liabilities Increase (Decrease) in Operating Capital [Abstract] 2017 Exercise Price Range Five [Member] Exercise Price Range Five [Member] Expiration period Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Impairment of intangible assets (excluding goodwill) Impairment of Intangible Assets (Excluding Goodwill) Payments to acquire businesses, gross Payments to Acquire Businesses, Gross Schedule of Purchase Price Allocation Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Management fees, as a percentage of funds from operations Property Management Fee, Percent Fee of Funds from Operations Property Management Fee, Percent Fee of Funds from Operations Health Liability Insurance Health Liability Insurance [Member] Health Liability Insurance [Member] STANDARD BEARER Standard Bearer [Text Block] Standard Bearer Purchases of investments Payments to Acquire Investments Insider Trading Policies and Procedures [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Skilled Nursing Operations Skilled Nursing Operations [Member] Skilled Nursing Operations Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Five Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] COMMON STOCK REPURCHASE PROGRAM Equity [Text Block] Leases To Third Party Operators Leases To Third Party Operators [Member] Leases To Third Party Operators Weighted Average Dividend Yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Issuance of restricted stock, net of forfeitures (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Customer [Axis] Customer [Axis] Current liabilities: Liabilities, Current [Abstract] Federal Deferred Federal Income Tax Expense (Benefit) Goodwill, accumulated impairment loss Goodwill, Impaired, Accumulated Impairment Loss Subsequent Event Type [Domain] Subsequent Event Type [Domain] Christopher R. Christensen [Member] Christopher R. Christensen Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Diluted (in dollars per share) Diluted net income per common share (in dollars per share) Earnings Per Share, Diluted Restricted and other assets RESTRICTED AND OTHER ASSETS Restricted And Other Assets, Noncurrent Restricted And Other Assets, Noncurrent Capital improvement reserves with landlords and lenders Other Restricted Assets Accounts receivable—less allowance for doubtful accounts of $9,348 and $7,802 at December 31, 2023 and 2022, respectively ACCOUNTS RECEIVABLE, NET Accounts Receivable, after Allowance for Credit Loss, Current Texas TEXAS Assembled occupancy Assembled occupancy Assembled Occupancy Acquired [Member] Assembled occupancy acquired [Member] Other income (expense): Other Nonoperating Income (Expense) [Abstract] Trading Symbol Trading Symbol Letters of credit outstanding, pledged amount Letters of Credit Outstanding, Amount Weighted Average Exercise Price (in dollars per share) Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Five Schedule of Reconciliation of the Numerator and Denominator Used in the Calculation of Basic Net Income Per Common Share Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] TOTAL Lessor, Operating Lease, Payment to be Received Ensign Group, Inc. stockholders' equity: Equity, Attributable to Parent [Abstract] Series of Individually Immaterial Asset Acquisitions Series of Individually Immaterial Asset Acquisitions [Member] Base Management Fee Management Service, Base [Member] Executive Category: Executive Category [Axis] 2027 Lessor, Operating Lease, Payment to be Received, Year Four Sublease Of Stand Along Skilled Nursing Operations Sublease Of Stand Along Skilled Nursing Operations [Member] Sublease Of Stand Along Skilled Nursing Operations Non-Vested Restricted Awards Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Prepayment Fee, Period [Axis] Prepayment Fee, Period [Axis] Prepayment Fee, Period TOTAL DEFERRED TAX ASSETS Deferred Tax Assets, Net of Valuation Allowance Schedule of Property and Equipment, Net Property, Plant and Equipment [Table Text Block] Equity Components [Axis] Equity Components [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Number of shares available for grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant 2025 Long-Term Debt, Maturity, Year Two Granted (in shares) Options granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Schedule of Service Revenue by Major Payor Source Reconciliation of Revenue from Segments to Consolidated [Table Text Block] Noncontrolling Interest Noncontrolling Interest [Policy Text Block] The noncontrolling interest in a subsidiary initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's condensed consolidated balance sheets. Entity Small Business Entity Small Business Weighted Average Volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Four Local Phone Number Local Phone Number Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Letter of Credit Letter of Credit [Member] Accounts Receivable Accounts Receivable [Member] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Reduction in prepayment penalty Reduction In Prepayment Penalty Percentage that the prepayment penalty percentage is reduced during the fourth year. Retirement Benefits [Abstract] Retirement Benefits [Abstract] Lessor, Lease, Description [Table] Lessor, Lease, Description [Table] Self-Insurance Retention Per Claim Self-insurance Retention Per Claim [Member] Self-insurance retention per claim [Member] Owned Properties Wholly Owned Properties [Member] Schedule of Debt Schedule of Long-Term Debt Instruments [Table Text Block] Shares of common stock used to satisfy tax withholding obligations Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation After Year Ten After Year Ten [Member] After Year Ten Cost of Sales and General and Administrative Expense Cost of Sales and General and Administrative Expense [Member] Primary financial statement caption encompassing cost of services and general and administrative expense Management fees Management Fee Expense Prepaid expenses Deferred Tax Liabilities, Prepaid Expenses Number outstanding (in shares) Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding Grantee Status [Axis] Grantee Status [Axis] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Insurance Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Self Insurance Award Type [Axis] Award Type [Axis] Antidilutive securities excluded from computation of earnings per share, amount (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Granted restricted shares (in shares) Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag General and administrative expense General and Administrative Expense [Member] Goodwill [Line Items] Goodwill [Line Items] Property and equipment Property, Plant and Equipment, Gross Right-of-use assets obtained in exchange for new and modified operating lease obligations Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Less: present value adjustment Lessee, Operating Lease, Liability, Undiscounted Excess Amount Number of real estate properties leased with an option to purchase Number of Real Estate Properties Leased with an Option to Purchase Number of Real Estate Properties Leased with an Option to Purchase PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Schedule of Components of Income Tax Expense (Benefit) Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Lease liabilities—current Less: current lease liabilities Operating Lease, Liability, Current Schedule of Restricted and Other Assets Schedule of Other Assets [Table Text Block] Cash surrender value of life insurance policy premiums Life Insurance, Corporate or Bank Owned, Change in Value 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three Letter of credit increase Line of Credit Facility, Increase (Decrease), Net Net Finite-Lived Intangible Assets, Net Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Less: Net Income (Loss) Attributable to Noncontrolling Interest [Abstract] Long-term debt, threshold for EBITDA ratio increase election Long-Term Debt, Threshold For EBITDA Ratio Increase Election Long-Term Debt, Threshold For EBITDA Ratio Increase Election Counterparty Name [Domain] Counterparty Name [Domain] Segment Reporting, Revenue Reconciling Item [Line Items] Segment Reporting, Revenue Reconciling Item [Line Items] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two Deferred employer portion of social security taxes (Note 3) Increase (Decrease) Due To Deferred Employer Taxes, CARES Act Increase (Decrease) Due To Deferred Employer Taxes, CARES Act Insurance [Abstract] Accounts receivable, gross Accounts Receivable, before Allowance for Credit Loss Rental revenue Rental [Member] Rental Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Resident advances Contract with Customer, Liability, Current Schedule of Assumptions for Stock Options Granted Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Security Exchange Name Security Exchange Name Stock-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Award vesting rights, percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Stock Options Stock-based compensation expense related to stock options Employee Stock Option [Member] Insurance Subsidiary Deposits and Investments Investment, Policy [Policy Text Block] TOTAL EXPENSES Costs and Expenses Maximum Maximum [Member] Various Landlords Various Landlords [Member] Various Landlords[Member] Share-based compensation, nonvested awards, cost not yet recognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Document Type Document Type Goodwill Goodwill Additions Goodwill, Acquired During Period Revenue, FMAP payments received Revenue Recognition, Family First Coronavirus Response Act, Revenue Recognized Revenue Recognition, Family First Coronavirus Response Act, Revenue Recognized Tabular List, Table Tabular List [Table Text Block] Repurchase of common stock (Note 21) Repurchase of common stock, value Treasury Stock, Value, Acquired, Cost Method Thereafter Long-Term Debt, Maturity, after Year Five OPTIONS AND AWARDS Share-Based Payment Arrangement [Text Block] Federal Current Federal Tax Expense (Benefit) Basis of Presentation Basis of Accounting, Policy [Policy Text Block] 2021 Exercise Price Range Nine [Member] Exercise Price Range Nine [Member] Number of financing lease Number Of Financing Leases Number Of Financing Leases Business Acquisition [Axis] Business Acquisition [Axis] Allowance for doubtful accounts Less: allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Customer Concentration Risk Customer Concentration Risk [Member] Change in long-term insurance losses recoverable Liability for Future Policy Benefits, Other Increase (Decrease) Self-Insurance Self Insurance Reserve [Policy Text Block] State Deferred State and Local Income Tax Expense (Benefit) Real Estate Properties [Domain] Real Estate Properties [Domain] Variable Rate [Axis] Variable Rate [Axis] 2024 Lessor, Operating Lease, Payment to be Received, Year One Expense: Costs and Expenses [Abstract] Title of 12(b) Security Title of 12(b) Security Sublease income Sublease Income OPERATION EXPANSIONS Business Combination Disclosure [Text Block] Other indefinite-lived intangibles Indefinite-Lived Intangible Assets (Excluding Goodwill) Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Operating Segments Operating Segments [Member] Nonvested at beginning of period (in dollars per share) Nonvested at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Purchase of property and equipment Payments To Acquire Property And Equipment Payments To Acquire Property And Equipment Non-controlling interest distribution Payments to Noncontrolling Interests Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Schedule of Accounts Receivable Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Deconsolidation of an ancillary business Noncontrolling Interest, Decrease from Deconsolidation Lease, cost Lease, Cost Statistical Measurement [Axis] Statistical Measurement [Axis] Qualified Plan Qualified Plan [Member] Entity Interactive Data Current Entity Interactive Data Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Term of operating lease Lessor, Operating Lease, Term of Contract Intangible Assets and Goodwill Goodwill and Intangible Assets, Policy [Policy Text Block] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Standard Bearer Master Leases Standard Bearer Master Leases [Member] Standard Bearer Master Leases Lease Of Campus Operation Lease Of Campus Operation [Member] Lease Of Campus Operation Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Service Revenue Recognition, Rental Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Total net debt ratio, minimum Total Net Debt Ratio, Minimum Total Net Debt Ratio, Minimum Deposits with landlords Security Deposit Schedule of Deferred Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Counterparty Name [Axis] Counterparty Name [Axis] State taxes Deferred Tax Assets, State Taxes 2024 Finite-Lived Intangible Asset, Expected Amortization, Year One Lease liabilities Operating Lease, Payments Common shares outstanding Balance at beginning of period (in shares) Balance at end of period (in shares) Common Stock, Shares, Outstanding HUD Insured Mortgages HUD Insured Mortgages [Member] HUD Insured Mortgages Dividends declared Dividends New Master Lease Agreeement New Master Lease Agreeement [Member] New Master Lease Agreeement Accrued self-insurance liabilities—current Self Insurance Reserve, Current PEO PEO [Member] Schedule of Annual Rental Income Lessor, Operating Lease, Payment to be Received, Maturity [Table Text Block] Auditor Location Auditor Location General Liability General Liability [Member] Schedule of Employee Stock Option Roll Forward Schedule of Common Stock Outstanding Roll Forward [Table Text Block] Defined Contribution Plan Disclosure [Line Items] Defined Contribution Plan Disclosure [Line Items] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Accrued litigation (Note 20) Estimated Litigation Liability, Current Number of stand-alone leases Lessee, Operating Lease, Number Of Leases Lessee, Operating Lease, Number Of Leases NET CASH USED IN INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities Debt Instrument [Axis] Debt Instrument [Axis] Segment income (loss) Segment Income (Loss) Segment Income (Loss) Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Other long-term liabilities Deferred rent and other long-term liabilities Rental expense in excess of actual rental payments and other long-term liabilities Credit Facility [Axis] Credit Facility [Axis] Schedule of Maturities of Long-term Debt Schedule of Maturities of Long-Term Debt [Table Text Block] TOTAL LIABILITIES Liabilities Total current income tax expense (benefit) Current Income Tax Expense (Benefit) Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] PROPERTY AND EQUIPMENT— NET Property, Plant and Equipment Disclosure [Text Block] 2026 Lessor, Operating Lease, Payment to be Received, Year Three Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Schedule of Indefinite-lived Intangible Assets Schedule of Acquired Indefinite-Lived Intangible Assets by Major Class [Table Text Block] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Disposal Group, Disposed of by Sale, Not Discontinued Operations Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] General and administrative expense General and Administrative Expense Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] State Current State and Local Tax Expense (Benefit) Total current assets Assets, Current SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION Supplemental Cash Flow Information [Abstract] Restructuring Type [Axis] Restructuring Type [Axis] % of Revenue Revenue % Concentration percentage Concentration Risk, Percentage Cash from insurance proceeds Proceeds from Insurance Settlement, Investing Activities State income taxes - net of federal benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Real Estate Purchases Of Previous Operations Real Estate Purchases Of Previous Operations [Member] Real Estate Purchases Of Previous Operations Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Five 2016 Exercise Price Range Four [Member] Exercise Price Range Four [Member] Accounts Receivable Accounts Receivable [Policy Text Block] NET CASH PROVIDED BY OPERATING ACTIVITIES Net Cash Provided by (Used in) Operating Activities Vested Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Schedule of Estimated Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Health care facilities Number Of Health Care Facilities Number Of Health Care Facilities Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Insurance Coverage Limit Type [Axis] Insurance Coverage Limit Type [Axis] Insurance Coverage Limit Type [Axis] Depreciation and amortization Depreciation and amortization Depreciation and amortization Depreciation, Depletion and Amortization Equipment, furniture, and fixtures Furniture and fixtures Furniture and Fixtures [Member] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Prepayment penalty Prepayment Penalty Percentage that the prepayment penalty percentage is reduced during the first three years. Business Combination and Asset Acquisition [Abstract] Consolidation Items [Axis] Consolidation Items [Axis] Insurance subsidiary's deposits and investments Investments and Cash Valuation allowance Valuation allowance Deferred Tax Assets, Valuation Allowance Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Repayment of medicare accelerated and advance payment program Repayment Of Funds Received From The Medicare Accelerated and Advance Payment Program, CARES Act Repayment Of Funds Received From The Medicare Accelerated and Advance Payment Program, CARES Act Number of real estate skilled nursing properties acquired Number Of Properties Acquired Number Of Properties Acquired Number of operations transferred from third parties Number of Living Operations Transferred From Third-Parties Number of Living Operations Transferred From Third-Parties Medicaid Medicaid [Member] Revenue from Medicaid for custodial services [Member] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] RESTRICTED AND OTHER ASSETS Other Assets Disclosure [Text Block] Share-based compensation, nonvested awards (in shares) Employee Service Share-based Compensation, Nonvested Awards Employee Service Share-based Compensation, Nonvested Awards Entity Emerging Growth Company Entity Emerging Growth Company Less: debt issuance costs, net Debt Issuance Costs, Net Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Total deferred tax assets Deferred Tax Assets, Gross Parent Company Parent Company [Member] Schedule of Rental Income from Third-Party Sources Operating Lease, Lease Income [Table Text Block] 2024 Lessee, Operating Lease, Liability, to be Paid, Year One Number of asset acquisitions Number of Asset Acquisitions Number of Asset Acquisitions Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Non-california Non-California [Member] Non-California [Domain] Total net debt ratio, maximum Total Net Debt Ratio, Maximum Total Net Debt Ratio, Maximum Title Trading Arrangement, Individual Title Black-Scholes Fair Value Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Fair Value Fair value determined using a black-scholes model for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range Common Stock Common Stock [Member] Individual: Individual [Axis] Proceeds from issuance of preferred shares Proceeds from Issuance of Convertible Preferred Stock Entity Address, Postal Zip Code Entity Address, Postal Zip Code Income Statement Location [Domain] Income Statement Location [Domain] SELF INSURANCE LIABILITIES Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block] Total equity Balance at beginning of period Balance at end of period Equity, Including Portion Attributable to Noncontrolling Interest Noncontrolling interest attributable to subsidiary equity plan Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Master lease agreements Master Lease Agreements Master Lease agreements Minimum Minimum [Member] WEIGHTED AVERAGE COMMON SHARES OUTSTANDING DENOMINATOR: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Property and equipment, net PROPERTY AND EQUIPMENT, NET Property, Plant and Equipment, Net 2015 Exercise Price Range Three [Member] Exercise Price Range Three [Member] Lease Arrangement [Domain] Lease Arrangement [Domain] Lease Arrangement Long-term insurance losses recoverable asset Estimated Insurance Recoveries Escrow deposits Payments for (Proceeds from) Deposits on Real Estate Acquisitions Number of real estate properties Number of Real Estate Properties Disposal Group Classification [Axis] Disposal Group Classification [Axis] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] ASSETS Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Proceeds from debt (Note 15) Proceeds from Issuance of Long-Term Debt Operating lease obligations Increase (Decrease) in Operating Lease Liability Repurchase of shares of common stock to satisfy tax withholding obligations Payment, Tax Withholding, Share-Based Payment Arrangement General and Professional Liability Professional Malpractice Liability Insurance [Member] NET CASH USED IN FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities Deferred tax assets Deferred Income Tax Assets, Net Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Other restricted assets Payments for (Proceeds from) Other Investing Activities Retained Earnings Retained Earnings [Member] Current maturities of long-term debt Less: current maturities Long-Term Debt, Current Maturities Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Basic (in dollars per share) Basic net income per common share (in dollars per share) Earnings Per Share, Basic Accounting Policies [Abstract] Accounting Policies [Abstract] Class of Treasury Stock [Table] Class of Treasury Stock [Table] Gain on sale of assets Gain (Loss) on Disposition of Assets Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Forfeiture rate Share-Based Compensation Arrangement By Share-Based Award, Options, Fair Value, Assumptions Forfeiture Rate Share-Based Compensation Arrangement By Share-Based Award, Options, Fair Value, Assumptions Forfeiture Rate NET DEFERRED TAX ASSETS Deferred Tax Assets, Net Intrinsic value of options exercised in period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Operational senior living units Operational Senior Living Units Operational Assisted Living and Independent Living Units Remaining Contractual Life (Years) Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term Income taxes Income Taxes Paid Medicaid — skilled Medicaid-skilled Medicaid-skilled [Member] Revenue from Medicaid for skilled services [Member] Purchase Option Purchase Option [Member] Purchase Option Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Retirement Plan Tax Status [Domain] Retirement Plan Tax Status [Domain] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Conversion to reduce shares availability Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion To Reduce Shares Availability Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion To Reduce Shares Availability July 2022 Repurchase Program July 2022 Repurchase Program [Member] July 2022 Repurchase Program Accounts payable Increase (Decrease) in Accounts Payable Current year provisions Liability for Future Policy Benefits, Period Increase (Decrease) Proceeds from sale of subsidiary shares (Note 6) Proceeds From Sale Of Common Stock Associated With Subsidiary Equity Plans Proceeds From Sale Of Common Stock Associated With Subsidiary Equity Plans Entity Public Float Entity Public Float Non-cash financing and investing activity Other Noncash Investing and Financing Items [Abstract] Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Number of master lease arrangements Number of Lease Arrangements Number of Lease Arrangements Mortgage loans and promissory note Outstanding debt Long-Term Debt, Gross All Trading Arrangements All Trading Arrangements [Member] 2014 Exercise Price Range Two [Member] Exercise Price Range Two [Member] All Adjustments to Compensation All Adjustments to Compensation [Member] Number of real estate properties leased Number of Real Estate Properties Leased Number of Real Estate Properties Leased Compensation Amount Outstanding Recovery Compensation Amount Truist Truist Bank [Member] Truist Bank [Member] Provision for doubtful accounts Accounts Receivable, Credit Loss Expense (Reversal) Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Deferred income taxes Deferred Income Tax Expense (Benefit) Intercompany Elimination Consolidation, Eliminations [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Issuance of common stock upon exercise of options Proceeds from Stock Options Exercised Operating Entity [Domain] Operating Entity [Domain] [Domain] for Operating Entity [Axis] Share-based Payment Arrangement, Option, Exercise Price Range [Table] Share-Based Payment Arrangement, Option, Exercise Price Range [Table] Workers' Compensation Workers' Compensation Insurance [Member] Document Financial Statement Restatement Recovery Analysis [Flag] Document Financial Statement Error Correction [Flag] Insurance Coverage Limit Type [Domain] Insurance Coverage Limit Type [Domain] Insurance Coverage Limit Type [Domain] Long-term debt—less current maturities Long Term Debt, net of Current Maturities and Debt Discount Long Term Debt, net of Current Maturities and Debt Discount Payor [Domain] Payor [Domain] Payor [Domain] 2024 Long-Term Debt, Maturity, Year One Stop-Loss Insurance Limit Per Claim Stop-Loss Insurance Limit Per Claim [Member] Stop-Loss Insurance limit per claim[Member] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Claims paid and direct expenses Liability for Future Policy Benefit, Expected Future Policy Benefit, Benefit Payment All Other Other Segments [Member] Plus: incremental shares from assumed conversion (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Exercise price, upper range limit (in dollars per share) Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit Proceeds from sale of real estate Proceeds from Sale of Property, Plant, and Equipment Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Senior living facilities Senior Living Facilities Number of Assisted and Independent Living Facilities August 2023 Repurchase Program August 2023 Repurchase Program [Member] August 2023 Repurchase Program Document Period End Date Document Period End Date Adoption Date Trading Arrangement Adoption Date Treasury Stock Treasury Stock, Common [Member] 2019 LTI Plan 2019 LTI Plan [Member] 2019 LTI Plan [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Significant Accounting Policies [Text Block] Gain on sales property, plant and equipment Gain (Loss) on Disposition of Property Plant Equipment Number of senior living operations sharing property with skilled nursing facilities Number Of Senior Living Operations Sharing Property With Skilled Nursing Facilities Number Of Senior Living Operations Sharing Property With Skilled Nursing Facilities Provision for income taxes Provision for income taxes Income Tax Expense (Benefit) Deferred compensation liability, noncurrent Deferred Compensation Liability, Classified, Noncurrent Incentive Management Fee Management Service, Incentive [Member] FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Write-off of deferred financing fees Deferred Debt Issuance Cost, Writeoff Lender Name [Axis] Lender Name [Axis] EQUITY Equity [Abstract] Operating lease, weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Operating leases of lessee, contingent rentals, basis spread on variable rate Lessee, Operating Lease, Discount Rate 2025 Lessor, Operating Lease, Payment to be Received, Year Two Senior Living Facilities Senior Living Facilities [Member] Assisted Living Facilities [Member] 2020 Exercise Price Range Eight [Member] Exercise Price Range Eight [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Cash payments for business acquisitions (Note 7) Payments to Acquire Businesses, Net of Cash Acquired Shares of common stock used to satisfy tax withholding obligations (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Grant date intrinsic value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value Credit Facility [Domain] Credit Facility [Domain] Repurchase of common stock (in shares) Repurchase of common stock (in shares) Treasury Stock, Shares, Acquired Interest rate margin Debt Instrument, Basis Spread on Variable Rate Property, plant and equipment, useful life Property, Plant and Equipment, Useful Life Cash received from insurance proceeds Proceeds from Insurance Settlement, Operating Activities Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] CareTrust REIT CareTrust REIT [Member] CareTrust REIT [Member] REVENUE AND ACCOUNTS RECEIVABLE Revenue from Contract with Customer [Text Block] Additional paid-in capital Additional Paid in Capital, Common Stock Lease liability Deferred Tax Assets, Tax, Deferred Expense, Reserves And Accruals, Lease Liability Deferred Tax Assets, Tax, Deferred Expense, Reserves And Accruals, Lease Liability Additional Paid-In Capital Additional Paid-in Capital [Member] Document Annual Report Document Annual Report Revenue related reserves Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss Cash payments for asset acquisitions (Note 7) Payments To Acquire Asset Acquisitions Cash paid to acquire acquisitions. Cash and cash equivalents beginning of period Cash and cash equivalents end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Secured Overnight Financing Rate (SOFR) Secured Overnight Financing Rate (SOFR) [Member] Secured Overnight Financing Rate (SOFR) Cover page. Cover [Abstract] 2019 Exercise Price Range Seven [Member] Exercise Price Range Seven [Member] Number of businesses acquired Number of Businesses Acquired Accrued self-insurance liabilities—less current portion Self Insurance Reserve, Noncurrent Other Other Liabilities, Noncurrent Dividends paid Payments of Dividends TOTAL LEASE PAYMENTS Lessee, Operating Lease, Liability, to be Paid Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Investments—current Short-Term Investments Amended of separate master leases Amended Separate Master Leases Amended Separate Master Leases DEFINED CONTRIBUTION PLANS Compensation and Employee Benefit Plans [Text Block] Asset acquisition, purchase price Asset Acquisition, Consideration Transferred BUSINESS SEGMENTS Segment Reporting Disclosure [Text Block] Net increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Lessee, operating lease, renewal term Lessee, Operating Lease, Renewal Term Equity Component [Domain] Equity Component [Domain] Number of facilities Number Of Facilities Number Of Facilities Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Depreciation and Amortization Depreciation and amortization Depreciation And Amortization [Member] Depreciation And Amortization [Member] Entity Current Reporting Status Entity Current Reporting Status Concentration Risk Type [Domain] Concentration Risk Type [Domain] Income from operations Operating Income (Loss) Owned Properties Owned Properties [Member] Owned Properties Aggregate Deductible Aggregate Deductible [Member] Aggregate Deductible [Member] TOTAL DEFERRED TAX LIABILITIES Deferred Tax Liabilities, Gross Consolidated Entities [Domain] Consolidated Entities [Domain] Segments [Axis] Segments [Axis] Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] (Gain)/loss on insurance claims, legal matters and asset disposals Gain (Loss) On Insurance Claims And Disposal Of Assets Gain (Loss) On Insurance Claims And Disposal Of Assets Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Customer relationships Customer Relationships [Member] 2022 Plan 2022 Plan [Member] 2022 Plan Self insurance reserve Self Insurance Reserve Real Estate Properties [Line Items] Real Estate Properties [Line Items] Type of Restructuring [Domain] Type of Restructuring [Domain] Transitional and skilled service facilities Skilled Service Facilities Skilled Service Facilities Consolidated Entities [Axis] Consolidated Entities [Axis] Property, plant and equipment Property, Plant and Equipment, Additions Variable Rate [Domain] Variable Rate [Domain] Net income (loss) attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Non-employee Directors Share-Based Payment Arrangement, Nonemployee [Member] Pay vs Performance Disclosure [Line Items] Business And Asset Acquisitions [Domain] Business And Asset Acquisitions [Domain] Business And Asset Acquisitions Total Medicare and Medicaid Total Medicaid and Medicare Medicaid and Medicare [Member] Total revenue from Medicaid and Medicare [Member] Entity Voluntary Filers Entity Voluntary Filers Business And Asset Acquisitions [Axis] Business And Asset Acquisitions [Axis] Business And Asset Acquisitions Statistical Measurement [Domain] Statistical Measurement [Domain] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Nonvested at beginning of period (in shares) Nonvested at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number DEBT Debt Disclosure [Text Block] Number of option plans Number Of Option Plans Number Of Option Plans Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Lessee, operating lease, number of renewal options Lessee, Operating Lease, Number Of Renewal Options Lessee, Operating Lease, Number Of Renewal Options Revolving credit facility with Truist Revolving Credit Facility [Member] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Segment Reporting [Abstract] Segment Reporting [Abstract] Accounts payable Accounts Payable, Current Restatement Determination Date: Restatement Determination Date [Axis] Total net debt ratio, maximum after increase election Total Net Debt Ratio, Maximum After Increase Election Total Net Debt Ratio, Maximum After Increase Election Mortgage loans and promissory note Collateralized Debt Obligations [Member] Other income (expense), net Nonoperating Income (Expense) Income tax expense at statutory rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Commitments and contingencies (Notes 15 and 20) Commitments and Contingencies Year Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Number of installments Share-based Compensation Arrangement By Share-based Payment Award, Number Of Installments Share-based Compensation Arrangement By Share-based Payment Award, Number Of Installments Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Schedule of Goodwill [Table] Schedule of Goodwill [Table] Geographical [Axis] Geographical [Axis] Award requisite service period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period INCOME TAXES Income Tax Disclosure [Text Block] Concentration Risk [Line Items] Concentration Risk [Line Items] Nonqualified Plan Nonqualified Plan [Member] Leases Lessee, Leases [Policy Text Block] Business Acquisition [Line Items] Business Acquisition [Line Items] Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] PEO Total Compensation Amount PEO Total Compensation Amount Property, Plant and Equipment [Table] Schedule of Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Facilities under master lease arrangement Facilities Under Master Lease Arrangement Facilities operated under two separate three-facility master lease arrangements. Under these master leases, a breach at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk. Amended Master Lease Amended Master Lease [Member] Amended Master Lease Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Common shares in treasury, at cost Balance at beginning of period (in shares) Balance at end of period (in shares) Treasury Stock, Common, Shares LEASES Lessor, Operating Leases [Text Block] Balance at beginning of period, (in shares) Balance at end of period, (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Building and improvements Buildings and improvements Building and Building Improvements [Member] Payor [Axis] Payor [Axis] Payor [Axis] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Weighted Average Fair Value of Options (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Net income attributable to The Ensign Group, Inc. Net income attributable to the Ensign Group, Inc. Net Income (Loss) Net Income (Loss) Total current liabilities Liabilities, Current Lease Arrangement [Axis] Lease Arrangement [Axis] Information by group of related lease arrangements. Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name LEASES Lessee, Operating Leases [Text Block] LIABILITIES AND EQUITY Liabilities and Equity [Abstract] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Blanket Aggregate Blanket Aggregate [Member] Blanket Aggregate [Member] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Operating Entity [Axis] Operating Entity [Axis] Operating Entity [Axis] Cost of services Cost of Goods and Services Sold Award vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Cash proceeds from the sale of assets Proceeds from Sale of Productive Assets Exercise Price Range [Domain] Exercise Price Range [Domain] Years Five Through Ten Years Five Through Ten [Member] Years Five Through Ten Weighted Average Life (Years) Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Name Measure Name Name Forgone Recovery, Individual Name Goodwill Goodwill Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Asset Acquisition [Domain] Asset Acquisition [Domain] Underlying Securities Award Underlying Securities Amount Accounts receivable Increase (Decrease) in Accounts Receivable The Pennant Group, Inc. Pennant The Pennant Group, Inc. [Member] The Pennant Group, Inc. Audit Information [Abstract] Audit Information Captive Insurance Subsidiary Subsidiaries [Member] Dividends declared (in dollars per share) Common Stock, Dividends, Per Share, Declared Equity compensation Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent Real Estate Property Ownership [Axis] Real Estate Property Ownership [Axis] Long-term lease liabilities—less current portion LONG-TERM OPERATING LEASE LIABILITIES Operating Lease, Liability, Noncurrent Debt instrument, term Debt Instrument, Term Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Income Statement Location [Axis] Income Statement Location [Axis] Schedule of Real Estate Properties [Table] Schedule of Real Estate Properties [Table] Schedule of Future Minimum Lease Payments Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Defined Contribution Plan [Table] Defined Contribution Plan [Table] Payables and Accruals [Abstract] Payables and Accruals [Abstract] Product and Service [Domain] Product and Service [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Schedule of Operating Lease Expenses Lease, Cost [Table Text Block] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Plan Name [Domain] Plan Name [Domain] Interest expense Interest expense Interest Expense Accrued capital expenditures Capital Expenditures Incurred but Not yet Paid Skilled Services Skilled Services Segment [Member] Skilled Services Segment Number of shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Share-based compensation, options outstanding, weighted average remaining contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Trading Arrangement: Trading Arrangement [Axis] Estimates and Assumptions Use of Estimates, Policy [Policy Text Block] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Schedule of Exercise Price and Fair Value Displayed at Grant Date for Stock Option Grants Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five 2026 Long-Term Debt, Maturity, Year Three Auditor Firm ID Auditor Firm ID Amortization of intangible assets Amortization of Intangible Assets Entity Shell Company Entity Shell Company Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Restatement Determination Date Restatement Determination Date Other accrued liabilities Increase (Decrease) in Other Operating Liabilities Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Third Parties Third Parties [Member] Third Parties Operational skilled nursing beds Operational Skilled Nursing Beds Number of skilled nursing beds available for use at a skilled nursing facility Variable lease, costs Variable Lease, Cost Operating lease expense Operating Lease, Cost Impairment of Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Common shares issued Common Stock, Shares, Issued Schedule of Nonvested Restricted Stock Awards Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Maturities of investments Proceeds from Sale, Maturity and Collection of Investments Common stock in treasury, at cost, 3,390 and 3,368 shares at December 31, 2023 and 2022, respectively Treasury Stock, Common, Value Beverly B. Wittekind [Member] Beverly B. Wittekind Long-term Debt Long-Term Debt 2027 Long-Term Debt, Maturity, Year Four Share-based compensation, nonvested awards, cost not yet recognized, period for recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition OperatingLeaseIncomeComprehensiveIncomeExtensibleListNotDisclosedFlag Operating Lease, Lease Income, Statement of Income or Comprehensive Income [Extensible Enumeration] CPI increases and short term-lease cost Short-Term Lease, Cost Aggregate intrinsic value of options that vested in period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested Entity Address, Address Line One Entity Address, Address Line One Repayments of CARES Act Provider Relief Fund and Medicare Advance Payment Program (Note 3) Coronavirus Aid, Relief, and Economic Security (“CARES”) Funds Repaid Coronavirus Aid, Relief, and Economic Security (“CARES”) Funds, Repayment Standard Bearer Healthcare REIT, Inc. Standard Bearer Healthcare REIT, Inc. [Member] Standard Bearer Healthcare REIT, Inc. Schedule of Aggregate Intrinsic Value of Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable [Table Text Block] Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Loss-Sensitive Limit Per Claim Loss-Sensitive Limit Per Claim [Member] Loss-Sensitive limit per claim [Member] Subsequent Event Subsequent Event [Member] Schedule of Finite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Coronavirus Aid, Relief, and Economic Security (“CARES”) funds received and returned Coronavirus Aid, Relief, and Economic Security (“CARES”) Funds Received And Returned Coronavirus Aid, Relief, and Economic Security (“CARES”) Funds Received And Returned Income Statement [Abstract] Income Statement [Abstract] Twenty Three Subsidiaries Twenty Three Subsidiaries [Member] Twenty Three Subsidiaries Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards (in shares) Stock Issued During Period, Shares, New Issues Prepaid income taxes Increase (Decrease) in Prepaid Taxes Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Accrued expenses Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities NUMERATOR: Net Income (Loss) Attributable to Parent [Abstract] Other Other Assets, Current Medicare Medicare Medicare Medicare [Member] Revenue from Medicare [Member] Retirement Plan Tax Status [Axis] Retirement Plan Tax Status [Axis] Current: Current Federal, State and Local, Tax Expense (Benefit) [Abstract] Land Land Land [Member] Per Occurence Per Occurence [Member] Per Occurence [Member] Share-based compensation, restricted awards, exercise price (in dollars per share) Share-based Compensation, Restricted Awards, Exercise Price Share-based Compensation, Restricted Awards, Exercise Price 2023 Exercise Price Range Eleven [Member] Exercise Price Range Eleven Threshold event period after vesting of restricted awards or exercise of stock options Share-Based Compensation Arrangement by Share-Based Payment Award, Event Period After Vesting Of Restricted Awards Or Exercise Of Stock Options Share-Based Compensation Arrangement by Share-Based Payment Award, Event Period After Vesting Of Restricted Awards Or Exercise Of Stock Options Total Shareholder Return Amount Total Shareholder Return Amount Stock options vested and exercisable (in shares) Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable Repurchase of shares of common stock (Note 21) Payments for Repurchase of Common Stock Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Real Estate Purchases Real Estate Purchases [Member] Real Estate Purchases Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Facilities under medicare probe reviews Independent Operating Subsidiaries Under Medicare Probe Reviews Facilities under Medicare Probe reviews relating to Medicare services, billings and potential overpayments Segments [Domain] Segments [Domain] FMAP payments received Family First Coronavirus Response Act, Payments Received Family First Coronavirus Response Act, Payments Received Deferred rent receivable Deferred Compensation Plan Assets Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Retained earnings Retained Earnings (Accumulated Deficit) Expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value Exercise Price Range [Axis] Exercise Price Range [Axis] Number of operations lease and operated by third parties Number Of Operations Number Of Operations Current assets: Assets, Current [Abstract] Leases [Abstract] Leases [Abstract] Acquired Operations Acquired Operations [Member] Acquired Operations Transitional and skilled services and senior living campuses Skilled Services And Senior Living Campuses Transitional and Skilled Services and Assistant and Independent Living Campuses Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Colorado COLORADO Share-based compensation, options expected to vest, number (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Number As of the balance sheet date, the number of shares which are expected to vest into stock options outstanding can be converted under the option plan. Disposal Group Name [Domain] Disposal Group Name [Domain] Series of Individually Immaterial Business Acquisitions Series of Individually Immaterial Business Acquisitions [Member] Cash paid during the period for: Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract] California CALIFORNIA Per Facility Per Facility [Member] Per Facility [Member] Beginning balance Ending balance Liability for Future Policy Benefit, before Reinsurance Net income Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Liability for Claims and Claims Adjustment Expense [Line Items] Liability for Claims and Claims Adjustment Expense [Line Items] Gain on sale of assets and insurance recoveries from real estate, net Profit (Loss) from Real Estate Operations Maximum annual contributions per employee Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent Other adjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Customer [Domain] Customer [Domain] First Three Years First Three Years [Member] First Three Years Number of Options Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Litigation Litigation Settlement, Expense TOTAL INCOME TAX PROVISION Effective income tax rate Effective Income Tax Rate Reconciliation, Percent PRESENT VALUE OF TOTAL LEASE LIABILITIES Operating Lease, Liability Schedule of Liability for Future Policy Benefits, by Product Segment Schedule of Liability for Future Policy Benefits, by Product Segment [Table Text Block] Capital contribution from noncontrolling interest holder and Issuance of noncontrolling interests through subsidiary equity plan Noncontrolling Interest, Increase from Subsidiary Equity Issuance Skilled nursing, assisted living and independent living facilities Skilled Nursing, Senior Living and Independent Living Facilities Skilled Nursing, Senior Living and Independent Living Facilities Service revenue Service [Member] Asset Acquisition [Axis] Asset Acquisition [Axis] DESCRIPTION OF BUSINESS Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Long-term debt threshold for EBITDA ratio increase election period Long Term Debt Threshold For EBITDA Ratio Increase Election Period Long Term Debt Threshold For EBITDA Ratio Increase Election Period Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Type and Tier Identifier [Domain] Type and Tier Identifier [Domain] Defined contribution plan, cost Defined Contribution Plan, Cost All Executive Categories All Executive Categories [Member] Plan Name [Axis] Plan Name [Axis] OTHER ACCRUED LIABILITIES Accounts Payable and Accrued Liabilities Disclosure [Text Block] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Liability for Claims and Claims Adjustment Expense [Table] Liability for Claims and Claims Adjustment Expense [Table] Number of reportable segments Number of Reportable Segments NET INCOME PER SHARE ATTRIBUTABLE TO THE ENSIGN GROUP INC. Earnings Per Share [Abstract] Common stock: $0.001 par value; 150,000, 59,987 and 56,597 shares authorized, shares issued and shares outstanding at December 31, 2023, respectively, and 100,000, 59,029 and 55,661 shares authorized, shares issued and shares outstanding at December 31, 2022, respectively Common Stock, Value, Issued Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Trade name Facility trade name Trade Names [Member] Other long-term liabilities Increase (Decrease) in Other Deferred Liability 2028 Lessor, Operating Lease, Payment to be Received, Year Five Accrued self-insurance liabilities Increase (Decrease) in Self Insurance Reserve Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] All Individuals All Individuals [Member] Property taxes Accrual for Taxes Other than Income Taxes Other income Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Stock repurchase program, authorized amount Stock Repurchase Program, Authorized Amount Schedule of Effective Income Tax Rate Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] PEO Name PEO Name Liability for Future Policy Benefit, by Product Segment [Line Items] Liability for Future Policy Benefit, by Product Segment [Line Items] Amortization of deferred rent Deferred Rent Adjustment Adjustment to deferred rent arising from the difference between rent expense recognized and rental payments made in the current period. Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Schedule of Reconciliation of the Numerator and Denominator Used in the Calculation of Diluted Net Income Per Common Share Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block] Base Rate Base Rate [Member] Schedule of Goodwill Schedule of Goodwill [Table Text Block] Tax credits Deferred Tax Assets, Tax Credit Carryforwards Spinoff Spinoff [Member] Non-cash leasing arrangement Non-Cash Lease Expense Non-Cash Lease Expense Other accrued liabilities OTHER ACCRUED LIABILITIES Other Accrued Liabilities, Current All Other Corporate, Non-Segment [Member] Number of leases Lessor, Operating Lease, Number Of Leases Lessor, Operating Lease, Number Of New Leases Litigation settlement, amount awarded to other party Litigation Settlement, Amount Awarded to Other Party Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Debt instrument, interest rate, stated percentage Debt Instrument, Interest Rate, Stated Percentage Accrued wages and related liabilities Increase (Decrease) in Employee Related Liabilities Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Total Ensign Group, Inc. stockholders' equity Equity, Attributable to Parent Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Unapplied state relief funds Accrued Liabilities, State Relief Contract Liabilities Accrued Liabilities, State Relief Contract Liabilities Restricted Stock Awards Stock-based compensation expense related to restricted stock awards Restricted Stock [Member] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Expected Life Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Income before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Fair Value, Inputs, Level 2 Fair Value, Inputs, Level 2 [Member] Debt issuance costs, net Debt Issuance Costs, Line of Credit Arrangements, Net Campus Operation Campus Operation [Member] Campus Operation Disposal Group Classification [Domain] Disposal Group Classification [Domain] Debt instrument, interest rate, effective percentage Debt Instrument, Interest Rate, Effective Percentage Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Less: net income (loss) attributable to noncontrolling interests Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest Document Fiscal Period Focus Document Fiscal Period Focus Liability for Future Policy Benefit, by Product Segment [Table] Liability for Future Policy Benefit, by Product Segment [Table] Finite-lived intangible asset, useful life Finite-Lived Intangible Asset, Useful Life 2027 Lessee, Operating Lease, Liability, to be Paid, Year Four Rent expense Operating Lease, Expense Balance at beginning of period (in dollars per share) Balance at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Lessee leasing arrangements, operating leases, number of renewal terms Lessee Leasing Arrangements, Operating Leases, Number Of Renewal Terms Lessee Leasing Arrangements, Operating Leases, Number Of Renewal Terms Cash payments for Medicare and Medicaid licenses Payments For Medicare and Medicaid Licenses Payments For Medicare and Medicaid Licenses Stock repurchase program, period in force Stock Repurchase Program, Period in Force 5.3% Promissory Note 5.3% Promissory Note [Member] 5.3% Promissory Note City Area Code City Area Code COMPUTATION OF NET INCOME PER COMMON SHARE Earnings Per Share [Text Block] Product and Service [Axis] Product and Service [Axis] Standard Bearer Equity Plan Standard Bearer Equity Plan [Member] Standard Bearer Equity Plan Quality assurance fee Quality Assurance Fee Quality assurance fee represents amounts payable to California, Utah, Idaho, Washington, Colorado, Iowa, and Nebraska in respect of a mandated fee based on resident days Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Private and other Private and other payors Private Pay and Other [Member] Revenue from self-pay and Other payors [Member] Lessee, operating lease, term of contract Lessee, Operating Lease, Term of Contract Third-Party Payor 524292 Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds [Member] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Exercise price, lower range limit (in dollars per share) Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit Exercise Price Award Exercise Price Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Equity, Class of Treasury Stock [Line Items] Equity, Class of Treasury Stock [Line Items] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] NET INCOME Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Thereafter Lessor, Operating Lease, Payment to be Received, after Year Five Offsetting expense (income) Investment Expense (Income) Investment Expense (Income) Number of operating subsidiaries Number Of Operating Subsidiaries Number Of operating subsidiaries entered into mortgage loans that are insured with HUD. Schedule of Stock-Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] TOTAL LIABILITIES AND EQUITY Liabilities and Equity Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount 2022 Exercise Price Range Ten [Member] Exercise Price Range Ten [Member] Weighted Average Risk-Free Rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Right-of-use assets Operating Lease, Right-of-Use Asset Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Management fees, as a percentage of total revenues Property Management Fee, Percent Fee of Total Revenues Property Management Fee, Percent Fee of Total Revenues Consumer price index Lessee, Operating Lease, Consumer Price Index Lessee, Operating Lease, Consumer Price Index Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Right of use asset Deferred Tax Liabilities, Right Of Use Asset Deferred Tax Liabilities, Right Of Use Asset Indefinite-lived Intangible Assets [Line Items] Indefinite-Lived Intangible Assets [Line Items] Other States, Except California, Texas and Washington Other states, except California, Texas and Washington [Member] Other states, except California, Texas and Washington Arrangement Duration Trading Arrangement Duration Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Schedule of Segment Financial Information Schedule of Segment Reporting Information, by Segment [Table Text Block] Leased asset Leased Assets, Acquired During Period Leased Assets, Acquired During Period Proceeds from CARES Act Provider Relief Fund and Medicare Advance Payment Program (Note 3) Proceeds From CARES Act Provider Relief Funds And Medicare Advance Payment Program Proceeds From CARES Act Provider Relief Funds And Medicare Advance Payment Program Medicare accelerated and advance payment Medicare Accelerated And Advance Payment, CARES ACT Medicare Accelerated And Advance Payment, CARES ACT Deconsolidation of an ancillary business Cash Divested from Deconsolidation Fair Value Considerations Fair Value of Financial Instruments, Policy [Policy Text Block] Acquisition of noncontrolling interest shares Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests Termination Date Trading Arrangement Termination Date Common shares authorized Common Stock, Shares Authorized Total Management Fee Management Service, Total [Member] Management Service, Total Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] Insurance subsidiary deposits and investments Insurance Subsidiary Deposits And Investments Captive insurance subsidiary cash and equivalents designated to support long-term insurance subsidiary liabilities and debt security investments held to maturity. Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Award Timing Disclosures [Line Items] Accrued dividends declared Dividends payable Dividends Payable Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Gain (loss) on deferral investment Gain (Loss) on Investments Escrow deposits Escrow Deposit Movement in Liability for Future Policy Benefits [Roll Forward] Movement in Liability for Future Policy Benefits [Roll Forward] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Income Taxes Income Tax, Policy [Policy Text Block] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Three Purchase of non-controlling interest Purchases of Non-Controlling Interest Purchases of Non-Controlling Interest Insider Trading Arrangements [Line Items] Managed care Managed care Managed care Managed Care [Member] Revenue from managed care payors [Member] Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Two Adjustment to Compensation, Amount Adjustment to Compensation Amount Cost of Services Cost of Sales [Member] Total deferred income tax expense (benefit) Deferred Federal, State and Local, Tax Expense (Benefit) Non-controlling interest Equity, Attributable to Noncontrolling Interest Amended Master Lease Agreement Amended Master Lease Agreement [Member] Amended Master Lease Agreement Auditor Name Auditor Name Deferred compensation liability Increase (Decrease) in Deferred Compensation Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Issuance of restricted stock, net of forfeitures Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Disposal Group Name [Axis] Disposal Group Name [Axis] Weighted Average Exercise Price of Options Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Prepayment Fee, Period [Domain] Prepayment Fee, Period [Domain] Prepayment Fee, Period [Domain] Reconciliation of Revenue from Segments to Consolidated [Table] Reconciliation of Revenue from Segments to Consolidated [Table] Payments on debt (Note 15) Repayments of Long-Term Debt Entity Central Index Key Entity Central Index Key Amortization of deferred financing fees Amortization of Debt Issuance Costs and Discounts Share-based compensation Stock-based compensation expense related to stock options Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Gross Carrying Amount Finite-Lived Intangible Assets, Gross Rent—cost of services Rent Cost Of Services Rent cost of services Non-deductible expenses Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent Third Party Operators Third Party Operators [Member] Third Party Operators Accrued wages and related liabilities Employee-related Liabilities, Current Payments of deferred financing costs Payments of deferred financing costs Payments of Financing Costs Revenue Revenue Benchmark [Member] Name Trading Arrangement, Individual Name Schedule of Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards Stock Issued During Period, Value, New Issues Lessor, Lease, Description [Line Items] Lessor, Lease, Description [Line Items] TOTAL REVENUE Revenue Total Service Revenue Revenue from Contract with Customer, Excluding Assessed Tax Entity [Domain] Entity [Domain] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag In The Fourth Year In The Fourth Year [Member] In The Fourth Year INTANGIBLE ASSETS — NET Intangible Assets Disclosure [Text Block] Medicare and Medicaid licenses Medicare and Medicaid Licenses [Member] Medicare licenses for home health and hospice segment and all other segment. Legal Entity [Axis] Legal Entity [Axis] TOTAL ACQUISITIONS Business Combination And Asset Acquisition, Assets Acquired And Liabilities Assumed, Net Business Combination And Asset Acquisition, Assets Acquired And Liabilities Assumed, Net Operating lease, weighted average discount rate, percent Operating Lease, Weighted Average Discount Rate, Percent Interest Interest Paid, Excluding Capitalized Interest, Operating Activities Standard Bearer Standard Bearer Segment [Member] Standard Bearer Segment Senior Living Operations Senior Living Operations [Member] Senior Living Operations LONG-TERM DEBT LESS CURRENT MATURITIES Long-Term Debt, Excluding Current Maturities State taxes Deferred Tax Liabilities, State Taxes Deferred Tax Liabilities, State Taxes GOODWILL Goodwill Disclosure [Text Block] Leasehold improvements Leasehold Improvements [Member] Diluted (in shares) Adjusted weighted average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Grantee Status [Domain] Grantee Status [Domain] Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Other indefinite-lived intangible assets Indefinite-lived intangible assets Indefinite-Lived Intangible Assets Acquired Total deferred payment of social security taxes Liabilities, Deferred Tax Payments Under CARES Act Liabilities, Deferred Tax Payments Under CARES Act Operating lease, variable lease income Operating Lease, Variable Lease Income Company Selected Measure Amount Company Selected Measure Amount Share-based Payment Arrangement, Option, Exercise Price Range [Line Items] Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] TOTAL ASSETS Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Share Repurchase Program [Axis] Share Repurchase Program [Axis] Equipment Equipment [Member] Refunds payable Resident Refunds Payable Resident refunds payable includes amounts due to residents for overpayments and duplicate payments Employee stock award compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition 2028 Long-Term Debt, Maturity, Year Five Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors Stock awards [Member] Stock awards [Member] 2018 Exercise Price Range Six [Member] Exercise Price Range Six [Member] Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Non-NEOs Non-NEOs [Member] Construction in progress Construction in Progress [Member] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Non-PEO NEO Non-PEO NEO [Member] Other than options, conversion to reduce shares availability Share-based Compensation Arrangement By Share-based Payment Award, Other Than Options, Conversion To Reduce Shares Availability Share-based Compensation Arrangement By Share-based Payment Award, Other Than Options, Conversion To Reduce Shares Availability Adjustment to Compensation: Adjustment to Compensation [Axis] Debt Instrument [Line Items] Debt Instrument [Line Items] Basic (in shares) Weighted average shares outstanding for basic net income per share (in shares) Weighted Average Number of Shares Outstanding, Basic Triple Net Lease Arrangements Triple Net Lease Arrangements [Member] Triple Net Lease Arrangements Depreciation and amortization Deferred Tax Liabilities, Property, Plant and Equipment Reclassifications Reclassification, Comparability Adjustment [Policy Text Block] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Insurance Type and Tier Identifier [Axis] Insurance Type and Tier Identifier [Axis] Schedule of Indefinite-Lived Intangible Assets [Table] Schedule of Indefinite-Lived Intangible Assets [Table] Forfeited (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Forfeited Rental revenue Operating Lease, Lease Income Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Line of credit facility, unused capacity, commitment fee percentage Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Statement [Line Items] Statement [Line Items] Deferred: Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract] Concentration Risk [Table] Concentration Risk [Table] Number of Options Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Non-Controlling Interest Noncontrolling Interest [Member] EX-101.PRE 13 ensg-20231231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 14 ensg-20231231_g1.jpg GRAPHIC begin 644 ensg-20231231_g1.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_X1#Z17AI9@ 34T *@ @ ! $[ ( M 0 (2H=I 0 ! (6IR= $ @ 0TNH< < @, /@ M FMC.60G/SX- M"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B/CQR9&8Z4D1& M('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO&UL;G,Z'!A8VME="!E;F0])W7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#Z*I1R124J M_>'UK00_RQZT>6/6GT5%V,9Y8]:/+'K3Z*+L!GECUH\L>M/HHNP&>6/6CRQZ MT^BB[ 9Y8]:/+'K3Z*+L!GECUH\L>M.9U12S, ,DD]*PM1\<>&]*4F]UBU1 MA_ ) 6/X5+FH[LF4HQ5Y.QM^6/6CRQZUYQJ7QR\,VF19K<7C#^ZNT'\:X_4_ MC_J4NX:3ID%N#T\\ER/R(KGEC*4?M'+/&T(?:/=_+'K5>YN[.R&;R[AMQZRR M!?YU\P:G\3_%FJ9$NJR11G_EG$ !_C7-7&I7MVY:ZNYI2>N^0FN:68K[*..> M:07PQ/J'4?B1X2TS<+C5XW(_YX@R?^@YKF+SX[>'8,_9;6[NOH-O\Z^?**YY M9A6>VARRS*L]K(]HN?C^V3]CT88[>:_^!JA_PO[6.VCV/_?3_P"->345B\97 M?VC!XW$/[1ZQ_P +^UG_ * ]C_WT_P#C1_PO[6?^@/8_]]/_ (UY/11];K_S M"^N8C^8]FMOC_+Q]LT=/?RG/]36_IOQS\.76!J$%S9>I*[Q_X[FOGJBJCCJZ MZFDM/HK2[-1GECUH\L>M/HHNP&>6/6HZG/2H*I""E7[P^M)2K M]X?6F!-11168PJOJ"74FGS+I\BQ7)0^4[C*ANV1Z58HH$]4>#WGQE\5Z!JDM MAK>GVSS0MA@%*9_G4Z?M#3A '\/(S=R+HC/_ ([7SU6V>WF0XPPX/T/>O'K2Q%!_%H>%B)XK#R^+0]? MD_:$41J8M!W/W!N< ?CMJM+^T+UM(CC@LN[%85Y\6_&%YG_ (F1@S_SP7;BN*HK-XBJ]Y,S MEBJTMY,TK[Q#J^ID_;]1N)\G)WN:SF9F^\2?J:2BLFV]S!MO<****1(4444 M%%%% !1110 4444 %%216\TYQ!#)(?\ 84G^5:EGX2U^_P#^/72+I^<R*49/9&/179VOPF\97(!.CO$I&07D3G]:TX?@AXJE8AQ;Q#'5GZ_E6J MH57]EFRPU9[19YS7<>!OB;JGA*X2"5VNM-+?/ Q^Z.Y6M3_A17B?_GM9_P#? M;?X56E^"GBR,MLAADV]-LG7\ZN-*O3?-%,UA1Q-*7-&+1]"Z)KECXATN*_TR M82PR#\5/H:T*\%\!:9XV\!Z\JW>D7#:9.P6=5=6'^\ #7O0YKVJ-1U(^\K,^ M@P]9U87DK,****W.@#TJ"ISTJ"JB(*5?O#ZTE*OWA]:H":BBBLQA1110 5C> M(_"FD^*;$V^K6JR''RR@8=/H:V:*3BI*S)E%25F?/'BKX(ZMI6^XT-_[0MAS MLX$BCZ=_PKS6ZL[FQG,-Y;RP2+U25"I_(U]HUG:GX?TG6(C'J>GP7"GKN7G\ MQS7G5,!%ZP=CRZV6PEK3=CXXHKZ/U7X'>&;W@1P5'X$9_6N.U'X M:E&Y.FZI#.AZ*Z;2/QS7%+!UH]+GGSP%>/2YY#17H%U\%O%]MDK;03+V\N4$ MG\*SI/A9XOC&?['F;_=!-8NC46\6<[P]9;Q9R%%=8OPP\7LP']BW(SW*&K4/ MPB\83$@:;LQ_?;%+V-1_98E0JO[+^XXFBO3+7X%>*)@#BC%.K MIC@*:^)W.N&64U\3;/&M-_9^ME8'5M6D?'\,"@ _F*Z_3/A'X2TW#?V?]HD' M\'UI*5?O#ZU0$U M%%%9C"BBB@ HHHH **** "BBB@ HHHH **** "BD9U12SL%4=23@5EWWB?0] M-4M>ZI:QXZCS 3^0YI-I;B//<#^1-82Q-&.\CFEBZ$-Y'L]%?/-W\>?$,Q/V6UMK;TXW8_, M5B77Q>\8W>=VI",?],HPO\JQ>.I+:YSRS*@MKL^H:*^39OB)XKG#!M;NUW?W M)2N/RJK_ ,)MXH_ZO_ I_\:S_ +0AV,_[4I_RL^O**^0_^$V\4?\ 0P:E M_P"!3_XU;A^(_BR'&W6KIL#'SR$T?VA#L"S2GUBSZQHKYDL_C+XOM#AKR.9? M22)2?SKHM/\ C_J41VZEI<,P_O1M@_ETK2..HO?0UCF-![W1[S17F>D?'/PY M?%5OX[BP;NTB@K_XZ2:[C3/$VBZQ&'TW4K><'H ^#^1YKIA6IS^%G7"O2J?# M(U****U-@HHHH #TJ"ISTJ"JB(*5?O#ZTE,FF%O"\S*SB-2Q5%RQQV [FJ8% MJBN,@^+'A&:0H^H^0P.")EV8-:]OXT\-70'V?6[*3/3;,#7.JL'LT9JM3EM) M&Y16='X@TB5PD>HVS,>@$@J5]8TZ)"TE[ JCJ2XJ^9=R^:/ZL"\^/VCQ _8]+N+@YXS($_I6AD!=A^((KE=2^)WBS4P5EU:2.,]4B _QKGECJ2VU.:>948[79]1 MW6H6=BNZ]NX;<>LL@7^=682?PHY)YI)_!$]YU+X_Z='E=,TR:8]GD.%_+K7(:I\P7H/+3:T5RRQ5:74XYXVO/[1MZCXR\0ZJ62)QT:-BI_,5'10,[KPY\6_$F@%8Y;C[?;C_EG<O\ MA3XO:#XAV07;C3KL\;)CA2?9NE?,U*"0<@X/K752Q52GUNCLHXVM2ZW7F?:R ML'4,A#*PR"#P12U\R^"OBMJ_AB:.WO':]T_.&C<_,@_V37T)X>\2Z9XGTY;S M2;A95/WES\R'T(KUZ.(A66FY[N'Q5.NM-'V-8]*@J<]*@KKB=04J_>'UI*5? MO#ZU0'AOQ?\ AP]G<2>(=&BS;R'-Q"HY0_WA[5Y &(Z$CZ&OM66))HFCE0.C M##*PR"*\.^(OP>DADFU7PO&&B^]):+U7_=]O:O%Q6$=^>!XF-P3NZE/YH\<\ MQQT=OSI?-D/61O\ OJDDC>&1HY49'4X*L,$4VO+/''>8_P#>;\Z;G/6BB@ H MHHH$%%%% !1110 4444 %%%% !1110 4444 %%%% !112@9.!R: $HJ];:+J M=ZP%KI]S+GIMB8C\ZWK'X8>+K]AY6C2JIZL[JN/S.:J,)RV1I&G.7PILY.BO M3K/X$>);E09[BSMO:1F/\@:V+?\ 9]NCC[5K$(YY\M2?YBMEA:S^R;QP==_9 M/&:*]SB_9[M,GS]JK>Z9+@]'C)^5QZ&O6I?V>[3(\C7)B.^^(#^54;K]GVY /V+ M68B>WFJ1_(4UA:\7=(%@L3!\R6IZKX2\56/BW0X[ZQ8!L8EB)YC;TK6KR+P9 M\/\ Q=X%\1+<0R6]Y9R?)<1Q.?F'J V.:]=KVL/.H(S7)6PM.KKLSBKX*E6UV9\4D%201 M@CJ#25]6Z]\-O#/B$L]W8+%,W_+:#Y6_P_2O-]:^ -RDC/H6I+(G:*=<'_OK M_P"M7FU,%5CMJ>14R^M#X=3QJBNNU/X7>+=+)\S2I9U7JUN-X_2N9N;&ZLY# M'=6\D3CJKJ0:Y)0E'XD<4JBE((ZBDJ3,**** "BBE )Z"@!**GM[* MYNGV6\$DC>BKFMZQ^'OBK4 #;Z+=;#T=HR!^=4HRELBXPE+X5 M)[G:;M[:U4^K[B/PXKK-,_9_L8BIU;599_40*$_GFMXX6M+H=,,%7E]D\(J> MVLKJ]?;9VTL[>D2%C^E?3^F_"GPCII#+IBW#CH\[$D?EBNHMM+L+) EK9PQ! M>FV,"NF.7R?Q,ZX97-_%(^7M+^&'BS5MIATJ6)6[W'[O'_?6*[#3/@#JDV&U M348;<=T0;F_/I7O=%=4<#26^IV0RVC'>[/,=+^!7ARS*M?37-Z>ZNVT?^.X- M=?I_@;PUI8'V31[8;>AD7?\ ^A9K?HKIC1IPVB=<,/2A\,410VT%NNVWACB' MHB!?Y5+116IN%%%% !1110 4444 !Z5!4YZ5!51$%*OWA]:2E7[P^M4!-111 M68PHHHH **** "H9[*VN4*7$$]8M,0S6 M9+\)O!\C[O[+5/9#@5V=%9NE3>Z1DZ--[Q1P9^#7@\L3]CE&?23_ .M3H_@[ MX/1L_89&]FDS_2NZHJ?84OY43]7H_P J./@^%?@^#_F$12<_\M!FM2V\%^&[ M/_CUT6SB_P!V(5N452IP6R12HTUM%$,-G;6\82""-%'0*HJ8 #H,445H:A14 M4UU;VXS<3Q1?[[A?YUCWGC;PW8,1=:Q:J1UVON_EFI?#<2DI:7TI!Z*J\_F:R>(I+>2,7BJ"WDCU" MBO*/^&@= _Z!6I?E'_\ %4Z+X_>'GD"MINH1C^\P3 _)J7UJC_,3]V: V)Z*\QA^.G MA\3-%J%I=VKJ<, N_!_2M)/C+X/=0?MDHSV,6,?K6"Q%)_:1SK%4']I'>45Q M#_%WP>B;O[1)]@N34$OQH\'1+N^U3O[)#D_SI^WI?S(?UBBOM([ZBO+;GX]> M'H\_9K2ZF^HV_P!*PK_]H*1B1IVC"/G@RR[L_D!6+->U7/V_5;F7/^WC^582Q] M-?"KG-+,Z:^%-GU/J'B[0-+0M>ZM:(1_#YREORSFN0U+XX>%[,E;3S[UAV1" MOZD5\XO(\AS([.?5CFFUS2Q]1_"K')/,ZK^%)'L6I_M 7LFY=*TJ&('HTY)( M_(XKD-3^*_BW4R0VI-!'_1=N=9U.\8M=:A MBF0LOY'(KT/P_P#'C4K5ECU^T2\C[RQC:_\ A^E>245K"M4I_"S> MGB*M/X9'UMX;\=:#XI1?[,O5\XC)@D^5Q^!ZUT5?%EO<36LRS6TKQ2*Q_#_XS.CQZ;XK;]>%NCQ.4D4JP."",$5]K5P'C? MX4:7XI+W=GML;_!.]1A7/^T!_.O-Q.#YGST]SR,7@.=\]+?L?,U%=!XC\$ZY MX8N6CU*RD\L'Y9HQN1AZY'3\:Y^O(E%Q=FCPY1E%VDK!1112)"BBB@ HHHH M**** "BBB@ HI0"QP!D^@K3L?#6M:DP6RTRZEST(B('YGBFDWL4HMZ(RZ*] MTKX,>*]0VFXMX[%3_%.X/'_ V&+>".+C'R*!4U;++UUD;K*UUE^!\@?\ "(Z__P! FY_[XJO)X?U> M)2SZ=<@+U_=FOL>BG_9\?YA_V7'^8\$^$OCR\T>]30=;6464IQ!)(I'E-Z?0 M_P!*][JI-I6GW+;KBRMY6ZY>(&K?3I791IRIQY6[GH8>E*E#DD[A1116YT > ME05.>E0541!2K]X?6DHJ@)Z*AS1FIY1DU%0YHS1R@345#FC-'* Z>WAN8C'< MQ)*AZJZA@?P-<-K_ ,'_ QK9:2&!K"=N2]N>I^AR*[?-&:B=&,U:2N9SIPJ M*TU<\)U/X!:K"2VEZC# M"*3_ %D2-_O*#4+:=9,TOP.=Y7VE^!\< $G &35A-.O9& MQ':3,?01DU]?_P!F6 _Y*WM/^$'B^_/\ QX+ O@% M.S6DD? M>5V"@_E@UZ1FC-;QP5&/0Z88*A'[)CZ=X(\-Z5C[%H]LN.A==_\ Z%FMN*&. M%-D,:1KZ(H IF:,UTJFH['7&,8_"K$U%0YHS3Y2B:BH GRAPHIC 15 ensg-20231231_g2.jpg GRAPHIC begin 644 ensg-20231231_g2.jpg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end GRAPHIC 16 ensg-20231231_g3.jpg GRAPHIC begin 644 ensg-20231231_g3.jpg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ensg-20231231_g6.jpg PERFORMANCE GRAPH begin 644 ensg-20231231_g6.jpg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
  •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end XML 20 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Cover - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2023
    Jan. 29, 2024
    Jun. 30, 2023
    Cover [Abstract]      
    Document Type 10-K    
    Document Annual Report true    
    Current Fiscal Year End Date --12-31    
    Document Period End Date Dec. 31, 2023    
    Document Transition Report false    
    Entity File Number 001-33757    
    Entity Registrant Name ENSIGN GROUP, INC    
    Entity Incorporation, State or Country Code DE    
    Entity Tax Identification Number 33-0861263    
    Entity Address, Address Line One 29222 Rancho Viejo Road, Suite 127    
    Entity Address, City or Town San Juan Capistrano    
    Entity Address, State or Province CA    
    Entity Address, Postal Zip Code 92675    
    City Area Code 949    
    Local Phone Number 487-9500    
    Title of 12(b) Security Common Stock, par value $0.001 per share    
    Trading Symbol ENSG    
    Security Exchange Name NASDAQ    
    Entity Well-known Seasoned Issuer Yes    
    Entity Voluntary Filers No    
    Entity Current Reporting Status Yes    
    Entity Interactive Data Current Yes    
    Entity Filer Category Large Accelerated Filer    
    Entity Small Business false    
    Entity Emerging Growth Company false    
    ICFR Auditor Attestation Flag true    
    Document Financial Statement Restatement Recovery Analysis [Flag] false    
    Entity Shell Company false    
    Entity Public Float     $ 3,156,373
    Entity Common Stock, Shares Outstanding   56,665,741  
    Documents Incorporated by Reference
    Part III of this Form 10-K incorporates information by reference from the Registrant's definitive proxy statement for the Registrant's 2024 Annual Meeting of Stockholders to be filed within 120 days after the close of the fiscal year covered by this annual report.
       
    Entity Central Index Key 0001125376    
    Document Fiscal Year Focus 2023    
    Document Fiscal Period Focus FY    
    Amendment Flag false    

    XML 21 R2.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Audit Information
    12 Months Ended
    Dec. 31, 2023
    Audit Information [Abstract]  
    Auditor Name DELOITTE & TOUCHE LLP
    Auditor Location Costa Mesa, California
    Auditor Firm ID 34
    XML 22 R3.htm IDEA: XBRL DOCUMENT v3.24.0.1
    CONSOLIDATED BALANCE SHEETS - USD ($)
    $ in Thousands
    Dec. 31, 2023
    Dec. 31, 2022
    Current assets:    
    Cash and cash equivalents $ 509,626 $ 316,270
    Accounts receivable—less allowance for doubtful accounts of $9,348 and $7,802 at December 31, 2023 and 2022, respectively 485,039 408,432
    Investments—current 17,229 15,441
    Prepaid expenses and other current assets 35,036 40,982
    Total current assets 1,046,930 781,125
    Property and equipment, net 1,090,771 992,010
    Right-of-use assets 1,756,430 1,450,995
    Insurance subsidiary deposits and investments 92,687 67,652
    Deferred tax assets 67,124 39,643
    Restricted and other assets 40,205 37,291
    Intangible assets, net 6,525 6,437
    Goodwill 76,869 76,869
    TOTAL ASSETS 4,177,541 3,452,022
    Current liabilities:    
    Accounts payable 92,811 77,087
    Accrued wages and related liabilities 332,568 289,810
    Lease liabilities—current 82,526 65,796
    Accrued self-insurance liabilities—current 54,664 48,187
    Other accrued liabilities 168,228 97,309
    Current maturities of long-term debt 3,950 3,883
    Total current liabilities 734,747 582,072
    Long-term debt—less current maturities 145,497 149,269
    Long-term lease liabilities—less current portion 1,639,326 1,355,113
    Accrued self-insurance liabilities—less current portion 111,246 83,495
    Other long-term liabilities 49,408 33,273
    TOTAL LIABILITIES 2,680,224 2,203,222
    Commitments and contingencies (Notes 15 and 20)
    Ensign Group, Inc. stockholders' equity:    
    Common stock: $0.001 par value; 150,000, 59,987 and 56,597 shares authorized, shares issued and shares outstanding at December 31, 2023, respectively, and 100,000, 59,029 and 55,661 shares authorized, shares issued and shares outstanding at December 31, 2022, respectively 60 59
    Additional paid-in capital 465,707 415,560
    Retained earnings 1,142,653 946,339
    Common stock in treasury, at cost, 3,390 and 3,368 shares at December 31, 2023 and 2022, respectively (116,555) (114,626)
    Total Ensign Group, Inc. stockholders' equity 1,491,865 1,247,332
    Non-controlling interest 5,452 1,468
    Total equity 1,497,317 1,248,800
    TOTAL LIABILITIES AND EQUITY $ 4,177,541 $ 3,452,022
    XML 23 R4.htm IDEA: XBRL DOCUMENT v3.24.0.1
    CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
    shares in Thousands, $ in Thousands
    Dec. 31, 2023
    Dec. 31, 2022
    Statement of Financial Position [Abstract]    
    Allowance for doubtful accounts $ 9,348 $ 7,802
    Common stock, par value (in dollars per share) $ 0.001 $ 0.001
    Common shares authorized 150,000 100,000
    Common shares issued 59,987 59,029
    Common shares outstanding 56,597 55,661
    Common shares in treasury, at cost 3,390 3,368
    XML 24 R5.htm IDEA: XBRL DOCUMENT v3.24.0.1
    CONSOLIDATED STATEMENTS OF INCOME - USD ($)
    shares in Thousands, $ in Thousands
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    TOTAL REVENUE $ 3,729,355 $ 3,025,468 $ 2,627,461
    Expense:      
    Cost of services 2,941,238 2,354,434 2,019,879
    Rent—cost of services 197,358 153,049 139,371
    General and administrative expense 263,005 158,805 151,761
    Depreciation and amortization 72,387 62,355 55,985
    TOTAL EXPENSES 3,473,988 2,728,643 2,366,996
    Income from operations 255,367 296,825 260,465
    Other income (expense):      
    Interest expense (8,087) (8,931) (6,849)
    Other income 25,482 1,195 4,388
    Other income (expense), net 17,395 (7,736) (2,461)
    Income before provision for income taxes 272,762 289,089 258,004
    Provision for income taxes 62,912 64,437 60,279
    NET INCOME 209,850 224,652 197,725
    Less:      
    Net income (loss) attributable to noncontrolling interests 451 (29) 3,073
    Net income attributable to The Ensign Group, Inc. $ 209,399 $ 224,681 $ 194,652
    NET INCOME PER SHARE ATTRIBUTABLE TO THE ENSIGN GROUP INC.      
    Basic (in dollars per share) $ 3.76 $ 4.09 $ 3.57
    Diluted (in dollars per share) $ 3.65 $ 3.95 $ 3.42
    WEIGHTED AVERAGE COMMON SHARES OUTSTANDING      
    Basic (in shares) 55,708 54,887 54,486
    Diluted (in shares) 57,323 56,871 56,925
    Service revenue      
    TOTAL REVENUE $ 3,708,071 $ 3,008,711 $ 2,611,476
    Rental revenue      
    TOTAL REVENUE $ 21,284 $ 16,757 $ 15,985
    XML 25 R6.htm IDEA: XBRL DOCUMENT v3.24.0.1
    CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
    shares in Thousands, $ in Thousands
    Total
    Common Stock
    Additional Paid-In Capital
    Retained Earnings
    Treasury Stock
    Non-Controlling Interest
    Balance at beginning of period (in shares) at Dec. 31, 2020   54,626        
    Balance at beginning of period at Dec. 31, 2020 $ 818,227 $ 58 $ 338,177 $ 551,055 $ (71,213) $ 150
    Balance at beginning of period (in shares) at Dec. 31, 2020         2,791  
    Increase (Decrease) in Stockholders' Equity [Roll Forward]            
    Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards (in shares)   516        
    Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards 9,180   9,180      
    Issuance of restricted stock, net of forfeitures (in shares)   201        
    Issuance of restricted stock, net of forfeitures 3,725   3,725      
    Shares of common stock used to satisfy tax withholding obligations (in shares)   21     21  
    Shares of common stock used to satisfy tax withholding obligations (1,711)       $ (1,711)  
    Dividends declared (11,715)     (11,715)    
    Employee stock award compensation $ 18,678   18,678      
    Repurchase of common stock (in shares) 132 132     132  
    Repurchase of common stock (Note 21) $ (10,118)       $ (10,118)  
    Deconsolidation of an ancillary business (1,369)         (1,369)
    Capital contribution from noncontrolling interest holder and Issuance of noncontrolling interests through subsidiary equity plan 2,000         2,000
    Net income (loss) attributable to noncontrolling interests 3,073         3,073
    Noncontrolling interest attributable to subsidiary equity plan (2,908)         (2,908)
    Net income attributable to the Ensign Group, Inc. 194,652     194,652    
    Balance at end of period (in shares) at Dec. 31, 2021   55,190        
    Balance at end of period at Dec. 31, 2021 1,021,714 $ 58 369,760 733,992 $ (83,042) 946
    Balance at end of period (in shares) at Dec. 31, 2021         2,944  
    Increase (Decrease) in Stockholders' Equity [Roll Forward]            
    Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards (in shares)   688        
    Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards 12,677 $ 1 12,676      
    Issuance of restricted stock, net of forfeitures (in shares)   207        
    Issuance of restricted stock, net of forfeitures 5,241   5,241      
    Shares of common stock used to satisfy tax withholding obligations (in shares)   20     20  
    Shares of common stock used to satisfy tax withholding obligations (1,702)       $ (1,702)  
    Dividends declared (12,334)     (12,334)    
    Employee stock award compensation $ 22,720   22,720      
    Repurchase of common stock (in shares) 404 404     404  
    Repurchase of common stock (Note 21) $ (29,882)       $ (29,882)  
    Acquisition of noncontrolling interest shares (704)   (1,539)     835
    Capital contribution from noncontrolling interest holder and Issuance of noncontrolling interests through subsidiary equity plan 6,693   6,693      
    Net income (loss) attributable to noncontrolling interests (29)         (29)
    Noncontrolling interest attributable to subsidiary equity plan (275)   9     (284)
    Net income attributable to the Ensign Group, Inc. $ 224,681     224,681    
    Balance at end of period (in shares) at Dec. 31, 2022 55,661 55,661        
    Balance at end of period at Dec. 31, 2022 $ 1,248,800 $ 59 415,560 946,339 $ (114,626) 1,468
    Balance at end of period (in shares) at Dec. 31, 2022 3,368       3,368  
    Increase (Decrease) in Stockholders' Equity [Roll Forward]            
    Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards (in shares)   759        
    Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards $ 18,369 $ 1 18,368      
    Issuance of restricted stock, net of forfeitures (in shares)   199        
    Issuance of restricted stock, net of forfeitures 5,068   5,068      
    Shares of common stock used to satisfy tax withholding obligations (in shares)   22     22  
    Shares of common stock used to satisfy tax withholding obligations (1,929)       $ (1,929)  
    Dividends declared (13,085)     (13,085)    
    Employee stock award compensation 30,754   30,754      
    Acquisition of noncontrolling interest shares (256)   (256)      
    Net income (loss) attributable to noncontrolling interests 451         451
    Noncontrolling interest attributable to subsidiary equity plan (254)   (3,787)     3,533
    Net income attributable to the Ensign Group, Inc. $ 209,399     209,399    
    Balance at end of period (in shares) at Dec. 31, 2023 56,597 56,597        
    Balance at end of period at Dec. 31, 2023 $ 1,497,317 $ 60 $ 465,707 $ 1,142,653 $ (116,555) $ 5,452
    Balance at end of period (in shares) at Dec. 31, 2023 3,390       3,390  
    XML 26 R7.htm IDEA: XBRL DOCUMENT v3.24.0.1
    CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) - $ / shares
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Statement of Stockholders' Equity [Abstract]      
    Dividends declared (in dollars per share) $ 0.2325 $ 0.2225 $ 0.2125
    XML 27 R8.htm IDEA: XBRL DOCUMENT v3.24.0.1
    CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Cash flows from operating activities:      
    Net income $ 209,850 $ 224,652 $ 197,725
    Adjustments to reconcile net income to net cash provided by operating activities:      
    Depreciation and amortization 72,387 62,355 55,985
    Amortization of deferred financing fees 1,067 1,036 859
    Non-cash leasing arrangement 870 493 485
    Write-off of deferred financing fees 0 566 0
    Deferred income taxes (27,481) (6,496) (724)
    Provision for doubtful accounts 3,408 2,390 2,609
    Stock-based compensation 30,767 22,720 18,678
    Cash received from insurance proceeds 1,396 1,282 2,382
    Gain on sale of assets (123) (3,467) (1,371)
    (Gain)/loss on insurance claims, legal matters and asset disposals (1,368) 3,926 (977)
    Litigation 48,000 0 0
    Change in operating assets and liabilities      
    Accounts receivable (79,818) (82,426) (30,771)
    Prepaid income taxes 814 809 (4,228)
    Prepaid expenses and other assets 6,993 (9,141) (4,898)
    Deferred employer portion of social security taxes (Note 3) 0 (24,155) (24,154)
    Cash surrender value of life insurance policy premiums (16,072) (7,614) (10,953)
    Deferred compensation liability 16,044 7,637 11,078
    Operating lease obligations (6,564) 345 (5,814)
    Accounts payable 15,924 17,870 7,117
    Accrued wages and related liabilities 47,967 38,982 47,701
    Other accrued liabilities 23,828 3,010 1,297
    Accrued self-insurance liabilities 28,827 17,785 13,724
    Other long-term liabilities (50) (46) (66)
    NET CASH PROVIDED BY OPERATING ACTIVITIES 376,666 272,513 275,684
    Cash flows from investing activities:      
    Purchase of property and equipment (106,180) (87,545) (69,550)
    Cash payments for business acquisitions (Note 7) 0 (16,400) (6,000)
    Cash payments for asset acquisitions (Note 7) (67,798) (84,736) (98,224)
    Escrow deposits (1,216) 0 100
    Cash from insurance proceeds 2,029 1,339 6,899
    Cash proceeds from the sale of assets 248 8,630 1,854
    Deconsolidation of an ancillary business 0 0 (1,984)
    Cash payments for Medicare and Medicaid licenses 0 0 (106)
    Purchases of investments (29,603) (21,975) (32,257)
    Maturities of investments 18,852 14,356 27,481
    Other restricted assets 970 149 (2,120)
    NET CASH USED IN INVESTING ACTIVITIES (182,698) (186,182) (173,907)
    Cash flows from financing activities:      
    Proceeds from debt (Note 15) 150 411 45,218
    Payments on debt (Note 15) (4,033) (4,106) (3,056)
    Issuance of common stock upon exercise of options 18,369 12,677 9,180
    Repurchase of shares of common stock to satisfy tax withholding obligations (1,929) (1,702) (1,711)
    Repurchase of shares of common stock (Note 21) 0 (29,882) (10,118)
    Dividends paid (12,890) (12,168) (11,548)
    Proceeds from sale of subsidiary shares (Note 6) 0 6,693 0
    Non-controlling interest distribution (4) (284) (2,908)
    Purchase of non-controlling interest (256) (704) 2,000
    Payments of deferred financing costs (19) (3,197) (1,172)
    Proceeds from CARES Act Provider Relief Fund and Medicare Advance Payment Program (Note 3) 0 0 11,637
    Repayments of CARES Act Provider Relief Fund and Medicare Advance Payment Program (Note 3) 0 0 (113,660)
    NET CASH USED IN FINANCING ACTIVITIES (612) (32,262) (76,138)
    Net increase in cash and cash equivalents 193,356 54,069 25,639
    Cash and cash equivalents beginning of period 316,270 262,201 236,562
    Cash and cash equivalents end of period 509,626 316,270 262,201
    Cash paid during the period for:      
    Interest 7,025 7,604 5,690
    Income taxes 89,730 70,055 65,547
    Lease liabilities 196,942 151,870 138,795
    Non-cash financing and investing activity      
    Accrued capital expenditures 4,600 4,800 3,700
    Accrued dividends declared 3,396 3,201 3,035
    Right-of-use assets obtained in exchange for new and modified operating lease obligations $ 376,550 $ 370,753 $ 198,593
    XML 28 R9.htm IDEA: XBRL DOCUMENT v3.24.0.1
    DESCRIPTION OF BUSINESS
    12 Months Ended
    Dec. 31, 2023
    Organization, Consolidation and Presentation of Financial Statements [Abstract]  
    DESCRIPTION OF BUSINESS DESCRIPTION OF BUSINESS
    The Company — The Ensign Group, Inc. (collectively, Ensign or the Company), is a holding company with no direct operating assets, employees or revenue. The Company's independent subsidiaries provide health care services across the post-acute care continuum and engage in the ownership, acquisition, development and leasing of skilled nursing, senior living and other healthcare-related properties and other ancillary businesses. As of December 31, 2023, the Company's independent subsidiaries operated 297 facilities and other ancillary operations located in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. Subsequent to December 31, 2023, one of the Company's independent subsidiaries expanded its operations into Tennessee. The Company's independent subsidiaries have a collective capacity of approximately 30,600 operational skilled nursing beds and 3,100 senior living units. As of December 31, 2023, the Company's independent subsidiaries operated 214 facilities under long-term lease arrangements and had options to purchase 11 of those 214 facilities. The Company's real estate portfolio includes 113 owned real estate properties, which includes 83 facilities operated and managed by the Company's independent subsidiaries, 30 operations leased to and operated by third-party operators, and the Service Center (defined below) location. Of those 30 operations, one senior living facility is located on the same real estate property as a skilled nursing facility that an independent subsidiary owns and operates.
    Certain of the Company’s wholly-owned independent subsidiaries, collectively referred to as the Service Center, provide specific accounting, payroll, human resources, information technology, legal, risk management and other centralized services to the other independent subsidiaries through contractual relationships with such subsidiaries. The Company also has a wholly-owned captive insurance subsidiary that provides some claims-made coverage to the Company’s independent subsidiaries for general and professional liabilities, as well as coverage for certain workers’ compensation insurance liabilities.
    In 2022, the Company formed a captive real estate investment trust (REIT), which owns and manages its real estate business, called Standard Bearer Healthcare REIT, Inc. (Standard Bearer). The REIT structure provides the Company with an efficient vehicle for future acquisitions of properties that could be operated by Ensign's independent subsidiaries or other third parties. Refer to Note 6, Standard Bearer for additional information on Standard Bearer.
    Each of the Company's independent subsidiaries are operated by wholly-owned subsidiaries that have their own management, employees and assets. References herein to the consolidated “Company” and “its” assets and activities in this Annual Report are not meant to imply, nor should it be construed as meaning that The Ensign Group, Inc. has direct operating assets, employees or revenue, or that any of the subsidiaries, are operated by The Ensign Group, Inc.
    XML 29 R10.htm IDEA: XBRL DOCUMENT v3.24.0.1
    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
    12 Months Ended
    Dec. 31, 2023
    Accounting Policies [Abstract]  
    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
    Basis of Presentation The accompanying consolidated financial statements (the Financial Statements) have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company is the sole member or stockholder of various consolidated limited liability companies and corporations established to operate various acquired skilled nursing operations, senior living operations and related ancillary services. All intercompany transactions and balances have been eliminated in consolidation. The Company presents noncontrolling interests within the equity section of its consolidated balance sheets and the amount of consolidated net income that is attributable to The Ensign Group, Inc. and the noncontrolling interests in its consolidated statements of income. The Financial Statements include the accounts of all independent subsidiaries controlled by the Company through its ownership of a majority voting interest.
    ReclassificationsCertain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements.
    Estimates and Assumptions The preparation of the Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Company’s Financial Statements relate to revenue, acquired property and equipment, intangible assets and goodwill, right-of-use assets, impairment of long-lived assets, lease liabilities, general and professional liabilities, workers' compensation and healthcare claims included in accrued self-insurance liabilities and income taxes. Actual results could differ from those estimates.
    Fair Value ConsiderationsThe Company’s financial instruments consist principally of cash and cash equivalents, debt security investments, accounts receivable, insurance subsidiary deposits, deferred compensation investment funds, equity investments, accounts payable and borrowings. The Company believes all of the financial instruments’ recorded values approximate fair values because of their nature or respective short durations.

    Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions. See Note 5, Fair Value Measurements for additional information.

    The Company's non-financial assets, which includes goodwill, intangible assets, property and equipment and right-of-use assets, are not required to be measured at fair value on a recurring basis. However, on a periodic basis, or whenever events or changes in circumstances indicate that their carrying value may not be recoverable, the Company assesses its long-lived assets for impairment. When impairment has occurred, such long-lived assets are written down to fair value.
    Service Revenue RecognitionThe Company recognizes revenue in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with Customers (ASC 606). The Company's service revenue is derived primarily from providing healthcare services to its patients. Revenue is recognized when services are provided to patients at the amount that reflects the consideration that the Company expects to be entitled from patients and third-party payors, including Medicaid, Medicare and insurers (private and Medicare replacement plans), in exchange for providing patient care. The healthcare services provided pursuant to skilled patient contracts include routine services in exchange for a contractual agreed-upon amount or rate. Routine services are treated as a single performance obligation satisfied over time as services are rendered. As such, patient care services represent a bundle of services that are not capable of being distinct. Additionally, there may be ancillary services that are not included in the daily rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time, if and when those services are rendered.

    Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction price. The Company determines the transaction price based on contractually agreed-upon amounts or rate on a per day basis, adjusted for estimates of variable consideration. The Company uses the expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The amount of variable consideration that is included in the transaction price may be constrained and is included in net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from the Company’s estimates, the Company adjusts these estimates, which would affect net revenue in the period such variances become known.

    As the Company’s contracts with its patients have an original duration of one year or less, the Company uses the practical expedient applicable to its contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of the end of each reporting period or when the Company expects to recognize this revenue. In addition, the Company has applied the practical expedient provided by FASB ASC Topic 340, Other Assets and Deferred Costs, and all incremental customer contract acquisition costs are expensed as they are incurred because the amortization period would have been one year or less.
    Rental Revenue Recognition The Company's rental revenues are primarily generated by leasing healthcare-related properties through triple-net lease arrangements, under which the tenant is solely responsible for the costs related to the property. Revenue for operating leases is recognized on a straight-line basis over the lease term when collectability of all minimum lease payments is probable in accordance with FASB ASC Topic 842, Leases (ASC 842). The Company has elected the single component practical expedient, which allows a lessor, by class of underlying asset, not to allocate the total consideration to the lease and non-lease components based on their relative stand-alone selling prices where certain criteria are met.

    Tenant reimbursements related to property taxes and insurance are neither considered lease nor non-lease components under ASC 842. Lessee payments for taxes and insurance paid directly to a third party, on behalf of the Company, are excluded from variable lease payments and rental revenue in the Company’s consolidated statements of income. Otherwise, tenant reimbursements for taxes and insurance that are paid by the Company directly to a third party are classified as additional rental revenue and expense and recognized by the Company on a gross basis.
    Accounts Receivable Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources, net of estimates for variable consideration.
    Cash and Cash Equivalents Cash and cash equivalents consist of bank term deposits, money market funds and treasury bill related investments with original maturities of three months or less at time of purchase and therefore approximate fair value. The fair value of money market funds is determined based on “Level 1” inputs, which consist of unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets. The Company places its cash and short-term investments with high credit quality financial institutions.
    Insurance Subsidiary Deposits and Investments — The Company's captive insurance subsidiary cash and cash equivalents, deposits and investments are designated to support long-term insurance subsidiary liabilities and have been classified as short-term and long-term assets based on the timing of expected future payments of the Company's captive insurance liabilities. The majority of these deposits and investments are currently held in AA, A and BBB rated debt security investments and the remainder is held in a bank account with a high credit quality financial institution.
    The Company's non-qualified deferred compensation plan (the DCP)'s contracts insuring the lives of certain employees who are eligible to participate in the DCP are held in a rabbi trust. Cash surrender value of the contracts is based on funds that shadow the investment allocations specified by participants in the deferred compensation plan.
    When evaluating an investment for its current expected credit losses, the Company reviews factors such as historical experience with defaults, losses, credit ratings, term, market sector and macroeconomic trends, including current conditions and forecasts to the extent they are reasonable and supportable.
    Property and Equipment Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from three to 59 years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term.
    Leases The Company leases skilled nursing facilities, senior living facilities and commercial office space. The Company determines if an arrangement is a lease and performs an evaluation to determine whether the lease should be classified as an operating or finance lease at the inception of the lease. As of December 31, 2023, the Company has one financing lease that is not material to the consolidated balance sheet. Rights and obligations of these leases are included as right-of-use assets and current and long-term lease liabilities on the Company's consolidated balance sheets. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of future lease payments. The Company utilizes a third-party valuation specialist to assist in estimating the incremental borrowing rate.
    The Company records rent expense for operating leases on a straight-line basis over the term of the lease. The lease term used for straight-line rent expense is calculated from the date the Company is given control of the leased premises through the end of the lease term. Renewals are not assumed in the determination of the lease term unless they are deemed to be reasonably assured at the inception of the lease. The lease term used for this evaluation also provides the basis for establishing depreciable lives for buildings subject to lease and leasehold improvements.
    The Company's real estate leases generally have initial lease terms of ten years or more and typically include one or more options to renew, with renewal terms that generally extend the lease term for an additional ten to 15 years. Exercise of the renewal options is generally subject to the satisfaction of certain conditions which vary by contract and generally follow payment terms that are consistent with those in place during the initial term. The Company reassesses the renewal option using a "reasonably certain" threshold, which is understood to be a high threshold. For leases where the Company is reasonably certain to exercise its renewal option, the option periods are included within the lease term and, therefore, the measurement of the right-of-use asset and lease liability. The Company's leases generally contain annual escalation clauses that are either fixed or variable in nature, some of which are dependent upon published indices. The Company recognizes lease expense for leases with an initial term of 12 months or less on a straight-line basis over the lease term. These leases are not recorded on the consolidated balance sheets. Certain of the Company's lease agreements include rental payments that are adjusted periodically for inflation. The lease agreements do not contain any material residual value guarantees or material restrictive covenants.
    The Company subleases skilled nursing facilities to third-party operators and considers the subleases to be separate contracts as the Company is not relieved of its primary obligation under its operating lease. The rental income from third-parties related to these subleases is presented on a gross basis from the rent expense associated with the Company's lease obligations and is not material to the consolidated statements of income.
    Impairment of Long-Lived Assets The Company reviews the carrying value of long-lived assets that are held and used in the Company’s independent subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the independent subsidiaries to which the assets relate, utilizing management’s best estimate, appropriate assumptions and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset. Management has evaluated its long-lived assets and determined there was no impairment during the years ended December 31, 2023, 2022, and 2021.
    Intangible Assets and Goodwill Definite-lived intangible assets consist primarily of patient base, facility trade names and customer relationships. Patient base is amortized over a period of four to eight months, depending on the classification of the patients and the level of occupancy in a new acquisition on the acquisition date. Trade names at independent subsidiaries are amortized over 30 years and customer relationships are amortized over a period of up to 20 years.
    The Company's indefinite-lived intangible assets consist of trade names and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable.
    Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. The Company tests goodwill during the fourth quarter of each year or more often if events or circumstances indicate there may be impairment. The Company performs its analysis for each reporting unit that constitutes a business for which discrete financial information is produced and reviewed by operating segment management and provides services that are distinct from the other components of the operating segment, in accordance with the provisions of FASB ASC Topic 350, Intangibles—Goodwill and Other (ASC 350). This guidance provides the option to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. If, based on a review of qualitative factors, it is more likely than not that the fair value of a reporting unit is less than its carrying value, the Company performs a goodwill impairment test by comparing the carrying value of each reporting unit to its respective fair value. The Company determines the estimated fair value of each reporting unit using a discounted cash flow analysis. The fair value of the reporting unit is the implied fair value of goodwill. In the event a reporting unit's carrying value exceeds its fair value, an impairment loss will be recognized. An impairment loss is measured by the difference between the carrying value of the reporting unit and its fair value.
    Management has evaluated its goodwill and intangible assets and determined there was no impairment during the years ended December 31, 2023, 2022, and 2021. The Company has recognized cumulative goodwill impairment losses of $7,410, since inception in 1999.
    Self-Insurance — The Company is partially self-insured for general and professional liability claims up to a base amount per claim (the self-insured retention) with an aggregate, one-time deductible above this limit. Losses beyond these amounts are insured through third-party policies with coverage limits per claim, per location and on an aggregate basis for the Company. The combined self-insured retention is $500 per claim, subject to an additional one-time deductible of $1,250 for the Company's independent subsidiaries in California and a separate, one-time, deductible of $1,250 for the Company's independent subsidiaries not in California. For all independent subsidiaries, except those located in Colorado, the third-party coverage above these limits is $1,000 per claim, $3,000 per operation, with a $5,000 blanket aggregate limit and an additional state-specific aggregate where required by state law. In Colorado, the third-party coverage above these limits is $1,000 per claim and $3,000 per operation, which is independent of the aforementioned blanket aggregate limits that apply outside of Colorado.
    Subsequent to December 31, 2023, the self-insured retention is $750 per claim, subject to an additional one-time deductible of $1,500 for the Company's independent subsidiaries in California. For the independent subsidiaries not in California, the self-insured retention is $650 per claim, subject to an additional one-time deductible of $1,350. For all independent subsidiaries, except those located in Colorado, the third-party coverage above these limits is $1,000 per claim, $3,000 per operation, with a $10,000 blanket aggregate limit and an additional state-specific aggregate where required by state law.
    The majority of the self-insured retention and deductible limits for general and professional liabilities and workers' compensation liabilities are self-insured through the captive insurance subsidiary, the related assets and liabilities of which are included in the accompanying consolidated balance sheets. The captive insurance subsidiary is subject to certain statutory requirements as an insurance provider.
    The Company’s policy is to accrue amounts equal to the actuarial estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. The Company develops information about the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluates the estimates for claim loss exposure on a quarterly basis. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information.
    The Company’s independent subsidiaries are self-insured for workers’ compensation liabilities in California. To protect itself against loss exposure in California with this policy, the Company has purchased individual specific excess insurance coverage that insures individual claims that exceed $625 per occurrence. In Texas, the independent subsidiaries have elected non-subscriber status for workers’ compensation claims and the Company has purchased individual stop-loss coverage that insures individual claims that exceed $750 per occurrence. The Company’s independent subsidiaries in all other states, with the exception of Washington, are under a loss sensitive plan that insures individual claims that exceed $350 per occurrence. In the state of Washington, the Company is self-insured and has purchased individual specific excess insurance coverage that insures individual claims that exceed $500 per occurrence. For all of the self-insured plans and retention, the Company accrues amounts equal to the estimated costs to settle open claims, as well as an estimate of the cost of claims that have been incurred but not reported. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information.
    The Company self-funds medical (including prescription drugs) and dental healthcare benefits to the majority of its employees. The Company is fully liable for all financial and legal aspects of these benefit plans. To protect itself against loss exposure with this policy, the Company has purchased individual stop-loss insurance coverage that insures individual claims that exceed $525 for each covered person for fiscal years 2023 and 2022, respectively, and $500 for each covered person for fiscal year 2021.
    The Company believes that adequate provision has been made in the Financial Statements for liabilities that may arise out of patient care, workers’ compensation, healthcare benefits and related services provided to date. The amount of the Company’s reserves was determined based on an estimation process that uses information obtained from both company-specific and industry data. This estimation process requires the Company to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and the Company’s assumptions about emerging trends, the Company, with the assistance of an independent actuary, develops information about the size of ultimate claims based on the Company’s historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damage awards with respect to unpaid claims. The self-insured liabilities are based upon estimates, and while management believes that the estimates of loss are reasonable, the ultimate liability may be in excess of or less than the recorded amounts. Due to the inherent volatility of actuarially determined loss estimates, it is reasonably possible that the Company could experience changes in estimated losses that could be material to net income. If the Company’s actual liabilities exceed its estimates of losses, its future earnings, cash flows and financial condition would be adversely affected.
    Income Taxes — Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized.
    In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company’s estimates and assumptions, actual results could differ.
    Standard Bearer elected to be taxed as a REIT, for U.S. federal income tax purposes, commencing with its taxable year ended December 31, 2022. Standard Bearer was organized, has operated and intends to continue to operate in a manner to qualify for taxation as a REIT. In order to qualify as a REIT, Standard Bearer must meet certain organizational and operational requirements, including a requirement to distribute to its shareholders, which in this case is the Company, at least 90% of its annual taxable income. As a REIT, Standard Bearer generally will not be subject to federal income tax to the extent it distributes as qualifying dividends, all of its REIT taxable income to its shareholders. If Standard Bearer fails to qualify as a REIT in any taxable year, it will be subject to federal income tax on its taxable income at regular corporate income tax rates and generally will not be permitted to qualify for treatment as a REIT for federal income tax purposes for the four taxable years following the year during which qualification is lost unless the Internal Revenue Service grants the Company relief under certain statutory provisions.
    Noncontrolling Interest The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to The Ensign Group, Inc. in its consolidated statements of income. Net income per share is calculated based on net income attributable to The Ensign Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest.
    Stock-Based CompensationThe Company measures and recognizes compensation expense for all stock-based payment awards made to employees and directors including employee stock options based on estimated fair values, ratably over the requisite service period of the award. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is based upon the number of grants and other variables.
    Comprehensive Income The Company does not have any components of other comprehensive income recorded within its Financial Statements and, therefore, does not separately present a statement of comprehensive income in its Financial Statements.
    Recent Accounting Pronouncements Except for rules and interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal securities laws and a limited number of grandfathered standards, the FASB ASC is the sole source of authoritative GAAP literature recognized by the FASB and applicable to the Company. For any new pronouncements announced, the Company considers whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on the Company's reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company's financial management and certain standards are under consideration.
    Recent Accounting Standards Issued But Not Yet Adopted by the Company In October 2023, the FASB issued ASU 2023-06 "Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative", which amends U.S. GAAP to include 14 disclosure requirements that are currently required under SEC Regulation S-X or Regulation S-K. Each amendment will be effective on the date on which the SEC removes the related disclosure requirement from SEC Regulation S-X or Regulation S-K. The adoption is not expected to have a material impact on the Company's Notes to the Consolidated Financial Statements as these requirements were previously incorporated under the SEC Regulations.
    In November 2023, the FASB issued ASU 2023-07 "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures", which requires the Company to expand the breadth and frequency of segment disclosures to include additional information about significant segment expenses, the chief operating decision maker (CODM) and other items, and also require the annual disclosures on an interim basis. This guidance is effective for annual periods beginning after December 15, 2023, which will be the Company's fiscal year 2024, with early adoption permitted. The Company is currently evaluating the impact of the ASU on its Quarterly and Annual Reports.
    In December 2023, the FASB issued ASU 2023-09 "Income Taxes (Topic 740): Improvements to Income Tax Disclosures", which requires the Company to disclose disaggregated jurisdictional and categorical information for the tax rate reconciliation, income taxes paid and other income tax related amounts. This guidance is effective for annual periods beginning after December 15, 2024, which will be the Company's fiscal year 2025, with early adoption permitted. The adoption is expected to enhance the Company's Notes to the Consolidated Financial Statements. The Company is currently evaluating the impact of the ASU on its Annual Report.
    XML 30 R11.htm IDEA: XBRL DOCUMENT v3.24.0.1
    REVENUE AND ACCOUNTS RECEIVABLE
    12 Months Ended
    Dec. 31, 2023
    Revenue from Contract with Customer [Abstract]  
    REVENUE AND ACCOUNTS RECEIVABLE REVENUE AND ACCOUNTS RECEIVABLE
    Disaggregation of Revenue
    The Company disaggregates revenue from contracts with its patients by payors. The Company determines that disaggregating revenue into these categories achieves the disclosure objectives to depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.
    Revenue by Payor

    The Company’s revenue is derived primarily from providing healthcare services to patients and is recognized on the date services are provided at amounts billable to individual patients, adjusted for estimates for variable consideration. For patients under reimbursement arrangements with third-party payors, including Medicaid, Medicare and private insurers, revenue is recorded based on contractually agreed-upon amounts or rates, adjusted for estimates for variable consideration, on a per patient, daily basis or as services are performed.

    Revenue from the Medicare and Medicaid programs accounted for 72.6%, 73.7% and 73.6% for the years ended December 31, 2023, 2022, and 2021, respectively. Settlements with Medicare and Medicaid payors for retroactive adjustments due to audits and reviews are considered variable consideration and are included in the determination of the estimated transaction price. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Company’s historical settlement activity. Consistent with healthcare industry practices, any changes to these revenue estimates are recorded in the period the change or adjustment becomes known based on the final settlement. The Company recorded adjustments to revenue which were not material to the Company's revenue for the years ended December 31, 2023, 2022, and 2021.

    Service revenue for the years ended December 31, 2023, 2022, and 2021 is summarized in the following tables:
     Year Ended December 31,
    202320222021
    Revenue% of RevenueRevenue% of RevenueRevenue% of Revenue
    Medicaid(1)
    $1,459,449 39.4 %$1,183,156 39.3 %$1,022,460 39.2 %
    Medicare985,749 26.6 832,160 27.7 727,103 27.8 
    Medicaid — skilled245,663 6.6 200,878 6.7 172,770 6.6 
    Total Medicaid and Medicare2,690,861 72.6 2,216,194 73.7 1,922,333 73.6 
    Managed care666,129 18.0 525,710 17.5 456,728 17.5 
    Private and other(2)
    351,081 9.4 266,807 8.8 232,415 8.9 
    SERVICE REVENUE$3,708,071 100.0 %$3,008,711 100.0 %$2,611,476 100.0 %
    (1) Medicaid payor includes revenue for senior living operations and revenue related to state relief funding.
    (2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.
    In addition to the service revenue above, the Company's rental revenue derived from triple-net lease arrangements with third parties is $21,284, $16,757 and $15,985 for the years ended December 31, 2023, 2022, and 2021.
    State relief funding
    The Company received state relief funding through Medicaid programs from various states, including healthcare relief funding under the American Rescue Plan Act (ARPA), increases in the Federal Medical Assistance Percentage (FMAP) under the Families First Coronavirus Response Act (FFCRA) and other state specific relief programs. The funding generally incorporates specific use requirements primarily for direct patient care including labor related expenses that are attributable to the COVID-19 pandemic or are associated with providing patient care.
    Revenues from these additional payments are recognized in accordance with ASC 606, subject to variable consideration constraints. In certain operations where the Company received additional payments that exceeded expenses incurred related to specific qualifiers, the Company recorded deferred revenue for the excess amount until additional expenses are incurred for recognition. Accordingly, the amount of state relief revenue recognized is limited to the actual related expenses incurred. As of years ended December 31, 2023 and 2022, the Company had $486 and $1,001 in unapplied state relief funds, respectively. During the years ended December 31, 2023, 2022, and 2021, the Company received an additional $64,238, $81,057, and $70,484 in state relief funding and recognized $64,753, $81,837, and $75,231, respectively, as revenue.
    Federal relief funding
    In prior years, as part of the Coronavirus Aid, Relief, and Economic Security Act of 2020 (the CARES Act), the Company received cash distributions of relief fund payments (Provider Relief Funds) and funds authorized by U.S. Department of Health and Human Services (HHS) to be used to protect residents of nursing homes and long-term care (LTC) facilities from the impact of COVID-19. During the years ended December 31, 2023 and 2022, the Company did not receive Provider Relief Funds. During the year ended December 31, 2021, the Company received and returned $11,637 in Provider Relief Funds.
    In fiscal year 2020, the Company applied for and received $105,255 through the Medicare Accelerated and Advance Payment Program under the CARES Act. The purpose of the program is to assist in providing needed liquidity to care delivery providers. The Company repaid $3,232 of the funds in 2020 and the remaining funds of $102,023 in March 2021.
    The CARES Act also provides for deferred payment of the employer portion of social security taxes through the end of 2020, with approximately 50% of the deferred amount due by December 31, 2021 and the remaining 50% due by December 31, 2022. The Company recorded $48,309 of deferred payments of social security taxes as a liability during 2020, and paid the first and second half of the payments in the fourth quarters of 2021 and 2022, respectively.
    Balance Sheet Impact
    Included in the Company’s consolidated balance sheets are contract balances, comprised of billed accounts receivable and unbilled receivables, which are the result of the timing of revenue recognition, billings and cash collections, as well as, contract liabilities, which primarily represent payments the Company receives in advance of services provided. The Company had no material contract liabilities and contract assets as of December 31, 2023 and 2022, or activity during the years ended December 31, 2023, 2022, and 2021.

    Accounts receivable as of December 31, 2023 and 2022, is summarized in the following table:
    December 31,
    20232022
    Medicaid$178,285 $157,878 
    Managed care125,907 95,940 
    Medicare85,512 76,526 
    Private and other payors104,683 85,890 
     494,387 416,234 
    Less: allowance for doubtful accounts(9,348)(7,802)
    ACCOUNTS RECEIVABLE, NET$485,039 $408,432 
    XML 31 R12.htm IDEA: XBRL DOCUMENT v3.24.0.1
    COMPUTATION OF NET INCOME PER COMMON SHARE
    12 Months Ended
    Dec. 31, 2023
    Earnings Per Share [Abstract]  
    COMPUTATION OF NET INCOME PER COMMON SHARE COMPUTATION OF NET INCOME PER COMMON SHARE
    Basic net income per share is computed by dividing income from operations attributable to stockholders of The Ensign Group, Inc. by the weighted average number of outstanding common shares for the period. The computation of diluted net income per share is similar to the computation of basic net income per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued.
    A reconciliation of the numerator and denominator used in the calculation of basic net income per common share follows:
    Year Ended December 31,
     202320222021
    NUMERATOR:
    Net income$209,850 $224,652 $197,725 
    Less: net income (loss) attributable to noncontrolling interests 451 (29)3,073 
    Net income attributable to The Ensign Group, Inc. $209,399 $224,681 $194,652 
    DENOMINATOR:
    Weighted average shares outstanding for basic net income per share55,708 54,887 54,486 
    Basic net income per common share:$3.76 $4.09 $3.57 

    A reconciliation of the numerator and denominator used in the calculation of diluted net income per common share follows:

    Year Ended December 31,
     202320222021
    NUMERATOR:
    Net income $209,850 $224,652 $197,725 
    Less: net income (loss) attributable to noncontrolling interests451 (29)3,073 
    Net income attributable to The Ensign Group, Inc. $209,399 $224,681 $194,652 
    DENOMINATOR:
    Weighted average common shares outstanding55,708 54,887 54,486 
    Plus: incremental shares from assumed conversion (1)
    1,615 1,984 2,439 
    Adjusted weighted average common shares outstanding57,323 56,871 56,925 
    Diluted net income per common share:$3.65 $3.95 $3.42 
    (1) Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were 1,429, 780 and 198 for the years ended December 31, 2023, 2022 and 2021, respectively.
    XML 32 R13.htm IDEA: XBRL DOCUMENT v3.24.0.1
    FAIR VALUE MEASUREMENTS
    12 Months Ended
    Dec. 31, 2023
    Fair Value Disclosures [Abstract]  
    FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTS
    The Company's financial assets include the captive insurance subsidiary's deposits and investments designated to support long-term insurance subsidiary liabilities and are carried at amortized cost basis of $59,530 and $53,924 as of December 31, 2023 and 2022, respectively. As of December 31, 2023 and 2022, the amortized cost basis of the Company's financial assets included in the captive insurance subsidiary's investments are considered to approximate the fair value of these financial assets and are derived using Level 2 inputs.

    Also included are contracts insuring the lives of certain employees who are eligible to participate in non-qualified deferred compensation plans that are held in a rabbi trust. The cash surrender value of these contracts is based on funds that shadow the investment allocations specified by participants in the deferred compensation plan and are held at fair value. As of December 31, 2023, and 2022, the fair value of the investment funds was $41,216 and $25,144, respectively, which are derived using Level 2 inputs.

    Additionally, the Company has other investments held at historical cost basis, which are not material, where the fair value is derived using Level 3 inputs. The Company believes its amortized cost basis investments that were in an unrealized loss position as of December 31, 2023 and 2022 do not require an allowance for expected credit losses, nor has any event occurred through the filing date of this report that would indicate differently.
    XML 33 R14.htm IDEA: XBRL DOCUMENT v3.24.0.1
    STANDARD BEARER
    12 Months Ended
    Dec. 31, 2023
    Segment Reporting [Abstract]  
    STANDARD BEARER STANDARD BEARER
    Standard Bearer's real estate portfolio consists of 108 of the Company's 113 owned real estate properties, of which 79 are operated and managed by the Company's independent subsidiaries and 30 are leased to and operated by third-party operators. Of those 30 operations, one senior living facility is located on the same real estate property as a skilled nursing facility that an independent subsidiary owns and operates. Standard Bearer elected to be taxed as a REIT, for U.S. federal income tax purposes, commencing with its taxable year ended December 31, 2022.
    During the year ended December 31, 2023, Standard Bearer acquired the real estate of three stand-alone skilled nursing facilities and two campus operations for an aggregate purchase price of $65,899. Of these additions, the three skilled nursing facilities and one campus operation acquired are operated by the Company's independent subsidiaries and the other campus operation is leased to a third-party operator. During the year ended December 31, 2022, Standard Bearer acquired the real estate of ten skilled nursing facilities for an aggregate purchase price of $84,656, three of which were previously operated and managed by the Company's independent subsidiaries. Refer to Note 7, Operation Expansions, for additional information.
    As part of the formation of Standard Bearer, certain of the Company's independent subsidiaries, Standard Bearer and Standard Bearer's independent real estate subsidiaries entered into several agreements that include leasing, management services and debt arrangements between the operations. All intercompany transactions have been eliminated in consolidation. Refer to Note 8, Business Segments, for additional information related to these intercompany eliminations as well as Standard Bearer as a reportable segment.
    Intercompany master lease agreements
    Certain of the Company's independent subsidiaries and 79 Standard Bearer independent real estate subsidiaries have entered into five triple-net master lease agreements (collectively, the Standard Bearer Master Leases). The lease periods range from 15 to 19 years with three five-year renewal options beyond the initial term, on the same terms and conditions. The rent structure under the Standard Bearer Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the independent subsidiaries are required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties; (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. Rental revenue generated from the Company's independent subsidiaries was $66,712, $57,967, and $44,165 for the years ended December 31, 2023, 2022, and 2021, respectively.
    Intercompany management agreement
    Standard Bearer has no employees. The Service Center provides personnel and services to Standard Bearer pursuant to the management agreement between Standard Bearer and the Service Center. The management agreement provides for a base management fee that is equal to 5% of total rental revenue and an incentive management fee that is equal to 5% of funds from operations (FFO) and is capped at 1% of total rental revenue, for a total of 6%. Management fee generated between Standard Bearer and the Service Center for the year ended December 31, 2023 and 2022 was $4,948 and $4,367, respectively. No management fees were recorded in 2021, which was prior to the formation of Standard Bearer.
    Intercompany debt arrangements

    Standard Bearer obtains its funding through various sources including operating cash flows, access to debt arrangements and intercompany loans. The intercompany debt arrangements include mortgage loans and the Credit Facility to fund acquisitions and working capital needs. The interest rate under the Credit Facility is a base rate plus a margin ranging from 0.25% to 1.25% per annum or SOFR plus a margin range from 1.25% to 2.25% per annum.

    In addition, as the Department of Housing and Urban Development (HUD) mortgage loans and promissory note are entered into by real estate subsidiaries of Standard Bearer, the interest expense incurred from these debts are included in Standard Bearer's segment income. Refer to Note 15, Debt, for additional information related to these debts.
    Equity Instrument Denominated in the Shares of a Subsidiary
    As part of the formation of Standard Bearer in January of 2022, the Company established the Standard Bearer Healthcare REIT, Inc. 2022 Omnibus Incentive Plan (Standard Bearer Equity Plan). The Company may grant stock options and restricted stock awards under the Standard Bearer Equity Plan to employees and management of Ensign's independent subsidiaries. These awards generally vest over a period of five years or upon the occurrence of certain prescribed events. The value of the stock options and restricted stock awards is tied to the value of the common stock of Standard Bearer, which is determined based on an independent valuation of Standard Bearer. The awards can be put to Standard Bearer at various prescribed dates, which in no event is earlier than six months after vesting of the restricted awards or exercise of the stock options. The Company can also call the awards, generally upon employee termination. During the year ended December 31, 2022, Standard Bearer sold fully vested common shares from the Standard Bearer Equity Plan to shareholders for cash of $6,544. During the year ended December 31, 2023 and 2022, the Company did not grant any stock options nor restricted shares under the Standard Bearer Equity Plan.
    Also, during the year ended December 31, 2022, Standard Bearer established shareholders of its preferred shares through contributions of cash of $149. These preferred shares were fully vested at the time of the contributions by the shareholders. The value of Standard Bearer common and preferred shares held by the Company are eliminated in consolidation and the value held by other shareholders are classified as noncontrolling interests on the Company's consolidated balance sheets.
    XML 34 R15.htm IDEA: XBRL DOCUMENT v3.24.0.1
    OPERATION EXPANSIONS
    12 Months Ended
    Dec. 31, 2023
    Business Combination and Asset Acquisition [Abstract]  
    OPERATION EXPANSIONS OPERATION EXPANSIONS
    The expansion focus of the Company's independent subsidiaries is to purchase or lease operations that are complementary to the current operations, accretive to the business, or otherwise advance the Company's strategy. The results of all independent subsidiaries are included in the Financial Statements subsequent to the date of acquisition. Acquisitions are accounted for using the acquisition method of accounting. The Company's independent subsidiaries also enter into long-term leases that may include options to purchase the facilities. As a result, from time to time, an independent real estate subsidiary will acquire the property of facilities that have previously been operated under third-party leases.
    2023 Expansions
    During the year ended December 31, 2023, the Company expanded its operations and real estate portfolio through a combination of long-term leases and real estate purchases, with the addition of 25 stand-alone skilled nursing operations and one campus operation. Of these additions, Standard Bearer acquired the real estate of three of the stand-alone skilled nursing operations and one campus operation, which were leased back to the Company's independent subsidiaries. Refer to Note 6, Standard Bearer, for additional information on the purchase of real estate properties. These new operations added a total of 2,483 operational skilled nursing beds and 94 operational senior living units to be operated by the Company's independent subsidiaries. The Company also invested in new ancillary services that are complementary to its existing businesses.
    In connection with the new operations obtained through long-term leases, the Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with each prior operator as part of each transaction.
    Subsequent to December 31, 2023, the Company expanded its operations through a long-term lease, with the addition of two stand-alone skilled nursing operations, totaling 241 operational skilled nursing beds operated by the Company's independent subsidiaries, including one in a new state, Tennessee.
    2022 Expansions
    During the year ended December 31, 2022, the Company expanded its operations and real estate portfolio through a combination of long-term leases and real estate purchases, with the addition of 23 stand-alone skilled nursing operations and one campus operation. Of these additions, Standard Bearer acquired the real estate of seven of the stand-alone skilled nursing operations, which were leased back to Ensign's independent subsidiaries. Refer to Note 6, Standard Bearer, for additional information on the purchases of real estate properties. In addition, the Company added five senior living operations that were transferred from The Pennant Group, Inc. (Pennant), three of which are part of campuses operated by the Company's independent subsidiaries. These new operations added a total of 3,058 operational skilled nursing beds and 674 operational senior living units to be operated by the Company's independent subsidiaries. The Company also invested in new ancillary services that are complementary to its existing businesses.
    Of the new operations acquired during the year ended December 31, 2022, $16,400 was concentrated in goodwill and accordingly, the transactions were classified as business combinations.
    In connection with the new operations obtained through long-term leases, the Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with each prior operator as part of each transaction.
    2021 Acquisitions
    During the year ended December 31, 2021, the Company expanded its operations through a combination of long-term leases and a real estate purchase, with the addition of 17 stand-alone skilled nursing operations and five real estate purchases, four of which the Company previously operated and continues to operate. The remaining real estate purchase is operated by Pennant. These new operations added a total of 1,832 operational skilled nursing beds operated by the Company's independent subsidiaries.
    Of the new operations acquired during the year ended December 31, 2021, $6,000 was concentrated in goodwill and accordingly, the transactions were classified as business combinations.
    In connection with the new operations made through long-term leases, the Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with the prior operator as part of each transaction.
    The table below presents the allocation of the purchase price for the operations acquired during the years ended December 31, 2023, 2022, and 2021:
    Year Ended December 31,
    202320222021
    Land$7,794 $15,527 $19,928 
    Building and improvements57,488 65,070 77,975 
    Equipment, furniture, and fixtures1,840 1,618 217 
    Assembled occupancy346 367 29 
    Goodwill— 16,400 6,000 
    Leased asset— 1,909 — 
    Other indefinite-lived intangible assets330 245 75 
    TOTAL ACQUISITIONS$67,798 $101,136 $104,224 
    The Company’s acquisition strategy has been focused on identifying both opportunistic and strategic acquisitions within its target markets that offer strong opportunities for return. The operations added by the Company are frequently underperforming financially and can have regulatory and clinical challenges to overcome. Financial information, especially with underperforming operations, is often inadequate, inaccurate or unavailable. Consequently, the Company believes that prior operating results are not a meaningful representation of the Company’s current operating results or indicative of the integration potential of its newly acquired independent subsidiaries. The assets added during the year ended December 31, 2023 were not material operations to the Company individually or in the aggregate. Accordingly, pro forma financial information is not presented. These additions have been included in the consolidated balance sheets of the Company, and the operating results have been included in the consolidated statements of income of the Company since the date the Company gained effective control.
    XML 35 R16.htm IDEA: XBRL DOCUMENT v3.24.0.1
    BUSINESS SEGMENTS
    12 Months Ended
    Dec. 31, 2023
    Segment Reporting [Abstract]  
    BUSINESS SEGMENTS BUSINESS SEGMENTS
    The Company has two reportable segments: (1) skilled services, which includes the operation of skilled nursing facilities and rehabilitation therapy services and (2) Standard Bearer, which is comprised of selected real estate properties owned by Standard Bearer and leased to skilled nursing and senior living operators.

    As of December 31, 2023, the skilled services segment includes 259 skilled nursing operations and 27 campus operations that provide both skilled nursing and rehabilitative care services and senior living services. The Company's Standard Bearer segment consists of 108 owned real estate properties.
    The Company also reports an “All Other” category that includes results from its senior living operations, which includes 11 stand-alone senior living operations and the senior living operations at 27 campus operations that provide both skilled nursing and rehabilitative care services and senior living services. In addition, the "All Other" category includes mobile diagnostics, medical transportation, other real estate and other ancillary operations. Services included in the “All Other” category are insignificant individually, and therefore do not constitute a reportable segment.

    The Company’s reportable segments are significant operating segments that offer differentiated services. The Company's CODM reviews financial information for each operating segment to evaluate performance and allocate capital resources. This structure reflects its current operational and financial management and provides the best structure to maximize the quality of care and investment strategy provided, while maintaining financial discipline. The Company's CODM does not review assets by segment in his resource allocation and therefore assets by segment are not disclosed below.

    The accounting policies of the reportable segments are the same as those described in Note 2, Summary of Significant Accounting Policies. Intercompany revenue is eliminated in consolidation, along with corresponding intercompany expenses. Segment income and loss is defined as profit or loss from operations before provision for income taxes, excluding gain or loss from sale of real estate, real estate insurance recoveries and losses and impairment charges from operations. Included in segment income for Standard Bearer is expense for intercompany services provided by the Service Center as described in Note 6, Standard Bearer, as it is part of the CODM financial information.

    The following tables set forth financial information for the segments:
     Year Ended December 31, 2023
     Skilled ServicesStandard Bearer
    All Other (1)
    Intercompany EliminationTotal
    Service revenue(2)
    $3,578,855 $— $144,667 $(15,451)$3,708,071 
    Rental revenue(3)
    — 82,486 11,137 (72,339)21,284 
    TOTAL REVENUE$3,578,855 $82,486 $155,804 $(87,790)$3,729,355 
    Segment income (loss)464,925 29,065 (221,251)— 272,739 
    Gain on sale of assets and insurance recoveries from real estate, net
    23 
    Income before provision for income taxes$272,762 
    Depreciation and amortization38,766 25,205 8,416 — 72,387 
    Interest expense(4)
    $— $19,761 $1,228 $(12,902)$8,087 
    (1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center.
    (2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's independent subsidiaries and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service.
    (3) All Other rental revenue includes rental revenue associated with the Company's subleases to third parties of $3,897 for the year ended December 31, 2023. Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's independent subsidiaries. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense.
    (4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. Intercompany interest expense is eliminated in the "Intercompany Elimination" column.
     Year Ended December 31, 2022
     Skilled ServicesStandard Bearer
    All Other (1)
    Intercompany EliminationTotal
    Service revenue(2)
    $2,906,215 $— $115,214 $(12,718)$3,008,711 
    Rental revenue(3)
    — 72,937 7,396 (63,576)16,757 
    TOTAL REVENUE$2,906,215 $72,937 $122,610 $(76,294)$3,025,468 
    Segment income (loss)408,732 27,871 (150,781)— 285,822 
    Gain on sale of assets and insurance recoveries from real estate, net
    3,267 
    Income before provision for income taxes$289,089 
    Depreciation and amortization33,224 21,613 7,518 — 62,355 
    Interest expense(4)
    $— $15,707 $1,870 $(8,646)$8,931 
    (1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center.
    (2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's independent subsidiaries and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service.
    (3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's independent subsidiaries. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense.
    (4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. Intercompany interest expense is eliminated in the "Intercompany Elimination" column.
     
    Year Ended December 31, 2021
     Skilled ServicesStandard Bearer
    All Other (1)
    Intercompany EliminationTotal
    Service revenue(2)
    $2,523,234 $— $95,276 $(7,034)$2,611,476 
    Rental revenue(3)
    — 58,127 7,409 (49,551)15,985 
    TOTAL REVENUE$2,523,234 $58,127 $102,685 $(56,585)$2,627,461 
    Segment income (loss)373,603 31,876 (147,915)— 257,564 
    Gain on real estate insurance recoveries440 
    Income before provision for income taxes $258,004 
    Depreciation and amortization30,681 17,558 7,746 — 55,985 
    Interest expense$— $6,842 $$— $6,849 
    (1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center.
    (2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's independent subsidiaries and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service.
    (3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's independent subsidiaries. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense.

    Service revenue by major payor source were as follows:
     Year Ended December 31, 2023
     Skilled Services
    All Other (3)
    Total Service RevenueRevenue %
    Medicaid(1)
    $1,429,473 $29,976 $1,459,449 39.4 %
    Medicare985,749 — 985,749 26.6 
    Medicaid-skilled245,663 — 245,663 6.6 
    Subtotal2,660,885 29,976 2,690,861 72.6 
    Managed care666,129 — 666,129 18.0 
    Private and other(2)
    251,841 99,240 351,081 9.4 
    TOTAL SERVICE REVENUE$3,578,855 $129,216 $3,708,071 100.0 %
    (1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding.
    (2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.
    (3) All Other incorporates intercompany eliminations.
     Year Ended December 31, 2022
     Skilled Services
    All Other (3)
    Total Service RevenueRevenue %
    Medicaid(1)
    $1,158,309 $24,847 $1,183,156 39.3 %
    Medicare832,160 — 832,160 27.7 
    Medicaid-skilled200,878 — 200,878 6.7 
    Subtotal2,191,347 24,847 2,216,194 73.7 
    Managed care525,710 — 525,710 17.5 
    Private and other(2)
    189,158 77,649 266,807 8.8 
    TOTAL SERVICE REVENUE$2,906,215 $102,496 $3,008,711 100.0 %
    (1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding.
    (2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.
    (3) All Other incorporates intercompany eliminations.
     
    Year Ended December 31, 2021
     Skilled Services
    All Other (3)
    Total Service RevenueRevenue %
    Medicaid(1)
    $1,007,061 $15,399 $1,022,460 39.2 %
    Medicare727,103 — 727,103 27.8 
    Medicaid-skilled172,770 — 172,770 6.6 
    Subtotal1,906,934 15,399 1,922,333 73.6 
    Managed care456,728 — 456,728 17.5 
    Private and other(2)
    159,572 72,843 232,415 8.9 
    TOTAL SERVICE REVENUE$2,523,234 $88,242 $2,611,476 100.0 %
    (1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding.
    (2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.
    (3) All Other incorporates intercompany eliminations.
    XML 36 R17.htm IDEA: XBRL DOCUMENT v3.24.0.1
    PROPERTY AND EQUIPMENT— NET
    12 Months Ended
    Dec. 31, 2023
    Property, Plant and Equipment [Abstract]  
    PROPERTY AND EQUIPMENT— NET PROPERTY AND EQUIPMENT - NET
    Property and equipment, net consists of the following:
    December 31,
    20232022
    Land$142,656 $134,864 
    Buildings and improvements803,155 728,231 
    Leasehold improvements172,064 150,903 
    Equipment339,383 295,739 
    Furniture and fixtures4,192 4,544 
    Construction in progress25,563 17,521 
     1,487,013 1,331,802 
    Less: accumulated depreciation(396,242)(339,792)
    PROPERTY AND EQUIPMENT, NET$1,090,771 $992,010 
    The Company completed the sale of assets for a sale price of $8,607 and recorded a gain of $3,467 within the Company's consolidated statement of income as cost of services during the year ended December 31, 2022. In addition, the Company evaluated its long-lived assets and did not record an impairment charge for the fiscal years ended 2023, 2022, and 2021. See also Note 6, Standard Bearer and Note 7, Operation Expansions for information on acquisitions during the year ended December 31, 2023.
    XML 37 R18.htm IDEA: XBRL DOCUMENT v3.24.0.1
    INTANGIBLE ASSETS — NET
    12 Months Ended
    Dec. 31, 2023
    Goodwill and Intangible Assets Disclosure [Abstract]  
    INTANGIBLE ASSETS — NET INTANGIBLE ASSETS - NET
    Weighted Average Life (Years)December 31,
    20232022
    Gross Carrying AmountAccumulated AmortizationGross Carrying AmountAccumulated Amortization
    Intangible AssetsNetNet
    Assembled occupancy0.3$781 $(742)$39 $435 $(388)$47 
    Facility trade name30.0733 (439)294 733 (415)318 
    Customer relationships18.44,582 (2,692)1,890 4,582 (2,482)2,100 
    TOTAL $6,096 $(3,873)$2,223 $5,750 $(3,285)$2,465 

    During the years ended December 31, 2023, 2022, and 2021, amortization expense was $1,790, $1,714 and $1,435, respectively, of which $1,202, $1,160 and $1,158 was related to the amortization of right-of-use assets, respectively. The Company did not record any impairment charge to intangible assets during the years ended December 31, 2023, 2022, and 2021.

    Estimated amortization expense for each of the years ending December 31 is as follows:
    YearAmount
    2024274 
    2025234 
    2026234 
    2027234 
    2028234 
    Thereafter1,013 
     $2,223 

    Other indefinite-lived intangible assets consist of the following:
    December 31,
    20232022
    Trade name$889 $889 
    Medicare and Medicaid licenses3,413 3,083 
    TOTAL$4,302 $3,972 
    During the year ended December 31, 2023, the Company acquired $330 in Medicare and Medicaid licenses compared to $245 and $181 in the fiscal years 2022 and 2021, respectively.
    XML 38 R19.htm IDEA: XBRL DOCUMENT v3.24.0.1
    GOODWILL
    12 Months Ended
    Dec. 31, 2023
    Goodwill and Intangible Assets Disclosure [Abstract]  
    GOODWILL GOODWILL
    The Company anticipates that the majority of goodwill recognized will be fully deductible for tax purposes as of December 31, 2023. All of the Company's acquisitions during the year ended December 31, 2023 were classified as asset acquisitions and accordingly, no goodwill was recognized for these acquisitions. There were no other activities in goodwill during the year ended December 31, 2023. Provided that goodwill corresponds to the acquisition of a business and not merely the acquisition of real estate property, the Company's Standard Bearer segment appropriately does not carry a goodwill balance. The following table represents activity in goodwill by skilled service segment and "all other" category as of December 31, 2023, 2022 and 2021:
    Goodwill
     Skilled ServicesAll OtherTotal
    January 1, 2021$45,486 $8,983 $54,469 
    Additions6,000 — 6,000 
    December 31, 2021$51,486 $8,983 $60,469 
    Additions16,400 — 16,400 
    December 31, 2022$67,886 $8,983 $76,869 
    December 31, 2023$67,886 $8,983 $76,869 
    XML 39 R20.htm IDEA: XBRL DOCUMENT v3.24.0.1
    RESTRICTED AND OTHER ASSETS
    12 Months Ended
    Dec. 31, 2023
    Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
    RESTRICTED AND OTHER ASSETS RESTRICTED AND OTHER ASSETS
    Restricted and other assets consist of the following:
    December 31,
    20232022
    Debt issuance costs, net$2,883 $3,753 
    Long-term insurance losses recoverable asset15,913 10,512 
    Capital improvement reserves with landlords and lenders4,870 6,446 
    Deposits with landlords2,661 2,527 
    Escrow deposits1,216 — 
    Other12,662 14,053 
    RESTRICTED AND OTHER ASSETS$40,205 $37,291 
    Included in restricted and other assets as of December 31, 2023 and 2022 are anticipated insurance recoveries related to the Company's workers' compensation and general and professional liability claims that are recorded on a gross, rather than net, basis.
    XML 40 R21.htm IDEA: XBRL DOCUMENT v3.24.0.1
    OTHER ACCRUED LIABILITIES
    12 Months Ended
    Dec. 31, 2023
    Payables and Accruals [Abstract]  
    OTHER ACCRUED LIABILITIES OTHER ACCRUED LIABILITIES
    Other accrued liabilities consist of the following:
    December 31,
    20232022
    Quality assurance fee$14,035 $7,701 
    Refunds payable51,248 40,783 
    Resident advances10,834 9,698 
    Unapplied state relief funds486 1,001 
    Cash held in trust for patients6,215 6,400 
    Dividends payable3,396 3,201 
    Property taxes12,875 10,926 
    Accrued litigation (Note 20)
    51,734 4,553 
    Other17,405 13,046 
    OTHER ACCRUED LIABILITIES$168,228 $97,309 

    Quality assurance fee represents the aggregate of amounts payable to Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, Utah, Washington and Wisconsin as a result of a mandated fee based on patient days or licensed beds. Refunds payable includes payables related to overpayments, duplicate payments and credit balances from various payor sources. Resident advances occur when the Company receives payments in advance of services provided. Cash held in trust for patients reflects monies received from or on behalf of patients. Maintaining a trust account for patients is a regulatory requirement and, while the trust assets offset the liabilities, the Company assumes a fiduciary responsibility for these funds. The cash balance related to this liability is included in other current assets in the consolidated balance sheets.
    XML 41 R22.htm IDEA: XBRL DOCUMENT v3.24.0.1
    INCOME TAXES
    12 Months Ended
    Dec. 31, 2023
    Income Tax Disclosure [Abstract]  
    INCOME TAXES INCOME TAXES
    The provision for income taxes on continuing operations for the years ended December 31, 2023, 2022 and 2021 is summarized as follows:
     Year Ended December 31,
     2023 2022 2021
    Current:   
    Federal$73,092 $56,717 $49,105 
    State17,301 14,216 11,898 
     90,393 70,933 61,003 
    Deferred: 
    Federal(22,280)(5,158)(716)
    State(5,201)(1,338)(8)
    (27,481)(6,496)(724)
         TOTAL$62,912 $64,437 $60,279 

    A reconciliation of the federal statutory rate to the effective tax rate for income from continuing operations for the years ended December 31, 2023, 2022 and 2021, respectively, is comprised as follows:

     December 31,
     202320222021
    Income tax expense at statutory rate21.0 %21.0 %21.0 %
    State income taxes - net of federal benefit3.5 3.5 3.7 
    Non-deductible expenses3.4 2.0 2.4 
    Equity compensation(4.2)(3.6)(3.3)
    Other adjustments(0.6)(0.6)(0.4)
    TOTAL INCOME TAX PROVISION23.1 %22.3 %23.4 %

    The Company's effective tax rate was 23.1% for the year ended December 31, 2023, compared to 22.3% for the same period in 2022 and 23.4% in 2021. The higher effective tax rate is due to higher non-deductible expenses compared to tax benefits from stock compensation.

    The Company's deferred tax assets and liabilities as of December 31, 2023 and 2022 are summarized below.
     December 31,
     2023 2022
    Deferred tax assets (liabilities): 
    Accrued expenses$81,502 $61,685 
    Revenue related reserves23,714 18,046 
    Tax credits1,192 1,742 
    Insurance16,864 11,910 
    Lease liability 444,590 364,408 
    State taxes — 28 
    567,862 457,819 
    Valuation allowance(789)(789)
    TOTAL DEFERRED TAX ASSETS567,073 457,030 
    State taxes(280)— 
    Depreciation and amortization(52,334)(49,146)
    Prepaid expenses(4,113)(5,150)
    Right of use asset (443,222)(363,091)
    TOTAL DEFERRED TAX LIABILITIES(499,949)(417,387)
    NET DEFERRED TAX ASSETS$67,124 $39,643 
    The Company had state credit carryforwards as of December 31, 2023 and 2022 of $1,192 and $1,742, respectively. These carryforwards almost entirely relate to state limitations on the application of Enterprise Zone employment-related tax credits. Unless the Company uses the Enterprise Zone credits beforehand, the carryforward began to expire in 2023. The remainder of these carryforwards relate to credits against the Texas margin tax and is expected to carryforward until 2027. As of December 31, 2023 and 2022, the valuation allowance of $789, for both years, was primarily recorded against the Enterprise Zone credits as the Company believes it is more likely than not that some of the benefit of the credits will not be realized.
    The Company's operating loss carry forwards for states were not material during the year ended December 31, 2023 and 2022.
    As of December 31, 2023, 2022 and 2021, the Company did not have any unrecognized tax benefits, net of its state benefits that would affect the Company's effective tax rate. The Company classifies interest and/or penalties on income tax liabilities or refunds as additional income tax expense or income. Such amounts are not material.
    The federal statutes of limitations on the Company's 2019, 2018, and 2017 income tax years lapsed during the third quarter of 2023, 2022, and 2021, respectively. During the fourth quarter of each year, various state statutes of limitations also lapsed. The lapses during the years ended December 31, 2023 and 2022 had no impact on the Company's unrecognized tax benefits.
    During the year ended December 31, 2021, the state of Wisconsin initiated and completed an examination of the Company's 2019, 2018, and 2017 state tax years with no adjustments. The Company is not under examination by any major income tax jurisdiction.
    XML 42 R23.htm IDEA: XBRL DOCUMENT v3.24.0.1
    DEBT
    12 Months Ended
    Dec. 31, 2023
    Debt Disclosure [Abstract]  
    DEBT DEBT
    Debt consists of the following:
    December 31,
    20232022
    Mortgage loans and promissory note$152,388 $156,271 
    Less: current maturities(3,950)(3,883)
    Less: debt issuance costs, net(2,941)(3,119)
    LONG-TERM DEBT LESS CURRENT MATURITIES$145,497 $149,269 
    Credit Facility with a Lending Consortium Arranged by Truist

    The Company maintains a revolving credit facility between the Company and its independent subsidiaries, including Standard Bearer as co-borrowers, and Truist Securities (Truist) (the Credit Facility) with a revolving line of credit of up to $600,000 in aggregate principal amount with a maturity date of April 8, 2027. Borrowings are supported by a lending consortium arranged by Truist. The interest rates applicable to loans under the Credit Facility are, at the Company's option, equal to either a base rate plus a margin ranging from 0.25% to 1.25% per annum or SOFR plus a margin range from 1.25% to 2.25% per annum, based on the Consolidated Total Net Debt to Consolidated EBITDA ratio (as defined in the Credit Facility). In addition, there is a commitment fee on the unused portion of the commitments that ranges from 0.20% to 0.40% per annum, depending on the Consolidated Total Net Debt to Consolidated EBITDA ratio. When the Company amended the Credit Facility in 2022 with the terms and conditions described above, it wrote off deferred financing costs of $566 and additional deferred financing costs of $3,197 were capitalized during the year ended December 31, 2022.

    Borrowings made under the Credit Facility are guaranteed, jointly and severally, by certain of the Company’s wholly-owned subsidiaries, and are secured by a pledge of stock of the Company's material independent subsidiaries as well as a first lien on substantially all of such independent subsidiaries' personal property. The Credit Facility contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its independent subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend certain material agreements and pay certain dividends and other restricted payments. The Company must comply with financial maintenance covenants to be tested quarterly, consisting of (i) a maximum consolidated total net debt to consolidated EBITDA ratio (which shall not be greater than 3.00:1.00; provided that if the aggregate consideration for approved acquisitions in a six month period is greater than $50,000, then the ratio can be increased at the election of the Company with notice to the administrative agent to 3.50:1.00 for the first fiscal quarter and the immediately following three fiscal quarters), and (ii) a minimum interest/rent coverage ratio (which cannot be less than 1.50:1.00). As of December 31, 2023, there was no outstanding debt under the Credit Facility. The Company was in compliance with all loan covenants as of December 31, 2023.
    Mortgage Loans and Promissory Note

    The Company has 23 subsidiaries that have mortgage loans insured with HUD in the aggregate amount of $150,244, which subjects these subsidiaries to HUD oversight and periodic inspections. The mortgage loans bear effective interest rates in a range of 3.1% to 4.2%, including fixed interest rates in a range of 2.4% to 3.3% per annum. In addition to the interest rate, the Company incurs other fees for HUD placement, including but not limited to audit fees. Amounts borrowed under the mortgage loans may be prepaid, subject to prepayment fees based on the principal balance on the date of prepayment. For the majority of the loans, during the first three years, the prepayment fee is 10.0% and is reduced by 3.0% in the fourth year of the loan, and reduced by 1.0% per year for years five through ten of the loan. There is no prepayment penalty after year ten. The terms for all the mortgage loans are 25 to 35 years.

    In addition to the HUD mortgage loans above, the Company has a promissory note of $2,144 that bears a fixed interest rate of 5.3% per annum and has a term of 12 years. The note, which was assumed as part of an acquisition, is secured by the real property comprising the facility and the rent, issues and profits thereof, as well as all personal property used in the operation of the facility.

    Future principal payments due under the long-term debt arrangements discussed above are as follows:

    Years Ending December 31,Amount
    2024$3,950 
    20254,086 
    20264,227 
    20273,897 
    20283,779 
    Thereafter132,449 
     $152,388 
    Based on Level 2 inputs, the carrying value of the Company's long-term debt is considered to approximate the fair value of such debt for all periods presented based upon the interest rates that the Company believes it can currently obtain for similar debt.
    Off-Balance Sheet Arrangements

    As of December 31, 2023, the Company had approximately $6,255 of borrowing capacity under the Credit Facility pledged as collateral to secure outstanding letters of credit, which decreased by $455 from prior year.
    XML 43 R24.htm IDEA: XBRL DOCUMENT v3.24.0.1
    OPTIONS AND AWARDS
    12 Months Ended
    Dec. 31, 2023
    Share-Based Payment Arrangement [Abstract]  
    OPTIONS AND AWARDS OPTIONS AND AWARDS
    Stock-based compensation expense consists of stock-based payment awards made to employees and directors, including employee stock options and restricted stock awards, based on estimated fair values. As stock-based compensation expense recognized in the Company’s consolidated statements of income for the years ended December 31, 2023, 2022, and 2021 was based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. The Company estimates forfeitures at the time of grant and, if necessary, revises the estimate in subsequent periods if actual forfeitures differ.
    2022 Omnibus Incentive Plan (2022 Plan)  The Company has one active stock incentive plan, the 2022 Omnibus Incentive Plan (the 2022 Plan). Including the shares rolled over from the 2017 Omnibus Incentive Plan, the 2022 Plan provides for the issuance of 3,452 shares of common stock. The number of shares available to be issued under the 2022 Plan will be reduced by (i) one share for each share that relates to an option or stock appreciation right award and (ii) two shares for each share which relates to an award other than a stock option or stock appreciation right award (a full-value award). Non-employee director options, to the extent granted, will vest and become exercisable in three equal annual installments, or the length of the term if less than three years, on the completion of each year of service measured from the grant date. All other options generally vest over five years at 20% per year on the anniversary of the grant date. Options expire ten years from the date of grant. At December 31, 2023, the total number of shares available for issuance under the 2022 Plan was 1,454.
    The Company uses the Black-Scholes option-pricing model to recognize the value of stock-based compensation expense for stock option awards. Determining the appropriate fair-value model and calculating the fair value of stock option awards at the grant date requires judgment, including estimating stock price volatility, expected option life, and forfeiture rates. The fair-value of the restricted stock awards at the grant date is based on the market price on the grant date, adjusted for forfeiture rates. The Company develops estimates based on historical data and market information, which can change significantly over time. The Black-Scholes model required the Company to make several key judgments including:
    The expected option term is calculated by the average of the contractual term of the options and the weighted average vesting period for all options. The calculation of the expected option term is based on the Company's experience due to sufficient history.
    The Company utilizes its own experience to calculate estimated volatility for options granted.
    The dividend yield is based on the Company's historical pattern of dividends as well as expected dividend patterns.
    The risk-free rate is based on the implied yield of U.S. Treasury notes as of the grant date with a remaining term approximately equal to the expected term.
    Estimated forfeiture rate of approximately 5.08% per year is based on the Company's historical forfeiture activity of unvested stock options.
    Stock Options
    The Company granted 1,008, 581 and 621 stock options during the years ended December 31, 2023, 2022, and 2021, respectively. The Company used the following assumptions for stock options granted during the years ended December 31, 2023, 2022 and 2021:
    Grant YearOptions GrantedWeighted Average Risk-Free RateExpected LifeWeighted Average VolatilityWeighted Average Dividend Yield
    20231,0084.3%6.2 years41.3%0.2%
    20225812.8%6.2 years42.1%0.3%
    20216211.0%6.2 years42.4%0.3%
    For the years ended December 31, 2023, 2022 and 2021, the following represents the exercise price and fair value displayed at grant date for stock option grants:
    Grant YearGrantedWeighted Average Exercise PriceWeighted Average Fair Value of Options
    20231,008$95.05 $43.85 
    2022581$85.74 $37.83 
    2021621$80.19 $32.82 
    The weighted average exercise price equaled the weighted average fair value of common stock on the grant date for all options granted during the periods ended December 31, 2023, 2022 and 2021 and therefore, the intrinsic value was $0 at the date of grant.
    The following table represents the employee stock option activity during the year ended December 31, 2023:
    Number of Options OutstandingWeighted Average
    Exercise Price
    Number of
    Options Vested
    Weighted Average Exercise Price of Options Vested
    January 1, 20214,038 $27.71 2,148 $16.66 
    Granted621 80.19 
    Forfeited(105)44.76 
    Exercised(516)17.80 
    December 31, 20214,038 $36.60 2,183 $21.02 
    Granted581 85.74 
    Forfeited(98)59.52 
    Exercised(688)18.43 
    December 31, 20223,833 $46.72 2,069 $28.87 
    Granted1,008 95.05 
    Forfeited(91)71.44 
    Exercised(759)24.21 
    December 31, 20233,991 $62.65 1,887 $39.58 
    The following summary information reflects stock options outstanding, vested and related details as of December 31, 2023:
     Stock Options OutstandingStock Options Vested
    Number OutstandingBlack-Scholes Fair ValueRemaining Contractual Life (Years)Vested and Exercisable
    Year of GrantExercise Price
    20148.94-16.0599 $484 199 
    201518.20-21.39175 1,369 2175 
    201615.93-16.86155 916 3155 
    201715.80-19.41194 1,138 4194 
    201822.49-32.71336 3,523 5336 
    201941.07-45.76510 8,014 6383 
    202044.84-59.49476 9,383 7257 
    202173.47-83.64513 16,844 8189 
    202279.79-94.88540 20,466 999 
    2023$89.83-$98.83993 43,566 10— 
    TOTAL 3,991 $105,703  1,887 
    The aggregate intrinsic value of options outstanding, vested and expected to vest as of December 31, 2023, 2022 and 2021 is as follows:
    December 31,
    Options202320222021
    Outstanding$197,819 $183,593 $191,242 
    Vested137,048 136,000 137,382 
    Expected to vest56,759 43,232 48,548 
    The intrinsic value is calculated as the difference between the market value of the underlying common stock and the exercise price of the options. At December 31, 2023, 2022 and 2021, the aggregate intrinsic value of options that vested during the years ended December 31, 2023, 2022 and 2021 was $31,658, $27,955, and $27,731, respectively. The total intrinsic value of options exercised during the years ended December 31, 2023, 2022 and 2021 was $56,186, $47,441, and $34,278, respectively.
    Restricted Stock Awards
    The Company granted 219, 233 and 222 restricted stock awards during the years ended December 31, 2023, 2022 and 2021, respectively. All awards were granted at an issue price of $0 and generally vest over five years. The fair value per share of restricted awards granted during the years ended December 31, 2023, 2022 and 2021 ranged from $89.83 to $98.31, $73.17 to $94.88 and $72.84 to $93.31, respectively. The fair value per share includes quarterly stock awards to non-employee directors.
    A summary of the status of the Company's non-vested restricted stock awards as of December 31, 2023 and changes during the years ended December 31, 2023, 2022 and 2021 is presented below:
    Non-Vested Restricted AwardsWeighted Average Grant Date Fair Value
    Nonvested at January 1, 2021591 $38.90 
    Granted222 81.65 
    Vested(244)47.45 
    Forfeited(20)45.64 
    Nonvested at December 31, 2021549 $52.16 
    Granted233 81.57 
    Vested(269)54.06 
    Forfeited(26)57.29 
    Nonvested at December 31, 2022487 $64.92 
    Granted219 92.04 
    Vested(255)64.21 
    Forfeited(20)71.53 
    Nonvested at December 31, 2023431 $78.91 
    During the year ended December 31, 2023, the Company granted 18 quarterly stock awards to non-employee directors for their service on the Company's board of directors from the 2022 Plan. The fair value per share of these stock awards ranged from $89.94 to $98.31 based on the market price on the grant date.
    Long-Term Incentive Plan
    On August 27, 2019, the Board approved the Long-Term Incentive Plan (the 2019 LTI Plan). The 2019 LTI Plan provides that certain employees of the Company who assisted in the consummation of the spin-off of Pennant from the Company in 2019 (spin-off transaction) were granted shares of restricted stock upon successful completion of the spin-off. The 2019 LTI Plan provides for the issuance of 500 shares of Pennant restricted stock. The shares are vested over five years at 20% per year on the anniversary of the grant date. If a recipient is terminated or voluntarily leaves the Company, all shares subject to restriction or not yet vested are entirely forfeited. The total stock-based compensation related to the 2019 LTI Plan was approximately $827, $836, and $854 for the years ended December 31, 2023, 2022 and 2021, respectively.
    Stock-based compensation expense
    Stock-based compensation expense recognized for the Company's equity incentive plans and long-term incentive plan for the years ended December 31, 2023, 2022 and 2021 was as follows:

    Year Ended December 31,
     202320222021
    Stock-based compensation expense related to stock options$17,221 $11,361 $8,459 
    Stock-based compensation expense related to restricted stock awards11,845 9,920 8,385 
    Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors1,688 1,439 1,834 
    TOTAL$30,754 $22,720 $18,678 
    In future periods, the Company expects to recognize approximately $67,750 and $29,245 in stock-based compensation expense for unvested options and unvested restricted stock awards, respectively, that were outstanding as of December 31, 2023. Future stock-based compensation expense will be recognized over 3.9 and 3.4 weighted average years for unvested options and restricted stock awards, respectively. There were 2,104 unvested and outstanding options as of December 31, 2023, of which 1,940 shares are expected to vest. The weighted average contractual life for options outstanding, vested and expected to vest as of December 31, 2023 was 6.7 years.
    XML 44 R25.htm IDEA: XBRL DOCUMENT v3.24.0.1
    LEASES
    12 Months Ended
    Dec. 31, 2023
    Leases [Abstract]  
    LEASES LEASES
    The Company leases from CareTrust REIT, Inc. (CareTrust) real property associated with 97 independent skilled nursing and senior living facilities used in the Company’s operations, 96 of which are under nine “triple-net” master lease agreements (collectively, the Master Leases), which range in terms from 13 to 20 years. At the Company’s option, the Master Leases may be extended for two or three five-year renewal terms beyond the initial term, on the same terms and conditions. The extension of the term of any of the Master Leases is subject to the following conditions: (1) no event of default under any of the Master Leases having occurred and been continuing; and (2) the tenants providing timely notice of their intent to renew. The term of the Master Leases is subject to termination prior to the expiration of the current term upon default by the tenants in their obligations, if not cured within any applicable cure periods set forth in the Master Leases. If the Company elects to renew the term of a Master Lease, the renewal will be effective to all, but not less than all, of the leased property then subject to the Master Lease. Additionally, four of the 97 facilities leased from CareTrust include an option to purchase that the Company can exercise starting on December 1, 2024.
    The Company does not have the ability to terminate the obligations under a Master Lease prior to its expiration without CareTrust’s consent. If a Master Lease is terminated prior to its expiration other than with CareTrust’s consent, the Company may be liable for damages and incur charges such as continued payment of rent through the end of the lease term as well as maintenance and repair costs for the leased property.
    The rent structure under the Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the Company is required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The terms and conditions of the one stand-alone lease are substantially the same as those for the master leases described above. Total rent expense for continuing operations under the Master Leases was approximately $66,439, $64,178 and $59,571 for the years ended December 31, 2023, 2022 and 2021, respectively.
    Among other things, under the Master Leases, the Company must maintain compliance with specified financial covenants measured on a quarterly basis, including a portfolio coverage ratio and a minimum rent coverage ratio. The Master Leases also include certain reporting, legal and authorization requirements. The Company is in compliance with requirements of the Master Leases as of December 31, 2023.
    In connection with the spin-off that occurred in 2019, the Company guaranteed certain leases of Pennant based on the underlying terms of the leases. The Company does not consider these guarantees to be probable and the likelihood of Pennant defaulting is remote, and therefore no liabilities have been accrued.
    The Company leases facilities where its independent subsidiaries operate and certain administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from five to 20 years. In addition, the Company leases certain of its equipment under non-cancelable operating leases with initial terms ranging from three to five years. Most of these leases contain renewal options, certain of which involve rent increases. Total rent expense for continuing operations inclusive of straight-line rent adjustments and rent associated with the Master Leases noted above, was $197,856, $153,174 and $139,458 for the years ended December 31, 2023, 2022 and 2021, respectively.
    Eighty of the Company’s independent subsidiaries, excluding the subsidiaries that are operated under the Master Leases with CareTrust, are operated under 13 separate master lease arrangements. During 2023, the Company expanded its operations through three separate master lease arrangements for 22 stand-alone skilled nursing operations, of which 19 are operated by the Company's independent subsidiaries and the remaining three are subleased to a third-party operator. These three master leases increased the lease liabilities and right-of-use assets by $346,789 to reflect the new lease obligations and have initial lease terms of 18, 20 and 20 years, respectively. Under these master leases, a default at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of the Company’s leases, master lease agreements and debt financing instruments. In addition, other potential defaults related to an individual facility may cause a default of an entire master lease portfolio and could trigger cross-default provisions in the Company’s outstanding debt arrangements and other leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the lease without the consent of the landlord.

    The components of operating lease expense are as follows:
    Year Ended December 31,
    202320222021
    Rent - cost of services(1)
    $197,358 $153,049 $139,371 
    General and administrative expense498 125 87 
    Depreciation and amortization(2)
    1,202 1,160 1,158 
    Variable lease costs(3)
    20,454 16,938 14,077 
    $219,512 $171,272 $154,693 
    (1)Rent- cost of services includes deferred rent expense adjustments of $870, $493 and $485 for the years ended December 31, 2023, 2022 and 2021, respectively. Additionally, rent- cost of services includes other variable lease costs such as consumer price index increases and short-term leases of $10,259, $5,878, $3,702 for the years ended December 31, 2023, 2022, and 2021 respectively.
    (2) Depreciation and amortization is related to the amortization of favorable and direct lease costs.
    (3) Variable lease costs, including property taxes and insurance, are classified in cost of services in the Company's consolidated statements of income.

    Future minimum lease payments for all third-party leases as of December 31, 2023 are as follows:
    YearAmount
    2024$191,352 
    2025191,269 
    2026191,058 
    2027190,481 
    2028189,224 
    Thereafter1,722,259 
    TOTAL LEASE PAYMENTS2,675,643 
    Less: present value adjustment (953,791)
    PRESENT VALUE OF TOTAL LEASE LIABILITIES1,721,852 
    Less: current lease liabilities(82,526)
    LONG-TERM OPERATING LEASE LIABILITIES$1,639,326 
    Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company used its incremental borrowing rate based on the information available at the lease commencement date. As of December 31, 2023 and 2022, the weighted average remaining lease term is 14.9 years and 15.0 years and the weighted average discount rate used to determine the operating lease liabilities is 6.5% and 6.7%.
    Subsequent to December 31, 2023, the Company amended an existing separate master lease arrangement to add two stand-alone skilled nursing facilities and extend the initial term to 20 years. This added a total of 241 operational skilled nursing beds operated by the Company's independent subsidiaries and the aggregate impact to the carrying value of lease liabilities and right-of-use assets related to the separate master lease agreement is estimated to be approximately $30,980.
    Lessor Activities

    The Company leases its owned real estate properties to third-party operators, of which 29 senior living operations are operated by Pennant. All of these properties are triple-net leases, whereby the respective tenants are responsible for all costs at the properties including: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The initial terms range from 14 to 16 years.

    During 2023, the Company entered into a sublease agreement for three stand-alone skilled nursing operations with a third-party operator with an initial lease term of 18 years. Additionally, during the year, the Company entered into a lease agreement with a third-party operator for one campus operation with an initial lease term of 15 years.
    Total rental income from all third-party sources for the years ended December 31, 2023, 2022 and 2021 is as follows:

    Year Ended December 31,
    202320222021
    Pennant(1)
    $15,048 $14,915 $14,073 
    Other third-party(2)
    6,236 1,842 1,912 
    TOTAL$21,284 $16,757 $15,985 
    (1) Pennant rental income includes variable rent such as property taxes of $1,296, $1,318, and $1,199 during the year ended December 31, 2023, 2022, and 2021. In addition, the number of senior living operations leased to and operated by Pennant was 29 during the year ended December 31, 2023 and decreased from 32 to 29 during the year ended December 31, 2022.
    (2) Other third-party includes rental revenue associated with the Company's subleases to third parties of $3,897 for the year ended December 31, 2023. There was no sublease rental revenue for the years ended December 31, 2022 and 2021.
    Future annual rental income for all third-party leases as of December 31, 2023 were as follows:
    Year
    Amount(1)
    2024$22,191 
    202521,565 
    202621,269 
    202721,176 
    202821,151 
    Thereafter129,586 
    TOTAL$236,938 
    (1) Annual rental income includes base rents and variable rental income pursuant to existing leases as of December 31, 2023.
    LEASES LEASES
    The Company leases from CareTrust REIT, Inc. (CareTrust) real property associated with 97 independent skilled nursing and senior living facilities used in the Company’s operations, 96 of which are under nine “triple-net” master lease agreements (collectively, the Master Leases), which range in terms from 13 to 20 years. At the Company’s option, the Master Leases may be extended for two or three five-year renewal terms beyond the initial term, on the same terms and conditions. The extension of the term of any of the Master Leases is subject to the following conditions: (1) no event of default under any of the Master Leases having occurred and been continuing; and (2) the tenants providing timely notice of their intent to renew. The term of the Master Leases is subject to termination prior to the expiration of the current term upon default by the tenants in their obligations, if not cured within any applicable cure periods set forth in the Master Leases. If the Company elects to renew the term of a Master Lease, the renewal will be effective to all, but not less than all, of the leased property then subject to the Master Lease. Additionally, four of the 97 facilities leased from CareTrust include an option to purchase that the Company can exercise starting on December 1, 2024.
    The Company does not have the ability to terminate the obligations under a Master Lease prior to its expiration without CareTrust’s consent. If a Master Lease is terminated prior to its expiration other than with CareTrust’s consent, the Company may be liable for damages and incur charges such as continued payment of rent through the end of the lease term as well as maintenance and repair costs for the leased property.
    The rent structure under the Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the Company is required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The terms and conditions of the one stand-alone lease are substantially the same as those for the master leases described above. Total rent expense for continuing operations under the Master Leases was approximately $66,439, $64,178 and $59,571 for the years ended December 31, 2023, 2022 and 2021, respectively.
    Among other things, under the Master Leases, the Company must maintain compliance with specified financial covenants measured on a quarterly basis, including a portfolio coverage ratio and a minimum rent coverage ratio. The Master Leases also include certain reporting, legal and authorization requirements. The Company is in compliance with requirements of the Master Leases as of December 31, 2023.
    In connection with the spin-off that occurred in 2019, the Company guaranteed certain leases of Pennant based on the underlying terms of the leases. The Company does not consider these guarantees to be probable and the likelihood of Pennant defaulting is remote, and therefore no liabilities have been accrued.
    The Company leases facilities where its independent subsidiaries operate and certain administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from five to 20 years. In addition, the Company leases certain of its equipment under non-cancelable operating leases with initial terms ranging from three to five years. Most of these leases contain renewal options, certain of which involve rent increases. Total rent expense for continuing operations inclusive of straight-line rent adjustments and rent associated with the Master Leases noted above, was $197,856, $153,174 and $139,458 for the years ended December 31, 2023, 2022 and 2021, respectively.
    Eighty of the Company’s independent subsidiaries, excluding the subsidiaries that are operated under the Master Leases with CareTrust, are operated under 13 separate master lease arrangements. During 2023, the Company expanded its operations through three separate master lease arrangements for 22 stand-alone skilled nursing operations, of which 19 are operated by the Company's independent subsidiaries and the remaining three are subleased to a third-party operator. These three master leases increased the lease liabilities and right-of-use assets by $346,789 to reflect the new lease obligations and have initial lease terms of 18, 20 and 20 years, respectively. Under these master leases, a default at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of the Company’s leases, master lease agreements and debt financing instruments. In addition, other potential defaults related to an individual facility may cause a default of an entire master lease portfolio and could trigger cross-default provisions in the Company’s outstanding debt arrangements and other leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the lease without the consent of the landlord.

    The components of operating lease expense are as follows:
    Year Ended December 31,
    202320222021
    Rent - cost of services(1)
    $197,358 $153,049 $139,371 
    General and administrative expense498 125 87 
    Depreciation and amortization(2)
    1,202 1,160 1,158 
    Variable lease costs(3)
    20,454 16,938 14,077 
    $219,512 $171,272 $154,693 
    (1)Rent- cost of services includes deferred rent expense adjustments of $870, $493 and $485 for the years ended December 31, 2023, 2022 and 2021, respectively. Additionally, rent- cost of services includes other variable lease costs such as consumer price index increases and short-term leases of $10,259, $5,878, $3,702 for the years ended December 31, 2023, 2022, and 2021 respectively.
    (2) Depreciation and amortization is related to the amortization of favorable and direct lease costs.
    (3) Variable lease costs, including property taxes and insurance, are classified in cost of services in the Company's consolidated statements of income.

    Future minimum lease payments for all third-party leases as of December 31, 2023 are as follows:
    YearAmount
    2024$191,352 
    2025191,269 
    2026191,058 
    2027190,481 
    2028189,224 
    Thereafter1,722,259 
    TOTAL LEASE PAYMENTS2,675,643 
    Less: present value adjustment (953,791)
    PRESENT VALUE OF TOTAL LEASE LIABILITIES1,721,852 
    Less: current lease liabilities(82,526)
    LONG-TERM OPERATING LEASE LIABILITIES$1,639,326 
    Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company used its incremental borrowing rate based on the information available at the lease commencement date. As of December 31, 2023 and 2022, the weighted average remaining lease term is 14.9 years and 15.0 years and the weighted average discount rate used to determine the operating lease liabilities is 6.5% and 6.7%.
    Subsequent to December 31, 2023, the Company amended an existing separate master lease arrangement to add two stand-alone skilled nursing facilities and extend the initial term to 20 years. This added a total of 241 operational skilled nursing beds operated by the Company's independent subsidiaries and the aggregate impact to the carrying value of lease liabilities and right-of-use assets related to the separate master lease agreement is estimated to be approximately $30,980.
    Lessor Activities

    The Company leases its owned real estate properties to third-party operators, of which 29 senior living operations are operated by Pennant. All of these properties are triple-net leases, whereby the respective tenants are responsible for all costs at the properties including: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The initial terms range from 14 to 16 years.

    During 2023, the Company entered into a sublease agreement for three stand-alone skilled nursing operations with a third-party operator with an initial lease term of 18 years. Additionally, during the year, the Company entered into a lease agreement with a third-party operator for one campus operation with an initial lease term of 15 years.
    Total rental income from all third-party sources for the years ended December 31, 2023, 2022 and 2021 is as follows:

    Year Ended December 31,
    202320222021
    Pennant(1)
    $15,048 $14,915 $14,073 
    Other third-party(2)
    6,236 1,842 1,912 
    TOTAL$21,284 $16,757 $15,985 
    (1) Pennant rental income includes variable rent such as property taxes of $1,296, $1,318, and $1,199 during the year ended December 31, 2023, 2022, and 2021. In addition, the number of senior living operations leased to and operated by Pennant was 29 during the year ended December 31, 2023 and decreased from 32 to 29 during the year ended December 31, 2022.
    (2) Other third-party includes rental revenue associated with the Company's subleases to third parties of $3,897 for the year ended December 31, 2023. There was no sublease rental revenue for the years ended December 31, 2022 and 2021.
    Future annual rental income for all third-party leases as of December 31, 2023 were as follows:
    Year
    Amount(1)
    2024$22,191 
    202521,565 
    202621,269 
    202721,176 
    202821,151 
    Thereafter129,586 
    TOTAL$236,938 
    (1) Annual rental income includes base rents and variable rental income pursuant to existing leases as of December 31, 2023.
    XML 45 R26.htm IDEA: XBRL DOCUMENT v3.24.0.1
    DEFINED CONTRIBUTION PLANS
    12 Months Ended
    Dec. 31, 2023
    Retirement Benefits [Abstract]  
    DEFINED CONTRIBUTION PLANS DEFINED CONTRIBUTION PLANS
    The Company has a 401(k) defined contribution plan (the 401(k) Plan), whereby eligible employees may contribute up to 90% of their annual basic earnings, subject to applicable annual Internal Revenue Code limits. Additionally, the 401(k) Plan provides for discretionary matching contributions (as defined in the 401(k) Plan) by the Company. The Company expensed matching contributions to the 401(k) Plan of $2,836, $2,418, and $2,121 during the years ended December 31, 2023, 2022 and 2021, respectively.

    The Company has a non-qualified deferred compensation plan (DCP), whereby certain highly compensated employees who are otherwise ineligible to participate in the Company's 401(k) plan, may defer the receipt of a portion of their base compensation and, for certain employees, up to 100% of their eligible bonuses. Additionally, the DCP allows for the employee deferrals to be deposited into a rabbi trust and the funds are generally invested in individual variable life insurance contracts owned by the Company that are specifically designed to fund savings plans of this nature. The Company paid for related administrative costs, which were not significant during fiscal years 2023, 2022 and 2021.
    As of the years ended December 31, 2023 and 2022, the Company accrued $49,201 and $33,017, respectively, as long term deferred compensation in other long term liabilities on the consolidated balance sheet. Cash surrender value of the contracts is based on investment funds that shadow the investment allocations specified by participants in the deferred compensation plan. Refer to Note 5, Fair Value Measurements for more information on the funds.
    For the years ended December 31, 2023 and 2021, the Company recorded gains related to its DCP of $4,634 and $1,612, respectively, which are included in other income (expense), net, and recorded offsetting expenses of $4,887 and $1,758, respectively, which are allocated between cost of services and general and administrative expenses. For the year ended December 31, 2022, the Company recorded a loss related to its DCP of $4,188, which is included in other income (expense), net, and recorded an offsetting reduction in expense of $4,051, which is allocated between cost of services and general and administrative expenses.
    XML 46 R27.htm IDEA: XBRL DOCUMENT v3.24.0.1
    SELF INSURANCE LIABILITIES
    12 Months Ended
    Dec. 31, 2023
    Insurance [Abstract]  
    SELF INSURANCE LIABILITIES SELF INSURANCE LIABILITIES
    The following table represents activity in our insurance liabilities as of and for the years ended December 31, 2023 and 2022:
     
    Amount
    Balance January 1, 2022
    $110,139 
    Current year provisions115,793 
    Claims paid and direct expenses(98,007)
    Change in long-term insurance losses recoverable3,757 
    Balance December 31, 2022
    $131,682 
    Current year provisions164,627 
    Claims paid and direct expenses(135,799)
    Change in long-term insurance losses recoverable5,400 
    Balance December 31, 2023
    $165,910 
     
     
    Included in the table above are accrued general liability and professional malpractice liabilities on an undiscounted basis, net of anticipated insurance recoveries, of $117,744 and $87,000 as of December 31, 2023 and 2022, respectively. Included in long-term insurance losses recoverable as of December 31, 2023 and 2022 are anticipated insurance recoveries related to the Company's general and professional liability claims that are recorded on a gross rather than net basis in accordance with GAAP.
    XML 47 R28.htm IDEA: XBRL DOCUMENT v3.24.0.1
    COMMITMENTS AND CONTINGENCIES
    12 Months Ended
    Dec. 31, 2023
    Commitments and Contingencies Disclosure [Abstract]  
    COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
    Indemnities From time to time, the Company enters into certain types of contracts that contingently require the Company to indemnify parties against third-party claims. These contracts primarily include (i) certain real estate leases, under which the Company may be required to indemnify property owners or prior facility operators for post-transfer environmental obligations or other liabilities and other claims arising from the Company’s use of the applicable premises, (ii) operations transfer agreements, in which the Company agrees to indemnify past operators of facilities the Company acquires against certain liabilities arising from the transfer of the operation and/or the operation thereof after the transfer to the Company's independent subsidiary, (iii) certain lending agreements, under which the Company may be required to indemnify the lender against various claims and liabilities, and (iv) certain agreements with the Company’s officers, directors and others, under which the Company may be required to indemnify such persons for liabilities based on the nature of their relationship to the Company. The terms of such obligations vary by contract and, in most instances, do not expressly state or include a specific or maximum dollar amount. Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted. Consequently, because no claims have been asserted, no liabilities have been recorded for these obligations on the Company’s consolidated balance sheets for any of the periods presented.
    In connection with the spin-off in 2019, certain landlords required, in exchange for their consent to the transaction, that the Company's lease guarantees remain in place for a certain period of time following the transaction. These guarantees could result in significant additional liabilities and obligations for the Company if Pennant were to default on their obligations under their leases with respect to these properties.
    Litigation and Regulatory Matters Laws and regulations governing Medicare and Medicaid programs are complex and subject to review and interpretation. Compliance with such laws and regulations is evaluated regularly, the results of which can be subject to future governmental review and interpretation, and can include significant regulatory action including fines, penalties, and exclusion from certain governmental programs. Included in these laws and regulations is monitoring performed by the Office of Civil Rights which covers the Health Insurance Portability and Accountability Act of 1996, the terms of which require healthcare providers (among other things) to safeguard the privacy and security of certain patient protected health information.
    Both government and private pay sources have instituted cost-containment measures designed to limit payments made to providers of healthcare services, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect us.
    The Company and its independent subsidiaries are party to various legal actions and administrative proceedings and are subject to various claims arising in the ordinary course of business, including claims that services provided to patients by the Company’s independent subsidiaries have resulted in injury or death, and claims related to employment and commercial matters. For example, in a four-week medical negligence trial in the State of Arizona, the jury returned a verdict against one of the Company’s independent subsidiaries in late November 2023. The Company intends to appeal the verdict. The Company has in the past appealed and have in some circumstances received returned decisions in its favor. Although the Company intends to vigorously defend against these claims and in general these types of claims and cases, there can be no assurance that the outcomes of these matters will not have a material adverse effect on operational results and financial condition. Additionally, in certain states in which the Company has or has had independent subsidiaries, insurance coverage for the risk of punitive damages arising from general and professional liability litigation may not be available due to state law and/or public policy prohibitions. There can be no assurance that the Company or its independent subsidiaries will not be liable for punitive damages awarded in litigation arising in states for which punitive damage insurance coverage is not available.
    The skilled nursing and post-acute care industry is heavily regulated. As such, the Company and its independent subsidiaries are continuously subject to state and federal regulatory scrutiny, supervision and control in the ordinary course of business. Such regulatory scrutiny often includes inquiries, investigations, examinations, audits, site visits and surveys, some of which are non-routine. In addition to being subject to direct regulatory oversight from state and federal agencies, the skilled nursing and post-acute care industry is also subject to regulatory requirements which, if noncompliance is identified, could result in civil, administrative or criminal fines, penalties or restitutionary relief, and reimbursement; authorities could also seek the suspension or exclusion of the provider or individual from participation in their programs. The Company believes that there has been, and will continue to be, an increase in governmental investigations of post-acute providers, particularly in the area of Medicare/Medicaid false claims, as well as an increase in enforcement actions resulting from these investigations. Adverse determinations in civil legal proceedings or governmental investigations, whether currently asserted or arising in the future, could have a material adverse effect on the Company’s financial position, results of operations, and cash flows. Additionally, such proceedings and/or investigation can be a distraction to the business.
    For example, in 2020, the U.S. House of Representatives Select Subcommittee on the Coronavirus Crisis launched a nation-wide investigation into the COVID-19 pandemic, which included the impact of the coronavirus on residents and employees in nursing homes. In June 2020, the Company and its independent subsidiaries received a document and information request from the House Select Subcommittee. The Company and its independent subsidiaries cooperated in responding to this inquiry. In July 2022 and thereafter, the Company and its independent subsidiaries received follow up requests for additional documents and information. The Company and its independent subsidiaries responded to these requests and cooperated with the House Select Subcommittee in connection with its investigation. On December 9, 2022, the House Select Subcommittee issued its final report summarizing its investigation and related recommendations designed "to strengthen the nation's ability to prevent and respond to public health and economic emergencies." According to the information provided by the House Select Subcommittee, the issuance of this report was the House Select Subcommittee's final official act in connection with their assigned responsibilities. Also, the Company, on behalf of its independent subsidiaries, received a Civil Investigative Demand (CID) from the U.S. Department of Justice (DOJ) in January of 2024 indicating that the DOJ is investigating the Company to determine whether it has caused the submission of claims to Medicare and Texas Medicaid for services which were unnecessary or otherwise not consistent with existing reimbursement requirements. The CID covers the period from January 1, 2016, to the present. As a general matter, the Company's independent subsidiaries maintain policies and procedures to promote compliance with all applicable Medicare and Medicaid requirements, including but not limited to those relating to the presentation of claims for reimbursement for services provided. The Company intends to fully cooperate with the DOJ in response to the CID. However, the Company cannot predict the outcome of the investigation or its potential impact on the consolidated financial statements.
    In addition to the potential lawsuits and claims described above, the Company and its independent subsidiaries are also subject to potential lawsuits under the FCA and comparable state laws alleging submission of fraudulent claims for services to any healthcare program (such as Medicare or Medicaid) or other payor. A violation may provide the basis for exclusion from federally funded healthcare programs. Such exclusions could have a correlative negative impact on the Company’s financial performance. In addition, and pursuant to the qui tam or "whistleblower" provisions of the FCA, a private individual with knowledge of fraud or potential fraud may bring a claim on behalf of the federal government and receive a percentage of the federal government's recovery. Due to these whistleblower incentives, qui tam lawsuits have become more frequent.
    For example, on May 31, 2018, the Company, on behalf of its independent subsidiaries, received a CID from the DOJ stating that it was investigating to determine whether there had been a violation of the False Claims Act (FCA) and/or the Anti-Kickback Statute (AKS) with respect to the relationships between certain of the Company’s independent subsidiaries and persons who serve or have served as medical directors. The Company fully cooperated with the DOJ and promptly responded to its requests for information. In April 2020, the Company was advised that the DOJ declined to intervene in any subsequent action filed in connection with the subject matter of this investigation. Despite the decision of the DOJ to decline to participate in litigation based on the subject matter of its previously issued CID, the involved qui tam relator moved forward with the complaint in December 2020. From that time until December 2023, and notwithstanding the Company's success in early pre-trial motions, the Company continued to incur legal defense costs and fees, including significant amounts as part of discovery in the fourth quarter of 2023. In early January 2024, the Company entered into mediation and on January 19, 2024, the parties agreed to settle the civil case for $48,000, subject to the review of the DOJ and other relevant government entities. The settlement does not include admissions on the part of the Company or its independent subsidiaries and the Company maintains that it has and continues to comply with all applicable State and Federal statutes (including but not limited to the FCA and the AKS).
    In addition to the FCA, some states, including California, Arizona and Texas, have enacted similar whistleblower and false claims laws and regulations. Further, the Deficit Reduction Act of 2005 created incentives for states to enact anti-fraud legislation modeled on the FCA. As such, the Company and its independent subsidiaries could face increased scrutiny, potential liability and legal expenses and costs based on claims under state false claims acts in markets in which its independent subsidiaries do business.
    In May 2009, Congress passed the FERA which made significant changes to the FCA and expanded the types of activities subject to prosecution and whistleblower liability. Following changes by FERA, health care providers face significant penalties for the knowing retention of government overpayments, even if no false claim was involved. Health care providers can now be liable for knowingly and improperly avoiding or decreasing an obligation to pay money or property to the government. This includes the retention of any government overpayment. The government can argue, therefore, that an FCA violation can occur without any affirmative fraudulent action or statement, as long as the action or statement is knowingly improper. In addition, FERA extended protections against retaliation for whistleblowers, including protections not only for employees, but also contractors and agents. Thus, an employment relationship is generally not required in order to qualify for protection against retaliation for whistleblowing.
    Healthcare litigation (including class action litigation) is common and is filed based upon a wide variety of claims and theories, and the Company's independent subsidiaries are routinely subjected to varying types of claims, including class action "staffing" suits where the allegation is understaffing at the facility level. These class-action “staffing” suits have the potential to result in large jury verdicts and settlements and may result in significant legal costs. The Company expects the plaintiffs' bar to continue to be aggressive in their pursuit of these staffing and similar claims. While the Company has been able to settle these claims without an ongoing material adverse effect on its business, future claims could be brought that may materially affect its business, financial condition and results of operations.
    Other claims and suits, including class actions, continue to be filed against the Company and other companies in its industry. The Company and its independent subsidiaries have been subjected to, and are currently involved in, class action litigation alleging violations (alone or in combination) of state and federal wage and hour laws as related to the alleged failure to pay wages, to timely provide and authorize meal and rest breaks, and related causes of action. The Company does not believe that the ultimate resolution of these actions will have an ongoing material adverse effect on the Company’s business, cash flows, financial condition or results of operations.
    The Company and its independent subsidiaries are also subject to requests for information and investigations by other state and federal governmental entities (e.g., Offices of the Attorney General and Offices of the Inspector General). The Company cannot predict or provide any assurance as to the possible outcome of any inquiry, investigation or litigation. If any such inquiry, investigation or litigation were to proceed, and the Company and its independent subsidiaries are subjected to, alleged to be liable for, or agree to a settlement of, claims or obligations under federal Medicare statutes, the FCA, or similar state and federal statutes and related regulations, or if the Company or its independent subsidiaries are alleged or found to be liable on theories of general or professional negligence or wage and hour violations, the Company's business, financial condition and results of operations and cash flows could be materially and adversely affected and its stock price could be adversely impacted. Among other things, any settlement or litigation could involve the payment of substantial sums to settle any alleged violations and may also include the assumption of specific procedural and financial obligations by the Company or its independent subsidiaries under a Corporate Integrity Agreement and/or other such arrangement.
    Cost-Containment Measures Both government and private pay sources have instituted cost-containment measures designed to limit payments made to providers of healthcare services, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect the Company.
    Medicare Revenue Recoupments The Company's independent subsidiaries are subject to regulatory reviews relating to the provision of Medicare services, billings and potential overpayments as a result of Recovery Audit Contractors (RAC), Program Safeguard Contractors, and Medicaid Integrity Contractors programs (collectively referred to as Reviews). For several months during the COVID-19 pandemic, the Centers for Medicare and Medicaid Services (CMS) suspended its Targeted Probe and Educate (TPE) Program. Beginning in August 2020, CMS resumed TPE Program activity. If an operation fails a Review and/or subsequent Reviews, the operation could then be subject to extended review or an extrapolation of the identified error rate to billings in the same time period. The Company anticipates that these Reviews could increase in frequency in the future. As of December 31, 2023 and through the filing date of this report, 40 of the Company's independent subsidiaries had Reviews scheduled or in process.
    In June 2023, CMS announced a new nationwide audit, the “SNF 5-Claim Probe & Educate Review”, in which the Medicare Administrative Contractors (MACs) will review five claims from each SNF to check for compliance. In implementing this SNF 5-Claim Probe & Educate Review, CMS acknowledged that the increase in observed improper payments from 2021 to 2022 may have arisen from a "misunderstanding" by SNFs about how to appropriately bill for claims of service after October 1, 2019. All facilities that are not undergoing TPE reviews, or have not recently passed a TPE review, will be subject to the nationwide audit. MACs will complete only one round of probe-and-educate for each SNF, rather than three rounds that typically occur in the TPE. Additionally, CMS's education for each SNF will be individualized and based on observed claim review errors, with rationales for denial explained to the SNF on a claim-by-claim basis. This program applies only to claims submitted after October 1, 2019, and will exclude claims containing a COVID-19 diagnosis.
    Concentrations
    Credit Risk — The Company has significant accounts receivable balances, the collectability of which is dependent on the availability of funds from certain governmental programs, primarily Medicare and Medicaid. These receivables represent the only significant concentration of credit risk for the Company. The Company does not believe there are significant credit risks associated with these governmental programs. The Company believes that an appropriate allowance has been recorded for the possibility of these receivables proving uncollectible, and continually monitors and adjusts these allowances as necessary.
    The Company’s receivables from Medicare and Medicaid payor programs accounted for 53.4% and 56.3% of its total accounts receivable as of December 31, 2023 and 2022, respectively. Revenue from reimbursement under the Medicare and Medicaid programs accounted for 72.6%, 73.7% and 73.6% of the Company's revenue for the years ended December 31, 2023, 2022 and 2021, respectively.
    Cash in Excess of FDIC Limits — The Company currently has bank deposits with financial institutions in the U.S. that exceed FDIC insurance limits. FDIC insurance provides protection for bank deposits up to $250. In addition, the Company has uninsured bank deposits with a financial institution outside the U.S. As of December 31, 2023, the Company's uninsured cash deposits are not material. All uninsured bank deposits are held at high quality credit institutions.
    XML 48 R29.htm IDEA: XBRL DOCUMENT v3.24.0.1
    COMMON STOCK REPURCHASE PROGRAM
    12 Months Ended
    Dec. 31, 2023
    Equity [Abstract]  
    COMMON STOCK REPURCHASE PROGRAM COMMON STOCK REPURCHASE PROGRAM
    On August 29, 2023, the Board of Directors approved a stock repurchase program pursuant to which the Company could repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months from September 1, 2023. Under this program, the Company is authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. The share repurchase program does not obligate us to acquire any specific number of shares. The Company did not purchase any shares pursuant to this stock repurchase program during the year ended December 31, 2023.
    On July 28, 2022, the Board of Directors approved a stock repurchase program pursuant to which the Company could repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months from August 2, 2022. Under this program, the Company was authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. The share repurchase program did not obligate the Company to acquire any specific number of shares. The stock repurchase program expired on August 2, 2023 and is no longer in effect. The Company did not purchase any shares pursuant to this stock repurchase program.
    In addition, the Company repurchased 404 shares of its common stock for $29,882 during the year ended December 31, 2022, and 132 shares of its common stock for $10,118 during the year ended December 31, 2021, related to two separate stock repurchase programs that are no longer in effect.
    XML 49 R30.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Pay vs Performance Disclosure - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Pay vs Performance Disclosure      
    Net Income (Loss) $ 209,399 $ 224,681 $ 194,652
    XML 50 R31.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Insider Trading Arrangements
    3 Months Ended 12 Months Ended
    Dec. 31, 2023
    shares
    Dec. 31, 2023
    shares
    Trading Arrangements, by Individual    
    Non-Rule 10b5-1 Arrangement Adopted false  
    Rule 10b5-1 Arrangement Terminated false  
    Non-Rule 10b5-1 Arrangement Terminated false  
    Christopher R. Christensen [Member]    
    Trading Arrangements, by Individual    
    Material Terms of Trading Arrangement   Christopher R. Christensen, Co-founder, Executive Chairman and Chairman of the Board, entered into a Rule 10b5-1 trading arrangement on November 2, 2023 (the "Rule 10b5-1 Plan"). Mr. Christensen's 10b5-1 Plan provides for the potential sale of up to 110,700 shares of the Company's common stock between February 6, 2024 and December 31, 2024.
    Name Christopher R. Christensen  
    Title Co-founder, Executive Chairman and Chairman of the Board  
    Rule 10b5-1 Arrangement Adopted true  
    Adoption Date November 2, 2023  
    Arrangement Duration 334 days  
    Aggregate Available 110,700 110,700
    Beverly B. Wittekind [Member]    
    Trading Arrangements, by Individual    
    Material Terms of Trading Arrangement   Beverly B. Wittekind, Vice President & General Counsel, entered into a Rule 10b5-1 trading arrangement on December 8, 2023 (the "Rule 10b5-1 Plan"). Ms. Wittekind's 10b5-1 Plan provides for the potential exercise of vested stock options and the associated sale of up to 10,000 shares of the Company's common stock between March 14, 2024 and October 31, 2024.
    Name Beverly B. Wittekind  
    Title Vice President & General Counsel  
    Rule 10b5-1 Arrangement Adopted true  
    Adoption Date December 8, 2023  
    Arrangement Duration 231 days  
    Aggregate Available 10,000 10,000
    XML 51 R32.htm IDEA: XBRL DOCUMENT v3.24.0.1
    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
    12 Months Ended
    Dec. 31, 2023
    Accounting Policies [Abstract]  
    Basis of Presentation Basis of Presentation The accompanying consolidated financial statements (the Financial Statements) have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company is the sole member or stockholder of various consolidated limited liability companies and corporations established to operate various acquired skilled nursing operations, senior living operations and related ancillary services. All intercompany transactions and balances have been eliminated in consolidation. The Company presents noncontrolling interests within the equity section of its consolidated balance sheets and the amount of consolidated net income that is attributable to The Ensign Group, Inc. and the noncontrolling interests in its consolidated statements of income. The Financial Statements include the accounts of all independent subsidiaries controlled by the Company through its ownership of a majority voting interest.
    Reclassifications ReclassificationsCertain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements.
    Estimates and Assumptions
    Estimates and Assumptions The preparation of the Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Company’s Financial Statements relate to revenue, acquired property and equipment, intangible assets and goodwill, right-of-use assets, impairment of long-lived assets, lease liabilities, general and professional liabilities, workers' compensation and healthcare claims included in accrued self-insurance liabilities and income taxes. Actual results could differ from those estimates.
    Fair Value Considerations
    Fair Value ConsiderationsThe Company’s financial instruments consist principally of cash and cash equivalents, debt security investments, accounts receivable, insurance subsidiary deposits, deferred compensation investment funds, equity investments, accounts payable and borrowings. The Company believes all of the financial instruments’ recorded values approximate fair values because of their nature or respective short durations.
    Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.The Company's non-financial assets, which includes goodwill, intangible assets, property and equipment and right-of-use assets, are not required to be measured at fair value on a recurring basis. However, on a periodic basis, or whenever events or changes in circumstances indicate that their carrying value may not be recoverable, the Company assesses its long-lived assets for impairment. When impairment has occurred, such long-lived assets are written down to fair value.
    Service Revenue Recognition, Rental Revenue Recognition
    Service Revenue RecognitionThe Company recognizes revenue in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with Customers (ASC 606). The Company's service revenue is derived primarily from providing healthcare services to its patients. Revenue is recognized when services are provided to patients at the amount that reflects the consideration that the Company expects to be entitled from patients and third-party payors, including Medicaid, Medicare and insurers (private and Medicare replacement plans), in exchange for providing patient care. The healthcare services provided pursuant to skilled patient contracts include routine services in exchange for a contractual agreed-upon amount or rate. Routine services are treated as a single performance obligation satisfied over time as services are rendered. As such, patient care services represent a bundle of services that are not capable of being distinct. Additionally, there may be ancillary services that are not included in the daily rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time, if and when those services are rendered.

    Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction price. The Company determines the transaction price based on contractually agreed-upon amounts or rate on a per day basis, adjusted for estimates of variable consideration. The Company uses the expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The amount of variable consideration that is included in the transaction price may be constrained and is included in net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from the Company’s estimates, the Company adjusts these estimates, which would affect net revenue in the period such variances become known.

    As the Company’s contracts with its patients have an original duration of one year or less, the Company uses the practical expedient applicable to its contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of the end of each reporting period or when the Company expects to recognize this revenue. In addition, the Company has applied the practical expedient provided by FASB ASC Topic 340, Other Assets and Deferred Costs, and all incremental customer contract acquisition costs are expensed as they are incurred because the amortization period would have been one year or less.
    Rental Revenue Recognition The Company's rental revenues are primarily generated by leasing healthcare-related properties through triple-net lease arrangements, under which the tenant is solely responsible for the costs related to the property. Revenue for operating leases is recognized on a straight-line basis over the lease term when collectability of all minimum lease payments is probable in accordance with FASB ASC Topic 842, Leases (ASC 842). The Company has elected the single component practical expedient, which allows a lessor, by class of underlying asset, not to allocate the total consideration to the lease and non-lease components based on their relative stand-alone selling prices where certain criteria are met.
    Tenant reimbursements related to property taxes and insurance are neither considered lease nor non-lease components under ASC 842. Lessee payments for taxes and insurance paid directly to a third party, on behalf of the Company, are excluded from variable lease payments and rental revenue in the Company’s consolidated statements of income. Otherwise, tenant reimbursements for taxes and insurance that are paid by the Company directly to a third party are classified as additional rental revenue and expense and recognized by the Company on a gross basis.
    Accounts Receivable
    Accounts Receivable Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources, net of estimates for variable consideration.
    Cash and Cash Equivalents
    Cash and Cash Equivalents Cash and cash equivalents consist of bank term deposits, money market funds and treasury bill related investments with original maturities of three months or less at time of purchase and therefore approximate fair value. The fair value of money market funds is determined based on “Level 1” inputs, which consist of unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets. The Company places its cash and short-term investments with high credit quality financial institutions.
    Insurance Subsidiary Deposits and Investments
    Insurance Subsidiary Deposits and Investments — The Company's captive insurance subsidiary cash and cash equivalents, deposits and investments are designated to support long-term insurance subsidiary liabilities and have been classified as short-term and long-term assets based on the timing of expected future payments of the Company's captive insurance liabilities. The majority of these deposits and investments are currently held in AA, A and BBB rated debt security investments and the remainder is held in a bank account with a high credit quality financial institution.
    The Company's non-qualified deferred compensation plan (the DCP)'s contracts insuring the lives of certain employees who are eligible to participate in the DCP are held in a rabbi trust. Cash surrender value of the contracts is based on funds that shadow the investment allocations specified by participants in the deferred compensation plan.
    When evaluating an investment for its current expected credit losses, the Company reviews factors such as historical experience with defaults, losses, credit ratings, term, market sector and macroeconomic trends, including current conditions and forecasts to the extent they are reasonable and supportable.
    Property and Equipment Property and Equipment Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from three to 59 years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term.
    Leases
    Leases The Company leases skilled nursing facilities, senior living facilities and commercial office space. The Company determines if an arrangement is a lease and performs an evaluation to determine whether the lease should be classified as an operating or finance lease at the inception of the lease. As of December 31, 2023, the Company has one financing lease that is not material to the consolidated balance sheet. Rights and obligations of these leases are included as right-of-use assets and current and long-term lease liabilities on the Company's consolidated balance sheets. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of future lease payments. The Company utilizes a third-party valuation specialist to assist in estimating the incremental borrowing rate.
    The Company records rent expense for operating leases on a straight-line basis over the term of the lease. The lease term used for straight-line rent expense is calculated from the date the Company is given control of the leased premises through the end of the lease term. Renewals are not assumed in the determination of the lease term unless they are deemed to be reasonably assured at the inception of the lease. The lease term used for this evaluation also provides the basis for establishing depreciable lives for buildings subject to lease and leasehold improvements.
    The Company's real estate leases generally have initial lease terms of ten years or more and typically include one or more options to renew, with renewal terms that generally extend the lease term for an additional ten to 15 years. Exercise of the renewal options is generally subject to the satisfaction of certain conditions which vary by contract and generally follow payment terms that are consistent with those in place during the initial term. The Company reassesses the renewal option using a "reasonably certain" threshold, which is understood to be a high threshold. For leases where the Company is reasonably certain to exercise its renewal option, the option periods are included within the lease term and, therefore, the measurement of the right-of-use asset and lease liability. The Company's leases generally contain annual escalation clauses that are either fixed or variable in nature, some of which are dependent upon published indices. The Company recognizes lease expense for leases with an initial term of 12 months or less on a straight-line basis over the lease term. These leases are not recorded on the consolidated balance sheets. Certain of the Company's lease agreements include rental payments that are adjusted periodically for inflation. The lease agreements do not contain any material residual value guarantees or material restrictive covenants.
    The Company subleases skilled nursing facilities to third-party operators and considers the subleases to be separate contracts as the Company is not relieved of its primary obligation under its operating lease. The rental income from third-parties related to these subleases is presented on a gross basis from the rent expense associated with the Company's lease obligations and is not material to the consolidated statements of income.
    Impairment of Long-Lived Assets Impairment of Long-Lived Assets The Company reviews the carrying value of long-lived assets that are held and used in the Company’s independent subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the independent subsidiaries to which the assets relate, utilizing management’s best estimate, appropriate assumptions and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset.
    Intangible Assets and Goodwill
    Intangible Assets and Goodwill Definite-lived intangible assets consist primarily of patient base, facility trade names and customer relationships. Patient base is amortized over a period of four to eight months, depending on the classification of the patients and the level of occupancy in a new acquisition on the acquisition date. Trade names at independent subsidiaries are amortized over 30 years and customer relationships are amortized over a period of up to 20 years.
    The Company's indefinite-lived intangible assets consist of trade names and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable.
    Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. The Company tests goodwill during the fourth quarter of each year or more often if events or circumstances indicate there may be impairment. The Company performs its analysis for each reporting unit that constitutes a business for which discrete financial information is produced and reviewed by operating segment management and provides services that are distinct from the other components of the operating segment, in accordance with the provisions of FASB ASC Topic 350, Intangibles—Goodwill and Other (ASC 350). This guidance provides the option to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. If, based on a review of qualitative factors, it is more likely than not that the fair value of a reporting unit is less than its carrying value, the Company performs a goodwill impairment test by comparing the carrying value of each reporting unit to its respective fair value. The Company determines the estimated fair value of each reporting unit using a discounted cash flow analysis. The fair value of the reporting unit is the implied fair value of goodwill. In the event a reporting unit's carrying value exceeds its fair value, an impairment loss will be recognized. An impairment loss is measured by the difference between the carrying value of the reporting unit and its fair value.
    Self-Insurance
    Self-Insurance — The Company is partially self-insured for general and professional liability claims up to a base amount per claim (the self-insured retention) with an aggregate, one-time deductible above this limit. Losses beyond these amounts are insured through third-party policies with coverage limits per claim, per location and on an aggregate basis for the Company. The combined self-insured retention is $500 per claim, subject to an additional one-time deductible of $1,250 for the Company's independent subsidiaries in California and a separate, one-time, deductible of $1,250 for the Company's independent subsidiaries not in California. For all independent subsidiaries, except those located in Colorado, the third-party coverage above these limits is $1,000 per claim, $3,000 per operation, with a $5,000 blanket aggregate limit and an additional state-specific aggregate where required by state law. In Colorado, the third-party coverage above these limits is $1,000 per claim and $3,000 per operation, which is independent of the aforementioned blanket aggregate limits that apply outside of Colorado.
    Subsequent to December 31, 2023, the self-insured retention is $750 per claim, subject to an additional one-time deductible of $1,500 for the Company's independent subsidiaries in California. For the independent subsidiaries not in California, the self-insured retention is $650 per claim, subject to an additional one-time deductible of $1,350. For all independent subsidiaries, except those located in Colorado, the third-party coverage above these limits is $1,000 per claim, $3,000 per operation, with a $10,000 blanket aggregate limit and an additional state-specific aggregate where required by state law.
    The majority of the self-insured retention and deductible limits for general and professional liabilities and workers' compensation liabilities are self-insured through the captive insurance subsidiary, the related assets and liabilities of which are included in the accompanying consolidated balance sheets. The captive insurance subsidiary is subject to certain statutory requirements as an insurance provider.
    The Company’s policy is to accrue amounts equal to the actuarial estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. The Company develops information about the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluates the estimates for claim loss exposure on a quarterly basis. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information.
    The Company’s independent subsidiaries are self-insured for workers’ compensation liabilities in California. To protect itself against loss exposure in California with this policy, the Company has purchased individual specific excess insurance coverage that insures individual claims that exceed $625 per occurrence. In Texas, the independent subsidiaries have elected non-subscriber status for workers’ compensation claims and the Company has purchased individual stop-loss coverage that insures individual claims that exceed $750 per occurrence. The Company’s independent subsidiaries in all other states, with the exception of Washington, are under a loss sensitive plan that insures individual claims that exceed $350 per occurrence. In the state of Washington, the Company is self-insured and has purchased individual specific excess insurance coverage that insures individual claims that exceed $500 per occurrence. For all of the self-insured plans and retention, the Company accrues amounts equal to the estimated costs to settle open claims, as well as an estimate of the cost of claims that have been incurred but not reported. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information.
    The Company self-funds medical (including prescription drugs) and dental healthcare benefits to the majority of its employees. The Company is fully liable for all financial and legal aspects of these benefit plans. To protect itself against loss exposure with this policy, the Company has purchased individual stop-loss insurance coverage that insures individual claims that exceed $525 for each covered person for fiscal years 2023 and 2022, respectively, and $500 for each covered person for fiscal year 2021.
    The Company believes that adequate provision has been made in the Financial Statements for liabilities that may arise out of patient care, workers’ compensation, healthcare benefits and related services provided to date. The amount of the Company’s reserves was determined based on an estimation process that uses information obtained from both company-specific and industry data. This estimation process requires the Company to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and the Company’s assumptions about emerging trends, the Company, with the assistance of an independent actuary, develops information about the size of ultimate claims based on the Company’s historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damage awards with respect to unpaid claims. The self-insured liabilities are based upon estimates, and while management believes that the estimates of loss are reasonable, the ultimate liability may be in excess of or less than the recorded amounts. Due to the inherent volatility of actuarially determined loss estimates, it is reasonably possible that the Company could experience changes in estimated losses that could be material to net income. If the Company’s actual liabilities exceed its estimates of losses, its future earnings, cash flows and financial condition would be adversely affected.
    Income Taxes
    Income Taxes — Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized.
    In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company’s estimates and assumptions, actual results could differ.
    Standard Bearer elected to be taxed as a REIT, for U.S. federal income tax purposes, commencing with its taxable year ended December 31, 2022. Standard Bearer was organized, has operated and intends to continue to operate in a manner to qualify for taxation as a REIT. In order to qualify as a REIT, Standard Bearer must meet certain organizational and operational requirements, including a requirement to distribute to its shareholders, which in this case is the Company, at least 90% of its annual taxable income. As a REIT, Standard Bearer generally will not be subject to federal income tax to the extent it distributes as qualifying dividends, all of its REIT taxable income to its shareholders. If Standard Bearer fails to qualify as a REIT in any taxable year, it will be subject to federal income tax on its taxable income at regular corporate income tax rates and generally will not be permitted to qualify for treatment as a REIT for federal income tax purposes for the four taxable years following the year during which qualification is lost unless the Internal Revenue Service grants the Company relief under certain statutory provisions.
    Noncontrolling Interest Noncontrolling Interest The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to The Ensign Group, Inc. in its consolidated statements of income. Net income per share is calculated based on net income attributable to The Ensign Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest.
    Stock-Based Compensation
    Stock-Based CompensationThe Company measures and recognizes compensation expense for all stock-based payment awards made to employees and directors including employee stock options based on estimated fair values, ratably over the requisite service period of the award. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is based upon the number of grants and other variables.
    Recent Accounting Pronouncements
    Recent Accounting Pronouncements Except for rules and interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal securities laws and a limited number of grandfathered standards, the FASB ASC is the sole source of authoritative GAAP literature recognized by the FASB and applicable to the Company. For any new pronouncements announced, the Company considers whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on the Company's reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company's financial management and certain standards are under consideration.
    Recent Accounting Standards Issued But Not Yet Adopted by the Company In October 2023, the FASB issued ASU 2023-06 "Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative", which amends U.S. GAAP to include 14 disclosure requirements that are currently required under SEC Regulation S-X or Regulation S-K. Each amendment will be effective on the date on which the SEC removes the related disclosure requirement from SEC Regulation S-X or Regulation S-K. The adoption is not expected to have a material impact on the Company's Notes to the Consolidated Financial Statements as these requirements were previously incorporated under the SEC Regulations.
    In November 2023, the FASB issued ASU 2023-07 "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures", which requires the Company to expand the breadth and frequency of segment disclosures to include additional information about significant segment expenses, the chief operating decision maker (CODM) and other items, and also require the annual disclosures on an interim basis. This guidance is effective for annual periods beginning after December 15, 2023, which will be the Company's fiscal year 2024, with early adoption permitted. The Company is currently evaluating the impact of the ASU on its Quarterly and Annual Reports.
    In December 2023, the FASB issued ASU 2023-09 "Income Taxes (Topic 740): Improvements to Income Tax Disclosures", which requires the Company to disclose disaggregated jurisdictional and categorical information for the tax rate reconciliation, income taxes paid and other income tax related amounts. This guidance is effective for annual periods beginning after December 15, 2024, which will be the Company's fiscal year 2025, with early adoption permitted. The adoption is expected to enhance the Company's Notes to the Consolidated Financial Statements. The Company is currently evaluating the impact of the ASU on its Annual Report.
    XML 52 R33.htm IDEA: XBRL DOCUMENT v3.24.0.1
    REVENUE AND ACCOUNTS RECEIVABLE (Tables)
    12 Months Ended
    Dec. 31, 2023
    Revenue from Contract with Customer [Abstract]  
    Schedule of Disaggregation of Revenue
    Service revenue for the years ended December 31, 2023, 2022, and 2021 is summarized in the following tables:
     Year Ended December 31,
    202320222021
    Revenue% of RevenueRevenue% of RevenueRevenue% of Revenue
    Medicaid(1)
    $1,459,449 39.4 %$1,183,156 39.3 %$1,022,460 39.2 %
    Medicare985,749 26.6 832,160 27.7 727,103 27.8 
    Medicaid — skilled245,663 6.6 200,878 6.7 172,770 6.6 
    Total Medicaid and Medicare2,690,861 72.6 2,216,194 73.7 1,922,333 73.6 
    Managed care666,129 18.0 525,710 17.5 456,728 17.5 
    Private and other(2)
    351,081 9.4 266,807 8.8 232,415 8.9 
    SERVICE REVENUE$3,708,071 100.0 %$3,008,711 100.0 %$2,611,476 100.0 %
    (1) Medicaid payor includes revenue for senior living operations and revenue related to state relief funding.
    (2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.
    Schedule of Accounts Receivable
    Accounts receivable as of December 31, 2023 and 2022, is summarized in the following table:
    December 31,
    20232022
    Medicaid$178,285 $157,878 
    Managed care125,907 95,940 
    Medicare85,512 76,526 
    Private and other payors104,683 85,890 
     494,387 416,234 
    Less: allowance for doubtful accounts(9,348)(7,802)
    ACCOUNTS RECEIVABLE, NET$485,039 $408,432 
    XML 53 R34.htm IDEA: XBRL DOCUMENT v3.24.0.1
    COMPUTATION OF NET INCOME PER COMMON SHARE (Tables)
    12 Months Ended
    Dec. 31, 2023
    Earnings Per Share [Abstract]  
    Schedule of Reconciliation of the Numerator and Denominator Used in the Calculation of Basic Net Income Per Common Share
    A reconciliation of the numerator and denominator used in the calculation of basic net income per common share follows:
    Year Ended December 31,
     202320222021
    NUMERATOR:
    Net income$209,850 $224,652 $197,725 
    Less: net income (loss) attributable to noncontrolling interests 451 (29)3,073 
    Net income attributable to The Ensign Group, Inc. $209,399 $224,681 $194,652 
    DENOMINATOR:
    Weighted average shares outstanding for basic net income per share55,708 54,887 54,486 
    Basic net income per common share:$3.76 $4.09 $3.57 
    Schedule of Reconciliation of the Numerator and Denominator Used in the Calculation of Diluted Net Income Per Common Share
    A reconciliation of the numerator and denominator used in the calculation of diluted net income per common share follows:

    Year Ended December 31,
     202320222021
    NUMERATOR:
    Net income $209,850 $224,652 $197,725 
    Less: net income (loss) attributable to noncontrolling interests451 (29)3,073 
    Net income attributable to The Ensign Group, Inc. $209,399 $224,681 $194,652 
    DENOMINATOR:
    Weighted average common shares outstanding55,708 54,887 54,486 
    Plus: incremental shares from assumed conversion (1)
    1,615 1,984 2,439 
    Adjusted weighted average common shares outstanding57,323 56,871 56,925 
    Diluted net income per common share:$3.65 $3.95 $3.42 
    (1) Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were 1,429, 780 and 198 for the years ended December 31, 2023, 2022 and 2021, respectively.
    XML 54 R35.htm IDEA: XBRL DOCUMENT v3.24.0.1
    OPERATION EXPANSIONS (Tables)
    12 Months Ended
    Dec. 31, 2023
    Business Combination and Asset Acquisition [Abstract]  
    Schedule of Purchase Price Allocation
    The table below presents the allocation of the purchase price for the operations acquired during the years ended December 31, 2023, 2022, and 2021:
    Year Ended December 31,
    202320222021
    Land$7,794 $15,527 $19,928 
    Building and improvements57,488 65,070 77,975 
    Equipment, furniture, and fixtures1,840 1,618 217 
    Assembled occupancy346 367 29 
    Goodwill— 16,400 6,000 
    Leased asset— 1,909 — 
    Other indefinite-lived intangible assets330 245 75 
    TOTAL ACQUISITIONS$67,798 $101,136 $104,224 
    XML 55 R36.htm IDEA: XBRL DOCUMENT v3.24.0.1
    BUSINESS SEGMENTS (Tables)
    12 Months Ended
    Dec. 31, 2023
    Segment Reporting [Abstract]  
    Schedule of Segment Financial Information
    The following tables set forth financial information for the segments:
     Year Ended December 31, 2023
     Skilled ServicesStandard Bearer
    All Other (1)
    Intercompany EliminationTotal
    Service revenue(2)
    $3,578,855 $— $144,667 $(15,451)$3,708,071 
    Rental revenue(3)
    — 82,486 11,137 (72,339)21,284 
    TOTAL REVENUE$3,578,855 $82,486 $155,804 $(87,790)$3,729,355 
    Segment income (loss)464,925 29,065 (221,251)— 272,739 
    Gain on sale of assets and insurance recoveries from real estate, net
    23 
    Income before provision for income taxes$272,762 
    Depreciation and amortization38,766 25,205 8,416 — 72,387 
    Interest expense(4)
    $— $19,761 $1,228 $(12,902)$8,087 
    (1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center.
    (2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's independent subsidiaries and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service.
    (3) All Other rental revenue includes rental revenue associated with the Company's subleases to third parties of $3,897 for the year ended December 31, 2023. Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's independent subsidiaries. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense.
    (4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. Intercompany interest expense is eliminated in the "Intercompany Elimination" column.
     Year Ended December 31, 2022
     Skilled ServicesStandard Bearer
    All Other (1)
    Intercompany EliminationTotal
    Service revenue(2)
    $2,906,215 $— $115,214 $(12,718)$3,008,711 
    Rental revenue(3)
    — 72,937 7,396 (63,576)16,757 
    TOTAL REVENUE$2,906,215 $72,937 $122,610 $(76,294)$3,025,468 
    Segment income (loss)408,732 27,871 (150,781)— 285,822 
    Gain on sale of assets and insurance recoveries from real estate, net
    3,267 
    Income before provision for income taxes$289,089 
    Depreciation and amortization33,224 21,613 7,518 — 62,355 
    Interest expense(4)
    $— $15,707 $1,870 $(8,646)$8,931 
    (1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center.
    (2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's independent subsidiaries and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service.
    (3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's independent subsidiaries. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense.
    (4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. Intercompany interest expense is eliminated in the "Intercompany Elimination" column.
     
    Year Ended December 31, 2021
     Skilled ServicesStandard Bearer
    All Other (1)
    Intercompany EliminationTotal
    Service revenue(2)
    $2,523,234 $— $95,276 $(7,034)$2,611,476 
    Rental revenue(3)
    — 58,127 7,409 (49,551)15,985 
    TOTAL REVENUE$2,523,234 $58,127 $102,685 $(56,585)$2,627,461 
    Segment income (loss)373,603 31,876 (147,915)— 257,564 
    Gain on real estate insurance recoveries440 
    Income before provision for income taxes $258,004 
    Depreciation and amortization30,681 17,558 7,746 — 55,985 
    Interest expense$— $6,842 $$— $6,849 
    (1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center.
    (2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's independent subsidiaries and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service.
    (3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's independent subsidiaries. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense.
    Schedule of Service Revenue by Major Payor Source
    Service revenue by major payor source were as follows:
     Year Ended December 31, 2023
     Skilled Services
    All Other (3)
    Total Service RevenueRevenue %
    Medicaid(1)
    $1,429,473 $29,976 $1,459,449 39.4 %
    Medicare985,749 — 985,749 26.6 
    Medicaid-skilled245,663 — 245,663 6.6 
    Subtotal2,660,885 29,976 2,690,861 72.6 
    Managed care666,129 — 666,129 18.0 
    Private and other(2)
    251,841 99,240 351,081 9.4 
    TOTAL SERVICE REVENUE$3,578,855 $129,216 $3,708,071 100.0 %
    (1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding.
    (2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.
    (3) All Other incorporates intercompany eliminations.
     Year Ended December 31, 2022
     Skilled Services
    All Other (3)
    Total Service RevenueRevenue %
    Medicaid(1)
    $1,158,309 $24,847 $1,183,156 39.3 %
    Medicare832,160 — 832,160 27.7 
    Medicaid-skilled200,878 — 200,878 6.7 
    Subtotal2,191,347 24,847 2,216,194 73.7 
    Managed care525,710 — 525,710 17.5 
    Private and other(2)
    189,158 77,649 266,807 8.8 
    TOTAL SERVICE REVENUE$2,906,215 $102,496 $3,008,711 100.0 %
    (1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding.
    (2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.
    (3) All Other incorporates intercompany eliminations.
     
    Year Ended December 31, 2021
     Skilled Services
    All Other (3)
    Total Service RevenueRevenue %
    Medicaid(1)
    $1,007,061 $15,399 $1,022,460 39.2 %
    Medicare727,103 — 727,103 27.8 
    Medicaid-skilled172,770 — 172,770 6.6 
    Subtotal1,906,934 15,399 1,922,333 73.6 
    Managed care456,728 — 456,728 17.5 
    Private and other(2)
    159,572 72,843 232,415 8.9 
    TOTAL SERVICE REVENUE$2,523,234 $88,242 $2,611,476 100.0 %
    (1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding.
    (2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.
    (3) All Other incorporates intercompany eliminations.
    XML 56 R37.htm IDEA: XBRL DOCUMENT v3.24.0.1
    PROPERTY AND EQUIPMENT— NET (Tables)
    12 Months Ended
    Dec. 31, 2023
    Property, Plant and Equipment [Abstract]  
    Schedule of Property and Equipment, Net
    Property and equipment, net consists of the following:
    December 31,
    20232022
    Land$142,656 $134,864 
    Buildings and improvements803,155 728,231 
    Leasehold improvements172,064 150,903 
    Equipment339,383 295,739 
    Furniture and fixtures4,192 4,544 
    Construction in progress25,563 17,521 
     1,487,013 1,331,802 
    Less: accumulated depreciation(396,242)(339,792)
    PROPERTY AND EQUIPMENT, NET$1,090,771 $992,010 
    XML 57 R38.htm IDEA: XBRL DOCUMENT v3.24.0.1
    INTANGIBLE ASSETS — NET (Tables)
    12 Months Ended
    Dec. 31, 2023
    Goodwill and Intangible Assets Disclosure [Abstract]  
    Schedule of Finite-Lived Intangible Assets
    Weighted Average Life (Years)December 31,
    20232022
    Gross Carrying AmountAccumulated AmortizationGross Carrying AmountAccumulated Amortization
    Intangible AssetsNetNet
    Assembled occupancy0.3$781 $(742)$39 $435 $(388)$47 
    Facility trade name30.0733 (439)294 733 (415)318 
    Customer relationships18.44,582 (2,692)1,890 4,582 (2,482)2,100 
    TOTAL $6,096 $(3,873)$2,223 $5,750 $(3,285)$2,465 
    Schedule of Estimated Amortization Expense
    Estimated amortization expense for each of the years ending December 31 is as follows:
    YearAmount
    2024274 
    2025234 
    2026234 
    2027234 
    2028234 
    Thereafter1,013 
     $2,223 
    Schedule of Indefinite-lived Intangible Assets
    Other indefinite-lived intangible assets consist of the following:
    December 31,
    20232022
    Trade name$889 $889 
    Medicare and Medicaid licenses3,413 3,083 
    TOTAL$4,302 $3,972 
    XML 58 R39.htm IDEA: XBRL DOCUMENT v3.24.0.1
    GOODWILL (Tables)
    12 Months Ended
    Dec. 31, 2023
    Goodwill and Intangible Assets Disclosure [Abstract]  
    Schedule of Goodwill The following table represents activity in goodwill by skilled service segment and "all other" category as of December 31, 2023, 2022 and 2021:
    Goodwill
     Skilled ServicesAll OtherTotal
    January 1, 2021$45,486 $8,983 $54,469 
    Additions6,000 — 6,000 
    December 31, 2021$51,486 $8,983 $60,469 
    Additions16,400 — 16,400 
    December 31, 2022$67,886 $8,983 $76,869 
    December 31, 2023$67,886 $8,983 $76,869 
    XML 59 R40.htm IDEA: XBRL DOCUMENT v3.24.0.1
    RESTRICTED AND OTHER ASSETS (Tables)
    12 Months Ended
    Dec. 31, 2023
    Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
    Schedule of Restricted and Other Assets
    Restricted and other assets consist of the following:
    December 31,
    20232022
    Debt issuance costs, net$2,883 $3,753 
    Long-term insurance losses recoverable asset15,913 10,512 
    Capital improvement reserves with landlords and lenders4,870 6,446 
    Deposits with landlords2,661 2,527 
    Escrow deposits1,216 — 
    Other12,662 14,053 
    RESTRICTED AND OTHER ASSETS$40,205 $37,291 
    XML 60 R41.htm IDEA: XBRL DOCUMENT v3.24.0.1
    OTHER ACCRUED LIABILITIES (Tables)
    12 Months Ended
    Dec. 31, 2023
    Payables and Accruals [Abstract]  
    Schedule of Other Accrued Liabilities
    Other accrued liabilities consist of the following:
    December 31,
    20232022
    Quality assurance fee$14,035 $7,701 
    Refunds payable51,248 40,783 
    Resident advances10,834 9,698 
    Unapplied state relief funds486 1,001 
    Cash held in trust for patients6,215 6,400 
    Dividends payable3,396 3,201 
    Property taxes12,875 10,926 
    Accrued litigation (Note 20)
    51,734 4,553 
    Other17,405 13,046 
    OTHER ACCRUED LIABILITIES$168,228 $97,309 
    XML 61 R42.htm IDEA: XBRL DOCUMENT v3.24.0.1
    INCOME TAXES (Tables)
    12 Months Ended
    Dec. 31, 2023
    Income Tax Disclosure [Abstract]  
    Schedule of Components of Income Tax Expense (Benefit)
    The provision for income taxes on continuing operations for the years ended December 31, 2023, 2022 and 2021 is summarized as follows:
     Year Ended December 31,
     2023 2022 2021
    Current:   
    Federal$73,092 $56,717 $49,105 
    State17,301 14,216 11,898 
     90,393 70,933 61,003 
    Deferred: 
    Federal(22,280)(5,158)(716)
    State(5,201)(1,338)(8)
    (27,481)(6,496)(724)
         TOTAL$62,912 $64,437 $60,279 
    Schedule of Effective Income Tax Rate Reconciliation
    A reconciliation of the federal statutory rate to the effective tax rate for income from continuing operations for the years ended December 31, 2023, 2022 and 2021, respectively, is comprised as follows:

     December 31,
     202320222021
    Income tax expense at statutory rate21.0 %21.0 %21.0 %
    State income taxes - net of federal benefit3.5 3.5 3.7 
    Non-deductible expenses3.4 2.0 2.4 
    Equity compensation(4.2)(3.6)(3.3)
    Other adjustments(0.6)(0.6)(0.4)
    TOTAL INCOME TAX PROVISION23.1 %22.3 %23.4 %
    Schedule of Deferred Tax Assets and Liabilities
    The Company's deferred tax assets and liabilities as of December 31, 2023 and 2022 are summarized below.
     December 31,
     2023 2022
    Deferred tax assets (liabilities): 
    Accrued expenses$81,502 $61,685 
    Revenue related reserves23,714 18,046 
    Tax credits1,192 1,742 
    Insurance16,864 11,910 
    Lease liability 444,590 364,408 
    State taxes — 28 
    567,862 457,819 
    Valuation allowance(789)(789)
    TOTAL DEFERRED TAX ASSETS567,073 457,030 
    State taxes(280)— 
    Depreciation and amortization(52,334)(49,146)
    Prepaid expenses(4,113)(5,150)
    Right of use asset (443,222)(363,091)
    TOTAL DEFERRED TAX LIABILITIES(499,949)(417,387)
    NET DEFERRED TAX ASSETS$67,124 $39,643 
    XML 62 R43.htm IDEA: XBRL DOCUMENT v3.24.0.1
    DEBT (Tables)
    12 Months Ended
    Dec. 31, 2023
    Debt Disclosure [Abstract]  
    Schedule of Debt
    Debt consists of the following:
    December 31,
    20232022
    Mortgage loans and promissory note$152,388 $156,271 
    Less: current maturities(3,950)(3,883)
    Less: debt issuance costs, net(2,941)(3,119)
    LONG-TERM DEBT LESS CURRENT MATURITIES$145,497 $149,269 
    Schedule of Maturities of Long-term Debt
    Future principal payments due under the long-term debt arrangements discussed above are as follows:

    Years Ending December 31,Amount
    2024$3,950 
    20254,086 
    20264,227 
    20273,897 
    20283,779 
    Thereafter132,449 
     $152,388 
    XML 63 R44.htm IDEA: XBRL DOCUMENT v3.24.0.1
    OPTIONS AND AWARDS (Tables)
    12 Months Ended
    Dec. 31, 2023
    Share-Based Payment Arrangement [Abstract]  
    Schedule of Assumptions for Stock Options Granted The Company used the following assumptions for stock options granted during the years ended December 31, 2023, 2022 and 2021:
    Grant YearOptions GrantedWeighted Average Risk-Free RateExpected LifeWeighted Average VolatilityWeighted Average Dividend Yield
    20231,0084.3%6.2 years41.3%0.2%
    20225812.8%6.2 years42.1%0.3%
    20216211.0%6.2 years42.4%0.3%
    Schedule of Exercise Price and Fair Value Displayed at Grant Date for Stock Option Grants
    For the years ended December 31, 2023, 2022 and 2021, the following represents the exercise price and fair value displayed at grant date for stock option grants:
    Grant YearGrantedWeighted Average Exercise PriceWeighted Average Fair Value of Options
    20231,008$95.05 $43.85 
    2022581$85.74 $37.83 
    2021621$80.19 $32.82 
    Schedule of Employee Stock Option Roll Forward
    The following table represents the employee stock option activity during the year ended December 31, 2023:
    Number of Options OutstandingWeighted Average
    Exercise Price
    Number of
    Options Vested
    Weighted Average Exercise Price of Options Vested
    January 1, 20214,038 $27.71 2,148 $16.66 
    Granted621 80.19 
    Forfeited(105)44.76 
    Exercised(516)17.80 
    December 31, 20214,038 $36.60 2,183 $21.02 
    Granted581 85.74 
    Forfeited(98)59.52 
    Exercised(688)18.43 
    December 31, 20223,833 $46.72 2,069 $28.87 
    Granted1,008 95.05 
    Forfeited(91)71.44 
    Exercised(759)24.21 
    December 31, 20233,991 $62.65 1,887 $39.58 
    Stock Options Outstanding, Vested and Related Details
    The following summary information reflects stock options outstanding, vested and related details as of December 31, 2023:
     Stock Options OutstandingStock Options Vested
    Number OutstandingBlack-Scholes Fair ValueRemaining Contractual Life (Years)Vested and Exercisable
    Year of GrantExercise Price
    20148.94-16.0599 $484 199 
    201518.20-21.39175 1,369 2175 
    201615.93-16.86155 916 3155 
    201715.80-19.41194 1,138 4194 
    201822.49-32.71336 3,523 5336 
    201941.07-45.76510 8,014 6383 
    202044.84-59.49476 9,383 7257 
    202173.47-83.64513 16,844 8189 
    202279.79-94.88540 20,466 999 
    2023$89.83-$98.83993 43,566 10— 
    TOTAL 3,991 $105,703  1,887 
    Schedule of Aggregate Intrinsic Value of Options
    The aggregate intrinsic value of options outstanding, vested and expected to vest as of December 31, 2023, 2022 and 2021 is as follows:
    December 31,
    Options202320222021
    Outstanding$197,819 $183,593 $191,242 
    Vested137,048 136,000 137,382 
    Expected to vest56,759 43,232 48,548 
    Schedule of Nonvested Restricted Stock Awards
    Non-Vested Restricted AwardsWeighted Average Grant Date Fair Value
    Nonvested at January 1, 2021591 $38.90 
    Granted222 81.65 
    Vested(244)47.45 
    Forfeited(20)45.64 
    Nonvested at December 31, 2021549 $52.16 
    Granted233 81.57 
    Vested(269)54.06 
    Forfeited(26)57.29 
    Nonvested at December 31, 2022487 $64.92 
    Granted219 92.04 
    Vested(255)64.21 
    Forfeited(20)71.53 
    Nonvested at December 31, 2023431 $78.91 
    Schedule of Stock-Based Compensation Expense
    Stock-based compensation expense recognized for the Company's equity incentive plans and long-term incentive plan for the years ended December 31, 2023, 2022 and 2021 was as follows:

    Year Ended December 31,
     202320222021
    Stock-based compensation expense related to stock options$17,221 $11,361 $8,459 
    Stock-based compensation expense related to restricted stock awards11,845 9,920 8,385 
    Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors1,688 1,439 1,834 
    TOTAL$30,754 $22,720 $18,678 
    XML 64 R45.htm IDEA: XBRL DOCUMENT v3.24.0.1
    LEASES (Tables)
    12 Months Ended
    Dec. 31, 2023
    Leases [Abstract]  
    Schedule of Operating Lease Expenses
    The components of operating lease expense are as follows:
    Year Ended December 31,
    202320222021
    Rent - cost of services(1)
    $197,358 $153,049 $139,371 
    General and administrative expense498 125 87 
    Depreciation and amortization(2)
    1,202 1,160 1,158 
    Variable lease costs(3)
    20,454 16,938 14,077 
    $219,512 $171,272 $154,693 
    (1)Rent- cost of services includes deferred rent expense adjustments of $870, $493 and $485 for the years ended December 31, 2023, 2022 and 2021, respectively. Additionally, rent- cost of services includes other variable lease costs such as consumer price index increases and short-term leases of $10,259, $5,878, $3,702 for the years ended December 31, 2023, 2022, and 2021 respectively.
    (2) Depreciation and amortization is related to the amortization of favorable and direct lease costs.
    (3) Variable lease costs, including property taxes and insurance, are classified in cost of services in the Company's consolidated statements of income.
    Schedule of Future Minimum Lease Payments
    Future minimum lease payments for all third-party leases as of December 31, 2023 are as follows:
    YearAmount
    2024$191,352 
    2025191,269 
    2026191,058 
    2027190,481 
    2028189,224 
    Thereafter1,722,259 
    TOTAL LEASE PAYMENTS2,675,643 
    Less: present value adjustment (953,791)
    PRESENT VALUE OF TOTAL LEASE LIABILITIES1,721,852 
    Less: current lease liabilities(82,526)
    LONG-TERM OPERATING LEASE LIABILITIES$1,639,326 
    Schedule of Rental Income from Third-Party Sources
    Total rental income from all third-party sources for the years ended December 31, 2023, 2022 and 2021 is as follows:

    Year Ended December 31,
    202320222021
    Pennant(1)
    $15,048 $14,915 $14,073 
    Other third-party(2)
    6,236 1,842 1,912 
    TOTAL$21,284 $16,757 $15,985 
    (1) Pennant rental income includes variable rent such as property taxes of $1,296, $1,318, and $1,199 during the year ended December 31, 2023, 2022, and 2021. In addition, the number of senior living operations leased to and operated by Pennant was 29 during the year ended December 31, 2023 and decreased from 32 to 29 during the year ended December 31, 2022.
    (2) Other third-party includes rental revenue associated with the Company's subleases to third parties of $3,897 for the year ended December 31, 2023. There was no sublease rental revenue for the years ended December 31, 2022 and 2021.
    Schedule of Annual Rental Income
    Future annual rental income for all third-party leases as of December 31, 2023 were as follows:
    Year
    Amount(1)
    2024$22,191 
    202521,565 
    202621,269 
    202721,176 
    202821,151 
    Thereafter129,586 
    TOTAL$236,938 
    (1) Annual rental income includes base rents and variable rental income pursuant to existing leases as of December 31, 2023.
    XML 65 R46.htm IDEA: XBRL DOCUMENT v3.24.0.1
    SELF INSURANCE LIABILITIES (Tables)
    12 Months Ended
    Dec. 31, 2023
    Insurance [Abstract]  
    Schedule of Liability for Future Policy Benefits, by Product Segment
    The following table represents activity in our insurance liabilities as of and for the years ended December 31, 2023 and 2022:
     
    Amount
    Balance January 1, 2022
    $110,139 
    Current year provisions115,793 
    Claims paid and direct expenses(98,007)
    Change in long-term insurance losses recoverable3,757 
    Balance December 31, 2022
    $131,682 
    Current year provisions164,627 
    Claims paid and direct expenses(135,799)
    Change in long-term insurance losses recoverable5,400 
    Balance December 31, 2023
    $165,910 
    XML 66 R47.htm IDEA: XBRL DOCUMENT v3.24.0.1
    DESCRIPTION OF BUSINESS (Details)
    Dec. 31, 2023
    facility
    senior_living_unit
    operation
    bed
    property
    Real Estate Properties [Line Items]  
    Health care facilities 297
    Operational skilled nursing beds | bed 30,600
    Operational senior living units | senior_living_unit 3,100
    Number of real estate properties leased 214
    Number of real estate properties leased with an option to purchase 11
    Number of real estate properties | property 113
    Third Party Operators  
    Real Estate Properties [Line Items]  
    Number of operations lease and operated by third parties | operation 30
    Number of senior living operations sharing property with skilled nursing facilities 1
    Owned Properties  
    Real Estate Properties [Line Items]  
    Number of facilities 83
    XML 67 R48.htm IDEA: XBRL DOCUMENT v3.24.0.1
    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)
    Dec. 31, 2023
    Minimum  
    Property, Plant and Equipment [Line Items]  
    Property, plant and equipment, useful life 3 years
    Maximum  
    Property, Plant and Equipment [Line Items]  
    Property, plant and equipment, useful life 59 years
    XML 68 R49.htm IDEA: XBRL DOCUMENT v3.24.0.1
    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Leases and Leasehold Improvements (Details)
    12 Months Ended
    Dec. 31, 2023
    option
    lease
    Real Estate Properties [Line Items]  
    Number of financing lease | lease 1
    Lessee, operating lease, term of contract 10 years
    Lessee, operating lease, number of renewal options | option 1
    Minimum  
    Real Estate Properties [Line Items]  
    Lessee, operating lease, renewal term 10 years
    Maximum  
    Real Estate Properties [Line Items]  
    Lessee, operating lease, renewal term 15 years
    XML 69 R50.htm IDEA: XBRL DOCUMENT v3.24.0.1
    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets and Goodwill (Details)
    $ in Thousands
    Dec. 31, 2023
    USD ($)
    Finite-Lived Intangible Assets [Line Items]  
    Goodwill, accumulated impairment loss $ 7,410
    Trade name  
    Finite-Lived Intangible Assets [Line Items]  
    Finite-lived intangible asset, useful life 30 years
    Customer relationships  
    Finite-Lived Intangible Assets [Line Items]  
    Finite-lived intangible asset, useful life 20 years
    Minimum | Assembled occupancy  
    Finite-Lived Intangible Assets [Line Items]  
    Finite-lived intangible asset, useful life 4 months
    Maximum | Assembled occupancy  
    Finite-Lived Intangible Assets [Line Items]  
    Finite-lived intangible asset, useful life 8 months
    XML 70 R51.htm IDEA: XBRL DOCUMENT v3.24.0.1
    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Self-Insurance (Details) - USD ($)
    $ in Thousands
    Feb. 01, 2024
    Dec. 31, 2023
    Dec. 31, 2021
    Workers' Compensation      
    Liability for Claims and Claims Adjustment Expense [Line Items]      
    Self insurance reserve   $ 625  
    Workers' Compensation | Texas      
    Liability for Claims and Claims Adjustment Expense [Line Items]      
    Self insurance reserve   750  
    Self-Insurance Retention Per Claim | General Liability      
    Liability for Claims and Claims Adjustment Expense [Line Items]      
    Self insurance reserve   500  
    Self-Insurance Retention Per Claim | Parent Company | General Liability      
    Liability for Claims and Claims Adjustment Expense [Line Items]      
    Self insurance reserve   500  
    Self-Insurance Retention Per Claim | Parent Company | General Liability | California | Subsequent Event      
    Liability for Claims and Claims Adjustment Expense [Line Items]      
    Self insurance reserve $ 750    
    Self-Insurance Retention Per Claim | Parent Company | General Liability | Non-california | Subsequent Event      
    Liability for Claims and Claims Adjustment Expense [Line Items]      
    Self insurance reserve 650    
    Aggregate Deductible | Parent Company | General Liability | California      
    Liability for Claims and Claims Adjustment Expense [Line Items]      
    Self insurance reserve   1,250  
    Aggregate Deductible | Parent Company | General Liability | California | Subsequent Event      
    Liability for Claims and Claims Adjustment Expense [Line Items]      
    Self insurance reserve 1,500    
    Aggregate Deductible | Parent Company | General Liability | Non-california      
    Liability for Claims and Claims Adjustment Expense [Line Items]      
    Self insurance reserve   1,250  
    Aggregate Deductible | Parent Company | General Liability | Non-california | Subsequent Event      
    Liability for Claims and Claims Adjustment Expense [Line Items]      
    Self insurance reserve 1,350    
    Per Occurence | Third-Party Payor | General Liability | All States Except Colorado      
    Liability for Claims and Claims Adjustment Expense [Line Items]      
    Self insurance reserve   1,000  
    Per Occurence | Third-Party Payor | General Liability | All States Except Colorado | Subsequent Event      
    Liability for Claims and Claims Adjustment Expense [Line Items]      
    Self insurance reserve 1,000    
    Per Occurence | Third-Party Payor | General Liability | Colorado      
    Liability for Claims and Claims Adjustment Expense [Line Items]      
    Self insurance reserve   1,000  
    Per Facility | Third-Party Payor | General Liability | All States Except Colorado      
    Liability for Claims and Claims Adjustment Expense [Line Items]      
    Self insurance reserve   3,000  
    Per Facility | Third-Party Payor | General Liability | All States Except Colorado | Subsequent Event      
    Liability for Claims and Claims Adjustment Expense [Line Items]      
    Self insurance reserve 3,000    
    Per Facility | Third-Party Payor | General Liability | Colorado      
    Liability for Claims and Claims Adjustment Expense [Line Items]      
    Self insurance reserve   3,000  
    Blanket Aggregate | Third-Party Payor | General Liability | All States Except Colorado      
    Liability for Claims and Claims Adjustment Expense [Line Items]      
    Self insurance reserve   5,000  
    Blanket Aggregate | Third-Party Payor | General Liability | All States Except Colorado | Subsequent Event      
    Liability for Claims and Claims Adjustment Expense [Line Items]      
    Self insurance reserve $ 10,000    
    Loss-Sensitive Limit Per Claim | Workers' Compensation | Other States, Except California, Texas and Washington      
    Liability for Claims and Claims Adjustment Expense [Line Items]      
    Self insurance reserve   350  
    Stop-Loss Insurance Limit Per Claim | Health Liability Insurance      
    Liability for Claims and Claims Adjustment Expense [Line Items]      
    Self insurance reserve   $ 525 $ 500
    XML 71 R52.htm IDEA: XBRL DOCUMENT v3.24.0.1
    REVENUE AND ACCOUNTS RECEIVABLE -Narrative (Details) - USD ($)
    $ in Thousands
    1 Months Ended 12 Months Ended
    Mar. 31, 2021
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Dec. 31, 2020
    Disaggregation of Revenue [Line Items]          
    Revenue   $ 3,729,355 $ 3,025,468 $ 2,627,461  
    Unapplied state relief funds   486 1,001    
    FMAP payments received   64,238 81,057 70,484  
    Revenue, FMAP payments received   64,753 81,837 75,231  
    Coronavirus Aid, Relief, and Economic Security (“CARES”) funds received and returned       11,637  
    Medicare accelerated and advance payment         $ 105,255
    Repayment of medicare accelerated and advance payment program $ 102,023       3,232
    Total deferred payment of social security taxes         $ 48,309
    Rental revenue          
    Disaggregation of Revenue [Line Items]          
    Revenue   $ 21,284 $ 16,757 $ 15,985  
    Customer Concentration Risk | Revenue | Total Medicare and Medicaid          
    Disaggregation of Revenue [Line Items]          
    % of Revenue   72.60% 73.70% 73.60%  
    XML 72 R53.htm IDEA: XBRL DOCUMENT v3.24.0.1
    REVENUE AND ACCOUNTS RECEIVABLE - Disaggregation of Revenue (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Disaggregation of Revenue [Line Items]      
    Revenue $ 3,729,355 $ 3,025,468 $ 2,627,461
    Total Medicaid and Medicare | Customer Concentration Risk | Revenue      
    Disaggregation of Revenue [Line Items]      
    % of Revenue 72.60% 73.70% 73.60%
    Service revenue      
    Disaggregation of Revenue [Line Items]      
    Revenue $ 3,708,071 $ 3,008,711 $ 2,611,476
    Service revenue | Customer Concentration Risk | Revenue      
    Disaggregation of Revenue [Line Items]      
    % of Revenue 100.00% 100.00% 100.00%
    Service revenue | Total Medicaid and Medicare      
    Disaggregation of Revenue [Line Items]      
    Revenue $ 2,690,861 $ 2,216,194 $ 1,922,333
    Service revenue | Total Medicaid and Medicare | Customer Concentration Risk | Revenue      
    Disaggregation of Revenue [Line Items]      
    % of Revenue 72.60% 73.70% 73.60%
    Service revenue | Medicaid      
    Disaggregation of Revenue [Line Items]      
    Revenue $ 1,459,449 $ 1,183,156 $ 1,022,460
    Service revenue | Medicaid | Customer Concentration Risk | Revenue      
    Disaggregation of Revenue [Line Items]      
    % of Revenue 39.40% 39.30% 39.20%
    Service revenue | Medicare      
    Disaggregation of Revenue [Line Items]      
    Revenue $ 985,749 $ 832,160 $ 727,103
    Service revenue | Medicare | Customer Concentration Risk | Revenue      
    Disaggregation of Revenue [Line Items]      
    % of Revenue 26.60% 27.70% 27.80%
    Service revenue | Medicaid — skilled      
    Disaggregation of Revenue [Line Items]      
    Revenue $ 245,663 $ 200,878 $ 172,770
    Service revenue | Medicaid — skilled | Customer Concentration Risk | Revenue      
    Disaggregation of Revenue [Line Items]      
    % of Revenue 6.60% 6.70% 6.60%
    Service revenue | Managed care      
    Disaggregation of Revenue [Line Items]      
    Revenue $ 666,129 $ 525,710 $ 456,728
    Service revenue | Managed care | Customer Concentration Risk | Revenue      
    Disaggregation of Revenue [Line Items]      
    % of Revenue 18.00% 17.50% 17.50%
    Service revenue | Private and other      
    Disaggregation of Revenue [Line Items]      
    Revenue $ 351,081 $ 266,807 $ 232,415
    Service revenue | Private and other | Customer Concentration Risk | Revenue      
    Disaggregation of Revenue [Line Items]      
    % of Revenue 9.40% 8.80% 8.90%
    XML 73 R54.htm IDEA: XBRL DOCUMENT v3.24.0.1
    REVENUE AND ACCOUNTS RECEIVABLE - Accounts Receivable (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2023
    Dec. 31, 2022
    Accounts, Notes, Loans and Financing Receivable [Line Items]    
    Accounts receivable, gross $ 494,387 $ 416,234
    Less: allowance for doubtful accounts (9,348) (7,802)
    ACCOUNTS RECEIVABLE, NET 485,039 408,432
    Medicaid    
    Accounts, Notes, Loans and Financing Receivable [Line Items]    
    Accounts receivable, gross 178,285 157,878
    Managed care    
    Accounts, Notes, Loans and Financing Receivable [Line Items]    
    Accounts receivable, gross 125,907 95,940
    Medicare    
    Accounts, Notes, Loans and Financing Receivable [Line Items]    
    Accounts receivable, gross 85,512 76,526
    Private and other payors    
    Accounts, Notes, Loans and Financing Receivable [Line Items]    
    Accounts receivable, gross $ 104,683 $ 85,890
    XML 74 R55.htm IDEA: XBRL DOCUMENT v3.24.0.1
    COMPUTATION OF NET INCOME PER COMMON SHARE (Details) - USD ($)
    $ / shares in Units, shares in Thousands, $ in Thousands
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    NUMERATOR:      
    Net income $ 209,850 $ 224,652 $ 197,725
    Less: net income (loss) attributable to noncontrolling interests 451 (29) 3,073
    Net income attributable to The Ensign Group, Inc. $ 209,399 $ 224,681 $ 194,652
    DENOMINATOR:      
    Weighted average shares outstanding for basic net income per share (in shares) 55,708 54,887 54,486
    Plus: incremental shares from assumed conversion (in shares) 1,615 1,984 2,439
    Adjusted weighted average common shares outstanding (in shares) 57,323 56,871 56,925
    Basic net income per common share (in dollars per share) $ 3.76 $ 4.09 $ 3.57
    Diluted net income per common share (in dollars per share) $ 3.65 $ 3.95 $ 3.42
    Antidilutive securities excluded from computation of earnings per share, amount (in shares) 1,429 780 198
    XML 75 R56.htm IDEA: XBRL DOCUMENT v3.24.0.1
    FAIR VALUE MEASUREMENTS (Details) - Fair Value, Inputs, Level 2 - USD ($)
    $ in Thousands
    Dec. 31, 2023
    Dec. 31, 2022
    Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
    Deferred rent receivable $ 41,216 $ 25,144
    Captive Insurance Subsidiary    
    Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
    Insurance subsidiary's deposits and investments $ 59,530 $ 53,924
    XML 76 R57.htm IDEA: XBRL DOCUMENT v3.24.0.1
    STANDARD BEARER (Details)
    1 Months Ended 12 Months Ended
    Apr. 08, 2022
    Jan. 31, 2022
    renewal
    lease
    Dec. 31, 2023
    operation
    property
    facility
    Dec. 31, 2023
    operation
    property
    facility
    Dec. 31, 2023
    operation
    property
    facility
    Dec. 31, 2023
    USD ($)
    operation
    property
    facility
    Dec. 31, 2023
    operation
    property
    facility
    Dec. 31, 2023
    operation
    property
    facility
    shares
    Dec. 31, 2022
    USD ($)
    property
    skilled_nursing_property
    shares
    Dec. 31, 2021
    USD ($)
    shares
    Segment Reporting Information [Line Items]                    
    Number of real estate properties | property     113 113 113 113 113 113    
    Number of master lease arrangements | lease   5                
    Lessee, operating lease, term of contract     10 years 10 years 10 years 10 years 10 years 10 years    
    Granted (in shares) | shares               1,008,000 581,000 621,000
    Restricted Stock Awards                    
    Segment Reporting Information [Line Items]                    
    Award vesting period     5 years              
    Granted restricted shares (in shares) | shares               219,000 233,000 222,000
    Standard Bearer Equity Plan                    
    Segment Reporting Information [Line Items]                    
    Award vesting period   5 years                
    Threshold event period after vesting of restricted awards or exercise of stock options   6 months                
    Proceeds from issuance of common stock                 $ 6,544,000  
    Granted (in shares) | shares               0 0  
    Proceeds from issuance of preferred shares                 $ 149,000  
    Standard Bearer Equity Plan | Restricted Stock Awards                    
    Segment Reporting Information [Line Items]                    
    Granted restricted shares (in shares) | shares               0 0  
    Minimum                    
    Segment Reporting Information [Line Items]                    
    Lessee, operating lease, renewal term     10 years 10 years 10 years 10 years 10 years 10 years    
    Minimum | Revolving credit facility with Truist | Truist | Base Rate                    
    Segment Reporting Information [Line Items]                    
    Interest rate margin 0.25%                  
    Minimum | Revolving credit facility with Truist | Truist | Secured Overnight Financing Rate (SOFR)                    
    Segment Reporting Information [Line Items]                    
    Interest rate margin 1.25%                  
    Maximum                    
    Segment Reporting Information [Line Items]                    
    Lessee, operating lease, renewal term     15 years 15 years 15 years 15 years 15 years 15 years    
    Maximum | Revolving credit facility with Truist | Truist | Base Rate                    
    Segment Reporting Information [Line Items]                    
    Interest rate margin 1.25%                  
    Maximum | Revolving credit facility with Truist | Truist | Secured Overnight Financing Rate (SOFR)                    
    Segment Reporting Information [Line Items]                    
    Interest rate margin 2.25%                  
    Standard Bearer Master Leases                    
    Segment Reporting Information [Line Items]                    
    Lessee leasing arrangements, operating leases, number of renewal terms | renewal   3                
    Lessee, operating lease, renewal term   5 years                
    Operating leases of lessee, contingent rentals, basis spread on variable rate   2.50%                
    Rental revenue           $ 66,712,000     $ 57,967,000 $ 44,165,000
    Standard Bearer Master Leases | Total Management Fee                    
    Segment Reporting Information [Line Items]                    
    Management fees, as a percentage of total revenues             6.00%      
    Standard Bearer Master Leases | Base Management Fee                    
    Segment Reporting Information [Line Items]                    
    Management fees, as a percentage of total revenues             5.00%      
    Management fees           $ 4,948,000     4,367,000 $ 0
    Standard Bearer Master Leases | Incentive Management Fee                    
    Segment Reporting Information [Line Items]                    
    Management fees, as a percentage of total revenues             1.00%      
    Management fees, as a percentage of funds from operations             5.00%      
    Standard Bearer Master Leases | Minimum                    
    Segment Reporting Information [Line Items]                    
    Lessee, operating lease, term of contract   15 years                
    Operating leases of lessee, contingent rentals, basis spread on variable rate   0.00%                
    Standard Bearer Master Leases | Maximum                    
    Segment Reporting Information [Line Items]                    
    Lessee, operating lease, term of contract   19 years                
    Third Party Operators                    
    Segment Reporting Information [Line Items]                    
    Number of operations lease and operated by third parties | operation     30 30 30 30 30 30    
    Number of senior living operations sharing property with skilled nursing facilities | facility     1 1 1 1 1 1    
    Standard Bearer Healthcare REIT, Inc.                    
    Segment Reporting Information [Line Items]                    
    Number of real estate properties | property     108 108 108 108 108 108    
    Standard Bearer Healthcare REIT, Inc. | Series of Individually Immaterial Asset Acquisitions                    
    Segment Reporting Information [Line Items]                    
    Asset acquisition, purchase price           $ 65,899,000     $ 84,656,000  
    Standard Bearer Healthcare REIT, Inc. | Skilled Nursing Operations                    
    Segment Reporting Information [Line Items]                    
    Number of real estate skilled nursing properties acquired | skilled_nursing_property                 3  
    Standard Bearer Healthcare REIT, Inc. | Owned Properties                    
    Segment Reporting Information [Line Items]                    
    Number of real estate skilled nursing properties acquired       1 3       10  
    Standard Bearer Healthcare REIT, Inc. | Third Parties                    
    Segment Reporting Information [Line Items]                    
    Number of real estate properties | operation     30 30 30 30 30 30    
    Standard Bearer Healthcare REIT, Inc. | Owned Properties                    
    Segment Reporting Information [Line Items]                    
    Number of real estate properties | operation     79 79 79 79 79 79    
    XML 77 R58.htm IDEA: XBRL DOCUMENT v3.24.0.1
    OPERATION EXPANSIONS- Narrative (Details)
    $ in Thousands
    1 Months Ended 12 Months Ended
    Feb. 01, 2024
    operation
    bed
    Jan. 31, 2022
    lease
    Dec. 31, 2023
    bed
    senior_living_unit
    property
    Dec. 31, 2023
    operation
    senior_living_unit
    bed
    Dec. 31, 2022
    USD ($)
    senior_living_unit
    property
    operation
    skilled_nursing_property
    bed
    Dec. 31, 2021
    USD ($)
    business
    bed
    operation
    Business Acquisition [Line Items]            
    Operational senior living units | senior_living_unit     3,100 3,100    
    Operational skilled nursing beds | bed     30,600 30,600    
    Number of master lease arrangements | lease   5        
    Goodwill | $         $ 16,400 $ 6,000
    Real Estate Purchases            
    Business Acquisition [Line Items]            
    Number of asset acquisitions | business           5
    Real Estate Purchases Of Previous Operations            
    Business Acquisition [Line Items]            
    Number of asset acquisitions | business           4
    Subsequent Event | Skilled Nursing Operations            
    Business Acquisition [Line Items]            
    Operational skilled nursing beds | bed 241          
    Standard Bearer Healthcare REIT, Inc. | Skilled Nursing Operations            
    Business Acquisition [Line Items]            
    Number of real estate skilled nursing properties acquired | skilled_nursing_property         3  
    Skilled Nursing Operations            
    Business Acquisition [Line Items]            
    Number of businesses acquired       25 23 17
    Operational skilled nursing beds | bed     2,483 2,483 3,058 1,832
    Number of master lease arrangements         7  
    Skilled Nursing Operations | Subsequent Event            
    Business Acquisition [Line Items]            
    Number of businesses acquired 2          
    Campus Operation            
    Business Acquisition [Line Items]            
    Number of businesses acquired       1 1  
    Campus Operation | Standard Bearer Healthcare REIT, Inc.            
    Business Acquisition [Line Items]            
    Number of real estate skilled nursing properties acquired       2    
    Owned Properties | Standard Bearer Healthcare REIT, Inc.            
    Business Acquisition [Line Items]            
    Number of real estate skilled nursing properties acquired     3 1 10  
    Senior Living Facilities            
    Business Acquisition [Line Items]            
    Number of businesses acquired         5  
    Operational senior living units | senior_living_unit     94 94 674  
    Number of operations transferred from third parties         3  
    Series of Individually Immaterial Business Acquisitions            
    Business Acquisition [Line Items]            
    Goodwill | $         $ 16,400  
    Payments to acquire businesses, gross | $           $ 6,000
    XML 78 R59.htm IDEA: XBRL DOCUMENT v3.24.0.1
    OPERATION EXPANSIONS - Purchase Price Allocation (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Business Acquisition [Line Items]      
    Goodwill   $ 16,400 $ 6,000
    Acquired Operations      
    Business Acquisition [Line Items]      
    Goodwill $ 0 16,400 6,000
    Leased asset 0 1,909 0
    Other indefinite-lived intangible assets 330 245 75
    TOTAL ACQUISITIONS 67,798 101,136 104,224
    Land | Acquired Operations      
    Business Acquisition [Line Items]      
    Property, plant and equipment 7,794 15,527 19,928
    Building and improvements | Acquired Operations      
    Business Acquisition [Line Items]      
    Property, plant and equipment 57,488 65,070 77,975
    Equipment, furniture, and fixtures | Acquired Operations      
    Business Acquisition [Line Items]      
    Property, plant and equipment 1,840 1,618 217
    Assembled occupancy | Acquired Operations      
    Business Acquisition [Line Items]      
    Property, plant and equipment $ 346 $ 367 $ 29
    XML 79 R60.htm IDEA: XBRL DOCUMENT v3.24.0.1
    BUSINESS SEGMENTS - Narrative (Details)
    12 Months Ended
    Dec. 31, 2023
    property
    segment
    operation
    facility
    Segment Reporting Information [Line Items]  
    Number of reportable segments | segment 2
    Transitional and skilled service facilities | operation 259
    Transitional and skilled services and senior living campuses | operation 27
    Number of real estate properties | property 113
    Senior living facilities | facility 11
    Standard Bearer Healthcare REIT, Inc.  
    Segment Reporting Information [Line Items]  
    Number of real estate properties | property 108
    XML 80 R61.htm IDEA: XBRL DOCUMENT v3.24.0.1
    BUSINESS SEGMENTS - Schedule of Segment Financial Information (Details) - USD ($)
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Segment Reporting Information [Line Items]      
    TOTAL REVENUE $ 3,729,355,000 $ 3,025,468,000 $ 2,627,461,000
    Segment income (loss) 272,739,000 285,822,000 257,564,000
    Gain on sale of assets and insurance recoveries from real estate, net 23,000 3,267,000 440,000
    Income before provision for income taxes 272,762,000 289,089,000 258,004,000
    Depreciation and amortization 72,387,000 62,355,000 55,985,000
    Interest expense 8,087,000 8,931,000 6,849,000
    Service revenue      
    Segment Reporting Information [Line Items]      
    TOTAL REVENUE 3,708,071,000 3,008,711,000 2,611,476,000
    Rental revenue      
    Segment Reporting Information [Line Items]      
    TOTAL REVENUE 21,284,000 16,757,000 15,985,000
    Operating Segments | Skilled Services      
    Segment Reporting Information [Line Items]      
    TOTAL REVENUE 3,578,855,000 2,906,215,000 2,523,234,000
    Segment income (loss) 464,925,000 408,732,000 373,603,000
    Depreciation and amortization 38,766,000 33,224,000 30,681,000
    Interest expense 0 0 0
    Operating Segments | Skilled Services | Service revenue      
    Segment Reporting Information [Line Items]      
    TOTAL REVENUE 3,578,855,000 2,906,215,000 2,523,234,000
    Operating Segments | Skilled Services | Rental revenue      
    Segment Reporting Information [Line Items]      
    TOTAL REVENUE 0 0 0
    Operating Segments | Standard Bearer      
    Segment Reporting Information [Line Items]      
    TOTAL REVENUE 82,486,000 72,937,000 58,127,000
    Segment income (loss) 29,065,000 27,871,000 31,876,000
    Depreciation and amortization 25,205,000 21,613,000 17,558,000
    Interest expense 19,761,000 15,707,000 6,842,000
    Operating Segments | Standard Bearer | Service revenue      
    Segment Reporting Information [Line Items]      
    TOTAL REVENUE 0 0 0
    Operating Segments | Standard Bearer | Rental revenue      
    Segment Reporting Information [Line Items]      
    TOTAL REVENUE 82,486,000 72,937,000 58,127,000
    Operating Segments | All Other      
    Segment Reporting Information [Line Items]      
    TOTAL REVENUE 155,804,000 122,610,000 102,685,000
    Segment income (loss) (221,251,000) (150,781,000) (147,915,000)
    Depreciation and amortization 8,416,000 7,518,000 7,746,000
    Interest expense 1,228,000 1,870,000 7,000
    Operating Segments | All Other | Service revenue      
    Segment Reporting Information [Line Items]      
    TOTAL REVENUE 144,667,000 115,214,000 95,276,000
    Operating Segments | All Other | Rental revenue      
    Segment Reporting Information [Line Items]      
    TOTAL REVENUE 11,137,000 7,396,000 7,409,000
    Sublease income 3,897,000 0 0
    Intercompany Elimination      
    Segment Reporting Information [Line Items]      
    TOTAL REVENUE (87,790,000) (76,294,000) (56,585,000)
    Segment income (loss) 0 0 0
    Depreciation and amortization 0 0 0
    Interest expense (12,902,000) (8,646,000) 0
    Intercompany Elimination | Service revenue      
    Segment Reporting Information [Line Items]      
    TOTAL REVENUE (15,451,000) (12,718,000) (7,034,000)
    Intercompany Elimination | Rental revenue      
    Segment Reporting Information [Line Items]      
    TOTAL REVENUE $ (72,339,000) $ (63,576,000) $ (49,551,000)
    XML 81 R62.htm IDEA: XBRL DOCUMENT v3.24.0.1
    BUSINESS SEGMENTS - Schedule of Service Revenue by Major Payor Source (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Total Service Revenue $ 3,729,355 $ 3,025,468 $ 2,627,461
    Operating Segments | Skilled Services      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Total Service Revenue $ 3,578,855 $ 2,906,215 $ 2,523,234
    Total Medicaid and Medicare | Revenue | Customer Concentration Risk      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Revenue % 72.60% 73.70% 73.60%
    Service revenue      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Total Service Revenue $ 3,708,071 $ 3,008,711 $ 2,611,476
    Service revenue | Revenue | Customer Concentration Risk      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Revenue % 100.00% 100.00% 100.00%
    Service revenue | Operating Segments | Skilled Services      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Total Service Revenue $ 3,578,855 $ 2,906,215 $ 2,523,234
    Service revenue | All Other      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Total Service Revenue 129,216 102,496 88,242
    Service revenue | Total Medicaid and Medicare      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Total Service Revenue $ 2,690,861 $ 2,216,194 $ 1,922,333
    Service revenue | Total Medicaid and Medicare | Revenue | Customer Concentration Risk      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Revenue % 72.60% 73.70% 73.60%
    Service revenue | Total Medicaid and Medicare | Operating Segments | Skilled Services      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Total Service Revenue $ 2,660,885 $ 2,191,347 $ 1,906,934
    Service revenue | Total Medicaid and Medicare | All Other      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Total Service Revenue 29,976 24,847 15,399
    Service revenue | Medicaid      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Total Service Revenue $ 1,459,449 $ 1,183,156 $ 1,022,460
    Service revenue | Medicaid | Revenue | Customer Concentration Risk      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Revenue % 39.40% 39.30% 39.20%
    Service revenue | Medicaid | Operating Segments | Skilled Services      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Total Service Revenue $ 1,429,473 $ 1,158,309 $ 1,007,061
    Service revenue | Medicaid | All Other      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Total Service Revenue 29,976 24,847 15,399
    Service revenue | Medicare      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Total Service Revenue $ 985,749 $ 832,160 $ 727,103
    Service revenue | Medicare | Revenue | Customer Concentration Risk      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Revenue % 26.60% 27.70% 27.80%
    Service revenue | Medicare | Operating Segments | Skilled Services      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Total Service Revenue $ 985,749 $ 832,160 $ 727,103
    Service revenue | Medicare | All Other      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Total Service Revenue 0 0 0
    Service revenue | Medicaid-skilled      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Total Service Revenue $ 245,663 $ 200,878 $ 172,770
    Service revenue | Medicaid-skilled | Revenue | Customer Concentration Risk      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Revenue % 6.60% 6.70% 6.60%
    Service revenue | Medicaid-skilled | Operating Segments | Skilled Services      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Total Service Revenue $ 245,663 $ 200,878 $ 172,770
    Service revenue | Medicaid-skilled | All Other      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Total Service Revenue 0 0 0
    Service revenue | Managed care      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Total Service Revenue $ 666,129 $ 525,710 $ 456,728
    Service revenue | Managed care | Revenue | Customer Concentration Risk      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Revenue % 18.00% 17.50% 17.50%
    Service revenue | Managed care | Operating Segments | Skilled Services      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Total Service Revenue $ 666,129 $ 525,710 $ 456,728
    Service revenue | Managed care | All Other      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Total Service Revenue 0 0 0
    Service revenue | Private and other      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Total Service Revenue $ 351,081 $ 266,807 $ 232,415
    Service revenue | Private and other | Revenue | Customer Concentration Risk      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Revenue % 9.40% 8.80% 8.90%
    Service revenue | Private and other | Operating Segments | Skilled Services      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Total Service Revenue $ 251,841 $ 189,158 $ 159,572
    Service revenue | Private and other | All Other      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Total Service Revenue $ 99,240 $ 77,649 $ 72,843
    XML 82 R63.htm IDEA: XBRL DOCUMENT v3.24.0.1
    PROPERTY AND EQUIPMENT— NET - Schedule of Property and Equipment (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2023
    Dec. 31, 2022
    Property, Plant and Equipment [Line Items]    
    Property and equipment $ 1,487,013 $ 1,331,802
    Less: accumulated depreciation (396,242) (339,792)
    PROPERTY AND EQUIPMENT, NET 1,090,771 992,010
    Land    
    Property, Plant and Equipment [Line Items]    
    Property and equipment 142,656 134,864
    Buildings and improvements    
    Property, Plant and Equipment [Line Items]    
    Property and equipment 803,155 728,231
    Leasehold improvements    
    Property, Plant and Equipment [Line Items]    
    Property and equipment 172,064 150,903
    Equipment    
    Property, Plant and Equipment [Line Items]    
    Property and equipment 339,383 295,739
    Furniture and fixtures    
    Property, Plant and Equipment [Line Items]    
    Property and equipment 4,192 4,544
    Construction in progress    
    Property, Plant and Equipment [Line Items]    
    Property and equipment $ 25,563 $ 17,521
    XML 83 R64.htm IDEA: XBRL DOCUMENT v3.24.0.1
    PROPERTY AND EQUIPMENT— NET - Narrative (Details) - Senior Living Operations - Disposal Group, Disposed of by Sale, Not Discontinued Operations
    $ in Thousands
    12 Months Ended
    Dec. 31, 2022
    USD ($)
    Property, Plant and Equipment [Line Items]  
    Proceeds from sale of real estate $ 8,607
    Gain on sales property, plant and equipment $ 3,467
    XML 84 R65.htm IDEA: XBRL DOCUMENT v3.24.0.1
    INTANGIBLE ASSETS — NET - Schedule of Finite Lived Intangible Assets (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Finite-Lived Intangible Assets [Line Items]    
    Gross Carrying Amount $ 6,096 $ 5,750
    Accumulated Amortization (3,873) (3,285)
    Net $ 2,223 2,465
    Assembled occupancy    
    Finite-Lived Intangible Assets [Line Items]    
    Weighted Average Life (Years) 3 months 18 days  
    Gross Carrying Amount $ 781 435
    Accumulated Amortization (742) (388)
    Net $ 39 47
    Facility trade name    
    Finite-Lived Intangible Assets [Line Items]    
    Weighted Average Life (Years) 30 years  
    Gross Carrying Amount $ 733 733
    Accumulated Amortization (439) (415)
    Net $ 294 318
    Customer relationships    
    Finite-Lived Intangible Assets [Line Items]    
    Weighted Average Life (Years) 18 years 4 months 24 days  
    Gross Carrying Amount $ 4,582 4,582
    Accumulated Amortization (2,692) (2,482)
    Net $ 1,890 $ 2,100
    XML 85 R66.htm IDEA: XBRL DOCUMENT v3.24.0.1
    INTANGIBLE ASSETS — NET - Narrative (Details) - USD ($)
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Finite-Lived Intangible Assets [Line Items]      
    Amortization of intangible assets $ 1,790,000 $ 1,714,000 $ 1,435,000
    Impairment of intangible assets (excluding goodwill) 0 0 0
    Medicare and Medicaid licenses      
    Finite-Lived Intangible Assets [Line Items]      
    Indefinite-lived intangible assets 330,000 245,000 181,000
    Depreciation and Amortization      
    Finite-Lived Intangible Assets [Line Items]      
    Operating lease expense $ 1,202,000 $ 1,160,000 $ 1,158,000
    XML 86 R67.htm IDEA: XBRL DOCUMENT v3.24.0.1
    INTANGIBLE ASSETS — NET - Future Amortization (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2023
    Dec. 31, 2022
    Goodwill and Intangible Assets Disclosure [Abstract]    
    2024 $ 274  
    2025 234  
    2026 234  
    2027 234  
    2028 234  
    Thereafter 1,013  
    Net $ 2,223 $ 2,465
    XML 87 R68.htm IDEA: XBRL DOCUMENT v3.24.0.1
    INTANGIBLE ASSETS — NET - Schedule of Indefinite-lived Intangible Assets (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2023
    Dec. 31, 2022
    Indefinite-lived Intangible Assets [Line Items]    
    Other indefinite-lived intangibles $ 4,302 $ 3,972
    Trade name    
    Indefinite-lived Intangible Assets [Line Items]    
    Other indefinite-lived intangibles 889 889
    Medicare and Medicaid licenses    
    Indefinite-lived Intangible Assets [Line Items]    
    Other indefinite-lived intangibles $ 3,413 $ 3,083
    XML 88 R69.htm IDEA: XBRL DOCUMENT v3.24.0.1
    GOODWILL (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2022
    Dec. 31, 2021
    Dec. 31, 2023
    Dec. 31, 2020
    Goodwill [Line Items]        
    Goodwill $ 76,869 $ 60,469 $ 76,869 $ 54,469
    Additions 16,400 6,000    
    Operating Segments | Skilled Services        
    Goodwill [Line Items]        
    Goodwill 67,886 51,486 67,886 45,486
    Additions 16,400 6,000    
    All Other        
    Goodwill [Line Items]        
    Goodwill 8,983 8,983 $ 8,983 $ 8,983
    Additions $ 0 $ 0    
    XML 89 R70.htm IDEA: XBRL DOCUMENT v3.24.0.1
    RESTRICTED AND OTHER ASSETS (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2023
    Dec. 31, 2022
    Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
    Debt issuance costs, net $ 2,883 $ 3,753
    Long-term insurance losses recoverable asset 15,913 10,512
    Capital improvement reserves with landlords and lenders 4,870 6,446
    Deposits with landlords 2,661 2,527
    Escrow deposits 1,216 0
    Other 12,662 14,053
    RESTRICTED AND OTHER ASSETS $ 40,205 $ 37,291
    XML 90 R71.htm IDEA: XBRL DOCUMENT v3.24.0.1
    OTHER ACCRUED LIABILITIES (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Payables and Accruals [Abstract]      
    Quality assurance fee $ 14,035 $ 7,701  
    Refunds payable 51,248 40,783  
    Resident advances 10,834 9,698  
    Unapplied state relief funds 486 1,001  
    Cash held in trust for patients 6,215 6,400  
    Dividends payable 3,396 3,201 $ 3,035
    Property taxes 12,875 10,926  
    Accrued litigation (Note 20) 51,734 4,553  
    Other 17,405 13,046  
    OTHER ACCRUED LIABILITIES $ 168,228 $ 97,309  
    XML 91 R72.htm IDEA: XBRL DOCUMENT v3.24.0.1
    INCOME TAXES - Expense (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Current:      
    Federal $ 73,092 $ 56,717 $ 49,105
    State 17,301 14,216 11,898
    Total current income tax expense (benefit) 90,393 70,933 61,003
    Deferred:      
    Federal (22,280) (5,158) (716)
    State (5,201) (1,338) (8)
    Total deferred income tax expense (benefit) (27,481) (6,496) (724)
    Provision for income taxes $ 62,912 $ 64,437 $ 60,279
    XML 92 R73.htm IDEA: XBRL DOCUMENT v3.24.0.1
    INCOME TAXES - Tax Rate (Details)
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Income Tax Disclosure [Abstract]      
    Income tax expense at statutory rate 21.00% 21.00% 21.00%
    State income taxes - net of federal benefit 3.50% 3.50% 3.70%
    Non-deductible expenses 3.40% 2.00% 2.40%
    Equity compensation (4.20%) (3.60%) (3.30%)
    Other adjustments (0.60%) (0.60%) (0.40%)
    TOTAL INCOME TAX PROVISION 23.10% 22.30% 23.40%
    XML 93 R74.htm IDEA: XBRL DOCUMENT v3.24.0.1
    INCOME TAXES - Narrative (YE) (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Income Tax Disclosure [Abstract]      
    Effective income tax rate 23.10% 22.30% 23.40%
    Tax credits $ 1,192 $ 1,742  
    Valuation allowance $ 789 $ 789  
    XML 94 R75.htm IDEA: XBRL DOCUMENT v3.24.0.1
    INCOME TAXES - Deferred Tax Assets and Liabilities (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2023
    Dec. 31, 2022
    Income Tax Disclosure [Abstract]    
    Accrued expenses $ 81,502 $ 61,685
    Revenue related reserves 23,714 18,046
    Tax credits 1,192 1,742
    Insurance 16,864 11,910
    Lease liability 444,590 364,408
    State taxes 0 28
    Total deferred tax assets 567,862 457,819
    Valuation allowance (789) (789)
    TOTAL DEFERRED TAX ASSETS 567,073 457,030
    State taxes (280) 0
    Depreciation and amortization (52,334) (49,146)
    Prepaid expenses (4,113) (5,150)
    Right of use asset (443,222) (363,091)
    TOTAL DEFERRED TAX LIABILITIES (499,949) (417,387)
    NET DEFERRED TAX ASSETS $ 67,124 $ 39,643
    XML 95 R76.htm IDEA: XBRL DOCUMENT v3.24.0.1
    DEBT - Schedule of Long-term Debt (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2023
    Dec. 31, 2022
    Debt Instrument [Line Items]    
    Less: current maturities $ (3,950) $ (3,883)
    Less: debt issuance costs, net (2,941) (3,119)
    LONG-TERM DEBT LESS CURRENT MATURITIES 145,497 149,269
    Mortgage loans and promissory note    
    Debt Instrument [Line Items]    
    Mortgage loans and promissory note $ 152,388 $ 156,271
    XML 96 R77.htm IDEA: XBRL DOCUMENT v3.24.0.1
    DEBT - Credit Facility with a Lending Consortium Arranged by Truist (Details)
    12 Months Ended
    Apr. 08, 2022
    USD ($)
    Dec. 31, 2023
    USD ($)
    Dec. 31, 2022
    USD ($)
    Dec. 31, 2021
    USD ($)
    Debt Instrument [Line Items]        
    Write-off of deferred financing fees   $ 0 $ 566,000 $ 0
    Payments of deferred financing costs   19,000 $ 3,197,000 $ 1,172,000
    Revolving credit facility with Truist | Truist        
    Debt Instrument [Line Items]        
    Line of credit facility, maximum borrowing capacity   600,000,000    
    Total net debt ratio, maximum 3.00      
    Long-term debt threshold for EBITDA ratio increase election period 6 months      
    Long-term debt, threshold for EBITDA ratio increase election $ 50,000,000      
    Total net debt ratio, maximum after increase election 3.50      
    Total net debt ratio, minimum 1.50      
    Outstanding debt   $ 0    
    Revolving credit facility with Truist | Truist | Minimum        
    Debt Instrument [Line Items]        
    Line of credit facility, unused capacity, commitment fee percentage 0.20%      
    Revolving credit facility with Truist | Truist | Maximum        
    Debt Instrument [Line Items]        
    Line of credit facility, unused capacity, commitment fee percentage 0.40%      
    Revolving credit facility with Truist | Truist | Base Rate | Minimum        
    Debt Instrument [Line Items]        
    Interest rate margin 0.25%      
    Revolving credit facility with Truist | Truist | Base Rate | Maximum        
    Debt Instrument [Line Items]        
    Interest rate margin 1.25%      
    Revolving credit facility with Truist | Truist | Secured Overnight Financing Rate (SOFR) | Minimum        
    Debt Instrument [Line Items]        
    Interest rate margin 1.25%      
    Revolving credit facility with Truist | Truist | Secured Overnight Financing Rate (SOFR) | Maximum        
    Debt Instrument [Line Items]        
    Interest rate margin 2.25%      
    XML 97 R78.htm IDEA: XBRL DOCUMENT v3.24.0.1
    DEBT - Mortgage Loans and Promissory Notes and Off-Balance Sheet Arrangements (Details)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2023
    USD ($)
    subsidiary
    Dec. 31, 2022
    USD ($)
    Debt Instrument [Line Items]    
    Letters of credit outstanding, pledged amount $ 6,255  
    Letter of Credit    
    Debt Instrument [Line Items]    
    Letter of credit increase (455)  
    Mortgage loans and promissory note    
    Debt Instrument [Line Items]    
    Outstanding debt $ 152,388 $ 156,271
    Mortgage loans and promissory note | HUD Insured Mortgages | First Three Years    
    Debt Instrument [Line Items]    
    Prepayment penalty 10.00%  
    Mortgage loans and promissory note | HUD Insured Mortgages | In The Fourth Year    
    Debt Instrument [Line Items]    
    Reduction in prepayment penalty 3.00%  
    Mortgage loans and promissory note | HUD Insured Mortgages | Years Five Through Ten    
    Debt Instrument [Line Items]    
    Reduction in prepayment penalty 1.00%  
    Mortgage loans and promissory note | HUD Insured Mortgages | After Year Ten    
    Debt Instrument [Line Items]    
    Prepayment penalty 0.00%  
    Mortgage loans and promissory note | HUD Insured Mortgages | Minimum    
    Debt Instrument [Line Items]    
    Debt instrument, interest rate, effective percentage 3.10%  
    Debt instrument, interest rate, stated percentage 2.40%  
    Debt instrument, term 25 years  
    Mortgage loans and promissory note | HUD Insured Mortgages | Maximum    
    Debt Instrument [Line Items]    
    Debt instrument, interest rate, effective percentage 4.20%  
    Debt instrument, interest rate, stated percentage 3.30%  
    Debt instrument, term 35 years  
    Mortgage loans and promissory note | HUD Insured Mortgages | Twenty Three Subsidiaries    
    Debt Instrument [Line Items]    
    Number of operating subsidiaries | subsidiary 23  
    Outstanding debt $ 150,244  
    Mortgage loans and promissory note | 5.3% Promissory Note    
    Debt Instrument [Line Items]    
    Outstanding debt $ 2,144  
    Debt instrument, interest rate, stated percentage 5.30%  
    Debt instrument, term 12 years  
    XML 98 R79.htm IDEA: XBRL DOCUMENT v3.24.0.1
    DEBT - Long-term Debt Arrangements (Details)
    $ in Thousands
    Dec. 31, 2023
    USD ($)
    Debt Disclosure [Abstract]  
    2024 $ 3,950
    2025 4,086
    2026 4,227
    2027 3,897
    2028 3,779
    Thereafter 132,449
    Long-term Debt $ 152,388
    XML 99 R80.htm IDEA: XBRL DOCUMENT v3.24.0.1
    OPTIONS AND AWARDS - Stock Options, Narrative (Details)
    $ / shares in Units, shares in Thousands, $ in Thousands
    12 Months Ended
    Dec. 31, 2023
    USD ($)
    installment
    plan
    $ / shares
    shares
    Dec. 31, 2022
    USD ($)
    $ / shares
    shares
    Dec. 31, 2021
    USD ($)
    $ / shares
    shares
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Number of option plans | plan 1    
    Forfeiture rate 5.08%    
    Options granted (in shares) 1,008 581 621
    Grant date intrinsic value (in dollars per share) | $ / shares $ 0 $ 0 $ 0
    Intrinsic value of options exercised in period | $ $ 56,186 $ 47,441 $ 34,278
    Stock Options      
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Aggregate intrinsic value of options that vested in period | $ $ 31,658 $ 27,955 $ 27,731
    2022 Plan      
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Number of shares authorized (in shares) 3,452    
    Conversion to reduce shares availability 1    
    Other than options, conversion to reduce shares availability 2    
    Award vesting period 5 years    
    Award vesting rights, percentage 20.00%    
    Expiration period 10 years    
    Number of shares available for grant (in shares) 1,454    
    2022 Plan | Non-employee Directors      
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Number of installments | installment 3    
    Award requisite service period 3 years    
    XML 100 R81.htm IDEA: XBRL DOCUMENT v3.24.0.1
    OPTIONS AND AWARDS - Valuation Assumptions (Details) - shares
    shares in Thousands
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Share-Based Payment Arrangement [Abstract]      
    Options granted (in shares) 1,008 581 621
    Weighted Average Risk-Free Rate 4.30% 2.80% 1.00%
    Expected Life 6 years 2 months 12 days 6 years 2 months 12 days 6 years 2 months 12 days
    Weighted Average Volatility 41.30% 42.10% 42.40%
    Weighted Average Dividend Yield 0.20% 0.30% 0.30%
    XML 101 R82.htm IDEA: XBRL DOCUMENT v3.24.0.1
    OPTIONS AND AWARDS - Exercise Price and Fair Value (Details) - $ / shares
    shares in Thousands
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Share-Based Payment Arrangement [Abstract]      
    Granted (in shares) 1,008 581 621
    Weighted Average Exercise Price (in dollars per share) $ 95.05 $ 85.74 $ 80.19
    Weighted Average Fair Value of Options (in dollars per share) $ 43.85 $ 37.83 $ 32.82
    XML 102 R83.htm IDEA: XBRL DOCUMENT v3.24.0.1
    OPTIONS AND AWARDS - Options Outstanding Rollforward (Details) - $ / shares
    shares in Thousands
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Dec. 31, 2020
    Number of Options Outstanding        
    Balance at beginning of period, (in shares) 3,833 4,038 4,038  
    Granted (in shares) 1,008 581 621  
    Forfeited (in shares) (91) (98) (105)  
    Exercised (in shares) (759) (688) (516)  
    Balance at end of period, (in shares) 3,991 3,833 4,038  
    Weighted Average Exercise Price        
    Balance at beginning of period (in dollars per share) $ 46.72 $ 36.60 $ 27.71  
    Granted (in dollars per share) 95.05 85.74 80.19  
    Forfeited (in dollars per share) 71.44 59.52 44.76  
    Exercised (in dollars per share) 24.21 18.43 17.80  
    Balance at end of period (in dollars per share) $ 62.65 $ 46.72 $ 36.60  
    Number of Options Vested (in shares) 1,887 2,069 2,183 2,148
    Weighted Average Exercise Price of Options Vested (in dollars per share) $ 39.58 $ 28.87 $ 21.02 $ 16.66
    XML 103 R84.htm IDEA: XBRL DOCUMENT v3.24.0.1
    OPTIONS AND AWARDS - Options Outstanding by Exercise Price (Details)
    $ / shares in Units, shares in Thousands, $ in Thousands
    12 Months Ended
    Dec. 31, 2023
    USD ($)
    $ / shares
    shares
    Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
    Number outstanding (in shares) 3,991
    Black-Scholes Fair Value | $ $ 105,703
    Stock options vested and exercisable (in shares) 1,887
    2014  
    Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
    Exercise price, lower range limit (in dollars per share) | $ / shares $ 8.94
    Exercise price, upper range limit (in dollars per share) | $ / shares $ 16.05
    Number outstanding (in shares) 99
    Black-Scholes Fair Value | $ $ 484
    Remaining Contractual Life (Years) 1 year
    Stock options vested and exercisable (in shares) 99
    2015  
    Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
    Exercise price, lower range limit (in dollars per share) | $ / shares $ 18.20
    Exercise price, upper range limit (in dollars per share) | $ / shares $ 21.39
    Number outstanding (in shares) 175
    Black-Scholes Fair Value | $ $ 1,369
    Remaining Contractual Life (Years) 2 years
    Stock options vested and exercisable (in shares) 175
    2016  
    Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
    Exercise price, lower range limit (in dollars per share) | $ / shares $ 15.93
    Exercise price, upper range limit (in dollars per share) | $ / shares $ 16.86
    Number outstanding (in shares) 155
    Black-Scholes Fair Value | $ $ 916
    Remaining Contractual Life (Years) 3 years
    Stock options vested and exercisable (in shares) 155
    2017  
    Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
    Exercise price, lower range limit (in dollars per share) | $ / shares $ 15.80
    Exercise price, upper range limit (in dollars per share) | $ / shares $ 19.41
    Number outstanding (in shares) 194
    Black-Scholes Fair Value | $ $ 1,138
    Remaining Contractual Life (Years) 4 years
    Stock options vested and exercisable (in shares) 194
    2018  
    Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
    Exercise price, lower range limit (in dollars per share) | $ / shares $ 22.49
    Exercise price, upper range limit (in dollars per share) | $ / shares $ 32.71
    Number outstanding (in shares) 336
    Black-Scholes Fair Value | $ $ 3,523
    Remaining Contractual Life (Years) 5 years
    Stock options vested and exercisable (in shares) 336
    2019  
    Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
    Exercise price, lower range limit (in dollars per share) | $ / shares $ 41.07
    Exercise price, upper range limit (in dollars per share) | $ / shares $ 45.76
    Number outstanding (in shares) 510
    Black-Scholes Fair Value | $ $ 8,014
    Remaining Contractual Life (Years) 6 years
    Stock options vested and exercisable (in shares) 383
    2020  
    Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
    Exercise price, lower range limit (in dollars per share) | $ / shares $ 44.84
    Exercise price, upper range limit (in dollars per share) | $ / shares $ 59.49
    Number outstanding (in shares) 476
    Black-Scholes Fair Value | $ $ 9,383
    Remaining Contractual Life (Years) 7 years
    Stock options vested and exercisable (in shares) 257
    2021  
    Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
    Exercise price, lower range limit (in dollars per share) | $ / shares $ 73.47
    Exercise price, upper range limit (in dollars per share) | $ / shares $ 83.64
    Number outstanding (in shares) 513
    Black-Scholes Fair Value | $ $ 16,844
    Remaining Contractual Life (Years) 8 years
    Stock options vested and exercisable (in shares) 189
    2022  
    Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
    Exercise price, lower range limit (in dollars per share) | $ / shares $ 79.79
    Exercise price, upper range limit (in dollars per share) | $ / shares $ 94.88
    Number outstanding (in shares) 540
    Black-Scholes Fair Value | $ $ 20,466
    Remaining Contractual Life (Years) 9 years
    Stock options vested and exercisable (in shares) 99
    2023  
    Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
    Exercise price, lower range limit (in dollars per share) | $ / shares $ 89.83
    Exercise price, upper range limit (in dollars per share) | $ / shares $ 98.83
    Number outstanding (in shares) 993
    Black-Scholes Fair Value | $ $ 43,566
    Remaining Contractual Life (Years) 10 years
    Stock options vested and exercisable (in shares) 0
    XML 104 R85.htm IDEA: XBRL DOCUMENT v3.24.0.1
    OPTIONS AND AWARDS - Intrinsic Values (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Share-Based Payment Arrangement [Abstract]      
    Outstanding $ 197,819 $ 183,593 $ 191,242
    Vested 137,048 136,000 137,382
    Expected to vest $ 56,759 $ 43,232 $ 48,548
    XML 105 R86.htm IDEA: XBRL DOCUMENT v3.24.0.1
    OPTIONS AND AWARDS - Restricted Stock Awards, Narrative (Details) - $ / shares
    shares in Thousands
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Share-based compensation, restricted awards, exercise price (in dollars per share) $ 0    
    Restricted Stock Awards      
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Granted (in shares) 219 233 222
    Award vesting period 5 years    
    Granted (in dollars per share) $ 92.04 $ 81.57 $ 81.65
    Restricted Stock Awards | Non-employee Directors      
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Granted (in shares) 18    
    Restricted Stock Awards | Minimum      
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Granted (in dollars per share) $ 89.83 73.17 72.84
    Restricted Stock Awards | Minimum | Non-employee Directors      
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Granted (in dollars per share) 89.94    
    Restricted Stock Awards | Maximum      
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Granted (in dollars per share) 98.31 $ 94.88 $ 93.31
    Restricted Stock Awards | Maximum | Non-employee Directors      
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Granted (in dollars per share) $ 98.31    
    XML 106 R87.htm IDEA: XBRL DOCUMENT v3.24.0.1
    OPTIONS AND AWARDS - Restricted Award Rollforward (Details) - Restricted Stock Awards - $ / shares
    shares in Thousands
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Non-Vested Restricted Awards      
    Nonvested at beginning of period (in shares) 487 549 591
    Granted (in shares) 219 233 222
    Vested (in shares) (255) (269) (244)
    Forfeited (in shares) (20) (26) (20)
    Nonvested at end of period (in shares) 431 487 549
    Weighted Average Grant Date Fair Value      
    Nonvested at beginning of period (in dollars per share) $ 64.92 $ 52.16 $ 38.90
    Granted (in dollars per share) 92.04 81.57 81.65
    Vested (in dollars per share) 64.21 54.06 47.45
    Forfeited (in dollars per share) 71.53 57.29 45.64
    Nonvested at end of period (in dollars per share) $ 78.91 $ 64.92 $ 52.16
    XML 107 R88.htm IDEA: XBRL DOCUMENT v3.24.0.1
    OPTIONS AND AWARDS - Long-Term Incentive Plan (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Aug. 27, 2019
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
    Share-based compensation   $ 30,754 $ 22,720 $ 18,678
    Spinoff | 2019 LTI Plan        
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
    Number of shares authorized (in shares) 500,000      
    Award vesting period 5 years      
    Award vesting rights, percentage 20.00%      
    Share-based compensation   $ 827 $ 836 $ 854
    XML 108 R89.htm IDEA: XBRL DOCUMENT v3.24.0.1
    OPTIONS AND AWARDS - Compensation Expense (Details) - USD ($)
    shares in Thousands, $ in Thousands
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]      
    Stock-based compensation expense related to stock options $ 30,754 $ 22,720 $ 18,678
    Share-based compensation, options outstanding, weighted average remaining contractual term 6 years 8 months 12 days    
    Stock-based compensation expense related to stock options      
    Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]      
    Stock-based compensation expense related to stock options $ 17,221 11,361 8,459
    Share-based compensation, nonvested awards, cost not yet recognized $ 67,750    
    Share-based compensation, nonvested awards, cost not yet recognized, period for recognition 3 years 10 months 24 days    
    Share-based compensation, nonvested awards (in shares) 2,104    
    Share-based compensation, options expected to vest, number (in shares) 1,940    
    Stock-based compensation expense related to restricted stock awards      
    Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]      
    Stock-based compensation expense related to stock options $ 11,845 9,920 8,385
    Share-based compensation, nonvested awards, cost not yet recognized $ 29,245    
    Share-based compensation, nonvested awards, cost not yet recognized, period for recognition 3 years 4 months 24 days    
    Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors      
    Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]      
    Stock-based compensation expense related to stock options $ 1,688 $ 1,439 $ 1,834
    XML 109 R90.htm IDEA: XBRL DOCUMENT v3.24.0.1
    LEASES - Lessee Narrative (Details)
    $ in Thousands
    1 Months Ended 12 Months Ended
    Feb. 01, 2024
    USD ($)
    operation
    bed
    Dec. 31, 2023
    USD ($)
    lease
    operation
    renewal
    bed
    facility
    agreement
    Dec. 31, 2022
    USD ($)
    lease
    operation
    bed
    Dec. 31, 2021
    USD ($)
    bed
    lease
    operation
    Lessee, Lease, Description [Line Items]        
    Lessee, operating lease, term of contract   10 years    
    Right-of-use assets obtained in exchange for new and modified operating lease obligations | $   $ 376,550 $ 370,753 $ 198,593
    Operating lease, weighted average remaining lease term   14 years 10 months 24 days 15 years  
    Operating lease, weighted average discount rate, percent   6.50% 6.70%  
    Operational skilled nursing beds | bed   30,600    
    Skilled Nursing Operations        
    Lessee, Lease, Description [Line Items]        
    Number of businesses acquired | operation   25 23 17
    Operational skilled nursing beds | bed   2,483 3,058 1,832
    Skilled Nursing Operations | Subsequent Event        
    Lessee, Lease, Description [Line Items]        
    Number of businesses acquired | operation 2      
    Cost of Sales and General and Administrative Expense        
    Lessee, Lease, Description [Line Items]        
    Rent expense | $   $ 197,856 $ 153,174 $ 139,458
    Minimum        
    Lessee, Lease, Description [Line Items]        
    Lessee, operating lease, renewal term   10 years    
    Maximum        
    Lessee, Lease, Description [Line Items]        
    Lessee, operating lease, renewal term   15 years    
    Amended Master Lease Agreement        
    Lessee, Lease, Description [Line Items]        
    Amended of separate master leases | agreement   3    
    Amended Master Lease Agreement | Skilled Nursing Operations | Subsequent Event        
    Lessee, Lease, Description [Line Items]        
    Number of businesses acquired | operation 2      
    Right-of-use assets obtained in exchange for new and modified operating lease obligations | $ $ 30,980      
    Term of operating lease 20 years      
    Operational skilled nursing beds | bed 241      
    New Master Lease Agreeement        
    Lessee, Lease, Description [Line Items]        
    Right-of-use assets obtained in exchange for new and modified operating lease obligations | $   $ 346,789    
    New Master Lease Agreeement | Skilled Nursing Operations        
    Lessee, Lease, Description [Line Items]        
    Number of businesses acquired | operation   22    
    Amended Master Lease | Skilled Nursing Operations        
    Lessee, Lease, Description [Line Items]        
    Number of businesses acquired | operation   19    
    Leases To Third Party Operators | Minimum        
    Lessee, Lease, Description [Line Items]        
    Term of operating lease   14 years    
    Leases To Third Party Operators | Maximum        
    Lessee, Lease, Description [Line Items]        
    Term of operating lease   16 years    
    Sublease Of Stand Along Skilled Nursing Operations        
    Lessee, Lease, Description [Line Items]        
    Number of leases | lease   3    
    Term of operating lease   18 years 20 years 20 years
    Lease Of Campus Operation        
    Lessee, Lease, Description [Line Items]        
    Number of leases | lease   1    
    Term of operating lease   15 years    
    CareTrust REIT        
    Lessee, Lease, Description [Line Items]        
    Skilled nursing, assisted living and independent living facilities | facility   97    
    Consumer price index   0.00%    
    Operating leases of lessee, contingent rentals, basis spread on variable rate   2.50%    
    Number of stand-alone leases | lease   1    
    Rent expense | $   $ 66,439 $ 64,178 $ 59,571
    CareTrust REIT | Triple Net Lease Arrangements        
    Lessee, Lease, Description [Line Items]        
    Skilled nursing, assisted living and independent living facilities | facility   96    
    Master lease agreements | agreement   9    
    Lessee, operating lease, renewal term   5 years    
    CareTrust REIT | Triple Net Lease Arrangements | Minimum        
    Lessee, Lease, Description [Line Items]        
    Lessee, operating lease, term of contract   13 years    
    Lessee leasing arrangements, operating leases, number of renewal terms | renewal   2    
    CareTrust REIT | Triple Net Lease Arrangements | Maximum        
    Lessee, Lease, Description [Line Items]        
    Lessee, operating lease, term of contract   20 years    
    Lessee leasing arrangements, operating leases, number of renewal terms | renewal   3    
    CareTrust REIT | Purchase Option        
    Lessee, Lease, Description [Line Items]        
    Skilled nursing, assisted living and independent living facilities | facility   4    
    Various Landlords        
    Lessee, Lease, Description [Line Items]        
    Master lease agreements | agreement   13    
    Facilities under master lease arrangement | facility   80    
    Various Landlords | Minimum        
    Lessee, Lease, Description [Line Items]        
    Lessee, operating lease, term of contract   5 years    
    Various Landlords | Minimum | Equipment        
    Lessee, Lease, Description [Line Items]        
    Lessee, operating lease, term of contract   3 years    
    Various Landlords | Maximum        
    Lessee, Lease, Description [Line Items]        
    Lessee, operating lease, term of contract   20 years    
    Various Landlords | Maximum | Equipment        
    Lessee, Lease, Description [Line Items]        
    Lessee, operating lease, term of contract   5 years    
    The Pennant Group, Inc. | Leases To Third Party Operators        
    Lessee, Lease, Description [Line Items]        
    Number of leases | lease   29 29 32
    XML 110 R91.htm IDEA: XBRL DOCUMENT v3.24.0.1
    LEASES - Lessee Lease Cost (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Lessee, Lease, Description [Line Items]      
    Lease, cost $ 219,512 $ 171,272 $ 154,693
    Amortization of deferred rent 870 493 485
    Cost of Services      
    Lessee, Lease, Description [Line Items]      
    Operating lease expense 197,358 153,049 139,371
    Variable lease, costs 20,454 16,938 14,077
    CPI increases and short term-lease cost 10,259 5,878 3,702
    General and administrative expense      
    Lessee, Lease, Description [Line Items]      
    Operating lease expense 498 125 87
    Depreciation and amortization      
    Lessee, Lease, Description [Line Items]      
    Operating lease expense $ 1,202 $ 1,160 $ 1,158
    XML 111 R92.htm IDEA: XBRL DOCUMENT v3.24.0.1
    LEASES - Lessee Future Minimum Lease Payments (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2023
    Dec. 31, 2022
    Year    
    2024 $ 191,352  
    2025 191,269  
    2026 191,058  
    2027 190,481  
    2028 189,224  
    Thereafter 1,722,259  
    TOTAL LEASE PAYMENTS 2,675,643  
    Less: present value adjustment (953,791)  
    PRESENT VALUE OF TOTAL LEASE LIABILITIES 1,721,852  
    Less: current lease liabilities (82,526) $ (65,796)
    LONG-TERM OPERATING LEASE LIABILITIES $ 1,639,326 $ 1,355,113
    XML 112 R93.htm IDEA: XBRL DOCUMENT v3.24.0.1
    LEASES - Lessor Narrative (Details) - lease
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Leases To Third Party Operators | Minimum      
    Lessor, Lease, Description [Line Items]      
    Term of operating lease 14 years    
    Leases To Third Party Operators | Maximum      
    Lessor, Lease, Description [Line Items]      
    Term of operating lease 16 years    
    Leases To Third Party Operators | The Pennant Group, Inc.      
    Lessor, Lease, Description [Line Items]      
    Number of leases 29 29 32
    Sublease Of Stand Along Skilled Nursing Operations      
    Lessor, Lease, Description [Line Items]      
    Number of leases 3    
    Term of operating lease 18 years 20 years 20 years
    Lease Of Campus Operation      
    Lessor, Lease, Description [Line Items]      
    Number of leases 1    
    Term of operating lease 15 years    
    XML 113 R94.htm IDEA: XBRL DOCUMENT v3.24.0.1
    LEASES - Lessor Rental Income (Details)
    12 Months Ended
    Dec. 31, 2023
    USD ($)
    lease
    Dec. 31, 2022
    USD ($)
    lease
    Dec. 31, 2021
    USD ($)
    lease
    Lessor, Lease, Description [Line Items]      
    OperatingLeaseIncomeComprehensiveIncomeExtensibleListNotDisclosedFlag TOTAL REVENUE    
    Operating Segments | Rental revenue | All Other      
    Lessor, Lease, Description [Line Items]      
    Sublease income $ 3,897,000 $ 0 $ 0
    Leases To Third Party Operators      
    Lessor, Lease, Description [Line Items]      
    Rental revenue 21,284,000 16,757,000 15,985,000
    Pennant | Leases To Third Party Operators      
    Lessor, Lease, Description [Line Items]      
    Rental revenue 15,048,000 14,915,000 14,073,000
    Operating lease, variable lease income $ 1,296,000 $ 1,318,000 $ 1,199,000
    Number of leases | lease 29 29 32
    Other third-party | Leases To Third Party Operators      
    Lessor, Lease, Description [Line Items]      
    Rental revenue $ 6,236,000 $ 1,842,000 $ 1,912,000
    XML 114 R95.htm IDEA: XBRL DOCUMENT v3.24.0.1
    LEASES - Lessor Future Minimum Lease Payments Receivable (Details)
    $ in Thousands
    Dec. 31, 2023
    USD ($)
    Leases [Abstract]  
    2024 $ 22,191
    2025 21,565
    2026 21,269
    2027 21,176
    2028 21,151
    Thereafter 129,586
    TOTAL $ 236,938
    XML 115 R96.htm IDEA: XBRL DOCUMENT v3.24.0.1
    DEFINED CONTRIBUTION PLANS (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Defined Contribution Plan Disclosure [Line Items]      
    Deferred compensation liability, noncurrent $ 49,201 $ 33,017  
    Gain (loss) on deferral investment 4,634 (4,188) $ 1,612
    Offsetting expense (income) $ 4,887 (4,051) 1,758
    Qualified Plan      
    Defined Contribution Plan Disclosure [Line Items]      
    Maximum annual contributions per employee 90.00%    
    Defined contribution plan, cost $ 2,836 $ 2,418 $ 2,121
    Nonqualified Plan      
    Defined Contribution Plan Disclosure [Line Items]      
    Maximum annual contributions per employee 100.00%    
    XML 116 R97.htm IDEA: XBRL DOCUMENT v3.24.0.1
    SELF INSURANCE LIABILITIES (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Movement in Liability for Future Policy Benefits [Roll Forward]    
    Beginning balance $ 131,682 $ 110,139
    Current year provisions 164,627 115,793
    Claims paid and direct expenses (135,799) (98,007)
    Change in long-term insurance losses recoverable 5,400 3,757
    Ending balance 165,910 131,682
    General and Professional Liability    
    Movement in Liability for Future Policy Benefits [Roll Forward]    
    Beginning balance 87,000  
    Ending balance $ 117,744 $ 87,000
    XML 117 R98.htm IDEA: XBRL DOCUMENT v3.24.0.1
    COMMITMENTS AND CONTINGENCIES (Details)
    $ in Thousands
    12 Months Ended
    Jan. 19, 2024
    USD ($)
    Dec. 31, 2023
    subsidiary
    Dec. 31, 2022
    Dec. 31, 2021
    Feb. 01, 2024
    subsidiary
    Concentration Risk [Line Items]          
    Facilities under medicare probe reviews   40      
    Customer Concentration Risk | Total Medicaid and Medicare | Accounts Receivable          
    Concentration Risk [Line Items]          
    Concentration percentage   53.40% 56.30%    
    Customer Concentration Risk | Total Medicaid and Medicare | Revenue          
    Concentration Risk [Line Items]          
    Concentration percentage   72.60% 73.70% 73.60%  
    Subsequent Event          
    Concentration Risk [Line Items]          
    Litigation settlement, amount awarded to other party | $ $ 48,000        
    Facilities under medicare probe reviews         40
    XML 118 R99.htm IDEA: XBRL DOCUMENT v3.24.0.1
    COMMON STOCK REPURCHASE PROGRAM (Details) - USD ($)
    shares in Thousands
    12 Months Ended
    Aug. 29, 2023
    Jul. 28, 2022
    Dec. 31, 2022
    Dec. 31, 2021
    Equity, Class of Treasury Stock [Line Items]        
    Repurchase of common stock (in shares)     404 132
    Repurchase of common stock, value     $ 29,882,000 $ 10,118,000
    August 2023 Repurchase Program        
    Equity, Class of Treasury Stock [Line Items]        
    Stock repurchase program, authorized amount $ 20,000,000      
    Stock repurchase program, period in force 12 months      
    July 2022 Repurchase Program        
    Equity, Class of Treasury Stock [Line Items]        
    Stock repurchase program, authorized amount   $ 20,000,000    
    Stock repurchase program, period in force   12 months    
    EXCEL 120 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 121 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 122 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 124 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 447 491 1 false 131 0 false 19 false false R1.htm 0000001 - Document - Cover Sheet http://www.ensigngroup.net/role/Cover Cover Cover 1 false false R2.htm 0000002 - Document - Audit Information Sheet http://www.ensigngroup.net/role/AuditInformation Audit Information Cover 2 false false R3.htm 0000003 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS CONSOLIDATED BALANCE SHEETS Statements 3 false false R4.htm 0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETSParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 4 false false R5.htm 0000005 - Statement - CONSOLIDATED STATEMENTS OF INCOME Sheet http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME CONSOLIDATED STATEMENTS OF INCOME Statements 5 false false R6.htm 0000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 6 false false R7.htm 0000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) Sheet http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) Statements 7 false false R8.htm 0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 8 false false R9.htm 0000009 - Disclosure - DESCRIPTION OF BUSINESS Sheet http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESS DESCRIPTION OF BUSINESS Notes 9 false false R10.htm 0000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 10 false false R11.htm 0000011 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE Sheet http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLE REVENUE AND ACCOUNTS RECEIVABLE Notes 11 false false R12.htm 0000012 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE Sheet http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARE COMPUTATION OF NET INCOME PER COMMON SHARE Notes 12 false false R13.htm 0000013 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTS FAIR VALUE MEASUREMENTS Notes 13 false false R14.htm 0000014 - Disclosure - STANDARD BEARER Sheet http://www.ensigngroup.net/role/STANDARDBEARER STANDARD BEARER Notes 14 false false R15.htm 0000015 - Disclosure - OPERATION EXPANSIONS Sheet http://www.ensigngroup.net/role/OPERATIONEXPANSIONS OPERATION EXPANSIONS Notes 15 false false R16.htm 0000016 - Disclosure - BUSINESS SEGMENTS Sheet http://www.ensigngroup.net/role/BUSINESSSEGMENTS BUSINESS SEGMENTS Notes 16 false false R17.htm 0000017 - Disclosure - PROPERTY AND EQUIPMENT??? NET Sheet http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNET PROPERTY AND EQUIPMENT??? NET Notes 17 false false R18.htm 0000018 - Disclosure - INTANGIBLE ASSETS ??? NET Sheet http://www.ensigngroup.net/role/INTANGIBLEASSETSNET INTANGIBLE ASSETS ??? NET Notes 18 false false R19.htm 0000019 - Disclosure - GOODWILL Sheet http://www.ensigngroup.net/role/GOODWILL GOODWILL Notes 19 false false R20.htm 0000020 - Disclosure - RESTRICTED AND OTHER ASSETS Sheet http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETS RESTRICTED AND OTHER ASSETS Notes 20 false false R21.htm 0000021 - Disclosure - OTHER ACCRUED LIABILITIES Sheet http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIES OTHER ACCRUED LIABILITIES Notes 21 false false R22.htm 0000022 - Disclosure - INCOME TAXES Sheet http://www.ensigngroup.net/role/INCOMETAXES INCOME TAXES Notes 22 false false R23.htm 0000023 - Disclosure - DEBT Sheet http://www.ensigngroup.net/role/DEBT DEBT Notes 23 false false R24.htm 0000024 - Disclosure - OPTIONS AND AWARDS Sheet http://www.ensigngroup.net/role/OPTIONSANDAWARDS OPTIONS AND AWARDS Notes 24 false false R25.htm 0000025 - Disclosure - LEASES Sheet http://www.ensigngroup.net/role/LEASES LEASES Notes 25 false false R26.htm 0000026 - Disclosure - DEFINED CONTRIBUTION PLANS Sheet http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANS DEFINED CONTRIBUTION PLANS Notes 26 false false R27.htm 0000027 - Disclosure - SELF INSURANCE LIABILITIES Sheet http://www.ensigngroup.net/role/SELFINSURANCELIABILITIES SELF INSURANCE LIABILITIES Notes 27 false false R28.htm 0000028 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 28 false false R29.htm 0000029 - Disclosure - COMMON STOCK REPURCHASE PROGRAM Sheet http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAM COMMON STOCK REPURCHASE PROGRAM Notes 29 false false R30.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 30 false false R31.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 31 false false R32.htm 9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 32 false false R33.htm 9954472 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE (Tables) Sheet http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLETables REVENUE AND ACCOUNTS RECEIVABLE (Tables) Tables http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLE 33 false false R34.htm 9954473 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE (Tables) Sheet http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARETables COMPUTATION OF NET INCOME PER COMMON SHARE (Tables) Tables http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARE 34 false false R35.htm 9954474 - Disclosure - OPERATION EXPANSIONS (Tables) Sheet http://www.ensigngroup.net/role/OPERATIONEXPANSIONSTables OPERATION EXPANSIONS (Tables) Tables http://www.ensigngroup.net/role/OPERATIONEXPANSIONS 35 false false R36.htm 9954475 - Disclosure - BUSINESS SEGMENTS (Tables) Sheet http://www.ensigngroup.net/role/BUSINESSSEGMENTSTables BUSINESS SEGMENTS (Tables) Tables http://www.ensigngroup.net/role/BUSINESSSEGMENTS 36 false false R37.htm 9954476 - Disclosure - PROPERTY AND EQUIPMENT??? NET (Tables) Sheet http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETTables PROPERTY AND EQUIPMENT??? NET (Tables) Tables http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNET 37 false false R38.htm 9954477 - Disclosure - INTANGIBLE ASSETS ??? NET (Tables) Sheet http://www.ensigngroup.net/role/INTANGIBLEASSETSNETTables INTANGIBLE ASSETS ??? NET (Tables) Tables http://www.ensigngroup.net/role/INTANGIBLEASSETSNET 38 false false R39.htm 9954478 - Disclosure - GOODWILL (Tables) Sheet http://www.ensigngroup.net/role/GOODWILLTables GOODWILL (Tables) Tables http://www.ensigngroup.net/role/GOODWILL 39 false false R40.htm 9954479 - Disclosure - RESTRICTED AND OTHER ASSETS (Tables) Sheet http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSTables RESTRICTED AND OTHER ASSETS (Tables) Tables http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETS 40 false false R41.htm 9954480 - Disclosure - OTHER ACCRUED LIABILITIES (Tables) Sheet http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESTables OTHER ACCRUED LIABILITIES (Tables) Tables http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIES 41 false false R42.htm 9954481 - Disclosure - INCOME TAXES (Tables) Sheet http://www.ensigngroup.net/role/INCOMETAXESTables INCOME TAXES (Tables) Tables http://www.ensigngroup.net/role/INCOMETAXES 42 false false R43.htm 9954482 - Disclosure - DEBT (Tables) Sheet http://www.ensigngroup.net/role/DEBTTables DEBT (Tables) Tables http://www.ensigngroup.net/role/DEBT 43 false false R44.htm 9954483 - Disclosure - OPTIONS AND AWARDS (Tables) Sheet http://www.ensigngroup.net/role/OPTIONSANDAWARDSTables OPTIONS AND AWARDS (Tables) Tables http://www.ensigngroup.net/role/OPTIONSANDAWARDS 44 false false R45.htm 9954484 - Disclosure - LEASES (Tables) Sheet http://www.ensigngroup.net/role/LEASESTables LEASES (Tables) Tables http://www.ensigngroup.net/role/LEASES 45 false false R46.htm 9954485 - Disclosure - SELF INSURANCE LIABILITIES (Tables) Sheet http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESTables SELF INSURANCE LIABILITIES (Tables) Tables http://www.ensigngroup.net/role/SELFINSURANCELIABILITIES 46 false false R47.htm 9954486 - Disclosure - DESCRIPTION OF BUSINESS (Details) Sheet http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails DESCRIPTION OF BUSINESS (Details) Details http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESS 47 false false R48.htm 9954487 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details) Sheet http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details) Details 48 false false R49.htm 9954488 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Leases and Leasehold Improvements (Details) Sheet http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Leases and Leasehold Improvements (Details) Details 49 false false R50.htm 9954489 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets and Goodwill (Details) Sheet http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets and Goodwill (Details) Details 50 false false R51.htm 9954490 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Self-Insurance (Details) Sheet http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Self-Insurance (Details) Details 51 false false R52.htm 9954491 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE -Narrative (Details) Sheet http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails REVENUE AND ACCOUNTS RECEIVABLE -Narrative (Details) Details 52 false false R53.htm 9954492 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE - Disaggregation of Revenue (Details) Sheet http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails REVENUE AND ACCOUNTS RECEIVABLE - Disaggregation of Revenue (Details) Details 53 false false R54.htm 9954493 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE - Accounts Receivable (Details) Sheet http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails REVENUE AND ACCOUNTS RECEIVABLE - Accounts Receivable (Details) Details 54 false false R55.htm 9954494 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE (Details) Sheet http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails COMPUTATION OF NET INCOME PER COMMON SHARE (Details) Details http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARETables 55 false false R56.htm 9954495 - Disclosure - FAIR VALUE MEASUREMENTS (Details) Sheet http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails FAIR VALUE MEASUREMENTS (Details) Details http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTS 56 false false R57.htm 9954496 - Disclosure - STANDARD BEARER (Details) Sheet http://www.ensigngroup.net/role/STANDARDBEARERDetails STANDARD BEARER (Details) Details http://www.ensigngroup.net/role/STANDARDBEARER 57 false false R58.htm 9954497 - Disclosure - OPERATION EXPANSIONS- Narrative (Details) Sheet http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails OPERATION EXPANSIONS- Narrative (Details) Details 58 false false R59.htm 9954498 - Disclosure - OPERATION EXPANSIONS - Purchase Price Allocation (Details) Sheet http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails OPERATION EXPANSIONS - Purchase Price Allocation (Details) Details 59 false false R60.htm 9954499 - Disclosure - BUSINESS SEGMENTS - Narrative (Details) Sheet http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails BUSINESS SEGMENTS - Narrative (Details) Details 60 false false R61.htm 9954500 - Disclosure - BUSINESS SEGMENTS - Schedule of Segment Financial Information (Details) Sheet http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails BUSINESS SEGMENTS - Schedule of Segment Financial Information (Details) Details 61 false false R62.htm 9954501 - Disclosure - BUSINESS SEGMENTS - Schedule of Service Revenue by Major Payor Source (Details) Sheet http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails BUSINESS SEGMENTS - Schedule of Service Revenue by Major Payor Source (Details) Details 62 false false R63.htm 9954502 - Disclosure - PROPERTY AND EQUIPMENT??? NET - Schedule of Property and Equipment (Details) Sheet http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails PROPERTY AND EQUIPMENT??? NET - Schedule of Property and Equipment (Details) Details 63 false false R64.htm 9954503 - Disclosure - PROPERTY AND EQUIPMENT??? NET - Narrative (Details) Sheet http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails PROPERTY AND EQUIPMENT??? NET - Narrative (Details) Details 64 false false R65.htm 9954504 - Disclosure - INTANGIBLE ASSETS ??? NET - Schedule of Finite Lived Intangible Assets (Details) Sheet http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails INTANGIBLE ASSETS ??? NET - Schedule of Finite Lived Intangible Assets (Details) Details 65 false false R66.htm 9954505 - Disclosure - INTANGIBLE ASSETS ??? NET - Narrative (Details) Sheet http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails INTANGIBLE ASSETS ??? NET - Narrative (Details) Details 66 false false R67.htm 9954506 - Disclosure - INTANGIBLE ASSETS ??? NET - Future Amortization (Details) Sheet http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails INTANGIBLE ASSETS ??? NET - Future Amortization (Details) Details 67 false false R68.htm 9954507 - Disclosure - INTANGIBLE ASSETS ??? NET - Schedule of Indefinite-lived Intangible Assets (Details) Sheet http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofIndefinitelivedIntangibleAssetsDetails INTANGIBLE ASSETS ??? NET - Schedule of Indefinite-lived Intangible Assets (Details) Details 68 false false R69.htm 9954508 - Disclosure - GOODWILL (Details) Sheet http://www.ensigngroup.net/role/GOODWILLDetails GOODWILL (Details) Details http://www.ensigngroup.net/role/GOODWILLTables 69 false false R70.htm 9954509 - Disclosure - RESTRICTED AND OTHER ASSETS (Details) Sheet http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails RESTRICTED AND OTHER ASSETS (Details) Details http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSTables 70 false false R71.htm 9954510 - Disclosure - OTHER ACCRUED LIABILITIES (Details) Sheet http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails OTHER ACCRUED LIABILITIES (Details) Details http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESTables 71 false false R72.htm 9954511 - Disclosure - INCOME TAXES - Expense (Details) Sheet http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails INCOME TAXES - Expense (Details) Details 72 false false R73.htm 9954512 - Disclosure - INCOME TAXES - Tax Rate (Details) Sheet http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails INCOME TAXES - Tax Rate (Details) Details 73 false false R74.htm 9954513 - Disclosure - INCOME TAXES - Narrative (YE) (Details) Sheet http://www.ensigngroup.net/role/INCOMETAXESNarrativeYEDetails INCOME TAXES - Narrative (YE) (Details) Details 74 false false R75.htm 9954514 - Disclosure - INCOME TAXES - Deferred Tax Assets and Liabilities (Details) Sheet http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails INCOME TAXES - Deferred Tax Assets and Liabilities (Details) Details 75 false false R76.htm 9954515 - Disclosure - DEBT - Schedule of Long-term Debt (Details) Sheet http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails DEBT - Schedule of Long-term Debt (Details) Details 76 false false R77.htm 9954516 - Disclosure - DEBT - Credit Facility with a Lending Consortium Arranged by Truist (Details) Sheet http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails DEBT - Credit Facility with a Lending Consortium Arranged by Truist (Details) Details 77 false false R78.htm 9954517 - Disclosure - DEBT - Mortgage Loans and Promissory Notes and Off-Balance Sheet Arrangements (Details) Notes http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails DEBT - Mortgage Loans and Promissory Notes and Off-Balance Sheet Arrangements (Details) Details 78 false false R79.htm 9954518 - Disclosure - DEBT - Long-term Debt Arrangements (Details) Sheet http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails DEBT - Long-term Debt Arrangements (Details) Details 79 false false R80.htm 9954519 - Disclosure - OPTIONS AND AWARDS - Stock Options, Narrative (Details) Sheet http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails OPTIONS AND AWARDS - Stock Options, Narrative (Details) Details 80 false false R81.htm 9954520 - Disclosure - OPTIONS AND AWARDS - Valuation Assumptions (Details) Sheet http://www.ensigngroup.net/role/OPTIONSANDAWARDSValuationAssumptionsDetails OPTIONS AND AWARDS - Valuation Assumptions (Details) Details 81 false false R82.htm 9954521 - Disclosure - OPTIONS AND AWARDS - Exercise Price and Fair Value (Details) Sheet http://www.ensigngroup.net/role/OPTIONSANDAWARDSExercisePriceandFairValueDetails OPTIONS AND AWARDS - Exercise Price and Fair Value (Details) Details 82 false false R83.htm 9954522 - Disclosure - OPTIONS AND AWARDS - Options Outstanding Rollforward (Details) Sheet http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails OPTIONS AND AWARDS - Options Outstanding Rollforward (Details) Details 83 false false R84.htm 9954523 - Disclosure - OPTIONS AND AWARDS - Options Outstanding by Exercise Price (Details) Sheet http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails OPTIONS AND AWARDS - Options Outstanding by Exercise Price (Details) Details 84 false false R85.htm 9954524 - Disclosure - OPTIONS AND AWARDS - Intrinsic Values (Details) Sheet http://www.ensigngroup.net/role/OPTIONSANDAWARDSIntrinsicValuesDetails OPTIONS AND AWARDS - Intrinsic Values (Details) Details 85 false false R86.htm 9954525 - Disclosure - OPTIONS AND AWARDS - Restricted Stock Awards, Narrative (Details) Sheet http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails OPTIONS AND AWARDS - Restricted Stock Awards, Narrative (Details) Details 86 false false R87.htm 9954526 - Disclosure - OPTIONS AND AWARDS - Restricted Award Rollforward (Details) Sheet http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails OPTIONS AND AWARDS - Restricted Award Rollforward (Details) Details 87 false false R88.htm 9954527 - Disclosure - OPTIONS AND AWARDS - Long-Term Incentive Plan (Details) Sheet http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails OPTIONS AND AWARDS - Long-Term Incentive Plan (Details) Details 88 false false R89.htm 9954528 - Disclosure - OPTIONS AND AWARDS - Compensation Expense (Details) Sheet http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails OPTIONS AND AWARDS - Compensation Expense (Details) Details 89 false false R90.htm 9954529 - Disclosure - LEASES - Lessee Narrative (Details) Sheet http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails LEASES - Lessee Narrative (Details) Details 90 false false R91.htm 9954530 - Disclosure - LEASES - Lessee Lease Cost (Details) Sheet http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails LEASES - Lessee Lease Cost (Details) Details 91 false false R92.htm 9954531 - Disclosure - LEASES - Lessee Future Minimum Lease Payments (Details) Sheet http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails LEASES - Lessee Future Minimum Lease Payments (Details) Details 92 false false R93.htm 9954532 - Disclosure - LEASES - Lessor Narrative (Details) Sheet http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails LEASES - Lessor Narrative (Details) Details 93 false false R94.htm 9954533 - Disclosure - LEASES - Lessor Rental Income (Details) Sheet http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails LEASES - Lessor Rental Income (Details) Details 94 false false R95.htm 9954534 - Disclosure - LEASES - Lessor Future Minimum Lease Payments Receivable (Details) Sheet http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails LEASES - Lessor Future Minimum Lease Payments Receivable (Details) Details 95 false false R96.htm 9954535 - Disclosure - DEFINED CONTRIBUTION PLANS (Details) Sheet http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails DEFINED CONTRIBUTION PLANS (Details) Details http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANS 96 false false R97.htm 9954536 - Disclosure - SELF INSURANCE LIABILITIES (Details) Sheet http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESDetails SELF INSURANCE LIABILITIES (Details) Details http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESTables 97 false false R98.htm 9954537 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIES 98 false false R99.htm 9954538 - Disclosure - COMMON STOCK REPURCHASE PROGRAM (Details) Sheet http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails COMMON STOCK REPURCHASE PROGRAM (Details) Details http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAM 99 false false All Reports Book All Reports ensg-20231231.htm ensg-20231231.xsd ensg-20231231_cal.xml ensg-20231231_def.xml ensg-20231231_lab.xml ensg-20231231_pre.xml ensg-20231231_g1.jpg ensg-20231231_g2.jpg ensg-20231231_g3.jpg ensg-20231231_g4.jpg ensg-20231231_g5.jpg ensg-20231231_g6.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 127 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ensg-20231231.htm": { "nsprefix": "ensg", "nsuri": "http://www.ensigngroup.net/20231231", "dts": { "inline": { "local": [ "ensg-20231231.htm" ] }, "schema": { "local": [ "ensg-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "calculationLink": { "local": [ "ensg-20231231_cal.xml" ] }, "definitionLink": { "local": [ "ensg-20231231_def.xml" ] }, "labelLink": { "local": [ "ensg-20231231_lab.xml" ] }, "presentationLink": { "local": [ "ensg-20231231_pre.xml" ] } }, "keyStandard": 409, "keyCustom": 82, "axisStandard": 37, "axisCustom": 6, "memberStandard": 52, "memberCustom": 76, "hidden": { "total": 12, "http://xbrl.sec.gov/dei/2023": 4, "http://fasb.org/us-gaap/2023": 6, "http://xbrl.sec.gov/ecd/2023": 2 }, "contextCount": 447, "entityCount": 1, "segmentCount": 131, "elementCount": 880, "unitCount": 19, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 1361, "http://xbrl.sec.gov/dei/2023": 38, "http://xbrl.sec.gov/ecd/2023": 17 }, "report": { "R1": { "role": "http://www.ensigngroup.net/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.ensigngroup.net/role/AuditInformation", "longName": "0000002 - Document - Audit Information", "shortName": "Audit Information", "isDefault": "false", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "2", "firstAnchor": { "contextRef": "c-1", "name": "dei:AuditorName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:AuditorName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS", "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETSParenthetical", "longName": "0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "unique": true } }, "R5": { "role": "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME", "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF INCOME", "shortName": "CONSOLIDATED STATEMENTS OF INCOME", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "unique": true } }, "R6": { "role": "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical", "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)", "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "unique": true } }, "R9": { "role": "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESS", "longName": "0000009 - Disclosure - DESCRIPTION OF BUSINESS", "shortName": "DESCRIPTION OF BUSINESS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "longName": "0000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLE", "longName": "0000011 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE", "shortName": "REVENUE AND ACCOUNTS RECEIVABLE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARE", "longName": "0000012 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE", "shortName": "COMPUTATION OF NET INCOME PER COMMON SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTS", "longName": "0000013 - Disclosure - FAIR VALUE MEASUREMENTS", "shortName": "FAIR VALUE MEASUREMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.ensigngroup.net/role/STANDARDBEARER", "longName": "0000014 - Disclosure - STANDARD BEARER", "shortName": "STANDARD BEARER", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "ensg:StandardBearerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ensg:StandardBearerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.ensigngroup.net/role/OPERATIONEXPANSIONS", "longName": "0000015 - Disclosure - OPERATION EXPANSIONS", "shortName": "OPERATION EXPANSIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.ensigngroup.net/role/BUSINESSSEGMENTS", "longName": "0000016 - Disclosure - BUSINESS SEGMENTS", "shortName": "BUSINESS SEGMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNET", "longName": "0000017 - Disclosure - PROPERTY AND EQUIPMENT\u2014 NET", "shortName": "PROPERTY AND EQUIPMENT\u2014 NET", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.ensigngroup.net/role/INTANGIBLEASSETSNET", "longName": "0000018 - Disclosure - INTANGIBLE ASSETS \u2014 NET", "shortName": "INTANGIBLE ASSETS \u2014 NET", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.ensigngroup.net/role/GOODWILL", "longName": "0000019 - Disclosure - GOODWILL", "shortName": "GOODWILL", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETS", "longName": "0000020 - Disclosure - RESTRICTED AND OTHER ASSETS", "shortName": "RESTRICTED AND OTHER ASSETS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIES", "longName": "0000021 - Disclosure - OTHER ACCRUED LIABILITIES", "shortName": "OTHER ACCRUED LIABILITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.ensigngroup.net/role/INCOMETAXES", "longName": "0000022 - Disclosure - INCOME TAXES", "shortName": "INCOME TAXES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.ensigngroup.net/role/DEBT", "longName": "0000023 - Disclosure - DEBT", "shortName": "DEBT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDS", "longName": "0000024 - Disclosure - OPTIONS AND AWARDS", "shortName": "OPTIONS AND AWARDS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.ensigngroup.net/role/LEASES", "longName": "0000025 - Disclosure - LEASES", "shortName": "LEASES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANS", "longName": "0000026 - Disclosure - DEFINED CONTRIBUTION PLANS", "shortName": "DEFINED CONTRIBUTION PLANS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIES", "longName": "0000027 - Disclosure - SELF INSURANCE LIABILITIES", "shortName": "SELF INSURANCE LIABILITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIES", "longName": "0000028 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAM", "longName": "0000029 - Disclosure - COMMON STOCK REPURCHASE PROGRAM", "shortName": "COMMON STOCK REPURCHASE PROGRAM", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R30": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true }, "uniqueAnchor": null }, "R31": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "31", "firstAnchor": { "contextRef": "c-441", "name": "ecd:NonRule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:Rule10b51ArrTrmntdFlag", "ecd:NonRule10b51ArrTrmntdFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-441", "name": "ecd:NonRule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:Rule10b51ArrTrmntdFlag", "ecd:NonRule10b51ArrTrmntdFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "longName": "9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLETables", "longName": "9954472 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE (Tables)", "shortName": "REVENUE AND ACCOUNTS RECEIVABLE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARETables", "longName": "9954473 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE (Tables)", "shortName": "COMPUTATION OF NET INCOME PER COMMON SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSTables", "longName": "9954474 - Disclosure - OPERATION EXPANSIONS (Tables)", "shortName": "OPERATION EXPANSIONS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.ensigngroup.net/role/BUSINESSSEGMENTSTables", "longName": "9954475 - Disclosure - BUSINESS SEGMENTS (Tables)", "shortName": "BUSINESS SEGMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETTables", "longName": "9954476 - Disclosure - PROPERTY AND EQUIPMENT\u2014 NET (Tables)", "shortName": "PROPERTY AND EQUIPMENT\u2014 NET (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETTables", "longName": "9954477 - Disclosure - INTANGIBLE ASSETS \u2014 NET (Tables)", "shortName": "INTANGIBLE ASSETS \u2014 NET (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.ensigngroup.net/role/GOODWILLTables", "longName": "9954478 - Disclosure - GOODWILL (Tables)", "shortName": "GOODWILL (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSTables", "longName": "9954479 - Disclosure - RESTRICTED AND OTHER ASSETS (Tables)", "shortName": "RESTRICTED AND OTHER ASSETS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESTables", "longName": "9954480 - Disclosure - OTHER ACCRUED LIABILITIES (Tables)", "shortName": "OTHER ACCRUED LIABILITIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.ensigngroup.net/role/INCOMETAXESTables", "longName": "9954481 - Disclosure - INCOME TAXES (Tables)", "shortName": "INCOME TAXES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.ensigngroup.net/role/DEBTTables", "longName": "9954482 - Disclosure - DEBT (Tables)", "shortName": "DEBT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSTables", "longName": "9954483 - Disclosure - OPTIONS AND AWARDS (Tables)", "shortName": "OPTIONS AND AWARDS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.ensigngroup.net/role/LEASESTables", "longName": "9954484 - Disclosure - LEASES (Tables)", "shortName": "LEASES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESTables", "longName": "9954485 - Disclosure - SELF INSURANCE LIABILITIES (Tables)", "shortName": "SELF INSURANCE LIABILITIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "46", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfLiabilityForFuturePolicyBenefitsByProductSegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfLiabilityForFuturePolicyBenefitsByProductSegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "longName": "9954486 - Disclosure - DESCRIPTION OF BUSINESS (Details)", "shortName": "DESCRIPTION OF BUSINESS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-4", "name": "ensg:NumberOfHealthCareFacilities", "unitRef": "facility", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ensg:NumberOfHealthCareFacilities", "unitRef": "facility", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails", "longName": "9954487 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-54", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-54", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails", "longName": "9954488 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Leases and Leasehold Improvements (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Leases and Leasehold Improvements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-4", "name": "ensg:NumberOfFinancingLeases", "unitRef": "lease", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:LesseeLeasesPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ensg:NumberOfFinancingLeases", "unitRef": "lease", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:LesseeLeasesPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails", "longName": "9954489 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets and Goodwill (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets and Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails", "longName": "9954490 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Self-Insurance (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Self-Insurance (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-74", "name": "us-gaap:SelfInsuranceReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-74", "name": "us-gaap:SelfInsuranceReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails", "longName": "9954491 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE -Narrative (Details)", "shortName": "REVENUE AND ACCOUNTS RECEIVABLE -Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ensg:FamilyFirstCoronavirusResponseActPaymentsReceived", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "unique": true } }, "R53": { "role": "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "longName": "9954492 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE - Disaggregation of Revenue (Details)", "shortName": "REVENUE AND ACCOUNTS RECEIVABLE - Disaggregation of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true }, "uniqueAnchor": null }, "R54": { "role": "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails", "longName": "9954493 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE - Accounts Receivable (Details)", "shortName": "REVENUE AND ACCOUNTS RECEIVABLE - Accounts Receivable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:AccountsReceivableGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:AccountsReceivableGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails", "longName": "9954494 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE (Details)", "shortName": "COMPUTATION OF NET INCOME PER COMMON SHARE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails", "longName": "9954495 - Disclosure - FAIR VALUE MEASUREMENTS (Details)", "shortName": "FAIR VALUE MEASUREMENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-132", "name": "us-gaap:DeferredCompensationPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-132", "name": "us-gaap:DeferredCompensationPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.ensigngroup.net/role/STANDARDBEARERDetails", "longName": "9954496 - Disclosure - STANDARD BEARER (Details)", "shortName": "STANDARD BEARER (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:NumberOfRealEstateProperties", "unitRef": "property", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-159", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "unique": true } }, "R58": { "role": "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails", "longName": "9954497 - Disclosure - OPERATION EXPANSIONS- Narrative (Details)", "shortName": "OPERATION EXPANSIONS- Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-4", "name": "ensg:OperationalSeniorLivingUnits", "unitRef": "senior_living_unit", "xsiNil": "false", "lang": "en-US", "decimals": "-2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-177", "name": "ensg:NumberOfAssetAcquisitions", "unitRef": "business", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "unique": true } }, "R59": { "role": "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails", "longName": "9954498 - Disclosure - OPERATION EXPANSIONS - Purchase Price Allocation (Details)", "shortName": "OPERATION EXPANSIONS - Purchase Price Allocation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-193", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "unique": true } }, "R60": { "role": "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails", "longName": "9954499 - Disclosure - BUSINESS SEGMENTS - Narrative (Details)", "shortName": "BUSINESS SEGMENTS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails", "longName": "9954500 - Disclosure - BUSINESS SEGMENTS - Schedule of Segment Financial Information (Details)", "shortName": "BUSINESS SEGMENTS - Schedule of Segment Financial Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ensg:SegmentIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "unique": true } }, "R62": { "role": "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "longName": "9954501 - Disclosure - BUSINESS SEGMENTS - Schedule of Service Revenue by Major Payor Source (Details)", "shortName": "BUSINESS SEGMENTS - Schedule of Service Revenue by Major Payor Source (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-244", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "unique": true } }, "R63": { "role": "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails", "longName": "9954502 - Disclosure - PROPERTY AND EQUIPMENT\u2014 NET - Schedule of Property and Equipment (Details)", "shortName": "PROPERTY AND EQUIPMENT\u2014 NET - Schedule of Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails", "longName": "9954503 - Disclosure - PROPERTY AND EQUIPMENT\u2014 NET - Narrative (Details)", "shortName": "PROPERTY AND EQUIPMENT\u2014 NET - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-283", "name": "us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-283", "name": "us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails", "longName": "9954504 - Disclosure - INTANGIBLE ASSETS \u2014 NET - Schedule of Finite Lived Intangible Assets (Details)", "shortName": "INTANGIBLE ASSETS \u2014 NET - Schedule of Finite Lived Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails", "longName": "9954505 - Disclosure - INTANGIBLE ASSETS \u2014 NET - Narrative (Details)", "shortName": "INTANGIBLE ASSETS \u2014 NET - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails", "longName": "9954506 - Disclosure - INTANGIBLE ASSETS \u2014 NET - Future Amortization (Details)", "shortName": "INTANGIBLE ASSETS \u2014 NET - Future Amortization (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofIndefinitelivedIntangibleAssetsDetails", "longName": "9954507 - Disclosure - INTANGIBLE ASSETS \u2014 NET - Schedule of Indefinite-lived Intangible Assets (Details)", "shortName": "INTANGIBLE ASSETS \u2014 NET - Schedule of Indefinite-lived Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.ensigngroup.net/role/GOODWILLDetails", "longName": "9954508 - Disclosure - GOODWILL (Details)", "shortName": "GOODWILL (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-30", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "unique": true } }, "R70": { "role": "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails", "longName": "9954509 - Disclosure - RESTRICTED AND OTHER ASSETS (Details)", "shortName": "RESTRICTED AND OTHER ASSETS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails", "longName": "9954510 - Disclosure - OTHER ACCRUED LIABILITIES (Details)", "shortName": "OTHER ACCRUED LIABILITIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-4", "name": "ensg:QualityAssuranceFee", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ensg:QualityAssuranceFee", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails", "longName": "9954511 - Disclosure - INCOME TAXES - Expense (Details)", "shortName": "INCOME TAXES - Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R73": { "role": "http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails", "longName": "9954512 - Disclosure - INCOME TAXES - Tax Rate (Details)", "shortName": "INCOME TAXES - Tax Rate (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.ensigngroup.net/role/INCOMETAXESNarrativeYEDetails", "longName": "9954513 - Disclosure - INCOME TAXES - Narrative (YE) (Details)", "shortName": "INCOME TAXES - Narrative (YE) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true }, "uniqueAnchor": null }, "R75": { "role": "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails", "longName": "9954514 - Disclosure - INCOME TAXES - Deferred Tax Assets and Liabilities (Details)", "shortName": "INCOME TAXES - Deferred Tax Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails", "longName": "9954515 - Disclosure - DEBT - Schedule of Long-term Debt (Details)", "shortName": "DEBT - Schedule of Long-term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:LongTermDebtCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:DeferredFinanceCostsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "unique": true } }, "R77": { "role": "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "longName": "9954516 - Disclosure - DEBT - Credit Facility with a Lending Consortium Arranged by Truist (Details)", "shortName": "DEBT - Credit Facility with a Lending Consortium Arranged by Truist (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:WriteOffOfDeferredDebtIssuanceCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-313", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "unique": true } }, "R78": { "role": "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "longName": "9954517 - Disclosure - DEBT - Mortgage Loans and Promissory Notes and Off-Balance Sheet Arrangements (Details)", "shortName": "DEBT - Mortgage Loans and Promissory Notes and Off-Balance Sheet Arrangements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:LettersOfCreditOutstandingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:LettersOfCreditOutstandingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R79": { "role": "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails", "longName": "9954518 - Disclosure - DEBT - Long-term Debt Arrangements (Details)", "shortName": "DEBT - Long-term Debt Arrangements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R80": { "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails", "longName": "9954519 - Disclosure - OPTIONS AND AWARDS - Stock Options, Narrative (Details)", "shortName": "OPTIONS AND AWARDS - Stock Options, Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c-4", "name": "ensg:NumberOfOptionPlans", "unitRef": "plan", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ensg:NumberOfOptionPlans", "unitRef": "plan", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R81": { "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSValuationAssumptionsDetails", "longName": "9954520 - Disclosure - OPTIONS AND AWARDS - Valuation Assumptions (Details)", "shortName": "OPTIONS AND AWARDS - Valuation Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "unique": true } }, "R82": { "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSExercisePriceandFairValueDetails", "longName": "9954521 - Disclosure - OPTIONS AND AWARDS - Exercise Price and Fair Value (Details)", "shortName": "OPTIONS AND AWARDS - Exercise Price and Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "unique": true } }, "R83": { "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails", "longName": "9954522 - Disclosure - OPTIONS AND AWARDS - Options Outstanding Rollforward (Details)", "shortName": "OPTIONS AND AWARDS - Options Outstanding Rollforward (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-19", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "unique": true } }, "R84": { "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails", "longName": "9954523 - Disclosure - OPTIONS AND AWARDS - Options Outstanding by Exercise Price (Details)", "shortName": "OPTIONS AND AWARDS - Options Outstanding by Exercise Price (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R85": { "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSIntrinsicValuesDetails", "longName": "9954524 - Disclosure - OPTIONS AND AWARDS - Intrinsic Values (Details)", "shortName": "OPTIONS AND AWARDS - Intrinsic Values (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R86": { "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "longName": "9954525 - Disclosure - OPTIONS AND AWARDS - Restricted Stock Awards, Narrative (Details)", "shortName": "OPTIONS AND AWARDS - Restricted Stock Awards, Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "c-1", "name": "ensg:SharebasedCompensationRestrictedAwardsExercisePrice", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ensg:SharebasedCompensationRestrictedAwardsExercisePrice", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R87": { "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails", "longName": "9954526 - Disclosure - OPTIONS AND AWARDS - Restricted Award Rollforward (Details)", "shortName": "OPTIONS AND AWARDS - Restricted Award Rollforward (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "c-366", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-364", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "unique": true } }, "R88": { "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails", "longName": "9954527 - Disclosure - OPTIONS AND AWARDS - Long-Term Incentive Plan (Details)", "shortName": "OPTIONS AND AWARDS - Long-Term Incentive Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-371", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "unique": true } }, "R89": { "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails", "longName": "9954528 - Disclosure - OPTIONS AND AWARDS - Compensation Expense (Details)", "shortName": "OPTIONS AND AWARDS - Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "unique": true } }, "R90": { "role": "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "longName": "9954529 - Disclosure - LEASES - Lessee Narrative (Details)", "shortName": "LEASES - Lessee Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:LesseeLeasesPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "unique": true } }, "R91": { "role": "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails", "longName": "9954530 - Disclosure - LEASES - Lessee Lease Cost (Details)", "shortName": "LEASES - Lessee Lease Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R92": { "role": "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails", "longName": "9954531 - Disclosure - LEASES - Lessee Future Minimum Lease Payments (Details)", "shortName": "LEASES - Lessee Future Minimum Lease Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R93": { "role": "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "longName": "9954532 - Disclosure - LEASES - Lessor Narrative (Details)", "shortName": "LEASES - Lessor Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef": "c-413", "name": "us-gaap:LessorOperatingLeaseTermOfContract", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true }, "uniqueAnchor": null }, "R94": { "role": "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails", "longName": "9954533 - Disclosure - LEASES - Lessor Rental Income (Details)", "shortName": "LEASES - Lessor Rental Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "c-202", "name": "us-gaap:SubleaseIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-422", "name": "us-gaap:OperatingLeaseLeaseIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "unique": true } }, "R95": { "role": "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails", "longName": "9954534 - Disclosure - LEASES - Lessor Future Minimum Lease Payments Receivable (Details)", "shortName": "LEASES - Lessor Future Minimum Lease Payments Receivable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R96": { "role": "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails", "longName": "9954535 - Disclosure - DEFINED CONTRIBUTION PLANS (Details)", "shortName": "DEFINED CONTRIBUTION PLANS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "96", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R97": { "role": "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESDetails", "longName": "9954536 - Disclosure - SELF INSURANCE LIABILITIES (Details)", "shortName": "SELF INSURANCE LIABILITIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "97", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:LiabilityForFuturePolicyBenefits", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfLiabilityForFuturePolicyBenefitsByProductSegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-30", "name": "us-gaap:LiabilityForFuturePolicyBenefits", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfLiabilityForFuturePolicyBenefitsByProductSegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "unique": true } }, "R98": { "role": "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails", "longName": "9954537 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "98", "firstAnchor": { "contextRef": "c-4", "name": "ensg:IndependentOperatingSubsidiariesUnderMedicareProbeReviews", "unitRef": "subsidiary", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "ensg:IndependentOperatingSubsidiariesUnderMedicareProbeReviews", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ensg:IndependentOperatingSubsidiariesUnderMedicareProbeReviews", "unitRef": "subsidiary", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "ensg:IndependentOperatingSubsidiariesUnderMedicareProbeReviews", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true, "unique": true } }, "R99": { "role": "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails", "longName": "9954538 - Disclosure - COMMON STOCK REPURCHASE PROGRAM (Details)", "shortName": "COMMON STOCK REPURCHASE PROGRAM (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "99", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:TreasuryStockSharesAcquired", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-437", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ensg-20231231.htm", "unique": true } } }, "tag": { "ensg_A2019LTIPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "A2019LTIPlanMember", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2019 LTI Plan", "label": "2019 LTI Plan [Member]", "documentation": "2019 LTI Plan [Member]" } } }, "auth_ref": [] }, "ensg_A2022PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "A2022PlanMember", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2022 Plan", "label": "2022 Plan [Member]", "documentation": "2022 Plan" } } }, "auth_ref": [] }, "ensg_A53PromissoryNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "A53PromissoryNoteMember", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5.3% Promissory Note", "label": "5.3% Promissory Note [Member]", "documentation": "5.3% Promissory Note" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsNotesAndLoansReceivableLineItems", "presentation": [ "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIES" ], "lang": { "en-us": { "role": { "terseLabel": "OTHER ACCRUED LIABILITIES", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r24" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r23", "r785" ] }, "us-gaap_AccountsReceivableGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableGross", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails": { "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, gross", "label": "Accounts Receivable, before Allowance for Credit Loss", "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business." } } }, "auth_ref": [ "r224", "r316", "r1062" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableMember", "presentation": [ "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable", "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r730" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 }, "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable\u2014less allowance for doubtful accounts of $9,348 and $7,802 at December\u00a031, 2023 and 2022, respectively", "totalLabel": "ACCOUNTS RECEIVABLE, NET", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r316", "r317" ] }, "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property taxes", "label": "Accrual for Taxes Other than Income Taxes", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes." } } }, "auth_ref": [ "r93", "r116", "r1059" ] }, "ensg_AccruedLiabilitiesStateReliefContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "AccruedLiabilitiesStateReliefContractLiabilities", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unapplied state relief funds", "label": "Accrued Liabilities, State Relief Contract Liabilities", "documentation": "Accrued Liabilities, State Relief Contract Liabilities" } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r74", "r218", "r604" ] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Life (Years)", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r150" ] }, "ensg_AcquiredOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "AcquiredOperationsMember", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired Operations", "label": "Acquired Operations [Member]", "documentation": "Acquired Operations" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r842" ] }, "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid during the period for:", "label": "Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r128" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r491", "r492", "r493", "r654", "r905", "r906", "r907", "r1038", "r1071" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r848" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r848" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r848" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r848" ] }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Shares of common stock used to satisfy tax withholding obligations", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Employee stock award compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r91", "r92", "r453" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ensg_AfterYearTenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "AfterYearTenMember", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "After Year Ten", "label": "After Year Ten [Member]", "documentation": "After Year Ten" } } }, "auth_ref": [] }, "ensg_AggregateDeductibleMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "AggregateDeductibleMember", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Deductible", "label": "Aggregate Deductible [Member]", "documentation": "Aggregate Deductible [Member]" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r812", "r824", "r834", "r860" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r815", "r827", "r837", "r863" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r848" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r855" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r819", "r828", "r838", "r855", "r864", "r868", "r876" ] }, "us-gaap_AllOtherSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllOtherSegmentsMember", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails", "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "All Other", "label": "Other Segments [Member]", "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items." } } }, "auth_ref": [ "r283", "r299", "r300", "r301", "r302", "r303" ] }, "ensg_AllStatesExceptColoradoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "AllStatesExceptColoradoMember", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "All States Except Colorado", "label": "All States Except Colorado [Member]", "documentation": "All States Except Colorado [Domain]" } } }, "auth_ref": [] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r874" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "verboseLabel": "Stock-based compensation expense related to stock options", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r486", "r498" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails": { "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for doubtful accounts", "negatedTerseLabel": "Less: allowance for doubtful accounts", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r225", "r320", "r325" ] }, "ensg_AmendedMasterLeaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "AmendedMasterLeaseAgreementMember", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amended Master Lease Agreement", "label": "Amended Master Lease Agreement [Member]", "documentation": "Amended Master Lease Agreement" } } }, "auth_ref": [] }, "ensg_AmendedMasterLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "AmendedMasterLeaseMember", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amended Master Lease", "label": "Amended Master Lease [Member]", "documentation": "Amended Master Lease" } } }, "auth_ref": [] }, "ensg_AmendedSeparateMasterLeases": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "AmendedSeparateMasterLeases", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amended of separate master leases", "label": "Amended Separate Master Leases", "documentation": "Amended Separate Master Leases" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of deferred financing fees", "label": "Amortization of Debt Issuance Costs and Discounts", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r398", "r557", "r761", "r762", "r900" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r7", "r68", "r73" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r276" ] }, "ensg_AssembledOccupancyAcquiredMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "AssembledOccupancyAcquiredMember", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assembled occupancy", "verboseLabel": "Assembled occupancy", "label": "Assembled Occupancy Acquired [Member]", "documentation": "Assembled occupancy acquired [Member]" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionAxis", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Axis]", "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": [ "r1034" ] }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionConsiderationTransferred", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset acquisition, purchase price", "label": "Asset Acquisition, Consideration Transferred", "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer." } } }, "auth_ref": [ "r780", "r1035", "r1036", "r1037" ] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionDomain", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Domain]", "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": [ "r1034" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r181", "r221", "r247", "r286", "r301", "r307", "r322", "r363", "r364", "r366", "r367", "r368", "r370", "r372", "r374", "r375", "r530", "r534", "r548", "r597", "r681", "r785", "r801", "r932", "r933", "r1049" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r214", "r227", "r247", "r322", "r363", "r364", "r366", "r367", "r368", "r370", "r372", "r374", "r375", "r530", "r534", "r548", "r785", "r932", "r933", "r1049" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "ensg_AuditInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "AuditInformationAbstract", "lang": { "en-us": { "role": { "label": "Audit Information [Abstract]", "documentation": "Audit Information" } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://www.ensigngroup.net/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Firm ID", "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r806", "r807", "r820" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://www.ensigngroup.net/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Location", "label": "Auditor Location" } } }, "auth_ref": [ "r806", "r807", "r820" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://www.ensigngroup.net/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Name", "label": "Auditor Name" } } }, "auth_ref": [ "r806", "r807", "r820" ] }, "ensg_August2023RepurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "August2023RepurchaseProgramMember", "presentation": [ "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails" ], "lang": { "en-us": { "role": { "terseLabel": "August 2023 Repurchase Program", "label": "August 2023 Repurchase Program [Member]", "documentation": "August 2023 Repurchase Program" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r871" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r872" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r867" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r867" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r867" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r867" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r867" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r867" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r457", "r458", "r459", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r481", "r482", "r483", "r484", "r485" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r870" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r869" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r868" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r868" ] }, "us-gaap_BaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BaseRateMember", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Base Rate", "label": "Base Rate [Member]", "documentation": "Minimum rate investor will accept." } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" ], "lang": { "en-us": { "role": { "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r148" ] }, "ensg_BeverlyBWittekindMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "BeverlyBWittekindMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Beverly B. Wittekind [Member]", "documentation": "Beverly B. Wittekind" } } }, "auth_ref": [] }, "ensg_BlanketAggregateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "BlanketAggregateMember", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Blanket Aggregate", "label": "Blanket Aggregate [Member]", "documentation": "Blanket Aggregate [Member]" } } }, "auth_ref": [] }, "us-gaap_BuildingAndBuildingImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BuildingAndBuildingImprovementsMember", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails", "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Building and improvements", "terseLabel": "Buildings and improvements", "label": "Building and Building Improvements [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r526", "r774", "r775" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r96", "r97", "r526", "r774", "r775" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r526" ] }, "ensg_BusinessAndAssetAcquisitionsAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "BusinessAndAssetAcquisitionsAxis", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business And Asset Acquisitions [Axis]", "label": "Business And Asset Acquisitions [Axis]", "documentation": "Business And Asset Acquisitions" } } }, "auth_ref": [] }, "ensg_BusinessAndAssetAcquisitionsDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "BusinessAndAssetAcquisitionsDomain", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business And Asset Acquisitions [Domain]", "label": "Business And Asset Acquisitions [Domain]", "documentation": "Business And Asset Acquisitions" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "auth_ref": [] }, "ensg_BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL ACQUISITIONS", "label": "Business Combination And Asset Acquisition, Assets Acquired And Liabilities Assumed, Net", "documentation": "Business Combination And Asset Acquisition, Assets Acquired And Liabilities Assumed, Net" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONS" ], "lang": { "en-us": { "role": { "terseLabel": "OPERATION EXPANSIONS", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r174", "r527" ] }, "stpr_CA": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2023", "localname": "CA", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "California", "label": "CALIFORNIA" } } }, "auth_ref": [] }, "stpr_CO": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2023", "localname": "CO", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Colorado", "label": "COLORADO" } } }, "auth_ref": [] }, "ensg_CampusOperationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "CampusOperationMember", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Campus Operation", "label": "Campus Operation [Member]", "documentation": "Campus Operation" } } }, "auth_ref": [] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued capital expenditures", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r47", "r48", "r49" ] }, "ensg_CareTrustREITMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "CareTrustREITMember", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CareTrust REIT", "label": "CareTrust REIT [Member]", "documentation": "CareTrust REIT [Member]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r44", "r216", "r749" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r45" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents beginning of period", "periodEndLabel": "Cash and cash equivalents end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r44", "r145", "r244" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r2", "r145" ] }, "us-gaap_CashDivestedFromDeconsolidation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashDivestedFromDeconsolidation", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Deconsolidation of an ancillary business", "label": "Cash Divested from Deconsolidation", "documentation": "Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash." } } }, "auth_ref": [ "r144" ] }, "ensg_CashHeldInTrustForResidents": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "CashHeldInTrustForResidents", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash held in trust for patients", "label": "Cash Held in Trust for Residents", "documentation": "Cash held in trust for residents reflects monies received from, or on behalf of, residents. Maintaining a trust account for residents is a regulatory requirement and, while the trust assets offset the liability, the Company assumes a fiduciary responsibility for these funds." } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r846" ] }, "ensg_ChristopherRChristensenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "ChristopherRChristensenMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Christopher R. Christensen [Member]", "documentation": "Christopher R. Christensen" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfTreasuryStockTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfTreasuryStockTable", "presentation": [ "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Treasury Stock [Table]", "label": "Class of Treasury Stock [Table]", "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock." } } }, "auth_ref": [ "r79", "r80", "r81", "r82" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r847" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r847" ] }, "us-gaap_CollateralizedDebtObligationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollateralizedDebtObligationsMember", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mortgage loans and promissory note", "label": "Collateralized Debt Obligations [Member]", "documentation": "Securities collateralized by a pool of assets." } } }, "auth_ref": [ "r911", "r912", "r963" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Notes 15 and 20)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r32", "r117", "r598", "r668" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIES" ], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r157", "r357", "r358", "r731", "r927" ] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockDividendsPerShareDeclared", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends declared (in dollars per share)", "label": "Common Stock, Dividends, Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r162" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r790", "r791", "r792", "r794", "r795", "r796", "r797", "r905", "r906", "r1038", "r1068", "r1071" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r127" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r127", "r669" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares issued", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r127" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares outstanding", "periodStartLabel": "Balance at beginning of period (in shares)", "periodEndLabel": "Balance at end of period (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r14", "r127", "r669", "r687", "r1071", "r1072" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock: $0.001 par value; 150,000, 59,987 and 56,597 shares authorized, shares issued and shares outstanding at December\u00a031, 2023, respectively, and 100,000, 59,029 and 55,661 shares authorized, shares issued and shares outstanding at December 31, 2022, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r127", "r599", "r785" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r852" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r851" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r853" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r850" ] }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "presentation": [ "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANS" ], "lang": { "en-us": { "role": { "terseLabel": "DEFINED CONTRIBUTION PLANS", "label": "Compensation and Employee Benefit Plans [Text Block]", "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans." } } }, "auth_ref": [ "r163", "r164", "r165", "r166" ] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Retirement Benefits [Abstract]", "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r54", "r56", "r108", "r109", "r315", "r730" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r54", "r56", "r108", "r109", "r315", "r640", "r730" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r54", "r56", "r108", "r109", "r315", "r730", "r888" ] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskLineItems", "presentation": [ "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Line Items]", "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r730" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "% of Revenue", "terseLabel": "Revenue %", "netLabel": "Concentration percentage", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r54", "r56", "r108", "r109", "r315" ] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTable", "presentation": [ "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Table]", "label": "Concentration Risk [Table]", "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r53", "r54", "r56", "r57", "r108", "r180", "r730" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r54", "r56", "r108", "r109", "r315", "r730" ] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesAxis", "presentation": [ "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities [Axis]", "label": "Consolidated Entities [Axis]" } } }, "auth_ref": [ "r251", "r530", "r531", "r534", "r535", "r583", "r742", "r931", "r934", "r935" ] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesDomain", "presentation": [ "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities [Domain]", "label": "Consolidated Entities [Domain]" } } }, "auth_ref": [ "r251", "r530", "r531", "r534", "r535", "r583", "r742", "r931", "r934", "r935" ] }, "srt_ConsolidationEliminationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationEliminationsMember", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intercompany Elimination", "label": "Consolidation, Eliminations [Member]" } } }, "auth_ref": [] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsAxis", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails", "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/GOODWILLDetails", "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]" } } }, "auth_ref": [ "r251", "r288", "r299", "r300", "r301", "r302", "r303", "r305", "r309", "r363", "r364", "r365", "r366", "r368", "r369", "r371", "r373", "r374", "r932", "r933" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsDomain", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails", "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/GOODWILLDetails", "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Domain]", "label": "Consolidation Items [Domain]" } } }, "auth_ref": [ "r251", "r288", "r299", "r300", "r301", "r302", "r303", "r305", "r309", "r363", "r364", "r365", "r366", "r368", "r369", "r371", "r373", "r374", "r932", "r933" ] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionInProgressMember", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Construction in progress", "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Resident advances", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r420", "r421", "r440" ] }, "ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsReceivedAndReturned": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "CoronavirusAidReliefAndEconomicSecurityCARESFundsReceivedAndReturned", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Coronavirus Aid, Relief, and Economic Security (\u201cCARES\u201d) funds received and returned", "label": "Coronavirus Aid, Relief, and Economic Security (\u201cCARES\u201d) Funds Received And Returned", "documentation": "Coronavirus Aid, Relief, and Economic Security (\u201cCARES\u201d) Funds Received And Returned" } } }, "auth_ref": [] }, "ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsRepaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "CoronavirusAidReliefAndEconomicSecurityCARESFundsRepaid", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayments of CARES Act Provider Relief Fund and Medicare Advance Payment Program (Note 3)", "label": "Coronavirus Aid, Relief, and Economic Security (\u201cCARES\u201d) Funds Repaid", "documentation": "Coronavirus Aid, Relief, and Economic Security (\u201cCARES\u201d) Funds, Repayment" } } }, "auth_ref": [] }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateNonSegmentMember", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/GOODWILLDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "All Other", "label": "Corporate, Non-Segment [Member]", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": [ "r19", "r300", "r301", "r302", "r303", "r309", "r910" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of services", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r137", "r590" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesMember", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of Services", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "ensg_CostofSalesandGeneralandAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "CostofSalesandGeneralandAdministrativeExpenseMember", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of Sales and General and Administrative Expense", "label": "Cost of Sales and General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing cost of services and general and administrative expense" } } }, "auth_ref": [] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL EXPENSES", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r136" ] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpensesAbstract", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Expense:", "label": "Costs and Expenses [Abstract]" } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r249", "r250", "r380", "r408", "r582", "r750", "r752" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover page.", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract", "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current:", "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal", "label": "Current Federal Tax Expense (Benefit)", "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r891", "r903", "r1032" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "verboseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total current income tax expense (benefit)", "label": "Current Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations." } } }, "auth_ref": [ "r173", "r515", "r521", "r903" ] }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentStateAndLocalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State", "label": "Current State and Local Tax Expense (Benefit)", "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r891", "r903", "r1032" ] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r55", "r315" ] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerRelationshipsMember", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer relationships", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": [ "r99" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.ensigngroup.net/role/DEBT" ], "lang": { "en-us": { "role": { "terseLabel": "DEBT", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r158", "r245", "r376", "r382", "r383", "r384", "r385", "r386", "r387", "r392", "r399", "r400", "r402" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r22", "r121", "r122", "r182", "r185", "r251", "r377", "r378", "r379", "r380", "r381", "r383", "r388", "r389", "r390", "r391", "r393", "r394", "r395", "r396", "r397", "r398", "r558", "r758", "r759", "r760", "r761", "r762", "r901" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate margin", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails": { "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mortgage loans and promissory note", "verboseLabel": "Outstanding debt", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r22", "r185", "r403" ] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, interest rate, effective percentage", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r29", "r111", "r405", "r558" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, interest rate, stated percentage", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r29", "r378" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r251", "r377", "r378", "r379", "r380", "r381", "r383", "r388", "r389", "r390", "r391", "r393", "r394", "r395", "r396", "r397", "r398", "r401", "r558", "r758", "r759", "r760", "r761", "r762", "r901" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r30", "r251", "r377", "r378", "r379", "r380", "r381", "r383", "r388", "r389", "r390", "r391", "r393", "r394", "r395", "r396", "r397", "r398", "r558", "r758", "r759", "r760", "r761", "r762", "r901" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r30", "r76", "r77", "r110", "r111", "r113", "r118", "r160", "r161", "r251", "r377", "r378", "r379", "r380", "r381", "r383", "r388", "r389", "r390", "r391", "r393", "r394", "r395", "r396", "r397", "r398", "r401", "r558", "r758", "r759", "r760", "r761", "r762", "r901" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTerm", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, term", "label": "Debt Instrument, Term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtIssuanceCostsLineOfCreditArrangementsNet", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails": { "parentTag": "ensg_RestrictedAndOtherAssetsNoncurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt issuance costs, net", "label": "Debt Issuance Costs, Line of Credit Arrangements, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r21" ] }, "us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCompensationLiabilityClassifiedNoncurrent", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred compensation liability, noncurrent", "label": "Deferred Compensation Liability, Classified, Noncurrent", "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer)." } } }, "auth_ref": [] }, "us-gaap_DeferredCompensationPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCompensationPlanAssets", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred rent receivable", "label": "Deferred Compensation Plan Assets", "documentation": "Carrying amount as of the balance sheet date of assets held under deferred compensation agreements." } } }, "auth_ref": [ "r893" ] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails": { "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal", "label": "Deferred Federal Income Tax Expense (Benefit)", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r903", "r1031", "r1032" ] }, "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFederalStateAndLocalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total deferred income tax expense (benefit)", "label": "Deferred Federal, State and Local, Tax Expense (Benefit)", "documentation": "Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1027" ] }, "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract", "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred:", "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails": { "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: debt issuance costs, net", "label": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r112", "r937" ] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets", "label": "Deferred Income Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [ "r502", "r503" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r7", "r173", "r206", "r520", "r521", "r903" ] }, "us-gaap_DeferredIncomeTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilities", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "TOTAL DEFERRED TAX LIABILITIES", "label": "Deferred Tax Liabilities, Gross", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences." } } }, "auth_ref": [ "r124", "r125", "r183", "r509" ] }, "ensg_DeferredRentAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "DeferredRentAdjustment", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of deferred rent", "label": "Deferred Rent Adjustment", "documentation": "Adjustment to deferred rent arising from the difference between rent expense recognized and rental payments made in the current period." } } }, "auth_ref": [] }, "ensg_DeferredRentAndOtherLongTermLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "DeferredRentAndOtherLongTermLiabilities", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Other long-term liabilities", "label": "Deferred rent and other long-term liabilities", "documentation": "Rental expense in excess of actual rental payments and other long-term liabilities" } } }, "auth_ref": [] }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails": { "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State", "label": "Deferred State and Local Income Tax Expense (Benefit)", "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r903", "r1031", "r1032" ] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total deferred tax assets", "label": "Deferred Tax Assets, Gross", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r510" ] }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsLiabilitiesNet", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "NET DEFERRED TAX ASSETS", "label": "Deferred Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } }, "auth_ref": [ "r1029" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL DEFERRED TAX ASSETS", "label": "Deferred Tax Assets, Net of Valuation Allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r1029" ] }, "us-gaap_DeferredTaxAssetsStateTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsStateTaxes", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State taxes", "label": "Deferred Tax Assets, State Taxes", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from state taxes." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails", "http://www.ensigngroup.net/role/INCOMETAXESNarrativeYEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax credits", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards." } } }, "auth_ref": [ "r94", "r95", "r1030" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities." } } }, "auth_ref": [ "r95", "r1030" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue related reserves", "label": "Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r95", "r1030" ] }, "ensg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLeaseLiability", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liability", "label": "Deferred Tax Assets, Tax, Deferred Expense, Reserves And Accruals, Lease Liability", "documentation": "Deferred Tax Assets, Tax, Deferred Expense, Reserves And Accruals, Lease Liability" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Insurance", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Self Insurance", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated losses under self insurance." } } }, "auth_ref": [ "r95", "r1030" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails", "http://www.ensigngroup.net/role/INCOMETAXESNarrativeYEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation allowance", "negatedLabel": "Valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r511" ] }, "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesPrepaidExpenses", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses", "label": "Deferred Tax Liabilities, Prepaid Expenses", "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Depreciation and amortization", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment." } } }, "auth_ref": [ "r95", "r1030" ] }, "ensg_DeferredTaxLiabilitiesRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "DeferredTaxLiabilitiesRightOfUseAsset", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Right of use asset", "label": "Deferred Tax Liabilities, Right Of Use Asset", "documentation": "Deferred Tax Liabilities, Right Of Use Asset" } } }, "auth_ref": [] }, "ensg_DeferredTaxLiabilitiesStateTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "DeferredTaxLiabilitiesStateTaxes", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "State taxes", "label": "Deferred Tax Liabilities, State Taxes", "documentation": "Deferred Tax Liabilities, State Taxes" } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanCostRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanCostRecognized", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined contribution plan, cost", "label": "Defined Contribution Plan, Cost", "documentation": "Amount of cost for defined contribution plan." } } }, "auth_ref": [ "r449" ] }, "us-gaap_DefinedContributionPlanDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanDisclosureLineItems", "presentation": [ "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Contribution Plan Disclosure [Line Items]", "label": "Defined Contribution Plan Disclosure [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r449" ] }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "presentation": [ "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum annual contributions per employee", "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent", "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanTable", "presentation": [ "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Contribution Plan [Table]", "label": "Defined Contribution Plan [Table]", "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans." } } }, "auth_ref": [ "r449" ] }, "ensg_DepreciationAndAmortizationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "DepreciationAndAmortizationMember", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and Amortization", "verboseLabel": "Depreciation and amortization", "label": "Depreciation And Amortization [Member]", "documentation": "Depreciation And Amortization [Member]" } } }, "auth_ref": [] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 }, "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "verboseLabel": "Depreciation and amortization", "netLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r7", "r291" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r439", "r764", "r765", "r766", "r767", "r768", "r769", "r770" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r439", "r764", "r765", "r766", "r767", "r768", "r769", "r770" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Disaggregation of Revenue", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r939" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDS" ], "lang": { "en-us": { "role": { "terseLabel": "OPTIONS AND AWARDS", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r451", "r456", "r487", "r488", "r490", "r777" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationAxis", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Axis]", "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r212" ] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationDomain", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Domain]", "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations", "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]", "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations." } } }, "auth_ref": [ "r8", "r16" ] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Domain]", "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": [ "r774", "r775" ] }, "us-gaap_Dividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Dividends", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Dividends declared", "label": "Dividends", "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock." } } }, "auth_ref": [ "r4", "r162" ] }, "us-gaap_DividendsPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsPayableCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued dividends declared", "terseLabel": "Dividends payable", "label": "Dividends Payable", "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding." } } }, "auth_ref": [ "r122", "r123", "r184", "r798", "r1059" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Annual Report", "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r806", "r807", "r820" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Financial Statement Restatement Recovery Analysis [Flag]", "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r806", "r807", "r820", "r856" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r841" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Documents Incorporated by Reference", "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r804" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "NET INCOME PER SHARE ATTRIBUTABLE TO THE ENSIGN GROUP INC.", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in dollars per share)", "verboseLabel": "Basic net income per common share (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r235", "r257", "r258", "r259", "r260", "r261", "r266", "r268", "r273", "r274", "r275", "r279", "r544", "r545", "r594", "r610", "r753" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in dollars per share)", "verboseLabel": "Diluted net income per common share (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r235", "r257", "r258", "r259", "r260", "r261", "r268", "r273", "r274", "r275", "r279", "r544", "r545", "r594", "r610", "r753" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARE" ], "lang": { "en-us": { "role": { "terseLabel": "COMPUTATION OF NET INCOME PER COMMON SHARE", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r265", "r276", "r277", "r278" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESNarrativeYEDetails", "http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL INCOME TAX PROVISION", "terseLabel": "Effective income tax rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r505" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax expense at statutory rate", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r248", "r505", "r522" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense", "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-deductible expenses", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses." } } }, "auth_ref": [ "r1028", "r1033" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other adjustments", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r1028", "r1033" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent", "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity compensation", "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent", "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement." } } }, "auth_ref": [ "r884", "r1028" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State income taxes\u00a0- net of federal benefit", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": [ "r1028", "r1033" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued wages and related liabilities", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r27" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "ensg_EmployeeServiceShareBasedCompensationNonvestedAwards": { "xbrltype": "sharesItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwards", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation, nonvested awards (in shares)", "label": "Employee Service Share-based Compensation, Nonvested Awards", "documentation": "Employee Service Share-based Compensation, Nonvested Awards" } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation, nonvested awards, cost not yet recognized", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r489" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation, nonvested awards, cost not yet recognized, period for recognition", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r489" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options", "verboseLabel": "Stock-based compensation expense related to stock options", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r803" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails", "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r803" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r803" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r881" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Public Float", "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r803" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r803" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r803" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r803" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Voluntary Filers", "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Well-known Seasoned Issuer", "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r882" ] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquipmentMember", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equipment", "label": "Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "EQUITY", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityClassOfTreasuryStockLineItems", "presentation": [ "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity, Class of Treasury Stock [Line Items]", "label": "Equity, Class of Treasury Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r14", "r209", "r231", "r232", "r233", "r252", "r253", "r254", "r256", "r262", "r264", "r281", "r323", "r324", "r419", "r491", "r492", "r493", "r516", "r517", "r536", "r537", "r538", "r539", "r540", "r541", "r543", "r549", "r550", "r551", "r552", "r553", "r554", "r581", "r634", "r635", "r636", "r654", "r708" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r849" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r812", "r824", "r834", "r860" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r809", "r821", "r831", "r857" ] }, "us-gaap_EscrowDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EscrowDeposit", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails": { "parentTag": "ensg_RestrictedAndOtherAssetsNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Escrow deposits", "label": "Escrow Deposit", "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy." } } }, "auth_ref": [ "r115", "r732" ] }, "us-gaap_EstimatedInsuranceRecoveries": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EstimatedInsuranceRecoveries", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails": { "parentTag": "ensg_RestrictedAndOtherAssetsNoncurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term insurance losses recoverable asset", "label": "Estimated Insurance Recoveries", "documentation": "Carrying amount as of the balance sheet date of amounts expected to be recovered under the terms of insurance contracts." } } }, "auth_ref": [ "r893" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r855" ] }, "ensg_ExercisePriceRangeEightMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "ExercisePriceRangeEightMember", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2020", "label": "Exercise Price Range Eight [Member]", "documentation": "Exercise Price Range Eight [Member]" } } }, "auth_ref": [] }, "ensg_ExercisePriceRangeElevenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "ExercisePriceRangeElevenMember", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023", "label": "Exercise Price Range Eleven [Member]", "documentation": "Exercise Price Range Eleven" } } }, "auth_ref": [] }, "ensg_ExercisePriceRangeFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "ExercisePriceRangeFiveMember", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2017", "label": "Exercise Price Range Five [Member]", "documentation": "Exercise Price Range Five [Member]" } } }, "auth_ref": [] }, "ensg_ExercisePriceRangeFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "ExercisePriceRangeFourMember", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2016", "label": "Exercise Price Range Four [Member]", "documentation": "Exercise Price Range Four [Member]" } } }, "auth_ref": [] }, "ensg_ExercisePriceRangeNineMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "ExercisePriceRangeNineMember", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2021", "label": "Exercise Price Range Nine [Member]", "documentation": "Exercise Price Range Nine [Member]" } } }, "auth_ref": [] }, "ensg_ExercisePriceRangeSevenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "ExercisePriceRangeSevenMember", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2019", "label": "Exercise Price Range Seven [Member]", "documentation": "Exercise Price Range Seven [Member]" } } }, "auth_ref": [] }, "ensg_ExercisePriceRangeSixMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "ExercisePriceRangeSixMember", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2018", "label": "Exercise Price Range Six [Member]", "documentation": "Exercise Price Range Six [Member]" } } }, "auth_ref": [] }, "ensg_ExercisePriceRangeTenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "ExercisePriceRangeTenMember", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2022", "label": "Exercise Price Range Ten [Member]", "documentation": "Exercise Price Range Ten [Member]" } } }, "auth_ref": [] }, "ensg_ExercisePriceRangeThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "ExercisePriceRangeThreeMember", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2015", "label": "Exercise Price Range Three [Member]", "documentation": "Exercise Price Range Three [Member]" } } }, "auth_ref": [] }, "ensg_ExercisePriceRangeTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "ExercisePriceRangeTwoMember", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2014", "label": "Exercise Price Range Two [Member]", "documentation": "Exercise Price Range Two [Member]" } } }, "auth_ref": [] }, "ensg_FacilitiesUnderMasterLeaseArrangement": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "FacilitiesUnderMasterLeaseArrangement", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Facilities under master lease arrangement", "label": "Facilities Under Master Lease Arrangement", "documentation": "Facilities operated under two separate three-facility master lease arrangements. Under these master leases, a breach at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk." } } }, "auth_ref": [] }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "presentation": [ "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByBalanceSheetGroupingTable", "presentation": [ "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]", "label": "Fair Value, by Balance Sheet Grouping [Table]", "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r105", "r106", "r107" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r390", "r443", "r444", "r445", "r446", "r447", "r448", "r547", "r585", "r586", "r587", "r759", "r760", "r771", "r772", "r773" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "FAIR VALUE MEASUREMENTS", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r546" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Inputs, Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r390", "r443", "r448", "r547", "r586", "r759", "r760", "r771", "r772", "r773" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r390", "r443", "r444", "r445", "r446", "r447", "r448", "r585", "r586", "r587", "r759", "r760", "r771", "r772", "r773" ] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Considerations", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r11", "r20" ] }, "ensg_FamilyFirstCoronavirusResponseActPaymentsReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "FamilyFirstCoronavirusResponseActPaymentsReceived", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "FMAP payments received", "label": "Family First Coronavirus Response Act, Payments Received", "documentation": "Family First Coronavirus Response Act, Payments Received" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-lived intangible asset, useful life", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r220", "r345" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r152" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r152" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r152" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r152" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r152" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r342", "r344", "r345", "r347", "r591", "r592" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Carrying Amount", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r151", "r592" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails", "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r591" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r69", "r72" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails", "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r151", "r591" ] }, "ensg_FirstThreeYearsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "FirstThreeYearsMember", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "First Three Years", "label": "First Three Years [Member]", "documentation": "First Three Years" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r816", "r828", "r838", "r864" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r816", "r828", "r838", "r864" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r816", "r828", "r838", "r864" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r816", "r828", "r838", "r864" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r816", "r828", "r838", "r864" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails", "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Equipment, furniture, and fixtures", "terseLabel": "Furniture and fixtures", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GainLossOnDispositionOfAssets1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnDispositionOfAssets1", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 17.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gain on sale of assets", "label": "Gain (Loss) on Disposition of Assets", "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee." } } }, "auth_ref": [ "r900" ] }, "ensg_GainLossOnInsuranceClaimsAndDisposalOfAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "GainLossOnInsuranceClaimsAndDisposalOfAssets", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "(Gain)/loss on insurance claims, legal matters and asset disposals", "label": "Gain (Loss) On Insurance Claims And Disposal Of Assets", "documentation": "Gain (Loss) On Insurance Claims And Disposal Of Assets" } } }, "auth_ref": [] }, "us-gaap_GainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnInvestments", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Gain (loss) on deferral investment", "label": "Gain (Loss) on Investments", "documentation": "Amount of realized and unrealized gain (loss) on investment." } } }, "auth_ref": [ "r139", "r883" ] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain on sales property, plant and equipment", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": [ "r7" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative expense", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r138", "r691" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative expense", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r135" ] }, "us-gaap_GeneralLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralLiabilityMember", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "General Liability", "label": "General Liability [Member]", "documentation": "Type of business insurance which provides insurance coverage for a wide variety of liability exposures including, but not limited to, contractual liability, product liability and personal injury liability." } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS", "http://www.ensigngroup.net/role/GOODWILLDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r219", "r328", "r593", "r757", "r785", "r916", "r923" ] }, "us-gaap_GoodwillAcquiredDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails": { "parentTag": "ensg_BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/GOODWILLDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Goodwill", "netLabel": "Goodwill", "terseLabel": "Additions", "label": "Goodwill, Acquired During Period", "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination." } } }, "auth_ref": [ "r331", "r757" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets and Goodwill", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets." } } }, "auth_ref": [ "r12", "r66" ] }, "us-gaap_GoodwillDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillDisclosureTextBlock", "presentation": [ "http://www.ensigngroup.net/role/GOODWILL" ], "lang": { "en-us": { "role": { "terseLabel": "GOODWILL", "label": "Goodwill Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill." } } }, "auth_ref": [ "r327", "r329", "r339", "r757" ] }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill, accumulated impairment loss", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r330", "r337", "r757" ] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillLineItems", "presentation": [ "http://www.ensigngroup.net/role/GOODWILLDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Line Items]", "label": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r340", "r757" ] }, "us-gaap_GranteeStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GranteeStatusAxis", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Grantee Status [Axis]", "label": "Grantee Status [Axis]", "documentation": "Information by status of recipient to whom award is granted." } } }, "auth_ref": [ "r452", "r454", "r457", "r458", "r459", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r481", "r482", "r483", "r484", "r485" ] }, "us-gaap_GranteeStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GranteeStatusDomain", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Grantee Status [Domain]", "label": "Grantee Status [Domain]", "documentation": "Status of recipient to whom award is granted." } } }, "auth_ref": [ "r452", "r454", "r457", "r458", "r459", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r481", "r482", "r483", "r484", "r485" ] }, "ensg_HUDInsuredMortgagesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "HUDInsuredMortgagesMember", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "HUD Insured Mortgages", "label": "HUD Insured Mortgages [Member]", "documentation": "HUD Insured Mortgages" } } }, "auth_ref": [] }, "ensg_HealthLiabilityInsuranceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "HealthLiabilityInsuranceMember", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Health Liability Insurance", "label": "Health Liability Insurance [Member]", "documentation": "Health Liability Insurance [Member]" } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "ICFR Auditor Attestation Flag", "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r806", "r807", "r820" ] }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of intangible assets (excluding goodwill)", "label": "Impairment of Intangible Assets (Excluding Goodwill)", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value." } } }, "auth_ref": [ "r7", "r17" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of Long-Lived Assets", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r156" ] }, "ensg_InTheFourthYearMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "InTheFourthYearMember", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "In The Fourth Year", "label": "In The Fourth Year [Member]", "documentation": "In The Fourth Year" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Less: net income (loss) attributable to noncontrolling interests", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest." } } }, "auth_ref": [ "r100", "r177" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 2.0 }, "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "Income before provision for income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r1", "r133", "r190", "r286", "r300", "r306", "r309", "r595", "r606", "r755" ] }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Net income", "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r177", "r247", "r255", "r286", "r300", "r306", "r309", "r322", "r363", "r364", "r366", "r367", "r368", "r370", "r372", "r374", "r375", "r545", "r548", "r606", "r755", "r932" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Axis]", "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r774", "r775" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails", "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r348", "r352", "r692" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails", "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r352", "r692" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXES" ], "lang": { "en-us": { "role": { "terseLabel": "INCOME TAXES", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r248", "r499", "r506", "r507", "r513", "r518", "r523", "r524", "r525", "r651" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 1.0 }, "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for income taxes", "totalLabel": "Provision for income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r198", "r207", "r263", "r264", "r294", "r504", "r519", "r612" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r230", "r500", "r501", "r507", "r508", "r512", "r514", "r647" ] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes", "label": "Income Taxes Paid", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income." } } }, "auth_ref": [ "r43", "r46" ] }, "ensg_IncreaseDecreaseDueToDeferredEmployerTaxesCARESAct": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "IncreaseDecreaseDueToDeferredEmployerTaxesCARESAct", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 20.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Deferred employer portion of social security taxes (Note 3)", "label": "Increase (Decrease) Due To Deferred Employer Taxes, CARES Act", "documentation": "Increase (Decrease) Due To Deferred Employer Taxes, CARES Act" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 16.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInDeferredCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDeferredCompensation", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred compensation liability", "label": "Increase (Decrease) in Deferred Compensation", "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued wages and related liabilities", "label": "Increase (Decrease) in Employee Related Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Change in operating assets and liabilities", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease obligations", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r889", "r899" ] }, "us-gaap_IncreaseDecreaseInOtherDeferredLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherDeferredLiability", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Increase (Decrease) in Other Deferred Liability", "documentation": "Amount of increase (decrease) in deferred obligations classified as other." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 19.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Other accrued liabilities", "label": "Increase (Decrease) in Other Operating Liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInPrepaidTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidTaxes", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 22.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Prepaid income taxes", "label": "Increase (Decrease) in Prepaid Taxes", "documentation": "Amount of increase (decrease) of consideration paid in advance for income and other taxes that provide economic benefits in future periods." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInSelfInsuranceReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInSelfInsuranceReserve", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 21.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued self-insurance liabilities", "label": "Increase (Decrease) in Self Insurance Reserve", "documentation": "The increase (decrease) during the period in the carrying amount of accrued known and estimated losses incurred for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's' compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property." } } }, "auth_ref": [ "r899" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plus: incremental shares from assumed conversion (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r269", "r270", "r271", "r275", "r455" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails", "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofIndefinitelivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Axis]", "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r343", "r346" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofIndefinitelivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Line Items]", "label": "Indefinite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofIndefinitelivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other indefinite-lived intangibles", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r153" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails", "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofIndefinitelivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": [ "r70", "r153" ] }, "us-gaap_IndefinitelivedIntangibleAssetsAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefinitelivedIntangibleAssetsAcquired", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails": { "parentTag": "ensg_BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other indefinite-lived intangible assets", "terseLabel": "Indefinite-lived intangible assets", "label": "Indefinite-Lived Intangible Assets Acquired", "documentation": "Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition." } } }, "auth_ref": [] }, "ensg_IndependentOperatingSubsidiariesUnderMedicareProbeReviews": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "IndependentOperatingSubsidiariesUnderMedicareProbeReviews", "presentation": [ "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Facilities under medicare probe reviews", "label": "Independent Operating Subsidiaries Under Medicare Probe Reviews", "documentation": "Facilities under Medicare Probe reviews relating to Medicare services, billings and potential overpayments" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r819", "r828", "r838", "r855", "r864", "r868", "r876" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r874" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r808", "r880" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r808", "r880" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r808", "r880" ] }, "us-gaap_InsuranceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InsuranceAbstract", "lang": { "en-us": { "role": { "label": "Insurance [Abstract]" } } }, "auth_ref": [] }, "ensg_InsuranceCoverageLimitTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "InsuranceCoverageLimitTypeAxis", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Insurance Coverage Limit Type [Axis]", "label": "Insurance Coverage Limit Type [Axis]", "documentation": "Insurance Coverage Limit Type [Axis]" } } }, "auth_ref": [] }, "ensg_InsuranceCoverageLimitTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "InsuranceCoverageLimitTypeDomain", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Insurance Coverage Limit Type [Domain]", "label": "Insurance Coverage Limit Type [Domain]", "documentation": "Insurance Coverage Limit Type [Domain]" } } }, "auth_ref": [] }, "ensg_InsuranceSubsidiaryDepositsAndInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "InsuranceSubsidiaryDepositsAndInvestments", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Insurance subsidiary deposits and investments", "label": "Insurance Subsidiary Deposits And Investments", "documentation": "Captive insurance subsidiary cash and equivalents designated to support long-term insurance subsidiary liabilities and debt security investments held to maturity." } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNET" ], "lang": { "en-us": { "role": { "terseLabel": "INTANGIBLE ASSETS \u2014 NET", "label": "Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": [ "r341" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r67", "r71" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest expense", "terseLabel": "Interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r112", "r193", "r234", "r290", "r556", "r693", "r799", "r1070" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r238", "r242", "r243" ] }, "ensg_InvestmentExpenseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "InvestmentExpenseIncome", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Offsetting expense (income)", "label": "Investment Expense (Income)", "documentation": "Investment Expense (Income)" } } }, "auth_ref": [] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentPolicyTextBlock", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Insurance Subsidiary Deposits and Investments", "label": "Investment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": [ "r611", "r643", "r644", "r645", "r646", "r715", "r716" ] }, "us-gaap_InvestmentsAndCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsAndCash", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Insurance subsidiary's deposits and investments", "label": "Investments and Cash", "documentation": "Sum of investments and unrestricted cash as of the balance sheet date." } } }, "auth_ref": [ "r1057", "r1061" ] }, "ensg_July2022RepurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "July2022RepurchaseProgramMember", "presentation": [ "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails" ], "lang": { "en-us": { "role": { "terseLabel": "July 2022 Repurchase Program", "label": "July 2022 Repurchase Program [Member]", "documentation": "July 2022 Repurchase Program" } } }, "auth_ref": [] }, "us-gaap_LandMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LandMember", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails", "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Land", "terseLabel": "Land", "label": "Land [Member]", "documentation": "Part of earth's surface not covered by water." } } }, "auth_ref": [ "r940" ] }, "ensg_LeaseArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "LeaseArrangementAxis", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Arrangement [Axis]", "label": "Lease Arrangement [Axis]", "documentation": "Information by group of related lease arrangements." } } }, "auth_ref": [] }, "ensg_LeaseArrangementDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "LeaseArrangementDomain", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Arrangement [Domain]", "label": "Lease Arrangement [Domain]", "documentation": "Lease Arrangement" } } }, "auth_ref": [] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Lease, cost", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r565", "r784" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.ensigngroup.net/role/LEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Operating Lease Expenses", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r1042" ] }, "ensg_LeaseOfCampusOperationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "LeaseOfCampusOperationMember", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Of Campus Operation", "label": "Lease Of Campus Operation [Member]", "documentation": "Lease Of Campus Operation" } } }, "auth_ref": [] }, "ensg_LeasedAssetsAcquiredDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "LeasedAssetsAcquiredDuringPeriod", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails": { "parentTag": "ensg_BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leased asset", "label": "Leased Assets, Acquired During Period", "documentation": "Leased Assets, Acquired During Period" } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r155" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "ensg_LeasesToThirdPartyOperatorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "LeasesToThirdPartyOperatorsMember", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leases To Third Party Operators", "label": "Leases To Third Party Operators [Member]", "documentation": "Leases To Third Party Operators" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails", "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails", "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r564" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails", "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r564" ] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r563" ] }, "ensg_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee leasing arrangements, operating leases, number of renewal terms", "label": "Lessee Leasing Arrangements, Operating Leases, Number Of Renewal Terms", "documentation": "Lessee Leasing Arrangements, Operating Leases, Number Of Renewal Terms" } } }, "auth_ref": [] }, "ensg_LesseeOperatingLeaseConsumerPriceIndex": { "xbrltype": "percentItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "LesseeOperatingLeaseConsumerPriceIndex", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consumer price index", "label": "Lessee, Operating Lease, Consumer Price Index", "documentation": "Lessee, Operating Lease, Consumer Price Index" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseDiscountRate", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating leases of lessee, contingent rentals, basis spread on variable rate", "label": "Lessee, Operating Lease, Discount Rate", "documentation": "Discount rate used by lessee to determine present value of operating lease payments." } } }, "auth_ref": [ "r783" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.ensigngroup.net/role/LEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Minimum Lease Payments", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1043" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LEASE PAYMENTS", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r574" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r574" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r574" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r574" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r574" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r574" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r574" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: present value adjustment", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r574" ] }, "ensg_LesseeOperatingLeaseNumberOfLeases": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "LesseeOperatingLeaseNumberOfLeases", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of stand-alone leases", "label": "Lessee, Operating Lease, Number Of Leases", "documentation": "Lessee, Operating Lease, Number Of Leases" } } }, "auth_ref": [] }, "ensg_LesseeOperatingLeaseNumberOfRenewalOptions": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "LesseeOperatingLeaseNumberOfRenewalOptions", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, operating lease, number of renewal options", "label": "Lessee, Operating Lease, Number Of Renewal Options", "documentation": "Lessee, Operating Lease, Number Of Renewal Options" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, operating lease, renewal term", "label": "Lessee, Operating Lease, Renewal Term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1041" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, operating lease, term of contract", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1041" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.ensigngroup.net/role/LEASES" ], "lang": { "en-us": { "role": { "terseLabel": "LEASES", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r559" ] }, "us-gaap_LessorLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorLeaseDescriptionLineItems", "presentation": [ "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessor, Lease, Description [Line Items]", "label": "Lessor, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r578" ] }, "us-gaap_LessorLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorLeaseDescriptionTable", "presentation": [ "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessor, Lease, Description [Table]", "label": "Lessor, Lease, Description [Table]", "documentation": "Disclosure of information about lessor's leases." } } }, "auth_ref": [ "r578" ] }, "ensg_LessorOperatingLeaseNumberOfLeases": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "LessorOperatingLeaseNumberOfLeases", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of leases", "label": "Lessor, Operating Lease, Number Of Leases", "documentation": "Lessor, Operating Lease, Number Of New Leases" } } }, "auth_ref": [] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceived", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL", "label": "Lessor, Operating Lease, Payment to be Received", "documentation": "Amount of lease payments to be received by lessor for operating lease." } } }, "auth_ref": [ "r577" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedFiveYears", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessor, Operating Lease, Payment to be Received, Year Five", "documentation": "Amount of lease payment to be received by lessor for operating lease in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r577" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessor, Operating Lease, Payment to be Received, Year Four", "documentation": "Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r577" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "presentation": [ "http://www.ensigngroup.net/role/LEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Annual Rental Income", "label": "Lessor, Operating Lease, Payment to be Received, Maturity [Table Text Block]", "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease." } } }, "auth_ref": [ "r1044" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Lessor, Operating Lease, Payment to be Received, Year One", "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r577" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedThereafter", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessor, Operating Lease, Payment to be Received, after Year Five", "documentation": "Amount of lease payment to be received by lessor for operating lease after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r577" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessor, Operating Lease, Payment to be Received, Year Three", "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r577" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessor, Operating Lease, Payment to be Received, Year Two", "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r577" ] }, "us-gaap_LessorOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeaseTermOfContract", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term of operating lease", "label": "Lessor, Operating Lease, Term of Contract", "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1045" ] }, "us-gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LetterOfCreditMember", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letter of Credit", "label": "Letter of Credit [Member]", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)." } } }, "auth_ref": [] }, "us-gaap_LettersOfCreditOutstandingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LettersOfCreditOutstandingAmount", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letters of credit outstanding, pledged amount", "label": "Letters of Credit Outstanding, Amount", "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r26", "r247", "r322", "r363", "r364", "r366", "r367", "r368", "r370", "r372", "r374", "r375", "r531", "r534", "r535", "r548", "r667", "r754", "r801", "r932", "r1049", "r1050" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES AND EQUITY", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r132", "r187", "r602", "r785", "r902", "r913", "r1039" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r28", "r215", "r247", "r322", "r363", "r364", "r366", "r367", "r368", "r370", "r372", "r374", "r375", "r531", "r534", "r535", "r548", "r785", "r932", "r1049", "r1050" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "ensg_LiabilitiesDeferredTaxPaymentsUnderCARESAct": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "LiabilitiesDeferredTaxPaymentsUnderCARESAct", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total deferred payment of social security taxes", "label": "Liabilities, Deferred Tax Payments Under CARES Act", "documentation": "Liabilities, Deferred Tax Payments Under CARES Act" } } }, "auth_ref": [] }, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liability for Claims and Claims Adjustment Expense [Line Items]", "label": "Liability for Claims and Claims Adjustment Expense [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseTable", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liability for Claims and Claims Adjustment Expense [Table]", "label": "Liability for Claims and Claims Adjustment Expense [Table]", "documentation": "Disclosure of information about the liability for claims and claims adjustment expense." } } }, "auth_ref": [] }, "us-gaap_LiabilityForFuturePolicyBenefitByProductSegmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForFuturePolicyBenefitByProductSegmentLineItems", "presentation": [ "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liability for Future Policy Benefit, by Product Segment [Line Items]", "label": "Liability for Future Policy Benefit, by Product Segment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_LiabilityForFuturePolicyBenefitByProductSegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForFuturePolicyBenefitByProductSegmentTable", "presentation": [ "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liability for Future Policy Benefit, by Product Segment [Table]", "label": "Liability for Future Policy Benefit, by Product Segment [Table]", "documentation": "Reflects the carrying amount of and other relevant, pertinent information about the liability as of the balance sheet date for future benefits to be paid to or on behalf of policyholders and related expenses less the present value of future net premiums by major product line segment." } } }, "auth_ref": [] }, "us-gaap_LiabilityForFuturePolicyBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForFuturePolicyBenefits", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Liability for Future Policy Benefit, before Reinsurance", "documentation": "Amount, before effect of reinsurance, of present value of future benefit to be paid to or on behalf of policyholder and related expense less present value of future net premium receivable under insurance contract." } } }, "auth_ref": [ "r631", "r632", "r637", "r788", "r1058" ] }, "us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock", "presentation": [ "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIES" ], "lang": { "en-us": { "role": { "terseLabel": "SELF INSURANCE LIABILITIES", "label": "Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]", "documentation": "The entire disclosure for liabilities related to future policy benefits and unpaid claims and claim adjustments." } } }, "auth_ref": [ "r630" ] }, "us-gaap_LiabilityForFuturePolicyBenefitsOtherIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForFuturePolicyBenefitsOtherIncreaseDecrease", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in long-term insurance losses recoverable", "label": "Liability for Future Policy Benefits, Other Increase (Decrease)", "documentation": "Amount of other increase (decrease) in accrued obligations to policyholders pertaining to insured events for the period." } } }, "auth_ref": [ "r119" ] }, "us-gaap_LiabilityForFuturePolicyBenefitsPaymentForBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForFuturePolicyBenefitsPaymentForBenefits", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Claims paid and direct expenses", "label": "Liability for Future Policy Benefit, Expected Future Policy Benefit, Benefit Payment", "documentation": "Amount of cash outflow to policyholder from benefit payment for expected future policy benefit and expense component of liability for future policy benefit." } } }, "auth_ref": [ "r787", "r788", "r898", "r1064", "r1067" ] }, "us-gaap_LiabilityForFuturePolicyBenefitsPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForFuturePolicyBenefitsPeriodIncreaseDecrease", "presentation": [ "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current year provisions", "label": "Liability for Future Policy Benefits, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) in accrued obligations to policy and contract holders for long-duration insurance contracts." } } }, "auth_ref": [ "r119" ] }, "us-gaap_LifeInsuranceCorporateOrBankOwnedChangeInValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LifeInsuranceCorporateOrBankOwnedChangeInValue", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 18.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash surrender value of life insurance policy premiums", "label": "Life Insurance, Corporate or Bank Owned, Change in Value", "documentation": "The change in cash surrender or contract value during the period which adjusted the amount of premiums paid in determining the expense or income recognized under the contract for the period." } } }, "auth_ref": [ "r914" ] }, "us-gaap_LineOfCreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityAxis", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lender Name [Axis]", "label": "Lender Name [Axis]", "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit." } } }, "auth_ref": [ "r25", "r901" ] }, "us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityIncreaseDecreaseForPeriodNet", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letter of credit increase", "label": "Line of Credit Facility, Increase (Decrease), Net", "documentation": "Amount of increase (decrease) of the credit facility." } } }, "auth_ref": [ "r901" ] }, "us-gaap_LineOfCreditFacilityLenderDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityLenderDomain", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility, Lender [Domain]", "label": "Line of Credit Facility, Lender [Domain]", "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "auth_ref": [ "r25", "r901" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r25" ] }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, unused capacity, commitment fee percentage", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility." } } }, "auth_ref": [] }, "us-gaap_LitigationReserveCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationReserveCurrent", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued litigation (Note 20)", "label": "Estimated Litigation Liability, Current", "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position." } } }, "auth_ref": [ "r32", "r928" ] }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationSettlementAmountAwardedToOtherParty", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation settlement, amount awarded to other party", "label": "Litigation Settlement, Amount Awarded to Other Party", "documentation": "Amount awarded to other party in judgment or settlement of litigation." } } }, "auth_ref": [] }, "us-gaap_LitigationSettlementExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationSettlementExpense", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 24.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation", "label": "Litigation Settlement, Expense", "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Long-term Debt", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r22", "r185", "r389", "r404", "r759", "r760", "r1060" ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails": { "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0, "order": 3.0 }, "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS", "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current maturities of long-term debt", "negatedTerseLabel": "Less: current maturities", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r222" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Long-Term Debt, Maturity, after Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r10", "r251", "r938" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r10", "r251", "r394" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Long-Term Debt, Maturity, Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r10", "r251", "r394" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r10", "r251", "r394" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r10", "r251", "r394" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r10", "r251", "r394" ] }, "ensg_LongTermDebtNetOfCurrentMaturitiesAndDebtDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "LongTermDebtNetOfCurrentMaturitiesAndDebtDiscount", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt\u2014less current maturities", "label": "Long Term Debt, net of Current Maturities and Debt Discount", "documentation": "Long Term Debt, net of Current Maturities and Debt Discount" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "totalLabel": "LONG-TERM DEBT LESS CURRENT MATURITIES", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r223" ] }, "ensg_LongTermDebtThresholdForEBITDARatioIncreaseElection": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "LongTermDebtThresholdForEBITDARatioIncreaseElection", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, threshold for EBITDA ratio increase election", "label": "Long-Term Debt, Threshold For EBITDA Ratio Increase Election", "documentation": "Long-Term Debt, Threshold For EBITDA Ratio Increase Election" } } }, "auth_ref": [] }, "ensg_LongTermDebtThresholdForEBITDARatioIncreaseElectionPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "LongTermDebtThresholdForEBITDARatioIncreaseElectionPeriod", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt threshold for EBITDA ratio increase election period", "label": "Long Term Debt Threshold For EBITDA Ratio Increase Election Period", "documentation": "Long Term Debt Threshold For EBITDA Ratio Increase Election Period" } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r30" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r30", "r75" ] }, "ensg_LossSensitiveLimitPerClaimMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "LossSensitiveLimitPerClaimMember", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss-Sensitive Limit Per Claim", "label": "Loss-Sensitive Limit Per Claim [Member]", "documentation": "Loss-Sensitive limit per claim [Member]" } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]" } } }, "auth_ref": [ "r315", "r766", "r939", "r1063", "r1065" ] }, "ensg_ManagedCareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "ManagedCareMember", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Managed care", "verboseLabel": "Managed care", "netLabel": "Managed care", "label": "Managed Care [Member]", "documentation": "Revenue from managed care payors [Member]" } } }, "auth_ref": [] }, "us-gaap_ManagementFeeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ManagementFeeExpense", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Management fees", "label": "Management Fee Expense", "documentation": "Amount of expense for investment management fee, including, but not limited to, expense in connection with research, selection, supervision, and custody of investment." } } }, "auth_ref": [ "r114", "r691", "r799", "r1069" ] }, "us-gaap_ManagementServiceBaseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ManagementServiceBaseMember", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Base Management Fee", "label": "Management Service, Base [Member]", "documentation": "Contractually stipulated right to receive base compensation for operating and managing business." } } }, "auth_ref": [ "r940" ] }, "us-gaap_ManagementServiceIncentiveMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ManagementServiceIncentiveMember", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Incentive Management Fee", "label": "Management Service, Incentive [Member]", "documentation": "Contractually stipulated right to receive incentive compensation for operating and managing business." } } }, "auth_ref": [ "r940" ] }, "ensg_ManagementServiceTotalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "ManagementServiceTotalMember", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total Management Fee", "label": "Management Service, Total [Member]", "documentation": "Management Service, Total" } } }, "auth_ref": [] }, "ensg_MasterLeaseAgreements": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "MasterLeaseAgreements", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Master lease agreements", "label": "Master Lease Agreements", "documentation": "Master Lease agreements" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r359", "r360", "r361", "r362", "r450", "r589", "r633", "r659", "r660", "r713", "r717", "r719", "r720", "r722", "r743", "r744", "r756", "r763", "r776", "r789", "r936", "r1051", "r1052", "r1053", "r1054", "r1055", "r1056" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r847" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r847" ] }, "ensg_MedicaidAndMedicareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "MedicaidAndMedicareMember", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total Medicare and Medicaid", "verboseLabel": "Total Medicaid and Medicare", "label": "Medicaid and Medicare [Member]", "documentation": "Total revenue from Medicaid and Medicare [Member]" } } }, "auth_ref": [] }, "ensg_MedicaidMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "MedicaidMember", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medicaid", "label": "Medicaid [Member]", "documentation": "Revenue from Medicaid for custodial services [Member]" } } }, "auth_ref": [] }, "ensg_MedicaidSkilledMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "MedicaidSkilledMember", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medicaid \u2014 skilled", "verboseLabel": "Medicaid-skilled", "label": "Medicaid-skilled [Member]", "documentation": "Revenue from Medicaid for skilled services [Member]" } } }, "auth_ref": [] }, "ensg_MedicareAcceleratedAndAdvancePaymentCARESACT": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "MedicareAcceleratedAndAdvancePaymentCARESACT", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medicare accelerated and advance payment", "label": "Medicare Accelerated And Advance Payment, CARES ACT", "documentation": "Medicare Accelerated And Advance Payment, CARES ACT" } } }, "auth_ref": [] }, "ensg_MedicareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "MedicareMember", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medicare", "verboseLabel": "Medicare", "netLabel": "Medicare", "label": "Medicare [Member]", "documentation": "Revenue from Medicare [Member]" } } }, "auth_ref": [] }, "ensg_MedicareandMedicaidLicensesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "MedicareandMedicaidLicensesMember", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails", "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofIndefinitelivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medicare and Medicaid licenses", "label": "Medicare and Medicaid Licenses [Member]", "documentation": "Medicare licenses for home health and hospice segment and all other segment." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r359", "r360", "r361", "r362", "r450", "r589", "r633", "r659", "r660", "r713", "r717", "r719", "r720", "r722", "r743", "r744", "r756", "r763", "r776", "r789", "r936", "r1051", "r1052", "r1053", "r1054", "r1055", "r1056" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling interest", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r36", "r186", "r247", "r322", "r363", "r366", "r367", "r368", "r374", "r375", "r548", "r601", "r671" ] }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Noncontrolling interest attributable to subsidiary equity plan", "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders." } } }, "auth_ref": [ "r162" ] }, "us-gaap_MinorityInterestDecreaseFromRedemptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestDecreaseFromRedemptions", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisition of noncontrolling interest shares", "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests", "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests)." } } }, "auth_ref": [ "r102", "r162", "r178" ] }, "us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Less:", "label": "Net Income (Loss) Attributable to Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r867" ] }, "us-gaap_MovementInLiabilityForFuturePolicyBenefitsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MovementInLiabilityForFuturePolicyBenefitsRollForward", "presentation": [ "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Movement in Liability for Future Policy Benefits [Roll Forward]", "label": "Movement in Liability for Future Policy Benefits [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r875" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]" } } }, "auth_ref": [ "r315", "r766", "r939", "r1063", "r1065" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r848" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "NET CASH USED IN FINANCING ACTIVITIES", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r241" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "NET CASH USED IN INVESTING ACTIVITIES", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r241" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "NET CASH PROVIDED BY OPERATING ACTIVITIES", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r145", "r146", "r147" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net income attributable to The Ensign Group, Inc.", "verboseLabel": "Net income attributable to the Ensign Group, Inc.", "terseLabel": "Net Income (Loss)", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r134", "r147", "r191", "r213", "r228", "r229", "r233", "r247", "r255", "r257", "r258", "r259", "r260", "r263", "r264", "r272", "r286", "r300", "r306", "r309", "r322", "r363", "r364", "r366", "r367", "r368", "r370", "r372", "r374", "r375", "r545", "r548", "r609", "r689", "r706", "r707", "r755", "r799", "r932" ] }, "us-gaap_NetIncomeLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAbstract", "presentation": [ "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "NUMERATOR:", "label": "Net Income (Loss) Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss) attributable to noncontrolling interests", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r104", "r179", "r228", "r229", "r263", "r264", "r608", "r896" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ensg_NewMasterLeaseAgreeementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "NewMasterLeaseAgreeementMember", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New Master Lease Agreeement", "label": "New Master Lease Agreeement [Member]", "documentation": "New Master Lease Agreeement" } } }, "auth_ref": [] }, "ensg_NonCaliforniaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "NonCaliforniaMember", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-california", "label": "Non-California [Member]", "documentation": "Non-California [Domain]" } } }, "auth_ref": [] }, "ensg_NonCashLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "NonCashLeaseExpense", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash leasing arrangement", "label": "Non-Cash Lease Expense", "documentation": "Non-Cash Lease Expense" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r847" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r816", "r828", "r838", "r855", "r864" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r845" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r844" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r855" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r875" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r875" ] }, "us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestDecreaseFromDeconsolidation", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Deconsolidation of an ancillary business", "label": "Noncontrolling Interest, Decrease from Deconsolidation", "documentation": "The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest." } } }, "auth_ref": [ "r13", "r78" ] }, "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Capital contribution from noncontrolling interest holder and Issuance of noncontrolling interests through subsidiary equity plan", "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance", "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders." } } }, "auth_ref": [ "r13", "r78", "r178" ] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestMember", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Controlling Interest", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r100", "r419", "r905", "r906", "r907", "r1071" ] }, "ensg_NoncontrollingInterestPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "NoncontrollingInterestPolicyTextBlock", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest", "label": "Noncontrolling Interest [Policy Text Block]", "documentation": "The noncontrolling interest in a subsidiary initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's condensed consolidated balance sheets." } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "Other income (expense), net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r140" ] }, "us-gaap_NonqualifiedPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonqualifiedPlanMember", "presentation": [ "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nonqualified Plan", "label": "Nonqualified Plan [Member]", "documentation": "Plan without tax-exempt status in accordance with applicable tax provision of designated taxing authority. Taxing authority includes, but is not limited to, U.S. Internal Revenue Service (IRS). Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r886", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000" ] }, "ensg_NumberOfAssetAcquisitions": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "NumberOfAssetAcquisitions", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of asset acquisitions", "label": "Number of Asset Acquisitions", "documentation": "Number of Asset Acquisitions" } } }, "auth_ref": [] }, "us-gaap_NumberOfBusinessesAcquired": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfBusinessesAcquired", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of businesses acquired", "label": "Number of Businesses Acquired", "documentation": "The number of businesses acquired by the entity during the period." } } }, "auth_ref": [] }, "ensg_NumberOfFacilities": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "NumberOfFacilities", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of facilities", "label": "Number Of Facilities", "documentation": "Number Of Facilities" } } }, "auth_ref": [] }, "ensg_NumberOfFinancingLeases": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "NumberOfFinancingLeases", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of financing lease", "label": "Number Of Financing Leases", "documentation": "Number Of Financing Leases" } } }, "auth_ref": [] }, "ensg_NumberOfHealthCareFacilities": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "NumberOfHealthCareFacilities", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Health care facilities", "label": "Number Of Health Care Facilities", "documentation": "Number Of Health Care Facilities" } } }, "auth_ref": [] }, "ensg_NumberOfLeaseArrangements": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "NumberOfLeaseArrangements", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of master lease arrangements", "label": "Number of Lease Arrangements", "documentation": "Number of Lease Arrangements" } } }, "auth_ref": [] }, "ensg_NumberOfLivingOperationsTransferredFromThirdParties": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "NumberOfLivingOperationsTransferredFromThirdParties", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operations transferred from third parties", "label": "Number of Living Operations Transferred From Third-Parties", "documentation": "Number of Living Operations Transferred From Third-Parties" } } }, "auth_ref": [] }, "ensg_NumberOfOperatingSubsidiaries": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "NumberOfOperatingSubsidiaries", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating subsidiaries", "label": "Number Of Operating Subsidiaries", "documentation": "Number Of operating subsidiaries entered into mortgage loans that are insured with HUD." } } }, "auth_ref": [] }, "ensg_NumberOfOperations": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "NumberOfOperations", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operations lease and operated by third parties", "label": "Number Of Operations", "documentation": "Number Of Operations" } } }, "auth_ref": [] }, "ensg_NumberOfOptionPlans": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "NumberOfOptionPlans", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of option plans", "label": "Number Of Option Plans", "documentation": "Number Of Option Plans" } } }, "auth_ref": [] }, "ensg_NumberOfPropertiesAcquired": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "NumberOfPropertiesAcquired", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of real estate skilled nursing properties acquired", "label": "Number Of Properties Acquired", "documentation": "Number Of Properties Acquired" } } }, "auth_ref": [] }, "us-gaap_NumberOfRealEstateProperties": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfRealEstateProperties", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails", "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of real estate properties", "label": "Number of Real Estate Properties", "documentation": "The number of real estate properties owned as of the balance sheet date." } } }, "auth_ref": [] }, "ensg_NumberOfRealEstatePropertiesLeased": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "NumberOfRealEstatePropertiesLeased", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of real estate properties leased", "label": "Number of Real Estate Properties Leased", "documentation": "Number of Real Estate Properties Leased" } } }, "auth_ref": [] }, "ensg_NumberOfRealEstatePropertiesLeasedWithOptionToPurchase": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "NumberOfRealEstatePropertiesLeasedWithOptionToPurchase", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of real estate properties leased with an option to purchase", "label": "Number of Real Estate Properties Leased with an Option to Purchase", "documentation": "Number of Real Estate Properties Leased with an Option to Purchase" } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r909" ] }, "ensg_NumberOfSeniorLivingOperationsSharingPropertyWithSkilledNursingFacilities": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "NumberOfSeniorLivingOperationsSharingPropertyWithSkilledNursingFacilities", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of senior living operations sharing property with skilled nursing facilities", "label": "Number Of Senior Living Operations Sharing Property With Skilled Nursing Facilities", "documentation": "Number Of Senior Living Operations Sharing Property With Skilled Nursing Facilities" } } }, "auth_ref": [] }, "ensg_OperatingEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "OperatingEntityAxis", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Entity [Axis]", "label": "Operating Entity [Axis]", "documentation": "Operating Entity [Axis]" } } }, "auth_ref": [] }, "ensg_OperatingEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "OperatingEntityDomain", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Entity [Domain]", "label": "Operating Entity [Domain]", "documentation": "[Domain] for Operating Entity [Axis]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "Income from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r286", "r300", "r306", "r309", "r755" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease expense", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r566", "r784" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rent expense", "label": "Operating Lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r1040" ] }, "us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseIncomeComprehensiveIncomeExtensibleList", "presentation": [ "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OperatingLeaseIncomeComprehensiveIncomeExtensibleListNotDisclosedFlag", "label": "Operating Lease, Lease Income, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of comprehensive income that includes operating lease income." } } }, "auth_ref": [ "r576" ] }, "us-gaap_OperatingLeaseLeaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLeaseIncome", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rental revenue", "label": "Operating Lease, Lease Income", "documentation": "Amount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable." } } }, "auth_ref": [ "r280", "r576", "r579" ] }, "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLeaseIncomeTableTextBlock", "presentation": [ "http://www.ensigngroup.net/role/LEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Rental Income from Third-Party Sources", "label": "Operating Lease, Lease Income [Table Text Block]", "documentation": "Tabular disclosure of components of income from operating lease." } } }, "auth_ref": [ "r280", "r579" ] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Year", "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 }, "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "PRESENT VALUE OF TOTAL LEASE LIABILITIES", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r561" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 }, "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS", "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities\u2014current", "negatedLabel": "Less: current lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r561" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS", "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term lease liabilities\u2014less current portion", "verboseLabel": "LONG-TERM OPERATING LEASE LIABILITIES", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r561" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r562", "r570" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r560" ] }, "us-gaap_OperatingLeaseVariableLeaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseVariableLeaseIncome", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, variable lease income", "label": "Operating Lease, Variable Lease Income", "documentation": "Amount of operating lease income from variable lease payments paid and payable to lessor, excluding amount included in measurement of lease receivable." } } }, "auth_ref": [ "r280", "r580" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, weighted average discount rate, percent", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r573", "r784" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, weighted average remaining lease term", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r572", "r784" ] }, "us-gaap_OperatingLeasesOfLessorDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasesOfLessorDisclosureTextBlock", "presentation": [ "http://www.ensigngroup.net/role/LEASES" ], "lang": { "en-us": { "role": { "terseLabel": "LEASES", "label": "Lessor, Operating Leases [Text Block]", "documentation": "The entire disclosure for lessor's operating leases." } } }, "auth_ref": [ "r575" ] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingSegmentsMember", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails", "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/GOODWILLDetails", "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r299", "r300", "r301", "r302", "r303", "r309" ] }, "ensg_OperationalSeniorLivingUnits": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "OperationalSeniorLivingUnits", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operational senior living units", "label": "Operational Senior Living Units", "documentation": "Operational Assisted Living and Independent Living Units" } } }, "auth_ref": [] }, "ensg_OperationalSkilledNursingBeds": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "OperationalSkilledNursingBeds", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operational skilled nursing beds", "label": "Operational Skilled Nursing Beds", "documentation": "Number of skilled nursing beds available for use at a skilled nursing facility" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESS" ], "lang": { "en-us": { "role": { "terseLabel": "DESCRIPTION OF BUSINESS", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r120", "r176", "r641", "r642" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 }, "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS", "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other accrued liabilities", "totalLabel": "OTHER ACCRUED LIABILITIES", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r27" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails": { "parentTag": "ensg_RestrictedAndOtherAssetsNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r226", "r785" ] }, "us-gaap_OtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsDisclosureTextBlock", "presentation": [ "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETS" ], "lang": { "en-us": { "role": { "terseLabel": "RESTRICTED AND OTHER ASSETS", "label": "Other Assets Disclosure [Text Block]", "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r31" ] }, "us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash financing and investing activity", "label": "Other Noncash Investing and Financing Items [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Other income", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r142" ] }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense):", "label": "Other Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r847" ] }, "us-gaap_OtherRestrictedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherRestrictedAssets", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails": { "parentTag": "ensg_RestrictedAndOtherAssetsNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital improvement reserves with landlords and lenders", "label": "Other Restricted Assets", "documentation": "Total assets that cannot be used for operating purposes because of contract or regulatory requirements that are in effect for a period that extends beyond one year." } } }, "auth_ref": [ "r728", "r729", "r893" ] }, "ensg_OtherStatesExceptCaliforniaTexasAndWashingtonMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "OtherStatesExceptCaliforniaTexasAndWashingtonMember", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other States, Except California, Texas and Washington", "label": "Other states, except California, Texas and Washington [Member]", "documentation": "Other states, except California, Texas and Washington" } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r814", "r826", "r836", "r862" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r817", "r829", "r839", "r865" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r817", "r829", "r839", "r865" ] }, "ensg_OwnedPropertiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "OwnedPropertiesMember", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Owned Properties", "label": "Owned Properties [Member]", "documentation": "Owned Properties" } } }, "auth_ref": [] }, "srt_ParentCompanyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ParentCompanyMember", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Parent Company", "label": "Parent Company [Member]" } } }, "auth_ref": [ "r251" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r843" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Payables and Accruals [Abstract]", "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "ensg_PaymentsForMedicareAndMedicaidLicenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "PaymentsForMedicareAndMedicaidLicenses", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash payments for Medicare and Medicaid licenses", "label": "Payments For Medicare and Medicaid Licenses", "documentation": "Payments For Medicare and Medicaid Licenses" } } }, "auth_ref": [] }, "us-gaap_PaymentsForProceedsFromDepositsOnRealEstateAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForProceedsFromDepositsOnRealEstateAcquisitions", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Escrow deposits", "label": "Payments for (Proceeds from) Deposits on Real Estate Acquisitions", "documentation": "Net cash outflow or inflow from the amount given in advance to show intention to complete the acquisition piece of land, anything permanently fixed to it, including buildings, structures on it, and so forth." } } }, "auth_ref": [] }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Other restricted assets", "label": "Payments for (Proceeds from) Other Investing Activities", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other." } } }, "auth_ref": [ "r885", "r897" ] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Repurchase of shares of common stock (Note 21)", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r41" ] }, "us-gaap_PaymentsOfDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDividends", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Dividends paid", "label": "Payments of Dividends", "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests." } } }, "auth_ref": [ "r41" ] }, "us-gaap_PaymentsOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfFinancingCosts", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments of deferred financing costs", "terseLabel": "Payments of deferred financing costs", "label": "Payments of Financing Costs", "documentation": "The cash outflow for loan and debt issuance costs." } } }, "auth_ref": [ "r40" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Repurchase of shares of common stock to satisfy tax withholding obligations", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r237" ] }, "ensg_PaymentsToAcquireAssetAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "PaymentsToAcquireAssetAcquisitions", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash payments for asset acquisitions (Note 7)", "label": "Payments To Acquire Asset Acquisitions", "documentation": "Cash paid to acquire acquisitions." } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments to acquire businesses, gross", "label": "Payments to Acquire Businesses, Gross", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r38", "r528" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash payments for business acquisitions (Note 7)", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r38" ] }, "us-gaap_PaymentsToAcquireInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireInvestments", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of investments", "label": "Payments to Acquire Investments", "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period." } } }, "auth_ref": [ "r144" ] }, "ensg_PaymentsToAcquirePropertyAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "PaymentsToAcquirePropertyAndEquipment", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of property and equipment", "label": "Payments To Acquire Property And Equipment", "documentation": "Payments To Acquire Property And Equipment" } } }, "auth_ref": [] }, "us-gaap_PaymentsToMinorityShareholders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToMinorityShareholders", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Non-controlling interest distribution", "label": "Payments to Noncontrolling Interests", "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest." } } }, "auth_ref": [ "r40" ] }, "ensg_PayorAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "PayorAxis", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payor [Axis]", "label": "Payor [Axis]", "documentation": "Payor [Axis]" } } }, "auth_ref": [] }, "ensg_PayorDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "PayorDomain", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payor [Domain]", "label": "Payor [Domain]", "documentation": "Payor [Domain]" } } }, "auth_ref": [] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r846" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r846" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r845" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r855" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r848" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r844" ] }, "ensg_PerFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "PerFacilityMember", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Per Facility", "label": "Per Facility [Member]", "documentation": "Per Facility [Member]" } } }, "auth_ref": [] }, "ensg_PerOccurenceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "PerOccurenceMember", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Per Occurence", "label": "Per Occurence [Member]", "documentation": "Per Occurence [Member]" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r895" ] }, "ensg_PrepaymentFeePeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "PrepaymentFeePeriodAxis", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepayment Fee, Period [Axis]", "label": "Prepayment Fee, Period [Axis]", "documentation": "Prepayment Fee, Period" } } }, "auth_ref": [] }, "ensg_PrepaymentFeePeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "PrepaymentFeePeriodDomain", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepayment Fee, Period [Domain]", "label": "Prepayment Fee, Period [Domain]", "documentation": "Prepayment Fee, Period [Domain]" } } }, "auth_ref": [] }, "ensg_PrepaymentPenalty": { "xbrltype": "percentItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "PrepaymentPenalty", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepayment penalty", "label": "Prepayment Penalty", "documentation": "Percentage that the prepayment penalty percentage is reduced during the first three years." } } }, "auth_ref": [] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassifications", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r892" ] }, "ensg_PrivatePayAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "PrivatePayAndOtherMember", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Private and other", "terseLabel": "Private and other payors", "label": "Private Pay and Other [Member]", "documentation": "Revenue from self-pay and Other payors [Member]" } } }, "auth_ref": [] }, "ensg_ProceedsFromCARESActProviderReliefFundsAndMedicareAdvancePaymentProgram": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "ProceedsFromCARESActProviderReliefFundsAndMedicareAdvancePaymentProgram", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from CARES Act Provider Relief Fund and Medicare Advance Payment Program (Note 3)", "label": "Proceeds From CARES Act Provider Relief Funds And Medicare Advance Payment Program", "documentation": "Proceeds From CARES Act Provider Relief Funds And Medicare Advance Payment Program" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromInsuranceSettlementInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromInsuranceSettlementInvestingActivities", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash from insurance proceeds", "label": "Proceeds from Insurance Settlement, Investing Activities", "documentation": "Amount of cash inflow for proceeds from settlement of insurance claim, classified as investing activities. Excludes insurance settlement classified as operating activities." } } }, "auth_ref": [ "r5", "r37" ] }, "us-gaap_ProceedsFromInsuranceSettlementOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromInsuranceSettlementOperatingActivities", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash received from insurance proceeds", "label": "Proceeds from Insurance Settlement, Operating Activities", "documentation": "Amount of cash inflow for proceeds from settlement of insurance claim, classified as operating activities. Excludes insurance settlement classified as investing activities." } } }, "auth_ref": [ "r240", "r745" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of common stock", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r3" ] }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of preferred shares", "label": "Proceeds from Issuance of Convertible Preferred Stock", "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock." } } }, "auth_ref": [ "r3" ] }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from debt (Note 15)", "label": "Proceeds from Issuance of Long-Term Debt", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r39", "r648" ] }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Maturities of investments", "label": "Proceeds from Sale, Maturity and Collection of Investments", "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period." } } }, "auth_ref": [ "r37" ] }, "ensg_ProceedsFromSaleOfCommonStockAssociatedWithSubsidiaryEquityPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "ProceedsFromSaleOfCommonStockAssociatedWithSubsidiaryEquityPlans", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of subsidiary shares (Note 6)", "label": "Proceeds From Sale Of Common Stock Associated With Subsidiary Equity Plans", "documentation": "Proceeds From Sale Of Common Stock Associated With Subsidiary Equity Plans" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfProductiveAssets", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash proceeds from the sale of assets", "label": "Proceeds from Sale of Productive Assets", "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": [ "r143" ] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of real estate", "label": "Proceeds from Sale of Property, Plant, and Equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r143" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock upon exercise of options", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r3", "r15" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails", "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r311", "r590", "r624", "r625", "r626", "r627", "r628", "r629", "r747", "r764", "r786", "r890", "r929", "r930", "r939", "r1063" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails", "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r311", "r590", "r624", "r625", "r626", "r627", "r628", "r629", "r747", "r764", "r786", "r890", "r929", "r930", "r939", "r1063" ] }, "us-gaap_ProfessionalMalpracticeLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfessionalMalpracticeLiabilityMember", "presentation": [ "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "General and Professional Liability", "label": "Professional Malpractice Liability Insurance [Member]", "documentation": "Business insurance coverage for professionals, such as doctors, lawyers, insurance agents, accountants, real estate agents, veterinarians, and others. This liability coverage insures losses for claims arising from mistakes and errors or omissions in the course of professional activities." } } }, "auth_ref": [] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "NET INCOME", "terseLabel": "Net income", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r213", "r228", "r229", "r239", "r247", "r255", "r263", "r264", "r286", "r300", "r306", "r309", "r322", "r363", "r364", "r366", "r367", "r368", "r370", "r372", "r374", "r375", "r529", "r532", "r533", "r545", "r548", "r595", "r607", "r653", "r689", "r706", "r707", "r755", "r781", "r782", "r800", "r896", "r932" ] }, "us-gaap_ProfitLossFromRealEstateOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLossFromRealEstateOperations", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain on sale of assets and insurance recoveries from real estate, net", "label": "Profit (Loss) from Real Estate Operations", "documentation": "The net cost of operation of other real estate (including provisions for real estate losses, rental income, and gains and losses on sales of real estate)." } } }, "auth_ref": [ "r192" ] }, "ensg_PropertyManagementFeePercentFeeOfFundsFromOperations": { "xbrltype": "percentItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "PropertyManagementFeePercentFeeOfFundsFromOperations", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Management fees, as a percentage of funds from operations", "label": "Property Management Fee, Percent Fee of Funds from Operations", "documentation": "Property Management Fee, Percent Fee of Funds from Operations" } } }, "auth_ref": [] }, "ensg_PropertyManagementFeePercentFeeOfTotalRevenues": { "xbrltype": "percentItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "PropertyManagementFeePercentFeeOfTotalRevenues", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Management fees, as a percentage of total revenues", "label": "Property Management Fee, Percent Fee of Total Revenues", "documentation": "Property Management Fee, Percent Fee of Total Revenues" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Abstract]", "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAdditions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAdditions", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails": { "parentTag": "ensg_BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment", "label": "Property, Plant and Equipment, Additions", "documentation": "Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails", "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r9" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNET" ], "lang": { "en-us": { "role": { "terseLabel": "PROPERTY AND EQUIPMENT\u2014 NET", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r154", "r201", "r204", "r205" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r155", "r217", "r605" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails", "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 }, "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS", "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "totalLabel": "PROPERTY AND EQUIPMENT, NET", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r9", "r596", "r605", "r785" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Property and Equipment", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r9", "r201", "r204", "r603" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property and Equipment, Net", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r9" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails", "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r155" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, useful life", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for doubtful accounts", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r236", "r326" ] }, "ensg_PurchaseOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "PurchaseOptionMember", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase Option", "label": "Purchase Option [Member]", "documentation": "Purchase Option" } } }, "auth_ref": [] }, "ensg_PurchasesOfNonControllingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "PurchasesOfNonControllingInterest", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of non-controlling interest", "label": "Purchases of Non-Controlling Interest", "documentation": "Purchases of Non-Controlling Interest" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r843" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r843" ] }, "us-gaap_QualifiedPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "QualifiedPlanMember", "presentation": [ "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Qualified Plan", "label": "Qualified Plan [Member]", "documentation": "Plan with tax-exempt status designed and operated in accordance with applicable tax provision of designated taxing authority. Taxing authority includes, but is not limited to, U.S. Internal Revenue Service (IRS). Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r886", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000" ] }, "ensg_QualityAssuranceFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "QualityAssuranceFee", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quality assurance fee", "label": "Quality Assurance Fee", "documentation": "Quality assurance fee represents amounts payable to California, Utah, Idaho, Washington, Colorado, Iowa, and Nebraska in respect of a mandated fee based on resident days" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r359", "r360", "r361", "r362", "r442", "r450", "r482", "r483", "r484", "r588", "r589", "r633", "r659", "r660", "r713", "r717", "r719", "r720", "r722", "r743", "r744", "r756", "r763", "r776", "r789", "r792", "r926", "r936", "r1052", "r1053", "r1054", "r1055", "r1056" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r359", "r360", "r361", "r362", "r442", "r450", "r482", "r483", "r484", "r588", "r589", "r633", "r659", "r660", "r713", "r717", "r719", "r720", "r722", "r743", "r744", "r756", "r763", "r776", "r789", "r792", "r926", "r936", "r1052", "r1053", "r1054", "r1055", "r1056" ] }, "us-gaap_RealEstatePropertiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstatePropertiesAxis", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate Property Ownership [Axis]", "label": "Real Estate Property Ownership [Axis]", "documentation": "Information by ownership of the property." } } }, "auth_ref": [] }, "us-gaap_RealEstatePropertiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstatePropertiesDomain", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate Properties [Domain]", "label": "Real Estate Properties [Domain]", "documentation": "Represents categories of ownership of real estate properties." } } }, "auth_ref": [] }, "us-gaap_RealEstatePropertiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstatePropertiesLineItems", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate Properties [Line Items]", "label": "Real Estate Properties [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "ensg_RealEstatePurchasesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "RealEstatePurchasesMember", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate Purchases", "label": "Real Estate Purchases [Member]", "documentation": "Real Estate Purchases" } } }, "auth_ref": [] }, "ensg_RealEstatePurchasesOfPreviousOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "RealEstatePurchasesOfPreviousOperationsMember", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate Purchases Of Previous Operations", "label": "Real Estate Purchases Of Previous Operations [Member]", "documentation": "Real Estate Purchases Of Previous Operations" } } }, "auth_ref": [] }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Revenue from Segments to Consolidated [Table]", "label": "Reconciliation of Revenue from Segments to Consolidated [Table]", "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues." } } }, "auth_ref": [ "r64", "r65" ] }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Service Revenue by Major Payor Source", "label": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]", "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues." } } }, "auth_ref": [ "r64", "r65" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r809", "r821", "r831", "r857" ] }, "ensg_ReductionInPrepaymentPenalty": { "xbrltype": "percentItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "ReductionInPrepaymentPenalty", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reduction in prepayment penalty", "label": "Reduction In Prepayment Penalty", "documentation": "Percentage that the prepayment penalty percentage is reduced during the fourth year." } } }, "auth_ref": [] }, "ensg_RentCostOfServices": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "RentCostOfServices", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Rent\u2014cost of services", "label": "Rent Cost Of Services", "documentation": "Rent cost of services" } } }, "auth_ref": [] }, "ensg_RentalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "RentalMember", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rental revenue", "label": "Rental [Member]", "documentation": "Rental" } } }, "auth_ref": [] }, "ensg_RepaymentOfFundsReceivedFromTheMedicareAcceleratedAndAdvancePaymentProgramCARESAct": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "RepaymentOfFundsReceivedFromTheMedicareAcceleratedAndAdvancePaymentProgramCARESAct", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repayment of medicare accelerated and advance payment program", "label": "Repayment Of Funds Received From The Medicare Accelerated and Advance Payment Program, CARES Act", "documentation": "Repayment Of Funds Received From The Medicare Accelerated and Advance Payment Program, CARES Act" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments on debt (Note 15)", "label": "Repayments of Long-Term Debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r42", "r649" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r249", "r250", "r380", "r408", "r582", "r751", "r752" ] }, "ensg_ResidentRefundsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "ResidentRefundsPayable", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Refunds payable", "label": "Resident Refunds Payable", "documentation": "Resident refunds payable includes amounts due to residents for overpayments and duplicate payments" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r810", "r822", "r832", "r858" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r811", "r823", "r833", "r859" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r818", "r830", "r840", "r866" ] }, "ensg_RestrictedAndOtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "RestrictedAndOtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 }, "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS", "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted and other assets", "totalLabel": "RESTRICTED AND OTHER ASSETS", "label": "Restricted And Other Assets, Noncurrent", "documentation": "Restricted And Other Assets, Noncurrent" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Awards", "verboseLabel": "Stock-based compensation expense related to restricted stock awards", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r51" ] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveAxis", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Type [Axis]", "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": [ "r350", "r351", "r354", "r355" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r129", "r162", "r600", "r638", "r639", "r650", "r670", "r785" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r209", "r252", "r253", "r254", "r256", "r262", "r264", "r323", "r324", "r491", "r492", "r493", "r516", "r517", "r536", "r538", "r539", "r541", "r543", "r634", "r636", "r654", "r1071" ] }, "us-gaap_RetirementPlanTaxStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetirementPlanTaxStatusAxis", "presentation": [ "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Tax Status [Axis]", "label": "Retirement Plan Tax Status [Axis]", "documentation": "Information by tax status of plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r886", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000" ] }, "us-gaap_RetirementPlanTaxStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetirementPlanTaxStatusDomain", "presentation": [ "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Tax Status [Domain]", "label": "Retirement Plan Tax Status [Domain]", "documentation": "Tax status of plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r886", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]", "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails", "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "TOTAL REVENUE", "netLabel": "Revenue", "verboseLabel": "Total Service Revenue", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r287", "r288", "r299", "r304", "r305", "r311", "r313", "r315", "r438", "r439", "r590" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Service Revenue Recognition, Rental Revenue Recognition", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r208", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r746" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLE" ], "lang": { "en-us": { "role": { "terseLabel": "REVENUE AND ACCOUNTS RECEIVABLE", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r208", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r441" ] }, "ensg_RevenueRecognitionFamilyFirstCoronavirusResponseActRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "RevenueRecognitionFamilyFirstCoronavirusResponseActRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, FMAP payments received", "label": "Revenue Recognition, Family First Coronavirus Response Act, Revenue Recognized", "documentation": "Revenue Recognition, Family First Coronavirus Response Act, Revenue Recognized" } } }, "auth_ref": [] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving credit facility with Truist", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets obtained in exchange for new and modified operating lease obligations", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r571", "r784" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r875" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r875" ] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesRevenueNetMember", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r315", "r887" ] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "presentation": [ "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]", "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth_ref": [ "r34" ] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "presentation": [ "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accounts Receivable", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth_ref": [ "r34" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Accrued Liabilities", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Indefinite-lived Intangible Assets", "label": "Schedule of Acquired Indefinite-Lived Intangible Assets by Major Class [Table Text Block]", "documentation": "Tabular disclosure of acquired indefinite-lived intangible assets. Indefinite-lived intangible assets are assets that have no physical form, but have expected future economic benefit. Indefinite-lived assets are assets that are not subject to amortization. Acquired indefinite-lived intangible assets are disclosed by major class (assets that can be grouped together because they are similar, either by their nature or by their use in operations of the entity) and in total." } } }, "auth_ref": [ "r70" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": [ "r96", "r97", "r526" ] }, "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Employee Stock Option Roll Forward", "label": "Schedule of Common Stock Outstanding Roll Forward [Table Text Block]", "documentation": "Tabular disclosure of the change in common stock outstanding." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r172" ] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://www.ensigngroup.net/role/DEBTTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Debt", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r30", "r76", "r77", "r110", "r111", "r113", "r118", "r160", "r161", "r759", "r761", "r904" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Deferred Tax Assets and Liabilities", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r171" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "presentation": [ "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciliation of the Numerator and Denominator Used in the Calculation of Basic Net Income Per Common Share", "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block]", "documentation": "Tabular disclosure of the effect of income (loss) on basic earnings per share." } } }, "auth_ref": [ "r50", "r52", "r908" ] }, "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "presentation": [ "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciliation of the Numerator and Denominator Used in the Calculation of Diluted Net Income Per Common Share", "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block]", "documentation": "Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share." } } }, "auth_ref": [ "r50", "r52", "r908" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r170" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r90" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock-Based Compensation Expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r90" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails", "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r69", "r72", "r591" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r69", "r72" ] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTable", "presentation": [ "http://www.ensigngroup.net/role/GOODWILLDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill [Table]", "label": "Schedule of Goodwill [Table]", "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons." } } }, "auth_ref": [ "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r340", "r757" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://www.ensigngroup.net/role/GOODWILLTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r757", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925" ] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofIndefinitelivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]", "label": "Schedule of Indefinite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity." } } }, "auth_ref": [ "r18", "r153" ] }, "us-gaap_ScheduleOfLiabilityForFuturePolicyBenefitsByProductSegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfLiabilityForFuturePolicyBenefitsByProductSegmentTextBlock", "presentation": [ "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Liability for Future Policy Benefits, by Product Segment", "label": "Schedule of Liability for Future Policy Benefits, by Product Segment [Table Text Block]", "documentation": "The entire disclosure for the present values of future benefits to be paid to or on behalf of policyholders and related expenses less the present value of future net premiums using assumptions such as estimates of expected investment yields, mortality, morbidity, terminations and expenses, applicable at the time the insurance contracts are made and unpaid claim costs relating to insurance contracts including estimates of costs relating to incurred but not reported claims based on the estimated ultimate cost of settling the claims (including effects of inflation and other societal and economic factors), using past experience adjusted for current trends and any other factors that would modify past experience by element such as business segment, country and interest rate range." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis", "presentation": [ "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Insurance Type and Tier Identifier [Axis]", "label": "Insurance Type and Tier Identifier [Axis]", "documentation": "Information by type of insurance coverage or layer of insurance that covers malpractice claims." } } }, "auth_ref": [ "r194" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://www.ensigngroup.net/role/DEBTTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Maturities of Long-term Debt", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r10" ] }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Nonvested Restricted Stock Awards", "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units." } } }, "auth_ref": [ "r85" ] }, "us-gaap_ScheduleOfOtherAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOtherAssetsTableTextBlock", "presentation": [ "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restricted and Other Assets", "label": "Schedule of Other Assets [Table Text Block]", "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails", "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Property, Plant and Equipment [Table]", "terseLabel": "Schedule of Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r9" ] }, "us-gaap_ScheduleOfRealEstatePropertiesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRealEstatePropertiesTable", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Real Estate Properties [Table]", "label": "Schedule of Real Estate Properties [Table]", "documentation": "Schedule detailing quantitative information concerning real estate properties and units within those properties by ownership of the property." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Purchase Price Allocation", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": [ "r175" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails", "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r61", "r62", "r63", "r66" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Financial Information", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r61", "r62", "r63", "r66" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r452", "r454", "r457", "r458", "r459", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r481", "r482", "r483", "r484", "r485" ] }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]", "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "auth_ref": [ "r83" ] }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options Outstanding, Vested and Related Details", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]", "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms." } } }, "auth_ref": [ "r83" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assumptions for Stock Options Granted", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r169" ] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Estimated Amortization Expense", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r72" ] }, "ensg_SecuredOvernightFinancingRateSOFRMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "SecuredOvernightFinancingRateSOFRMember", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Overnight Financing Rate (SOFR)", "label": "Secured Overnight Financing Rate (SOFR) [Member]", "documentation": "Secured Overnight Financing Rate (SOFR)" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r802" ] }, "us-gaap_SecurityDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecurityDeposit", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails": { "parentTag": "ensg_RestrictedAndOtherAssetsNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deposits with landlords", "label": "Security Deposit", "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease." } } }, "auth_ref": [ "r893" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r805" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDomain", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails", "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/GOODWILLDetails", "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r283", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r309", "r315", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r353", "r356", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r757", "r890", "r1063" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r313", "r314", "r656", "r657", "r658", "r714", "r718", "r721", "r723", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r748", "r765", "r792", "r939", "r1063" ] }, "ensg_SegmentIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "SegmentIncomeLoss", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment income (loss)", "label": "Segment Income (Loss)", "documentation": "Segment Income (Loss)" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "BUSINESS SEGMENTS", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r282", "r283", "r284", "r285", "r286", "r298", "r303", "r307", "r308", "r309", "r310", "r311", "r312", "r315" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails", "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingRevenueReconcilingItemLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingRevenueReconcilingItemLineItems", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting, Revenue Reconciling Item [Line Items]", "label": "Segment Reporting, Revenue Reconciling Item [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SelfInsuranceReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SelfInsuranceReserve", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Self insurance reserve", "label": "Self Insurance Reserve", "documentation": "Carrying amount (including both current and noncurrent portions) of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property." } } }, "auth_ref": [ "r31" ] }, "us-gaap_SelfInsuranceReserveCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SelfInsuranceReserveCurrent", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued self-insurance liabilities\u2014current", "label": "Self Insurance Reserve, Current", "documentation": "Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid within one year (or the normal operating cycle, if longer)." } } }, "auth_ref": [] }, "us-gaap_SelfInsuranceReserveNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SelfInsuranceReserveNoncurrent", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued self-insurance liabilities\u2014less current portion", "label": "Self Insurance Reserve, Noncurrent", "documentation": "Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid after one year (or the normal operating cycle, if longer)." } } }, "auth_ref": [] }, "us-gaap_SelfInsuranceReservePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SelfInsuranceReservePolicyTextBlock", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Self-Insurance", "label": "Self Insurance Reserve [Policy Text Block]", "documentation": "Disclosure of accounting policy for self-insurance reserves, including, but not limited to incurred but not reported reserves (IBNR)." } } }, "auth_ref": [] }, "ensg_SelfInsuranceRetentionPerClaimMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "SelfInsuranceRetentionPerClaimMember", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Self-Insurance Retention Per Claim", "label": "Self-insurance Retention Per Claim [Member]", "documentation": "Self-insurance retention per claim [Member]" } } }, "auth_ref": [] }, "ensg_SeniorLivingFacilities": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "SeniorLivingFacilities", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior living facilities", "label": "Senior Living Facilities", "documentation": "Number of Assisted and Independent Living Facilities" } } }, "auth_ref": [] }, "ensg_SeniorLivingFacilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "SeniorLivingFacilitiesMember", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Living Facilities", "label": "Senior Living Facilities [Member]", "documentation": "Assisted Living Facilities [Member]" } } }, "auth_ref": [] }, "ensg_SeniorLivingOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "SeniorLivingOperationsMember", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Living Operations", "label": "Senior Living Operations [Member]", "documentation": "Senior Living Operations" } } }, "auth_ref": [] }, "us-gaap_SeriesOfIndividuallyImmaterialAssetAcquisitionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesOfIndividuallyImmaterialAssetAcquisitionsMember", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series of Individually Immaterial Asset Acquisitions", "label": "Series of Individually Immaterial Asset Acquisitions [Member]", "documentation": "Series of individually immaterial asset acquisitions." } } }, "auth_ref": [ "r1034" ] }, "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series of Individually Immaterial Business Acquisitions", "label": "Series of Individually Immaterial Business Acquisitions [Member]", "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period." } } }, "auth_ref": [ "r97" ] }, "us-gaap_ServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ServiceMember", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails", "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Service revenue", "label": "Service [Member]", "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service." } } }, "auth_ref": [ "r764" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 23.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r6" ] }, "ensg_ShareBasedCompensationArrangementByShareBasedAwardOptionsFairValueAssumptionsForfeitureRate": { "xbrltype": "percentItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedAwardOptionsFairValueAssumptionsForfeitureRate", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeiture rate", "label": "Share-Based Compensation Arrangement By Share-Based Award, Options, Fair Value, Assumptions Forfeiture Rate", "documentation": "Share-Based Compensation Arrangement By Share-Based Award, Options, Fair Value, Assumptions Forfeiture Rate" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award requisite service period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period", "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r777" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r777" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r474" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted restricted shares (in shares)", "verboseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r472" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r472" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Nonvested at beginning of period (in shares)", "periodEndLabel": "Nonvested at end of period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r469", "r470" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Vested Restricted Awards", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Nonvested at beginning of period (in dollars per share)", "periodEndLabel": "Nonvested at end of period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r469", "r470" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Date Fair Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r473" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r473" ] }, "ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEventPeriodAfterVestingOfRestrictedAwardsOrExerciseOfStockOptions": { "xbrltype": "durationItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEventPeriodAfterVestingOfRestrictedAwardsOrExerciseOfStockOptions", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Threshold event period after vesting of restricted awards or exercise of stock options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Event Period After Vesting Of Restricted Awards Or Exercise Of Stock Options", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Event Period After Vesting Of Restricted Awards Or Exercise Of Stock Options" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Dividend Yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r483" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Risk-Free Rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r484" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate", "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement." } } }, "auth_ref": [ "r482" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r452", "r454", "r457", "r458", "r459", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r481", "r482", "r483", "r484", "r485" ] }, "ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallments": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallments", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of installments", "label": "Share-based Compensation Arrangement By Share-based Payment Award, Number Of Installments", "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Number Of Installments" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares authorized (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r779" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares available for grant (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r83" ] }, "ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConversionToReduceSharesAvailability": { "xbrltype": "pureItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConversionToReduceSharesAvailability", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion to reduce shares availability", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion To Reduce Shares Availability", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion To Reduce Shares Availability" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price of Options Vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r463" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intrinsic value of options exercised in period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r476" ] }, "ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber": { "xbrltype": "sharesItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation, options expected to vest, number (in shares)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Number", "documentation": "As of the balance sheet date, the number of shares which are expected to vest into stock options outstanding can be converted under the option plan." } } }, "auth_ref": [] }, "ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSIntrinsicValuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected to vest", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": [ "r1007" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": [ "r1007" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Grant date intrinsic value (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value", "documentation": "The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r475" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSExercisePriceandFairValueDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSValuationAssumptionsDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "verboseLabel": "Options granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r465" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSExercisePriceandFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Fair Value of Options (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r475" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Exercise Price and Fair Value Displayed at Grant Date for Stock Option Grants", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]", "documentation": "Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year." } } }, "auth_ref": [ "r87" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSIntrinsicValuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r83" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at beginning of period, (in shares)", "periodEndLabel": "Balance at end of period, (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r461", "r462" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Options Outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at beginning of period (in dollars per share)", "periodEndLabel": "Balance at end of period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r461", "r462" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Aggregate Intrinsic Value of Options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable [Table Text Block]", "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for exercisable or convertible options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r168" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Options Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r477" ] }, "ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionToReduceSharesAvailability": { "xbrltype": "pureItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionToReduceSharesAvailability", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other than options, conversion to reduce shares availability", "label": "Share-based Compensation Arrangement By Share-based Payment Award, Other Than Options, Conversion To Reduce Shares Availability", "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Other Than Options, Conversion To Reduce Shares Availability" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r457", "r458", "r459", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r481", "r482", "r483", "r484", "r485" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r466" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSExercisePriceandFairValueDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price (in dollars per share)", "verboseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r465" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-Based Compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r451", "r460", "r479", "r480", "r481", "r482", "r485", "r494", "r495", "r496", "r497" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price Range [Axis]", "label": "Exercise Price Range [Axis]", "documentation": "Information by range of option prices pertaining to options granted." } } }, "auth_ref": [ "r88" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price Range [Domain]", "label": "Exercise Price Range [Domain]", "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "auth_ref": [ "r89" ] }, "ensg_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Black-Scholes Fair Value", "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Fair Value", "documentation": "Fair value determined using a black-scholes model for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price, lower range limit (in dollars per share)", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit", "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range." } } }, "auth_ref": [ "r89" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options vested and exercisable (in shares)", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable", "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied." } } }, "auth_ref": [ "r86" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number outstanding (in shares)", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding", "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices." } } }, "auth_ref": [ "r84" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price, upper range limit (in dollars per share)", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit", "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range." } } }, "auth_ref": [ "r89" ] }, "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedPaymentArrangementNonemployeeMember", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-employee Directors", "label": "Share-Based Payment Arrangement, Nonemployee [Member]", "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires." } } }, "auth_ref": [ "r452", "r457", "r458", "r459", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r481", "r482", "r483", "r484", "r485" ] }, "us-gaap_ShareRepurchaseProgramAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareRepurchaseProgramAxis", "presentation": [ "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Axis]", "label": "Share Repurchase Program [Axis]", "documentation": "Information by share repurchase program." } } }, "auth_ref": [] }, "us-gaap_ShareRepurchaseProgramDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareRepurchaseProgramDomain", "presentation": [ "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Domain]", "label": "Share Repurchase Program [Domain]", "documentation": "Name of the share repurchase program." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award vesting rights, percentage", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r1001" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value of options that vested in period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested", "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r778" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected Life", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r481" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSIntrinsicValuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r83" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation, options outstanding, weighted average remaining contractual term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r167" ] }, "ensg_SharebasedCompensationRestrictedAwardsExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "SharebasedCompensationRestrictedAwardsExercisePrice", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation, restricted awards, exercise price (in dollars per share)", "label": "Share-based Compensation, Restricted Awards, Exercise Price", "documentation": "Share-based Compensation, Restricted Awards, Exercise Price" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining Contractual Life (Years)", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r168" ] }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Shares of common stock used to satisfy tax withholding obligations (in shares)", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermInvestments", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Investments\u2014current", "label": "Short-Term Investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": [ "r188", "r189", "r894" ] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermLeaseCost", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CPI increases and short term-lease cost", "label": "Short-Term Lease, Cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": [ "r567", "r784" ] }, "ensg_SkilledNursingOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "SkilledNursingOperationsMember", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Skilled Nursing Operations", "label": "Skilled Nursing Operations [Member]", "documentation": "Skilled Nursing Operations" } } }, "auth_ref": [] }, "ensg_SkilledNursingSeniorLivingAndIndependentLivingFacilities": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "SkilledNursingSeniorLivingAndIndependentLivingFacilities", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Skilled nursing, assisted living and independent living facilities", "label": "Skilled Nursing, Senior Living and Independent Living Facilities", "documentation": "Skilled Nursing, Senior Living and Independent Living Facilities" } } }, "auth_ref": [] }, "ensg_SkilledServiceFacilities": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "SkilledServiceFacilities", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transitional and skilled service facilities", "label": "Skilled Service Facilities", "documentation": "Skilled Service Facilities" } } }, "auth_ref": [] }, "ensg_SkilledServicesAndSeniorLivingCampuses": { "xbrltype": "integerItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "SkilledServicesAndSeniorLivingCampuses", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transitional and skilled services and senior living campuses", "label": "Skilled Services And Senior Living Campuses", "documentation": "Transitional and Skilled Services and Assistant and Independent Living Campuses" } } }, "auth_ref": [] }, "ensg_SkilledServicesSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "SkilledServicesSegmentMember", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails", "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/GOODWILLDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Skilled Services", "label": "Skilled Services Segment [Member]", "documentation": "Skilled Services Segment" } } }, "auth_ref": [] }, "us-gaap_SpinoffMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SpinoffMember", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Spinoff", "label": "Spinoff [Member]", "documentation": "Creation of an independent entity from an existing entity through divestiture, for example, but not limited to, sale or distribution of new shares." } } }, "auth_ref": [] }, "ensg_StandardBearerEquityPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "StandardBearerEquityPlanMember", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Standard Bearer Equity Plan", "label": "Standard Bearer Equity Plan [Member]", "documentation": "Standard Bearer Equity Plan" } } }, "auth_ref": [] }, "ensg_StandardBearerHealthcareREITIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "StandardBearerHealthcareREITIncMember", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Standard Bearer Healthcare REIT, Inc.", "label": "Standard Bearer Healthcare REIT, Inc. [Member]", "documentation": "Standard Bearer Healthcare REIT, Inc." } } }, "auth_ref": [] }, "ensg_StandardBearerMasterLeasesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "StandardBearerMasterLeasesMember", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Standard Bearer Master Leases", "label": "Standard Bearer Master Leases [Member]", "documentation": "Standard Bearer Master Leases" } } }, "auth_ref": [] }, "ensg_StandardBearerSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "StandardBearerSegmentMember", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Standard Bearer", "label": "Standard Bearer Segment [Member]", "documentation": "Standard Bearer Segment" } } }, "auth_ref": [] }, "ensg_StandardBearerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "StandardBearerTextBlock", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARER" ], "lang": { "en-us": { "role": { "terseLabel": "STANDARD BEARER", "label": "Standard Bearer [Text Block]", "documentation": "Standard Bearer" } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails", "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails", "http://www.ensigngroup.net/role/GOODWILLDetails", "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r211", "r283", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r309", "r315", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r349", "r353", "r356", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r757", "r890", "r1063" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r14", "r33", "r209", "r231", "r232", "r233", "r252", "r253", "r254", "r256", "r262", "r264", "r281", "r323", "r324", "r419", "r491", "r492", "r493", "r516", "r517", "r536", "r537", "r538", "r539", "r540", "r541", "r543", "r549", "r550", "r551", "r552", "r553", "r554", "r581", "r634", "r635", "r636", "r654", "r708" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r313", "r314", "r656", "r657", "r658", "r714", "r718", "r721", "r723", "r727", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r748", "r765", "r792", "r939", "r1063" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r252", "r253", "r254", "r281", "r590", "r643", "r655", "r661", "r662", "r663", "r664", "r665", "r666", "r669", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r682", "r683", "r684", "r685", "r686", "r688", "r690", "r691", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r708", "r793" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r252", "r253", "r254", "r281", "r590", "r643", "r655", "r661", "r662", "r663", "r664", "r665", "r666", "r669", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r682", "r683", "r684", "r685", "r686", "r688", "r690", "r691", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r708", "r793" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r813", "r825", "r835", "r861" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "ensg_StockAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "StockAwardsMember", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors", "label": "Stock awards [Member]", "documentation": "Stock awards [Member]" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r14", "r126", "r127", "r162", "r648", "r708", "r724" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Forfeited (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited", "documentation": "Number of shares related to Restricted Stock Award forfeited during the period." } } }, "auth_ref": [ "r14", "r126", "r127", "r162" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of restricted stock, net of forfeitures (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": [ "r14", "r126", "r127", "r162" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r14", "r126", "r127", "r162", "r466" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r14", "r126", "r127", "r162", "r654", "r708", "r724", "r800" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of restricted stock, net of forfeitures", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": [ "r14", "r162" ] }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock repurchase program, authorized amount", "label": "Stock Repurchase Program, Authorized Amount", "documentation": "Amount of stock repurchase plan authorized." } } }, "auth_ref": [] }, "us-gaap_StockRepurchaseProgramPeriodInForce1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramPeriodInForce1", "presentation": [ "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock repurchase program, period in force", "label": "Stock Repurchase Program, Period in Force", "documentation": "Period which shares may be purchased under a stock repurchase plan authorized by an entity's Board of Directors, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total Ensign Group, Inc. stockholders' equity", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r127", "r130", "r131", "r149", "r671", "r687", "r709", "r710", "r785", "r801", "r902", "r913", "r1039", "r1071" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Ensign Group, Inc. stockholders' equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "totalLabel": "Total equity", "periodStartLabel": "Balance at beginning of period", "periodEndLabel": "Balance at end of period", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r100", "r101", "r103", "r209", "r210", "r232", "r252", "r253", "r254", "r256", "r262", "r323", "r324", "r419", "r491", "r492", "r493", "r516", "r517", "r536", "r537", "r538", "r539", "r540", "r541", "r543", "r549", "r550", "r554", "r581", "r635", "r636", "r652", "r671", "r687", "r709", "r710", "r725", "r800", "r902", "r913", "r1039", "r1071" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAM" ], "lang": { "en-us": { "role": { "verboseLabel": "COMMON STOCK REPURCHASE PROGRAM", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r159", "r246", "r406", "r407", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r542", "r711", "r712", "r726" ] }, "ensg_StopLossInsuranceLimitPerClaimMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "StopLossInsuranceLimitPerClaimMember", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stop-Loss Insurance Limit Per Claim", "label": "Stop-Loss Insurance Limit Per Claim [Member]", "documentation": "Stop-Loss Insurance limit per claim[Member]" } } }, "auth_ref": [] }, "us-gaap_SubleaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubleaseIncome", "crdr": "credit", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails", "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sublease income", "label": "Sublease Income", "documentation": "Amount of sublease income excluding finance and operating lease expense." } } }, "auth_ref": [ "r569", "r784" ] }, "ensg_SubleaseOfStandAlongSkilledNursingOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "SubleaseOfStandAlongSkilledNursingOperationsMember", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sublease Of Stand Along Skilled Nursing Operations", "label": "Sublease Of Stand Along Skilled Nursing Operations [Member]", "documentation": "Sublease Of Stand Along Skilled Nursing Operations" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r555", "r584" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r555", "r584" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r555", "r584" ] }, "srt_SubsidiariesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SubsidiariesMember", "presentation": [ "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Captive Insurance Subsidiary", "label": "Subsidiaries [Member]" } } }, "auth_ref": [ "r986", "r1046", "r1047", "r1048" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "stpr_TX": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2023", "localname": "TX", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Texas", "label": "TEXAS" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r854" ] }, "ensg_ThePennantGroupInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "ThePennantGroupInc.Member", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "The Pennant Group, Inc.", "verboseLabel": "Pennant", "label": "The Pennant Group, Inc. [Member]", "documentation": "The Pennant Group, Inc." } } }, "auth_ref": [] }, "ensg_ThirdPartiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "ThirdPartiesMember", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Third Parties", "label": "Third Parties [Member]", "documentation": "Third Parties" } } }, "auth_ref": [] }, "ensg_ThirdPartyOperatorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "ThirdPartyOperatorsMember", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Third Party Operators", "label": "Third Party Operators [Member]", "documentation": "Third Party Operators" } } }, "auth_ref": [] }, "ensg_ThirdPartyTenantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "ThirdPartyTenantsMember", "presentation": [ "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other third-party", "label": "Third Party Tenants [Member]", "documentation": "Third Party Tenants [Member]" } } }, "auth_ref": [] }, "ensg_TotalNetDebtRatioMaximum": { "xbrltype": "pureItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "TotalNetDebtRatioMaximum", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total net debt ratio, maximum", "label": "Total Net Debt Ratio, Maximum", "documentation": "Total Net Debt Ratio, Maximum" } } }, "auth_ref": [] }, "ensg_TotalNetDebtRatioMaximumAfterIncreaseElection": { "xbrltype": "pureItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "TotalNetDebtRatioMaximumAfterIncreaseElection", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total net debt ratio, maximum after increase election", "label": "Total Net Debt Ratio, Maximum After Increase Election", "documentation": "Total Net Debt Ratio, Maximum After Increase Election" } } }, "auth_ref": [] }, "ensg_TotalNetDebtRatioMinimum": { "xbrltype": "pureItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "TotalNetDebtRatioMinimum", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total net debt ratio, minimum", "label": "Total Net Debt Ratio, Minimum", "documentation": "Total Net Debt Ratio, Minimum" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r846" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r853" ] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable", "label": "Accounts Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r195", "r196", "r197", "r318", "r319", "r321" ] }, "us-gaap_TradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeNamesMember", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofIndefinitelivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade name", "verboseLabel": "Facility trade name", "label": "Trade Names [Member]", "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": [ "r98" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r874" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r876" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r877" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r878" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r876" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r876" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r879" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r877" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r79" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares in treasury, at cost", "periodStartLabel": "Balance at beginning of period (in shares)", "periodEndLabel": "Balance at end of period (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r79" ] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Common stock in treasury, at cost, 3,390 and 3,368 shares at December\u00a031, 2023 and 2022, respectively", "label": "Treasury Stock, Common, Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r35", "r79", "r82" ] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockSharesAcquired", "presentation": [ "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Repurchase of common stock (in shares)", "verboseLabel": "Repurchase of common stock (in shares)", "label": "Treasury Stock, Shares, Acquired", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": [ "r14", "r127", "r162" ] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": [ "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedLabel": "Repurchase of common stock (Note 21)", "verboseLabel": "Repurchase of common stock, value", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": [ "r14", "r79", "r162" ] }, "ensg_TripleNetLeaseArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "TripleNetLeaseArrangementsMember", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Triple Net Lease Arrangements", "label": "Triple Net Lease Arrangements [Member]", "documentation": "Triple Net Lease Arrangements" } } }, "auth_ref": [] }, "ensg_TruistBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "TruistBankMember", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Truist", "label": "Truist Bank [Member]", "documentation": "Truist Bank [Member]" } } }, "auth_ref": [] }, "ensg_TwentyThreeSubsidiariesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "TwentyThreeSubsidiariesMember", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Twenty Three Subsidiaries", "label": "Twenty Three Subsidiaries [Member]", "documentation": "Twenty Three Subsidiaries" } } }, "auth_ref": [] }, "us-gaap_TypeAndTierIdentifierDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeAndTierIdentifierDomain", "presentation": [ "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Type and Tier Identifier [Domain]", "label": "Type and Tier Identifier [Domain]", "documentation": "Name of the type of insurance coverage or layer of insurance that covers malpractice claims." } } }, "auth_ref": [ "r194" ] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfRestructuringDomain", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Type of Restructuring [Domain]", "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": [ "r350", "r351", "r354", "r355" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r873" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Estimates and Assumptions", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r58", "r59", "r60", "r199", "r200", "r202", "r203" ] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableLeaseCost", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable lease, costs", "label": "Variable Lease, Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r568", "r784" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "ensg_VariousLandlordsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "VariousLandlordsMember", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Various Landlords", "label": "Various Landlords [Member]", "documentation": "Various Landlords[Member]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "totalLabel": "Adjusted weighted average common shares outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r267", "r275" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "WEIGHTED AVERAGE COMMON SHARES OUTSTANDING", "verboseLabel": "DENOMINATOR:", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "verboseLabel": "Basic (in shares)", "terseLabel": "Weighted average shares outstanding for basic net income per share (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r266", "r275" ] }, "us-gaap_WhollyOwnedPropertiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WhollyOwnedPropertiesMember", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Owned Properties", "label": "Wholly Owned Properties [Member]", "documentation": "Real estate properties and units within those properties that are wholly owned." } } }, "auth_ref": [] }, "us-gaap_WorkersCompensationInsuranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WorkersCompensationInsuranceMember", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Workers' Compensation", "label": "Workers' Compensation Insurance [Member]", "documentation": "Contract providing insurance coverage for employer's liability related to injury, disability, or death." } } }, "auth_ref": [ "r1066" ] }, "us-gaap_WriteOffOfDeferredDebtIssuanceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WriteOffOfDeferredDebtIssuanceCost", "crdr": "debit", "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Write-off of deferred financing fees", "label": "Deferred Debt Issuance Cost, Writeoff", "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt." } } }, "auth_ref": [ "r141" ] }, "ensg_YearsFiveThroughTenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ensigngroup.net/20231231", "localname": "YearsFiveThroughTenMember", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Years Five Through Ten", "label": "Years Five Through Ten [Member]", "documentation": "Years Five Through Ten" } } }, "auth_ref": [] }, "naics_ZZ524292": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/naics/2023", "localname": "ZZ524292", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Third-Party Payor", "label": "524292 Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds [Member]" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21B", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21B" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(2)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b),(d)", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-4" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "60", "Paragraph": "1", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "SubTopic": "30", "Topic": "835", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479359/835-30-S45-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.3,4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-3" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)-(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "720", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483384/720-30-45-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-24" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "40", "Section": "50", "Paragraph": "3", "Subparagraph": "(b),(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(c),9(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "710", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//710/tableOfContent" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "712", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//712/tableOfContent" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//715/tableOfContent" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "12", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "9", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-23" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r182": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r183": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r184": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r185": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r186": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r187": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r188": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r189": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r190": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r191": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r192": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.14(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r193": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r194": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "954", "SubTopic": "450", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480598/954-450-50-1" }, "r195": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r196": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15" }, "r197": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21B" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482964/270-10-50-6A" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350-20/tableOfContent" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350-30/tableOfContent" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-30/tableOfContent" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479016/842-30-45-3" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-12" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-3" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-5" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-5" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//944-40/tableOfContent" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-6" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-6" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "12", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-12" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-4" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480602/954-210-50-2" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-16" }, "r746": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r747": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r748": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r749": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r751": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r752": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r753": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r754": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r755": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r756": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r757": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r758": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r759": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r760": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r761": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r762": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r763": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r764": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r765": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r766": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r767": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r768": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r769": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r770": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r771": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r773": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r774": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r775": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r776": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r777": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r778": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r779": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r780": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479908/805-50-55-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r782": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r783": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r784": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r785": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r786": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r787": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13I" }, "r788": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29E" }, "r789": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r790": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r791": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r792": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r793": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r794": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r795": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r796": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r797": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "405", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480191/946-405-45-2" }, "r799": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r800": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r801": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r802": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r803": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r804": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r805": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r806": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r807": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r808": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r809": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r810": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r811": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r812": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r813": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r814": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r815": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r816": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r817": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r818": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r819": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r820": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r821": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r822": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r823": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r825": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r826": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r827": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r828": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r829": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r830": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r831": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r832": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r833": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r834": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r835": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r836": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r837": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r838": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r839": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r840": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r841": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r842": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r843": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r844": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r845": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r846": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r847": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r848": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r849": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r850": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r851": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r852": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r853": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r854": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r855": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r856": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r857": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r858": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r859": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r860": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r861": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r862": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r863": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r864": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r865": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r866": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r867": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r868": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r869": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r870": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r871": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r872": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r873": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r874": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r875": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r876": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r877": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r878": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r879": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r880": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r881": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r882": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r883": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "SubTopic": "740", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480887/718-740-35-2" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "325", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481551/325-30-35-2" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-8" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-12" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-3" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(13)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-6" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-9C" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 128 0001125376-24-000018-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001125376-24-000018-xbrl.zip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�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�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�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end XML 129 ensg-20231231_htm.xml IDEA: XBRL DOCUMENT 0001125376 2023-01-01 2023-12-31 0001125376 2023-06-30 0001125376 2024-01-29 0001125376 2023-12-31 0001125376 2022-12-31 0001125376 us-gaap:ServiceMember 2023-01-01 2023-12-31 0001125376 us-gaap:ServiceMember 2022-01-01 2022-12-31 0001125376 us-gaap:ServiceMember 2021-01-01 2021-12-31 0001125376 ensg:RentalMember 2023-01-01 2023-12-31 0001125376 ensg:RentalMember 2022-01-01 2022-12-31 0001125376 ensg:RentalMember 2021-01-01 2021-12-31 0001125376 2022-01-01 2022-12-31 0001125376 2021-01-01 2021-12-31 0001125376 us-gaap:CommonStockMember 2020-12-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001125376 us-gaap:RetainedEarningsMember 2020-12-31 0001125376 us-gaap:TreasuryStockCommonMember 2020-12-31 0001125376 us-gaap:NoncontrollingInterestMember 2020-12-31 0001125376 2020-12-31 0001125376 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001125376 us-gaap:TreasuryStockCommonMember 2021-01-01 2021-12-31 0001125376 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001125376 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-12-31 0001125376 us-gaap:CommonStockMember 2021-12-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001125376 us-gaap:RetainedEarningsMember 2021-12-31 0001125376 us-gaap:TreasuryStockCommonMember 2021-12-31 0001125376 us-gaap:NoncontrollingInterestMember 2021-12-31 0001125376 2021-12-31 0001125376 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001125376 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-12-31 0001125376 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001125376 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-12-31 0001125376 us-gaap:CommonStockMember 2022-12-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001125376 us-gaap:RetainedEarningsMember 2022-12-31 0001125376 us-gaap:TreasuryStockCommonMember 2022-12-31 0001125376 us-gaap:NoncontrollingInterestMember 2022-12-31 0001125376 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001125376 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-12-31 0001125376 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001125376 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-12-31 0001125376 us-gaap:CommonStockMember 2023-12-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001125376 us-gaap:RetainedEarningsMember 2023-12-31 0001125376 us-gaap:TreasuryStockCommonMember 2023-12-31 0001125376 us-gaap:NoncontrollingInterestMember 2023-12-31 0001125376 us-gaap:WhollyOwnedPropertiesMember 2023-12-31 0001125376 ensg:ThirdPartyOperatorsMember 2023-12-31 0001125376 srt:MinimumMember 2023-12-31 0001125376 srt:MaximumMember 2023-12-31 0001125376 srt:MinimumMember ensg:AssembledOccupancyAcquiredMember 2023-12-31 0001125376 srt:MaximumMember ensg:AssembledOccupancyAcquiredMember 2023-12-31 0001125376 us-gaap:TradeNamesMember 2023-12-31 0001125376 us-gaap:CustomerRelationshipsMember 2023-12-31 0001125376 us-gaap:GeneralLiabilityMember ensg:SelfInsuranceRetentionPerClaimMember srt:ParentCompanyMember 2023-12-31 0001125376 us-gaap:GeneralLiabilityMember stpr:CA ensg:AggregateDeductibleMember srt:ParentCompanyMember 2023-12-31 0001125376 us-gaap:GeneralLiabilityMember ensg:NonCaliforniaMember ensg:AggregateDeductibleMember srt:ParentCompanyMember 2023-12-31 0001125376 us-gaap:GeneralLiabilityMember ensg:AllStatesExceptColoradoMember ensg:PerOccurenceMember naics:ZZ524292 2023-12-31 0001125376 us-gaap:GeneralLiabilityMember ensg:AllStatesExceptColoradoMember ensg:PerFacilityMember naics:ZZ524292 2023-12-31 0001125376 us-gaap:GeneralLiabilityMember ensg:AllStatesExceptColoradoMember ensg:BlanketAggregateMember naics:ZZ524292 2023-12-31 0001125376 us-gaap:GeneralLiabilityMember stpr:CO ensg:PerOccurenceMember naics:ZZ524292 2023-12-31 0001125376 us-gaap:GeneralLiabilityMember stpr:CO ensg:PerFacilityMember naics:ZZ524292 2023-12-31 0001125376 us-gaap:GeneralLiabilityMember stpr:CA us-gaap:SubsequentEventMember ensg:SelfInsuranceRetentionPerClaimMember srt:ParentCompanyMember 2024-02-01 0001125376 us-gaap:GeneralLiabilityMember stpr:CA us-gaap:SubsequentEventMember ensg:AggregateDeductibleMember srt:ParentCompanyMember 2024-02-01 0001125376 us-gaap:GeneralLiabilityMember ensg:NonCaliforniaMember us-gaap:SubsequentEventMember ensg:SelfInsuranceRetentionPerClaimMember srt:ParentCompanyMember 2024-02-01 0001125376 us-gaap:GeneralLiabilityMember ensg:NonCaliforniaMember us-gaap:SubsequentEventMember ensg:AggregateDeductibleMember srt:ParentCompanyMember 2024-02-01 0001125376 us-gaap:GeneralLiabilityMember ensg:AllStatesExceptColoradoMember us-gaap:SubsequentEventMember ensg:PerOccurenceMember naics:ZZ524292 2024-02-01 0001125376 us-gaap:GeneralLiabilityMember ensg:AllStatesExceptColoradoMember us-gaap:SubsequentEventMember ensg:PerFacilityMember naics:ZZ524292 2024-02-01 0001125376 us-gaap:GeneralLiabilityMember ensg:AllStatesExceptColoradoMember us-gaap:SubsequentEventMember ensg:BlanketAggregateMember naics:ZZ524292 2024-02-01 0001125376 us-gaap:WorkersCompensationInsuranceMember 2023-12-31 0001125376 us-gaap:WorkersCompensationInsuranceMember stpr:TX 2023-12-31 0001125376 us-gaap:WorkersCompensationInsuranceMember ensg:OtherStatesExceptCaliforniaTexasAndWashingtonMember ensg:LossSensitiveLimitPerClaimMember 2023-12-31 0001125376 us-gaap:GeneralLiabilityMember ensg:SelfInsuranceRetentionPerClaimMember 2023-12-31 0001125376 ensg:HealthLiabilityInsuranceMember ensg:StopLossInsuranceLimitPerClaimMember 2023-12-31 0001125376 ensg:HealthLiabilityInsuranceMember ensg:StopLossInsuranceLimitPerClaimMember 2021-12-31 0001125376 ensg:MedicaidAndMedicareMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001125376 ensg:MedicaidAndMedicareMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001125376 ensg:MedicaidAndMedicareMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001125376 ensg:MedicaidMember us-gaap:ServiceMember 2023-01-01 2023-12-31 0001125376 ensg:MedicaidMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001125376 ensg:MedicaidMember us-gaap:ServiceMember 2022-01-01 2022-12-31 0001125376 ensg:MedicaidMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001125376 ensg:MedicaidMember us-gaap:ServiceMember 2021-01-01 2021-12-31 0001125376 ensg:MedicaidMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001125376 ensg:MedicareMember us-gaap:ServiceMember 2023-01-01 2023-12-31 0001125376 ensg:MedicareMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001125376 ensg:MedicareMember us-gaap:ServiceMember 2022-01-01 2022-12-31 0001125376 ensg:MedicareMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001125376 ensg:MedicareMember us-gaap:ServiceMember 2021-01-01 2021-12-31 0001125376 ensg:MedicareMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001125376 ensg:MedicaidSkilledMember us-gaap:ServiceMember 2023-01-01 2023-12-31 0001125376 ensg:MedicaidSkilledMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001125376 ensg:MedicaidSkilledMember us-gaap:ServiceMember 2022-01-01 2022-12-31 0001125376 ensg:MedicaidSkilledMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001125376 ensg:MedicaidSkilledMember us-gaap:ServiceMember 2021-01-01 2021-12-31 0001125376 ensg:MedicaidSkilledMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001125376 ensg:MedicaidAndMedicareMember us-gaap:ServiceMember 2023-01-01 2023-12-31 0001125376 ensg:MedicaidAndMedicareMember us-gaap:ServiceMember 2022-01-01 2022-12-31 0001125376 ensg:MedicaidAndMedicareMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001125376 ensg:MedicaidAndMedicareMember us-gaap:ServiceMember 2021-01-01 2021-12-31 0001125376 ensg:ManagedCareMember us-gaap:ServiceMember 2023-01-01 2023-12-31 0001125376 ensg:ManagedCareMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001125376 ensg:ManagedCareMember us-gaap:ServiceMember 2022-01-01 2022-12-31 0001125376 ensg:ManagedCareMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001125376 ensg:ManagedCareMember us-gaap:ServiceMember 2021-01-01 2021-12-31 0001125376 ensg:ManagedCareMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001125376 ensg:PrivatePayAndOtherMember us-gaap:ServiceMember 2023-01-01 2023-12-31 0001125376 ensg:PrivatePayAndOtherMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001125376 ensg:PrivatePayAndOtherMember us-gaap:ServiceMember 2022-01-01 2022-12-31 0001125376 ensg:PrivatePayAndOtherMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001125376 ensg:PrivatePayAndOtherMember us-gaap:ServiceMember 2021-01-01 2021-12-31 0001125376 ensg:PrivatePayAndOtherMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001125376 us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001125376 us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001125376 us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001125376 2020-01-01 2020-12-31 0001125376 2021-03-01 2021-03-31 0001125376 ensg:MedicaidMember 2023-12-31 0001125376 ensg:MedicaidMember 2022-12-31 0001125376 ensg:ManagedCareMember 2023-12-31 0001125376 ensg:ManagedCareMember 2022-12-31 0001125376 ensg:MedicareMember 2023-12-31 0001125376 ensg:MedicareMember 2022-12-31 0001125376 ensg:PrivatePayAndOtherMember 2023-12-31 0001125376 ensg:PrivatePayAndOtherMember 2022-12-31 0001125376 srt:SubsidiariesMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0001125376 srt:SubsidiariesMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0001125376 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001125376 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001125376 ensg:StandardBearerHealthcareREITIncMember 2023-12-31 0001125376 us-gaap:WhollyOwnedPropertiesMember ensg:StandardBearerHealthcareREITIncMember 2023-12-31 0001125376 ensg:ThirdPartiesMember ensg:StandardBearerHealthcareREITIncMember 2023-12-31 0001125376 ensg:OwnedPropertiesMember ensg:StandardBearerHealthcareREITIncMember 2023-01-01 2023-12-31 0001125376 ensg:CampusOperationMember ensg:StandardBearerHealthcareREITIncMember 2023-01-01 2023-12-31 0001125376 us-gaap:SeriesOfIndividuallyImmaterialAssetAcquisitionsMember ensg:StandardBearerHealthcareREITIncMember 2023-01-01 2023-12-31 0001125376 ensg:OwnedPropertiesMember ensg:StandardBearerHealthcareREITIncMember 2022-01-01 2022-12-31 0001125376 us-gaap:SeriesOfIndividuallyImmaterialAssetAcquisitionsMember ensg:StandardBearerHealthcareREITIncMember 2022-01-01 2022-12-31 0001125376 ensg:SkilledNursingOperationsMember ensg:StandardBearerHealthcareREITIncMember 2022-01-01 2022-12-31 0001125376 2022-01-01 2022-01-31 0001125376 srt:MinimumMember ensg:StandardBearerMasterLeasesMember 2022-01-31 0001125376 srt:MaximumMember ensg:StandardBearerMasterLeasesMember 2022-01-31 0001125376 ensg:StandardBearerMasterLeasesMember 2022-01-31 0001125376 ensg:StandardBearerMasterLeasesMember 2023-01-01 2023-12-31 0001125376 ensg:StandardBearerMasterLeasesMember 2022-01-01 2022-12-31 0001125376 ensg:StandardBearerMasterLeasesMember 2021-01-01 2021-12-31 0001125376 us-gaap:ManagementServiceBaseMember ensg:StandardBearerMasterLeasesMember 2023-01-01 2023-12-31 0001125376 us-gaap:ManagementServiceIncentiveMember ensg:StandardBearerMasterLeasesMember 2023-01-01 2023-12-31 0001125376 ensg:ManagementServiceTotalMember ensg:StandardBearerMasterLeasesMember 2023-01-01 2023-12-31 0001125376 us-gaap:ManagementServiceBaseMember ensg:StandardBearerMasterLeasesMember 2022-01-01 2022-12-31 0001125376 us-gaap:ManagementServiceBaseMember ensg:StandardBearerMasterLeasesMember 2021-01-01 2021-12-31 0001125376 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember us-gaap:BaseRateMember 2022-04-08 2022-04-08 0001125376 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember us-gaap:BaseRateMember 2022-04-08 2022-04-08 0001125376 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember ensg:SecuredOvernightFinancingRateSOFRMember 2022-04-08 2022-04-08 0001125376 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember ensg:SecuredOvernightFinancingRateSOFRMember 2022-04-08 2022-04-08 0001125376 ensg:StandardBearerEquityPlanMember 2022-01-01 2022-01-31 0001125376 ensg:StandardBearerEquityPlanMember 2022-01-01 2022-12-31 0001125376 ensg:StandardBearerEquityPlanMember 2023-01-01 2023-12-31 0001125376 us-gaap:RestrictedStockMember ensg:StandardBearerEquityPlanMember 2022-01-01 2022-12-31 0001125376 us-gaap:RestrictedStockMember ensg:StandardBearerEquityPlanMember 2023-01-01 2023-12-31 0001125376 ensg:SkilledNursingOperationsMember 2023-01-01 2023-12-31 0001125376 ensg:CampusOperationMember 2023-01-01 2023-12-31 0001125376 ensg:SkilledNursingOperationsMember 2023-12-31 0001125376 ensg:SeniorLivingFacilitiesMember 2023-12-31 0001125376 ensg:SkilledNursingOperationsMember us-gaap:SubsequentEventMember 2024-01-01 2024-02-01 0001125376 ensg:SkilledNursingOperationsMember us-gaap:SubsequentEventMember 2024-02-01 0001125376 ensg:SkilledNursingOperationsMember 2022-01-01 2022-12-31 0001125376 ensg:CampusOperationMember 2022-01-01 2022-12-31 0001125376 ensg:SeniorLivingFacilitiesMember 2022-01-01 2022-12-31 0001125376 ensg:SkilledNursingOperationsMember 2022-12-31 0001125376 ensg:SeniorLivingFacilitiesMember 2022-12-31 0001125376 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2022-01-01 2022-12-31 0001125376 ensg:SkilledNursingOperationsMember 2021-01-01 2021-12-31 0001125376 ensg:RealEstatePurchasesMember 2021-01-01 2021-12-31 0001125376 ensg:RealEstatePurchasesOfPreviousOperationsMember 2021-01-01 2021-12-31 0001125376 ensg:SkilledNursingOperationsMember 2021-12-31 0001125376 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2021-01-01 2021-12-31 0001125376 us-gaap:LandMember ensg:AcquiredOperationsMember 2023-01-01 2023-12-31 0001125376 us-gaap:LandMember ensg:AcquiredOperationsMember 2022-01-01 2022-12-31 0001125376 us-gaap:LandMember ensg:AcquiredOperationsMember 2021-01-01 2021-12-31 0001125376 us-gaap:BuildingAndBuildingImprovementsMember ensg:AcquiredOperationsMember 2023-01-01 2023-12-31 0001125376 us-gaap:BuildingAndBuildingImprovementsMember ensg:AcquiredOperationsMember 2022-01-01 2022-12-31 0001125376 us-gaap:BuildingAndBuildingImprovementsMember ensg:AcquiredOperationsMember 2021-01-01 2021-12-31 0001125376 us-gaap:FurnitureAndFixturesMember ensg:AcquiredOperationsMember 2023-01-01 2023-12-31 0001125376 us-gaap:FurnitureAndFixturesMember ensg:AcquiredOperationsMember 2022-01-01 2022-12-31 0001125376 us-gaap:FurnitureAndFixturesMember ensg:AcquiredOperationsMember 2021-01-01 2021-12-31 0001125376 ensg:AssembledOccupancyAcquiredMember ensg:AcquiredOperationsMember 2023-01-01 2023-12-31 0001125376 ensg:AssembledOccupancyAcquiredMember ensg:AcquiredOperationsMember 2022-01-01 2022-12-31 0001125376 ensg:AssembledOccupancyAcquiredMember ensg:AcquiredOperationsMember 2021-01-01 2021-12-31 0001125376 ensg:AcquiredOperationsMember 2023-01-01 2023-12-31 0001125376 ensg:AcquiredOperationsMember 2022-01-01 2022-12-31 0001125376 ensg:AcquiredOperationsMember 2021-01-01 2021-12-31 0001125376 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2023-01-01 2023-12-31 0001125376 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember ensg:StandardBearerSegmentMember 2023-01-01 2023-12-31 0001125376 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember us-gaap:AllOtherSegmentsMember 2023-01-01 2023-12-31 0001125376 srt:ConsolidationEliminationsMember us-gaap:ServiceMember 2023-01-01 2023-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:RentalMember ensg:SkilledServicesSegmentMember 2023-01-01 2023-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:RentalMember ensg:StandardBearerSegmentMember 2023-01-01 2023-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:RentalMember us-gaap:AllOtherSegmentsMember 2023-01-01 2023-12-31 0001125376 srt:ConsolidationEliminationsMember ensg:RentalMember 2023-01-01 2023-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:SkilledServicesSegmentMember 2023-01-01 2023-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:StandardBearerSegmentMember 2023-01-01 2023-12-31 0001125376 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2023-01-01 2023-12-31 0001125376 srt:ConsolidationEliminationsMember 2023-01-01 2023-12-31 0001125376 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2022-01-01 2022-12-31 0001125376 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember ensg:StandardBearerSegmentMember 2022-01-01 2022-12-31 0001125376 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember us-gaap:AllOtherSegmentsMember 2022-01-01 2022-12-31 0001125376 srt:ConsolidationEliminationsMember us-gaap:ServiceMember 2022-01-01 2022-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:RentalMember ensg:SkilledServicesSegmentMember 2022-01-01 2022-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:RentalMember ensg:StandardBearerSegmentMember 2022-01-01 2022-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:RentalMember us-gaap:AllOtherSegmentsMember 2022-01-01 2022-12-31 0001125376 srt:ConsolidationEliminationsMember ensg:RentalMember 2022-01-01 2022-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:SkilledServicesSegmentMember 2022-01-01 2022-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:StandardBearerSegmentMember 2022-01-01 2022-12-31 0001125376 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2022-01-01 2022-12-31 0001125376 srt:ConsolidationEliminationsMember 2022-01-01 2022-12-31 0001125376 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2021-01-01 2021-12-31 0001125376 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember ensg:StandardBearerSegmentMember 2021-01-01 2021-12-31 0001125376 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember us-gaap:AllOtherSegmentsMember 2021-01-01 2021-12-31 0001125376 srt:ConsolidationEliminationsMember us-gaap:ServiceMember 2021-01-01 2021-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:RentalMember ensg:SkilledServicesSegmentMember 2021-01-01 2021-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:RentalMember ensg:StandardBearerSegmentMember 2021-01-01 2021-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:RentalMember us-gaap:AllOtherSegmentsMember 2021-01-01 2021-12-31 0001125376 srt:ConsolidationEliminationsMember ensg:RentalMember 2021-01-01 2021-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:SkilledServicesSegmentMember 2021-01-01 2021-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:StandardBearerSegmentMember 2021-01-01 2021-12-31 0001125376 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2021-01-01 2021-12-31 0001125376 srt:ConsolidationEliminationsMember 2021-01-01 2021-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2023-01-01 2023-12-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidMember us-gaap:ServiceMember 2023-01-01 2023-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicareMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2023-01-01 2023-12-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicareMember us-gaap:ServiceMember 2023-01-01 2023-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidSkilledMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2023-01-01 2023-12-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidSkilledMember us-gaap:ServiceMember 2023-01-01 2023-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidAndMedicareMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2023-01-01 2023-12-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidAndMedicareMember us-gaap:ServiceMember 2023-01-01 2023-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:ManagedCareMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2023-01-01 2023-12-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:ManagedCareMember us-gaap:ServiceMember 2023-01-01 2023-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:PrivatePayAndOtherMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2023-01-01 2023-12-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:PrivatePayAndOtherMember us-gaap:ServiceMember 2023-01-01 2023-12-31 0001125376 us-gaap:CorporateNonSegmentMember us-gaap:ServiceMember 2023-01-01 2023-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2022-01-01 2022-12-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidMember us-gaap:ServiceMember 2022-01-01 2022-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicareMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2022-01-01 2022-12-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicareMember us-gaap:ServiceMember 2022-01-01 2022-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidSkilledMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2022-01-01 2022-12-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidSkilledMember us-gaap:ServiceMember 2022-01-01 2022-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidAndMedicareMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2022-01-01 2022-12-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidAndMedicareMember us-gaap:ServiceMember 2022-01-01 2022-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:ManagedCareMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2022-01-01 2022-12-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:ManagedCareMember us-gaap:ServiceMember 2022-01-01 2022-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:PrivatePayAndOtherMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2022-01-01 2022-12-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:PrivatePayAndOtherMember us-gaap:ServiceMember 2022-01-01 2022-12-31 0001125376 us-gaap:CorporateNonSegmentMember us-gaap:ServiceMember 2022-01-01 2022-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2021-01-01 2021-12-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidMember us-gaap:ServiceMember 2021-01-01 2021-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicareMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2021-01-01 2021-12-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicareMember us-gaap:ServiceMember 2021-01-01 2021-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidSkilledMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2021-01-01 2021-12-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidSkilledMember us-gaap:ServiceMember 2021-01-01 2021-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidAndMedicareMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2021-01-01 2021-12-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidAndMedicareMember us-gaap:ServiceMember 2021-01-01 2021-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:ManagedCareMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2021-01-01 2021-12-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:ManagedCareMember us-gaap:ServiceMember 2021-01-01 2021-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:PrivatePayAndOtherMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2021-01-01 2021-12-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:PrivatePayAndOtherMember us-gaap:ServiceMember 2021-01-01 2021-12-31 0001125376 us-gaap:CorporateNonSegmentMember us-gaap:ServiceMember 2021-01-01 2021-12-31 0001125376 us-gaap:LandMember 2023-12-31 0001125376 us-gaap:LandMember 2022-12-31 0001125376 us-gaap:BuildingAndBuildingImprovementsMember 2023-12-31 0001125376 us-gaap:BuildingAndBuildingImprovementsMember 2022-12-31 0001125376 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001125376 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001125376 us-gaap:EquipmentMember 2023-12-31 0001125376 us-gaap:EquipmentMember 2022-12-31 0001125376 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001125376 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001125376 us-gaap:ConstructionInProgressMember 2023-12-31 0001125376 us-gaap:ConstructionInProgressMember 2022-12-31 0001125376 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember ensg:SeniorLivingOperationsMember 2022-01-01 2022-12-31 0001125376 ensg:AssembledOccupancyAcquiredMember 2023-01-01 2023-12-31 0001125376 ensg:AssembledOccupancyAcquiredMember 2023-12-31 0001125376 ensg:AssembledOccupancyAcquiredMember 2022-12-31 0001125376 us-gaap:TradeNamesMember 2023-01-01 2023-12-31 0001125376 us-gaap:TradeNamesMember 2022-12-31 0001125376 us-gaap:CustomerRelationshipsMember 2023-01-01 2023-12-31 0001125376 us-gaap:CustomerRelationshipsMember 2022-12-31 0001125376 ensg:DepreciationAndAmortizationMember 2023-01-01 2023-12-31 0001125376 ensg:DepreciationAndAmortizationMember 2022-01-01 2022-12-31 0001125376 ensg:DepreciationAndAmortizationMember 2021-01-01 2021-12-31 0001125376 us-gaap:TradeNamesMember 2023-12-31 0001125376 us-gaap:TradeNamesMember 2022-12-31 0001125376 ensg:MedicareandMedicaidLicensesMember 2023-12-31 0001125376 ensg:MedicareandMedicaidLicensesMember 2022-12-31 0001125376 ensg:MedicareandMedicaidLicensesMember 2023-01-01 2023-12-31 0001125376 ensg:MedicareandMedicaidLicensesMember 2022-01-01 2022-12-31 0001125376 ensg:MedicareandMedicaidLicensesMember 2021-01-01 2021-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:SkilledServicesSegmentMember 2020-12-31 0001125376 us-gaap:CorporateNonSegmentMember 2020-12-31 0001125376 us-gaap:CorporateNonSegmentMember 2021-01-01 2021-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:SkilledServicesSegmentMember 2021-12-31 0001125376 us-gaap:CorporateNonSegmentMember 2021-12-31 0001125376 us-gaap:CorporateNonSegmentMember 2022-01-01 2022-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:SkilledServicesSegmentMember 2022-12-31 0001125376 us-gaap:CorporateNonSegmentMember 2022-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:SkilledServicesSegmentMember 2023-12-31 0001125376 us-gaap:CorporateNonSegmentMember 2023-12-31 0001125376 us-gaap:CollateralizedDebtObligationsMember 2023-12-31 0001125376 us-gaap:CollateralizedDebtObligationsMember 2022-12-31 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember 2023-12-31 0001125376 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember 2022-04-08 2022-04-08 0001125376 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember 2022-04-08 2022-04-08 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember 2022-04-08 0001125376 ensg:HUDInsuredMortgagesMember us-gaap:CollateralizedDebtObligationsMember ensg:TwentyThreeSubsidiariesMember 2023-12-31 0001125376 srt:MinimumMember ensg:HUDInsuredMortgagesMember us-gaap:CollateralizedDebtObligationsMember 2023-12-31 0001125376 srt:MaximumMember ensg:HUDInsuredMortgagesMember us-gaap:CollateralizedDebtObligationsMember 2023-12-31 0001125376 ensg:HUDInsuredMortgagesMember us-gaap:CollateralizedDebtObligationsMember ensg:FirstThreeYearsMember 2023-12-31 0001125376 ensg:HUDInsuredMortgagesMember us-gaap:CollateralizedDebtObligationsMember ensg:InTheFourthYearMember 2023-12-31 0001125376 ensg:HUDInsuredMortgagesMember us-gaap:CollateralizedDebtObligationsMember ensg:YearsFiveThroughTenMember 2023-12-31 0001125376 ensg:HUDInsuredMortgagesMember us-gaap:CollateralizedDebtObligationsMember ensg:AfterYearTenMember 2023-12-31 0001125376 srt:MinimumMember ensg:HUDInsuredMortgagesMember us-gaap:CollateralizedDebtObligationsMember 2023-01-01 2023-12-31 0001125376 srt:MaximumMember ensg:HUDInsuredMortgagesMember us-gaap:CollateralizedDebtObligationsMember 2023-01-01 2023-12-31 0001125376 ensg:A53PromissoryNoteMember us-gaap:CollateralizedDebtObligationsMember 2023-12-31 0001125376 ensg:A53PromissoryNoteMember us-gaap:CollateralizedDebtObligationsMember 2023-01-01 2023-12-31 0001125376 us-gaap:LetterOfCreditMember 2023-01-01 2023-12-31 0001125376 ensg:A2022PlanMember 2023-12-31 0001125376 ensg:A2022PlanMember 2023-01-01 2023-12-31 0001125376 us-gaap:ShareBasedPaymentArrangementNonemployeeMember ensg:A2022PlanMember 2023-01-01 2023-12-31 0001125376 ensg:ExercisePriceRangeTwoMember 2023-01-01 2023-12-31 0001125376 ensg:ExercisePriceRangeTwoMember 2023-12-31 0001125376 ensg:ExercisePriceRangeThreeMember 2023-01-01 2023-12-31 0001125376 ensg:ExercisePriceRangeThreeMember 2023-12-31 0001125376 ensg:ExercisePriceRangeFourMember 2023-01-01 2023-12-31 0001125376 ensg:ExercisePriceRangeFourMember 2023-12-31 0001125376 ensg:ExercisePriceRangeFiveMember 2023-01-01 2023-12-31 0001125376 ensg:ExercisePriceRangeFiveMember 2023-12-31 0001125376 ensg:ExercisePriceRangeSixMember 2023-01-01 2023-12-31 0001125376 ensg:ExercisePriceRangeSixMember 2023-12-31 0001125376 ensg:ExercisePriceRangeSevenMember 2023-01-01 2023-12-31 0001125376 ensg:ExercisePriceRangeSevenMember 2023-12-31 0001125376 ensg:ExercisePriceRangeEightMember 2023-01-01 2023-12-31 0001125376 ensg:ExercisePriceRangeEightMember 2023-12-31 0001125376 ensg:ExercisePriceRangeNineMember 2023-01-01 2023-12-31 0001125376 ensg:ExercisePriceRangeNineMember 2023-12-31 0001125376 ensg:ExercisePriceRangeTenMember 2023-01-01 2023-12-31 0001125376 ensg:ExercisePriceRangeTenMember 2023-12-31 0001125376 ensg:ExercisePriceRangeElevenMember 2023-01-01 2023-12-31 0001125376 ensg:ExercisePriceRangeElevenMember 2023-12-31 0001125376 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001125376 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001125376 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001125376 us-gaap:RestrictedStockMember 2023-01-01 2023-12-31 0001125376 us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0001125376 us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001125376 srt:MinimumMember us-gaap:RestrictedStockMember 2023-01-01 2023-12-31 0001125376 srt:MaximumMember us-gaap:RestrictedStockMember 2023-01-01 2023-12-31 0001125376 srt:MinimumMember us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0001125376 srt:MaximumMember us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0001125376 srt:MinimumMember us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001125376 srt:MaximumMember us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001125376 us-gaap:RestrictedStockMember 2020-12-31 0001125376 us-gaap:RestrictedStockMember 2021-12-31 0001125376 us-gaap:RestrictedStockMember 2022-12-31 0001125376 us-gaap:RestrictedStockMember 2023-12-31 0001125376 us-gaap:RestrictedStockMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2023-01-01 2023-12-31 0001125376 srt:MinimumMember us-gaap:RestrictedStockMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2023-01-01 2023-12-31 0001125376 srt:MaximumMember us-gaap:RestrictedStockMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2023-01-01 2023-12-31 0001125376 ensg:A2019LTIPlanMember us-gaap:SpinoffMember 2019-08-27 0001125376 ensg:A2019LTIPlanMember us-gaap:SpinoffMember 2019-08-27 2019-08-27 0001125376 ensg:A2019LTIPlanMember us-gaap:SpinoffMember 2023-01-01 2023-12-31 0001125376 ensg:A2019LTIPlanMember us-gaap:SpinoffMember 2022-01-01 2022-12-31 0001125376 ensg:A2019LTIPlanMember us-gaap:SpinoffMember 2021-01-01 2021-12-31 0001125376 ensg:StockAwardsMember 2023-01-01 2023-12-31 0001125376 ensg:StockAwardsMember 2022-01-01 2022-12-31 0001125376 ensg:StockAwardsMember 2021-01-01 2021-12-31 0001125376 us-gaap:EmployeeStockOptionMember 2023-12-31 0001125376 ensg:CareTrustREITMember 2023-12-31 0001125376 ensg:CareTrustREITMember ensg:TripleNetLeaseArrangementsMember 2023-12-31 0001125376 ensg:CareTrustREITMember srt:MinimumMember ensg:TripleNetLeaseArrangementsMember 2023-12-31 0001125376 ensg:CareTrustREITMember srt:MaximumMember ensg:TripleNetLeaseArrangementsMember 2023-12-31 0001125376 ensg:CareTrustREITMember ensg:PurchaseOptionMember 2023-12-31 0001125376 ensg:CareTrustREITMember 2023-01-01 2023-12-31 0001125376 ensg:CareTrustREITMember 2022-01-01 2022-12-31 0001125376 ensg:CareTrustREITMember 2021-01-01 2021-12-31 0001125376 ensg:VariousLandlordsMember srt:MinimumMember 2023-12-31 0001125376 ensg:VariousLandlordsMember srt:MaximumMember 2023-12-31 0001125376 ensg:VariousLandlordsMember srt:MinimumMember us-gaap:EquipmentMember 2023-12-31 0001125376 ensg:VariousLandlordsMember srt:MaximumMember us-gaap:EquipmentMember 2023-12-31 0001125376 ensg:CostofSalesandGeneralandAdministrativeExpenseMember 2023-01-01 2023-12-31 0001125376 ensg:CostofSalesandGeneralandAdministrativeExpenseMember 2022-01-01 2022-12-31 0001125376 ensg:CostofSalesandGeneralandAdministrativeExpenseMember 2021-01-01 2021-12-31 0001125376 ensg:VariousLandlordsMember 2023-12-31 0001125376 ensg:AmendedMasterLeaseAgreementMember 2023-12-31 0001125376 ensg:SkilledNursingOperationsMember ensg:NewMasterLeaseAgreeementMember 2023-01-01 2023-12-31 0001125376 ensg:SkilledNursingOperationsMember ensg:AmendedMasterLeaseMember 2023-01-01 2023-12-31 0001125376 ensg:SubleaseOfStandAlongSkilledNursingOperationsMember 2023-01-01 2023-12-31 0001125376 ensg:NewMasterLeaseAgreeementMember 2023-01-01 2023-12-31 0001125376 ensg:SubleaseOfStandAlongSkilledNursingOperationsMember 2023-12-31 0001125376 ensg:SubleaseOfStandAlongSkilledNursingOperationsMember 2022-12-31 0001125376 ensg:SubleaseOfStandAlongSkilledNursingOperationsMember 2021-12-31 0001125376 us-gaap:CostOfSalesMember 2023-01-01 2023-12-31 0001125376 us-gaap:CostOfSalesMember 2022-01-01 2022-12-31 0001125376 us-gaap:CostOfSalesMember 2021-01-01 2021-12-31 0001125376 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-12-31 0001125376 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-12-31 0001125376 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0001125376 ensg:SkilledNursingOperationsMember us-gaap:SubsequentEventMember ensg:AmendedMasterLeaseAgreementMember 2024-01-01 2024-02-01 0001125376 ensg:SkilledNursingOperationsMember us-gaap:SubsequentEventMember ensg:AmendedMasterLeaseAgreementMember 2024-02-01 0001125376 ensg:ThePennantGroupInc.Member ensg:LeasesToThirdPartyOperatorsMember 2023-01-01 2023-12-31 0001125376 srt:MinimumMember ensg:LeasesToThirdPartyOperatorsMember 2023-12-31 0001125376 srt:MaximumMember ensg:LeasesToThirdPartyOperatorsMember 2023-12-31 0001125376 ensg:LeaseOfCampusOperationMember 2023-01-01 2023-12-31 0001125376 ensg:LeaseOfCampusOperationMember 2023-12-31 0001125376 ensg:ThePennantGroupInc.Member ensg:LeasesToThirdPartyOperatorsMember 2022-01-01 2022-12-31 0001125376 ensg:ThePennantGroupInc.Member ensg:LeasesToThirdPartyOperatorsMember 2021-01-01 2021-12-31 0001125376 ensg:ThirdPartyTenantsMember ensg:LeasesToThirdPartyOperatorsMember 2023-01-01 2023-12-31 0001125376 ensg:ThirdPartyTenantsMember ensg:LeasesToThirdPartyOperatorsMember 2022-01-01 2022-12-31 0001125376 ensg:ThirdPartyTenantsMember ensg:LeasesToThirdPartyOperatorsMember 2021-01-01 2021-12-31 0001125376 ensg:LeasesToThirdPartyOperatorsMember 2023-01-01 2023-12-31 0001125376 ensg:LeasesToThirdPartyOperatorsMember 2022-01-01 2022-12-31 0001125376 ensg:LeasesToThirdPartyOperatorsMember 2021-01-01 2021-12-31 0001125376 us-gaap:QualifiedPlanMember 2023-01-01 2023-12-31 0001125376 us-gaap:QualifiedPlanMember 2022-01-01 2022-12-31 0001125376 us-gaap:QualifiedPlanMember 2021-01-01 2021-12-31 0001125376 us-gaap:NonqualifiedPlanMember 2023-01-01 2023-12-31 0001125376 us-gaap:ProfessionalMalpracticeLiabilityMember 2023-12-31 0001125376 us-gaap:ProfessionalMalpracticeLiabilityMember 2022-12-31 0001125376 us-gaap:SubsequentEventMember 2024-01-19 2024-01-19 0001125376 us-gaap:SubsequentEventMember 2024-02-01 0001125376 ensg:MedicaidAndMedicareMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001125376 ensg:MedicaidAndMedicareMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001125376 ensg:MedicaidAndMedicareMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001125376 ensg:MedicaidAndMedicareMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001125376 ensg:August2023RepurchaseProgramMember 2023-08-29 0001125376 ensg:August2023RepurchaseProgramMember 2023-08-29 2023-08-29 0001125376 ensg:July2022RepurchaseProgramMember 2022-07-28 0001125376 ensg:July2022RepurchaseProgramMember 2022-07-28 2022-07-28 0001125376 2023-10-01 2023-12-31 0001125376 ensg:ChristopherRChristensenMember 2023-10-01 2023-12-31 0001125376 ensg:ChristopherRChristensenMember 2023-01-01 2023-12-31 0001125376 ensg:ChristopherRChristensenMember 2023-12-31 0001125376 ensg:BeverlyBWittekindMember 2023-10-01 2023-12-31 0001125376 ensg:BeverlyBWittekindMember 2023-01-01 2023-12-31 0001125376 ensg:BeverlyBWittekindMember 2023-12-31 iso4217:USD shares iso4217:USD shares ensg:facility ensg:bed ensg:senior_living_unit ensg:property ensg:operation ensg:lease ensg:option pure ensg:skilled_nursing_property ensg:renewal ensg:business ensg:segment ensg:subsidiary ensg:plan ensg:installment ensg:agreement 0001125376 2023 FY false P3Y0M0D P10Y P4M0D P5Y0M P3Y0M http://fasb.org/us-gaap/2023#RevenueFromContractWithCustomerExcludingAssessedTax P334D P231D 10-K true 2023-12-31 --12-31 false 001-33757 ENSIGN GROUP, INC DE 33-0861263 29222 Rancho Viejo Road, Suite 127 San Juan Capistrano CA 92675 949 487-9500 Common Stock, par value $0.001 per share ENSG NASDAQ Yes No Yes Yes Large Accelerated Filer false false true false false 3156373000 56665741 <div style="margin-top:10pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Part III of this Form 10-K incorporates information by reference from the Registrant's definitive proxy statement for the Registrant's 2024 Annual Meeting of Stockholders to be filed within 120 days after the close of the fiscal year covered by this annual report.</span></div> DELOITTE & TOUCHE LLP Costa Mesa, California 509626000 316270000 9348000 7802000 485039000 408432000 17229000 15441000 35036000 40982000 1046930000 781125000 1090771000 992010000 1756430000 1450995000 92687000 67652000 67124000 39643000 40205000 37291000 6525000 6437000 76869000 76869000 4177541000 3452022000 92811000 77087000 332568000 289810000 82526000 65796000 54664000 48187000 168228000 97309000 3950000 3883000 734747000 582072000 145497000 149269000 1639326000 1355113000 111246000 83495000 49408000 33273000 2680224000 2203222000 0.001 0.001 150000000 59987000 56597000 100000000 59029000 55661000 60000 59000 465707000 415560000 1142653000 946339000 3390000 3368000 116555000 114626000 1491865000 1247332000 5452000 1468000 1497317000 1248800000 4177541000 3452022000 3708071000 3008711000 2611476000 21284000 16757000 15985000 3729355000 3025468000 2627461000 2941238000 2354434000 2019879000 197358000 153049000 139371000 263005000 158805000 151761000 72387000 62355000 55985000 3473988000 2728643000 2366996000 255367000 296825000 260465000 8087000 8931000 6849000 25482000 1195000 4388000 17395000 -7736000 -2461000 272762000 289089000 258004000 62912000 64437000 60279000 209850000 224652000 197725000 451000 -29000 3073000 209399000 224681000 194652000 3.76 4.09 3.57 3.65 3.95 3.42 55708000 54887000 54486000 57323000 56871000 56925000 54626000 58000 338177000 551055000 2791000 -71213000 150000 818227000 516000 9180000 9180000 201000 3725000 3725000 21000 21000 1711000 1711000 0.2125 11715000 11715000 18678000 18678000 132000 132000 10118000 10118000 1369000 1369000 2000000 2000000 3073000 3073000 2908000 2908000 194652000 194652000 55190000 58000 369760000 733992000 2944000 -83042000 946000 1021714000 688000 1000 12676000 12677000 207000 5241000 5241000 20000 20000 1702000 1702000 0.2225 12334000 12334000 22720000 22720000 404000 404000 29882000 29882000 1539000 -835000 704000 6693000 6693000 -29000 -29000 -9000 284000 275000 224681000 224681000 55661000 59000 415560000 946339000 3368000 -114626000 1468000 1248800000 759000 1000 18368000 18369000 199000 5068000 5068000 22000 22000 1929000 1929000 0.2325 13085000 13085000 30754000 30754000 256000 256000 451000 451000 3787000 -3533000 254000 209399000 209399000 56597000 60000 465707000 1142653000 3390000 -116555000 5452000 1497317000 209850000 224652000 197725000 72387000 62355000 55985000 1067000 1036000 859000 870000 493000 485000 0 566000 0 -27481000 -6496000 -724000 3408000 2390000 2609000 30767000 22720000 18678000 1396000 1282000 2382000 123000 3467000 1371000 1368000 -3926000 977000 48000000 0 0 79818000 82426000 30771000 -814000 -809000 4228000 -6993000 9141000 4898000 0 24155000 24154000 16072000 7614000 10953000 16044000 7637000 11078000 -6564000 345000 -5814000 15924000 17870000 7117000 47967000 38982000 47701000 23828000 3010000 1297000 28827000 17785000 13724000 -50000 -46000 -66000 376666000 272513000 275684000 106180000 87545000 69550000 0 16400000 6000000 67798000 84736000 98224000 1216000 0 -100000 2029000 1339000 6899000 248000 8630000 1854000 0 0 1984000 0 0 106000 29603000 21975000 32257000 18852000 14356000 27481000 -970000 -149000 2120000 -182698000 -186182000 -173907000 150000 411000 45218000 4033000 4106000 3056000 18369000 12677000 9180000 1929000 1702000 1711000 0 29882000 10118000 12890000 12168000 11548000 0 6693000 0 4000 284000 2908000 256000 704000 -2000000 19000 3197000 1172000 0 0 11637000 0 0 113660000 -612000 -32262000 -76138000 193356000 54069000 25639000 316270000 262201000 236562000 509626000 316270000 262201000 7025000 7604000 5690000 89730000 70055000 65547000 196942000 151870000 138795000 4600000 4800000 3700000 3396000 3201000 3035000 376550000 370753000 198593000 DESCRIPTION OF BUSINESS<div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Ensign Group, Inc. (collectively, Ensign or the Company), is a holding company with no direct operating assets, employees or revenue. The Company's independent subsidiaries provide health care services across the post-acute care continuum and engage in the ownership, acquisition, development and leasing of skilled nursing, senior living and other healthcare-related properties and other ancillary businesses. As of December 31, 2023, the Company's independent subsidiaries operated 297 facilities and other ancillary operations located in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. Subsequent to December 31, 2023, one of the Company's independent subsidiaries expanded its operations into Tennessee. The Company's independent subsidiaries have a collective capacity of approximately 30,600 operational skilled nursing beds and 3,100 senior living units. As of December 31, 2023, the Company's independent subsidiaries operated 214 facilities under long-term lease arrangements and had options to purchase 11 of those 214 facilities. The Company's real estate portfolio includes 113 owned real estate properties, which includes 83 facilities operated and managed by the Company's independent subsidiaries, 30 operations leased to and operated by third-party operators, and the Service Center (defined below) location. Of those 30 operations, one senior living facility is located on the same real estate property as a skilled nursing facility that an independent subsidiary owns and operates. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company’s wholly-owned independent subsidiaries, collectively referred to as the Service Center, provide specific accounting, payroll, human resources, information technology, legal, risk management and other centralized services to the other independent subsidiaries through contractual relationships with such subsidiaries. The Company also has a wholly-owned captive insurance subsidiary that provides some claims-made coverage to the Company’s independent subsidiaries for general and professional liabilities, as well as coverage for certain workers’ compensation insurance liabilities.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the Company formed a captive real estate investment trust (REIT), which owns and manages its real estate business, called Standard Bearer Healthcare REIT, Inc. (Standard Bearer). The REIT structure provides the Company with an efficient vehicle for future acquisitions of properties that could be operated by Ensign's independent subsidiaries or other third parties. Refer to Note 6, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Standard Bearer </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information on Standard Bearer.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the Company's independent subsidiaries are operated by wholly-owned subsidiaries that have their own management, employees and assets. References herein to the consolidated “Company” and “its” assets and activities in this Annual Report are not meant to imply, nor should it be construed as meaning that The Ensign Group, Inc. has direct operating assets, employees or revenue, or that any of the subsidiaries, are operated by The Ensign Group, Inc.</span></div> 297 30600 3100 214 11 214 113 83 30 30 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The accompanying consolidated financial statements (the Financial Statements) have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company is the sole member or stockholder of various consolidated limited liability companies and corporations established to operate various acquired skilled nursing operations, senior living operations and related ancillary services. All intercompany transactions and balances have been eliminated in consolidation. The Company presents noncontrolling interests within the equity section of its consolidated balance sheets and the amount of consolidated net income that is attributable to The Ensign Group, Inc. and the noncontrolling interests in its consolidated statements of income. The Financial Statements include the accounts of all independent subsidiaries controlled by the Company through its ownership of a majority voting interest. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Estimates and Assumptions</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of the Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Company’s Financial Statements relate to revenue, acquired property and equipment, intangible assets and goodwill, right-of-use assets, impairment of long-lived assets, lease liabilities, general and professional liabilities, workers' compensation and healthcare claims included in accrued self-insurance liabilities and income taxes. Actual results could differ from those estimates.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Considerations</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s financial instruments consist principally of cash and cash equivalents, debt security investments, accounts receivable, insurance subsidiary deposits, deferred compensation investment funds, equity investments, accounts payable and borrowings. The Company believes all of the financial instruments’ recorded values approximate fair values because of their nature or respective short durations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions. See Note 5, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's non-financial assets, which includes goodwill, intangible assets, property and equipment and right-of-use assets, are not required to be measured at fair value on a recurring basis. However, on a periodic basis, or whenever events or changes in circumstances indicate that their carrying value may not be recoverable, the Company assesses its long-lived assets for impairment. When impairment has occurred, such long-lived assets are written down to fair value. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service Revenue Recognition</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 606).</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's service revenue is derived primarily from providing healthcare services to its patients. Revenue is recognized when services are provided to patients at the amount that reflects the consideration that the Company expects to be entitled from patients and third-party payors, including Medicaid, Medicare and insurers (private and Medicare replacement plans), in exchange for providing patient care. The healthcare services provided pursuant to skilled patient contracts include routine services in exchange for a contractual agreed-upon amount or rate. Routine services are treated as a single performance obligation satisfied over time as services are rendered. As such, patient care services represent a bundle of services that are not capable of being distinct. Additionally, there may be ancillary services that are not included in the daily rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time, if and when those services are rendered.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction price. The Company determines the transaction price based on contractually agreed-upon amounts or rate on a per day basis, adjusted for estimates of variable consideration. The Company uses the expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The amount of variable consideration that is included in the transaction price may be constrained and is included in net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from the Company’s estimates, the Company adjusts these estimates, which would affect net revenue in the period such variances become known.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company’s contracts with its patients have an original duration of one year or less, the Company uses the practical expedient applicable to its contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of the end of each reporting period or when the Company expects to recognize this revenue. In addition, the Company has applied the practical expedient provided by FASB ASC Topic 340, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets and Deferred Costs</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and all incremental customer contract acquisition costs are expensed as they are incurred because the amortization period would have been one year or less.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rental Revenue Recognition</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company's rental revenues are primarily generated by leasing healthcare-related properties through triple-net lease arrangements, under which the tenant is solely responsible for the costs related to the property. Revenue for operating leases is recognized on a straight-line basis over the lease term when collectability of all minimum lease payments is probable in accordance with FASB ASC Topic 842, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 842). The Company has elected the single component practical expedient, which allows a lessor, by class of underlying asset, not to allocate the total consideration to the lease and non-lease components based on their relative stand-alone selling prices where certain criteria are met. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tenant reimbursements related to property taxes and insurance are neither considered lease nor non-lease components under ASC 842. Lessee payments for taxes and insurance paid directly to a third party, on behalf of the Company, are excluded from variable lease payments and rental revenue in the Company’s consolidated statements of income. Otherwise, tenant reimbursements for taxes and insurance that are paid by the Company directly to a third party are classified as additional rental revenue and expense and recognized by the Company on a gross basis. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources, net of estimates for variable consideration.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">— </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of bank term deposits, money market funds and treasury bill related investments with original maturities of three months or less at time of purchase and therefore approximate fair value. The fair value of money market funds is determined based on “Level 1” inputs, which consist of unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets. The Company places its cash and short-term investments with high credit quality financial institutions.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Insurance Subsidiary Deposits and Investments — </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's captive insurance subsidiary cash and cash equivalents, deposits and investments are designated to support long-term insurance subsidiary liabilities and have been classified as short-term and long-term assets based on the timing of expected future payments of the Company's captive insurance liabilities. The majority of these deposits and investments are currently held in AA, A and BBB rated debt security investments and the remainder is held in a bank account with a high credit quality financial institution. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's non-qualified deferred compensation plan (the DCP)'s contracts insuring the lives of certain employees who are eligible to participate in the DCP are held in a rabbi trust. Cash surrender value of the contracts is based on funds that shadow the investment allocations specified by participants in the deferred compensation plan. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When evaluating an investment for its current expected credit losses, the Company reviews factors such as historical experience with defaults, losses, credit ratings, term, market sector and macroeconomic trends, including current conditions and forecasts to the extent they are reasonable and supportable.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from <span style="-sec-ix-hidden:f-498">three</span> to 59 years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company leases skilled nursing facilities, senior living facilities and commercial office space.</span><span style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease and performs an evaluation to determine whether the lease should be classified as an operating or finance lease at the inception of the lease. As of December 31, 2023, the Company has one financing lease that is not material to the consolidated balance sheet. Rights and obligations of these leases are included as right-of-use assets and current and long-term lease liabilities on the Company's consolidated balance sheets. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of future lease payments. The Company utilizes a third-party valuation specialist to assist in estimating the incremental borrowing rate.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records rent expense for operating leases on a straight-line basis over the term of the lease. The lease term used for straight-line rent expense is calculated from the date the Company is given control of the leased premises through the end of the lease term. Renewals are not assumed in the determination of the lease term unless they are deemed to be reasonably assured at the inception of the lease. The lease term used for this evaluation also provides the basis for establishing depreciable lives for buildings subject to lease and leasehold improvements.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's real estate leases generally have initial lease terms of ten years or more and typically include one or more options to renew, with renewal terms that generally extend the lease term for an additional <span style="-sec-ix-hidden:f-504">ten</span> to 15 years. Exercise of the renewal options is generally subject to the satisfaction of certain conditions which vary by contract and generally follow payment terms that are consistent with those in place during the initial term. The Company reassesses the renewal option using a "reasonably certain" threshold, which is understood to be a high threshold. For leases where the Company is reasonably certain to exercise its renewal option, the option periods are included within the lease term and, therefore, the measurement of the right-of-use asset and lease liability. The Company's leases generally contain annual escalation clauses that are either fixed or variable in nature, some of which are dependent upon published indices. The Company recognizes lease expense for leases with an initial term of 12 months or less on a straight-line basis over the lease term. These leases are not recorded on the consolidated balance sheets. Certain of the Company's lease agreements include rental payments that are adjusted periodically for inflation. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company subleases skilled nursing facilities to third-party operators and considers the subleases to be separate contracts as the Company is not relieved of its primary obligation under its operating lease. The rental income from third-parties related to these subleases is presented on a gross basis from the rent expense associated with the Company's lease obligations and is not material to the consolidated statements of income. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">— </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews the carrying value of long-lived assets that are held and used in the Company’s independent subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the independent subsidiaries to which the assets relate, utilizing management’s best estimate, appropriate assumptions and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset. Management has evaluated its long-lived assets and determined there was no impairment during the years ended December 31, 2023, 2022, and 2021.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Definite-lived intangible assets consist primarily of patient base, facility trade names and customer relationships. Patient base is amortized over a period of <span style="-sec-ix-hidden:f-508">four</span> to eight months, depending on the classification of the patients and the level of occupancy in a new acquisition on the acquisition date. Trade names at independent subsidiaries are amortized over 30 years and customer relationships are amortized over a period of up to 20 years.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's indefinite-lived intangible assets consist of trade names and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. The Company tests goodwill during the fourth quarter of each year or more often if events or circumstances indicate there may be impairment. The Company performs its analysis for each reporting unit that constitutes a business for which discrete financial information is produced and reviewed by operating segment management and provides services that are distinct from the other components of the operating segment, in accordance with the provisions of FASB ASC Topic 350, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles—Goodwill and Other </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 350). This guidance provides the option to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. If, based on a review of qualitative factors, it is more likely than not that the fair value of a reporting unit is less than its carrying value, the Company performs a goodwill impairment test by comparing the carrying value of each reporting unit to its respective fair value. The Company determines the estimated fair value of each reporting unit using a discounted cash flow analysis. The fair value of the reporting unit is the implied fair value of goodwill. In the event a reporting unit's carrying value exceeds its fair value, an impairment loss will be recognized. An impairment loss is measured by the difference between the carrying value of the reporting unit and its fair value. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has evaluated its goodwill and intangible assets and determined there was no impairment during the years ended December 31, 2023, 2022, and 2021. The Company has recognized cumulative goodwill impairment losses of $7,410, since inception in 1999. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Self-Insurance</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — The Company is partially self-insured for general and professional liability claims up to a base amount per claim (the self-insured retention) with an aggregate, one-time deductible above this limit. Losses beyond these amounts are insured through third-party policies with coverage limits per claim, per location and on an aggregate basis for the Company. The combined self-insured retention is $500 per claim, subject to an additional one-time deductible of $1,250 for the Company's independent subsidiaries in California and a separate, one-time, deductible of $1,250 for the Company's independent subsidiaries not in California. For all independent subsidiaries, except those located in Colorado, the third-party coverage above these limits is $1,000 per claim, $3,000 per operation, with a $5,000 blanket aggregate limit and an additional state-specific aggregate where required by state law. In Colorado, the third-party coverage above these limits is $1,000 per claim and $3,000 per operation, which is independent of the aforementioned blanket aggregate limits that apply outside of Colorado. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to December 31, 2023, the self-insured retention is $750 per claim, subject to an additional one-time deductible of $1,500 for the Company's independent subsidiaries in California. For the independent subsidiaries not in California, the self-insured retention is $650 per claim, subject to an additional one-time deductible of $1,350. For all independent subsidiaries, except those located in Colorado, the third-party coverage above these limits is $1,000 per claim, $3,000 per operation, with a $10,000 blanket aggregate limit and an additional state-specific aggregate where required by state law. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the self-insured retention and deductible limits for general and professional liabilities and workers' compensation liabilities are self-insured through the captive insurance subsidiary, the related assets and liabilities of which are included in the accompanying consolidated balance sheets. The captive insurance subsidiary is subject to certain statutory requirements as an insurance provider. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s policy is to accrue amounts equal to the actuarial estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. The Company develops information about the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluates the estimates for claim loss exposure on a quarterly basis. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s independent subsidiaries are self-insured for workers’ compensation liabilities in California. To protect itself against loss exposure in California with this policy, the Company has purchased individual specific excess insurance coverage that insures individual claims that exceed $625 per occurrence. In Texas, the independent subsidiaries have elected non-subscriber status for workers’ compensation claims and the Company has purchased individual stop-loss coverage that insures individual claims that exceed $750 per occurrence. The Company’s independent subsidiaries in all other states, with the exception of Washington, are under a loss sensitive plan that insures individual claims that exceed $350 per occurrence. In the state of Washington, the Company is self-insured and has purchased individual specific excess insurance coverage that insures individual claims that exceed $500 per occurrence. For all of the self-insured plans and retention, the Company accrues amounts equal to the estimated costs to settle open claims, as well as an estimate of the cost of claims that have been incurred but not reported. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company self-funds medical (including prescription drugs) and dental healthcare benefits to the majority of its employees. The Company is fully liable for all financial and legal aspects of these benefit plans. To protect itself against loss exposure with this policy, the Company has purchased individual stop-loss insurance coverage that insures individual claims that exceed $525 for each covered person for fiscal years 2023 and 2022, respectively, and $500 for each covered person for fiscal year 2021. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that adequate provision has been made in the Financial Statements for liabilities that may arise out of patient care, workers’ compensation, healthcare benefits and related services provided to date. The amount of the Company’s reserves was determined based on an estimation process that uses information obtained from both company-specific and industry data. This estimation process requires the Company to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and the Company’s assumptions about emerging trends, the Company, with the assistance of an independent actuary, develops information about the size of ultimate claims based on the Company’s historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damage awards with respect to unpaid claims. The self-insured liabilities are based upon estimates, and while management believes that the estimates of loss are reasonable, the ultimate liability may be in excess of or less than the recorded amounts. Due to the inherent volatility of actuarially determined loss estimates, it is reasonably possible that the Company could experience changes in estimated losses that could be material to net income. If the Company’s actual liabilities exceed its estimates of losses, its future earnings, cash flows and financial condition would be adversely affected.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company’s estimates and assumptions, actual results could differ.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Standard Bearer elected to be taxed as a REIT, for U.S. federal income tax purposes, commencing with its taxable year ended December 31, 2022. Standard Bearer was organized, has operated and intends to continue to operate in a manner to qualify for taxation as a REIT. In order to qualify as a REIT, Standard Bearer must meet certain organizational and operational requirements, including a requirement to distribute to its shareholders, which in this case is the Company, at least 90% of its annual taxable income. As a REIT, Standard Bearer generally will not be subject to federal income tax to the extent it distributes as qualifying dividends, all of its REIT taxable income to its shareholders. If Standard Bearer fails to qualify as a REIT in any taxable year, it will be subject to federal income tax on its taxable income at regular corporate income tax rates and generally will not be permitted to qualify for treatment as a REIT for federal income tax purposes for the four taxable years following the year during which qualification is lost unless the Internal Revenue Service grants the Company relief under certain statutory provisions. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Noncontrolling Interest </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">— </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to The Ensign Group, Inc. in its consolidated statements of income. Net income per share is calculated based on net income attributable to The Ensign Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and recognizes compensation expense for all stock-based payment awards made to employees and directors including employee stock options based on estimated fair values, ratably over the requisite service period of the award. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is based upon the number of grants and other variables.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company does not have any components of other comprehensive income recorded within its Financial Statements and, therefore, does not separately present a statement of comprehensive income in its Financial Statements. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Except for rules and interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal securities laws and a limited number of grandfathered standards, the FASB ASC is the sole source of authoritative GAAP literature recognized by the FASB and applicable to the Company. For any new pronouncements announced, the Company considers whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on the Company's reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company's financial management and certain standards are under consideration.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Standards Issued But Not Yet Adopted by the Company</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In October 2023, the FASB issued ASU 2023-06</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> "Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative", </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which amends U.S. GAAP to include 14 disclosure requirements that are currently required under SEC Regulation S-X or Regulation S-K. Each amendment will be effective on the date on which the SEC removes the related disclosure requirement from SEC Regulation S-X or Regulation S-K. The adoption is not expected to have a material impact on the Company's Notes to the Consolidated Financial Statements as these requirements were previously incorporated under the SEC Regulations. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07 "</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">", which requires the Company to expand the breadth and frequency of segment disclosures to include additional information about significant segment expenses, the chief operating decision maker (CODM) and other items, and also require the annual disclosures on an interim basis. This guidance is effective for annual periods beginning after December 15, 2023, which will be the Company's fiscal year 2024, with early adoption permitted. The Company is currently evaluating the impact of the ASU on its Quarterly and Annual Reports. </span></div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09 "</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span>", which requires the Company to disclose disaggregated jurisdictional and categorical information for the tax rate reconciliation, income taxes paid and other income tax related amounts. This guidance is effective for annual periods beginning after December 15, 2024, which will be the Company's fiscal year 2025, with early adoption permitted. The adoption is expected to enhance the Company's Notes to the Consolidated Financial Statements. The Company is currently evaluating the impact of the ASU on its Annual Report. <span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span> The accompanying consolidated financial statements (the Financial Statements) have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company is the sole member or stockholder of various consolidated limited liability companies and corporations established to operate various acquired skilled nursing operations, senior living operations and related ancillary services. All intercompany transactions and balances have been eliminated in consolidation. The Company presents noncontrolling interests within the equity section of its consolidated balance sheets and the amount of consolidated net income that is attributable to The Ensign Group, Inc. and the noncontrolling interests in its consolidated statements of income. The Financial Statements include the accounts of all independent subsidiaries controlled by the Company through its ownership of a majority voting interest. <span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — </span>Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. <div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Estimates and Assumptions</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of the Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Company’s Financial Statements relate to revenue, acquired property and equipment, intangible assets and goodwill, right-of-use assets, impairment of long-lived assets, lease liabilities, general and professional liabilities, workers' compensation and healthcare claims included in accrued self-insurance liabilities and income taxes. Actual results could differ from those estimates.</span></div> <div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Considerations</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s financial instruments consist principally of cash and cash equivalents, debt security investments, accounts receivable, insurance subsidiary deposits, deferred compensation investment funds, equity investments, accounts payable and borrowings. The Company believes all of the financial instruments’ recorded values approximate fair values because of their nature or respective short durations. </span></div>Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.The Company's non-financial assets, which includes goodwill, intangible assets, property and equipment and right-of-use assets, are not required to be measured at fair value on a recurring basis. However, on a periodic basis, or whenever events or changes in circumstances indicate that their carrying value may not be recoverable, the Company assesses its long-lived assets for impairment. When impairment has occurred, such long-lived assets are written down to fair value. <div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service Revenue Recognition</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 606).</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's service revenue is derived primarily from providing healthcare services to its patients. Revenue is recognized when services are provided to patients at the amount that reflects the consideration that the Company expects to be entitled from patients and third-party payors, including Medicaid, Medicare and insurers (private and Medicare replacement plans), in exchange for providing patient care. The healthcare services provided pursuant to skilled patient contracts include routine services in exchange for a contractual agreed-upon amount or rate. Routine services are treated as a single performance obligation satisfied over time as services are rendered. As such, patient care services represent a bundle of services that are not capable of being distinct. Additionally, there may be ancillary services that are not included in the daily rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time, if and when those services are rendered.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction price. The Company determines the transaction price based on contractually agreed-upon amounts or rate on a per day basis, adjusted for estimates of variable consideration. The Company uses the expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The amount of variable consideration that is included in the transaction price may be constrained and is included in net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from the Company’s estimates, the Company adjusts these estimates, which would affect net revenue in the period such variances become known.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company’s contracts with its patients have an original duration of one year or less, the Company uses the practical expedient applicable to its contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of the end of each reporting period or when the Company expects to recognize this revenue. In addition, the Company has applied the practical expedient provided by FASB ASC Topic 340, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets and Deferred Costs</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and all incremental customer contract acquisition costs are expensed as they are incurred because the amortization period would have been one year or less.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rental Revenue Recognition</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company's rental revenues are primarily generated by leasing healthcare-related properties through triple-net lease arrangements, under which the tenant is solely responsible for the costs related to the property. Revenue for operating leases is recognized on a straight-line basis over the lease term when collectability of all minimum lease payments is probable in accordance with FASB ASC Topic 842, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 842). The Company has elected the single component practical expedient, which allows a lessor, by class of underlying asset, not to allocate the total consideration to the lease and non-lease components based on their relative stand-alone selling prices where certain criteria are met. </span></div>Tenant reimbursements related to property taxes and insurance are neither considered lease nor non-lease components under ASC 842. Lessee payments for taxes and insurance paid directly to a third party, on behalf of the Company, are excluded from variable lease payments and rental revenue in the Company’s consolidated statements of income. Otherwise, tenant reimbursements for taxes and insurance that are paid by the Company directly to a third party are classified as additional rental revenue and expense and recognized by the Company on a gross basis. <div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources, net of estimates for variable consideration.</span></div> <div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">— </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of bank term deposits, money market funds and treasury bill related investments with original maturities of three months or less at time of purchase and therefore approximate fair value. The fair value of money market funds is determined based on “Level 1” inputs, which consist of unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets. The Company places its cash and short-term investments with high credit quality financial institutions.</span></div> <div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Insurance Subsidiary Deposits and Investments — </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's captive insurance subsidiary cash and cash equivalents, deposits and investments are designated to support long-term insurance subsidiary liabilities and have been classified as short-term and long-term assets based on the timing of expected future payments of the Company's captive insurance liabilities. The majority of these deposits and investments are currently held in AA, A and BBB rated debt security investments and the remainder is held in a bank account with a high credit quality financial institution. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's non-qualified deferred compensation plan (the DCP)'s contracts insuring the lives of certain employees who are eligible to participate in the DCP are held in a rabbi trust. Cash surrender value of the contracts is based on funds that shadow the investment allocations specified by participants in the deferred compensation plan. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When evaluating an investment for its current expected credit losses, the Company reviews factors such as historical experience with defaults, losses, credit ratings, term, market sector and macroeconomic trends, including current conditions and forecasts to the extent they are reasonable and supportable.</span></div> <span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span> Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from <span style="-sec-ix-hidden:f-498">three</span> to 59 years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term. P59Y <div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company leases skilled nursing facilities, senior living facilities and commercial office space.</span><span style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease and performs an evaluation to determine whether the lease should be classified as an operating or finance lease at the inception of the lease. As of December 31, 2023, the Company has one financing lease that is not material to the consolidated balance sheet. Rights and obligations of these leases are included as right-of-use assets and current and long-term lease liabilities on the Company's consolidated balance sheets. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of future lease payments. The Company utilizes a third-party valuation specialist to assist in estimating the incremental borrowing rate.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records rent expense for operating leases on a straight-line basis over the term of the lease. The lease term used for straight-line rent expense is calculated from the date the Company is given control of the leased premises through the end of the lease term. Renewals are not assumed in the determination of the lease term unless they are deemed to be reasonably assured at the inception of the lease. The lease term used for this evaluation also provides the basis for establishing depreciable lives for buildings subject to lease and leasehold improvements.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's real estate leases generally have initial lease terms of ten years or more and typically include one or more options to renew, with renewal terms that generally extend the lease term for an additional <span style="-sec-ix-hidden:f-504">ten</span> to 15 years. Exercise of the renewal options is generally subject to the satisfaction of certain conditions which vary by contract and generally follow payment terms that are consistent with those in place during the initial term. The Company reassesses the renewal option using a "reasonably certain" threshold, which is understood to be a high threshold. For leases where the Company is reasonably certain to exercise its renewal option, the option periods are included within the lease term and, therefore, the measurement of the right-of-use asset and lease liability. The Company's leases generally contain annual escalation clauses that are either fixed or variable in nature, some of which are dependent upon published indices. The Company recognizes lease expense for leases with an initial term of 12 months or less on a straight-line basis over the lease term. These leases are not recorded on the consolidated balance sheets. Certain of the Company's lease agreements include rental payments that are adjusted periodically for inflation. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. </span></div>The Company subleases skilled nursing facilities to third-party operators and considers the subleases to be separate contracts as the Company is not relieved of its primary obligation under its operating lease. The rental income from third-parties related to these subleases is presented on a gross basis from the rent expense associated with the Company's lease obligations and is not material to the consolidated statements of income. 1 P10Y 1 P15Y <span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">— </span>The Company reviews the carrying value of long-lived assets that are held and used in the Company’s independent subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the independent subsidiaries to which the assets relate, utilizing management’s best estimate, appropriate assumptions and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset. <div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Definite-lived intangible assets consist primarily of patient base, facility trade names and customer relationships. Patient base is amortized over a period of <span style="-sec-ix-hidden:f-508">four</span> to eight months, depending on the classification of the patients and the level of occupancy in a new acquisition on the acquisition date. Trade names at independent subsidiaries are amortized over 30 years and customer relationships are amortized over a period of up to 20 years.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's indefinite-lived intangible assets consist of trade names and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable. </span></div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. The Company tests goodwill during the fourth quarter of each year or more often if events or circumstances indicate there may be impairment. The Company performs its analysis for each reporting unit that constitutes a business for which discrete financial information is produced and reviewed by operating segment management and provides services that are distinct from the other components of the operating segment, in accordance with the provisions of FASB ASC Topic 350, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles—Goodwill and Other </span>(ASC 350). This guidance provides the option to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. If, based on a review of qualitative factors, it is more likely than not that the fair value of a reporting unit is less than its carrying value, the Company performs a goodwill impairment test by comparing the carrying value of each reporting unit to its respective fair value. The Company determines the estimated fair value of each reporting unit using a discounted cash flow analysis. The fair value of the reporting unit is the implied fair value of goodwill. In the event a reporting unit's carrying value exceeds its fair value, an impairment loss will be recognized. An impairment loss is measured by the difference between the carrying value of the reporting unit and its fair value. P8M P30Y P20Y 7410000 <div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Self-Insurance</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — The Company is partially self-insured for general and professional liability claims up to a base amount per claim (the self-insured retention) with an aggregate, one-time deductible above this limit. Losses beyond these amounts are insured through third-party policies with coverage limits per claim, per location and on an aggregate basis for the Company. The combined self-insured retention is $500 per claim, subject to an additional one-time deductible of $1,250 for the Company's independent subsidiaries in California and a separate, one-time, deductible of $1,250 for the Company's independent subsidiaries not in California. For all independent subsidiaries, except those located in Colorado, the third-party coverage above these limits is $1,000 per claim, $3,000 per operation, with a $5,000 blanket aggregate limit and an additional state-specific aggregate where required by state law. In Colorado, the third-party coverage above these limits is $1,000 per claim and $3,000 per operation, which is independent of the aforementioned blanket aggregate limits that apply outside of Colorado. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to December 31, 2023, the self-insured retention is $750 per claim, subject to an additional one-time deductible of $1,500 for the Company's independent subsidiaries in California. For the independent subsidiaries not in California, the self-insured retention is $650 per claim, subject to an additional one-time deductible of $1,350. For all independent subsidiaries, except those located in Colorado, the third-party coverage above these limits is $1,000 per claim, $3,000 per operation, with a $10,000 blanket aggregate limit and an additional state-specific aggregate where required by state law. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the self-insured retention and deductible limits for general and professional liabilities and workers' compensation liabilities are self-insured through the captive insurance subsidiary, the related assets and liabilities of which are included in the accompanying consolidated balance sheets. The captive insurance subsidiary is subject to certain statutory requirements as an insurance provider. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s policy is to accrue amounts equal to the actuarial estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. The Company develops information about the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluates the estimates for claim loss exposure on a quarterly basis. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s independent subsidiaries are self-insured for workers’ compensation liabilities in California. To protect itself against loss exposure in California with this policy, the Company has purchased individual specific excess insurance coverage that insures individual claims that exceed $625 per occurrence. In Texas, the independent subsidiaries have elected non-subscriber status for workers’ compensation claims and the Company has purchased individual stop-loss coverage that insures individual claims that exceed $750 per occurrence. The Company’s independent subsidiaries in all other states, with the exception of Washington, are under a loss sensitive plan that insures individual claims that exceed $350 per occurrence. In the state of Washington, the Company is self-insured and has purchased individual specific excess insurance coverage that insures individual claims that exceed $500 per occurrence. For all of the self-insured plans and retention, the Company accrues amounts equal to the estimated costs to settle open claims, as well as an estimate of the cost of claims that have been incurred but not reported. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company self-funds medical (including prescription drugs) and dental healthcare benefits to the majority of its employees. The Company is fully liable for all financial and legal aspects of these benefit plans. To protect itself against loss exposure with this policy, the Company has purchased individual stop-loss insurance coverage that insures individual claims that exceed $525 for each covered person for fiscal years 2023 and 2022, respectively, and $500 for each covered person for fiscal year 2021. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that adequate provision has been made in the Financial Statements for liabilities that may arise out of patient care, workers’ compensation, healthcare benefits and related services provided to date. The amount of the Company’s reserves was determined based on an estimation process that uses information obtained from both company-specific and industry data. This estimation process requires the Company to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and the Company’s assumptions about emerging trends, the Company, with the assistance of an independent actuary, develops information about the size of ultimate claims based on the Company’s historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damage awards with respect to unpaid claims. The self-insured liabilities are based upon estimates, and while management believes that the estimates of loss are reasonable, the ultimate liability may be in excess of or less than the recorded amounts. Due to the inherent volatility of actuarially determined loss estimates, it is reasonably possible that the Company could experience changes in estimated losses that could be material to net income. If the Company’s actual liabilities exceed its estimates of losses, its future earnings, cash flows and financial condition would be adversely affected.</span></div> 500000 1250000 1250000 1000000 3000000 5000000 1000000 3000000 750000 1500000 650000 1350000 1000000 3000000 10000000 625000 750000 350000 500000 525000 500000 <div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company’s estimates and assumptions, actual results could differ.</span></div>Standard Bearer elected to be taxed as a REIT, for U.S. federal income tax purposes, commencing with its taxable year ended December 31, 2022. Standard Bearer was organized, has operated and intends to continue to operate in a manner to qualify for taxation as a REIT. In order to qualify as a REIT, Standard Bearer must meet certain organizational and operational requirements, including a requirement to distribute to its shareholders, which in this case is the Company, at least 90% of its annual taxable income. As a REIT, Standard Bearer generally will not be subject to federal income tax to the extent it distributes as qualifying dividends, all of its REIT taxable income to its shareholders. If Standard Bearer fails to qualify as a REIT in any taxable year, it will be subject to federal income tax on its taxable income at regular corporate income tax rates and generally will not be permitted to qualify for treatment as a REIT for federal income tax purposes for the four taxable years following the year during which qualification is lost unless the Internal Revenue Service grants the Company relief under certain statutory provisions. <span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Noncontrolling Interest </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">— </span>The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to The Ensign Group, Inc. in its consolidated statements of income. Net income per share is calculated based on net income attributable to The Ensign Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest. <div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and recognizes compensation expense for all stock-based payment awards made to employees and directors including employee stock options based on estimated fair values, ratably over the requisite service period of the award. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is based upon the number of grants and other variables.</span></div> <div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Except for rules and interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal securities laws and a limited number of grandfathered standards, the FASB ASC is the sole source of authoritative GAAP literature recognized by the FASB and applicable to the Company. For any new pronouncements announced, the Company considers whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on the Company's reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company's financial management and certain standards are under consideration.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Standards Issued But Not Yet Adopted by the Company</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In October 2023, the FASB issued ASU 2023-06</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> "Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative", </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which amends U.S. GAAP to include 14 disclosure requirements that are currently required under SEC Regulation S-X or Regulation S-K. Each amendment will be effective on the date on which the SEC removes the related disclosure requirement from SEC Regulation S-X or Regulation S-K. The adoption is not expected to have a material impact on the Company's Notes to the Consolidated Financial Statements as these requirements were previously incorporated under the SEC Regulations. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07 "</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">", which requires the Company to expand the breadth and frequency of segment disclosures to include additional information about significant segment expenses, the chief operating decision maker (CODM) and other items, and also require the annual disclosures on an interim basis. This guidance is effective for annual periods beginning after December 15, 2023, which will be the Company's fiscal year 2024, with early adoption permitted. The Company is currently evaluating the impact of the ASU on its Quarterly and Annual Reports. </span></div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09 "</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span>", which requires the Company to disclose disaggregated jurisdictional and categorical information for the tax rate reconciliation, income taxes paid and other income tax related amounts. This guidance is effective for annual periods beginning after December 15, 2024, which will be the Company's fiscal year 2025, with early adoption permitted. The adoption is expected to enhance the Company's Notes to the Consolidated Financial Statements. The Company is currently evaluating the impact of the ASU on its Annual Report. REVENUE AND ACCOUNTS RECEIVABLE<div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disaggregates revenue from contracts with its patients by payors. The Company determines that disaggregating revenue into these categories achieves the disclosure objectives to depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue by Payor</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s revenue is derived primarily from providing healthcare services to patients and is recognized on the date services are provided at amounts billable to individual patients, adjusted for estimates for variable consideration. For patients under reimbursement arrangements with third-party payors, including Medicaid, Medicare and private insurers, revenue is recorded based on contractually agreed-upon amounts or rates, adjusted for estimates for variable consideration, on a per patient, daily basis or as services are performed. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from the Medicare and Medicaid programs accounted for 72.6%, 73.7% and 73.6% for the years ended December 31, 2023, 2022, and 2021, respectively. Settlements with Medicare and Medicaid payors for retroactive adjustments due to audits and reviews are considered variable consideration and are included in the determination of the estimated transaction price. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Company’s historical settlement activity. Consistent with healthcare industry practices, any changes to these revenue estimates are recorded in the period the change or adjustment becomes known based on the final settlement. The Company recorded adjustments to revenue which were not material to the Company's revenue for the years ended December 31, 2023, 2022, and 2021.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service revenue for the years ended December 31, 2023, 2022, and 2021 is summarized in the following tables:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.086%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.582%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="33" style="border-bottom:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,459,449 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.4 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,183,156 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.3 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,022,460 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.2 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985,749 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832,160 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727,103 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid — skilled</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,663 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,878 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,770 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Medicaid and Medicare</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,690,861</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72.6</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,216,194</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.7</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,922,333</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.6</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666,129 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525,710 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,728 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351,081 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,807 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,415 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SERVICE REVENUE</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,708,071</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,008,711</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,611,476</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Medicaid payor includes revenue for senior living operations and </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">revenue related to state relief funding</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other an</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">cillary services.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the service revenue above, the Company's rental revenue derived from triple-net lease arrangements with third parties is $21,284, $16,757 and $15,985 for the years ended December 31, 2023, 2022, and 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">State relief funding</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received state relief funding through Medicaid programs from various states, including healthcare relief funding under the American Rescue Plan Act (ARPA), increases in the Federal Medical Assistance Percentage (FMAP) under the Families First Coronavirus Response Act (FFCRA) and other state specific relief programs. The funding generally incorporates specific use requirements primarily for direct patient care including labor related expenses that are attributable to the COVID-19 pandemic or are associated with providing patient care.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from these additional payments are recognized in accordance with ASC 606, subject to variable consideration constraints. In certain operations where the Company received additional payments that exceeded expenses incurred related to specific qualifiers, the Company recorded deferred revenue for the excess amount until additional expenses are incurred for recognition. Accordingly, the amount of state relief revenue recognized is limited to the actual related expenses incurred. As of years ended December 31, 2023 and 2022, the Company had $486 and $1,001 in unapplied state relief funds, respectively. During the years ended December 31, 2023, 2022, and 2021, the Company received an additional $64,238, $81,057, and $70,484 in state relief funding and recognized $64,753, $81,837, and $75,231, respectively, as revenue.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Federal relief funding</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In prior years, as part of the Coronavirus Aid, Relief, and Economic Security Act of 2020 (the CARES Act), the Company received cash distributions of relief fund payments (Provider Relief Funds) and funds authorized by U.S. Department of Health and Human Services (HHS) to be used to protect residents of nursing homes and long-term care (LTC) facilities from the impact of COVID-19. During the years ended December 31, 2023 and 2022, the Company did not receive Provider Relief Funds. During the year ended December 31, 2021, the Company received and returned $11,637 in Provider Relief Funds.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In fiscal year 2020, the Company applied for and received $105,255 through the Medicare Accelerated and Advance Payment Program under the CARES Act. The purpose of the program is to assist in providing needed liquidity to care delivery providers. The Company repaid $3,232 of the funds in 2020 and the remaining funds of $102,023 in March 2021.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The CARES Act also provides for deferred payment of the employer portion of social security taxes through the end of 2020, with approximately 50% of the deferred amount due by December 31, 2021 and the remaining 50% due by December 31, 2022. The Company recorded $48,309 of deferred payments of social security taxes as a liability during 2020, and paid the first and second half of the payments in the fourth quarters of 2021 and 2022, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Balance Sheet Impact</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the Company’s consolidated balance sheets are contract balances, comprised of billed accounts receivable and unbilled receivables, which are the result of the timing of revenue recognition, billings and cash collections, as well as, contract liabilities, which primarily represent payments the Company receives in advance of services provided. The Company had no material contract liabilities and contract assets as of December 31, 2023 and 2022, or activity during the years ended December 31, 2023, 2022, and 2021.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable as of December 31, 2023 and 2022, is summarized in the following table:</span></div><div style="margin-top:9.75pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,285 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,878 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,907 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,940 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,512 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,526 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other payors</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,683 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,890 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">494,387</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">416,234</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,348)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,802)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ACCOUNTS RECEIVABLE, NET</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">485,039</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">408,432</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0.726 0.737 0.736 <div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service revenue for the years ended December 31, 2023, 2022, and 2021 is summarized in the following tables:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.086%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.582%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="33" style="border-bottom:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,459,449 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.4 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,183,156 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.3 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,022,460 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.2 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985,749 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832,160 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727,103 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid — skilled</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,663 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,878 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,770 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Medicaid and Medicare</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,690,861</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72.6</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,216,194</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.7</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,922,333</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.6</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666,129 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525,710 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,728 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351,081 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,807 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,415 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SERVICE REVENUE</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,708,071</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,008,711</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,611,476</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Medicaid payor includes revenue for senior living operations and </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">revenue related to state relief funding</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other an</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">cillary services.</span></div> 1459449000 0.394 1183156000 0.393 1022460000 0.392 985749000 0.266 832160000 0.277 727103000 0.278 245663000 0.066 200878000 0.067 172770000 0.066 2690861000 0.726 2216194000 0.737 1922333000 0.736 666129000 0.180 525710000 0.175 456728000 0.175 351081000 0.094 266807000 0.088 232415000 0.089 3708071000 1.000 3008711000 1.000 2611476000 1.000 21284000 16757000 15985000 486000 1001000 64238000 81057000 70484000 64753000 81837000 75231000 11637000 105255000 3232000 102023000 48309000 <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable as of December 31, 2023 and 2022, is summarized in the following table:</span></div><div style="margin-top:9.75pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,285 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,878 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,907 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,940 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,512 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,526 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other payors</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,683 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,890 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">494,387</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">416,234</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,348)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,802)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ACCOUNTS RECEIVABLE, NET</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">485,039</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">408,432</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 178285000 157878000 125907000 95940000 85512000 76526000 104683000 85890000 494387000 416234000 9348000 7802000 485039000 408432000 COMPUTATION OF NET INCOME PER COMMON SHARE<div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per share is computed by dividing income from operations attributable to stockholders of The Ensign Group, Inc. by the weighted average number of outstanding common shares for the period. The computation of diluted net income per share is similar to the computation of basic net income per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of basic net income per common share follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NUMERATOR:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,850 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,652 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,725 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: net income (loss) attributable to noncontrolling interests </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,073 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to The Ensign Group, Inc. </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">209,399</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">224,681</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">194,652</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DENOMINATOR:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding for basic net income per share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,708 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,887 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,486 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic net income per common share:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.76</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.09</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.57</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of diluted net income per common share follows:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NUMERATOR:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,850 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,652 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,725 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: net income (loss) attributable to noncontrolling interests</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,073 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to The Ensign Group, Inc. </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">209,399</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">224,681</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">194,652</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DENOMINATOR:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,708 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,887 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,486 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plus: incremental shares from assumed conversion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,615 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,984 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,439 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted weighted average common shares outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">57,323</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56,871</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56,925</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted net income per common share:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.65</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.95</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.42</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> 1,429, </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">780 and 198 for the years ended December 31, 2023, 2022 and 2021, respectively.</span></div> <div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of basic net income per common share follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NUMERATOR:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,850 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,652 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,725 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: net income (loss) attributable to noncontrolling interests </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,073 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to The Ensign Group, Inc. </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">209,399</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">224,681</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">194,652</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DENOMINATOR:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding for basic net income per share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,708 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,887 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,486 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic net income per common share:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.76</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.09</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.57</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 209850000 224652000 197725000 451000 -29000 3073000 209399000 224681000 194652000 55708000 54887000 54486000 3.76 4.09 3.57 <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of diluted net income per common share follows:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NUMERATOR:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,850 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,652 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,725 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: net income (loss) attributable to noncontrolling interests</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,073 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to The Ensign Group, Inc. </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">209,399</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">224,681</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">194,652</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DENOMINATOR:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,708 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,887 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,486 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plus: incremental shares from assumed conversion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,615 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,984 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,439 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted weighted average common shares outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">57,323</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56,871</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56,925</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted net income per common share:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.65</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.95</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.42</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> 1,429, </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">780 and 198 for the years ended December 31, 2023, 2022 and 2021, respectively.</span></div> 209850000 224652000 197725000 451000 -29000 3073000 209399000 224681000 194652000 55708000 54887000 54486000 1615000 1984000 2439000 57323000 56871000 56925000 3.65 3.95 3.42 1429000 780000 198000 FAIR VALUE MEASUREMENTS<div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial assets include the captive insurance subsidiary's deposits and investments designated to support long-term insurance subsidiary liabilities and are carried at amortized cost basis of $59,530 and $53,924 as of December 31, 2023 and 2022, respectively. As of December 31, 2023 and 2022, the amortized cost basis of the Company's financial assets included in the captive insurance subsidiary's investments are considered to approximate the fair value of these financial assets and are derived using Level 2 inputs. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also included are contracts insuring the lives of certain employees who are eligible to participate in non-qualified deferred compensation plans that are held in a rabbi trust. The cash surrender value of these contracts is based on funds that shadow the investment allocations specified by participants in the deferred compensation plan and are held at fair value. As of December 31, 2023, and 2022, the fair value of the investment funds was $41,216 and $25,144, respectively, which are derived using Level 2 inputs.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company has other investments held at historical cost basis, which are not material, where the fair value is derived using Level 3 inputs. The Company believes its amortized cost basis investments that were in an unrealized loss position as of December 31, 2023 and 2022 do not require an allowance for expected credit losses, nor has any event occurred through the filing date of this report that would indicate differently.</span></div> 59530000 53924000 41216000 25144000 STANDARD BEARER<div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Standard Bearer's real estate portfolio consists of 108 of the Company's 113 owned real estate properties, of which 79 are operated and managed by the Company's independent subsidiaries and 30 are leased to and operated by third-party operators. Of those 30 operations, one senior living facility is located on the same real estate property as a skilled nursing facility that an independent subsidiary owns and operates. Standard Bearer elected to be taxed as a REIT, for U.S. federal income tax purposes, commencing with its taxable year ended December 31, 2022. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December 31, 2023,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Standard Bearer acquired the real estate of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> stand-alone skilled nursing facilities and </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">two</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> campus operations for an aggregate purchase price of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$65,899. Of these additions, the three</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> skilled nursing facilities and </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">one</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> campus operation acquired are </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operated by the Company's </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">independent</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> subsidiaries and</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the other campus operation is leased to a third-party operator. During the year ended December 31, 2022, Standard Bearer acquired the real estate of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ten skilled nursing facilities for an aggregate purchase price of $84,656, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three of which were previously operated and managed by the Company's independent subsidiaries. Refer to Note 7, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operation Expansions</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional information.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the formation of Standard Bearer, certain of the Company's </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">independent</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> subsidiaries, Standard Bearer and Standard Bearer's independent real estate subsidiaries entered into several agreements that include leasing, management services and debt arrangements between the operations</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All intercompany transactions have been eliminated in consolidation. Refer to Note 8, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Segments</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional information related to these intercompany eliminations as well as Standard Bearer as a reportable segment. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intercompany master lease agreements</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company's independent subsidiaries and 79 Standard Bearer independent real estate subsidiaries have entered into five triple-net master lease agreements (collectively, the Standard Bearer Master Leases). The lease periods range from 15 to 19 years with three five-year renewal options beyond the initial term, on the same terms and conditions. The rent structure under the Standard Bearer Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the independent subsidiaries are required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties; (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. Rental revenue generated from the Company's independent subsidiaries was $66,712, $57,967, and $44,165 for the years ended December 31, 2023, 2022, and 2021, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intercompany management agreement</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Standard Bearer has no employees. The Service Center provides personnel and services to Standard Bearer pursuant to the management agreement between Standard Bearer and the Service Center. The management agreement provides for a base management fee that is equal to 5% of total rental revenue and an incentive management fee that is equal to 5% of funds from operations (FFO) and is capped at 1% of total rental revenue, for a total of 6%. Management fee generated between Standard Bearer and the Service Center for the year ended December 31, 2023 and 2022 was $4,948 and $4,367, respectively. No management fees were recorded in 2021, which was prior to the formation of Standard Bearer.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intercompany debt arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Standard Bearer obtains its funding through various sources including operating cash flows, access to debt arrangements and intercompany loans. The intercompany debt arrangements include mortgage loans and the Credit Facility to fund acquisitions and working capital needs. The interest rate under the Credit Facility is a base rate plus a margin ranging from 0.25% to 1.25% per annum or SOFR plus a margin range from 1.25% to 2.25% per annum. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as the Department of Housing and Urban Development (HUD) mortgage loans and promissory note are entered into by real estate subsidiaries of Standard Bearer, the interest expense incurred from these debts are included in Standard Bearer's segment income. Refer to Note 15, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional information related to these debts. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Instrument Denominated in the Shares of a Subsidiary</span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the formation of Standard Bearer in January of 2022, the Company established the Standard Bearer Healthcare REIT, Inc. 2022 Omnibus Incentive Plan (Standard Bearer Equity Plan). The Company may grant stock options and restricted stock awards under the Standard Bearer Equity Plan to employees and management of Ensign's independent subsidiaries. These awards generally vest over a period of five years or upon the occurrence of certain prescribed events. The value of the stock options and restricted stock awards is tied to the value of the common stock of Standard Bearer, which is determined based on an independent valuation of Standard Bearer. The awards can be put to Standard Bearer at various prescribed dates, which in no event is earlier than six months after vesting of the restricted awards or exercise of the stock options. The Company can also call the awards, generally upon employee termination. During the year ended December 31, 2022, Standard Bearer sold fully vested common shares from the Standard Bearer Equity Plan to shareholders for cash of $6,544. During the year ended December 31, 2023 and 2022, the Company did not grant any stock options nor restricted shares under the Standard Bearer Equity Plan.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, during the year ended December 31, 2022, Standard Bearer established shareholders of its preferred shares through contributions of cash of $149. These preferred shares were fully vested at the time of the contributions by the shareholders. The value of Standard Bearer common and preferred shares held by the Company are eliminated in consolidation and the value held by other shareholders are classified as noncontrolling interests on the Company's consolidated balance sheets.</span></div> 108 113 79 30 30 1 3 2 65899000 3 1 10 84656000 3 79 5 P15Y P19Y 3 P5Y 0 0.025 66712000 57967000 44165000 0.05 0.05 0.01 0.06 4948000 4367000 0 0.0025 0.0125 0.0125 0.0225 P5Y P6M 6544000 0 0 0 0 149000 OPERATION EXPANSIONS<div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expansion focus of the Company's independent subsidiaries is to purchase or lease operations that are complementary to the current operations, accretive to the business, or otherwise advance the Company's strategy. The results of all independent subsidiaries are included in the Financial Statements subsequent to the date of acquisition. Acquisitions are accounted for using the acquisition method of accounting. The Company's independent subsidiaries also enter into long-term leases that may include options to purchase the facilities. As a result, from time to time, an independent real estate subsidiary will acquire the property of facilities that have previously been operated under third-party leases. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2023 Expansions</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company expanded its operations and real estate portfolio through a combination of long-term leases and real estate purchases</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the addition of 25 stand-alone skilled nursing operations and one campus operation. Of these additions, Standard Bearer acquired the real estate of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the stand-alone skilled nursing operations and </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">one</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> campus operation, which were leased back to the Company's independent subsidiaries.</span><span style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 6, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Standard Bearer, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information on the purchase of real estate properties. These new operations added a total of 2,483 operational skilled nursing beds and 94 operational senior living units to be operated by the Company's independent subsidiaries. The Company also invested in new ancillary services that are complementary to its existing businesses. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the new operations obtained through long-term leases, the Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with each prior operator as part of each transaction. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to December 31, 2023, the Company expanded its operations through a long-term lease, with the addition of two stand-alone skilled nursing operations, totaling 241 operational skilled nursing beds operated by the Company's independent subsidiaries, including one in a new state, Tennessee. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022 Expansions</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company expanded its operations and real estate portfolio through a combination of long-term leases and real estate purchases</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with the addition of 23 stand-alone skilled nursing operations and one campus operation. Of these additions, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Standard Bearer acquired the real estate of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">seven of the stand-alone skilled nursing operations, which were leased back to Ensign's </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">independent</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> subsidiaries.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Refer to Note 6, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Standard Bearer</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional information on the purchases of real estate properties. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company added five senior living operations that were transferred from The Pennant Group, Inc. (Pennant), three of which are part of campuses operated by the Company's </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">independent</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> subsidiaries. These new operations added a total of 3,058 operational skilled nursing beds and 674 operational senior living units to be operated by the Company's </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">independent</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> subsidiaries. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also invested in new ancillary services that are complementary to its existing businesses. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the new operations acquired during the year ended December 31, 2022, $16,400 was concentrated in goodwill and accordingly, the transactions were classified as business combinations. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the new operations obtained through long-term leases, the Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with each prior operator as part of each transaction.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#3d6702;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Acquisitions</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company expanded its operations through a combination of long-term leases and a real estate purchase,</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the addition of 17 stand-alone skilled nursing operations </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and five real estate purchases, four of which the Company previously operated and continues to operate. The remaining real estate purchase is operated by Pennant.</span><span style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These new operations added a total of 1,832 operational skilled nursing beds operated by the Company's </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">independent</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> subsidiaries.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the new operations acquired during the year ended December 31, 2021, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$6,000</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was concentrated in goodwill and accordingly, the transactions were classified as business combinations. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the new operations made through long-term leases, the Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with the prior operator as part of each transaction. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the allocation of the purchase price for the operations acquired during the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years ended December 31, 2023, 2022, and 2021:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,794 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,527 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,928 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,488 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,070 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,975 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment, furniture, and fixtures</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,840 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,618 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assembled occupancy</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,400 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased asset</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,909 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other indefinite-lived intangible assets</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL ACQUISITIONS</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67,798</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">101,136</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">104,224</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s acquisition strategy has been focused on identifying both opportunistic and strategic acquisitions within its target markets that offer strong opportunities for return. The operations added by the Company are frequently underperforming financially and can have regulatory and clinical challenges to overcome. Financial information, especially with underperforming operations, is often inadequate, inaccurate or unavailable. Consequently, the Company believes that prior operating results are not a meaningful representation of the Company’s current operating results or indicative of the integration potential of its newly acquired </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">independent subsidiaries</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The assets added during the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December 31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were not material operations to the Company individually or in the aggregate. Accordingly, pro forma financial information is not presented. These additions have been included in the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> balance sheets of the Company, and the operating results have been included in the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> statements of income of the Company since the date the Company gained effective control.</span></div> 25 1 3 1 2483 94 2 241 23 1 7 5 3 3058 674 16400000 17 5 4 1832 6000000 <div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the allocation of the purchase price for the operations acquired during the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years ended December 31, 2023, 2022, and 2021:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,794 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,527 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,928 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,488 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,070 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,975 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment, furniture, and fixtures</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,840 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,618 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assembled occupancy</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,400 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased asset</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,909 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other indefinite-lived intangible assets</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL ACQUISITIONS</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67,798</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">101,136</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">104,224</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 7794000 15527000 19928000 57488000 65070000 77975000 1840000 1618000 217000 346000 367000 29000 0 16400000 6000000 0 1909000 0 330000 245000 75000 67798000 101136000 104224000 BUSINESS SEGMENTS<div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has two reportable segments: (1) skilled services, which includes the operation of skilled nursing facilities and rehabilitation therapy services and (2) Standard Bearer, which is comprised of selected real estate properties owned by Standard Bearer and leased to skilled nursing and senior living operators. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the skilled services segment includes 259 skilled nursing operations and 27 campus operations that provide both skilled nursing and rehabilitative care services and senior living services. The Company's Standard Bearer segment consists of 108 owned real estate properties. </span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also reports an “All Other” category that includes results from its senior living operations, which includes 11 stand-alone senior living operations and the senior living operations at 27 campus operations that provide both skilled nursing and rehabilitative care services and senior living services. In addition, the "All Other" category includes mobile diagnostics, medical transportation, other real estate and other ancillary operations. Services included in the “All Other” category are insignificant individually, and therefore do not constitute a reportable segment.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s reportable segments are significant operating segments that offer differentiated services. The Company's CODM reviews financial information for each operating segment to evaluate performance and allocate capital resources. This structure reflects its current operational and financial management and provides the best structure to maximize the quality of care and investment strategy provided, while maintaining financial discipline. The Company's CODM does not review assets by segment in his resource allocation and therefore assets by segment are not disclosed below.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The accounting policies of the reportable segments are the same as those described in Note 2, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Intercompany revenue is eliminated in consolidation, along with corresponding intercompany expenses. Segment income and loss is defined as profit or loss from operations before provision for income taxes, excluding gain or loss from sale of real estate, real estate insurance recoveries and losses and impairment charges from operations. Included in segment income for Standard Bearer is expense for intercompany services provided by the Service Center as described in Note 6, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Standard Bearer</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as it is part of the CODM financial information. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth financial information for the segments:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Standard Bearer</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intercompany Elimination</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,578,855 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,667 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,451)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,708,071 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,486 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,137 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,339)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,284 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL REVENUE</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,578,855</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">82,486</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">155,804</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(87,790)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,729,355</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment income (loss)</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464,925 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,065 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221,251)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,739 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of assets and insurance recoveries from real estate, net</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before provision for income taxes</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">272,762</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,766 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,205 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,416 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,387 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,761 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,902)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,087 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's independent subsidiaries and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) All Other rental revenue includes rental revenue associated with the Company's subleases to third parties of $3,897 for the year ended December 31, 2023. Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's independent subsidiaries. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. Intercompany interest expense is eliminated in the "Intercompany Elimination" column. </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Standard Bearer</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intercompany Elimination</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,906,215 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,214 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,718)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,008,711 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,937 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,396 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,576)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,757 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL REVENUE</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,906,215</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72,937</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">122,610</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(76,294)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,025,468</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment income (loss)</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,732 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,871 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150,781)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,822 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of assets and insurance recoveries from real estate, net</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,267 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before provision for income taxes</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">289,089</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,224 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,613 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,518 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,355 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,707 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,870 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,646)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,931 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's independent subsidiaries and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's independent subsidiaries. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. Intercompany interest expense is eliminated in the "Intercompany Elimination" column. </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Standard Bearer</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intercompany Elimination</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,523,234 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,276 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,034)</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,611,476 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,127 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,409 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,551)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,985 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL REVENUE</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,523,234</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">58,127</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">102,685</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(56,585)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,627,461</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment income (loss)</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373,603 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,876 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147,915)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,564 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on real estate insurance recoveries</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before provision for income taxes </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">258,004</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,681 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,558 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,746 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,985 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,842 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,849 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's independent subsidiaries and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's independent subsidiaries. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service revenue by major payor source were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.355%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.355%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Service Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue %</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,429,473 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,976 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,459,449 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.4 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985,749 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985,749 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid-skilled</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,663 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,663 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,660,885</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29,976</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,690,861</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72.6</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666,129 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666,129 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251,841 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,240 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351,081 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL SERVICE REVENUE</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,578,855</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">129,216</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,708,071</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:80%">(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding. </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:80%">(3) All Other incorporates intercompany eliminations.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.355%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Service Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue %</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158,309 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,847 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,183,156 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.3 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832,160 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832,160 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid-skilled</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,878 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,878 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,191,347</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24,847</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,216,194</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.7</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525,710 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525,710 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,158 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,649 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,807 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL SERVICE REVENUE</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,906,215</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">102,496</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,008,711</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:80%">(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding. </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:80%">(3) All Other incorporates intercompany eliminations.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.379%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Service Revenue</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue %</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007,061 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,399 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,022,460 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.2 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727,103 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727,103 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid-skilled</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,770 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,770 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,906,934</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,399</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,922,333</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.6</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,728 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,728 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,572 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,843 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,415 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL SERVICE REVENUE</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,523,234</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">88,242</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,611,476</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:80%">(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding. </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:80%">(3) All Other incorporates intercompany eliminations.</span></div> 2 259 27 108 11 27 <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth financial information for the segments:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Standard Bearer</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intercompany Elimination</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,578,855 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,667 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,451)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,708,071 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,486 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,137 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,339)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,284 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL REVENUE</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,578,855</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">82,486</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">155,804</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(87,790)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,729,355</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment income (loss)</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464,925 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,065 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221,251)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,739 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of assets and insurance recoveries from real estate, net</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before provision for income taxes</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">272,762</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,766 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,205 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,416 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,387 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,761 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,902)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,087 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's independent subsidiaries and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) All Other rental revenue includes rental revenue associated with the Company's subleases to third parties of $3,897 for the year ended December 31, 2023. Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's independent subsidiaries. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. Intercompany interest expense is eliminated in the "Intercompany Elimination" column. </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Standard Bearer</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intercompany Elimination</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,906,215 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,214 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,718)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,008,711 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,937 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,396 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,576)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,757 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL REVENUE</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,906,215</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72,937</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">122,610</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(76,294)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,025,468</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment income (loss)</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,732 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,871 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150,781)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,822 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of assets and insurance recoveries from real estate, net</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,267 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before provision for income taxes</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">289,089</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,224 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,613 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,518 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,355 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,707 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,870 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,646)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,931 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's independent subsidiaries and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's independent subsidiaries. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. Intercompany interest expense is eliminated in the "Intercompany Elimination" column. </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Standard Bearer</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intercompany Elimination</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,523,234 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,276 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,034)</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,611,476 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,127 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,409 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,551)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,985 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL REVENUE</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,523,234</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">58,127</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">102,685</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(56,585)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,627,461</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment income (loss)</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373,603 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,876 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147,915)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,564 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on real estate insurance recoveries</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before provision for income taxes </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">258,004</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,681 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,558 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,746 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,985 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,842 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,849 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's independent subsidiaries and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. </span></div>(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's independent subsidiaries. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense. 3578855000 0 144667000 -15451000 3708071000 0 82486000 11137000 -72339000 21284000 3578855000 82486000 155804000 -87790000 3729355000 464925000 29065000 -221251000 0 272739000 23000 272762000 38766000 25205000 8416000 0 72387000 0 19761000 1228000 -12902000 8087000 3897000 2906215000 0 115214000 -12718000 3008711000 0 72937000 7396000 -63576000 16757000 2906215000 72937000 122610000 -76294000 3025468000 408732000 27871000 -150781000 0 285822000 3267000 289089000 33224000 21613000 7518000 0 62355000 0 15707000 1870000 -8646000 8931000 2523234000 0 95276000 -7034000 2611476000 0 58127000 7409000 -49551000 15985000 2523234000 58127000 102685000 -56585000 2627461000 373603000 31876000 -147915000 0 257564000 440000 258004000 30681000 17558000 7746000 0 55985000 0 6842000 7000 0 6849000 <div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service revenue by major payor source were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.355%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.355%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Service Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue %</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,429,473 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,976 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,459,449 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.4 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985,749 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985,749 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid-skilled</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,663 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,663 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,660,885</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29,976</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,690,861</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72.6</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666,129 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666,129 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251,841 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,240 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351,081 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL SERVICE REVENUE</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,578,855</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">129,216</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,708,071</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:80%">(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding. </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:80%">(3) All Other incorporates intercompany eliminations.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.355%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Service Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue %</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158,309 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,847 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,183,156 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.3 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832,160 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832,160 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid-skilled</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,878 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,878 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,191,347</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24,847</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,216,194</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.7</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525,710 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525,710 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,158 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,649 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,807 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL SERVICE REVENUE</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,906,215</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">102,496</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,008,711</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:80%">(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding. </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:80%">(3) All Other incorporates intercompany eliminations.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.379%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Service Revenue</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue %</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007,061 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,399 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,022,460 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.2 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727,103 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727,103 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid-skilled</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,770 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,770 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,906,934</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,399</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,922,333</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.6</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,728 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,728 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,572 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,843 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,415 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL SERVICE REVENUE</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,523,234</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">88,242</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,611,476</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:80%">(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding. </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:80%">(3) All Other incorporates intercompany eliminations.</span></div> 1429473000 29976000 1459449000 0.394 985749000 0 985749000 0.266 245663000 0 245663000 0.066 2660885000 29976000 2690861000 0.726 666129000 0 666129000 0.180 251841000 99240000 351081000 0.094 3578855000 129216000 3708071000 1.000 1158309000 24847000 1183156000 0.393 832160000 0 832160000 0.277 200878000 0 200878000 0.067 2191347000 24847000 2216194000 0.737 525710000 0 525710000 0.175 189158000 77649000 266807000 0.088 2906215000 102496000 3008711000 1.000 1007061000 15399000 1022460000 0.392 727103000 0 727103000 0.278 172770000 0 172770000 0.066 1906934000 15399000 1922333000 0.736 456728000 0 456728000 0.175 159572000 72843000 232415000 0.089 2523234000 88242000 2611476000 1.000 PROPERTY AND EQUIPMENT - NET<div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,656 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,864 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803,155 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728,231 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,064 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,903 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339,383 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,739 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,192 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,544 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,563 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,521 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,487,013</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,331,802</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(396,242)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(339,792)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PROPERTY AND EQUIPMENT, NET</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,090,771</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">992,010</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company completed the sale of assets for a sale price of $8,607 and recorded a gain of $3,467 within the Company's consolidated statement of income as cost of services during the year ended December 31, 2022. In addition, the Company evaluated its long-lived assets and did not record an impairment charge for the fiscal years ended 2023, 2022, and 2021. See also Note 6, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Standard Bearer </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Note 7, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operation Expansions </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for information on acquisitions during the year ended December 31, 2023.</span></div> <div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,656 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,864 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803,155 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728,231 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,064 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,903 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339,383 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,739 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,192 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,544 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,563 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,521 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,487,013</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,331,802</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(396,242)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(339,792)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PROPERTY AND EQUIPMENT, NET</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,090,771</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">992,010</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 142656000 134864000 803155000 728231000 172064000 150903000 339383000 295739000 4192000 4544000 25563000 17521000 1487013000 1331802000 396242000 339792000 1090771000 992010000 8607000 3467000 INTANGIBLE ASSETS - NET<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.806%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.682%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="5" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Life (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assembled occupancy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(742)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(388)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility trade name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(439)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(415)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,582 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,692)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,890 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,582 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,482)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,096</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,873)</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,223</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,750</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,285)</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,465</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2023, 2022, and 2021, amortization expense was $1,790, $1,714 and $1,435, respectively, of which $1,202, $1,160 and $1,158 was related to the amortization of right-of-use assets, respectively. The Company did not record any impairment charge to intangible assets during the years ended December 31, 2023, 2022, and 2021.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense for each of the years ending December 31 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.837%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.381%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,013 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,223</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other indefinite-lived intangible assets consist of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicaid licenses</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,413 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,083 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,302</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,972 </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>During the year ended December 31, 2023, the Company acquired $330 in Medicare and Medicaid licenses compared to $245 and $181 in the fiscal years 2022 and 2021, respectively. <div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.806%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.682%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="5" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Life (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assembled occupancy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(742)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(388)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility trade name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(439)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(415)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,582 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,692)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,890 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,582 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,482)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,096</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,873)</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,223</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,750</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,285)</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,465</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> P0Y3M18D 781000 742000 39000 435000 388000 47000 P30Y 733000 439000 294000 733000 415000 318000 P18Y4M24D 4582000 2692000 1890000 4582000 2482000 2100000 6096000 3873000 2223000 5750000 3285000 2465000 1790000 1714000 1435000 1202000 1160000 1158000 0 0 0 <div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense for each of the years ending December 31 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.837%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.381%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,013 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,223</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 274000 234000 234000 234000 234000 1013000 2223000 <div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other indefinite-lived intangible assets consist of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicaid licenses</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,413 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,083 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,302</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,972 </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 889000 889000 3413000 3083000 4302000 3972000 330000 245000 181000 GOODWILL <div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company anticipates that the majority of goodwill recognized will be fully deductible for tax purposes as of December 31, 2023. All of the Company's acquisitions during the year ended December 31, 2023 were classified as asset acquisitions and accordingly, no goodwill was recognized for these acquisitions. There were no other activities in goodwill during the year ended December 31, 2023. Provided that goodwill corresponds to the acquisition of a business and not merely the acquisition of real estate property, the Company's Standard Bearer segment appropriately does not carry a goodwill balance. The following table represents activity in goodwill by skilled service segment and "all other" category as of December 31, 2023, 2022 and 2021:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 1, 2021</span></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45,486</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,983</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54,469</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51,486</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,983</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">60,469</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,400 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,400 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67,886</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,983</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">76,869</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67,886</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,983</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">76,869</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> The following table represents activity in goodwill by skilled service segment and "all other" category as of December 31, 2023, 2022 and 2021:<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 1, 2021</span></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45,486</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,983</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54,469</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51,486</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,983</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">60,469</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,400 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,400 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67,886</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,983</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">76,869</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67,886</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,983</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">76,869</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 45486000 8983000 54469000 6000000 0 6000000 51486000 8983000 60469000 16400000 0 16400000 67886000 8983000 76869000 67886000 8983000 76869000 RESTRICTED AND OTHER ASSETS<div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted and other assets consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.591%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs, net</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,883 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,753 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term insurance losses recoverable asset</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,913 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,512 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital improvement reserves with landlords and lenders</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,870 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,446 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposits with landlords</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,661 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,527 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Escrow deposits</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,216 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,662 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,053 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RESTRICTED AND OTHER ASSETS</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40,205</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37,291</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Included in restricted and other assets as of December 31, 2023 and 2022 are anticipated insurance recoveries related to the Company's workers' compensation and general and professional liability claims that are recorded on a gross, rather than net, basis.</span></div> <div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted and other assets consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.591%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs, net</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,883 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,753 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term insurance losses recoverable asset</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,913 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,512 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital improvement reserves with landlords and lenders</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,870 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,446 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposits with landlords</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,661 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,527 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Escrow deposits</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,216 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,662 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,053 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RESTRICTED AND OTHER ASSETS</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40,205</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37,291</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2883000 3753000 15913000 10512000 4870000 6446000 2661000 2527000 1216000 0 12662000 14053000 40205000 37291000 OTHER ACCRUED LIABILITIES<div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality assurance fee</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,035 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,701 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Refunds payable</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,248 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,783 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Resident advances</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,834 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,698 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unapplied state relief funds</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash held in trust for patients</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,215 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,400 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,396 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,201 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property taxes</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,875 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,926 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued litigation (Note 20)</span></div></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,734 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,553 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,405 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,046 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTHER ACCRUED LIABILITIES</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">168,228</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">97,309</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quality assurance fee represents the aggregate of amounts payable to Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, Utah, Washington and Wisconsin as a result of a mandated fee based on patient days or licensed beds. Refunds payable includes payables related to overpayments, duplicate payments and credit balances from various payor sources. Resident advances occur when the Company receives payments in advance of services provided. Cash held in trust for patients reflects monies received from or on behalf of patients. Maintaining a trust account for patients is a regulatory requirement and, while the trust assets offset the liabilities, the Company assumes a fiduciary responsibility for these funds. The cash balance related to this liability is included in other current assets in the consolidated balance sheets.</span></div> <div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality assurance fee</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,035 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,701 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Refunds payable</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,248 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,783 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Resident advances</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,834 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,698 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unapplied state relief funds</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash held in trust for patients</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,215 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,400 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,396 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,201 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property taxes</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,875 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,926 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued litigation (Note 20)</span></div></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,734 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,553 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,405 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,046 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTHER ACCRUED LIABILITIES</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">168,228</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">97,309</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 14035000 7701000 51248000 40783000 10834000 9698000 486000 1001000 6215000 6400000 3396000 3201000 12875000 10926000 51734000 4553000 17405000 13046000 168228000 97309000 INCOME TAXES<div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes on continuing operations for the years ended December 31, 2023, 2022 and 2021 is summarized as follows: </span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,092 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,717 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,105 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,301 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,216 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,898 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">90,393</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70,933</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">61,003</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,280)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,158)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(716)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,201)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,338)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(27,481)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,496)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(724)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">     TOTAL</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">62,912</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">64,437</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">60,279</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the federal statutory rate to the effective tax rate for income from continuing operations for the years ended December 31, 2023, 2022 and 2021, respectively, is comprised as follows: </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense at statutory rate</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes - net of federal benefit</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL INCOME TAX PROVISION</span></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23.1</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22.3</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23.4</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's effective tax rate was 23.1% for the year ended December 31, 2023, compared to 22.3% for the same period in 2022 and 23.4% in 2021. The higher effective tax rate is due to higher non-deductible expenses compared to tax benefits from stock compensation.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's deferred tax assets and liabilities as of December 31, 2023 and 2022 are summarized below. </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets (liabilities):</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,502 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,685 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related reserves</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,714 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,046 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,192 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,742 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,864 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,910 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability </span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444,590 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364,408 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes </span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">567,862</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">457,819</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(789)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(789)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL DEFERRED TAX ASSETS</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">567,073</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">457,030</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(280)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,334)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,146)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,113)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,150)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset </span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(443,222)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(363,091)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL DEFERRED TAX LIABILITIES</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(499,949)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(417,387)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NET DEFERRED TAX ASSETS</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67,124</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39,643</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had state credit carryforwards as of December 31, 2023 and 2022 of $1,192 and $1,742, respectively. These carryforwards almost entirely relate to state limitations on the application of Enterprise Zone employment-related tax credits. Unless the Company uses the Enterprise Zone credits beforehand, the carryforward began to expire in 2023. The remainder of these carryforwards relate to credits against the Texas margin tax and is expected to carryforward until 2027. As of December 31, 2023 and 2022, the valuation allowance of $789, for both years, was primarily recorded against the Enterprise Zone credits as the Company believes it is more likely than not that some of the benefit of the credits will not be realized. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's operating loss carry forwards for states were not material during the year ended December 31, 2023 and 2022. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, 2022 and 2021, the Company did not have any unrecognized tax benefits, net of its state benefits that would affect the Company's effective tax rate. The Company classifies interest and/or penalties on income tax liabilities or refunds as additional income tax expense or income. Such amounts are not material.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal statutes of limitations on the Company's 2019, 2018, and 2017 income tax years lapsed during the third quarter of 2023, 2022, and 2021, respectively. During the fourth quarter of each year, various state statutes of limitations also lapsed. The lapses during the years ended December 31, 2023 and 2022 had no impact on the Company's unrecognized tax benefits.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, the state of Wisconsin initiated and completed an examination of the Company's 2019, 2018, and 2017 state tax years with no adjustments. The Company is not under examination by any major income tax jurisdiction.</span></div> <div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes on continuing operations for the years ended December 31, 2023, 2022 and 2021 is summarized as follows: </span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,092 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,717 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,105 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,301 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,216 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,898 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">90,393</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70,933</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">61,003</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,280)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,158)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(716)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,201)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,338)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(27,481)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,496)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(724)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">     TOTAL</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">62,912</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">64,437</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">60,279</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 73092000 56717000 49105000 17301000 14216000 11898000 90393000 70933000 61003000 -22280000 -5158000 -716000 -5201000 -1338000 -8000 -27481000 -6496000 -724000 62912000 64437000 60279000 <div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the federal statutory rate to the effective tax rate for income from continuing operations for the years ended December 31, 2023, 2022 and 2021, respectively, is comprised as follows: </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense at statutory rate</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes - net of federal benefit</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL INCOME TAX PROVISION</span></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23.1</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22.3</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23.4</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div> 0.210 0.210 0.210 0.035 0.035 0.037 0.034 0.020 0.024 -0.042 -0.036 -0.033 -0.006 -0.006 -0.004 0.231 0.223 0.234 0.231 0.223 0.234 <div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's deferred tax assets and liabilities as of December 31, 2023 and 2022 are summarized below. </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets (liabilities):</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,502 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,685 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related reserves</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,714 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,046 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,192 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,742 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,864 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,910 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability </span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444,590 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364,408 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes </span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">567,862</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">457,819</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(789)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(789)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL DEFERRED TAX ASSETS</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">567,073</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">457,030</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(280)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,334)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,146)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,113)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,150)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset </span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(443,222)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(363,091)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL DEFERRED TAX LIABILITIES</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(499,949)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(417,387)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NET DEFERRED TAX ASSETS</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67,124</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39,643</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 81502000 61685000 23714000 18046000 1192000 1742000 16864000 11910000 444590000 364408000 0 28000 567862000 457819000 789000 789000 567073000 457030000 280000 0 52334000 49146000 4113000 5150000 443222000 363091000 499949000 417387000 67124000 39643000 1192000 1742000 789000 789000 DEBT<div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt consists of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans and promissory note</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,388 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,271 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current maturities</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,950)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,883)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: debt issuance costs, net</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,941)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,119)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LONG-TERM DEBT LESS CURRENT MATURITIES</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">145,497</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">149,269</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility with a Lending Consortium Arranged by Truist </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a revolving credit facility between the Company and its independent subsidiaries, including Standard Bearer as co-borrowers, and Truist Securities (Truist) (the Credit Facility) with a revolving line of credit of up to $600,000 in aggregate principal amount with a maturity date of April 8, 2027. Borrowings are supported by a lending consortium arranged by Truist. The interest rates applicable to loans under the Credit Facility are, at the Company's option, equal to either a base rate plus a margin ranging from 0.25% to 1.25% per annum or SOFR plus a margin range from 1.25% to 2.25% per annum, based on the Consolidated Total Net Debt to Consolidated EBITDA ratio (as defined in the Credit Facility). In addition, there is a commitment fee on the unused portion of the commitments that ranges from 0.20% to 0.40% per annum, depending on the Consolidated Total Net Debt to Consolidated EBITDA ratio. When the Company amended the Credit Facility in 2022 with the terms and conditions described above, it wrote off deferred financing costs of $566 and additional deferred financing costs of $3,197 were capitalized during the year ended December 31, 2022.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings made under the Credit Facility are guaranteed, jointly and severally, by certain of the Company’s wholly-owned subsidiaries, and are secured by a pledge of stock of the Company's material independent subsidiaries as well as a first lien on substantially all of such independent subsidiaries' personal property. The Credit Facility contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its independent subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend certain material agreements and pay certain dividends and other restricted payments. The Company must comply with financial maintenance covenants to be tested quarterly, consisting of (i) a maximum consolidated total net debt to consolidated EBITDA ratio (which shall not be greater than 3.00:1.00; provided that if the aggregate consideration for approved acquisitions in a six month period is greater than $50,000, then the ratio can be increased at the election of the Company with notice to the administrative agent to 3.50:1.00 for the first fiscal quarter and the immediately following three fiscal quarters), and (ii) a minimum interest/rent coverage ratio (which cannot be less than 1.50:1.00). As of December 31, 2023, there was no outstanding debt under the Credit Facility. The Company was in compliance with all loan covenants as of December 31, 2023.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mortgage Loans and Promissory Note</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has 23 subsidiaries that have mortgage loans insured with HUD in the aggregate amount of $150,244, which subjects these subsidiaries to HUD oversight and periodic inspections. The mortgage loans bear effective interest rates in a range of 3.1% to 4.2%, including fixed interest rates in a range of 2.4% to 3.3% per annum. In addition to the interest rate, the Company incurs other fees for HUD placement, including but not limited to audit fees. Amounts borrowed under the mortgage loans may be prepaid, subject to prepayment fees based on the principal balance on the date of prepayment. For the majority of the loans, during the first three years, the prepayment fee is 10.0% and is reduced by 3.0% in the fourth year of the loan, and reduced by 1.0%</span><span style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">per year for years five through ten of the loan. There is no prepayment penalty after year ten. The terms for all the mortgage loans are 25 to 35 years. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the HUD mortgage loans above, the Company has a promissory note of $2,144 that bears a fixed interest rate of 5.3% per annum and has a term of 12 years. The note, which was assumed as part of an acquisition, is secured by the real property comprising the facility and the rent, issues and profits thereof, as well as all personal property used in the operation of the facility. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future principal payments due under the long-term debt arrangements discussed above are as follows:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,950 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,086 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,227 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,897 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,779 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,449 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">152,388</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on Level 2 inputs, the carrying value of the Company's long-term debt is considered to approximate the fair value of such debt for all periods presented based upon the interest rates that the Company believes it can currently obtain for similar debt.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the Company had approximately $6,255 of borrowing capacity under the Credit Facility pledged as collateral to secure outstanding letters of credit, which decreased by $455 from prior year.</span></div> <div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt consists of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans and promissory note</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,388 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,271 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current maturities</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,950)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,883)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: debt issuance costs, net</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,941)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,119)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LONG-TERM DEBT LESS CURRENT MATURITIES</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">145,497</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">149,269</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 152388000 156271000 3950000 3883000 2941000 3119000 145497000 149269000 600000000 0.0025 0.0125 0.0125 0.0225 0.0020 0.0040 566000 3197000 3.00 P6M 50000000 3.50 1.50 0 23 150244000 0.031 0.042 0.024 0.033 0.100 0.030 0.010 0 P25Y P35Y 2144000 0.053 P12Y <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future principal payments due under the long-term debt arrangements discussed above are as follows:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,950 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,086 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,227 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,897 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,779 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,449 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">152,388</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 3950000 4086000 4227000 3897000 3779000 132449000 152388000 6255000 -455000 OPTIONS AND AWARDS<div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense consists of stock-based payment awards made to employees and directors, including employee stock options and restricted stock awards, based on estimated fair values. As stock-based compensation expense recognized in the Company’s consolidated statements of income for the years ended December 31, 2023, 2022, and 2021 was based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. The Company estimates forfeitures at the time of grant and, if necessary, revises the estimate in subsequent periods if actual forfeitures differ.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022 Omnibus Incentive Plan (2022 Plan)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has one active stock incentive plan, the 2022 Omnibus Incentive Plan (the 2022 Plan). Including the shares rolled over from the 2017 Omnibus Incentive Plan, the 2022 Plan provides for the issuance of 3,452 shares of common stock. The number of shares available to be issued under the 2022 Plan will be reduced by (i) one share for each share that relates to an option or stock appreciation right award and (ii) two shares for each share which relates to an award other than a stock option or stock appreciation right award (a full-value award). Non-employee director options, to the extent granted, will vest and become exercisable in three equal annual installments, or the length of the term if less than three years, on the completion of each year of service measured from the grant date. All other options generally vest over five years at 20% per year on the anniversary of the grant date. Options expire ten years from the date of grant. At December 31, 2023, the total number of shares available for issuance under the 2022 Plan was 1,454.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option-pricing model to recognize the value of stock-based compensation expense for stock option awards. Determining the appropriate fair-value model and calculating the fair value of stock option awards at the grant date requires judgment, including estimating stock price volatility, expected option life, and forfeiture rates. The fair-value of the restricted stock awards at the grant date is based on the market price on the grant date, adjusted for forfeiture rates. The Company develops estimates based on historical data and market information, which can change significantly over time. The Black-Scholes model required the Company to make several key judgments including: </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">The expected option term is calculated by the average of the contractual term of the options and the weighted average vesting period for all options. The calculation of the expected option term is based on the Company's experience due to sufficient history.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">The Company utilizes its own experience to calculate estimated volatility for options granted. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">The dividend yield is based on the Company's historical pattern of dividends as well as expected dividend patterns.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">The risk-free rate is based on the implied yield of U.S. Treasury notes as of the grant date with a remaining term approximately equal to the expected term.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Estimated forfeiture rate of approximately 5.08% per year is based on the Company's historical forfeiture activity of unvested stock options.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted 1,008, 581 and 621 stock options during the years ended December 31, 2023, 2022, and 2021, respectively. The Company used the following assumptions for stock options granted during the years ended December 31, 2023, 2022 and 2021:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.428%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.428%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Risk-Free Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expected Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Volatility</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Dividend Yield</span></td></tr><tr><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3%</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 years</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.3%</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.1%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.4%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3%</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2023, 2022 and 2021, the following represents the exercise price and fair value displayed at grant date for stock option grants:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.687%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Fair Value of Options</span></td></tr><tr><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.05 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.85 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.74 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.83 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.19 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.82 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average exercise price equaled the weighted average fair value of common stock on the grant date for all options granted during the periods ended December 31, 2023, 2022 and 2021 and therefore, the intrinsic value was $0 at the date of grant. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the employee stock option activity during the year ended December 31, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.981%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of<br/>Options Vested</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Exercise Price of Options Vested</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 1, 2021</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,038 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.71 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,148 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.66 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.19 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.76 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(516)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.80 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,038 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.60 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,183 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.02 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.74 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.52 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(688)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.43 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,833 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.72 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,069 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.87 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.05 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.44 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(759)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.21 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,991 </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.65 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,887 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.58 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summary information reflects stock options outstanding, vested and related details as of December 31, 2023:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.892%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options Vested</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number Outstanding</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Black-Scholes Fair Value</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining Contractual Life (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vested and Exercisable</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year of Grant</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.94</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.05</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2015</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.20</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.39</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,369 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.93</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.86</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.80</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.41</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,138 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.49</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.71</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,523 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.07</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.76</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,014 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.84</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.49</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,383 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.47</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.64</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">513 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,844 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.79</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.88</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,466 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$89.83</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$98.83</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,566 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,991</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">105,703</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,887</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options outstanding, vested and expected to vest as of December 31, 2023, 2022 and 2021 is as follows:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.349%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,819 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,593 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,242 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,048 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,382 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,759 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,232 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,548 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intrinsic value is calculated as the difference between the market value of the underlying common stock and the exercise price of the options</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. At </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2023, 2022 and 2021, t</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he aggregate intrinsic value of options that vested </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the years ended December 31, 2023, 2022 and 2021 was</span><span style="color:#ff0090;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$31,658, $27,955, and $27,731, respectively. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of options exercised </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the years ended December 31, 2023, 2022 and 2021 was $56,186, $47,441, and $34,278, respectively. </span><span style="color:#ff0090;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Awards</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 219, 233</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 222 restricted stock awards during the years ended </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 and 2021, </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively. All awards were granted at an issue price of $0 and generally vest over five years. The fair value per share of restricted awards granted during the years ended </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 and 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ranged from</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $89.83 to $98.31,</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $73.17 to $94.88 and $72.84 to $93.31, respectively. The fair value per share includes quarterly stock awards to non-employee directors. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the status of the Company's non-vested restricted stock awards as of December 31, 2023 and changes during the years ended December 31, 2023, 2022 and 2021 is presented below:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.954%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Vested Restricted Awards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nonvested at January 1, 2021</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.90 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.65 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(244)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.45 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.64 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nonvested at December 31, 2021</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">549</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.16 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.57 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(269)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.06 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.29 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nonvested at December 31, 2022</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">487</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.92 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.04 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(255)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.21 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.53 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nonvested at December 31, 2023</span></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">431</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.91 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company granted</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 18</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> quarterly stock awards to non-employee directors for their service on the Company's board of directors from the 2022 Plan. The fair value per share of these stock awards ranged from </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$89.94 to $98.31</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> based on the market price on the grant date. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Term Incentive Plan</span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 27, 2019, the Board approved the Long-Term Incentive Plan (the 2019 LTI Plan). The 2019 LTI Plan provides that certain employees of the Company who assisted in the consummation of the spin-off of Pennant from the Company in 2019 (spin-off transaction) were granted shares of restricted stock upon successful completion of the spin-off. The 2019 LTI Plan provides for the issuance of 500 shares of Pennant restricted stock. The shares are vested over five years at 20% per year on the anniversary of the grant date. If a recipient is terminated or voluntarily leaves the Company, all shares subject to restriction or not yet vested are entirely forfeited. The total stock-based compensation related to the 2019 LTI Plan was approximately $827, $836, and $854 for the years ended December 31, 2023, 2022 and 2021, respectively. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation expense</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for the Company's equity incentive plans and long-term incentive plan for the years ended December 31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 and 2021 was as follows:</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.915%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,221 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,361 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,459 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to restricted stock awards</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,845 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,920 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,385 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,688 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,439 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,834 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30,754</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,720</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,678</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In future periods, the Company expects to recognize approximately</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $67,750 and $29,245 in stock-based compensation expense for unvested options and unvested restricted stock awards, respectively, that were outstanding as of December 31, 2023. Future stock-based compensation expense will be recognized over 3.9 and 3.4 weighted average years for unvested options and restricted stock awards, respectively. There were 2,104 unvested and outstanding options as of December 31, 2023, of which 1,940 shares are expected to vest. The weighted average contractual life for options outstanding, vested and expected to vest as of December 31, 2023 was 6.7 years.</span></div> 1 3452000 1 2 3 P3Y P5Y 0.20 P10Y 1454000 0.0508 1008000 581000 621000 The Company used the following assumptions for stock options granted during the years ended December 31, 2023, 2022 and 2021:<div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.428%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.428%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Risk-Free Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expected Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Volatility</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Dividend Yield</span></td></tr><tr><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3%</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 years</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.3%</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.1%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.4%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3%</span></td></tr></table></div> 1008000 0.043 P6Y2M12D 0.413 0.002 581000 0.028 P6Y2M12D 0.421 0.003 621000 0.010 P6Y2M12D 0.424 0.003 <div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2023, 2022 and 2021, the following represents the exercise price and fair value displayed at grant date for stock option grants:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.687%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Fair Value of Options</span></td></tr><tr><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.05 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.85 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.74 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.83 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.19 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.82 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1008000 95.05 43.85 581000 85.74 37.83 621000 80.19 32.82 0 0 0 <div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the employee stock option activity during the year ended December 31, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.981%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of<br/>Options Vested</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Exercise Price of Options Vested</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 1, 2021</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,038 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.71 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,148 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.66 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.19 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.76 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(516)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.80 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,038 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.60 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,183 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.02 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.74 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.52 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(688)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.43 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,833 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.72 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,069 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.87 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.05 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.44 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(759)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.21 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,991 </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.65 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,887 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.58 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 4038000 27.71 2148000 16.66 621000 80.19 105000 44.76 516000 17.80 4038000 36.60 2183000 21.02 581000 85.74 98000 59.52 688000 18.43 3833000 46.72 2069000 28.87 1008000 95.05 91000 71.44 759000 24.21 3991000 62.65 1887000 39.58 <div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summary information reflects stock options outstanding, vested and related details as of December 31, 2023:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.892%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options Vested</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number Outstanding</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Black-Scholes Fair Value</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining Contractual Life (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vested and Exercisable</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year of Grant</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.94</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.05</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2015</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.20</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.39</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,369 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.93</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.86</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.80</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.41</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,138 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.49</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.71</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,523 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.07</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.76</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,014 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.84</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.49</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,383 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.47</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.64</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">513 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,844 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.79</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.88</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,466 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$89.83</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$98.83</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,566 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,991</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">105,703</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,887</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 8.94 16.05 99000 484000 P1Y 99000 18.20 21.39 175000 1369000 P2Y 175000 15.93 16.86 155000 916000 P3Y 155000 15.80 19.41 194000 1138000 P4Y 194000 22.49 32.71 336000 3523000 P5Y 336000 41.07 45.76 510000 8014000 P6Y 383000 44.84 59.49 476000 9383000 P7Y 257000 73.47 83.64 513000 16844000 P8Y 189000 79.79 94.88 540000 20466000 P9Y 99000 89.83 98.83 993000 43566000 P10Y 0 3991000 105703000 1887000 <div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options outstanding, vested and expected to vest as of December 31, 2023, 2022 and 2021 is as follows:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.349%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,819 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,593 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,242 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,048 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,382 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,759 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,232 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,548 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 197819000 183593000 191242000 137048000 136000000 137382000 56759000 43232000 48548000 31658000 27955000 27731000 56186000 47441000 34278000 219000 233000 222000 0 P5Y 89.83 98.31 73.17 94.88 72.84 93.31 <div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.954%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Vested Restricted Awards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nonvested at January 1, 2021</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.90 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.65 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(244)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.45 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.64 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nonvested at December 31, 2021</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">549</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.16 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.57 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(269)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.06 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.29 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nonvested at December 31, 2022</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">487</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.92 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.04 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(255)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.21 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.53 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nonvested at December 31, 2023</span></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">431</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.91 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 591000 38.90 222000 81.65 244000 47.45 20000 45.64 549000 52.16 233000 81.57 269000 54.06 26000 57.29 487000 64.92 219000 92.04 255000 64.21 20000 71.53 431000 78.91 18000 89.94 98.31 500000 P5Y 0.20 827000 836000 854000 <div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for the Company's equity incentive plans and long-term incentive plan for the years ended December 31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 and 2021 was as follows:</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.915%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,221 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,361 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,459 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to restricted stock awards</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,845 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,920 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,385 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,688 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,439 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,834 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30,754</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,720</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,678</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 17221000 11361000 8459000 11845000 9920000 8385000 1688000 1439000 1834000 30754000 22720000 18678000 67750000 29245000 P3Y10M24D P3Y4M24D 2104000 1940000 P6Y8M12D LEASES<div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases from CareTrust REIT, Inc. (CareTrust) real property associated with 97 independent skilled nursing and senior living facilities used in the Company’s operations, 96 of which are under nine “triple-net” master lease agreements (collectively, the Master Leases), which range in terms from 13 to 20 years. At the Company’s option, the Master Leases may be extended for two or three five-year renewal terms beyond the initial term, on the same terms and conditions. The extension of the term of any of the Master Leases is subject to the following conditions: (1) no event of default under any of the Master Leases having occurred and been continuing; and (2) the tenants providing timely notice of their intent to renew. The term of the Master Leases is subject to termination prior to the expiration of the current term upon default by the tenants in their obligations, if not cured within any applicable cure periods set forth in the Master Leases. If the Company elects to renew the term of a Master Lease, the renewal will be effective to all, but not less than all, of the leased property then subject to the Master Lease. Additionally, four of the 97 facilities leased from CareTrust include an option to purchase that the Company can exercise starting on December 1, 2024. </span></div><div style="margin-top:10.05pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have the ability to terminate the obligations under a Master Lease prior to its expiration without CareTrust’s consent. If a Master Lease is terminated prior to its expiration other than with CareTrust’s consent, the Company may be liable for damages and incur charges such as continued payment of rent through the end of the lease term as well as maintenance and repair costs for the leased property.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rent structure under the Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the Company is required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The terms and conditions of the one stand-alone lease are substantially the same as those for the master leases described above. Total rent expense for continuing operations</span><span style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under the Master Leases was approximately $66,439, $64,178 and $59,571 for the years ended December 31, 2023, 2022 and 2021, respectively.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among other things, under the Master Leases, the Company must maintain compliance with specified financial covenants measured on a quarterly basis, including a portfolio coverage ratio and a minimum rent coverage ratio. The Master Leases also include certain reporting, legal and authorization requirements. The Company is in compliance with requirements of the Master Leases as of December 31, 2023. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the spin-off that occurred in 2019, the Company guaranteed certain leases of Pennant based on the underlying terms of the leases. The Company does not consider these guarantees to be probable and the likelihood of Pennant defaulting is remote, and therefore no liabilities have been accrued. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases facilities where its independent subsidiaries operate and certain administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from <span style="-sec-ix-hidden:f-1456">five</span> to 20 years. In addition, the Company leases certain of its equipment under non-cancelable operating leases with initial terms ranging from <span style="-sec-ix-hidden:f-1458">three</span> to five years. Most of these leases contain renewal options, certain of which involve rent increases. Total rent expense for continuing operations inclusive of straight-line rent adjustments and rent associated with the Master Leases noted above, was $197,856, $153,174 and $139,458 for the years ended December 31, 2023, 2022 and 2021, respectively.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eighty of the Company’s independent subsidiaries, excluding the subsidiaries that are operated under the Master Leases with CareTrust, are operated under 13 separate master lease arrangements. During 2023, the Company expanded its operations through three separate master lease arrangements for 22 stand-alone skilled nursing operations, of which 19 are operated by the Company's independent subsidiaries and the remaining three are subleased to a third-party operator. These three master leases increased the lease liabilities and right-of-use assets by $346,789 to reflect the new lease obligations and have initial lease terms of 18, 20 and 20 years, respectively. Under these master leases, a default at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of the Company’s leases, master lease agreements and debt financing instruments. In addition, other potential defaults related to an individual facility may cause a default of an entire master lease portfolio and could trigger cross-default provisions in the Company’s outstanding debt arrangements and other leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the lease without the consent of the landlord.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease expense are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent - cost of services</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,358 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,049 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,371 </span></td><td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,202 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,160 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158 </span></td><td style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,454 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,938 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,077 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">219,512</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">171,272</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">154,693</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.11pt">Rent- cost of services includes deferred rent expense adju</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">stments of</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> $870, $493 and $485 for the years ended December 31, 2023, 2022 and 2021, respectively. Additionally, rent- cost of services includes other variable lease costs such as consumer price index increases and short-term leases of $10,259, $5,878, $3,702 for the years ended December 31, 2023, 2022, and 2021 respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Depreciation and amortization is related to the amortization of favorable and direct lease costs.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Variable lease costs, including property taxes and insurance, are classified in cost of services in the Company's consolidated statements of income.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments for all third-party leases as of December 31, 2023 are as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.352%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,352 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,269 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,058 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,481 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,224 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,722,259 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL LEASE PAYMENTS</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,675,643</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(953,791)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PRESENT VALUE OF TOTAL LEASE LIABILITIES</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,721,852</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current lease liabilities</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82,526)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LONG-TERM OPERATING LEASE LIABILITIES</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,639,326</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company used its incremental borrowing rate based on the information available at the lease commencement date. As of December 31, 2023 and 2022, the weighted average remaining lease term is 14.9 years and 15.0 years and the weighted average discount rate used to determine the operating lease liabilities is 6.5% and 6.7%. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to December 31, 2023, the Company amended an existing separate master lease arrangement to add two stand-alone skilled nursing facilities and extend the initial term to 20 years. This added a total of 241 operational skilled nursing beds operated by the Company's independent subsidiaries and the aggregate impact to the carrying value of lease liabilities and right-of-use assets related to the separate master lease agreement is estimated to be approximately $30,980.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lessor Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases its owned real estate properties to third-party operators, of which 29 senior living operations are operated by Pennant. All of these properties are triple-net leases, whereby the respective tenants are responsible for all costs at the properties including: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The initial terms range from 14 to 16 years. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023, the Company entered into a sublease agreement for three stand-alone skilled nursing operations with a third-party operator with an initial lease term of 18 years. Additionally, during the year, the Company entered into a lease agreement with a third-party operator for one campus operation with an initial lease term of 15 years.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total rental income from all third-party sources for the years ended December 31, 2023, 2022 and 2021 is as follows:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennant</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,048 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,915 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,073 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,236 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,842 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,912 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-1530">TOTAL</span></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,284</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,757</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,985</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Pennant rental income includes variable rent such as property taxes of $1,296, $1,318, and $1,199 during the year ended December 31, 2023, 2022, and 2021. In addition, the number of senior living operations leased to and operated by Pennant was 29 during the year ended December 31, 2023 and decreased from 32 to 29 during the year ended December 31, 2022.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Other third-party includes rental revenue associated with the Company's subleases to third parties of $3,897 for the year ended December 31, 2023. There was no sublease rental revenue for the years ended December 31, 2022 and 2021.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future annual rental income for all third-party leases as of December 31, 2023 were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,191 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,565 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,269 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,176 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,151 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,586 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">236,938</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>(1) Annual rental income includes base rents and variable rental income pursuant to existing leases as of December 31, 2023. LEASES<div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases from CareTrust REIT, Inc. (CareTrust) real property associated with 97 independent skilled nursing and senior living facilities used in the Company’s operations, 96 of which are under nine “triple-net” master lease agreements (collectively, the Master Leases), which range in terms from 13 to 20 years. At the Company’s option, the Master Leases may be extended for two or three five-year renewal terms beyond the initial term, on the same terms and conditions. The extension of the term of any of the Master Leases is subject to the following conditions: (1) no event of default under any of the Master Leases having occurred and been continuing; and (2) the tenants providing timely notice of their intent to renew. The term of the Master Leases is subject to termination prior to the expiration of the current term upon default by the tenants in their obligations, if not cured within any applicable cure periods set forth in the Master Leases. If the Company elects to renew the term of a Master Lease, the renewal will be effective to all, but not less than all, of the leased property then subject to the Master Lease. Additionally, four of the 97 facilities leased from CareTrust include an option to purchase that the Company can exercise starting on December 1, 2024. </span></div><div style="margin-top:10.05pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have the ability to terminate the obligations under a Master Lease prior to its expiration without CareTrust’s consent. If a Master Lease is terminated prior to its expiration other than with CareTrust’s consent, the Company may be liable for damages and incur charges such as continued payment of rent through the end of the lease term as well as maintenance and repair costs for the leased property.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rent structure under the Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the Company is required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The terms and conditions of the one stand-alone lease are substantially the same as those for the master leases described above. Total rent expense for continuing operations</span><span style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under the Master Leases was approximately $66,439, $64,178 and $59,571 for the years ended December 31, 2023, 2022 and 2021, respectively.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among other things, under the Master Leases, the Company must maintain compliance with specified financial covenants measured on a quarterly basis, including a portfolio coverage ratio and a minimum rent coverage ratio. The Master Leases also include certain reporting, legal and authorization requirements. The Company is in compliance with requirements of the Master Leases as of December 31, 2023. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the spin-off that occurred in 2019, the Company guaranteed certain leases of Pennant based on the underlying terms of the leases. The Company does not consider these guarantees to be probable and the likelihood of Pennant defaulting is remote, and therefore no liabilities have been accrued. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases facilities where its independent subsidiaries operate and certain administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from <span style="-sec-ix-hidden:f-1456">five</span> to 20 years. In addition, the Company leases certain of its equipment under non-cancelable operating leases with initial terms ranging from <span style="-sec-ix-hidden:f-1458">three</span> to five years. Most of these leases contain renewal options, certain of which involve rent increases. Total rent expense for continuing operations inclusive of straight-line rent adjustments and rent associated with the Master Leases noted above, was $197,856, $153,174 and $139,458 for the years ended December 31, 2023, 2022 and 2021, respectively.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eighty of the Company’s independent subsidiaries, excluding the subsidiaries that are operated under the Master Leases with CareTrust, are operated under 13 separate master lease arrangements. During 2023, the Company expanded its operations through three separate master lease arrangements for 22 stand-alone skilled nursing operations, of which 19 are operated by the Company's independent subsidiaries and the remaining three are subleased to a third-party operator. These three master leases increased the lease liabilities and right-of-use assets by $346,789 to reflect the new lease obligations and have initial lease terms of 18, 20 and 20 years, respectively. Under these master leases, a default at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of the Company’s leases, master lease agreements and debt financing instruments. In addition, other potential defaults related to an individual facility may cause a default of an entire master lease portfolio and could trigger cross-default provisions in the Company’s outstanding debt arrangements and other leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the lease without the consent of the landlord.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease expense are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent - cost of services</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,358 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,049 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,371 </span></td><td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,202 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,160 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158 </span></td><td style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,454 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,938 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,077 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">219,512</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">171,272</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">154,693</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.11pt">Rent- cost of services includes deferred rent expense adju</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">stments of</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> $870, $493 and $485 for the years ended December 31, 2023, 2022 and 2021, respectively. Additionally, rent- cost of services includes other variable lease costs such as consumer price index increases and short-term leases of $10,259, $5,878, $3,702 for the years ended December 31, 2023, 2022, and 2021 respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Depreciation and amortization is related to the amortization of favorable and direct lease costs.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Variable lease costs, including property taxes and insurance, are classified in cost of services in the Company's consolidated statements of income.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments for all third-party leases as of December 31, 2023 are as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.352%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,352 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,269 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,058 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,481 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,224 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,722,259 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL LEASE PAYMENTS</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,675,643</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(953,791)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PRESENT VALUE OF TOTAL LEASE LIABILITIES</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,721,852</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current lease liabilities</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82,526)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LONG-TERM OPERATING LEASE LIABILITIES</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,639,326</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company used its incremental borrowing rate based on the information available at the lease commencement date. As of December 31, 2023 and 2022, the weighted average remaining lease term is 14.9 years and 15.0 years and the weighted average discount rate used to determine the operating lease liabilities is 6.5% and 6.7%. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to December 31, 2023, the Company amended an existing separate master lease arrangement to add two stand-alone skilled nursing facilities and extend the initial term to 20 years. This added a total of 241 operational skilled nursing beds operated by the Company's independent subsidiaries and the aggregate impact to the carrying value of lease liabilities and right-of-use assets related to the separate master lease agreement is estimated to be approximately $30,980.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lessor Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases its owned real estate properties to third-party operators, of which 29 senior living operations are operated by Pennant. All of these properties are triple-net leases, whereby the respective tenants are responsible for all costs at the properties including: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The initial terms range from 14 to 16 years. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023, the Company entered into a sublease agreement for three stand-alone skilled nursing operations with a third-party operator with an initial lease term of 18 years. Additionally, during the year, the Company entered into a lease agreement with a third-party operator for one campus operation with an initial lease term of 15 years.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total rental income from all third-party sources for the years ended December 31, 2023, 2022 and 2021 is as follows:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennant</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,048 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,915 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,073 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,236 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,842 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,912 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-1530">TOTAL</span></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,284</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,757</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,985</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Pennant rental income includes variable rent such as property taxes of $1,296, $1,318, and $1,199 during the year ended December 31, 2023, 2022, and 2021. In addition, the number of senior living operations leased to and operated by Pennant was 29 during the year ended December 31, 2023 and decreased from 32 to 29 during the year ended December 31, 2022.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Other third-party includes rental revenue associated with the Company's subleases to third parties of $3,897 for the year ended December 31, 2023. There was no sublease rental revenue for the years ended December 31, 2022 and 2021.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future annual rental income for all third-party leases as of December 31, 2023 were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,191 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,565 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,269 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,176 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,151 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,586 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">236,938</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>(1) Annual rental income includes base rents and variable rental income pursuant to existing leases as of December 31, 2023. 97 96 9 P13Y P20Y 2 3 P5Y 4 97 0 0.025 1 66439000 64178000 59571000 P20Y P5Y 197856000 153174000 139458000 80 13 3 22 19 3 3 346789000 P18Y P20Y P20Y <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease expense are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent - cost of services</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,358 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,049 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,371 </span></td><td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,202 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,160 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158 </span></td><td style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,454 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,938 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,077 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">219,512</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">171,272</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">154,693</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.11pt">Rent- cost of services includes deferred rent expense adju</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">stments of</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> $870, $493 and $485 for the years ended December 31, 2023, 2022 and 2021, respectively. Additionally, rent- cost of services includes other variable lease costs such as consumer price index increases and short-term leases of $10,259, $5,878, $3,702 for the years ended December 31, 2023, 2022, and 2021 respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Depreciation and amortization is related to the amortization of favorable and direct lease costs.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Variable lease costs, including property taxes and insurance, are classified in cost of services in the Company's consolidated statements of income.</span></div> 197358000 153049000 139371000 498000 125000 87000 1202000 1160000 1158000 20454000 16938000 14077000 219512000 171272000 154693000 870000 493000 485000 10259000 5878000 3702000 <div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments for all third-party leases as of December 31, 2023 are as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.352%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,352 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,269 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,058 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,481 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,224 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,722,259 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL LEASE PAYMENTS</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,675,643</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(953,791)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PRESENT VALUE OF TOTAL LEASE LIABILITIES</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,721,852</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current lease liabilities</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82,526)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LONG-TERM OPERATING LEASE LIABILITIES</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,639,326</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 191352000 191269000 191058000 190481000 189224000 1722259000 2675643000 953791000 1721852000 82526000 1639326000 P14Y10M24D P15Y 0.065 0.067 2 P20Y 241 30980000 29 P14Y P16Y 3 P18Y 1 P15Y <div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total rental income from all third-party sources for the years ended December 31, 2023, 2022 and 2021 is as follows:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennant</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,048 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,915 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,073 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,236 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,842 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,912 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-1530">TOTAL</span></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,284</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,757</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,985</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Pennant rental income includes variable rent such as property taxes of $1,296, $1,318, and $1,199 during the year ended December 31, 2023, 2022, and 2021. In addition, the number of senior living operations leased to and operated by Pennant was 29 during the year ended December 31, 2023 and decreased from 32 to 29 during the year ended December 31, 2022.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Other third-party includes rental revenue associated with the Company's subleases to third parties of $3,897 for the year ended December 31, 2023. There was no sublease rental revenue for the years ended December 31, 2022 and 2021.</span></div> 15048000 14915000 14073000 6236000 1842000 1912000 21284000 16757000 15985000 1296000 1318000 1199000 29 32 29 3897000 0 0 <div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future annual rental income for all third-party leases as of December 31, 2023 were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,191 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,565 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,269 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,176 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,151 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,586 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">236,938</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>(1) Annual rental income includes base rents and variable rental income pursuant to existing leases as of December 31, 2023. 22191000 21565000 21269000 21176000 21151000 129586000 236938000 DEFINED CONTRIBUTION PLANS<div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a 401(k) defined contribution plan (the 401(k) Plan), whereby eligible employees may contribute up to 90% of their annual basic earnings, subject to applicable annual Internal Revenue Code limits. Additionally, the 401(k) Plan provides for discretionary matching contributions (as defined in the 401(k) Plan) by the Company. The Company expensed matching contributions to the 401(k) Plan of $2,836, $2,418, and $2,121 during the years ended December 31, 2023, 2022 and 2021, respectively.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a non-qualified deferred compensation plan (DCP), whereby certain highly compensated employees who are otherwise ineligible to participate in the Company's 401(k) plan, may defer the receipt of a portion of their base compensation and, for certain employees, up to 100% of their eligible bonuses. Additionally, the DCP allows for the employee deferrals to be deposited into a rabbi trust and the funds are generally invested in individual variable life insurance contracts owned by the Company that are specifically designed to fund savings plans of this nature. The Company paid for related administrative costs, which were not significant during fiscal years 2023, 2022 and 2021. </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the years ended December 31, 2023 and 2022, the Company accrued $49,201 and $33,017, respectively, as long term deferred compensation in other long term liabilities on the consolidated balance sheet. Cash surrender value of the contracts is based on investment funds that shadow the investment allocations specified by participants in the deferred compensation plan. Refer to Note 5, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information on the funds.</span></div>For the years ended December 31, 2023 and 2021, the Company recorded gains related to its DCP of $4,634 and $1,612, respectively, which are included in other income (expense), net, and recorded offsetting expenses of $4,887 and $1,758, respectively, which are allocated between cost of services and general and administrative expenses. For the year ended December 31, 2022, the Company recorded a loss related to its DCP of $4,188, which is included in other income (expense), net, and recorded an offsetting reduction in expense of $4,051, which is allocated between cost of services and general and administrative expenses. 0.90 2836000 2418000 2121000 1 49201000 33017000 4634000 1612000 4887000 1758000 -4188000 -4051000 SELF INSURANCE LIABILITIES<div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents activity in our insurance liabilities as of and for the years ended December 31, 2023 and 2022: </span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.595%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance January 1, 2022</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,139 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year provisions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,793 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims paid and direct expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98,007)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in long-term insurance losses recoverable</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,757 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance December 31, 2022</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,682 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year provisions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,627 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims paid and direct expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135,799)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in long-term insurance losses recoverable</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,400 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance December 31, 2023</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,910 </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div>Included in the table above are accrued general liability and professional malpractice liabilities on an undiscounted basis, net of anticipated insurance recoveries, of $117,744 and $87,000 as of December 31, 2023 and 2022, respectively. Included in long-term insurance losses recoverable as of December 31, 2023 and 2022 are anticipated insurance recoveries related to the Company's general and professional liability claims that are recorded on a gross rather than net basis in accordance with GAAP. <div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents activity in our insurance liabilities as of and for the years ended December 31, 2023 and 2022: </span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.595%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance January 1, 2022</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,139 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year provisions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,793 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims paid and direct expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98,007)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in long-term insurance losses recoverable</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,757 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance December 31, 2022</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,682 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year provisions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,627 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims paid and direct expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135,799)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in long-term insurance losses recoverable</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,400 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance December 31, 2023</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,910 </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 110139000 115793000 98007000 3757000 131682000 164627000 135799000 5400000 165910000 117744000 87000000 COMMITMENTS AND CONTINGENCIES<div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnities</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> From time to time, the Company enters into certain types of contracts that contingently require the Company to indemnify parties against third-party claims. These contracts primarily include (i) certain real estate leases, under which the Company may be required to indemnify property owners or prior facility operators for post-transfer environmental obligations or other liabilities and other claims arising from the Company’s use of the applicable premises, (ii) operations transfer agreements, in which the Company agrees to indemnify past operators of facilities the Company acquires against certain liabilities arising from the transfer of the operation and/or the operation thereof after the transfer to the Company's independent subsidiary, (iii) certain lending agreements, under which the Company may be required to indemnify the lender against various claims and liabilities, and (iv) certain agreements with the Company’s officers, directors and others, under which the Company may be required to indemnify such persons for liabilities based on the nature of their relationship to the Company. The terms of such obligations vary by contract and, in most instances, do not expressly state or include a specific or maximum dollar amount. Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted. Consequently, because no claims have been asserted, no liabilities have been recorded for these obligations on the Company’s consolidated balance sheets for any of the periods presented.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the spin-off in 2019, certain landlords required, in exchange for their consent to the transaction, that the Company's lease guarantees remain in place for a certain period of time following the transaction. These guarantees could result in significant additional liabilities and obligations for the Company if Pennant were to default on their obligations under their leases with respect to these properties. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation and Regulatory Matters</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Laws and regulations governing Medicare and Medicaid programs are complex and subject to review and interpretation. Compliance with such laws and regulations is evaluated regularly, the results of which can be subject to future governmental review and interpretation, and can include significant regulatory action including fines, penalties, and exclusion from certain governmental programs. Included in these laws and regulations is monitoring performed by the Office of Civil Rights which covers the Health Insurance Portability and Accountability Act of 1996, the terms of which require healthcare providers (among other things) to safeguard the privacy and security of certain patient protected health information.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both government and private pay sources have instituted cost-containment measures designed to limit payments made to providers of healthcare services, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect us.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its independent subsidiaries are party to various legal actions and administrative proceedings and are subject to various claims arising in the ordinary course of business, including claims that services provided to patients by the Company’s independent subsidiaries have resulted in injury or death, and claims related to employment and commercial matters. For example, in a four-week medical negligence trial in the State of Arizona, the jury returned a verdict against one of the Company’s independent subsidiaries in late November 2023. The Company intends to appeal the verdict. The Company has in the past appealed and have in some circumstances received returned decisions in its favor. Although the Company intends to vigorously defend against these claims and in general these types of claims and cases, there can be no assurance that the outcomes of these matters will not have a material adverse effect on operational results and financial condition. Additionally, in certain states in which the Company has or has had independent subsidiaries, insurance coverage for the risk of punitive damages arising from general and professional liability litigation may not be available due to state law and/or public policy prohibitions. There can be no assurance that the Company or its independent subsidiaries will not be liable for punitive damages awarded in litigation arising in states for which punitive damage insurance coverage is not available. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The skilled nursing and post-acute care industry is heavily regulated. As such, the Company and its independent subsidiaries are continuously subject to state and federal regulatory scrutiny, supervision and control in the ordinary course of business. Such regulatory scrutiny often includes inquiries, investigations, examinations, audits, site visits and surveys, some of which are non-routine. In addition to being subject to direct regulatory oversight from state and federal agencies, the skilled nursing and post-acute care industry is also subject to regulatory requirements which, if noncompliance is identified, could result in civil, administrative or criminal fines, penalties or restitutionary relief, and reimbursement; authorities could also seek the suspension or exclusion of the provider or individual from participation in their programs. The Company believes that there has been, and will continue to be, an increase in governmental investigations of post-acute providers, particularly in the area of Medicare/Medicaid false claims, as well as an increase in enforcement actions resulting from these investigations. Adverse determinations in civil legal proceedings or governmental investigations, whether currently asserted or arising in the future, could have a material adverse effect on the Company’s financial position, results of operations, and cash flows. Additionally, such proceedings and/or investigation can be a distraction to the business.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in 2020, the U.S. House of Representatives Select Subcommittee on the Coronavirus Crisis launched a nation-wide investigation into the COVID-19 pandemic, which included the impact of the coronavirus on residents and employees in nursing homes. In June 2020, the Company and its independent subsidiaries received a document and information request from the House Select Subcommittee. The Company and its independent subsidiaries cooperated in responding to this inquiry. In July 2022 and thereafter, the Company and its independent subsidiaries received follow up requests for additional documents and information. The Company and its independent subsidiaries responded to these requests and cooperated with the House Select Subcommittee in connection with its investigation. On December 9, 2022, the House Select Subcommittee issued its final report summarizing its investigation and related recommendations designed "to strengthen the nation's ability to prevent and respond to public health and economic emergencies." According to the information provided by the House Select Subcommittee, the issuance of this report was the House Select Subcommittee's final official act in connection with their assigned responsibilities. Also</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company, on behalf of its independent subsidiaries, received a </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Civil Investigative Demand (CID)</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Department of Justice (DOJ)</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in January of 2024 indicating that the DOJ is investigating the Company to determine whether it has caused the submission of claims to Medicare and Texas Medicaid for services which were unnecessary or otherwise not consistent with existing reimbursement requirements. The CID covers the period from January 1, 2016, to the present. As a general matter, the Company's independent subsidiaries maintain policies and procedures to promote compliance with all applicable Medicare and Medicaid requirements, including but not limited to those relating to the presentation of claims for reimbursement for services provided. The Company intends to fully cooperate with the DOJ in response to the CID. However, the Company cannot predict the outcome of the investigation or its potential impact on the consolidated financial statements.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the potential lawsuits and claims described above, the Company and its independent subsidiaries are also subject to potential lawsuits under the FCA and comparable state laws alleging submission of fraudulent claims for services to any healthcare program (such as Medicare or Medicaid) or other payor. A violation may provide the basis for exclusion from federally funded healthcare programs. Such exclusions could have a correlative negative impact on the Company’s financial performance. In addition, and pursuant to the qui tam or "whistleblower" provisions of the FCA, a private individual with knowledge of fraud or potential fraud may bring a claim on behalf of the federal government and receive a percentage of the federal government's recovery. Due to these whistleblower incentives, qui tam lawsuits have become more frequent. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, on May 31, 2018, the Company, on behalf of its independent subsidiaries, received a CID from the DOJ stating that it was investigating to determine whether there had been a violation of the False Claims Act (FCA) and/or the Anti-Kickback Statute (AKS) with respect to the relationships between certain of the Company’s independent subsidiaries and persons who serve or have served as medical directors. The Company fully cooperated with the DOJ and promptly responded to its requests for information. In April 2020, the Company was advised that the DOJ declined to intervene in any subsequent action filed in connection with the subject matter of this investigation. Despite the decision of the DOJ to decline to participate in litigation based on the subject matter of its previously issued CID, the involved qui tam relator moved forward with the complaint in December 2020. From that time until December 2023, and notwithstanding the Company's success in early pre-trial motions, the Company continued to incur legal defense costs and fees, including significant amounts as part of discovery in the fourth quarter of 2023. In early January 2024, the Company entered into mediation and on January 19, 2024, the parties agreed to settle the civil case for $48,000, subject to the review of the DOJ and other relevant government entities. The settlement does not include admissions on the part of the Company or its independent subsidiaries and the Company maintains that it has and continues to comply with all applicable State and Federal statutes (including but not limited to the FCA and the AKS). </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the FCA, some states, including California, Arizona and Texas, have enacted similar whistleblower and false claims laws and regulations. Further, the Deficit Reduction Act of 2005 created incentives for states to enact anti-fraud legislation modeled on the FCA. As such, the Company and its independent subsidiaries could face increased scrutiny, potential liability and legal expenses and costs based on claims under state false claims acts in markets in which its independent subsidiaries do business.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2009, Congress passed the FERA which made significant changes to the FCA and expanded the types of activities subject to prosecution and whistleblower liability. Following changes by FERA, health care providers face significant penalties for the knowing retention of government overpayments, even if no false claim was involved. Health care providers can now be liable for knowingly and improperly avoiding or decreasing an obligation to pay money or property to the government. This includes the retention of any government overpayment. The government can argue, therefore, that an FCA violation can occur without any affirmative fraudulent action or statement, as long as the action or statement is knowingly improper. In addition, FERA extended protections against retaliation for whistleblowers, including protections not only for employees, but also contractors and agents. Thus, an employment relationship is generally not required in order to qualify for protection against retaliation for whistleblowing.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare litigation (including class action litigation) is common and is filed based upon a wide variety of claims and theories, and the Company's independent subsidiaries are routinely subjected to varying types of claims, including class action "staffing" suits where the allegation is understaffing at the facility level. These class-action “staffing” suits have the potential to result in large jury verdicts and settlements and may result in significant legal costs. The Company expects the plaintiffs' bar to continue to be aggressive in their pursuit of these staffing and similar claims. While the Company has been able to settle these claims without an ongoing material adverse effect on its business, future claims could be brought that may materially affect its business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other claims and suits, including class actions, continue to be filed against the Company and other companies in its industry. The Company and its independent subsidiaries have been subjected to, and are currently involved in, class action litigation alleging violations (alone or in combination) of state and federal wage and hour laws as related to the alleged failure to pay wages, to timely provide and authorize meal and rest breaks, and related causes of action. The Company does not believe that the ultimate resolution of these actions will have an ongoing material adverse effect on the Company’s business, cash flows, financial condition or results of operations.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its independent subsidiaries are also subject to requests for information and investigations by other state and federal governmental entities (e.g., Offices of the Attorney General and Offices of the Inspector General). The Company cannot predict or provide any assurance as to the possible outcome of any inquiry, investigation or litigation. If any such inquiry, investigation or litigation were to proceed, and the Company and its independent subsidiaries are subjected to, alleged to be liable for, or agree to a settlement of, claims or obligations under federal Medicare statutes, the FCA, or similar state and federal statutes and related regulations, or if the Company or its independent subsidiaries are alleged or found to be liable on theories of general or professional negligence or wage and hour violations, the Company's business, financial condition and results of operations and cash flows could be materially and adversely affected and its stock price could be adversely impacted. Among other things, any settlement or litigation could involve the payment of substantial sums to settle any alleged violations and may also include the assumption of specific procedural and financial obligations by the Company or its independent subsidiaries under a Corporate Integrity Agreement and/or other such arrangement.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost-Containment Measures</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Both government and private pay sources have instituted cost-containment measures designed to limit payments made to providers of healthcare services, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect the Company.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medicare Revenue Recoupments</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company's independent subsidiaries are subject to regulatory reviews relating to the provision of Medicare services, billings and potential overpayments as a result of Recovery Audit Contractors (RAC), Program Safeguard Contractors, and Medicaid Integrity Contractors programs (collectively referred to as Reviews). For several months during the COVID-19 pandemic, the Centers for Medicare and Medicaid Services (CMS) suspended its Targeted Probe and Educate (TPE) Program. Beginning in August 2020, CMS resumed TPE Program activity. If an operation fails a Review and/or subsequent Reviews, the operation could then be subject to extended review or an extrapolation of the identified error rate to billings in the same time period. The Company anticipates that these Reviews could increase in frequency in the future. As of December 31, 2023 and through the filing date of this report, 40 of the Company's independent subsidiaries had Reviews scheduled or in process. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, CMS announced a new nationwide audit, the “SNF 5-Claim Probe &amp; Educate Review”, in which the Medicare Administrative Contractors (MACs) will review five claims from each SNF to check for compliance. In implementing this SNF 5-Claim Probe &amp; Educate Review, CMS acknowledged that the increase in observed improper payments from 2021 to 2022 may have arisen from a "misunderstanding" by SNFs about how to appropriately bill for claims of service after October 1, 2019. All facilities that are not undergoing TPE reviews, or have not recently passed a TPE review, will be subject to the nationwide audit. MACs will complete only one round of probe-and-educate for each SNF, rather than three rounds that typically occur in the TPE. Additionally, CMS's education for each SNF will be individualized and based on observed claim review errors, with rationales for denial explained to the SNF on a claim-by-claim basis. This program applies only to claims submitted after October 1, 2019, and will exclude claims containing a COVID-19 diagnosis.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Risk</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — The Company has significant accounts receivable balances, the collectability of which is dependent on the availability of funds from certain governmental programs, primarily Medicare and Medicaid. These receivables represent the only significant concentration of credit risk for the Company. The Company does not believe there are significant credit risks associated with these governmental programs. The Company believes that an appropriate allowance has been recorded for the possibility of these receivables proving uncollectible, and continually monitors and adjusts these allowances as necessary. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s receivables from Medicare and Medicaid payor programs accounted for 53.4% and 56.3% of its total accounts receivable as of December 31, 2023 and 2022, respectively. Revenue from reimbursement under the Medicare and Medicaid programs accounted for 72.6%, 73.7% and 73.6% of the Company's revenue for the years ended December 31, 2023, 2022 and 2021, respectively.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash in Excess of FDIC Limits</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — The Company currently has bank deposits with financial institutions in the U.S. that exceed FDIC insurance limits. FDIC insurance provides protection for bank deposits up to $250. In addition, the Company has uninsured bank deposits with a financial institution outside the U.S. As of December 31, 2023, the Company's uninsured cash deposits are not material. All uninsured bank deposits are held at high quality credit institutions.</span></div> 48000000 40 40 0.534 0.563 0.726 0.737 0.736 COMMON STOCK REPURCHASE PROGRAM<div style="margin-top:9.75pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 29, 2023, the Board of Directors approved a stock repurchase program pursuant to which the Company could repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months from September 1, 2023. Under this program, the Company is authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. The share repurchase program does not obligate us to acquire any specific number of shares. The Company did not purchase any shares pursuant to this stock repurchase program during the year ended December 31, 2023.</span></div><div style="margin-top:9.75pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 28, 2022, the Board of Directors approved a stock repurchase program pursuant to which the Company could repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months from August 2, 2022. Under this program, the Company was authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. The share repurchase program did not obligate the Company to acquire any specific number of shares. The stock repurchase program expired on August 2, 2023 and is no longer in effect. The Company did not purchase any shares pursuant to this stock repurchase program. </span></div>In addition, the Company repurchased 404 shares of its common stock for $29,882 during the year ended December 31, 2022, and 132 shares of its common stock for $10,118 during the year ended December 31, 2021, related to two separate stock repurchase programs that are no longer in effect. 20000000 P12M 20000000 P12M 404000 29882000 132000 10118000 false false false Christopher R. Christensen, Co-founder, Executive Chairman and Chairman of the Board, entered into a Rule 10b5-1 trading arrangement on November 2, 2023 (the "Rule 10b5-1 Plan"). Mr. Christensen's 10b5-1 Plan provides for the potential sale of up to 110,700 shares of the Company's common stock between February 6, 2024 and December 31, 2024. Christopher R. Christensen Co-founder, Executive Chairman and Chairman of the Board true November 2, 2023 110700 Beverly B. Wittekind, Vice President &amp; General Counsel, entered into a Rule 10b5-1 trading arrangement on December 8, 2023 (the "Rule 10b5-1 Plan"). Ms. Wittekind's 10b5-1 Plan provides for the potential exercise of vested stock options and the associated sale of up to 10,000 shares of the Company's common stock between March 14, 2024 and October 31, 2024. Beverly B. Wittekind Vice President & General Counsel true December 8, 2023 10000 34

    Y])_6=M?3*OBQ'V:E#R093/4*%UVQ.,!HZ3"UX5J M,#)DX#(HEZCWPG7+TVV![B=FY]&5W:I=QS[)2\LUO;N]F=VX<1R-/S]I3_$A M%>W."^;&-U,7;F[==>FQP-"/L%)GH8&I4%[8F,%2EM&CL,I(XRDA34:6#;O, MG_-%.1=>/7^59)OO7GQ\]?%-FLU2>NMP_:6]R '93%L_KT[^4G?(E3*6 M%H]ZDUQ)C)J%Z>C;$O>2B"H(Q:4W$'51K%+SQ'4)4@9'#)[^7L7*&\8.2(=N MN^L_?G'K3S0E64D*B9;R4N],H7$ :2Q75#H7>>T:K"UPALKNJCFYQ<^RTBZ UBR L8V!XX$!M\KEZIL>O:Q,FZJZ7124;85 S\%SX?T[78:ON 27WR>ICF'GD)<]9#H M +)/+LP.(G0&-FQ22QT=3H92P-'8DH5SP=D,V5$&(MJ$AIV(X 2+C'K->.P4 M[SYMEFQ((3DB2?K(O?;U[$LTMC]-;VL8)R!#*F#%+P')= M&C@;';W%S5.(7?;HI@\?SOUIJ(-)10%6O!&;X_FG0Y?M=O8&G:3KR?U%,$U6 M"&X#A%P&"H?2G,1*CZ1VB3CFE1>JDT[7?_[%J;6"&&N_JI^^I/=I/';CFS^+ M8_9Z'/YKB0H=;\US]J D6C>"IP2.(/,L(S)(98DCW2*#&Q]Q*@^3X?REQP97OI-UUGWXI=GH=\;76YY*U M72"M-\L[:O885G8E#6S3YP'BJ[T9;X)&C%>)$4JM^JN+6IINGV%9'/A$I1$$=2*9#:2T$4&;C. MJ:1XQ*1=M\-UQY.&.V.KZ6+22I"UK>+W2WOB43*U9)13G35X&2R:Z,\%&".H)@:Q.]U)G3L?=>:ZK2O*VC;3V_2?I\@>0@M1)ZL,0P],:MQ% M=#'V$_[(RLVX\% M"]$8#LQF7"\W>&@PA$B)"LD;@W9Z-_MIYZ/.7+]U1;DQDV'?E+9;=,V+09 _ ME@2,%]>3\>>/_QI=7Y=YUM/9:/QY@;9D::Q.D>2830'7;S@:?((H0#N! #KQ MFN8<;0[=8H[]GWWF5&@L[.?<4(=O N_R2_?UV^WL#MDJ9"J"$"$9T%$Z$-DG M,(XJ)"WQ+D@4B.X6G-SVE#/7=S4!/M>L/NCNL"QP[O('A2"$P4=+CA:#- 'L M/#.1&4^X(R:33MU^=MT-KAYX*7')_:58T>ZZ W$7XMX-HV9:P/VCA[_XWU/X M3]5W@.1JW^<_@(.$5%DQ#RR4:80THN5'T&UC4M&41$Z1="JNC MEWC[BGU20V85 XAS(.[OAT"$#I%X!3$[Y%\@&2RA&KAP5'!I1%2AAO(>/O0, ME;>WS%H,-)A.T JX^5%*[\]LBX?RN7XR)98L)J&!ERM MI]2@;<=I-[7VF7*P&]:E6$*M--&@^F4CQ )P:>MW@=AJ_LEN>$<:BE);M5VI MAMQO'D"UF4A/%M.8,P@E,YC,$FZ)5%E)N(ZF=C7UT:BS:]3*"3"GCSI: ME/*O(*VBNDYQ)Z4!J60LK9\S.&H-L"SPV-7!J%R]O^YC"$>8WE);34\+W ^0 M<8/6):_'8?(U?;QQ-_,HTIME!=Z<[81*'[A,D$0JS>LT!\N8 VNDUS(@/E9[ M.,L6.)=FA-22?,4H^PYH2_9W =?([-@*[#@&1S4U=J/' 3IH<&!L!QF,#<3E M #S($HN6$HSP$HADG.>@,L(^?X+L,"N.PX\^HJ]>SS&9W4SR1W>=9FX<_TSC M-'77Y0HI?D6!SVX65;O+UETKUYS(*&(9,IJ$* 7=&KQ 3]U)8[*/W-/<[89F MCX MA^NA@>FQ&ZAC5AK)&;#B3PDK&'II1$ @3+@H@I&QMOMR)*+L,$&.PY,^XJ_> M\7=[HDJ,QCENRS16Z>>7=^ <28 N/;?.VL1\MS2_4\D :J2521N1-K C/M[Z M6?KW+1I3K[XO8S4+"SL(K02SD$4@("@"=#%&X#%FSCE-JGI?\ U0+LV.J"'Q MBJE"6V"M7.8.P%H-9=D$ZCAV0Q75[:;# 7)O,2AE(\"HH_6E0%Z5*E[<$CT8 M@ONBQHTQ:V>\5=5G4 ]+B!WVP;!\Z"/N]CQ8'E\IQ:2\M24A ,\P0C0@$ TL M1H<.MU1.RK8<.-KX@#J*VJ[^/:1,?V[1V MW(;J,GC12 OU6V>LEEXVJ ?5Y(\1SQ;]DDO3VG'ZSZ+EZ^Q*>"XM&D@@>2H) MP@QWK.@]J-+,BUO/[=/DRB--"_O6K5Y]CP]UO=OLU3=]/1R$5L^CO M*YJXUY2B'4Y*RI&7')R-"-&AY>,("U)VZRS0[7F7H?]6 FZ0^C62@] MQSZXFW1E3/1.*H-V;T1\H?1#():A02R%,D*8Z&K/Q]R%Z3)(TD0#]YG78;B6PBV043[,;;5 MQ#O"K+*E"V1D1N*Y)3PXSB-$F;.FT4K):\\K7 OD,JA03];/"6 .>O'O8R#_ MP&-J^M"9OK>!KY0K5[G(R6"T 6%D+#ED"H@N<1-MK&/=WOU.C[L,G3<2[W," MV!J]:CZF;PZIF1X@G%UQDK,C08.AQ:TA@@ RE:#AHF5T.BBMN\6@MCSD@I1= M2Y1KXE$'7V"OSIS5#7Z:+2_NXY6P&NT,Y8&+4-@7*" @@]Z)%GR>*!IJ3]W8 MC.8RZ%!9ZFL(<6AKS]EL,MUJE02=G/>" ;JHI!Q*"2S1"K07-/F@77@ZL'B+ MN;?]69>A\Q:"7:/X@P=6?R@SI=[E?^ 1A$*X>>=O4&(IOAZ_^CM\*4?2'T\7 M\&;D?#G%?EQEHM"%3;AM):=!4)+!.^K !* DI)N-,M,[3%M2W%&=70BHA=9+ @B@-? P!7Z9UA!"M(I8HE$ R 53J!%AX-56>EBK4S(H\XV30F&E2Y[M.6S[U] >@$)I ^"$^8II34-E/. M8+)I'P[TF6S:1]KKDK^&G&S:I8X[>AY,J791P0H0D7,P4J /9TKIBZ/9ZMIW MLV?6**.7QGLTRN@C^<'['W0!]ZM11F\U]FJ$L(\.!B<*OAS>6R/0C;?HU?/2 M \C@>X*_%B0&'D/UW([S:I31CA]]1-^ %\7*>[=HV; JI+0V4E$&6T7/0)#L MP9.,>R85FG$E2=*U.Q\\ W%J'3%Z*6E24\(-2E67?3E>;._+$;7SSB0+3! $ MF00RWCD%4BNFN<[!5*=!)V"71(WZFJA=Q_Y[^C9-8;38"!'FU\GT9O2_#SOS M"YH#4XZ"LBJCB>YQ_9QPW"-#(-8$[I\VQ=\0S]CYJ$O0? .A5BPZ6!]O*QO8 M51+)D%2F87%F$1%:TEX+#3YDDHF5)-*VZ5X%Q>E%M0YQ4 ^43]9%J[?.SWE--TFN*',K,V_O^W MLYMY,B'7@LHL"!+,DC)+IY2R*@LDB""%DY(YT_'$7O?YEZ')6@)L4,SU\0O: M"^7J],&Y$;,TA@@@R*I27I;PW"CE928D1C3UA-6.'C]'<1F*KR3EC55:[:Z: M)M.W;KIP(*I<-:WYO-I73;L@5[QJFDPW\T2X,C!2!9#*Y%+.$ M#>ADU6[ L@-2G7RJ]:%P&YCW@0G02DH0(G&P3M(R4DC%H#.>5[5;[F^!,^15 M4RT.K,^;.ES:Q[YJVCSM/B5MJ5(.8O04I1,$X.Z)AU_Q1#-N@MFQ3C;#ND\_ MYGU1%;4]&V-XB/AJAW VS&GL FG]W5!'S1[CJJ>2!K;I\P#Q#:191WDD) DP ME)?!Y=FBU8-,+D'#0'+,3'1K+CFD1C?>FU!*?0V M1+F$ ZS_3.- E+0Z(5Q1YET' MA3Z,=@Z\9SHK:BU3';M_G>D Z;VIT%C833:!3?./E:=2:<,A9D0GE"YC'[.! MNJ^+UI94^BBYCA!L MN=0SJIB6FD.6DA.6F/:IDQ.V8WSFNF=?BKE=1;:5=?TA?;N=AB\/6\T]A;BD M>1>0->=/=P4V_'3JPW4X&4H!%??\?F!E3$XGG2&G4AV>J05'/RY+MHS /A))^LB]MD'PZ4MZG\9C-[[YL\1/7X_#?ZW,%![?>/'O[PWE/X3]5W M@.1JG\D/X!#O;"P-.QTO\]JE0W?0I0!!Y!@$"0[/G7-0X)9SM:[^^@BLLM[^ M0DE]O?VZRLL0$"S(Y=/=X0"#)S*<;AI2#D=FF"II[]-"!S\Q]Q3ZI(;/* M!^%?[N\'0)APU%JC('/#2C=4AF= RL"-C8$3KW+N5/FW2WD/'WJ&RMM;9O4C M5SM[VEA%77!2@4H:3:M ''B9!!#)1?8RN M%QGWE=*7UGUD_0RFG< '2F)*QMNL"FTLB;@3X!'B,O*)<\E35CG2IRD:YYS$ MA"SVF/2>V5T!;/R7*Y<>NETUY5+']D>+8C>!>1/?.72 M2X=[1=/W4<#1V**Y<4X[ Y%9=(>9S>!I=I"STM8([O%M.7^6]+UR:4^2/G(? M[LK%LJ0="V6 #_6EV%."#ZRDAS 7)(V&NVYEKF=WY=)+']VN7/H(LW8*UGUB MV*=4L*U2?XAT6999D"Y&6;H0&D L%B2+EN#_9QN[S;?9\( +5._A@FR=$3O? MLKBFF1J>@2;ERG0=W+*DBF68@D_&2OQMU]C3>>2N[V/9U1%?_0%X:U/$ND"Z MH-SU7AKHD.J\C_@&REVGD82@.+X"V1,0WBC"F!(Y06SI(1V-]R,IU'11P%KGKO;31+W>]CR@K M7]&5B763ZU&<)]7.HTW+%"Q'1*FN);1TVD73#;P399:N\#YPQGA\\L+N&519 M]_1+.7PKR;=R2LMS1'>9D[LQ58RC;,)QC+#)X3K:JO(#!%PY3K(1&T,702H: MP5&B"S8!5@D%,G&5=?0"-Z&S4_K6*,@P.N\CUP9=8.XN#S\NHN^K$T>AMR8) MY2 -.G*"$XLG#E' 6%**!D,#[[2_[]/WZ3&481WH.GK:U/'I "%7/M;?3R?Q M-MR\FWY,T^^CL CR.>,]X=&!"E* PTX&#'.[[NV9=T MI!\LVXJCGA_@F;T8QR6B%:F[@*IXHF\$,OR1?KB.GBN\DH KG^B;P1%DL[3H MCG(KT1T-,H!)Z%\HQ:P57#IM.TU_/RVM;SG3!U)Z'[G6=LL762FKD"RS)G(\ MJ8AF"(0K!=9Y#='19+PLA:W=.GX]_-1AS^-*4I[4$%&#/+J['J.K09 K"V%! M3<&2,4I#4*:<0I*"PX.G)'@(:3BCWMDJ!@Z7.(2U>8 MC&0>1)9"N6"T:SQ>\ &8T\N3/R3%M8[,FY-A@>GEY.NW:?I2]LGORU^]*IGD MLU'I'CV:W5SE1#+1D4#T#D7AHQ%68I"X"8)-00-*(PFODJ?5K8N=H"Z9.(?JH'ZJSW"VS+JB25(JO>.Q]K'R&,%E*+^"= =K(O[[JS]>OWWU^\MW M;S]]>/W;/SZ]?O?V_9L7;S\>4(BWZR/K%.+U EZI$._W C?%>6GER-\6W.^O MW;C,H;Z>S&ZGZ9XW.J'QJ 0#(4LJD$,'QAM"T'=Q"0G$63:=VC;U>)6ZHSMT MV]CPI$4X3CMOO9$.HBJMF71*X)W+($U,A EC^5 K'[1 KQ$WGNXIU41_[&*] MU8(^I)O1=/Z1BW7\7>(^MXL@C[ L9!$42&E04,P(\)%)L(:PLB)'J@^WW0+G M6+'O>BJ?M!%] Z]E [153*@#N$:A\*W CA,:KZ;&;O0X0 >#$X7CMJJC8> % M=2#*E"UCT(X+3@;\58KQ:0'(.1)D1R#]./SH(_H&O/B_M^YZE$VLLQ11U[Y(7X_DDM1?0=8-7OT-]M*R:]:+\1@A M/_SC['V:OD+'=O(C)?PVE$%OE&CCN4U@N,X@J/%HHL<,+/+ J5&:R]HQT0JP MA^?6<;V>9BIML"]M6$(9+_A_4[QB,MGD.:(J940B9P4.=TU0*9G M*#4B#.0\/P;VLS'K +6TV='FTRC+91,:?6X1,'-^=#VZ^?'RVLUF\RT8M^-P MB_\.R>X5D8B20FG+@'+1'(QG'$BR4:&X;.Y6G-6/1_U 7C*G&JJKP=3O/U%X M;R:SV;OQZ_'WM)AU.KM21./9G>;)$13--Y/ Q7FG )(%X4EP5]M<7@OD8GER MN-@K7@G-;ZSN<;SZNU!W=75A4PYHT5&(+)8<62E*V7( *:BG-#GC9;/UVX__^/#B[?7K\ZY")HUT?6N0CJ M!;Q61\;5;O['9/K'[0W2Y?WD>A1^_);&N)";WWXLD]:7B6?W7/(Q>>4C!4M* MPK*P!BSS!JT)QH.V.;-4V[[;%^O!/1S[/7<1SHZB#&SF%J@+Y5U#<]TS]$9U M\I2CY&0@M=,>]\$Y6-?'(7CVK!UD:\6=RM73Q_ EQ=OK]"[_Y:Z_E6:YHX![ M-.[^;AS2)_R4%^/X:92FKR,^K=ALTWG0-$OI8RY-K.:SXI(B)=*1( 3G:0XI M!E6]*&,_J$I%@.HLH%CMQ;8,C#7!5JC2ZXML(Y4_3&$>B=M=3,P M?7C*-+A@P%@K002OP!@T8I4(*;E(BMZ>,FUV59"<&&OZJ*0!6W#/S6E6 M).>N'PCD;J]>1N^CR2J%P"#JLGI:^EL(W)4M\2YQ3B*MG@38#=GP3F(U94Z: M:Z)!Q/JOR?>YO?5ZO.,XGWV87%_CG_[CIO%*)B*)< H\B1H$"PJLS!D<-[J< MX)S[VCP$]0JKI,8SY]DIL,5MD!]0KRF-2P7J@5*-$(O=@:2GHBE(K881/ MI/;AM@O3\'P:0+7]/,-^>FEPPNW"]SY-1Y/X>ARFBWSOQ?]>H308T\D ,2D@ M:I;!4-S99=;&AYS1^:B=);0?TE\[=X5EJ:VA"IA4 M%D]WRW!#CQZ4(L1(X1F+M:]7^J/\Q;B#==>@;&<7XGG1\[-7A"L;J?OKXXNV\!NGUVS]?O7UYV'U9 MAT^M*2^; QE(DS1@R.QH"3B&3 MUPZLK$CGNPL%NT>GH.:QEB[ *L5<>O3:".=/]3 M0W6[Z7" W JP>C@($=J&#?X)=KS)L2NFYU!^=!'W.UY ML+HLOS_RKNRWC9N(/S>_\*&YY)\*2"G3D_' M@>VTCP)/>QM92G>U:?WO.UQ)\2'KLK@K1P6"P'""Y<>9C\/A<#BC', MDFOD,38IM5PARY1#TNL0*,-.9+\VZYT:&SR'0S!C%[%WP8BFGDYN0[4$<;[' MV8BU\2R], A@*SU@U$([5) 8I8Y<.Y$]+K$>4O\^13;U/:5%1MEG]"]27?4S M\]>D6N";50,(DFE;./":N(F(Z^B0*2ALG1C[0L=@O,W1^'AYY"/P'C*(-.-- M44*36KVFU+<'F.:,W@94QJ8?*X'TW_1C7PU-NA)O1KN_'IP70GK"'8H4CD=< M,(FTEQQ11@LN.'-LN]C!Z]+YFI8?O:A\%ZEF5'7[S.PL^-*9T@_&?O9C%1;= MI0*.TBL )-/SM<(29$1Z\JX4YSCEV]LGKVE6/-M;.42_K4 RR7^277C]'/U/ MPMC=W)KJ4TMB8+ H"%8HQK9DK!) 8A%1@9DBU$3)9.[K_$V8CF ;[T3\'=S% M+^-;H)NOB&WP]14.>(+MU<0$]M#H1KID4$86$9P.HQ MGLH!8>WA!!0D/@JZ[!XGZ),M.VBA Y8,G)LTXVE]$5PHOR1;.M\3N1>%"5C" MV3> XX2U1IK#GHB]%UQKXJ2CF=FQ"LLKB!'LI;6GK4IRB+P#-^32C * ^A+& M37@?%MN**BRQ9/M9F79F1=" M^.;ITJ,&^G!7Y\7\S'4@0X(Y9IP95%@%'AAEZ6X>?B(B4(4]]IIU?@!^@.>; MITIVH:^\ .\B'?O\_>75^=O?+DX_?+QX^_/@\O3#Q?E/%X.S/?.Q-WTV7T+V M3A/(E)%]^G>S*$EW'J_2(X.FNKN<3MP#*D6KB0RF0,*E\E>:8613IUP9(\82 ME*ZREX'; M;>EN69C\^B1LQX5^@HD&:! <-E!(:+Y&XY:K&4T?G<)9I6@NDK M4SLW#Y9,2A9IOYJL[1O8)B_"YZ9R-Z9.&^9U96YG;4F]\)0D#UU0@3@Q'/;+ MU,_).VJXIMSZW ?DU6@.%H[-H^VGAZ,\4N\B0?-99(N&PEM@ZRJ)>PVN ^5Q M9]+A5M380P&]DT3) "=\B9Q)3PD-^-HF"($DA5\XXFSALS=X[IT2>^]IVT%PW]33I90G=(CFHX$1S 4=U7X 3+WB!+!,126Z=]5X)'/0F'W:[ MH0Z0Q)U-+9/.9)H[$/)K,[H#;'05MF@IERE]76H<4A-0G9[WPJ%-10.G\(([ MLEVX8\- QZ+MG/+LPN(GOV?9H#73FTF5JLK/HG5DJ#R5,C4(YH8[Q#FCX%@; MAZ0#UTAPSZ/*?>6V);3^B=+U0:0+G71QZ_(LS$7IDW>3R@4RQ"YZ985$T4@" MIBPX9#5+K2V$AG43,0BI%]X\QO5_(VNBB%.3#:;?FMAXXD$L5_- (R1QW M"K%T2\T-"0?O#C)JP0)8ZG)P% ML'M^:'6@W&@P<5ISF+LK */V" -S@<.$<9[[SFX;7$=.E!S:6)DQ_L((^Y(J M6^F%X&_?G*:(AFG_?5;+,0WL$::7MDP"?_+*ANQS7]\#LSU3I_K]''7]YI->^",M.R;3?P$_#S'O5O&E25&5^W M2JY/[N[_S[PX7 OK*[;!N&V'F-+5?WP4][1P MLIF$Y\8X3#2C(X8L6XPU8LV85]X&5-HA6HSUU]PSQ:T#9X0*#^ZKI1'9U#Z1 M%9A;1@TE;+O&3TN?/DZU91#CLE)%7D/?RNR7L2^_E+XQHSJ[O7_Z[?TL_F:X M>QI^&&0X&(T>#+'1>*V?_\H/[K,VW]Y4X*E./M^$ZF+V<^HHMFBY2ZSE*A0* M42,IXDJ1]*)-(:E-)!%SBK?,E%L[3']K=I-.'JVW?*+)> )OD9V OU>-[D[ MR9N&3V5Z8S:[A5 \*L9\>G$(9[Q4,E,[L Q"!>*XB#)ROI6Z5@SP2A650QR[ M'GGGOTY_6;#K/WSW'U!+ P04 " "=@$%8A 'F1189 ">- % &5N MF]C(HA.)(2H(;I$U.BBEV#F'4_Y/_^VOO6^W_NM[_O6 M>OUF[77WN>?Y^[?W=PH[@IX(*&JKHJ0$! #S _P#<](5?*C[V-@"@ MI04( @! !A 1R 'G\-H%?$,CW!X@PNL$>-TT->WT"G#@NP:660%2_#TJ?%L1 M+P#K\F_/GN$,9SC#&;3B@%!H#X^+_TO]@%6>KIC&?LX@QG.,,9SG"&_]D BX'%9,7 MLN)2'&+2LA+BLF#PO[V'YR& />"!_SD!E@ <$ 8X@-MXS1-P ZSQ[=/_/BBY M[#P\7&1%1>'N5RUAS@^MKUHY.XGZ6+J(BE\5$P7DH3XNEE:.UAX<#ZUM[>$* M_#_KF_DY[&$*_$80+3$M%V5K._M;?F[6^G[:!E9^CE8R,'ZH(C6%O(^LCY.+ MD[6')8>/TR.XNZR/ M=OL\OB]=/;HER*\FXP&UF]FZI_C,"W%/YW]U5O MB:O.;K:BXC(R,J)B8%$P6 0_0L3=%^YAZ2,"=^?^8X*;UNY6;O8N'O;.<([3 MMN5#9T\/!2Y/3WN8K(VE#>0A# 81>6@I 1,1%X=9BEC"),1%8!(2,"F(N#38 M1OPAUQ_F859_L^[BZ?;H-]LP*U'K1]9.UG /=_QNB(MRB?Z?M8G?(H7_Y?;C M?<2/D55VL[;TL+Z)%\73,(N(@47$I0S^#/-5*?%K\J+_-$Y>])\6^O]@MQ3E M85:R5J=KM_+]J/[!7_B5K_[BC^_N\*W@(^_5%_][XO^Z& MZ!_9A]?^EJOX)SG^+^#,R)F1,R-G1LZ,G!DY,_+_EY&_^*XU'$]RO?%L%CG2979^SLMLO&R7 MF+BN%[ _'] !$M,1VG^'62B[J6I%RN].#@N"PR[AOE+0QZ_1L\ M$@_=0L@I&"\Q,;/P\O$+7!&4A%R3DI:15;ZIHJIV2UU#W^"NH9&QB:D5S-K& MUL[>P=W#T\O;Q]?OR=/0L/"(2&1\0F+2\Q?)+U.RWMG=V]_8/#G^=^D4 M$!+\B7_K%RW>KW-$1(1$I*=^$9SS/AU 2T3,*4Y"=UV7U-+U(A0LYMX3>!L-#MWX*1A[):=[-4]=^\^P_YUC(_Y9G?W/L+[_& 2I" GSP"&D! M*/!+,-%-A5?P9'H7303M8J_TM1K.4%$9_8B_HH3]OBQFKY+\9]670_058@!5 MO([&^\$ U^G&*^J-PR*ZX1OD!%8'!K6%ZY\2_F=+%7+;"\:!>E M&H>9H-MF:=;+/B-89G>AJ%^)]6$)^=?A-#KR+[BWN&KGH_- E6Y]EV^ [/81 MPGY#_J_JY3A?==4XM9>^(<9Z;I,4;$+;4O)OUI7&J2+F4Y4(L)">>PY&U7#3 MY75[]96F&XXI)L@C@=ET>^*-UE_AN@=QTR(2+C5#LV[0A0@P8E&F[.'V;'7X M@[XQ)_AZTQ/G;4R&0)FO#4/Z..N;[A*%4I1=[0%V#&K5'R;GB\&2%"+>8X?E M[/:@^U]P0(POA"'JHQ'"KF76E6:-O1P'4!Z9X(!,!=3)#@Z853L67;/%/OYS MK )](+QYFW(E&?5#(65B]K@AL$)-!W&E;Q?2G'_LOC$_3))%W/.B2*@!,5N+ M22\LCI6M6[9G#?39K=W]^&(6=-X1"(PR>LNSH_:,&_1NVRR+$%"&L3\U:HM8 MNTRB*O@ABY1A8!%ZX5A]>L&B?)F&1[E4/Z 3@5DQO].-2&-+W(94W3II'YK\ M?>]_L-,=3.0M]["5-3*]KH7+?\6NH78P=Y &Z;SQE\Y'@TL+.) []L,Q*CX5 M0WFF:7=]Y"+G4:;RY2LZV97U$.8_]:C7IVIL@8(@12Y'GD6#8F5BR7[X?!G@I2UA(UZ:Q'5P5CW,[RY2X.(0.XWOYHLV/Y(BD;#J@@GY MSV^9B*]D+.@7K%%+*X$^=/1\CR]7V]G$IPL%8\@/U<+5P3I11#4U3+CP.L,2S9M=AJB\-8"\Q#Z*LM!8W9 MV;Z(M%O55941LR%=]0RAOIO.'R^]Q &1<4^@VRU>,S7%0E(1Q?L)$L\%*ZL3 M)#$-RB7+L)-FW9H,?G[_E%X;FZ/6C*+<[#=.C=V7G5VRD5?HZ'55@'\0@SBS M'IG6"Y\X<8"E.O9ND>VT2! .P"IX1!4LL'XT.IQ)B?+G2H3MJ2HPC(T?\VTF M=1 M_J2+>W;_YL(N6CJ(S*?8D+.M09G-Y!?V;G'6W9/GCUX/I??;IHZX3CE' MUA4\+:,C-R^K'/@N3Q6TN&Y8!9U6\ MI.X4"F;_72X4DA=F([LM5>CO$!A/]3,A6+SG.N^?S]Z,:H>T4P%ZH \;YA>+GWQT=WZOF&U[<:]0P$ M$=P6=L->!=,G_,81[45+&_>NK-3Z'K=#%@S>J:R06G6AG[\W_>*E*)W=A!H* M(O6QV7UOS1!GO*W(/3&8./B+*?SCO7X=$Y>@Z,[HW M*%@WF'3HFC\\%MOT%P.-5G,K=+)4T;P79;I]BP7>C0@LUQP=1%A'WBG&=AW% M\B%WNBR"[PLD$[KMO;;%IL#1:]"]P*#+>L,&L4OTQMR;/,/E[X<1L&%IV:TC M?N3 8_5W;:*F]H+>&I(9# MN0$(*@H FES6?/M ;5I$BOHD8R^2=+.+&_1%NFP*4/S_<@=!8CF_>7GY;.% MVP309S\2[.'\/-4V:(9WRQ;, ;P/6I4]>:?9LJ)1)Y0,7?>QGUW.(2HJ[9EL M40KOL#>'Z5K[8[=D\J*RJ.?\%1BV>[ZW9USHUAESHN%"GK*[3#)-@<1,[4?B 97A_QWN<50G46XX#W M3C.H7TP0T6,*Q&8I#JCD'.T[TLO8JECI%)J#'F@UZ.( 99(\'!"L@X7 01%8 MX?#+GB7Y[]K[."41=LJOA0J"Y8[/W/P_+Q) V]O^4-'JY!&(]E@FXZSQ;\QJ^QA72 M?+#$5Q\CT3I^M9PI4$JO.I7]L2+-G&]9LF$!-#3-!:-1\(%;#W]4M4*0 ID M_JBZ#V061X2@G,^U/;9[E+"LJ M$X;PF2=#,,ZS.M3F!'N!\,[;.Q-BD-[BEM7^%+2VF?KE1$./((X!7I>XY6O= M[9ET%$F[,;(\(KRK%#E%5P4/7[@=YGRM5;&NCJQ4T3,SJ (\%>U*CS(B[E^L MZGAA_D;X/$5I9D9G7B^E%[\>I5=L/'+Z*E;\0''(?6^,3^&I[GHI91]J7%[I M!*594R,S"R;")J66TULU1%LCL]CF4*;934HK[G 6IYBJNO0P)?/P&;(R M([V#M)F>VPPO#..E^PPB .C'VOG8W+>#/]*M5>7,,W2_.3!Z"=7MK5]V71$. M1J2YLV2TB9+;FST=S];XD/F86>*@S''^*$9U;RWJWC>M*PK>M1#3VOED]6.! MN71[_HV;^VF:L]@T=J/;7_B2]WS/7]I:N1=6M-G5.I(;Q5O]^OZ3+JUV',#> MXXMFZ!*^:^\IO1"#@58Z+2N"-\\7N_N7F"OZA3[+A#YNLU+G[IS/\_)2T&1- M<6+HG9MVJ,F]>>5$_!KSLX-E1$ KJF,,CQYC"^V,G- M\7V=7A8I*)AF3RN0?/HGW5(Z_Y?GV^HU)@8G\WW=X9^1NXLSG";VM>O3FP8K M:,G &*N!S*(^C9"Z&4_B4V*9>UH.JI1\G-MP0#B-K2M_A(==A3-G3ZN@C/+) M]-I]):;8IZ@L3)5U)%]D3A)A#A5^#5P-\6N?#H_"C/J:2A87E,@5SV[+%$?SB\3EVO=:4#R:6\1H5QS0SI@ED?A' MR3G;,Z.V2-Z*X #;B1Q4E>.%6-^MP8P?0M:AI=A/#2Z>W\?D;9#[TLVV];2ST]PD1X.-F_T^3F?D,)QP,]./%NT&%SQDL3VM7H=ZY"B,50^!;H;Z<75 M=; :!79PD!%[6*.#Q=CZ%^Z.$3[NIH/'V+NJ*WN!MD,K:0S3 ML5A_@"%*(-KD.VWK)A7L*#:L0:X-1"6O//W"UM^F_NV:)*$W^Y0;E.572ER2 MN49=&&DA-^23&:5V6;T$LHDBR+LMEF4OD!46RZA5( M!VBT^5VYQ5V86R2!/UR/*03R@/00?+S3)SM_+.V9M?#$+):D3)8?^,^@E0B= ML[\]4F#+X0CRU _[ZAYKW=PM]N1V$.4 M1Q0-59G8[EX0T%E(F90V'5CT^$!\WP*V@4P?[US>W1N;T)3SNQF*6K+066JF M".#.?]:5+_(A%B5'IS:/7!:IK*?D(7>TI;KNYQ1-L11KP;\I4<9\[WL;]_R: M*#[S($[Y;(+&2?5?@WZ"]H>%7G]1!)83+*NT5"^[?KL =^[+\__&,,1*S=M4 M ./BT^N;K.)3AF%"W=6[8Q(%=35.X$.UJD]?R&"&R!YP7M:[*-.BS!S'/"+ MT3$(N13#XC+.?T]L)VNCC5;9B;ANK3I,.CR;PV)>KU_% ?Y?J]R"S*OHLCMY MK;0=!876)/G9C[\NK#>03_L/B[AGC75\GQ2G&H8UDS> N->Q709[RL'F:0RO M\K36XQ)RM'[2N]A.C3SINK@GHQK(@P-6]',.Y*9V'IV$J>[92YP(U647C.IA M#72&%G& H/2!(L.!(LWA4Q5^Z-9GFRJ1ADO3]="#W?Y',SC B],L\:Z@BQF/ M7HZ6$[TR=5I5@R5'B*3N9T%D,B!+I:MBYT!OH&]N-A']58?>XF>-Q8+Q/I[G M?GM"ZUEJ6L3FU?1S/N6% 'H,G&A5+V571K<]"WJR9AR!&9][\F2^]<-AL(E^ M@._&5PT-4PN-ZXO%#5B;-SY(35_N2\C,ZGB%&\@MU($=&R$VV/3%/ @',&A' MS>Z'IRNA\Y=I43_%;M-\*@IT0&U?W.V&;K.7J+A<0S W<+JC9'?7$"NYCQ#/ M(/U+6(F-]4+2T2I_HSZEOM?X3\E1-+=AZMMX2(R#W@$LINY*>4=\ID^:N8ZJ M?IPVFOH&OIB?^T/^J:CK829!IIE\V4@A\5!Z@TM?NIRLA85#] MUHXZ?A-&>YAP[VW63(__W;Z) M7;.7[MA):)*E<"!DHR1UH'L)$WHM4*?0IUYIX'/5.MKN*8(F-:]9^$9L M>.CJ)S,=Q=UPV(WF(H;MJ(XMUH[5A:%8^ZH>X4"UC1+6A.[EYE >?\:"(Z7[ MGVH]T(),P8M?XF\=QPH]&\0*'53K\US+_:QVTA&GMA(]PJSBKDEK:-8QERY8 MN1_GM6 R^).I:CC+71Q>_\/JQ"&)WI"ZNK9[PC^47E?IE%^=2S(N.9<;(GO! M7B"3.D:J+64OCJLQK,2=?1()$VZ.Z\ HXU_ [3$:0\\5@OI%N7\*6SGBZ^/2 M?7451XJA*\?"D^E<:&B8VO#DY?1*SY-Q$QF-#[WS^3ZM^F(F?M_+_Y'SAO8NDQ%T MC>!XI:=UZC!#0:&/^]+CA8"=ZM6 'A4/=NX-[=KIJ.*U3'YS M'L>.&1@N75CV>?_D8R /*WS$KAE2N!D#0#K<9NV[7O5 @ MBP@^3+^2.]DF4)T-7L0H#311^6#NC,-%9LOUC_5KY!'OW,W#7ATI?A3S='J0 MZFGF,87E9VAPJ>IL)N6.-#3C)]]0)R,?9 M+3%#W*#4CGJOR?/OQ2.67F(PF975;YFJ0Z1KVCLR#8;>=(V87"Y%>[Z8"@C& M 62QS3A Z57&T4S)I^F3^[S"OSP[*$?V;9K:LS/V A#)B#%7K%6+(MW!UK9: MHQ:IF8E*8L$%=:ZX>:F"S_C3M%]7="VIX.O;E2@A7[.R^QP.W[63QE13B]J3 MZM/#V!.+E..UI_&E>D&)/8E8V\^ 0??";T'5$'RZST?4VBL63:O*@K[DF[>A?K[[<(C, MX]&[,9K$?%XBC GS9I(L%P>8T$D==5+?&/=,8*U*JU7<%#TPI!%9$WVWX&MA M'T3:#M"YD&@9:\GNJ;9Z)8COT"986. &V.:0[=J'-"LB:7?M'4HF'_[-)"; M'F'3_..8Z$W3UC%- EH>-",T?.Z[2M,#1-3J*ND"16 Z2Z[8H,E;JUNDX\VBC$3I%DL=W67>(XZGWK<&$PYVR MBML'#--=6FA_2,\2R-<\Y,GA@Y%LGXB!'U MJ&;1W!L'+)J@:[)BZ<>H[%E^<3V^\C(',E!4N.KY41SUOE1+13E%0BWFS_W1F;Q3>,5=74N(#'\L,G^G,_\] M@>+&_@-02P,$% @ G8!!6$>&\WSVM@ >LP !0 !E;G-G+3(P,C,Q M,C,Q7V3B49GNGWSGO6:[K_/&>]WK/N=X_SM=UCYGK MF6>>SWU_[^]]?SZ/[V!-LG"@H]>OF5\#<1S@ -UG_X!8&Z CQF[^#]U![B#V MX&#-@*Z #G#\&_\>#_P;7)S_'KFYN#BY#G(?//@?QL-[B&T\!P\>XC_$R_=O ML)\)\/,)_'OQ[T/^TZD'N#DYN?EX#O+P_4\/5BM(Z-"!AP>*.#GD0 >$.#B% M.%B=(# ;(_=_P., _>?!<8"3B_L@#QL&/_L--4?9\#DYV:"YV8C91\/9QT%< M0MS")\\9'Q2Q?L C%R!Z_F7RET/RERO:Q&X/D14N/'P:PT=G5W?/S]Z^X9'1 ML?&)R:EI/('X9V%Q:7EEE;*U_7>'N@OL[?_SBP/$R?%_C_^A7T)LOP[\FP.> M?WYQ' CY]P8A+NZ3YPX*&UOS/ @0D3O_\I#HY>0O%6V\\A=ND\4>/AWB$U?0 MQ"M2_KGV'Y[]/W,LXO^59__%L?_JUS1(@).#/7F<0B (B$'/B3L%^I^W1<0% M^#VR5:M5E",+U.W_>K?*:=E%:D01/;I85^?E=O>M&\EDX<-?SE%J\2?BS2.W M@RWLNE2N"3WUZSVN)49>**3+Z+% 7!,_ZLV4*.EQG^T>:PX#-Q\67;PY?-/H MQ<08M&J7I$Y6IA:25>GF#!13R:M%>>A7]ITZ\3-]U*W[X#.>GTZ_;3EDX'P' M%QDO=._NO0GU;LP[0\L&3U: L&"(F<<;451;D.S0R9B\T'-GG._FHC:FW^W M-A$%64/5$!-HLH/@9#I5 W@90,XD6,76E$*[Q-6DO1W!T9I)U>9N"B;)7.7R M/4L@" :>@ZUVTYY[ZB:5DGJ[T\W/+W1!2N*!]I?9$ MK??>Y/I'U9\S9O/Q_UFE%1/R%:4K!'*-3U^\TB=B@Y7MVN2XUO)@2:&DLF+#:K-EWZDR4V)A#_(5 M"U1EWW'<@@CNQDH:?X$%FM_1R7A%:?K@*O2WR?WV6G?EOBNQ68 M6>E8^]<\-/U?EKRK-'4V@>O@L("N!Y.WG[!Y_ JN$24$*[\6$=IIO;:/B;D: MK*?,\3$W^8_)RK;F?=#3)QP]8^CC2,_-"&R51[L%)A$B:1CJD0=[-*CI3SIP M ^WIP0+9O?UVOWJ0!6HOXI57_JP0@-^^5R=QT_;4>'SN\6D?*Y?^7TOY">WV MKPIOYG@;K-45SPQ!Q>F"+%#$+@O49L34I=^L!.Q="6!A6/"F39.3L\XMRK7X M-&J(R 7?J]NN:58: 2(GH. M4!D.!(N=[S-W[T?&7_4PJ'%CHQRH Y10^JTQLIG)OJ? M[#/Y)\/\/>N#F_^B_:'R*U_56M$/48 *E.T@7"G?@RS?I=-?LG+T]'YZ3$T_ MN,JE@_.L]=E;OU*4"**5!KZ*5UR?+F%]2@1C.PC+7ZO=\B6J;B[/)WC;KA2/ MI'CM&)N(VBVRU\\MCO\=!C5B1\0.O2"#.H9>-VM@IOX5@[- +!"W3=V/!G:$ MG\$?1D_S)+- >)Y&WXIB9="!FSSW.90G[8^P,TANF@7"I3-3!A][T+*LR.C> M; YV%3L'*),#"2BZ".>E"N C.;=XVMT MKS5PR^K,]F?RLL%PEP(\M&/,;D?[];5O=%G*4BS\P8,B[*SQD00/[]-E MO5 MR849(WLE'2"SJ._/.5UZV+"R&&DLD%=Y(@M4I_R&C?LKI":DH[^<5[O\>#M@ M=754?5YR;BG!=VQ<#Q04(6VR9?N)4XG<;#E]O1JL=T'^P4\T@HI0U9S%ONO?-"UD%(.VR$HHQ\HY. ,E41 MH.'0K[)!0!#L-&$BB'%F>F/)\7VOZC7@1YQU[16NI%>VDYFZOG+E/73M>_ MY[=XW00LFD9%OEB0TK[&9\%!K5MW(I3&T6W !QF=#27:8< R4H06.EN#3 M>AOP\Q<#4@@[I4%Z_B<:A$PY&AH_126:#>7AI9=N1'89EDAG3'1UW_[67+H: M:!/XSJ]W2A7>5%&3FI%6$E(:\[*3Z#UQ.TCBX@*LWJ!YO5[=W5?+"MI*0( 0 M(VBR$QI0.9))@$Q#J'9 ) [" 5.^/NY>-=2D7K(ROG7(2^ MVG47T3.=I^YI8QP83>P@Y4%K/-;W)(&<:DKW*@KJ .^<@:% M7XN]<4O/NIEH4.;<7J69G'/YS^:>);R+[1J[UD64PD28O"BR3B>TDH=D3[;I MIF:?^0VW"@DH]-KW2Q<*S7"_Y+L@W!>M+7SR9*N[^Q-3JTQ[)K\:3E""[CR* M]OC7DC"=V"FT4Q-9DRDQ0@#2<45+G^YYV2T22;Z^FA6O\V)^)1(\7TU:EKW0 M'NX3Z#A7PHC2'STGDAJ<2Q+QGVU*>7<=DS)=*O[&R?-&0"#S5^KU('?5VGLK M=1MK96F[OK596A7+^TND&G8*'6'CA3&'6:##AB=IKHC?3'Z@$0>-E4J:/.-? M?5QI?)QH^M9"X*E^)NPAY&2V#D<'[U']%Z__2=(U9&U8]BOCME*E%3O@)MB MBCIBZ@J?%L3"-MXU-Z22 HS:?Y<^6S4^XZ"GF;WV,1]!'27N0(%3,71Q*%6/ M46JZGDJ9QK:C1.$.1'55$5RST?#@_/S8F3-9Q+ILO?O1M-9S_?ZUQHS@#7%W/!?WM"' 3^? M]/LV+$,U+]4+[6%MHK29Z[V[B;89A/ACA.@(,KO2;5X90[MC#DVN91OY'YZ9 M@3WML-&M%<;DS;9N6VQK](H^-3_7VRVW)!_W%QG#+E5(NN@(]13;H9> &M69 M_?LU@.W(/OL;(6_EPQV=F^,U3C'Q]"O0IEAP?9^9J>LU&DU6O++E'F/KVLJ< M1TH86M,,D&UAIY&>_H+TTV-P*$\$_:1OT9JC47Q4&:0*994Q3GAV;*G/(E)9 M%ZS\R_9IQP4"3T\>^SH89-N=EB-8YB#D2).Q+VXSQF;*Q2>CK.)12YT&DAF%"^KF9N!TL*YFUQ4!KV+7%8"9M;<:_9 MZ1I[5B$6GF6NFCUA5IK1T#P!-1HW2F*40OR3ID>(/*1="%VDAWH,>(E/.M"/ M'] A(+80 ZT% M 9252>5$]&%@R;I^.)O-9K+UR0N?M-FE7LV?BE(?%DT\7R"6#H@EX^7/'#N[ M9T7= *3)%E1/MHO5,!0!2V*0I9TI'FVHU]X3S^U*\JU"^-I"%*R%VT@%KZJ3 M+62*?J=CTD^\58/GM+"S(,)[CMTOI>#^-)E;4H3YNENEI\YY MYX?O/%[-?=TU^DLJU412-6WAZ?.>RJC2KV/7ESZNH,FW4(!:.DF:Y@1W8[ O M[!YN<36#9D)9S)5-)EB0Y 9/T2_D.;C,SGR8RE8RE[KM^][PC?R"M.?>&^55 M2.L'(S5'NB@YH:['I]\G2:H'WZA(\>WZ8"R:\?:ET>\^>;X/YSH?+1O5_>AUMJ#_-A2N]M^M^W\5A25 M?H;LN_XI>&#'[RX)R,\2V>WYH,K=+TA MNCUEC8 A0?/7F#)#I)T/RI4C1K(KCM^>SJZ,[TKT![:821P\Y;J5T%?H!22ZLDE^(N[$0C1ONF.F4*/0A9?P>$L$"6 M:3M[7]A 2>R\>T<_ .#)2_:,.$/P%U@!6 *F0[CJ^W7.6^KQNWN&F#1V?U;RQ$ Q\2^EZ5'=%_.93V<.LKW-8QB]G-FPEXN*6I!7+3,<4Z66!G21K?!6)$Y<+1!(0;527>1^YS77-:1? M'[U3?=Y"(,*L_Y3\$X'/J7IVD@*'%.PQ2+)%.:"2AR;?ME3ND?H-R&M$DNB* MQ8Y.,V;32S-V>QX.'P+_=%7\OJK#\0-!"2U+9_(ET5QA[ZB2C*0=3,(\'WG: MVY'HW%;@V8XWCQA?)#YQBGU!^_G2?*9[<;J>H](H==$A6%XM[3Q]]/',T&KJ MR%#YF>GLCNX'JKALN=W"1]3ENB%4-HK\).:5$6@5*H801?2CJDS;U;F-Y#4K M2^>S\.JR_*%V_.]$@X,3OW^-&,3/"=6;[/T0=EM!MOD;:A'\#]$O,M@$]"%2 M:*W2TL?W 7<:6N%V2IV]-L6+RJ]M=?O+AIDR:CZ#H@$H3=!%U:@G&1\1)]:@ M-:8D'SPVE@D!!LKF,?(^WSVI(M,KQ2=/SA_,V-?QRK.)?INS?F7A,_\/]! + M1'98KL'.Z%!O .RVRJW(R(2+E5GFP[PW-C:VNO=;PVN'A[T>GINUE+F),Y6I M=3MG=Y]K=:K;C+X:='8JT3FA:]AG^LXMQ*!!]R?WXZ2Q4O?)/96;B1J\L>4' MZPO[]NS-3$KII'HVKVCK07,PQ6$V5&6R1!Q=$N>K85Y/QB20GH6K5],48GZ. M+%0VJ/LU7MK3<6J_M*Q-FV K.9KZ M/:\?VY%*Q\/,RA14*Q?$WC0>IX7 .SVXXNALG1#Q"MEV^3$$5VET%/"ER3![ M4(?@MF?02 ),*SQ^%L44GPQC$ZXS]J0$ M"C_5&+#"60'*X+;&-Z7*-UL I%O+"U97 MB N-:?6/81YB%$%P.'[T<68/\UA5!9DGLNEJ1D%^D6=P_^&X_/R<*YI%\AS: MLW,EJB1\9_Z^G_RF_TPA=8C![M&X+*SH9R"2$HD[6/@50/?HV_3JO#8TP(=9 M?%R,F%3@%Y@0Z9>T;;,]Q'M,4KX <9,=BT?(-AL([@.TTO\5>V&>IXL#IA1' MY\ NJ:ZLLAI"ED5'QL/>KZLB^NV5_0NK1WKY)-JO?JD]\T3RX\>63XP""*X& MS99H;E;3@IW8JB62&!G:\QPVW'DX=ZTA.//P0$$-5^W0]<%LMV2AFCQ/LDZ9 MJYZ[WJVMACV$M$JQ[<,'4N^*?V$U-!^H^/2E98G8-] CN6WX33E5:)[%U^W] M)N*=5D;RQS#O(;A((U'R1#=J!DNH(R7CFZ]T9$N,^'\9[7Y#7NRP?8TU/KRP M_C1:>R6B=DB5:Z[F3J/2;] !-+2$@F3RAN,%19GC8/)=9R?J/ /%%/0VX@-L M/,*+G6>K' ^I3SVJ"'.OE88\&[&X$#NO<%ID40]OSOA<;A^)HBN:.]T,#9M3 M+N],2[/R"3T^RY:HDXYUTVG-BHR%*ZV)-34U6@Z/#3)[UM2^NB9I\7WGN\X!LEO/= MP^+Z=M7N>39HS=$=2^??^:J/C<^L;"PU.'$6=76HZ8GADS$ MS=S5U3JR97\[FO[^*ZTFK_*K8'A,'KLS?=![*O'"B0_=C>UOI65>!"2C6A%W M5D^9*[HII!SMD=9-?BM^ZW*%3/S.E]R$.3?/T4K&N'SRW_R<#]U[UGO9(6F- M5!(V,6 E(])RJ#I!4E8=?+VVVL%-0V[F4D6,ZUCB[_/AJP.BW\K$K]K7:NMG ME4RNV@7<,S[1^19S[)D?/;*MP"OC9FJ.XQE4KE<:]:U*7YL/7W?DLBB'W:F< MOEVQU VY'JD+^M<^U_;_ M;W!R1O8X5HE:&PNW<7F_CA,3DN"XM Q:5QF]7=G_YT_B)^]V(\5;>( 2 M/+)C$ZP158,\NOQNA9I]TD?DZ6/#A5-;WQZ:]3Z)G[F)KWGM%Q Y96US6ZC$ MLMU)RV]F+\==3/='\T"FYU7[]7R@^_GQ&6(JCPHZDY5].QR.-/+EZK_S*O(V$%= MF#WK-:<+\V%AEWYGV ]I&AAH9]7=]/5-N7!RQ_>S&\-[0?0V>QIX%<3L[7[_ M=49,.JPU7"Q=/QEYJ(PT;L(S(7!HP#$G^IW=_6%7=5+I.L["R4SX5.ZMBAZI M*%O.SZ!GHONG"OZWW.+Y/_9_[/_8_S\,FH651.(6().Y. VZJ,L2DW>,HHQ' M)SW>L= 07V'*H"D_*JOT+Y8N_ G0M#JI<\#VE>0ECZFW8I,J_!D,H?+%#NH( M(Q%+_),P<1\M"JA5_PW6_*U,1R:)/7:"SF/-7#C?Q MRN=45?T8O,MM^TB9SP>#Q+U'DVW9UT*3[3"O9!6!1K(K?B*.KB$1!;\Y+5M< M *OE?X8:/&IZ-FA+\:U89^83L_M]L&Y>>N$8"^3[3[KL4\K7^6F'C(M9(&^G MTDH8C9H8$_Q'1PJ2Y?E[D&",9"#1@)L![^#VU# J:37+)"G?%B^#_0HW90(Y?:>8!ZE9'VB M+H85$4\-,W*F\CS3)-QG% 0&)Y]^0]]'C+F( %5LW.S@1L8V>; 1S0.1M%MP M$R"0G(LK;%]S#M5$QK2<9 [4C_J[U0TO7A!777877AU*V$BJ-;BG-'+R(0<5 MTJH!J$TD(;01T^B:D/7,0N; 00K:P_+8_++\U7%9'Q9([$9%([]M; Z_3(K^ MJQOB"R].3#0AVPS1WN5O4+7^ZQWY+2T$70N1D,3N.89L'6O&[^ MJ7=@_?EYRY13LXTY5U:2HR&)2/)U< Q4B 5ZA)IYP^2S(6,[43(UFY*P-VU8 M_C)<4L_TM_6,K.TKW+T1BPZ>6]H9B%^X!>26S(#(,'S7\&.MF&9S^>CAOH5' M9RC=5\ U)+5XQ*;>WG>CG^5M;'FD74(=J61$LG5(#%,5&"E"8, B1DH]@30+ M[(I'!PO$UZ2M97E=_DQ,@3DUYO7/S/M091\CF)?\L;T?5'] M9#D2WO&AFT& MP:6:4_RI/(R/2$]HS/B^3M>/:A8H=EZ@>2CS,@51BE]^_&K$_/[;IDKSQ\/W MKL:["G3E/+'.->< ,909/Y">)2S0E 35 ,BDW5IQD8AQJB?S1&@=#\::_6@X MVP.C_C8L$3$3BSNHRG%")(Z=";B/D%K9_\.W\K?]WN4_5 =_]:N=3MIVNBKIJFNS;4\7 MCB1*=&X"IS0Z-:9LF+S&%$ZB59R1 /P,@,1)8T0SU:4=ZT>"!./L47[UJ)\1 MBU/IC_FE;[PX.,M=B@MX\LA"&5T1O?+9X=!MO$#^E:.\G+K'U89\]@!& WNF M4/$9@NOLO.)BD^V(<,# :AQQ27)TKG)9344N7Z<<]X[6$FG=L"*74 !ZF%% M9>/QBIL.'-,A)68CA>:%17W1%S8QTH*[XA,AF E>+TS5172]#%NBC4^\U$+@<58/IX2^?>D>U M!K)HYG>!X(LNR!BTH%:Y<$=>_],'%A/?*S*6+PUS/WSYR\F"6W?ND\S#IFTF MKQ7-=PU"MBZ?%,&S0*1, CB&VB+>3/FD_^:>IYT]*4BLRG'5W@YZ.C[N[ME: MP9]$A%ZW%8%G?88FBQABEQ8,H.!/$F2WAC@ PWYDMPDOBJJE=+>-4F0^$,E4 MT)%2S\Z2G_>R%W\,&;MWS2-*6,<,?T7H$,T,4HPF/Y:@?T;C[!E/*!+,O.?Y MH'#*_U*FX0[4]Q?;!B M3V 0W6#>T(3V )"UD0TI2"@IRVO=?_C[>B!IO'[M(?F'/_%.?+@C]&/J];^G M6"!A\^?528B<%G6*,EV&FYT"7;_KD(_@]\>#LG*3UK$\V++-PFFYN!]KFX"> M 9-WVY/F2[] 45WVDW\F*U/#N;8]5^ZX7=CI("K[XP,\#_7GJ85VOWRS)V.9 MP9F#-BA%XA:ADW*$RRGTK?WKX'P7X;\I+-"%G&P#;GMT/F #&((M^& M)H')MSZV:!X/1>AXC=>F .?]#Y]6R?MF<>CQ+.,+$L'5.U MC1A2:7BDXEU@61'PV,@J,Q;IC@1.Z+1A(Z 5V)[-R1*B1K<:%@QS)6+C_7;F MKA%FC)U5PV5Z%S3YA2[,\BI&W'7]Z'Y?M.&,:[>K'+GK759#]U98()HM]*-[:4[G(L>(?O&B6, MD6Z?$V[I"#@R99B?J"W@?.P*+U]\9N;?,VP(&_]QGPW+X*&J4E ]+)"X(V)B M7HE20G].YEN6*EV*JWYP)M.=WQLD$4%/K\C[JNV;FH 0(7!VOD?(,X>5V[.UR1JD_]@CX0"\H?1W1-PJW9(^G'LK8Q\-0S,/AS,*$*K, MGOV0=16*#Y-?C'#8 H^*]!LGXNNB?8V$'9QF5E+VUAX4D2O1#OK^_Q=.#$D7C4L:APO\V+Z"XT+@"++E%L1(9B>! =:CARH%KKR+M M!0_F'_JAP^[@\N#IT]=#SWOT<3Z9Z\&XZ+'SYPD\)!\Q!A9I.8WX^:_]:,C2 MI8$@2I5-.+&BHD2-O^=P]U"W;P&GD2<[L!2NC[BV'+PX.QD$&/CMR<: ] M4^:A?U-9]QN)2P%7)<4B/00%X"ZH;D=$/47Z%N5B%FGP]6F7/K4W81:P];Z] M[= "S>I[_:GS=^EOXDAH?RMVR?[$R*.+X &(&WHFYAX@0< <67O$5 ^S)"^T M5'@5=3Z 38]O].'']8C]/,Z=4>Z#PP%)L)P7$#TC=O3;0&5T,7(N-2V=V$/* M_ J_##33K&!V2UBS"]5!R[$/HZV]R";>NH686"B %!Q\2ERH3J-1UB :S5^ M5C4TW1]LX^OMX/T$'HD[Q?E', 9*OA[:),:>\F *F"X68P>P0(Q<) $:'G_V*![LZ$DO_U6+*?'XK,)LH6E#HF M;PR8%*9%@#^D_$4HR6K['^#2-[9(T':OHX%GDJ8A?V1$T5FR\.'+"3\@!7=N M\2SMDMAUFNL8N9S$3=-B#LYSD)5)D'(8)P&]WH_W53,%PBEAEX>2\Y 5TTZ7 M!BY^_.!GZG-WX9#2+[?*C2"/P\LL4 5D79$6"C\!9'ZE7V;4L].G6'^B)T&? MUCXAI5X8,8.?2WR9UZZ8)N[ST;4V.:JS3#1=[ J!S;0]-*16ZZ02=MM(&E=MD_\$V9H]:M&!-+]^'.MV M0/2"J7#N?7P/%DF^836)@ !*+-#Z!9S59*U&; )1"%=4PY[05\G5R'46J#:S M]-KJ7U35WDAHF&7OC="$K(]$7=D=$Y"H]?_'9N<1W^2#VXQQD6JDH)+H]@7+ MSTU>N;AO%)?,]_C[^Z'F0Q5.W@FW1 0AV(2)'+#9*ACE'XAC\UJ=]O-PXW%7 MQ2/-1:%I&5?55^L/^'P2^GE 2Y[;36OID62MVG7V:E\'WT?/!54.&((I71C7,;O M*VB_Q'5)9?U\,":9:W3C!J3Q]&L?$GEHI ML![R7^O:"23NTF7VB!;;VA]IYQ"#=E+/0N747;LG!@+E!:&5,Z)W'FQ>B*?N M )M$"%U<@LFG0^GL]R= ID/N#9]>^"DN*SR5EU/,/$[]FG*6!0J?;O'(:;D@ MV1DZK\\<;RJ=,K+=54,H8QY>@/>+4$:#UZNA+Y&="%4*)#Y(9YSN3#!@V%&M M=M*?IQ(Q:N'.O)(*[L*_T7X\; MB=!O4R2BSW3X21B!QY>JX/L;4:,3HU!V[N":P.3;D,BMCL,L4!?-ZMADNRG= M@NZ>VQ78A*PQ='%NH[N7)WJ6S9YQ36HSP*_V&27D[SY^9MU%^([9M0GX^YCQ M'N!D@7@,Z.?&\^J&D5[(J:4[O[->.P2A>*'J?R4AW;Z+6_-:LG%;X$O/[>=1 M54DD(NTDM\%T!BDM( MXB\OO.JTMU/MMV''NOST^9IPJ^+>JE_](F\2>*?-=VHRH.H03NKUN%,*'"E/ M>&R@7U%^HO9]TS&D-J*O-.%,L7I":G;A9^E%)S4'F_Z@J)N_^^6V^%U#?DEO MVI?!+S"^(43H)N4QNQOV2@;;K&(S%OFRF"2CB_!'C9<_RVHN@\F[4 MM YUAE'(GH0<"/DV-AY26=@!!53L4FDJ<#X&RJ-VB&Y)U-UX3*K1.+I6^?%6 M>YW$^:Z%EXK-!% *2'PF4+XZLI^15KXD@0]IAP**/&U00%V#5(?;!-337ST+ M"QJC.X<1D-%U\^KO;B5.K?N7^VL\VN*NXE 8-@YZY*I[1N#\:3=MW"5((!L! M"BJ 4*0K,CY4)_'!K1A5BP#CZ82]CKY_9^.;4R?#:)(*Z@+NG]/N9/9+0G5" MU4GQ@JEH7#.:;*TQ;4!U;P+.T<017]Q[5Q9UONTXZR+EO^^6ZN+U!VB4OK MTFSYXTE>8-;0M& _V[-/M_RH:WAY?T0CNX\*J3YT*$V..FRAU&GPL^:]0/)/ M'C;O^F[?_F_O8M4OL%#+Q14DV7$--8VU'#*2\89XDJ7?J/THW9FD6G&W6_J$ M&K0>BH 985XV8@;7/XM1"NDB54P^4]K='DH_6Y^/L24(GT0)W*2.D><+#PFD M=+3JSPUF,5)Q-%^U@;"P3,\OL> ;B9K70LY,NM>]90Q?RF4[RB07KD<5(]L& M'<5KV"\?5==!(Z;!;;1RP"G=131EH=JC/F6>)"2VH"#F-9AR.;*Z7^#;0=N? M5.ST"/4.XP,+Y&L%G)(M9I_:_T\V,C$N?&39CP=,OB(F4<<,#^/?.*E-5O>Z M"1=&X1KBSMH1=D8U5_/@)=L\6TN)+RXN,7F7*.G4?QMP/B,F,W;IHOH3!(DX MN!H[>I=<8#ZX] B2AE)59,^[$D.=;+G1DURAY(/S:92?A^QN39K&_D)]3J4O M 1K4&F"7C.G21R88B3.G9#5_(U0 *'6U#K#"HZ?\KU,>)!E7DQ7X3L0-P(UT MSR6T6,U<7U+K#T5?1%X3!?W'9O;_Y?:$+G,FO?Q]A=\Q5TBO_L8Q*;"3IZU2EC=3E7!P,*)50,%$*X M7IR_"5KU81/"4Q)T"10UF)'JLHW'M$95 TG$UQ8FYZ?F6*#.PAMOGUS=Y47I MM:V).BS;9I]7VUYB9PF;XK0#"S2WB[OMFY&/=EO11Q341=-NW?,=#?JP_VCC M#D3!#=E_:'#>+/A=/%P=^F&I";:QO( &I%F@&1LZ=FX4F,7$SLT9@IE<+)#) M/OK'SN9T/W6-403Q18JR0.VF%!:($#2?[R^:_Y=T<')/RC<:UJF]&AR9J%.[ M5&OW5@-=7;+O/3C._. Q-1NZO_W7<7_AL# M<7WB2'G. 1V!T$4$J0_!E9#U*SCHJY!]6-WXS30MB'#$#R1)NAQ[(V'5=?9[ M)&/2#BV Q+U%5PG2M3Q(:S@4]^KSD&G-BWR;3&&PL-J9/S3%CPX'=#;(8,@GM%4GS46DW<&*S<;;T3K[W$_ U=@D%@CO0C\^ MIL4?2G7&*D\^?JUKY/8YPK3A<[#LFC,#GD\+AK% --<><2-05>;992HS:#AR M//32"7 .MSQCVV7BM>0259!OHES":^#I%?KMX;4!M?X_X4H>K_=K^6X[-4M@ M]NOQ;":#E$1Q/>=I1TW;$/S;HQ,Q5F-&V (5T$K(NHL6>!W<#,;W%&GM\+0+ M3KOB)[JZDJSJ&ID#8Q_@T\YK+P:1*YG/WH8)Z-#D6L#YIK!9<^E4=ST[FPC! MTG 6B!](ZI31)%ID3@]!'UJY,Z;\P9:N?Y[##"?$7@W3A]AL[6;/RO$GX&,L MD#MXRI\:.WI:"SG-0_4A\R26_:WI_AA$!//<77WJ*+ DI/7KINL2*EUF(@9^ ME%%E> 4O+Q%CI"Q9XZSYP'648R[0#S*-V1_;I\\OO81:P_P[IWGB-3WA5_!9 M=M(S!E&_;%JG>$9E<8FX+4%'9CH^\5POK%P0\RJK(+V9)R]W:[5I;"+LHF!I M&Y$,3,X+NI04IQ+0D2P0KV$(F=1R%"#B_6.T4+S-3;<@43O.PO/$FYZYJJ[Q M,V;10@3Y*%G 258UR_B%]#=3U[([]V/$8>7((CJ<5.87MJ(1=H2(!93SXP,H% MB\7^?,"@([C!O;'EW(\>7RD57:+N@ 5Y!(=L2XK8]JD#'S(2 ?S;AV$HI\R[ M%(5L\-")*E][Z_>+3HV1PL49'A?=X!4[905Q(,($]0DC6X0P!.RC.)K$#8-= MMS )IE&ED)J^QU-UI&QH5@+ZC,XS8G[P^__Q6OC_UNS[P.0[5H"J1P<$4"[L MP.=/EM8V4L".U8_(V&B!F,>J3W.V-KWZ+GT[(A&=^OXKCN?98K?KV4D!S9*) M]-.NC!,9=0F[DFKK463;920N#\D)P66S0$>0=4VAP0WE<4''C@$> M;;4AH'O8[S^%]99^OM"93WVY?#G&/PV-0L_P4,?9DHOVA'[S'<&_!RI>,W+- M^5F"U,2YR95;%9A4?W$SZ];^3XTX\4,>>LVJ\U1.W%Y@UW_=$%+RE$T"6Y(E7BL/E0VWA]YX M KW8>,@MX-/7%NV4LS">BH)W8=R9JNR:_N*_OQ-48RB(PPC!KU'*DLFT=JDP MY]7IC6+_PI6TDG&?V+R[1..=1YR4PF/UYHJ-4I:-\E0?YN%RIW4A6??YQ[6[#Q'=R^M M.2#$[G^_E3OELS9!4?-Q;$Z*^1O6'&*3V5];61NZ(<,"\[QT7ZD ,>ZVBIVQJ<'2WY#/VW%-VU9N^;R0^CH MD4,OSVZ!.]>AN5( $XVB>PTRJS*&^E6:5.DM9CRK1B*S$ZN27@6 ME"UY7NZQ!0$T%F7T3[2)C=.5 S1/[)A@IH>K5'G]+.#E/'LSP<_GA_K\_%Z MLL036W?L[?BEW_176'<^*,#K-A9D93 ;2K-_-00I7_>^%>Q)F\$+=B?QP-U_ M(VO@!H$+SE=S2=./?QG.!!NAYVVF8G@F_QQI0!LTG20*LJ/6>12&:F_(2TM/ M([U/%A0P*#D27_C#4(IF@^/I43<@^D?-,Q[+CEA7J&:D_KCL*F#<(2_[]0EL MT/3*)&I50Y!^+;=SY7Y ;:+*F_]%^X2)JJ*\]A"K#DG M3FWGRM3_^CU+Y><9Y4AO3#2D(J;5V8>([7*:=?!*?EPQ0GS+6V/0S=-;\TJV M[$_0\E=)3%]>_)IM_N7W7^\$Q]O.A O+Y9O=COPTES*[S>;U&+HH$L\"T45Z M<&BZ@OTYI]5YK0EA,_AQ?&&Z+/PS?.+"_05?HH*X/'?LG=O\XM E5R*X6R,6 M#&Y1\F:!))AG8%^7'"A'ZH/]M*1I:0N9GVTY7YG<$K.^9&O+!P+Q+2/9[YK. M)*!)R12T/4"BQ-C3KN47]]:.#\LA,(6.Q4:VW_BL^J4.A$^F/5+\&+L=1U>. MA477AL95/\L'1R%)F $F_\U=>K_NP-='MG^'^=WWT9"?_];KNYY_@8!XHG&I M6'ZDFZ\%D[>"7'@36"*#V_6;6"!1>$@)X+AV;[1:VJ/1P4WJ7>O5]>A+2^O) M[:]D2O2%XNU[4&2KJT=>?#,CCJT.\4[&#<]Y^AP M3IPD]UUUZ#I)(.K8T2%_HF09"^0"O/D*UV:SU0-T$0HF!/C3\OV$A901W5HQ+! 8G_]ISRZP%6FKF*U8(+JC'N/FFWG JV?_:6ZZ.8A]R)]3OAIKC- M:+0/*EJ_KONP_#7F$!JP]T*>:K 5^A8MEO5>)=VGO,_6]!?O_<+P<'Z:"=P3 M""%#;=B^^\.M*8LE?AEGHG"9]N-^.CSBUMJHW,Y'3\Y?BD]9BF>NXX35IHTT MEJ%UV"BT=Q:4&LUX!WKG>(0]^7MR]!HP4MR>[:'W['95B45*T.6SZ6/P: M['?)F7-MK4&53>CCB:6.WV3F5@IRLD:==>L4VY:FJ;$CWZ-<9I4V"!$P\0@W(Q:.C$5QD=WS%>),M4>6& MM2*.S_%H7A&W3D]3XQF!HH,$,_#=?SNH$0=]L%4\]*-+N/)VRRM=\V"*Z+Y] MMVN >QD,L>Z\,AW5W#KAY[N8\+,CM^NT6[QKBMZJ/=7F-ULG 2H\=&$?0LQZ M';FJ#^O@/XMN^.;.RJ7L:J6M9(2(&3TL%B/X_.ES@-2;'W49HP0 MZZ 9LI\(M1Q%8)X7=J($@3=.9%1W@'_Y )YT]9ZQ3XB"_L!H6EO/O"?B=T5% MZ]Y+W+,R0R/.PZ_ZO&WS#XXN:Z]"0_5*VF>B54YT;MN\6'L[PO7VJ>Q]BCM"BAP.6Y$#F$1#Y M405%HDL_/!%5#C]B*3QBVU!O$C&]Y42KEQ,\J6O)A*;Q7G1WZ6[A912B<6_9 MV8M^A)58A4BP0%[8N!;18?KA<"+-RU)"0U*5\MNX]A*?EI.#ZZXSB[OX>)>7B:Z M/<7.?P)3\V9>@!T3.4CG\8?(*!=^!AIQV YL ^SWH'S1=P1O B>M'<<"WR/<_VB_R$ M@?G2XYC7-6]ZUS\<.KT8EGLR./ADE;1:^_'(A=JD5!;((R%XON,_?06HW^M; MWOD!PL4;EX=FN3WLTV]!TWG>MB;WW",V^]O';$UK>7VM)M%M%3[5_(DY[]4+ M110_;>E^U_?]V=(1F!.QP7*M7[H@6ZJ,[/Y%4FHHXCAK-5 !4RAOJ* MK%2'AW+!@K%.%(\NLYH3FL[:PV;Q,6%?X#^US;R!0!"LF+NW;,OGH*.$K*Q-=HET<(PQ]Q2^:^-K'W7M1\9LM[ M]DG\\)OD!&R[1B*JDO'-A:^>@HE_]B8,Q;-L!'F#2"?PRL7AI0;=9@ON"*R\ MYPEP<'AQ4BJ7?5J$-XI\"Q4)_MY210XCQJSGDWGPX)>&YH1,G713(%RX#1D. M^Y822XA3F\J59XAKA:A*>Q>MC PP?_6KNF$DI/RV;$+N#1@7;G0UI]24#Y0T M#_7N&(IN;?I]WKG]W'FK^J\ER6]WC%TI7.).E2<8P=0VH8#..^H#%BAJAN8O M^"9C/FMQ&2U0W3TZE74^H6B@0?JJ$7%WA'/-3PWWE1F!QKW\IR0O[*Z+Y0$3 M#B--68$$DQE8!"7K[)IGJZG;QXT",1'!*T_'=NX=3T=Z>KQ]ZD*"A-)KZ;Y; M]20R4V3-X;W3M-'VGB\P2?..4V.3O83/0!!YUX[R:2'D[E35I=*A! M&I@@ =\L962E@E8;+_/VMO2JU>V"\]GBGT?E<8W1#49Y$UO'\=9U&S1*.]0Y M>KX^?1]$=C8_CRK;LE^.:*I%!09>7/B5'F*CF=*W\"*4U>&6VC9%X.Z4 MZ\OZ,H_4/+_O1W]>>U^;=-&J1#:X/'"90[Z$.Z+KD>Z/!]]_!Q;KN*616""G MYI2Q96?]P!*M0VJUYF0G7$\LX@+PY9GOR1O:3]Y.)^:LO*^S6EWZI(&\SPOV M!01;LZ4 ?WPFDA>P:S7V\=-33D_%V ?2;X2A6N^#5%"""##, Y\>A2.CHDZ_ MLB/'-]9I7,BNU-OHH8-:079S2$>R\@&\K@4/2=7Q[L?RY\[H1O"9S="++FD6 MI,K9AF.J(<\'-E@@$X:WJ'TD)L]'E#K"3W@Y'5).B<9 M&16->'74^$0$8CP;PN,D=MKPW[\#8#8&K3O+3&ATNGJ\*K36?SN'=)HIK5U] M]M?:)%CVQ?_"NTD<1W*+5O:-4$;E)= K/CX^_):!@0$GS/ )QH^"7=N+0"E6 M(#YF, 17CB9;ASM1_S*^%-22$XOUX7KD]\/3L,O]J4Y5696K1PJ!!;6MB//) MKXX)0"$P=F/J9*]$>\"5O(6E*@!.Y<=VL.*._"CI>TX6T=7#L0;JYL>E\"]/ MZ^^9&7,_$@/*H>\#YN&K8\S!SXS)-8C.,$0=B_I"GK7,T,.LOI]_0]@.;W&& M,PZPE]U TMO_0E_55I.F+C /86E^S"FP0&G+>?@YB2O[JH.^1R@^>:\Z^OO#81 2X7*=M4BW]*49/N!ZE"=R7%U-FUJ"7CQ*6" M/DI IODO^$:1ID_'1M;U-8;.\KT])G:\YNELN(RAS^#[]XI57E-8?W0A(N8J M^GVR88X%49&7X%WKI3%/IDM_FO6<#X8$$-""G3!K 644Y M)G4)2JW,'QU>&*[FW&RRW;:/]9XR%)3F/=^:O*+$^>U!>5Y_A9,#+- E6S& M+>Q#;664&$EI=",/>3Z7B*$K&@Z(Q;R&NY<6H/SAJUUFKXX.$I^HH3TOM[[H M+.%X@T<#2AB2%@&2E*W)R&;VXN>,6"#\0M(,W*M\=5X^ FLZ7'I=_MO6_+E) MH=31)$(WX1)?5Q"S_U>6KM74]1'@V?.5<*/KS+@%AH5$O^13 PM?'4.^+(61 M&Z(6:MI=TYF9!J:?_XJML$ R$%=D$@M4Q0+U& A.8;OGCTBX*([G5J=W_%X. M40L5KQ ;\:U+&S?;4G0X)L85F'KBA/1/#_1B)?R-#M$O4W1B=M3# M;M1&[<#H!D47?]F)F&4.?$LY?^+""7F8?IQ M8T/67CX]N1_\:^349W9R?18T9;!YA ?#E5K(*&@2H4&6VR_-*T_@:QLS3J;5 M5?/\JO^ G- 5MF>!7MCO*'[V=(1$5:MI" !A5HG#'3>K$\>[Q\7:KPAX"PF9 MWA<%&:4"FRS0P3[F+\@,"R34Y$-S6ML/7O,]\!N&[*AL<+>%)( M>7BEA'H3[8Z3:5RMOU-QWF6'?8F44@EBR"[XRY,6D4F)"5);SKD<\>L2Z*DE7(C2WU-*42-D MEQ.*%M3]%7OC>K*YA.BO30LNS89/3KPA;(0R/G9 [D164P33F7..O4QKQ&V# MP%^F%>U/U1<*^\OWX(/7V0MNX0KQ7V@.Q*D5 #;DDBZP1),M.!JN^B MCSHS;;A%8O#<1@KKG_UPXR9$1,!(]HA-9J5%<-\KY=O>Y^P?O\.#VZU$Z \H MMV$A'93'L6=W)P;S>GQE$90=Y<[LHAI6M,,U[?HE?;=U_3<:'-530FSTXO.27<$:+T=')8T3^;8GN4J MXV/-2[TSZEI(2&/,Q6L/N@J-6V/S)2=IG\)V]![@;.>&UI<=%*5DY'Q1=\;TAHB)H9&X//A*:/S;^+G4NU"':-H*DA M!Z0N,++I0=MMBZ2_;N^Y"80@N$HZ7;D9.3$[2$_TL^R?G4XM, MS;M+>T+WZ!<*3Q?-'3/R&UT K^K2;*<0ARAOR9AXB#UPVS''B."6#F<2\IU*>X;7F%Y_DCN3$UUU&!^9*D R*:8MY]K4BJO< ML$=# R*G;!TJ8XI.Z8AP,UK]E%OUR,8*UJY"EJ:\96)PO^ #\62M:??0?0D2+U*:4G$R)]4V_M]>K=-5&Z?2E)]^=SJR:-Z\-DZ1C7. M'3.^2_T"!-#,4,U0J&=O://*K&BI4UL8-!9AHC0V3'J'R$B4G'_3_E;FG=9C MSN'JG'I&HXA01 \9'B)&25UXN0QYEFU<A;93[G:*/2RB+WAFZCSLO%^WD@YZ!=]?[WQG:.20A M",L+Q9/M@L9@A)HXYFGF *H,NUI,7),G@=N>\;X-D71KF\@SL1CT^)[BB?:V MUG%N7!KV.']'2Y7?ZE'A?#PJ&5_NR#9LZ#KSP#3SUU%(^Q+])N0^\+I'<-QO M0?'-C%,O"V0K!E$,[,M&ACYT=NCNIEA;YUOS(.EYI#X?W^_"-;LS-4O3[\?C MFFU3'[RQ:?@S\:=B=-J145C" IW83F/R2).#J(>&OT"]-L;[J'F,/+K/[%'- MGJ8130,!E(]=VU?2LY?C;;G+.'*SSXO?[$^[6BN*&$M)8(#&D M#K*)!:KT_$Y4.H#JFSE-T6W2,!ZN9.K6+O37V*90P<$J85 M>\5!':?&,_T2)W^T?+]!$8C%5_>U)$^*,'GX<%4F:QA"@S?\C%<\NZV?C8)U M'2;E]_1C4WW.<$IV>+X^9O%7\_S\DSV'#+>,X4]EIT(%?.2%1#9\N/@=/F<. M3(P[.?D_<5.!Z_3>R2/]FC +/TOR4SIP,(?'=PU>%ZEF@M"UI:A?C M-1+"_!4,H(C)R8TR\.!.1ZVV]/JAQU!)X+9#QMZ@;9;.Y=IIF?Y.^:SRZ[SK MKF82QPW=AIFGV-/L4&_J0T,MHZH6.BP/]10!H0YDQD(TK,71J+N=D?9/=_;9 MJ@J90[>%AP+C)!-BYB$I[<@)%J@*W[P1C^?Z0 M>H^'@7OHW.#P!_+OYIT>SI\M/GA206Q/LW#*"FN[JN7D1+ MJ61#.; F+L%MI2^Q[6Z9O8]!T%.MP,S0I.K).\A:!P@L>_%C'%MN_,N+03($ MOK3?5K";J.:S4$\PX-LW.=ILP#U4N5'I'2:)I\M(R=BZ=%%U59ZA23/;I#@!4U0A M ^,0<,$7+CH-$*LHOIR:.+ U$\5H62 MJ6;K>C3J/Q0V8U7]PTHYF\//_/'A34/%/ M<:Y!H17!.M5-Z[Y3SUS<"E\NG\U%X8?QY9<:TO"L6K!R$GMY3!W5IM_RZ. MA@;F_OR>)E$'GKMTH%UM5KX%QH< D\OAP:U?-U*^[HZ6_F,:+&>P%29@M,C5 M:+JLN-?:RCS02BX57]%^DQ^7-;S^#V8\F3FUMUJ)7U/]6:U]+KC/ =?:Q0D/ M6DNFW5O$572\F!$C_WP] Z_=DYAP?*_J<&9)+Y<%NF))U$-SJ3''H%7KD;1+ M\,>+6>*MSX@]@.G7,K?T*L-.S$5)$5KQ\*OM0\F_+(\#F:Z4)%PH,?FD;P7, M5V10-'!]'0R11B_\/? ;!"+8?6_3N_S5"NZORR!-LT 0.OC'7Z02\<=\&5Q/ MNL&NCFG)G-R<"L1A5UP51DKK38CZ%GZ3*^,3?G7%,16S.2NHUEJQ6X_)'-U3,0&&%J\Q,5XI7]'CQL[\J%+ M3LVCQGX0Y*'\MC%1>K=+ >FV:@,(N9T-A(S->%2E>0N4W.[1?^4GFU75B^SYO0>^=*]4BB'3HBY!P M+;UJ1,WDG\O1.^-VJS:?![$W-$ZO9]5"/WRR MRX_-%:N<)LED(6^RF_U[Z/]^2/O_ZV>!J<@F8-AF3+3!::"*%(^O6&2*]9>& M*-UP53T3K9GR(G+XE?.!J=>ZHYO]E!42.(X%\H8E2IT#\*2G\@)N(G<#\&X$6UD*+_6IS&C$%CH4.I7(I;HE< MPV\%.G!%N/%6 B8&QQ:#SQOWXY1W_R-.67%^;6ONVD'35\SMU*#7M._8!@)? MW8KH^S)KQ]N.J#A') \+%+$CH?22^JW+[MD5-M9S_AKY[%?;&Q.C;M9WS#?U M[Y,1S3[]UKVS"FY[/#6N*K1 . O$%,1$48 ; P$UEW;Z,IJDK@G.OF?*WV>< M&EUR-LR^_:/\!L!FT#W?JNOG*^U^F4/>[6I_7CD:DV[2CVI%RG>C(10-%BBA M_O8G./8V%#<$D4%?>;\VU18EU717X)Y#I16L-=UW"&M[Y[QNMWDUK:;8:^%1 MH'G--RLC?X"KR54.2"?ZH;@!Z[:^8)T>E=FS5T9,H"VYHXN'30_F\ B5W2$9 M)S@7RJ6:V4Z.RVAWW$Y-N#,))F_,+L0RY8&/ CQPVYY>].UW,H''CW0Z2%"M M]LCL!QNG 'UR9"OX,/U"UN%(\#N]M^%7&:/'G;N2"OM-M%V?AZ6:)A,ZF[%\ M=%%R[6*6*G?IGP-5DE=&!1Z>9H%^VP1'K:V;RG_%+N,%ZJ$?6H"0^/;\"S89 M#38G:"I;3!]$1A:NHGOS!X'4I\^>(P'(%@\%.[%!K2%OK,[.8E;7+K:&$W.N M'G_H*1EI\Q MRR7=ERGQJGE16]F8R]B#/DU)3M S([%YD"N\M4.L?G0OG=[A5%R4+9O\SRKH MU &3_=JR=OT4@6,F!T1B6NN&GN'FV71WLGJAEQ(D;*(8V7+/944?OPEAFI4O MU2T]@1>WNYZEX%YA]1R(O:Y^:\9,-Z7AH;6,)] ?!YZ#""!0DQ#&2.CO^WP% MT^KU<: M7Z&KVV)M_]CIZ_^HX'YL:[M,0+0QU^D7EX[Y[1A278%. MD4[+%UE:27/IYI28U8E:B+@RJ:6K,V!*&SS]$/;A ?+^LG4&?Y#]"MBB>&[G M+Z8$'IY=6RF?.136.9.<.XU X[3&ML7.?6P<8YS[KT8G9CB.@,.#LTE0^DF( M(SD]BI)Y$T#E.WD+?W":VVK)CL_HW'U94>G. @T*+BH2;S"V&44H MYR;(L: M3TFJH4!;9R"4T)=Z9MAE.['HW!"_3_$K#NN%*7D9=G%SZB\S[S\H_T?T-)\; M^ 3] 7NR?'!^+!#'W]']PX.R\-N=MD48Y0D?\(W&M$'!'K;=_U*D.-.BM:,+ M#$IE!Q:LTY KC3E"E6%*FM!+/S?])^!%(P_^F-?DX@JRF5P+DD(K8'$6Z)[E MY GJ ]4>2C'U <4SQN\PHM?"7.%/^:F5^$^A+2@NK#PVJ>1JM10B_3Z1ICY( MM\046>0K/.I5IV^S,:_\]/_;$-$&F4?_[(-=*'*21)RI*7PZ 6E54JDR\7+. M]54+C.X7^,;8;MJ;C&.0L;%00@1J?\N?!5H5R8?C'?_3GO^#%<__V//?BFGH ML9L,H?4=\<"/CTMJR&Y8SJ#T<;R(=23F]:Q!44:S_OP&%(V/>M&HR"C]=^L> MUV$V:>:S.^']^8(2&7XA[YW Z--[[.6[@VE'B;>2%V9G2D@*#J'CCBHUMHN# M6CUB3&4;NP5&VY:+Q:Z=:D67=$;*V%S%B51SI!O)-73UZQO5ST$.C4]143Y" MB]/X+U8];:?BKZK;N<"6&$_Y/L8-D8/8H$W:$'2".[5,!#O/N!@(BGQ,6NT$ M;/A-->@4XT1G(_N!?!$%T[S4X6JJ::B!J\J;O%0[_] (NB#1\A5:MH9<&.4O M1ER?_R8IK+&^CHHR"69<%Z*.-D->H,4!R&Q$OD^SR><+L4>R1?IE<643!M3(%'F#E&,4X7RPOLA=] M?)I6O"&(;\./BYFB6G]E2GRYR[Q@S/6H CF$KY)_R0)Y]G$Q2A=Z&D8WM/^OM[>@35J \G;0@C+"@!"XGT@.*N\$]XL\:G>7H"1E;] M-GR@W.>'%9>_14*38")7(QM,6*!4MGA8;0SJ:R+^4HR^S175JCL2CDH)189G M]FZ;H[4HN#BD-+Q@JP.M-B+;.(2=5W5VOO%4_BO'QT__PARGAY41TDWAQJ-' M:75>Q(KWR^:_ M>6)Y=/6AF=O1KWWW8N__TT%K) +UP0+@:20'(1_@W.YI8!8UFZO73G^66T2Q2/K6'B"V( M4R_*"E3P%5'EZLJGW+^>6@X9-<$6])'U];(O9MAE6;>5?-S9#H.V+*P,"]E= M':G<..Z=@3P[(']\ C9A$NQWCJD];:A OR($:-#DV7UNQY%O.4 )A50#$*.P M"LKK@C@RVJC+!G]ZCR5_9X!RN1=$%-__UZ(#^IC;NH" M'A!,337W[YO94]S",/GWXZYYR'[HUYB7!F*(8XQ8"_:0"C/E5D+3)LT^+ZT\ ME9$?N-2TE*-%) 6><'YQNA$?9S5NR&.*TRI5'-DOMVR'F$_;=4 MA#<9%^T:X&93-H(P42H?=_K9[WNB^:",X%Q]_C%0BH+GQ'77R@YDA!5,!=D) M(SLD W*PM5V*,.HEJARUYI('8-K(3J8/U!6V$PUO?D>?ZW#Y8$:#FS=9;6FE MUX&.PP\-@Q-@9*<-0-:RB1L)GX-6.=EY_+C2!ON\"IRS+*BQ\>=0N\0_:P0&1G+""KM99) MB<,3!%87V-)A8B-^PZP4D^OB79N1-?HSSB%U>B/@0](LM5AS;/QME,Q!3E"X MFQ&BB[:?/.R^GWB-^HII^V%P%#D,KBJ(F4T^V7LHV"!**B?\D[.33.3C@ ?5 MM\RI=[L-!;0\;:(ECOD%$=C"3@C*Y*902 0N-F?U146#J[1B($@I0&IQ$HYM M#T6'))9F:_Z8DL[^1+K_4S;AW*U0M2CGLG90^ $C1#/M#*K9"TIXBZ^):>MJ M/(KLQE>A$XFPD^U\J9T?+//Q2S4BIJ>4I)U*=NJA/CS_E&W6S%YQ:Y++8^2S M6UN.)]\,&MLEI6-7)VG7D:,SDN3.1&4$1LT8/;).<'CZCSK*+VM&]$SYU)=2 M@]\4>H+X^FMOCJ5:Q2V!_82[8B:4.8(Y8* -8$D+'8S@3NLEJ 1V]3$O(\C& M#U=AS\B8'CAEG_:JO#W=I%OKX4CC' .+"@P:5Z1R Z$"[9836Z2,9$*B\/+< MI'WOIU@/-/6NUBE"3824SQC_]41Q[SG"+:XO5C!MNC9[4NM0S9I(1>;/,/Q: M"@$SL=*RA= B3R\[K,Q(-VZM-C8_HB&^R=9\3](9,9FI.];Y?6LST@% MOXH_]KDWX>!EKJ%*NVZ\!(I0C2>;0<;K7"G)408:S+%+4C'%<"Y853_B3EYC M)DI_.G^MY3KEVM?6P WM2;XH]+$E*7Q.IK0NK%J++M3'Y.ZB'8 M7=):\Z%9 M+\X(#87TR-8/JK]=A6B(CRN]?9U6U9!PPDSBIB%GRO"=N*^'UK1!>P9QLS@O MZ 2,(+\63,98 O,T#;K- ,)MUOQ6[?B*F-Y\6IB$7N 7CO:S:#&M.R%]I^V" M_W>/G+:C*I/I(AS4QXQTG&]X*-47^$#>;F M?#TB<^M&A<3"_(_VAVX5$L).YC;MYE>5QK7P=GMJE])]^NVRRPV&3@N^4!6P M#L?U)[HB1#Z%Y2: M\&"]8M1!Y@!3\@75GW,0<477)Y2SCWS>Y16]@P5Z4%.FL9&QJ[F;L13J<\GL M9)R8CO3=[NZGAP2;3^;JU6CDYD;9T_-PUAX2!G+"J=8P.:3WO\S( ^J9++1/ MC XT:@*YS;N0##/]^T>JG(STTTW6/:S6!W0V^FX &Z08NG@=&]0X )<%& (Z M6*]%HLGTG"$SOU;OZG(]B5Z]IH4J3U@8U*"M&,'M?_'^4 G['"A0[X+C"@&D M+*1C'M7N?=K$R0>UW@' W4'MN/%)$K[)W(0&(<&:L2< V_LT-^9,OWRUJ26- M?UGXRGI>I', RBFK-"W?K_;QA'%-@=.,H[-*V2[7_75@ Y7PI[T$MTC#%A%G$+L>71N%.@UZ5.48E'5_;MW\$D>6%34:+U;[Z=,^ M_I\STO[]N";2SC+[]CK7S&DWX8I45/^U"+HEMM4O1-U0*6Y$% M:E+\Q58"S*/I^RSR-)!"@DW@88,U3G#D?P\,SOT;&,S2OF:Z7:NQXO[T6:^: MHSTR<84I5$SG7ZTY0OFVR+;#QG@[ %PF!?[]&,6SJ&D@0E['2!9@"L;;_=Q\ MCK08\GG_]S#DHSAC#R/E51"'3%J3$.-X:EPYU+%?>L%RF(0EMKVIJJ\QUH5<.8B(W>Y^WCF5 MU4KNC-; B_I5SXB11W)DI]>FLL]$JW3I=^F#.%(M07Q93&62Q$SAB8=WPK:# M9.:[S)6"A-8[>FB3DW4&7& 7(J7\3#^;< #!*^25[\/E[Z6-+.:[)%J=/1Z_9RZ_E3_ M>3Q!H$F?EX"-^;NY7E7\K9.:]*&&LIG;=^8 W3X!W11V%+DS.QKS!GB2VDDB MHN7,C&KW">+"\/8XFR"F*7:/"!L,%+(-50 XX^I&LV0.-AYC9.N)A9A?S_]3 M%990JYD$/JJ;3$(\*BM:GM[C-S>GF3$'&OD9V?4G0WI],E;NU-F:BYN8M$[] M@+YB@9YH_)C"/^\Z;?(S'%A(I+T2Q40T+$H@)_<(";=Z9_DN%:>6G M)1,A;3 1NBTE:B$)$5SJ.?(0X@+C=2#.+PB0XZ*?/!O$-_Z#>0[PH!E/P5=:U:ZD M7'CDL_9DU.G(WQIQ^3H>+EEJ& \C89]UP:=+$/>(F)C;YINN2_V^PHN6QE'T MFL[O)^09%)@I0N3?@L5]XS-][7NAS981>UPQ 734Y]XB^*^9CL&YX?5\/IE4 MC_N&@?Q-21@54A8#%4.!.G8KF*ZG8WHLNSNW17C1XU$E?MR/2B('K2JP0(>;$"*43O9$>D(YZ=9#=$,*UGH H5B M,*XPK=17M*8A<_7"HKJ_+73;.Y_C2\Q4:KB:Q6@"A&A'D3]P%9#FM?VD#^AS M*4ER323"7.-GXVDR-=W;%G_KV2OA&;=S,AG3QR]XR:]_XA!*@=!/A%)/8*B. MX#+]SM6Z61T#(:76*2-"T05>1T/=[D%U2FIH)^3M:HO174)9L] JYAH2TEI, M#PT"=$*I%G4 "T31I3X;U7-^+/YC@VMUR4==4U.XSZW(OZ;.QSTT]6KIO-G= MMSGP9K8J)IM QX.HCQ@?4(0:#/E6SC-29[, '[R;= 6(E"U(T+/,;0^7S+/+ M2BI0OFJB6GXXY6ZL&>G!+9MCHA&,ZHG^T3B]'JM*FVLUF&NG6F"MY-5G_4 L"A0DM@;J@[9KR" &W#BR,\ M 7URL#$;8-E:!Y^_D1328'"P8D6+9[.V2T7FA:&YX@,N97,0DA/5#,'YP6)P M7Y/IQTY0LRA]23BO1'$B.K* .1!YLY_.0:P+^38@^QU>67$HT^?L-^^/<.G, M4SUZ5J4VU3N1U!(@@F8(7V#R.+!;O4I9Z.R38OY,\ZWM;%^)@)'BW/286ZFF[JK&S>_.=!P[M?YD_5 :#3L+!N0AJRH$V ND,B.;KD13 MAAM/-J'UAO*&].[-NA7$7M@Q*Q2,5/\T1R=UORKF.^D]G'F(P]FNQ1(XBZEQO3-5>TOZ5/W)ZO^?G*_B/Z M:N1E,'M@15@@;Q;H./TB>XS+D3,S_ #D*5G8'BG;YS>K?W^+FDXIR8PI5?\K MUFWOF=$T?5UXN5=&-?#RE<=.FAU(\'L4!^#5 2. YF32Z,9RK XR9TL7R.7&^=')]J ME:6)&?&E7+.>]%'TCW!ON@/[@B/$0\DF9AMC*"9W,Q;)1M3J+,"IDZU&T,#G M+1<*]&7CSZ!*LU,+T1.R90G.A1M7&>\\()7WC?\&?[W>!%98PI2#V0]-Q%.7 MV'3.!Q,');.5V]@O82" ^,P!(9*/$#7^.J1G6B <[35X)N$7WAMVEONXNO.1 MD:=)1^XK]J((F>C]&O@(N!.3QW+_9H0T)D\-BKP\V69-O]I( ].5'OK:!IR@ M&=ZFW7QB]HC[P:TQ>LK!5;1QTV7L,&H,-4F&"'@!PT$0 D\L4 MEY=8Y>R2E^AE/U%1!P<"[5KY$7&_BS_O73\4$3<.[+"?^,!^Z4/F$%1<">6- MF^"@ZI%A5;I )]>WPR]!G-N>3]6$\'\) YSBV2$R^WRB^ M+G:C'J8U/WS3GTW*Z1JP6?]1S>RKW(SIVPKOQ3W#N/KQ,GDM2Q#G?T,)<^"Q M#5M&U9\!(@ .(A07Q*&$_9F=\8ZJRVZ( MCT.:?D5=L4S/P=P8R6A-$5NR84 MV][#&&]/4R2QJS1RFC'YC:L2Y>3>QBMB?PF]JG'($V3Z@"1S^&YNQ'.5)J$< MF@VSG04JQZXU$*X;B#%'P ?KH:0F7 9C,.0[R<"Y3/H)$>H51@P=18FD6C/0C4?H7K@&(/^#CX%T?^6TZJ^5 M*[!C#5]&GV1.Q$]^B)N=C>XMJZJ)&?NR:"I-LHRM98'6#CQES]86(R[$U,K!ZS2X"1[T)W8 M[@LA0--<9K=<)(H%<@]372=<+WU6 MQWFG3#@7*()S[U3"]F#B+!;!-]S=;& MSV!<"'_@! $LUE?H=&5V$C?!:YKE]RR']T?E9L#V0+GQ)[R7\/R;XXX:_GR* MH^N6K4'C\E1_ $K)[ !70EHAD;6:\208N#* !#GN<-EVP?;^6I7]0^;%GK:A\#%&P30I M/9?/_N4%&^'[()DYCC\P0"N7>JZ>D= (ION4P28Z9V%M/4%"=*MPZW H@;&0 MG0?X,DJ&"RMY&^ICQF4;SRZGY#G(2X,_WEE 5I_B,:\9H6YVG[@H2?@T]FD-6[\]Q]/_O7:#V'[4->M@K MQH5B;9D$KAQ-9BIK]&=!CP&X6PU5]X/C0W-^GM?/T(_3?XY=W* V "^0)Y'= MF.,&,IW03.580KCU^GA$\U;JB.$IKJ'&W_J]J(OI?RUCWV8R^V)@,VGTXPQ+ M$2U,,]A6"(^09'R&^D#&]V8] 45*3[N4F%% Q^B-$8^D&F.E7*%%A:0VB>H")+"#>4ES+-]91CY"AHH$%,@#HF[!(NB/_7^=KSG MDP_N7OU=:)U2Z5CSKHI&> C9CLEOP$A#^,R-T;T!/R+FT+2!7D_V8W/K;JAS M_3,YZ$LYW(E%;'[S0\PQPI?TP) )OVP*@#M1BH8*6:[!1F_O^0**M& D&[X> S031F<=#_+5+!M036Q7@FWPP#SD'72FCZ3R_2 MY1GY>K?O^1S6*U%=N:55[G M)T\SD(7;WXV0RO3]CJ6B?)*Y_]I")0SX ;<.X:[GNV'NY3ZA@;H9TKVO,/?$ M1D=AG"@"86-,EVB7YD'A01V'\U/(Y9)!IEJ:=&;]_L"W)IU^?K(,M:7Z8 M*>#FG^[!->&Z0=RF6RS#Z4J654$N A7UH63\++Y=\FB]&D6MR1'RJG+T%P/J M,C!;%U&QG%H,68(I(-@Z^04_"]2LC52++=UF@5[NHGEPV3)XN.*=9[<$_)VZ M96JLF*OW&], ,YHQ_2"PVQN'?F>!4D*^CMUT1CWEA-B\ Q8HK""[R"ZCFJ M87;J$:JR_EQQ\;5;(8^4S+K$6*#&^*0=QCDKF%H"02]-,-0L*WLS%!:,(_03 MB=INRL5?(%QSZSAQIM>FX:>EB>B4<.5WQ?;F?L$<;] SQ+/)XOP?WA B5WW% MF,5("+,75H%?.W#_,0N4B./4@Q#SQJMD1M6O!\J^0I5)*\#[:E_[S8&3P.1 M["H71?=7(_!0)+81/-/HJ/)A^<_RZ,/UW].QXN#5O%?Z%[6Q;SK@S]Y9U[4. M)8QBV/A\!T#+24>IO!YY,X3CVL.VT8]]Q-U@LB5^!;1*_J7>"@L4 1/54R+I MNG>9F=_04<_NW.8I['V)>9+N1\*RWVDI,!E*?;15".!H:G"L>65-7\[G29^. MS2Z5E6!_]Y=("%N8_ZA <#(:N&5G1F%AM71+ <$,-S*NO6!@HY8V$I/0;R0T M]_[T 7F0._H%K@"V7T9TE>VN^%)H H#(K.:'_1,I:3?%"F/O9 HP/H30EJP: M;C[+D-B[JDAFSX0(C4VL6FV9,VANLG%^(2/W6C\$.GN:9H1K*,UZ/UC, MMH+F!HL_,^&98:F,%WU<7(^?1TO_?LE_9>=@P_%&!T8YW;"8;@A@\^FRY/S* MFD=+E BJ]V&SJ9\<;H/S"6>ZEKY7)/E-D>C$IUJ\(SD0XA!CZOAT=YC/G_2) M+9,!SY!I/HGWH6$06WAH#$*W!%[A5$W>B'F\I+P1.,=]2)#?G@6ZO*^-#V71 M3*@(!J82]F)" /-P?MHO\V%R#?[ ZTALNM33(P+(+\:6=Z49.2R05XXTX5IK1FZ]"$T;.%-O0A01N13UP[U_^]7< M0;/OEUF@3JM'O%#_B*[3HE#OY EP,ZRB, +?[BK_QO*IP=S X[=S!YVZ+B]" M:R-/5Y!X!!Y=AF:!A9E*P"C)*W&]_BFIX7I?Z(,G[& M4DUE4BVGO/YNJTX@NS.J8$RS/W0:!(--:W>^;2F7OWI.=\2/!3K@LJ^>PX+ M[99Q:'6@A^2$DX)OV&AIU9A'6:5("";7G?2CG_M."#?MDD$_B5/<7/H5XKF@ M]637BRCD.U1B-?1I0[XXZ-_CE__# " 5/*;6[M6"JM**=G_ZI/63J49"*_19 M;U2+ .WO5Z;0'@?E!#6.@4$> ^I:\0+,"X@0*ZY^KZW'"%]LJ#B2DP#(Q/(C+,R> #[-])Q77F+]&2Y1-J:8I MR9O8]RA"&>XK5P3*'0)< *^:4:KQ1%PB(HADF0"NK%B64ARE>WW)3A-J:,3] MHY&$\3MU(&"M)'73OO^PA8 SYQV&R(N5X+O+@VN*C!7F@3T6*$8[1J^Q"CR? MB@*.LQVIY0SV%52P48J]4*,VVB!QC7K]]6K_^)3%:D@&MXGEV=H^*7JM9:K^ M\U.D#%^91!:)>9 Y#BXW6;/46*M9[:=9 !S$0Q/WN8;NDH/B5W<4E&S>'TY1 MFO,TDB$(@Z2&_[)]-=<#A!RE,Q;EUA>-DAP)5[0E"[2P0+'5>[@VZ('E&6ES M#3T3_UEK;9*7QY8[R/Q8DO[ 6NT3(]VCB 8VBT%1!-BT H%J1JI#)SJ9W)/D MY&L )WEWMK E,Z8-)9#WO6)P!RR,=W9R:99N+YB\WGTOL33@9^HY1684;_6X MW"V<)S(.=3E]_[AN3>8J-)22QA2=&*6V C#Y9.28/PLTRV>HI^@YM'3S.$%/-D!E2REP7C'ED89&(E&=;KV<,'@#D.Q2>NA]UYB17I& M-W&NY+.SL=]A_KUP&?H/+!%:9;+:2M/L*;A" MN\;L;^0@GUBQ5@^[!!]LISHZ-'J<5FU1]K!43VP]$YR0[(BG++1#HW&\C9++ M8!&D-$ S^4U7REOZ0[.F"!=_ZN1,K_HJNH7V.G/P;H($8 \I-VD MHX;5(9-.1#:$ZI!0$UPW]U,4#FT,UBL02BQ;F,+)CE(2E)SI/&OUW2.K_.@" MKPQ4];EN1NZ\V)1TY6^67!>A0%&?EV7 ? M+2;?%A0AI?:;?F7VJ$4[[/)PO4;H2:K:Y;Q_!/6N%9PLNIJ[GG[^\NF(@=__ M7XNC=E#PF_GH]?C7A&_;]8NE[3361 M2(P&3VHD<\5O4UE(WGQ&N7-9B\W\="*)AS'S]LC?^(JD],^0@RZ6+9?>9 3F MTF:N,;V#MU.X!O/_Y:.\.?NK 6B==_2%G0Q"B(8K@\HI&6^H!*F_:&D9'OV) M*[ ^AM".O;(>D4_VS=QGR 9DV(&QJZOPQ_Y3X,8RRF:&$T@A;Q"3XAIE !_2 MM$B;8S I@!GSV2B4N\\2+>?!\//%I5MR 0L=> &-3W13@L IWUJI7)&]8@;X M5NJ$^YZ>_RED")O,[1?\ZJ.?M"3TI?E!.J[37=SX5=Q(YOJ04%3#I=5OT(2J MG3'(\0>WR]NMWB"(0YE3JRR06BTZP)S^L*:@<%O4"&G[+UU]2]<*9G>\'UKA M,O^!8/X9KF7CT+QS=F+AGA4+%)#56 YI,(LSI!1$1 _:X41\T3L.NIV,W=8M(%X>1HI ?ZTAM M9!.F+&8-O&!.R:;ZD=%EH0\QNC8N*@'8;.CV3E!Y$!W9^.^-8H=_([N0ZEM8 M)A?=E@)[H9S7EQGP='YYQ&H/E/HT&!DLQA#MW\D!MUWRO_0KHM@)YC EMZB\ MNN!P/R7\SIO7)K^'LY;:Y]X9W\>Z)G@@JRMHPQBBQZN>!Z=*?&];]GGMEEC& MH0@I./(-)2^#CUX?.?\C?YKH;>KJKYD M*G)TNR5\C5/)0/ 1GF7-&O#33\4WA^ZR0,?T[.:GX;E..0NX;UR/)F("9JY= M8X&.$$[@.;X>K-M3U#-VBFHG*=SW4_:QKDNDFB_U!OTQN[8GM_8]K^AJ<,+\ M8- 6SRS*&YS,Y&:@]8[*Q],=H-EZ[\PA9K%-&53_\.%MJV:OQ=RAUWPX*0-= M0)H:3E:?4:.DCRSHF.M:Q,;D/-/4OB89\R0P3F>;:TN7!.O BM.?4GH[DQ!! MX8UV?Y64I.6[*F*@%ZR2FD+U3;MTY.KK:?J%Z8/4QSN?J9M;J(\,@30B^EQ^ MJA55W7_%S(->7,<0@9F3@$Y*? =>HOYA, DGL2P5T-89T%#K;N2WSTZP'J)[ M^]S$_%&E%2QCJ,BZRD2GKJ8.*E#B6'KVRV>;T+30@/4Q*R.AP_?^)T@#XN8Z M34B*KL;(_H)J]<$%!D[P$KD[,(;8%G-FQKX2.XXCF(PVSDXL&1._KA@**^'T:S:G&7OM1"-'][(^ MZ[A[1SQ'F2)FW_ M+-!E&1FXH&3@'(PN3)J%TD\F=V+(%G]QGN C] N_9P0$\;[,,U48&\K-%L6W MI!AW;O$?/+]>9SR>^"H=*0U6/D-3,D(^1WY%/DT^O']3!8J0C^'!^"GFR.>N-G2.X"2/D,Q\[1/0),N@+"8XO^OD9;8%14\V#KKA<79A/WF)N M4$/9G2#3?=D_W8%@YI$SI>SOTT'-2I0/[O0$0%V Z2)X]WAE9G] %:3&\-7O M8T\NM6YURB0M';'BI^JB_ND^Q\$VSLEGS= J%J@)/!8S"Z.?"&9R%Q-R/%&" M0.2U0?IAS,G$ZAZ!@]ZV3UY/.B_OJA[^J\PG?>QCSGQ/>6K_9]POM@K'TX_W MM>W7X>L0&.LC9JZB:+++>%$#461?-5J^C%+SXO&["]EV0Y J)\%C(PEV@2E3 M/W>Y>E]';IZZSR-T<)7A_?&YP7X-BH/(3I@DZCX$D#=((6.H<>2?!E(4N4)B MB1L,Q=W\5+)E47@W4W:V'"*HDG'GP(^K5]\=63X:7OQ?D _\]R_;RTM;4) M M:/%$\8.PN"<\,R2:KC7T)P_]*G8*#.@<_#&-;!$[1$!UUK0Q# R!,5_N_3O+ M9W>0)XB<+-"(//,41HO-FAH0K]FKGR*/_I^56PW!\"+U$/X N CE1Y< :HB6 MO%,B?)O>EWZ.--[;?B@.(HU''&XL^Q>CF0P<4N2IIJO&* )*JCM'_H*6[A_1 M:0F[,%)PUHE1*+"1!<3%;5]\6NV5B:/Z#B2G!N*?X"-*+NT4(8Y[,S+WOX-+ M =G'E-GT-]"E'Z6 HPK]%6<60ZU\GS3M>AZ=^Y$[?N?'[@K, _D+5=.Y&D6S MGTZ4)VAU*DD[#C%_#5;',3U*-CN^3>&]*UJLZNG#9PJ7$J/W]]*3:VCC+UG?Z;AO1A)H(3']LMR[<+ MC$U20X&*/\YL=280\&7#O>M24B(S7I-$-_'J7F#L^/[M(\;0CV/;Q5#O4.08 M(F=C[JDN5<@MIYUV]6)T;?]G:P3L>-,R43YUFDS\T0G[SIXZ&39]@DY-VBDG31, MQSK]AMI^?>O[D5'1_^'Y$F09LP^$9;,*@L>] M'^0G[S#T0TDX><4='*$WVP?/15O0C-#Z_AA%#C^KJ07DL& MXH4[]8;,9?KX0+^1T)[@WMA_9<(^18LNP?V/I!N3NZ_8]ZP^?MQ58: TMG/Z M9P$?"S3GC]0 5&#]*+K01C.6A 7D-MK#Q.H.QO"OWZ=3M?9M2V9:P8K"THB@H6 M0O+["CLR M V; XR=(=J\TX5IM-7B*V;+6(WJ69KXTZK,,8TS>K<_]331!+P%ZA9 DLQ<5 M].F^K&\P"7#'DTU4S2WL9.<6.)=1TU-&?D%W/FC>7,!\D[.+VK]8^TM@K33CUQLG__$3T7RT^\PGSFN,](FJ ML?=XZX(Q?T6AJ]:6HTOHQ:+W)%6Z86YL7*9G9>W&Y*9!S\=&.+EP[0XI7-Y? M2K:L9OB^I'MG&N1/K@\+U(@2V\;Q(/MQ?'3S:O$<\^VNR63%6R[QF-T..["U M03K>1+7%KO]&7\4@\\#RO8H$W(F/.1BO0KI VWKA"]Y/KA-_3J;JG"SN6.;Y MJG^%ZQ/V#/"!QH/L98%.ZO6\HQ^K55IEP[,%F<;KV5>4P"%H,*^VX5H7$!SP M].#4A+-,V;=N4_%H6ZE_DBKW)AI%CL;'*'DK0#2"BX5>-).6-N\K%&'5,=,L M$ @PVS?@/J)MU!\80I$2E=0 ZG)2G*6:83P.I8F'F\D/-(916* 6RU@<+P39 M3!%HFLAX/5^=.^-8WGF&!;IO^8T%NB.'<_XL:6(^6!6OH#[MV,);[)/I7[VK MPF4B%65_S&2DT4NT&> 9?2Q#8.X *P!&Y"T\/)T(N7 A1VN2F#RU0T>:D!*% M]DPHADSN#9HVW6A+>1O/;S9;-]HE(L;W0GMK\N)7E8C5#Y8-B(7]_XFD8%H: M/79;2P);VT9Z4K\&"F?:LT /NPP! \M\1+5:M)JS7%GRI0U)U%$V5T=HWFMV M6#^\?I&:LG$4-IU+2S/P_EBMY[%_3 @JH*&6"ZRT7$I*"?XU5L5K\NKKCDLK MGWZ'D=MHQ+GNXP]3*PRL'^3H?.MU*$TV9AN6Z9G_9#X<:X2,Y/(=S:*1HNGV\-']\MU!1S]5F9VPJXNCE>+_[.? ?8=: M_%?6B].!):$$1HE]S=!3B LAUGIFLP&&-\[4HO*<3$6@N],HI>!FC2\; 0]/ MR*1\=Q#LX/FJ?3JI U>\S/1!$3ZP0-P"3?C)2&),JTWUYMU*2OAP^TO[CAZG M#)H-!Y-A+HET(GH*U=HCKB[.BVQ5P-+T_&>D5KTV]3S9'>FR//9_V8XK@7#! M+5TI&_&5V(. XT_GY;"1?,[HG$!WFRVO+*,DC:FV QEW5:]SZ(V6(4=P9 O( M!(XJ]UL=*T1'D#5*,C*_S&CDHS\4+G^=-J$^CZ(7;HZ]N?_AK?O=*/_'&OV6 MW''%5T,^')Z5G+#H9N"OOI$_]UWVHYYR'!4_#F9R+]&LD9/58;^*R!S-FJ,C MCGQE1I]F\,L/'=O*?YSZXNLN_>R>Z9DK$RKO YW_0I,0HD1(C)3FB($4O/&' MD^\$?_'#0M^,%J.'0FW'U:WEYF4T)>W=C_-K?X3?O'->$*NMP>W:6R)94[', M?\+*VL_8P\KH,8JK4<(7?*I1"7":%4[[9.@32L0*CBU2:T)/OYU-_3-[QNYN M?3IGL_;"P;*7LM:^*HX-QU(#QB7FA78\,NG'[4C"WVE>\ 7JA=_("W!E?:^F MVI.72JA5):Z]/C[!?*\=?PKK&6]\XZWDDO:>:$._^VOUNV/^U L; F$.&3(8 MVT0DHSIBE,N3?RD/P.1LEGYAVNJ8XK%&)^W.'#!Z)K)VAR9$-V2D;$,.^C$O M40JCJKSIJ%E*\5(*$'S[64Q5O'] ]8/^?V['VG&:*9P'Y ,,:8+('XURC)I& M@W$$!QD3[Z]N5M?#FUWVR?=B? MJY]NZ=,58"F=6WAC@(*)#JP7(1VU:QX=%>PU2"NR]% O\W*KMU85=MYZ82>M MD>V<:J%4X%5&V[\0QFS_P/_%$;;>IQ^880RA)75 MK-TFUS!Y[M N3 (S'=H!&A>+V61.%/PXRR"O.-5.[^VD+BF(:-P\=REY]!M, M)RD\8B_I#).9M>M$LV*!-$;G:#G#"B8:+30%U'$H[\8\(PSM8.0#X%K"<"\0 MA@]G&WPE*YP:.03JSK) O-A/TAAF@Z?=X]QSINWKR^=E^MH?7TXP1=DVW$B^SARZ(WD@H%DMMG8>L%HYF6=6[+03R(9X 'L;?,$*OT9HT% M4MY[M9D4KG6BDG&@M%U2YHI,H*B]A[W$"T5BW 09UV8I#E=I)N-CE0->2_P] ML'L-^6D<-M#@JS.5D>ZV!9M[-A8HFS50#_F#ZV*!L@P:/]9#6C!5C?F')U&B MP$-ED0_?OP8D[YSK/,3@&R]JEYS10/:9 ,SH]899O !0:)YF3#&(\?HTWL,L']D; M]TQD?FZ*=!7:=PMU- -@Y6<]N:IJ(6H#)F/P3AG@#7OK_H-CG,?NM_KM]KL/ MX&,3]2<;;''(1?A4!>2G6T]L7N%RU5_]T2X,&G822LC"@1&"?UP![3&@H%?U MRM>TKF^3R_=?1V#%_M33[=IN/YKB 38:P/2CVVCHS[B+C//H9I5#8[ <3\;R(?S4;//"KKL MB6XA?ACXG&XG@2!PXU_"?:*&&@\\^^/J7:N$B_V2)F/^T:SVEOXL0L?@!WAE M_XCLU"A7<8SJ?W. '+,5_,?Z'JW4F*'U9S>0XDRNEU:V&B[2MK^#Y@:J>I6) MWJ#\15L=_$Z.81M><' E7HKVJVET#6I MQ4HSWN*_QMHLD-U<$5W* QJ%3![M1)%-6:"#;\HH7FUUKZ C9H??^1*",D_B ** B8B @!!!$1D#(C)$B(I(P) @ M,RI$4$!%B(*(@!B99T*8!7P0 <,@9$!$&1.&>$,&.GRGO]5O=Z]SUCEGO?VC MU_I^5%9^).NNJEU[[^NJJGM?X-Z6#L+(R4MBO_TEGK)#B$-KT#"JIUK[+ MO7))S171C_F]_2@Y 8*.0I,6'=!>?&+ZDYOW%IA@[YIK.?Q-'[UXB<8J%"/N M[NS+<=FM5#C@+V'G#UUO=>V_G2CPZP#4_:CW6O3,%BATCN^R!3BP_3CM>M8\ MO(ZS/_^AWL;OC5O_Q)#G4%IY/K>$#Z!$ MTEGX_1O,D0Z.4(&N)2@I;":27RMR]@.*_U^Q:(T7T"7H%?N!\*^4*' MI]2:+J(E]'AB@ M> M!MV_7:9A#3YZ-GX/1_M]09,EHCD4:I!YR].F;N"V>D=HZ]09 MK0.SO $PXQ(\86HG\)0YU Y6@D@$YZD#3LP^.''8V.%0[Y]#PW>73>F1$M-F ML<<7GNU6(N]3/%;;:QDU?^)SL%VF8H9C[JDOUO..+G9'X_-P-D8S)?="%XU" M%AF+70:_/8%G,0C.K<#T>?#4_CSJV^>=+@R3R\X:X5D&$< M^$ H.-O,)=OT*J?LFJ[=X5=:;&+DQ[OTG-GJXL)^[L2X+FMPBJ98%9ES!0:# M>N#(1;!B&$G=X*0L%?4A?8CB5RC6-*)CT3J&PH8LF.4 R-S+.CM^2C[]O&1/HV$ M$KTF_Y\7%=Q2$FDI_J&2QEXY+U*)27B&*RPV;]^VV"CZ$K=F&:*(>H<41RV3 M) (;0C,E)Z(KA OB''#HUWV?#IZ _;WZ1!EE3A9AJVP76-T"!8#W\3XK$A:. MLV]Q#C#%'Z+W':X*]Q*YR,CM#XHNZK]ZZDR%_?[6Z/X#$&S4G,L#:G':YV!Z MH;%V6/VU _[:DUHZ5D-W!B?=60WWH@7G?'],-#3/!H26E7H&D, RO %*E*FUM;U266 MP8R+AJ,3) )_05")W$).!%L&N$_-[L"*HCY.#581A.>^PI#1?OKE[?7?IZQ3 M;8_?14[I69 1U WDPCP_2FEMW\L.$$^#&'\"D&QC5($% )N&"5C2&GNJOGBI MDS/.'4>V2-JJ.JG'1NPZ5Q!T?LQC9L(-S&?B2.3H^!!+D!FPH,,^PE%E+KWP M*P%>#KE\(J,]WGMXPNX?^B+ZU/[.(9]/-:-JJ"/G\8ZNRRX*8;8GEH<(CMDMI."( M@;@Q(6IM7)-("&W",!DCI)B4JOGM18;7.8\QJXCCLNITFW.9$6()JZ.N=9@N MJ!S4]R[?OGGS<+Y?D9"CO>VDEY08:'55LWA7@W7^Q/+XJ#Q2K2'^0;VMZYB: M$>XY:3JRNXLHAZ5^B!(K9@:PPH!.QJ-6Q;?\8>Y"&ZODE(XCCIU+*;ZQYW7N MH<"QWH*.BO?W0*G4Q9.=40/Q_$Z6P1D.T 1PM4;WHB^CDF7!; (G1G_3!F- M&"O-H\K5&0QGI6ZERJV5CY.:O" MUWM;"G".VX!&L'=AOE[!2JYA(:OM#8E]4/E )Z+<=ZN6E=C;L]:VJ(FT.V\3 M[@W$.KDF=+J2KJEY/R[3;BSB8DYW"_>^&BYH@+XCROR9VL4MANS_ Y9MD9J_ M-_[*9/..]V_3S$9T[:V3DS.O5L2=$DFN@@?0(ZMK7_N0>A;F%](>NPQV[4TG M"=XS9LIQ]@_Q]O)3I.CJ]"C1WS 5HCI&Q4K#L9W0]UY]*X$OGR4IV4+O".<( M-*K'0P7>!G.MN84\"1]B!T[,G8']:2"*V+@@])OR8-V8'2JG;)E\9R8MO\SX M[?38W[7%F5\O(M])GAP'>[QMGF$:DC?__$852CMYSO;]YQ:>LEP"1!]MP;@Q MN@:5_*&O]^W[O=5#W:^O]( 3]T7!$Z"(>+,0#H*6+VY=/Y2CQMM6/1LC[F7J MZGU,,Y.QI&;EUMI@E(YW^]XM,@D=< %X2605&:"0"E;^U".PH+J9+=:+!4HF33P1H#:,>=@1UK-2W<%;^OH3,V[+>N939F M'BZX+]ALCM14^VW=*->D+]BG?-X^UZO7W:3#=O_]E]\??]J?$$]&Z,V#'W^^'G6A?-"#2?D,8>:@T_VGU"C9JS-_U7A M*1TAT;= 24:4$/R/'G0$HY%&[I@77QA(ANP="D?%/L&'5KL&;H%^H$,ME]XJ M;BQO;]Y,TUR3T7W+"3P=(F.=]-G#'K_6B/0QD3C$M:_]UI*?7]$Y\UST#I=K M1,$0HX9GNW_6>]\@C@?I0-C09C>>UB],K^P4N7VZ3DIUSTJH6Q$=H\F+^ M%J@5,:*CEG;2[VK^F9+7NUSD06(Q>]W9!XSWT#XQ"I7S,]BXKPQ4H _CV6_+ M0/66&1\^ O-[^^\LIZ '[<3(?>4@:2'V)(S6)_MF$]>A7Q7#(=?9E1:Z\C\M M%UR2.8BS#QUT]$['A6W<4L*O_BV0?I93CDO[74JBIQ[PJ7R: MS_^E?S?;KF<(FH-+K.V#TC]61A>AKD7?&(=*P/\\X3.X#Q=*M#(T5!/#<;>= MXGH.J&1NGF;K8C[S,3P2T(Y(; IC]+$P@"M3BO1R.<'(*2)H&BXQ?\-"^]I< M1I]B+T/[Q^NJ^]*9D]4/!'&N^KV(&Y6LNT4RA].?5F9E#]D 8Y$Y3F]TEP:# MMT O-AY919>Q%3$]\(KL).@UL"26=)9XDRO>H:(YJ(\^UV"8A%:@+9X9SZF/ ML$YT\[]R12%R#^C8XM57G)E,*T- NW8AC'T29<@*YR^0VYANULM_LJFXY%2- M7$KB>E_E;#MOG=&FV89PU'SK;->Q"V8=">C.SDQ?,U6@AN@@NS*7YX9!C>8W# M-T^86GR:L?+8BYB=P^0_L$4]?B#^Q'T"$=R^J!XY'7*8??$[/R 957\K0WN4 MD$I[;E)'/OI79 3*&M;U?II\?R!@E^U&Q>ZKH@5RSP=+KV0^"WHW$4JN".UK MK B=.O?MC6GYLX(*Z+% PC?X&(4GW,U6055: T<92MT\4:;,%N@QSYASG,BT MXYRI9$I9BL7I6LY:[G 7/-I?0M3+/C6YT&HXP.\1\08A#B\$O?XEC-7')7#T MN.5B+5J#+>(HC6J=1<=ZS,ELY_2R276V1KWRGCA^7M5. M8N4 H5!_>.KF^, T3O3/Q-W2/O*/<596C&&_Q_+ _K:6R+OC6Z"CDA) J@=% M%**)FJ:2.PS ='P[H^[:V#XV MB7YTQ*7@@TH&+IR'".%*(>=4R$\V-ON'OY.53 ?JS;]23<X?[)Y] MN'TH\%U%>OC>!%!YOF[HK;G"&^X:_%*,?/01Q.RF7DV:WZ,W^9GD@.(_OI5H MC-SY?^8KR3SQ']$XVA9(%@CHO+<%"F;\:D2@8OR;4BS\MT"1402ZGG6+7E53 MXZ7@#D M,$>/F=VZ!4K9_-L&3G;WK?K>=*K$P?<]Z1_SGM'47FR*O&]FP[%/:G'PX46, M"Y;4 ?Y4$'Q"%EX+;<^5?U'FK'R\>] ";"![UIUR MI@USK[M7WL*GGV!S;# M/%3 +\@0D\6[Q8?6,Q>1^_OG@[7 M:5@"VH6.W(G*Z.Z"B#)W_=YK;P=%&'L$F0D]SW:-OP@LF)YX8&/JBRE_1#1P8_JVMGG/]P3/[X_M8G M87";]HT:.9U7)2Z_(J9TK+KLOK@[S-7>AUL21+REE>X0WV5ABFIXO>!JH0X^ M$H<+-46P]<5'V^99,8!QV/2C]S>UTMH6K[$]D2HG?E@(?LZZ'.LK+S#<0AT- M7E\&]+#)2W(L$"# /HZ+583'<#SH8,D3E0&,@;."N9J@VJ.6(CH"\1^1ER)] M1"YH3!^, 6"L*&X]%@$>@YUK89 7N,S*RXRIW&)/[KN5MBGM&XFV#W45[EU( M*YEQL? 1.'@YX(%G-@YS"NT+%#*U>'+B'; 4]ZY*>D+>J0*RL$H$+U3$6YKM$BNZ W[AMAM2#F 94%88F4A] 5>I0A ![>BD1W>1"JB1<*0< MV@F[^XMD$'G (#[1I&9UK/#P'_G>B@>S:1!/\&=X*I_['L5\4SD!E>"=!#;9 M'5&4T>EJN;\S$?I'9Z_[:.\M$3G:JGPU[^W+I^WX*L,N_!Z.,AD:L 7:Q[$D M5C*0*7PF1$;S4_FAE>M',^_U3#ZYAGNC,'K<]0%=5&R'5'M7DK'>Y9F0:JT! MI?L_*IRBW$YD?@/"E<](L@M-9!JOHT#.3>X91@-U+4M$(WXD!BH M1Q3A" &WWPR$3Y=%5DU<"B\*#K(VZ/CYTM"Q0:J MSB^^>ERR>-F=,_B(%0>T(QDG8&,50UT9'H!F-)+M/6]94Y6HT="T5]K6*#G6 M[9/,K8\+)2[G03&(UX 2.P0S0JET3:@6%^2( #-E0)CM\*_C7J-N=HE0H_>6 MND)75M[J2LLY?#A+,!?5%]]_\8VUM%ZQHS"B_UFU@YOVYXE,*Z/L>S,AA])A M,O*=UJZ( 3AIC0^QCQ&#"0DM8. @^P(_-%.7$XQU#J\-B*+:G8:,V"FOC%)% M3<05D:H@3]V8#H'5G:T?=Q<2B2TCR'HW)82?9YC7MRCZ_+):3CN\1'"+T?B&?Y8DO , MYV7@!B'Y-J\?JL"QJ&SUUB6"Q^3(=S@O9=_^!'7@ZP6[]W+36<1>T7CN[&ZF MX)%,%?@C;/W[->3"9YXM3]Q[]IYLX2D2;1XAC!%EY].G[MM.?9^33;OZZFUZ M [5T9^R>!8MW?.Z^?:[>M/:4;I,4@KD+9AK'&K/;JUKOWT7>5.D@)Y%_7/LT MU/;]5G;?%_#Q--)P*UU9A_,?]Q/"7OT_[]/MHH@%NK9HDC1JHGL\'+[QO'6A&U2X44(_?C@YC[N"! M,T A"R9B'VW^F?XM1@&DHESKRE67K?HO"W"H%EN8PNT M?:5I 7SVWZXZO2UB]F(:*H3RHX/CPZ$" -DJSNF;<8[PS6HSD;MU6)+H2I94MRWQM $TWQ8V.O)K!9&8ODAYOVB M2N77Z=TY"MP?<;@7$0+5S_#"A-_L;8G7/2@;UE\N_G"+RI2\/@=6*-?,"*W5 MW0)U%_[Z(?_C 5[SXHZ3LV"]&#=98BX^&0)BXMJ(2G-$,QZ3@^S?C\RN)_82=>:!'+V3_!V^L"7I1@\*!C6M/WZC2918E5G$ Y M,B&+;-3A>?,:AL,@[)N<;K]SQ9IP#UAFO(0EN6^!6&F9(LJ'-C[7G$9GSUW3 M6ER"R>K*\CWVE8_&.+2+I^CX_-V!QZC?# MNBYF]-")7C3/7Z=^BTS.V"C[>XO MFL:-V'\M!ZZ[G&2TSZ;3=)&05/6\]H=7O]KC>PISL$\*6J.*A=Y_V8:<8R%: M#LADT\Z6PX9^8T4%8LXJR^NAE 4?,G M3XKQ'4_= HFYHQ#VGI9!>\Z,DL)&GK,S;*'N@_D/V5<[K74,TC?/^M^ MWB7=]RC90/5^:?$W[?RS*[9JNRY?/&:K%0-:=L/LX?/*!WS<'F4HAS9A?DRG M[],-N)MT:=!8^^/B3W^-J_KIQW548_<(Q1Z]4.#]KR7+_INR@ @]H!.,^B_L)K M>+-^I5UO^NNE_C/2 @0K/PX42**"'ZF(#&'4. ;,EG0Z3!PAVS9K2[ZK;*W7 M:#8*LSWT4O-ZNJ.X[GEZS?_:BZW_V@@/^$&X"LRPEV"[H:QAXUI4[T0\HWQ- M1!\>Q/HMP)3)$#LT7=;O@UE8#^>.#2RQN$RK6S+!_IA.+.D&E(K# M,2\&PZL)"Z4T-)!KZ8GJ;KLG@>WQ%,AJJK78 AFJE79!R=$T=G\*5/EM*OW> MP\NZO>?]?6/%WQ!F/RRK=_Z\VGVV8FBA[VTVUGN^Z,= =H?O;&)QG^'3)0UI M)^]3_]/J-:ZUF%9XS0 .ZFLX+@(#ZFG8$\NV>-D\W:]9%S0+??I%BLR%79>[ MMD!M[4(S-X0Z LL8HR\!\W,(I\Q"N;N*@U&1^)AQB'T;;P 2[96 M0BP\\_I"68TCZ$GMO-:B'N-QL.PR$]R>-?92G4\YWA[%K2<+2>)NF;+#1F=9 M_2JF21+^I4JV[F_OOD*S-\.]W4-3CYNKWUZ#5-O>GZ?#">M#7QE\$OT)O/]61?- IE[ M_R11D]K&6M11KY1&GP?=.W=Z+==D\YQX:<2: HOPWC=1#Y6UY]#EU7= M'%'+=/KV7>%-A:2U8$>"4_WSS"7;8OZ*YF.]:OSC+="U@31X;40[-):XK1#^ MF%)9N[!!=?#K]-YCVIW,&Q*N_R1E+Y/;_-LFS;@N3>G9L7.))B?:7"Q[3G:S 8=DJ$FO\-*]=17 H(6WF_H%>W-O"2Z$<$#N,[X8"N5L+Z^?QM MC4#@W0 U<[D]^@Y4A7.FD7D.[^M@IWPLJ&A(-=/@XF>EQQ:SL1]4/!>5K)?W M<5.(U'(*"$OE^R7C/#P>7&6SP.4/9K69P5_+>"4.;X1Y6SAT','!OVH0IH"Q07AM9C%'5#]X4O2G7J M4)&*G8:)ZR&*]T,LKN>XC$Q)GUC1?G+\;7I%:KW/G+6%S$K$@AK_<32@G&W% M9RTE$'/N,XPJ^@!3+&7Z32FB80L47Z4<<3;O&W==R>Q98_55V@N9U5,)9:3N M0_=VQ$#/0F\. +IK\$J;Q46V.::5*-HBW#V]+(&^W1*YKC2*OJ!/;A\_9IHX MO$,D$C-L7M7T[/!ODNQ-$_0&7)+[@4BMI# N0<=6R-T41?11?C]LF 84$B%Q MLW#!=""UR85Y>,"VI:6BNN[H:8YBV-F_.R9C-U(.?2@9?+(AD@'QWQXM1!@S MBJ_66ES&LJ-XDU!!C@LM"".&%OL*.8"&PN0#Y:X<\^S/:IORJ$OM#[R./:Q4 M^^1]:PCLP#KA.40W$%N-Z]X"[>5] ^\E4E_SJ2_T)A*,^?9W_'NI>#M.#'5U M3H>:"KVPG[=$\TOYOO/F8ZV0-]XZ!2LN D'*[W?.(8&34)[(/C8,2.()%S+, M6#AN@I&A,DJ$A)=:-N*&SM*[4NA;H$]>0;7>#G-X,0?!G>C'_3B]\^HK Z/, MZKCKT4E,!$\$P11B.7(?Z&^!@@D3?BPAIE;[%B@Y[R"SFW-H:B>@AZ3_-K;? M NV?- ]F]!\N>"!X%+H<(24EL](J,'[N$L-FL98MSQNF2&&I0^(Q6%%S)89< M9W:>/L,DY68U40*P-1+!+7H@C)^Z/O@Q?G,U;2A2Y(GG-?I/[ D_P\\ MD_^HKOB*N&<+%#(P1F8= ^H#B7LAVK8FR2T*B''[/U.JPVM#2"3K49\\-2#C M_/?+$NKI.S5%>O;?] %!:KBOL-1*>)4_<9%$I8SJ\?8ZL$$PADDG7&HMDL!3 MFAO'XD+"V?MLZ38152^H5OOM!$.)D6DK#YTL"TS&*%7D+G%)M @0L<^AH@! MQ^G0Y*B/<>]>K"WO0ME1O@P;1S[253_R4?S>KARAX-(38D>PAZ#4'(K8]IN7 M6Z #6R"D80)& S!D"V#&*(QL()@UQP,K1,^%ER\GE'JL MYMW>[TIMK3[^;-2\_W$WN_69P*H1E.&U!9J 4>46#1A%-$..-(XG;!G-0+;A M% M7XBHW=?N;1-*UC217U M*6_TGLP]O[&Z&VI&I!:#&9[P\3#>WEW\\28#N<7!1(8]5@Z 4@D=>J4&9B2P MG%Q'T/T]>0,>U<^X%0([Y N>C/?MS[R:/Y <=][6]P]\-]1G>?S2=-&B#-]3 M?0 O?T91A[L^43KD9RV +4%$F;.NN$\.X(OM]UK:!KB_^ NK=G/QV5O 6J&(G=9E[S-VU#ZO"MV8# MODHN!7L3#.9U81GV X#6E3(^W'4#[*9<.PC[/T_K1-<8*-IL*D0>!6,[FU6$$I;4:M+'IL_,(-M.4EI.'=3R4W^X)C / MY7L/M1DOB45@ 36ASBW0N!3K+/>EN==KM ,C860V@:?Q6P(HTU\73]K+,CEV MHEFY.X,0=L! \OV9)WV_D&"M[*P5\7AH#7&QFKVM4;HQ/#M7"*@A>=(%;"^,J$< MJ>.L=6"6:4+U+J*!#_"^2\PW$.(P"L%.SPDT2]D"^(&>JV.TX< MLCYH6>:+Z<$K8O0X@?SUC,08;.^YV2RX,+/;>>: *R-QLXV[3MDYL*^F/.SV M>T][Y>;D7Y'OKO8$/.XHC.RBQ9XYA1N]Q!,3!)C;Y<7Y63L O7<8;;E]!,+, M*V;HG:FJ8?Q3R<3,PNTM(E'^SWJ_7^F2D[2./U^R?.@M04GS]^CM37[&W,5W MY-@.$OLXV@ZXQ#Z"^8RM'%GN6GY,5*QJ+P'42#7N:^XN55&N62LB[-+B]'BG MS+0;3E4[:E9E46VQ%!'>&+R2V+T8QMLG"P0P7*T A6F1 84Q-Q1J$K CMYLX M!]\*&7Z1$UW2Y>^I(SAC+2"X_M&,MW> +8:V8V0ONK)U>12H-/'&\B/,*<#J M+4=HD'.0:78!L-68)"9S3H?MJAZ4O#:9<=4U?.%ZK(L\2=^QY[IG3/06B*V M)07R$VQE-U8)>L-P',\ZWP0X,=NI$?&%S,.UU$OT]^%F#AX.5R5=\L99VFTQ MZ D?C"O(LZMW8%4WLH@C)+X_4^3GP2J0 M$YA._*$?ZCW(9X9C5%;#O>YW%]66_C$#+D(..# MF5^<]VGWP"C]")OB _I%3ZM7X&NQ#U?#+I3N>N6K I92^H@KB1[B4XZB-YG! M1O/M68$\9^-U1C!01= M@GDQ4&HAF'$>'P^N=#/O%O&I7%X0H6;HU[&2%IO7\3^]1 ML1WX,\1WQ-A,0C=V9R<;C XEGVLQ9,P\4)$;-E3O0YC>1/3KPRAYN\"NR;M) M1QO!G2__0,3FH=)H,^:E]LUEDLEP]Z,RXT!_QC++R,!@L%%,])K11?L,U$1< MG>0>U73O6?'9JX^?'DT-CNK\H[T%XH<_R!3&U?1(78KO7+%!0\'F+F"#D=D" M1A G%$_7\WJ(3Y[?.EG[M#B9'0&_F39&@! *>?MK.PP?0RO?Q1DN@AE+4#$ M[S+H!U'[2JNWM2K\?NJZO[Z%9W"M%->^:/V/$ M:S>BNPRD7;X(G1GAP$HM\P.O&-X.,[MV\@GF>EYKA-8#[SN.CGUA[8_]==0S M)Z0LOZ[#)8._!KXTR/GAY0D9S;<8WL2?,K2T[%D[YVF7NC.'/[;2;#BK%];@F+E1^)O[XX)=QZD@RR?G< MX4MW9D?YB S.<-Z^(!*]^.5W^(NE>R"4]N.D4W.U<[?/?^3Y

  •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end GRAPHIC 17 ensg-20231231_g4.jpg GRAPHIC begin 644 ensg-20231231_g4.jpg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ensg-20231231_g5.jpg GRAPHIC begin 644 ensg-20231231_g5.jpg M_]C_X 02D9)1@ ! @$ 8 !@ #_[@ .061O8F4 90 !_]L 0P " 0$! M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D* M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H* M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\ $0@" M8@*H P$B (1 0,1 ?_$ !\ $% 0$! 0$! ! @,$!08'" D* M"__$ +40 (! P,"! ,%!00$ !?0$" P $$042(3%!!A-180'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H MJ:JRL[2UMK>XN;K"P\3%QL?(R;GZ.GJ\?+S]/7V M]_CY^O_$ !\! ,! 0$! 0$! 0$ ! @,$!08'" D*"__$ +41 (! M @0$ P0'!00$ $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P M%6)RT0H6)#3A)?$7&!D:)BH*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_: P# M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHKQC_@HG\1O&WPC_8=^*'Q*^''B";2M=T?P MC=7&F:E;A3);2@ !UW C<,\''!YK'$5HX>A.K+:*;^Y7,ZM14J4IO9)O[CV> MBOR)_8L^&?\ P6,_;-_9CL?VF_A=_P %)9["XN[R[AL] U^V)5GMY6C^>58I M%PQ7O&0,\U[K_P $I_\ @IK\?OB[\<_%'["/[$XCHXB=*-2E.FJOP.5N66ETKINS?1 M.QYM#-Z=64%.$H*?PMVL_FF[/U/T!HKPS]I'_@I5^P_^R1XJ3P-\??V@--T; M6FC21](MK&ZO[F%&&5:6.TBE:$$?,-X7(P1G(KT#X$_M#_!/]IOP''\3/@+\ M2--\3Z))*8C>:=(VMGI]Y>QVTP.UHY9K:&2*-E/#*S@J00<8->H_$3]IS]GWX3_""#X^_$/X MO:%IG@V[MH9[#Q#+?*UO>),F^(P%,F2MW#%YQ"@L0FXA020 #CI?B'^VY^RE\)OBK/\$_B9\;M' MT+Q+:Z"^M7-AJ?F1)#8JK,9FF9/*7A6PI?<<< Y%$,?@:E)58U8N+=K\RM?M M>]K^01Q6&G3YXS3CM>ZM?M<]4HKP#X,_\%2_V /C]J.L:5\,?VF=#N)M!T^6 M^U0:I!<::L=K$,R3JUY%$LB*.69"0!R>.:L_L_\ _!3']AG]J/XCR_"/X&?M M!Z;K7B*-)'CTQK"[M&N5C!+F!KF&-;C #,?++?*I;[HS4PS++JCBH5H/FT5I M+5]EKK\B8XS"3MRU(N^VJU].Y[M17Y1?M$_%3P]\*_\ @X\\*^,?B+X\@T/P MWI7A"274[[4K_P FUMXAH-\I.G)J,HR<4FU=VMJE\SW.BO*_VF?VVOV5_ MV.M/L]0_:0^,VF>&CJ()L+.6.:YNKE0<%TM[=))60' +A=H) )%._9F_;6_9 M:_;%TN\U7]F_XQZ;XF&G%?[0M8HIK>ZM@V0K/;W"1RJI((#%=I(."<5Z'US! M_6/8>TC[3^6ZYONW.KZQA_:^RYUS=KJ_W;GJ5%> >,?^"I7[ O@"W\7S^+?V MD-)M&\":\NB^)[8V-VT]M?LTRB!(EA+W#9MY\F$.H\IB2 ,U[/\ #[Q[X1^* MG@31OB9X!UE=1T/Q!I<&HZ/?I$Z"XMIHUDCDVN%9$KS< M*52,FNB:;WMT\U;U'3KT*LN6$DWY-/R-BBOBK]JW]D+_ (*B?M-_'#Q-<^!/ MVYX?A1\.K+R4\&:;X9MY3>W9^SQF62YDA,3J#,9 /WKX"\1CJWD'_!#?]M3] MK+XD_M ?$S]CW]I;XA2^-5\%6EQ/:>([F03R03VUZMI+#]HP&GCD+[T+Y8", MX.#@>7+.U3S&&%JT914VU&3M9M>2;:3Z-K4XGF*ABXT9TY)2;2;M9M?.]NQ^ MFE%?D_\ \%@OVRO^"IO@6RUWQAX$T&?X2_"SP[XW_P"$>TG6[>[5=5\3SXF* MW2DC>EL5A9E"JBD./FE_A_1C]CCQ3XB\<_LA_"KQMXOU>;4-6UCX;Z'?:I?W M+9DN;B73X)))6/=F=F8GU-:X/.*&-Q]3"PA)."3NU9/6VE];>=M2\/F%/$8J M=",6G%7NU:_IU/2***\H_;6MOVK]0_9\U32OV*[S2[3Q_>7=K;Z=J&L&+R;* M%YT$\_[T,A*1[B 5<]<*QP*]*O5]C1E4Y7*R;LM6_)+N=E2?LZ;E9NW1;OT/ M5Z*_$S]MW6/^"P/_ 2SU_P?\8?'W[=MSXOB\27DL9LTU">YLDGA"N\$EI#]PA2?K'_@I[_P5"^*GP/_ &(?A1XO^!]@FD_$#XW:39W6ELT" MS-I,#VEO/<&)9 5:4/=01+N! WLW517S\.)\-&%?ZQ3E3E12;3LVU+:UG:[= ME\SRHYS14:OM8.#II-IVZ[6L^I^@5%?CQ^U#=_\ !5G_ ()&6G@/]IKQ_P#M MK:C\3-*US6H['Q1X7UB:::SAN3$TQM%\YGRCI',%FC$3*8\A<&OL3]LOPG_P M47_:XD\"C]A3XWZ5\._A[KWA./5M;\37,@2^EEGVO##'L1Y5Q$RM\GEC);+G M"K6M'/G456#P\U5ARWAHVU+9IIVMWUT+IYGSJ<72ESQM[NE]=GO;U['V'17X M[_LD_M9?\%"/V._^"J>F_L%?M+_'F[^(VF:IK$&FZE_:%\]Z +JV6>WN[>:8 M>=$5$D9>,G;C>,$A7'U9^VU^SC_P5J_:3^/>L:+^S]^T]I?PN^&&G:?;#1)K M2[>&^U*Y:%6F9WMXVF51*63ET 4*51LDTL/Q L7A)U*5";G&7(X65TUO=WM; MSOOH%+-57H2G"E)RC+E<=+I_?:WF?;E%?E-_P1H_;D_;-G_;=\8?L%?M3?$: MY\:)HD>JP-J%_/\ :9]/U#3[@12[;D@/-"^'&'R/H>T@FM6FGNF@HHHKTSL"BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^? M?^"K7_*.3XQ?]B1=?TKZ"K@?VIO@5;_M-_L[>,?@!<^)7T9/%NA3:=_:L=H) MS:EQQ)Y99=X! )7"_!@^%FC?\%8/'ECX/?X6T M;0;JTLI!(29!Y*ZJ8AN)).4.2>'HU:?)&DXMMM.[BM$DK_B?E=_P3-\5_M-_$?X] M?&OXW^"_V"/#WQW\3:IKB'7KOQ5XJTZQ;0_/FNG:...]/S"4H5)4?*MLJ\ X M/N/['_[.?[=?[#O@7]K3XZ^+_@2GPOT+7?A[JVM^$-!T[Q18ZA'IM_$EU- D M(M9G(6WCD8!F5,A5'../:/BE_P $8?'_ (:_:+\0?M)?L'?MDZS\(;_Q9<23 M^(-$BTK[5:2RR.9)"F)4 C+DN(G1PK,=K*,*/;_V.OV*_BO\#]!\:VO[3_[6 M?B+XT7?CFVM[6_A\10/%8V5M&DZO!! TT@19!<,'(VA@B_*,5RY9D..HU84Z MT9J4'.TTZ?)[REKHO:.]U=-[^6AC@\LQ,)QC44KQ^(-+BNYK6*.*'9#$\@+0 M'#F7$?VO_V9/V0?A=\+(O$'@SP[H^G+X7^'MWK/ MD6NK3/?_ &9;*2XN&(^>.VAB,DC$@2L<_,2?7K+_ (('?%_X4>)]=T?]E/\ MX*->,?A_X$\1W)?4/#MI9SF98SE?+:2&[B6_:2;2WWM?WM+VN@^H8R>6?5U14912UO'WK. M]OGOKI<^3?VB?V2/^"D7[1G[0'PH^,7@;_@F-X:^$&H^ =>@FN-8\->/]#<7 M,"W$$D?FI#*AVP^7(0%5B1*RX/ J+]O3X+?#W]H;_@X-^'OP>^*VCMJ/A[5_ M#U@=4T\3-&+E(;:\G$;,N#L9HE# $$J2,C.:^F_A!_P39_;UTKXD^%O%'QY_ MX*K^,/$F@>%M;L]0/AO3-+DM!JPMYEE$%U-]HS)&^P*X=9-P)&1UKM_B)_P3 M2'CW_@IAX4_X*'_\+E^RKX9TI;1O"/\ PC^\W++;W$(877GC8,7&['E'[F,_ M-E=)9'B*]&_LIWE5IRDINGK&.C=H6C:VC6[[%2RVK5IWY)>].#DI.&RW=HV6 MWS9\!?M__L2_LSZ5_P %K?A!^SYX7^%]AH7@WQKH^D7/B#0-!3[';S,UY>PR M!5BQY0=+:,-LVDY8@ACFNG_;P^ ?P?\ V6?^"SO[,B?L\?#[3/!]KK6JZ$-0 ML- M1;P2,=6:V=]B8 9X6V,1]X#)R22?M?\ :$_X)ICX[_\ !0OX7G)W<'[6_P#P33'[ M4O[9WPE_:X_X7+_88^%][93OH'_"/_:?[2^S7WVL 3^>GD[C\A.Q\#GGI16X M>K\N(E3HI2=:$HM]5?^"DWP4^$W[)?_!7+]G'6?V6_!&E^$[[6=6T=]0T+PW:):P2'^U1;!Q#& M J>=$SQ-M #A#GDL3]2_MC?\$6=#_;"_:WU#]J76/VB]6\-S2^'K:UT:TT/2 M=EUIFH6X'D7JW/GC<%(R8PBDY.'4X89?[*?_ 15U[X;?M3V/[77[6G[5^L_ M%WQ-H15O#W]IV5*BE89I9)IY7?RP2R1KM57 ;+8Q6-;)_6Y MU4O&\8II_P"+H[+S>QE4R[%SJU(*DO>J(_$%I86ME:P0VT:7*&\/E.5\UG"8)WW#2# ME"=9T:[M/%FE:'XRTN\M6)L65"L M5K+N)DNH[:1@(\;@7)SDU[=^VK_P2,_X: _:)M/VP_V;_P!HK6/A-\3(H(XK M_6-,LS/#?A(_)5V"RQM&_E8C8[F1T55*=2>G_8]_8=_:O^#7Q@;XS?M-?\% M_%'Q-E72)K&S\,FQ:RTR%I&0F9HQ,R2. F 1&I&>IZ5OA\DQD,R?MH3:]LZB MDG3Y=[INZ]I>VC2=GT-:.78B.,?M(R:]ISIIPMOUNN;R:/@S_@GC^R)\"/VK M/^"M_P"T@WQ\\%P^(]/\+^,-?N[#1KUB;66XEUF>+S)4'^LVKNVJ?ERV2"0, M?L/X*\&>%OASX/TKP!X'T2#3=&T33X;'2M/M@1';6\2!(XUSSA54#GTKYL_8 MT_X)IC]DG]K+XN_M0?\ "Y?[?'Q1U2[NX]$_X1_[+_9@GOI+LJ9O/?SMI?9G M8F=N<#.!]35[G#N62R_!R]K34:CE)MZ7:5M#TLIP;PF'?/%*317Q9_P $.OBAJW[*/[;?CK_@FUXW^'/AN?57O;]+CQOH MB2&ZNKJPWMLFD=COMS'YA10J%&/()=L?2'[17_!*3]J/Q9\;/%'Q=_9=_P"" MDGC;X=V7C#4VOM6\+H;EK:&=P [PM#/_B'K<$D%UXEU*U\A((Y7$DOE1&21C)(X&^5Y&9@. NYP MWEU3DFFO) M7=K^BL>=?\'*'_*/K2O^REZ=_P"DE]7U;^P9_P F-?!C_LD_AW_TV6]?*7[8 MO_!%;X^_MB>//$6J>,/^"E_BF+PCJ_B.35=*\":AX8FOK'2"2_EQQ*=21/W: MNR*PC4X)XY-=I^SI^S?\0_\ @DY\&/'/QC^/W[#O#/@I%TCPWJNG2 MVEOI26BGRHK99+RX56<>7 B*$ RHYXQT4/[0I9]5QE:@XTG%1YG*&BC=\S2E M>S]+]S6E]:IYI4KU*34&K7O'2UW?>]C[-BN(+C=Y$Z/L+&!)1'=.#R&F:9V'K&L;9.X8^E MO^"B/[&-U^WK^S;=?L]6_P 6;CP:MWJ]I>S:I#I?VU95A8MY+P^=%O4L5;[X MPR*<'%>MAL=C,7E"Q4*-JDHMJ#?_ (#J[;Z/IN=]'$XBO@%7C3M-JZC?[M=- MS\[];TSXC_\ !P5^VQ9:MIFD:AH?[/'PQNWMQJ5PABDU#K@)&,#B M"$*S?.0)-W_@X;TO3?A_\;/V9-76RBLO#ND7EW!%'&FV&VB@N=-8H!T4"/;@ M>B^U=OX _P""#7[5_P */#$'@GX6_P#!8GXA^&M%MF=K;2- T6_L[6)G8LQ6 M*'6%126))P.2237O_P =_P#@E?H7[3_[$/AG]E/X^_';7?$GBCPH3<:;\4;V MV,E\]WF0&26.69VEC9'"-&TI+!$.\%01\G'*$L!CJ^#K1J4[59VDY-QLVFFHJS=E;8\;_X.8M8TNV_83\+Z M3/<1_:;SXGV3VL6?F94L+_>X'H-R@G_;'K7LOB7]L;X:?\$XO^":WPV\;_&J M9I-8L_AOHNG:-X:24+=:MJ,>G0J85!'RJK#,DA&$7G!8JK>(_#W_ ((/?$#Q M5\0?"FL_ML_MP>(/BGX6\$,G]@^$;FTF6%D4J1$[S7$OEQG8BNJ+N=5"[U % M>@_\%-/^".E[_P %%/C'X>^*\'[3]SX+C\/>'$TNWTA?"IU"/>MQ-,;A&%W! MY;L)$4@ Y$*<\8KN=//O:XG'T:'+4G&,(1VE]%?7J=3AF?/6Q5. ME:6[\#:)-" M4*)-'Y0O"C)8 M&B\&^&D_>,K,2@O)U'(A1N O65QL7@.R>4_#O_@D#^VWX+\=Z%XJUG_@L]\5 M=8L-)U>UN[K1KB#41%>PQ2J[6[;]7==KJI0[D88;E6'!B_;*_P""''B_]J?] ML+5OVO\ PK^W!JW@G5+R6RETFVL_"CSSZ0]M;10J8+E+^%D^:,R#:JE2YY)Y M,T:.=8')94<'AFJLI:RE*#;8X;+G3P]%J;>K19C_S M\32!9)!_!L1>&WBOO>OBG]ES_@E_^UW\!?CSX>^+7Q'_ ."K_P 2/B%HNCS3 M/?>#M:BOQ:ZD'@DC59/.U2=,*SJXS&W*#&#AA]K5[N18>6$R]471=/EZ.49- M]7)N+:U=_P#AK'IY92=#"JFZ;A;NTV_.Z[L****]D] **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *;-## M<1-#<1+(C##(ZY!^H-.HH H"J !P!1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%?"[>,_CG\5_#_A/3 #LN]>U2*V$I SMC#D&1O15!8]A M50A.I)1@KM]$3.<*<'*;LEU>QUU%?G'^T5_P/Q \ZR^$/A/P;X M&SY, M]KIK:E>IGUDNB86Q_P!=]H M*_X_#^)^_58'C3XK_"WX;Q&?XB?$K0-!C"[B^M:S!:@#US*RU_+E\5O^"D?[ M>_QL,J?$G]KKQ[>P3DF6PM_$4UI:MGUM[I)/)-?1X?PZJM7KXA+RC&_XMK\CYK$>)%).U##M^,X==/\ %5O=X/I^X9^?;M7$ZE_P7+_X)3Z5 M7/Q&S1OW*, M%Z\S_5']+ _X+W_\$ES=_8A^UK#OSC=_PA>M[.F?O?8MOZULZ1_P6S_X)9:V MZQV?[8>@(7 (^UZ=?6XY]3+;KC\:_F.HJWX>Y1;2I4^^/_R)"\1&_%FG+J_A;Q!8ZG:/\ &O%OBOP9J*ZQX/\ $^H: M3=K]VZTV]D@D'T9"#7%6\.J+7[K$->L4_P FCNH^)%=/][AT_237YIG]A%%? MR^?"'_@L)_P4M^"7E1^#_P!KWQ7>018"VOB:>/6(]O\ =Q?)*5&./E(QVQ7U MY\!O^#IW]HKPP8=._:*_9\\,^++=<+)J'AV\ETJZ([NROY\3M[*L8/3CK7A8 MO@/.J"O2<:B\G9_C9?B>]A/$#)*[M54J;\U=?A=_@?N/17Q#^S9_P<%_\$X_ MV@/(TOQ'\1KWX=:O-A38^.K/[/!N[XNXF>W"^\CQDCL*^S_"_BOPMXWT&V\4 M^"_$NGZOIEXF^TU'2[Q+B"=?[R21DJP]P:^5Q>7X[ 3Y<13<'YK\GL_D?6X/ M,<#F$.;#5(S7D[_>MU\R_1117&=@4444 %%%% !1110 4444 $O#5G]JUO6[U7:.UBW*@8A%9F)9E4*H))8 DUQO[(' M[>W[('[?'A35?&O[(7QVTCQOIVAWRV>L2:V6CWT-S++]GDD:-)9/(B=859T< R%<[ M6/0$U]"U_)E_P5)>]_;H^"7QJ_X+->(H99-.\9_M5Z/X"^%,LZE3'X>T_1]5 M9F53T618]/)QQYL4W4YK]:/^"R7_ 5X^,OPP_X*)>"_^":'P._;"\'?LYZ3 M<>%?^$@^(OQN\7:!;ZHVGB03&"QMK:Y_*_VMOC78:Q=>&/!UO;S:I;^'[2.>\D$UU#:H(DDDC5CYDZ9 MRZ@#)SQBOR^_X)Z?\%Z/C#X>T;]K'X:?M'?'CPM^T"O[/7@.?QAX%^+'A+28 M=,A\7621@+;316X$4;&:6UCW("49I@S2;%8_*O[7WQ'_ ."[7[5W_!"[QI^W M_P#M%?M-^ =<^$'Q+BMGU7X5)X4M[.[T/3%UR".UN[.XAB5RWVF&(>5++*3! M)N8M)PH!^ROC#_@LG^Q)\/M._9TOO''B+Q!ILO[4=K83_"VSD\/R2R.+P67E M"[,1=+<[K^V0_,P!9N2JEJ^JJ_%#Q]^V/\=/V:_AA_P1W^%'PIU318-&^)^E M^&=+\7QZIX6L+^:6V$/ABWQ!-O_ !3KUUY%CIEE+=WLP0MY<4:% MW;"@DX4$X )-?GW^V-XH_P""I?PH_91^$ME\6O\ @I_^SW^SYKL=OJ-M\8OB MMK>F03_VE=I*@L%TBUOTCMW,D E>9"(W5]OE@#('BW_!%S_@JS^U5\:?VNOV M@OV&?C9^UQX2_:!TOX>>!F\2^!?C'X:\/VMA'J,:_9U>(QVJK%(H:[C4@AF5 MX)5WR @@ _0O]@3_ (*$?LU?\%*_@A<_M!_LKZ_J>H>';/Q!<:+=2:MI$EE- M'>0QQ2NNR3J-D\3!AD?/C@@@97_!0#_@I5^SY_P3;T7P+KO[0&E>)KN'XA>- M(/#.ACPUIL5RT5W*I8/,)9HML0 Y*[F]%-?E!^SQ_P %UOVH?@/_ ,&Y'B#] MMOQ#_P (SJ7Q-U'XS77@OP;<6OA&QTVPLY98(KCSWM+&*&&1HXDNG&5^=PF_ M< 0?&_\ @L/\-_\ @LC\./ /[,-S_P %*OVEO!WQ-T+Q+\6M(U2QDTKP];Z? MJ/AO6&13)I[_ &:&&.X@,$_LC_\%;/^"=?[=_Q) MO/A!^R7^T]I/C+Q)8:-)JUWI5GIM[!(EG'+%$\V;B"-2 \\2X!)^<<8R0 >E M_M-?M5_L[?L:?"B[^.'[4'Q(]5\'?L2-2Z@J#(H)!89^4?^#G7_@GQ^U;^VM\ _AC\2OV3O ]K MXWU;X1>-)-=U3X<7H5TUZV=(^1"[*MRT9AVF#(:2.>4)EL*S/^",_P#P5C_8 ME_;9_:4U'X4>)?V&K'X!?M.:!X6GT[6-&N/#,-K/>Z?')#)<6L-P(8IP$>.* M5K2=%9 H9#(%=@ ?7'_!-3_@I?\ L^?\%4_@1JG[0_[-FC^)['0M(\6W'AVZ MA\6:=#:W)NX;>VN&94AFF4QE+J+!+ YW @8YM_'G_@I/^RI^S=^UM\-?V)?B MGXIU.V\>_%=2?"5G:Z+--;N/,:-/-F4;8M\B,HZX(RVT8-?SX?\ !%7_ (*7 M?M%?!W]A?0_^"8__ 3PU+2[']H/XT?M$:C<6'B+Q!;P-8>&M&72M*#W;"Y1 MHI9)#;7 5-DA"02X0R-"&_4/]LW]J7]JO]G#_@KU^PY^R+J?Q6TCQ1;^*M"N M(/B!X@U'P'I2W>LWBJTYBBCF=_L3+<%IB! XQ(L621ZDCO M_P!@3]N?X.?\%'/V8=$_:S^ VEZ]9>&M>NKRWL[;Q-916]XCVUS);R;TBEE0 M O&2,.<@C.#P/R3_ &3O^4A7_!7+_L1=6_\ 2;4:XC]D?_@J+X__ ."7'_!K M_P#"3QO\%+/2&\>^._B9K?AOPO?Z^F^RTDOJ5]--?S)P'$:1[0I^7?*K,&56 M5@#^@FBOQ _9F_X+$?M,? 7_ (*/? []G'QI_P %7OAW^U_X&^-NHG1O$$GA M?P58Z1=>#=6D:*.$QM9@>9"TLT85I.'1)L1Q,H8]1X(_;4_X+9?\%3/V]/V@ M=._X)T_M&^!?AE\-_P!GGQ.V@Z5X>\4>%H+V+Q?>QS7,(6YF:"2>-)C:3,SQ MO'Y22PA5+[I ?HI_P $[?\ @I7^SW_P4X^'?BKXF_L[:5XFM-.\'^,[CPSJ MB>*--AMI7NX8HI6>,132AHBLR8)*MD'*CO\ 0=?C_P#\&:\VKW'[$?QHGU^U MC@OW^/VH->P1-E(YCINGEU4Y.0&R!R?K7[ 4 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !117FG[4O[7W[/'[&/PYD^*'[1/Q)LM!T_YELK>0^9=:A*!GRK:!EU\[_MI?\%2_P!C M']A"QEMOC5\48KCQ"L6^W\&>'@MYJLV1D9B#!8 1R'F:-3C@D\5^27_!0/\ MX.-/VB_VB&O?AW^R?;7GPR\(2%HVU>.<'7;^/U,R$K9@\?+"2X_YZD'%?G%J M.HZAJ]_-JNK7TUU=7,K2W%S<2EY)78Y9F8Y+$DDDGDU^A9/P%6JI5,PERK^5 M;_-[+Y7]4?G.<^(%&BW2R^/,_P"9[?);OYV]&?I'^V)_PK^\_- MLPS;,71>B6B^X****] \X**** "BBB@ HHHH **** "BBB@ KT? M]G?]KW]IO]D[7_\ A)/V=OC;K_A6=I ]Q;Z=>DVMR1T\ZV?=#,..DB,*\XHK M.K2I5H.%2*DGT:NON-*56K1FITY.+6S3L_O1^O\ ^QG_ ,'1.M636O@_]N7X M3K>Q9"'QGX*A$NT7(L9BMQ:,>B3P.%E@8_P!V15)ZC(K^2NNR^ /Q%^.GPR^*^C:]^SAX MNU[1_%\][%::/-X MZV?FO(_9:3\PHJ.\O+33K274-0NHX(((VDGGF<*D:*,EF)X M !))Z55\,^*/#7C7P]9^+?!OB&QU;2M1MUGT_4],NTGM[F)AE9(Y$)5U(Y!! M(-3RRY>:VA5U>Q>HHHI#"BBB@#YM_P""O?[+'Q2_;9_X)O?%7]EOX*C3CXI\ M7Z+;VVCC5[PV]N9([VWG(>0*VWY8FP<'G'UKX6_X*-_\$'/VF?VJ/^"1?[,G M[/GPNOO#ME\'_ 05^/GC[_@A?\"O^"9O[+C>%Y/%OP]\9:7KWBRZU;5&M;2YN39: MG_:,T)R-OF;)@N&:/8T$3 N"Z']/** /S_P#@ M;^QM^V_^U/\ LV_'/X%_M^?LZ_ 3X.:1\2_ K>'?#%G\&K)YM1M)98KA9;N^ MESY4RH[V[Q1HW6-PV,Y;XCC_ ."1G_!P_P"*_P#@FYJO_!(;Q1XK^".E_"OP MY!.VD>);>^GGU7Q/%'>&]M=-#D;8(/M.QC(\44B(BKEP"K?NY10!^5'Q[_X( MZ_M@?$:/_@F8GAP^%<_LH2:,?BMY^MLN!;?\(\9?L?[H_:/^07<@9V9)3LQ( MH_&7_@FU_P %:OV(_P#@J'\3_P!OO_@D];_"[QCH'QPM8SXP\&_$F]GM_P"S MK[*.\X\N2(R*)1)*C)+N N)8VB.U7/ZRT4 ?D)^WK_P2H_X*N?'_ ,9_LP?M MF^,+/X/?&[XF?"6QU"+XB?#3Q*WV3PYJ$]S=RS126J21+&ZQ1210DR!6+6<$ MF)3N%=1_P39_X)1?MZ_!;_@I-\;?VY?VGO#/PFT"U^+?PA;1K3P]\,+F6.QT M>^9[%8K1(7B4[8X+,>9,.'E9BH(.:_5.B@#\5OAA_P &Y?[4'B/_ ((%>(/^ M";_Q>\3>%=&^)]M\69_&_@ZZMM4DN=-,ZP101Q3RK$&021&Y3*JVPR(Q#8*U MD_M*_P#!+[_@X6_X*,^!?@];?M@ZS\&-&MO@_P",](FLO#.@7\HN=<2+Y;G6 M;RYS*@F"1HJPQ;%V-[;O!>6=W"L MD4\3J5>-T8$,K*2"I!!!(-<9\+_V7/V9?@AKLWBCX+?LZ^!/"&IW-H;6XU'P MOX1LM/GE@+*YB:2")69"R(VTG&54XR!7=T4 ?+/_ 4IL?\ @K9IUQX(^(G_ M 2TUOX:7[:*=1C\=> ?B7 ZP:^DHMOLDD-Q'L>)X#'\86OAA]$\)> ?AJ\DL-N M&MS:F>XE=G&%@>4 >9*SM+DM&L:HWZC44 ?@S\&_^#8+]K?PO_P2W7P!=^(O M"OA?]ICX>_'.Y\<_";Q7H>NNT M9+32H6M9;H1!HR9+$SH=C;)(8N5$DE?6G MQE_X)V?\%!?VG_\ @H/^Q;^W-\7-!\$:;>_"3P_)'\8+73?$+.BZ@=^][)?* M'F1R$APN1LW;23MW'],J* /S(^ __!)C]J[X>_M:?M\_&7Q$WAE=%_:-\-7U MA\.3#K#-*99H+M5-TOE_N%!G0$Y;O@'%>/-_P;M?M-?$3_@A#\./V%O%/C7P MKX>^-/PM^(%_XN\-71O'N])FEEN[MA:32B(D*\5PK;A&X5XT!!4M7[,44 ?G M)^Q9\,O^"Q%S\?\ P9/^TK^P+^R1\._"6B732>+?%7A*T:;6;X+ ZHVG+$S+ M;.TQ1B9",)NP<\'Q;0?^"8G_ 6L_P""?7[<_P =_%?_ 2^\0_"*^^&W[0_ MB)M9N=7^(4TQG\(74LUQ,94MTP7>!KN=4P)TD01>8F5('["44 ? G_!OC_P3 M._:(_P""7?[/?Q.^#O[1GB#1M6O_ !#\7+[7-&U71KHN+ZP:TM8$N)4*CR9' M:!V,>6VYQDU]]T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%17]_8Z58S:IJE[%;6UM$T MMQ<3R!(XHU!+.S'A5 !))X %?BM_P5Y_X.!-5\=2:K^S/^P=XEFL=#!>U\0_ M$>TME&38W.L3[*@M%NWLEY_HMV>1G&=8+ M),-[7$/5[16\GY?J]D?4W_!4O_@O/\'OV,QJ/P8_9Z-AXW^)L8:&Z*R[]+T" M3H?M+H?WTRG_ )8(1@@^8R$!6_";]H+]I#XW_M3_ !'N_BS\?OB/J/B77;O@ MW5_+\D$>21%#&H"0Q@DXC1549/')KB69G8N[$DG))/)-)7[3DO#^ R2E:DKS M>\GN_3LO)?.Y^(9WQ%F&>5;U7:"VBMEZ]WYOY6"BBBO=/!"BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH *_4G_@VJ_X)_P#_ M?XP7W[;WQ(T7? MH'@:X-GX0CN(_DN]99 7G /!6WB<$?\ 329"#F,U^<_[/GP+\??M,?&OPS\! M?AAIOVK7/%.K16-BA!V1[CEYG(Z1QH&D=NRHQ[5_51^RU^SGX!_9*_9_\+?L M\?#2VV:5X8TM+9)V0*]W,(4_X4SXZ.H>%);CS-4\!Z^SSZ7=9 M/S,B9#6TI_YZQ%22!NW@;3P_[>?[87CK]N[]JOQ;^TOX[,D3Z[?E=(TQI-RZ M;IT?R6UJO;Y(PNXC&YR[XRQKQ^O["X4X*R_*>%XY=C*49NI[U1-)IR?3_MU: M)KM=6;/SS'YE5KXYUJ)O _B.Q\8^#/$ M-[I.K:9=)FW3P7%K,AW))'(A#(P(!!!!%?N5_P1_P#^#D;1_B;/I/[- M7_!0G6;32_$$I2UT/XFL%AL]18\+'J &%MY2< 3J!$V?G$9&Y_R/C;PHQ&5Q MEC7\T?\ R9?WM6OH,MSZ%=JGB-)=^C_R?X>A^P=%(CI(@DC< M,K#*L#D$>M+7XL?2'EO[:_[6?PV_85_94\:>2*)2> T@)XS7PU^Q;^U?_P '%/[7<_P\_:LN_P!GC]GGPI\% M/&^JZ?>/X1U/4-3;Q+%X9N)HR;Y)1)Y+3?96,L>X)N^7, SBM[_@ZTT;Q'J_ M_!$KXER:##-)%9ZUX?N-46$$_P"C#5K522!_"':,GTQGMFOS/_:[\$_%?_@F MI^PQ^R?_ ,%*OV._^"HWQI\9_$'X@7OA^V3P'X@\="\TB_LWTQIWL[;3XU&V MVMY8HK-[>0RJIF1?W;* 0#^DFOQ=A_X+@?\ !8K]LSP)\9OVU_\ @FS^SQ\' M1\ _@IJU]!(/'DE]/KGB6&R@6ZN9(E@GC0,+5HY_*^0J)E17F<8K]9T_:>_9 MV/QW7]EN3XW>%5^)3:3_ &F? ?\ ;L!U46N-WF_9MWF;=OS=/N_-TYK\:/CA M_P $J?VG_P#@DY^R9^T#KO[+7_!7GPQX(_9H\21:QJVH^&-3\%V=_J,DTEL\ M']E6L\K,IN9E2*R$D;QNQ5#Y89: /H_6?^"[GQB_:,_9Y_9(OOV(_AWX1TCX MB?M3^(=5THR?$#[3>:5X5?2"J:F&2V>&6X;S&!A^9-R8++EL#?\ V?O^"\S: M;_P3-^)/[7/[8O@;1K;Q_P#"[XK:O\,Y?#'@AIO(\7^);80FVM]-CF,DH$_V MA,@F0HL4LGW5VCQ3_@CG_P $P?@9\=/^"#OP5\6?M>:YXD\#7WA#7=<^(/A# MQ[X;\3/H>J^%;>2[F(O(KL<1126T*3DL"NPH_!4$?)4]HWP>^$&B?\%'OV8_ MAA]G^$WAKXPP^#_V1])^)DEQ?+K7B34[EUU+XB:P'*O'/%?[>A\/6_Q,UN)]1UK0_#&G-;VNAQS'?#I_P T MDAEEB0A9)-V"^X#<%#-[)7PY_P $J_VS?VK_ (G_ +4_[2'[!7[8?BWPUXP\ M2? 36-!%C\0/"_AUM*BUFTU2TEN%6:U\V5(98_* ^5L'>1SLW-]QT %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5?5M6TO0 M=*N=RLK*W>>\O+N98XH(D4L\CNQ 554$DDX !)JP2 ,DX ZDU^%/\ MP7B_X+&7'[0'B'4/V-?V8/%K#P'I=P8?&'B#3YOE\172-S;QNOWK2-AR1Q,X MSRBJ7]C)-GF=8;(\$Z]75O2,>K?^7=]/6R. M?_X+1_\ !;7Q#^UKK&I?LR_LP:_<:=\+;28P:MK%N6CG\5.IY)Z%+,$?+'P9 M,;GX*HOYNT45^[9=EV$RO"JAAXV2^]ON^[_K8_ \RS+%YKBY8C$2O)_*/V\?VL/#/[/^A">'3[F?[9XHU.%<_V?I4)!N)L] Q!$:9X,DL8/ M6LJ]>EAJ$JU1VC%-M^2-L/0JXJO&C25Y2:27FS]1/^#9S_@G_P#\(9X%U']O M3XE:)MU/Q)%+I?@**XC^:#3U?%S> 'H9I%\I3P0D3D966OUEK+\$^#/"_P . M?!VE?#_P1HL&FZ-H>G0V&E:?;+B.VMXD$<<:CT55 _"M2OY[S?,JN;9A/$SZ M[+LELOZZW9_163992RC+H86'1:ONWN_ZZ605^*O_ =0?\%%O*ATO_@G-\+M M=^:3R-:^)ORW+J?2V(/+"OU._;I_:[\!_L+_LL^+?VF/'[) M)#X?T\_V9IQDVMJ5_)\EM:KWR\I4$@':NYR,*:_DD^,?Q;\>?'OXK>(?C3\4 M-;?4?$/BC5Y]2U>\?C?-*Y9@H_A09VJHX50%' %?J/A#PM_:6:/-<1']W1?N M^=3_ .T6OJXG#Q!CO8T/80?O2W]/^#_F$?=R@"#^@# M1=:T?Q)H]IXB\.ZM;7^GW]LEQ8WUE.LL-Q"ZADD1U)5U92"&!((((K^*ROT] M_P""#O\ P7!U']CKQ#8_LG?M3^)9KGX4ZI=>7H>M73EV\)7#MUR>?L3L"X;\/\1O#6&-A/-,IA:JM9TTOC[RBOYNZ^UT][XOI\GSETFJ&(?N] M'V\GY?EZ;?T!_$WX9^ /C-\/=:^$_P 5?"-CK_AOQ%ILMAK>C:G )(+RVE4J M\;J>H(/U'48(!KXX_9I_X-RO^"1W[*'QRL/VA?A7^S3++XBT6]%YX=/B'Q+? M:E;:3<*VY)88;B5D+H<%'D#LC ,I# -7V]87]CJEC#J>F7D5S;7,2RV]Q!(' M25&&596'#*0001P0:EK^;VFF?8GAO_#N+]D+_ANK_AY#_P *RD_X6[_8/]D? M\)%_;%UY?D>1]GW?9O,\GS/)_=;MF=OOS7SSK7_!LQ_P1P\2_'6_^/\ XD_9 MCNM0U/4]:EU:^TF[\7ZB^FS74?M3 M?L9_!;]KO]FR\_9)^),&JZ9X%U&&UMK[2/".I-I?FV=NZ,EENA *6Y"(K1IM M!0;>!Q47QW_83_90_:2_9=7]C+XL_!S3KSX;P6%G::=X. $R&=:WPV&K8S$1HTE M>4G9(PQ6)HX/#RKUG:,5=L^//^#A3_@JX?@SX5NOV&/V?O$I3Q;KUD!X\U>R MFP^D:?*N19JR_=GG0Y;ND+>LH*_AO6KXZ\<>+?B9XTU7XB>/=>N-4UO7-0FO MM6U*[?=)\GW?\ EV78_GO/5SX#_9P_8V^)/Q^_;0T3 M]BQX9-*U^\\5RZ-K8=,6V=_MLI3(W>3'%,VW(R4QD9S7O7_!7+_@EG\+ M/^"=_AGX=^+_ (3_ !NU/QE8^-Y]4ADDU"PBB6(VGVQRC20\3 MD]?-)V'N=]>)3X@Q.+QU&M!M44FI1LM9*G*_\+;3X&>,3X4$7FGQ./#-W_9^S^]] MI\OR\>^[%97P^^&/Q)^+.OCPI\*_A[KGB;5#$THTWP_I,U[<;!C+>7"K-@9& M3C S7[I?'W]NGX ?LI?\%)];G^.G_!13Q5IWAS1;!-,U#X!I\*KJ31X[273D M$02=&9')9TG\T1DD$Q<)P/!OV7/B-I'[-O\ P21_:F_; _8/MAI^L7?QGNK' MP_K2::K7.F:!]KL5M1Y;JVWR[>\E5KGQ+J/Q-MXY=4DTT M6KZE!$;Z*&Y95"JQ9%4;U #;<^IKZ*^-?PT\ ?$__@NS^SE8?$+3;:]@TKX% MMJNFV5V@9);V"2_:$[3U,;?OE]&B![5Q4XHM+5:I= M-K=CMK9+A<5&-+#I+FCATFXV?ON2;T>C?7>_<_#CQM\!/CI\-/#MGXO^(WP7 M\6>'])U @6&J:WX"F^)6B_L^>.+ MSPXL!F;7[7PG>260C R7,ZQF/;CG.<5]/_MN?M^_\%%OVB/BI\8_V4O&OBK4 M=3\,:GXV;3KSPC+HL/E:.MOK$:6:))Y8:WQ,L$6\L!(7 8LS U^C_P"S1KO[ M0WP=_P""A7@;X)?M<_\ !5>;Q#X_U31Y)+OX'^&OAU(NBB V$[QH;U/+AB,8 MC\U6\H.?* /$G/IXS.\;@L)&I4A!S:E*R!QV M,E3ISGR)QCS-0C[S;76:OM=)7D]5;37\'_#_ ("\=>+-*U'7?"O@O5M3L=(6 M-M6O-/TZ6:*R$C%8S,Z*1&&8$+N(R00*OZ_\&OC!X5\;6_PT\4?"GQ+IOB.\ M6-K3P_?Z%<0WTXD&8RD#H)&##[N!SVK]?/\ @GCXGM_V;?&/_!2OQUX \+Z6 MP\ >(;S4_#VDW=J&M(I+"X\0S6R&,8^1'BCP!@@*,$$ USG_ 1M^/OCS]K' M5?VD_P!MW]IGXM>;\2/!GPOM=.T#QM#X4M[BYT"P>+4II;F"RMDC$[QF&,A5 M&YPNPDA\&:W$.(IJO45).%/DZN[BYM7OV15'AS#U'0I.JU4J<_162 MIN2;NVM7RZ+;NT?E/\2O@M\8_@S>V^F_>)O"EQ=H7M8/$N@W%B\RCJR+ M.BE@,CD>M*/CS\0'\36FL> ]?\4? M#^[T^ZTQA<6XFA\Z9G!3R1=+FF#P^"KQC1J*:<4]XNSU5FXMJ^E]'LT%%%%>B>:%?T._\&_'_ M 3_ /\ ADK]E%/C3X_T3R/'/Q/AAU"Z6>/$NGZ4!NM+;GE68,9W'!S(BL,Q M"ORH_P"")'[ +?MT_M@V+>,=&,_@+P*8M8\8&1,Q76'/V:Q/KYTBG<.\44V" M#BOZ45544(B@ # ' %?FG'N<\L5EU)[ZS_1?J_D?I_A_DG-*6955M=0_5_H MOF+117R=_P %F?\ @H/8_P#!._\ 8LUOXAZ%J,2^-_$F[1? -JV"POI4.ZZ* MGJEO'NE.05+B-#CS!7YWEN7XK-'5YU&HKY]_);M]%J?J%:M"A2E4F]% MJ?DC_P ',_\ P46_X:2_:8A_9!^&NN^;X-^%EVZZR]O)F/4/$!!28G'!%LI, M [B1KCJ"*_,*I;^_OM5OIM3U.\EN;FYE:6XN)Y"[RNQ)9F8\L2222>2345?V MWD&387A_**6 H;05F^[W[_#L@HHHKV#G"BBB@ HH MHH _9O\ X-R?^"S$V@7^C_\ !.S]J'Q.6L+J1;7X6>)+^;FUE/W=(E=O^6;' MB G[K'RN0T83]P:_BNT*SUS4=;L]/\,VMW/J4]U''I\%A&S3R3E@$6,)\QCW#C?R 0@B0_8U5J[J'IU?SV^3[GY/ MX@9TYU5EU)Z*SGZ]%\M_FNP4445^D'YF%%%% !1110 5Z[)^VU\;Y?V-X_V% MGGTK_A!(O$O]N*@T_P#TS[5DG'G;ON9).-N?>O(J*RJT:5;EYXIV::OT:V?J M:TJU:CS>SDUS)IVZI[KT/>?BQ_P4A_:E^-/[(_A3]B?QUXGL9?!'@^2V;3(X M+'9=2I;I)'!%-+N_>)&DF%7 ^XA.2H-9?QC_ &\/V@_C?\*?A;\'_%FL6-KI MGP=M#!X)NM(M#;7<'RP!7>4-EG7[/&58;2"">M>-45C# 8*FTXTTK-R6G5Z- M^K3U-IYAC:B?-4;NE%Z](ZI>B:5C[?3_ (+_ /[<5UIEA+XH\(_"S7O$FF6R MPV7CK6_ $4VL1!?NL) XC# DGB,#))QS7EG['/\ P5,_:Q_8CUGQ5?\ PKUG M1M3L/&MPUSXE\/\ B?21=6%W<-NS/Y:-&4M'W/I7]J+_@K'^V+^V'\ M(+OX'?''Q+HU]H%QXGBUNW@L]%2W:Q>*$PQ6T&P@1VZ*3A,$EB6+$DDYOQE_ MX*>?MSE .F0>F?_@X%_;Z>YT?Q$+3X=KXGTNWAMKGQJ/ \/\ :^IV ML;!OLUQ.6P(F8998ECSD],FOB.6WG@V^? Z;T#IO4CH]Z96*R3*/9J' ML(V5W:W>R?WV7W+L;_VYG'M'4]O+F=E>_:[7W7?WONSZ \(_\%*_VF/!4?QS MBT2YT(#]H9KEOB'YND[MQG-X9/LWS?N?^/Z?'WL97TKE/V0?VTOV@_V&OB@W MQ8_9Y\8)IM_<6AM-2L[NV6XM-0MBP8Q31-PPW $$892/E89.?*J*ZOJ.#<)P M=-6G;F5M[*ROZ))'*L?C5.$U4=X7Y7?:[N[>K;;/IS]J7_@JY^T+^U7\*KOX M+Z_\._AKX2\/ZG?0WFKVW@3P9'8/J$T3;XVED9Y'.&^;@C)Z\<5\QT456&PN M'P=/DHQ45OIW(Q.+Q.,J>TKR84\GOV75_)'ZH_\ !)K]A/3OV _V/M#^&&HV)KBXE5(T4L[NV H')))Z"OY;_ /@N+_P41E_X*#_MI:GK'A#6 M6G^'_@GS-$\"QH^8[B)7_?WX'K<2+N!P#Y20J>5K]_8R_86_:7_ &]_BI%\)_V;OA]-JMRI1M5U6?,6GZ3"QQYUU.05B7@X M7EWVD(K'BOKC_@E'_P &^/QW_;D;3?C/^T%_:'P_^%9 5((*)(,E?Z"?V;?V8?@1^R)\*['X,?L[_#?3_#/A^Q&1;649 M,EQ+@!IIY6R\\K8&9')8X S@ #\HXT\4^+& ETW3&Z$0]KN4>O^J4XR9/F0?@6$ MP7$_'^;VC%=$O1)L]O-(/VE=$U#]G;X^>*Y-0\<:2);_ $?5[UQYFKV3/ND1 MN@,L+-T'6(K@?NV-?H!7F\09%C^&\UJ8#%KWH]5M)/:2\G^&SU3-\BSO!<0Y M9#'85^[+H]TUNGYK_@K1A1117BGL!1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !3+JZMK*VDO+RX2&&%"\LLKA510,EB3P !SFGU\: M?\%W_P!K+_AEC_@GMXGM]$U+R/$/C\CPOHFQ\.JW"-]JE&.1MMEF 8?==X_4 M5U8'"5,=C*>'AO-I??U^6YR8[%T\!@ZF(J;03?W=/GL?AQ_P5+_;&NOVY/VU M_%_QJM+V230(KK^RO!\3YQ'I5L62%@#]TRDO.P[-.PKYYHHK^B\-AZ6$P\*- M-6C%)+T1_-N)Q%7%XB=>H[RDVWZL****W, HHHH **** "ONW_@F=_P54^-G M[-2U,DL:;YO.<(TA(4%HV2-60/([>#Q'5P=++7]8ASW=HK6SDT[7MT6K=_S ML?0<-4L95S-?5ZG)97E+2ZBFKVOU>B5ORN2?\%1O!W[!/@K_ (+D_!R+XGZ# MX=T[P[>Z?:7?Q2ME@CCL6NFEN?LDEZ@ 0;B+%?AT_[(VF>%)&^'L=C8V;- M:^"/!'[._@W]F;_@J;\+OCC_ ,%(?VK?A3\4M-\?:[JU]K&M:)XD_M&TLM1A MMU^S2:@)(D2&'SYH/+X\M1"0?8X+>R*80BUWQO'&7,S,.)6(SYJKNE:T4X:.KKK!W3LOM$=6_X*H?LU?LU M?%/]F#]M3PKX(N?AYH5OI_Q%TC6?&;Z?/I%U#':JUTD*9W/&T$Q4N$WHT95L M$X^DX@Q,,2Z44U[.,Y*?-&3BI*-TI)6NM=-;7MO:Q\SP[A9X95I-/VDH1<.6 M45)QFNE[7VO<\U_8XF_:'\4_MS?M)>(/CM\+?#WAC]J-_A/(?AQH M4VE6EL@UA+:*(3V,NP_:I_9!^%GQJ_:%\$_M' M?M=2:9I6D?"GX*:'J/[4%YHL<"MJOB?#;-&_T$/^"I/_!6K1/A?^R9XATK5(4T*R\,R>*%NE&GS20RW5S+<[-V4SZW^S#^V)^R/\/?^"@7PI_89^&7BO2+'X*?"HZDMGXJUJ2-+ M7Q/XS:TEC_MJZ=CL*B4M';DDJI*LAP8PGG588I4X8NDG&HZ5W!*SA%1M9.[M M>WN1M=2O+7E:/2I5,)*I/"56I4U5Y8S;NIR7 M[3WQ2_:V_:-U3XK?$[PW+H"""*R\,^%3;F&+0M(BR+6SB0JNU%4DDA0&=W; MW8'C5?H5_P %=/&'B6?]CCX#_#C]J3XF:'XL^/>D:EX@F\47VFZW::EM?8935A6P$7""BE>*2=U:+:33LKIVNG8^ M,SBC.CF$E.;DW:3;5G>23::N[-7LU<****](\P**** .F^#/PB\=?'SXK^'O M@O\ #/2&OM>\3:M#I^EVPX!ED8+N8_PHHRS,>%56)X%?U2?L!?V,OV; M?"O[.?P^C5[3P]IRI=WWEA7O[QSON+I_]J25F;&3M!"CA17YG?\ !LK_ ,$_ M_P"SM+U+_@H#\2M$Q/>+/I'P[CN(^4A!*7E\N?[Q!MT82?4\$\;57OU-O*/\ ]MOZ6"L3XD_$7P9\ M(?A[K?Q4^(NNPZ7H/AW2I]1UC4+@X2WMH8S)(Y]<*IX')Z#DUMU^-/\ P=._ M\%%O^$?\-Z9_P3K^%VNXO-62#6/B1+;RA'EA!**79)61^:U*DZM1SD[MZA111700%%%?5?_ 35_P"" M0G[4W_!2OQ8LOP_T<^'O MI=>5KGQ UFV;[';X^]%;KP;N<#_EFA 4E=[QA@ M3Q9AF.!RK"2Q.+J*%..[?]:M]$M7T-*5&K7J*%-7;/GGX0?!OXJ?'[XB:;\) MO@MX"U/Q+XCU>?RM/TC2;8RRRGN>.%11DL[$*J@LQ !-?O+_ ,$H/^#;GX6_ MLW_V;\=OVXK;3?&OCN/9<:?X1 $^CZ')U!D!&+V=?5AY*G.U7(62OL__ ()_ M_P#!,W]EG_@G%\._^$0^ _@\2:Q>0*OB'QEJJK)J>K,,']Y( /+B!&5A0*B] M<%B6/T'7\V<:>*N.SGFPF5WI4-G+:61'X>M+C] MQIS$RK_J_7RE_>-QG8&#U^+?[2?[4WQP_:U^(4OQ)^./C:?5;T[ELK4?) M:Z?$3GR;>(?+$G3IRQ&6+-DGCX)\+\SXE<<5C+T<-O?[4U_=3V7]YZ=E(^4X MQ\2[1]%_\ !0S_ (+&_&/]KY[WX:_"X7?@ MWX>2%HY-/BFQ?:NG3-W(AX0C_E@AV.7-QH7FOA+;5XT^Z,\#SXEV'U>*(#[QK\Y\7.%5G61_VA0C^^PZ;\W3^ MTO\ MWXEZ2MN?H'A9Q.\GSKZA6E^ZKM+TG]E_/X7\NQ^R5%%%?RCZAOL/ASX>$NH1*W"ZE?[)G! ZXMTM,9Z;V]>?WGKR?]H+]A M;]C[]JF*3_AH#]G7PMXDN94VG5+G35BOU7&,+=Q;)T&/[KCH/2O#DDFE:UTWI?7?2ZZ;G@\1Y7BLXRR6%H346VF[WLTM;:;:V?78_D_HK]U M?VA_^#7']ESQKY^J_LX_&;Q+X&NWRT>G:O&FKV"GLJ[C'.@/3!M)^(FEPY;[5X,U0/.$[9MK@12LW^S&LGU/6OU[ M!<5Y%CK*-51?:7N_B]/N9^.X[A+/\!=RHN2[Q][\%K]Z/A>BMOX@?#/XC_"? MQ#)X1^*7@#6_#>JP_P"MTW7M*FL[A/K'*JL/RK$KZ&,HSC>+NCYR490E:2LP MHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KU[]A/]D;QE^W#^U% MX6_9U\'^;"NKWGF:UJ4:;AIVG1_/_P -9/+.LTC1?P+67HNGSV_'H??/PS^''@WX M/_#S1/A7\.]$BTW0O#NEP:?I-C"/EA@B0(BY[G Y)Y)R3R:W***_ I2E.3E) MW;/Z$C&,(J,59(\O_;-_:J^'W[%'[,WBW]I?XER@Z?X9TQIH+(2!9-0NV(2W MM(R?XY961 ?X=Q8\*37\D'QX^-GQ!_:0^,OB7X[_ !5U@WWB'Q7K$VHZI< M2WDS'?:^R%60XX(M8V:+VEEG!'RJ:_*ZOZI\*.%O[%R7Z_7C:M72?G&'V5\_ MB?R3V/AL^QWUG$^RB_=A^+Z_Y!1117ZL>"%3:=IVH:QJ$&DZ18375W=3+#;6 MMM$7DFD8@*BJH)9B2 .237JG['7[$'[2?[>'Q5A^$G[-OP\N-8O?E?4]1DS M%8Z5"3CS[J;U?1,]/+\KQ&/E>.D>K_R[L^$?^"4/_!LUXA\;_P!F_'S_ (*,:?=: M/I!V7&E_"^&9HKV\7J#J,BD-;(1_RP0B4Y^=HBI1OV\\%>"?!WPW\)Z?X#^' MWA;3]$T32;5;;3-)TJT2WMK6%1A4CC0!44>@%:E>)_MG_M]?L^_L/>#O[<^* MWB'[1K-U"S:+X5TUE>^OSR 0I.(XLC!E?"C! W-A3_,F;9YQ+QYFL83O4DW[ ME.*?+'T7YR>MMW9'U]LKR#!2K59*$(KWI2?Z_DE\E<]:\7^,?"GP_P##-[XT M\<^([+2-(TV S7^I:C/)(S%>W@Z$6:-S;H1_P M6 E.?E$9&3\I?MP_\%&OV@OVZ/$QE\>Z MM_97A>UG+Z/X.TR9A:6W97D/!N)L?\M'Z9.U4!VUX#7[CP1X1X/*N7&9RE4K M;J&\(^O\[_\ )5YZ,_ ^,O%3%YGS83*6Z=+9SVG+T_E7_DS\M427=W=7]U+? M7US)-/-(TDTTKEGD223DDU'117[8DDC\=W"BBB@ J]X8\2Z[X,\2:? MXO\ "^IRV6IZ5?17FGWD#8>">)P\]>E5 M^57_ ;G?M*217_C+]D_7K_]W,@\1>'4=NCC9#=QC/J#;N%']R0^M?JK7\/< M:9"^&^)<1@DO<3O#_!+6/W;/S3/[-X/SQ<0\.T,8W[[5I_XHZ/[]UY-!1117 MRI],%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%?- M.H?MO>*-"\<:I9'P[8:EH\6H2QV>UVBF,2L0IWC<#D#/W>_6N\\'_MF_"#Q' ML@UN:[T6=N"+R O'GV>//'NP6OHL3PKGN&IJHZ+DFK^[K^"U_ ^]I^+T_$[KXD?"?X6_&/P\_A+XM_#?0O%&ER9WZ=X@TF&\@.1@G9* MK#/OBOB[]H?_ (-TO^"7]17W'H/B?PYXIM/M_AK7K._A[R6=RL@'UVDXJ]7F8;,,RRRI:C4E!K=7:^ M];?>CT\3E^69I3O6IQFGL[)_<]_N9^$/[0__ :[_M:>!//U3]G?XL^&/'UF MF3%I]^&TC4']%59&D@;TRTR?3T^%OC[^Q-^UM^RYO%/AF%'V?VC? M:4[63MG&$NH]T,G/]USU'K7]8],NK6VO;:2SO+=)H94*2Q2H&5U(P00>"".U M?68+C[-:%EB(1J+_ ,!?WK3\#Y''>'N4U[O#SE3?_@2^YZ_^3'\=5%?T\_M# M_P#!&W_@G'^TKY][XS_9IT;1]4GR3K/@\'2;@.>KL+;;'*WO*CU\)?M#?\&J M8_?ZI^RG^T]Z_9]$\?Z?^6;RT7\/^/?\:^NP7'.2XJRJMTWYJZ^]7_%(^.QW M >>86[I)5%Y.S^YV_!L_'.BOJ#]H?_@C7_P4=_9J\^]\9?LU:QK&EP9)UGP< M!JUN4'5V%MNEB7WD1*^8[JUN;&YDL[VWDAFB665PD44:EF=B< #DDGC% 'U9_P1Q_8(N/V]_P!L/2O"OB/3 M'D\$>%=FL^.)BIV26R./+L\_WKB0"/&0?+$K#[E?TS6UM;V=O':6D"111($B MBC4*J*!@ < <8KY3_X(X_L$6_[!'['FE>%?$>EI'XW\5;-9\<3%1OCN73] MW9Y_NV\9$>,D>896'WZ^KZ_"N*\Y_M?,WR/]W#2/GW?S?X)'[WPCDO\ 8^5K MG7[R>LO+M'Y+\6PKY?\ ^"O/[?VE?\$[/V+]?^+ME=P'Q?JP.C^ K&7#&74Y MD;;,5/WHX$#S-G@^6$R"XKZ?9E52S, ,DD]*_F _P""\O\ P44;]OG]M"^L M_ ^MFX^'GP],VB^#1%)F*\8./M6H#L?.D0!3WBAAX!S7J>'G"SXGS^,*BO1I M6E/LUTC_ -O/3TN^AZN;X[ZCA&XOWI:+_/Y?Y'Q9K&L:KXAU>ZU_7M2GO+Z^ MN7N+V\N92\D\KL6>1V/+,S$DD\DFJU%=%\)_A'\3OCM\0=,^%7P=\"ZGXD\1 MZQ<"'3=(TFU:::9NYP.B@9+,<*J@EB ":_L*-X]EQIW@I<3Z M/HK\$&?/RWTZ^_[E3G DPL@_5E$2)!'&@55&%51@ >E?A'&GBY"GS8/(W=[. MKT7^!/?_ !/3LGHSZG+>'W*U3%?^ _Y_Y'G_ .S-^RQ\ _V/?A59?!G]G7X; MV'AK0;,;FAM$)ENI< -//*V7GE; R[DG X 'H$DB1(TLKA54$LS' ]37% M_'W]HGX.?LQ?#VY^)_QM\<6FB:5;Y6-IVW2W4N"1##&,M+(<<*H)P"3@ D?C M+_P4,_X+&?&/]KY[WX:_"_[7X-^'CEHWT^&?%]JZ=,W2^;6Y'$_&62\(X;EJOFJ6]VG'?Y_P L M?-_),^O?^"B'_!^+& ETW3&Z$0]KN4>O^J4 MXYDY4?D=\0?B)XZ^+'C&^^(/Q*\67VMZUJY/0 8 48"@ M "L:BOZIX6X.R7A+"^SP<+S?Q3>LI?/HNT5IZO4_F+B7BW..*<3[3%SM!?# M!?#'Y=7W;U^6@4445]4?,A1110 4444 %%%% 'K'[#'Q[E_9F_:T\"_&9[MH M;+2]=B36&!ZV$V8;GZ_N9'(]P/2OZ0T=)$$D;!E895@<@BOY9*_HK_X)L_&A M_CY^PY\./B'=W7G7O_"/1Z?JT MG3[DUM,T;K]"I!%>C>#_ -K?XT^%-D-SKT6K0+_RRU6'S#C_ 'UPY/U)KS*B MN/%Y?@<='EQ%.,_5)_<]U\CLPF8X[ 2YL/5E#T;7WK9_,^H/!_[=?A&_V6_C M;PG=Z>YX,]DXGC^I!VLH]ANKU/PA\8?ACX\"KX6\:V-S*_W;9I?+F_[]OAOT MKX,H!(.0:^3QO 648B[H.5-_^!+[GK^)]?@?$#.,/98B,:B_\!?WK3\#]&** M^%O"'QY^+G@;9'H/CB]\E.!:W3^?$!Z!9,A?PQ7J?@_]O#6(-MOX[\%P7"]& MN=,E,;#WV/D$_P# A7R&-X$SG#7=%JHO)V?W/3[FS[' \?9+B;*NI4WYJZ^] M:_>D?2U>7?'W]BC]DK]J.V>'X_\ [/7A;Q/,Z;!J-]I2+>QKC&$NH]LT?_ 7 M'0>E7_!_[4GP6\8;(HO%BZ=.W_+#5D\@C_@9RGY-7?6MU:WMNMW9W,>?JG[._P 6/$_@"\?)BL+\+J^GIZ*%D9)U],F9_H>_PE^T/_P; MH_\ !1CX*>?J?@;PMHGQ&TN++"?PEJ@6Y"=BUMJ39;[7 MX,U0I 7[9M;@2PJO^S&L?U'6OKL%XA8*I98JDX/NO>7Z-?B?'8[PZQM.[PM5 M379^Z_U3_ _G/HK]0_VA_P#@UP_:C\%>?JO[./QG\->.;1,M'IVKQ/I%^WHJ MY,L#GMN:6//H.E?"O[0/["?[8G[+$LO_ OW]G/Q3X#?AA8[_7"-]O M'SPPA'[]L=&$ ((,OC!\0]$^%?P\T274M=\1:I!I^DV,(^::>5 MPB+GL,GDG@#)/ K^I[]A/]D;P;^P]^R[X6_9U\'^5,VD6?F:UJ4:;3J.HR?/ MO445E^./&WA3X:^"]6^(GCK7(-,T30M-GU#5]1NFVQVMM# M&9)96/HJ*2?I7XM&,IR48J[9^WMI*[/@;_@XN_X*+?\ #&W[($GP4^'>N^1X M^^*L$^F6+028ET[2L!;R[XY5F5A!&>#NE9U.8C7\V%?0'_!2#]M+QQ_P4;_; M.\1?'>ZM+QK34;Q=,\%:%M+R6>F1N4M;=47.9&W&1PN%(2S&:C5G[TDM92E;X8KKRJR[)W;:N?"8IXC.\>U15XK1=DN[] M?O/B'_@FW_P2/_:G_P""E?C!8_AKHG]A>"K.Z$>O?$#6;=A8VN,%HX1P;J?' M2)#QE=[1A@U?T7_\$^?^"87[+'_!-_X?_P#"+_ WPG]HUV]@5/$/C75D634] M488)#2 8BA!&5ACP@P"0S9<^Y>!/ ?@GX7^#].^'WPX\)Z=H6A:1:K;Z7I&D MV:6]M:Q+T1(T 51]!WJ3QAXQ\*?#_P ,7OC3QSXCLM(TC38#-?ZEJ-RL,%O& M.K.[$ "OQ+B[Q SGBZM]7A>G0OI3CO+MS-?$^RV717U/I,#E6%RV'M).\EO) M]/3LO,TJ^2?^"@O_ 5P^"'[%EK=>!?#+P>+OB%Y96/P]:7'[C3F(X>]E7_5 M^OE+^\;C.P,'KY$_X*(?\%VO$/CC[=\(/V*[NYT?1VW0WWCN2,Q7MXO0BS0\ MVZ'_ )ZL!*<_*(R,G\V+JZNKZZDOKZYDFFFD+S32N69V)R6)/))/))K[G@GP M@K8KEQN>IQANJ6TG_C?V5_=7O=W'9_E'&7BO2PW-@\E:E+9U=XK_ +[3_O/ MW>R>Z[[]I/\ :E^.'[6GQ"E^)/QQ\;3ZK>GP !1[>9:RM]7-?CQ7Z$?\&Z'C]]$_:K\7_#N6;;!KW@AKA5S]^>V MNH=H_P"^)IC^%?GOBE@%CN",5IK#EFO^W9*__DMS[SPTQKP7&6&UTGS0?_;T M7;_R:Q^M/QM^.?P>_9M^&6I_&?X]_$C2/"7A31Q$=4U_7;Q8+:V\V5(8PSMP M"TDB(!U+, .M9G[.G[4_[.7[77@67XF_LQ?&KPYXZT""_>QN-4\-ZFES%!,-+_X) M>?\ !1K6/V._'>LQZ1\/?V@/V?/#?Q3\&W-]+LABO8]'6ZO=N>$3']K!B/X; M"+CT_C4_K@_7KXP_\%$/V&?V?OC%IW[/OQL_:L\$>&/&VK?9OL'AG5]>BBNY M/M$GEP90G*;VX7=C/7IS7LU?R>?M-V?B#]KKQ3I7_!9/Q[9W"2_&K]LZRT/P M#%> A[;PWID?EPA>Q!!@@;_;L&X&3G]R_P#@J'\5?^"D_@?XQ06?P5_;V_9J M_9T^%R:%#)9^)_BQ=PMJVL:GND\^)8[S_1T@C41_,/GRY.6SA #[XHK\=?V2 MO^"YO[8?QI_X(W_M0?M"^,=3\%7?Q9_9^O[C3M.\8^&K-9M(UI?D$-XL6XQR M9/G89,1NGEL%&3GQWXN?\%@O^#@GX3?L,_#'_@KOXJ@^#=I\(]6N-*L+WX>V MU@TNI:PCQF-]2N9"G^CI6 /UVHK\!_'/_ 5L_P""X&B? []GO]IO0OVT M/@3J*_M->,K?0]"^'VD>"DFF\+R7$_EQ[L,\\Z1EE28$L\;LB?.6S7T/^W=_ MP5__ &IM/_X*&VG_ 2X^#W[8'P0^ ]]X(^']EK'Q9^-/Q5-M'9W&JRVUM,+ M'3H;V5(3N6ZAD"-F0J\A!00-O /UQKR']N/]N#X"_P#!/+]GS4/VF_VDM4U* MT\+:;?VMG<2Z3IK7M_!_XM7^C:O9:+X?TUK/6/"TD>/_#$[RZ;KFEV^H:=+ M)&49X)HUDC)4\J2K#@\BO+?VK/\ @H=^Q#^P]]AB_:Q_:=\)>![G4X_,T[3M M8U(?;+F/<5,J6T8:9HPP(+A-H/!-='^R)_R:=\,/^R=Z)_Z00U^,?_!"O]G/ MX*_\%:/^"CG[6O[>'[=GP[TCXCZGH'CB+2/"'AOQC8IJ%AI=M+->*BFUG#1O MY-O:VT$6]2$"R'&X[@ ?M!^SA^U3^SA^U_\ #U?BK^S#\:O#OCGP_P#:#;RZ MEX=U)+A8)P QAE4'=#(%96,;A6PP.,$5W]?(GQ9_9!D_8(_9R^(6M_\ !(;X M4_"'X8^+O&.NV6H:[=>,YY[+PQID:!8I[\P0GRX/*@!(CB5(RWS%6Y#?$7[, M_P#P5R_;L^#/_!5?X3_L2?M"?MS? 7]I+P?\7(KBVN-9^$BV8N/"]\J2F..0 MV;87+I'\LH8O&[$;2O(!^S%%?C!K7_!1S_@NS^UM_P %)_VBO^"?/[ .H_"[ M2[;X9^*UGLO&?C/3!''HVF0[XQ9-MBF,\MU(R89I&NQ!=T&H6Q#,-LF)!\I*-L$B[5D"+]WT %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\^_M[ZH8M$\-Z* M'XFNKB=E_P!Q44'_ ,B&OH*OF']O2\+^,-!L-W^JTV23'^])C_V2OJ.#:2J< M14;].9_^2O\ 4^5XUJNGPW6MUY5_Y,OT/!:***_=#\%"BBB@ HHHH **** " MM7PSXX\8^#+C[3X4\3WVGL3EA:W+(K?[R@X;\0:RJ*BI3IU8.,TFGT>J+IU* ME*:G!M-=5HSV3P?^VU\4M#VP>)K*QUJ(?>:2/R)C_P "0;?S4UZIX0_;5^$^ MO[(/$4-[HLQ^\;B'S8L^SQY/XE17R/17S>-X/R'&W?L^1]XZ?A\/X'T^!XSS M_!67M.==IJ_XZ2_$_0;PYXQ\*>+[;[7X6\266H1@99K2Y63;]0#D?C6E7YV6 M5]>Z=Z?>2P3(XB62-U*NCKD,#P00>HKP/PA^W?X?NMMOXY\&W-HW1KG3I1*F?4HV MTJ/H6KU/PA\3R92?0))@G\ :^1QN09QE]W6HR27 M5:K[U='V.!X@R;,;*A6BV^CT?W.S/%/VA_\ @D#_ ,$ZOVF?/O/'_P"S+H6G MZG/DG6O"L9TFZWG_ ):,;4HLK?\ 757'MP*^$OVA_P#@U4TF?S]5_93_ &G) MK=N3;Z)X^T\2*3V!O+105';_ (]V/OZ_L'15X+B+.LOLJ59V[/WE]SO;Y6(Q MW#>29C=UJ"OW7NO[U:_SN?EG_P $3O\ @B9\6/V.?C_XA_:$_:TT;1SK&AP' M3_ ,6F:BEW"S3(1<7X(PR$1GR4#A6Q)*2H^0G]3***Y,SS/%YOBGB,0_>LEI MLDNWY^K.O*\KPF3X18?#KW;MZ[MOO^7H@K\T_P#@NS\0?VD/VKM3T;_@DQ^P M[X8N=9\3>*HH-8^*.I02>7::'HPDS;Q7=Q]V!9I$,K _.R0HJJ_G!3^EE9/A MKP)X.\'7VJZIX8\-VEE=Z[J!OM:NX8@)KZX*JGF3/]Z0A%1%W$[41$7"JH'1 MD>9TLFS".-=-3G#6"?P\_24NK4=TE:[2UL=.*H2Q-%T[V3W[V[+U/BO_ ()7 M_P#!"?\ 9P_X)W65G\2O&"6WCOXJF(--XKOK3_1])#_[;^*OB'[1K M-U"S:+X5TUU>^OSR 0N<119',KX48(&YL*?Q-_;@_P""C7[07[<_B3H4_W6'_ )$]9>L-H7[?7PEO5;!?QO96__?Y_*_\ 9Z\/B>@L M3PWC:3^U2J+_ ,D9[7#=9X?B'!U5]FK3?_DR/UI_X+T?L@_'3]NS_@EU\0OV M8_V;O#EKJWC#7[S19=+T^\U**TCE6WU:TN9+K2/Q)!8F;39M(BM[I!T-\Z7DO4$U^RE%?P>?VT?DK^W]_P $3OV@=8_8'_8Y_8__ &2?"&EZ MQ)\#_'.E:CXTFEU>"S1@L1>_O4\YEW^9=/-)L7+?O. :Q_\ @H!_P3._;J/_ M 6=US_@H%X'_8)^'7[5G@'Q5X!M-"T/P=\1O%=A:6O@NZBAMHS< R2*) M()I@(HY"?MLV-C@,?V"HH _%7]DS_@BO_P % _@]_P $ROVV?V8_'WPO\&V? MC/XSZV;KP)IGA/6[>/2;H9+%;?<9K] M9** /QT_X*'_ /!+#]NO6OVX/V?OVQ? _P"QMX*_:8\(^ ?@Y9>$]=^#'C/Q M;8V-II^I10SI)=@7^;:5-TT3A@LK%H,%.(V'D.@?L/\ [6__ 3)_9;_ ."A MO[5W[6'A3PG\']&^*GP]L4\(CX/RPW-EIMU=R7$0TVTMD:-X$2:_@M#(1& 6 M>1"5 -?O36!\4OA9\./C=\/-7^$WQ>\$:9XD\,Z_9/::SH>L6BSVUY"W5'1@ M0>0"#U! (P0#0!_-?^SVGQ+_ .".G[,GP1_X*I_$_P#X)D?LO^)-#U>ST=-$ M\3Z5XXU1_%-QYUL72\\BXNI[*&^:-=[O;P$Q.6RJ8"74FX0H5DW5];?"?\ X-Y/^",WP3^)EI\7OA_^PKX?37+"[6ZLI-7US5-3 MMH9E;RE%Y;R:M<:>GE2HMU'$JF,$JCS':20# M\?\ QE_X)Z?\''_[5O\ P2WTC_@F3\1_V=?ACX:\,_"VQTVUTK4E\8V- MH;&6.&RMXF2XDBM$AA/F.\HA>3[,@ !9E;]]:* ./_9Z\'ZY\/?@%X'\ ^)[ M=(M2T/P?IFGZC%'('5)X;6..10PX8!E(R.#7Y-:U_P $T/\ @K]_P2>_X*"_ M%']JK_@D+X!\$?%3X;_&C46U'Q)\-/%.N0Z?+I]RTTL^ T\]NF(I+BX$,B2L M?+F9'B)57/[*T4 ?D!^W_P#L*?\ !=K_ (*A_P#!,'Q5X&_:/L_AOX<\?2_$ M[2M?\-_";PAK/E6L^B6MK<12Z==7C2,DDTEQ-%ZU7#1DJ%XCX5?\$J M?^"@'Q _X*1?LR_MC7O_ 2^^#/[.'@?X8ZK)!XB\'_#[Q+ID]\L:1Y-_>26 M@2.Z\QGVQ*AEE0)(9&^8,?VVHH _//\ X)J?\$^?VG_V;?\ @KA^UY^UG\6? M"%C9>"/BUJ=I-X'UD)Y+Q$FE=B\*,7AP&7[X7KQFOG;]J7_@DQ^V7^S=_ MP5%^)_[<7[-'_!/CX0?M5^ ?C'#'=:IX#^(UYI=M?>'M3^0RS02ZH/*56D$C M!DW%DE*,H,:NW[*T4 ?,O_!++X;_ !P\ ?!#7;K]H']A[X0_ '6]5\5RSV/@ MCX016Q@&GBW@6*6^EME$4UWY@G4LGR^6L0X.:^FJ** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^4_V[)"?BIID/]WP_ M&?SGF_PKZLKY3_;LC8?%33)2.&\/Q@?A/-_C7V' UO[?C_AE^1\;QY?_ %>E M_BC^9XG1117[8?AH4444 %%%% !1110 4444 %%%% !1110 4444 =3X/^-7 MQ4\";$\,^-[Z&%/NVTLGFP@>R/E1^ KU/P?^W;XEL]EOXX\'VMZ@X:XT^0PO M]2K;E8_3;7@=%>1CFO:][['W.3>(%:IB(4\$\6QQD\PJ5'BH=TO>BNW(MDO[MUU=CXCHI9(WB=HI4* MLI(96&"#Z&DK]F/R(**** "BBB@ HHHH **** "BBB@ HHHH **** "O6/V# MI7A_;?\ @\\9P3\3]!7\#J$ /Z&O)Z]?_P""?=BVH_MS_""W5<[?B1HTN!_L M7D3_ /LM>;G+2R?$M_\ /N?_ *2ST